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Choice, Trust and Risk - The Policy Context  
and Mammography Screening  
Karen Willis  
University of Tasmania 
Australia 
1. Introduction   
Mammography screening is now a well-established measure aimed at reducing mortality 
from breast cancer. However, while it is well established it is not without contention. 
Mammography screening has been the subject of fierce scientific debate about the evidence 
gathered using large scientific trials. There continues to be debate about the magnitude of 
benefit, issues of over-diagnosis, and the age at which screening should begin. These 
debates spill over into the policy arena where governments must decide which health 
measures to promote (and to fund).  It is remarkable that policies about mammography 
screening differ between and within countries. This is particularly the case for policies 
establishing the age at which women should commence screening and the recommended 
interval between screening. Any policy decision about frequency of screening and lowering 
the age limit has resource implications and these must be weighed against the potential for 
benefit.  
This chapter presents an international overview of the differing policy contexts in 
countries with mammography screening programs. It then explores the intersections 
between scientific knowledge, policy making and individual decision making with 
particular reference to the age at which screening should begin. Using research conducted 
with women in three different policy settings (two in Australian states and one in a 
Swedish county), it explores the differing ideas that form a crucial part of women’s 
decisions to participate in screening. While most research focuses on women who don’t 
participate in screening (there is a vast literature about the ‘underutilisation’ of 
mammography screening), we can learn much about health behaviour by talking with 
women who have chosen to be screened. This is particularly the case where screening is 
contentious.  
The research at each of the sites comprised qualitative interviews with women aged 40-49 
years who had participated in screening. Interestingly, the risk of breast cancer is not the 
main reason that women choose to be screened. For women in rural Uppsala, Sweden, trust 
in authorities was the dominant discourse; for women in rural Victoria, discourses of rights 
and choice predominated; and for women in rural Tasmania, trust in technology was a key 
reason for participating in screening. Women in rural areas also utilise services that are 
delivered in their local area because they highly value regional health services. These ideas 
are necessarily bound up in sociological concepts of choice, trust and risk. An 
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understanding of these differing ways that women in different policy settings view the 
‘invitation to be screened’ is an essential part of exploring what information women should 
receive about screening, and how they will respond to the provision of screening services. 
2. The intersections between scientific and policy knowledge 
In western developed countries, policies to reduce the mortality (and morbidity) from 
cancer have become a national health priority. Breast cancer is a major cause of mortality for 
women in many such countries, and the quest to reduce breast cancer mortality has seen 
early detection emerge as the leading policy strategy. The scientific evidence supporting 
early detection in the form of mammography screening is viewed as being strong – 
however, it is also contentious. The translation of scientific knowledge into public health 
policy is never a simple process, but this is all the more difficult when there is general 
agreement around the principle of early detection, but disagreement about factors such as 
the age at which screening should commence and screening intervals. The ‘story’ of the 
evidence surrounding mammography screening is quite well known. However, as is 
illustrated in the following re-cap of this story, scientific evidence alone doesn’t provide all 
the required knowledge for successful policy implementation. 
Randomised controlled trials are studies where the efficacy of an intervention is judged 
following random allocation of study participants into a study group that receives the 
intervention and a control group that does not receive the intervention. At the end of a 
specified period of time the results are compared. Evidence from such trials is regarded as 
‘the most scientifically rigorous method of hypothesis testing available in epidemiology’ 
(Last, 1995: 140). Eight randomised controlled trials of mammography screening were 
conducted in the United States, the United Kingdom, Sweden, and Canada. The earliest of 
the trials was the Health Insurance Plan (HIP) of New York which was conducted in the 
1960s (Shapiro et al., 1982). This was followed by Swedish trials commencing in the late 
1970s and early 1980s: Malmö (Andersson et al., 1988), Two County (Tabár et al., 1985) and 
Stockholm (Frisell et al., 1991). At approximately the same time, a randomised controlled 
trial arm of the broader United Kingdom screening research commenced in Edinburgh 
(Roberts et al., 1990). Trials have been also been conducted in Canada (Miller et al., 1992a; 
1992b), and Gothenberg in Sweden (Bjurstam et al., 1997). A trial in the United Kingdom 
from 1991 to 1997 aimed to identify the evidence of benefit for women below the age of 50 
found a reduction of 17%, but this was not statistically significant (Baines, 2011). Proponents 
of screening mammography cite evidence from these trials that mass mammography 
screening as a population-based strategy reduces mortality from breast cancer by 
approximately 30% for women aged 50–74 years.  
These findings have formed the scientific justification for breast cancer screening programs. 
The Australian policy setting can be used to illustrate the use of scientific policy and the 
broader political concerns that contribute to government decisions to establish a screening 
program. In the lead up to the introduction of the Australian screening program, the 
Screening Evaluation Coordination Unit (SECU) at the Australian Institute of Health 
conducted a review of the overseas evidence and reported to the Australian government on 
the feasibility of establishing a national breast cancer screening program (Australian Health 
Ministers’ Advisory Council, Breast Cancer Screening Evaluation Screening Committee, 
1990). In examining the scientific evidence, the SECU unit focused on the HIP and the Two 
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County trials as providing evidence of benefit. It also took into account other non-
randomised trials that also showed a benefit from screening and included a discussion of 
the Malmö and United Kingdom (Edinburgh) trials which had not achieved statistical 
significance but had reported the potential for benefit from mass screening. Based on all the 
evidence considered, the SECU predicted that with a 70% participation rate in the targeted 
age group, the reduction in mortality from breast cancer would be around 16% (noting that 
this figure included non-participants and those outside the targeted age group) (Australian 
Health Ministers’ Advisory Council, Breast Cancer Screening Evaluation Screening 
Committee, 1990: 26). The Australian policy documents reflect this claim by stating that an 
organised national screening program will result in a significant reduction in breast cancer 
mortality (National Advisory Committee for the Early Detection of Breast Cancer, 1992).  
This review of scientific evidence was accompanied by feasibility research aimed at 
understanding issues associated with policy implementation. Feasibility studies, often in the 
form of pilot screening programs, were conducted in the five most populous Australian 
States. These pilot programs were aimed at applying the Australian context to the 
application of the selected scientific knowledge. Issues examined included strategies for 
encouraging women to participate in screening, psycho-social issues in implementation, 
analysis of the costs of screening, and technical aspects of service delivery.  
Within the broader policy context in Australia, funding concerns also contributed to the 
need for a nationally organised program. The national universal health insurance program, 
Medicare, covered payments for diagnostic mammography for the relatively small number 
of symptomatic women (women with breast lumps or other potential signs of breast 
disease). However there was the perception that, increasingly, asymptomatic women were 
seeking to have mammograms. This blurring of the distinction between diagnostic and 
screening mammography (a population-wide program for well women) had the potential 
for a ‘blow-out’ of costs due to increased de facto screening mammography. Duckett (a 
former senior health bureaucrat and, from 1994 to 1996, secretary of the then Australian 
Department of Human Services and Health) points to the two aims of the mammography 
program: ‘In addition to the health enhancement objective of promoting early detection of 
cancer and thus reducing breast cancer mortality, this program had the objective of 
moderating the previous rapid growth in expenditure on mammography’ (1999: 81). 
Therefore, the decision to implement the screening policy seemed to bring together 
advocates arguing for the efficacy of reducing mortality from breast cancer, those 
establishing the feasibility of the programmatic aspects, as well as health bureaucrats 
concerned with expenditure.  
Population based screening, however, is not without its critics. Since the incidence of the 
disease is much lower than in a diagnostic population, such screening programs require large 
numbers of well people to participate, in order to demonstrate effectiveness. For most people 
who participate in the mammography screening program, there will be no benefit, in terms of 
reduced morbidity or mortality. In a radio interview, one health bureaucrat encapsulated this 
aspect of screening programs by stating: ‘It is a community action rather than an individual 
action and we can never, ever say to women that as individuals they individually will benefit’ 
(Australian Broadcasting Corporation, 1998). In fact, at an individual level, for some women 
the outcome will be worse. The possibility of having a ‘false negative’ test result may mean 
that women are falsely reassured about the absence of breast cancer, a ‘false positive’ test 
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result may subject women to a series of further tests, and the uncertainty resulting from 
indicators of benign breast disease may mean that treatment which is unwarranted will be 
recommended. Foster points out that, as a secondary prevention program, ‘breast cancer 
screening cannot prevent breast cancer, nor can it promise a cure; it is rather an attempt to gain 
better control over the disease’ (Foster, 1995: 116).  
In addition to the criticism of the potential harm of screening as a population based strategy, 
there has been criticism calling into question the epidemiological evidence of benefit (for 
example, Schmidt, 1990). From the commencement of the promising reports about the 
possibilities of mammography, Dr Petr Skrabanek, a senior lecturer in community medicine at 
Trinity College in Ireland, maintained that the reduction in mortality was a substantial over-
estimate of the evidence (Skrabanek, 1985). Dr Maureen Roberts (1989), who established the 
Edinburgh mammography program, argued that screening had not delivered the promised 
benefits in an article in the British Medical Journal published shortly after her death from breast 
cancer. More recently, following the Canadian study results, critics have focused on the lack of 
mortality benefit, the potential harm for women from the program in terms of over-diagnosis, 
and issues associated with screening asymptomatic, well women who have no breast 
problems. They claim that ‘although politically attractive, the benefits of mass population 
screening, even in older women, are too small and the harm and cost generated too great to 
justify widespread implementation of screening mammography as a publicly funded health 
measure’ (Wright & Mueller, 1995: 31). Further, in 1999, there was extensive media coverage in 
Sweden raising questions about the evidence from the trials, together with claims that the 
programs that have been implemented have not delivered the promised mortality benefits 
(Atterstam, 1999; Sjönell & Ståhle, 1999a; Gøtsche & Olsen, 2000). These critical voices, 
however, are not part of a vigorous and public debate about the efficacy of screening 
programs, rather emerging publicly only occasionally and generally dismissed by the central 
proponents of screening as ‘ill informed’, even endangering women’s lives. As noted by 
Atterstam, the space for a critical point of view is minimal (1999: 1). 
Ongoing debate has existed about the scientific evidence for screening women aged between 
40 and 49 years. More recently, studies have attempted to ascertain the magnitude of 
benefit, but these results are contested. Commentary, dispute and refutation of claims from 
the Canadian trials that, in 1992, resulted in a questioning of benefit of population-based 
mammography screening continues ferociously almost 20 years later (Baines, 2011). The 
level of dispute also reveals the entrenched positions that various experts and commentators 
occupy in their reading of the scientific results from the trials. A recent review by Fletcher 
(2011) problematizes the changed landscape of screening, arguing that while it had its place 
as a secondary prevention measure, it is an ‘imperfect tool’ and that with progress in 
primary prevention and treatment, the need for screening should decrease. Such a message 
may be difficult to reconcile with the ‘early detection is your best protection’ message that 
forms part of the dominant discourse about breast cancer screening. That policies rest on 
dominant beliefs and often imperfect and uncertain science is evident when policies for 
breast cancer screening are explored. 
3. Policy implementation and policy settings – an international overview 
In arguing that policy is an ongoing process, rather than a finite event, Considine says, 
‘policy is the continuing work done by groups of policy actors who use available public 
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institutions to articulate and express the things they value’ (1994: 4). Understanding policy 
choices relating to mammography screening involves more than identifying who benefits 
and who loses. It is about understanding the dominant ways of thinking about an issue, the 
cultural dimensions of the issue, and whether policy players have their voices heard, or are 
excluded from the debate. Health policy is a broad area. In intervening in health at a policy 
level, governments are called on to undertake a variety of tasks relating to health financing 
for medical and hospital systems, as well as undertaking measures to redress health 
inequalities. Increasingly, governments are required to ensure provision for expensive high 
technologies in health and put in place programs to protect health. Texts analysing the 
politics of health and health policy portray the health system as complex, resource intensive 
and a site of much political contestation in the formal political arena (see, for example, 
Palmer & Short, 2010). 
Palmer and Short claim that health policy is distinctive in three significant ways: first, the 
role of the dominant profession – the medical profession – in shaping policy direction is 
unprecedented in comparison to other policy areas; second, consumers are confronted 
with a complex arena of services where it is difficult to distinguish between ‘good’ and 
bad’ services; and, third, the nature of health care means that decision making is often 
associated with life and death issues and, therefore, is psychologically stressful. This leads 
‘the community to see health care and its providers as being “different” (2010: 25). 
Accompanying this latter perception is the implicit assumption that consumers can trust 
health care providers, that governments will provide effective and efficient health care 
and that health care policies and innovations will have a sound basis in scientific research. 
This is particularly the case with policies involving technologies. However, the 
relationship between health care provision and research evidence is not clear cut (Davis & 
Howden-Chapmen, 1996). 
As can be seen from the outline of evidence in the previous section, consensus about the 
evidence is widespread but not universal. Leaving aside the question of whether screening 
should be implemented at all, the lack of universal consensus is particularly important when 
governments and health authorities are deciding who they should be screening (i.e., the age 
at which screening should begin) and what the screening interval should be. These decisions 
are made combining a range of factors: resource implications and who should pay (it is 
more costly to extend the target group and to screen at shorter intervals); political 
implications (whether professional or consumer groups are demanding availability and 
access to services; where decision making fits within an election cycle); implementation 
implications including the structure of governance for health services and health workforce 
availability; geographical considerations; and how to access the target population groups – 
in particular whether active strategies for recruitment can be used or whether women are 
encouraged to self select into the screening program.  
In addition to the issues identified above governance of a population based health program 
will affect the claims that can be made about its effectiveness in meeting targets. In many 
jurisdictions in western countries, two tiers of government are involved in policy direction 
and implementation. The roles that different levels of governments play in screening 
programs are diverse, with many devolving responsibility from a national government to 
state or county governments (BreastScreen Australia Evaluation, 2009). Thus, while the 
screening policy is decided at the national level, operational responsibility for the programs 
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is devolved to levels of government such as states, territories, provinces or counties. This is 
particularly important to note in countries like Australia and Sweden where populations in 
various jurisdictions are low and may be dispersed. With different operational procedures, 
guidelines and recruitment strategies existing within countries, there is a risk of variation in 
population coverage, thus diminishing the capacity of the program to demonstrate overall 
population level benefits. In some countries, private providers coexist alongside the state 
services that are provided. Again, this has implications for determining policy parameters 
(such as eligibility and recruitment) as well as the determination of effectiveness.  
In order to explore the differences in policy settings a desk top search was undertaken. It 
draws on two main sources – the international review of selected policy settings carried out 
by Australian policy makers (BreastScreen Australia Evaluation, 2009) (based primarily on 
stakeholder interviews) and the information provided by participating countries to the 
International Cancer Screening Network (2010) where English was available. In addition to 
the information provided, reports or publications of specific network members were 
downloaded, and further searching was undertaken where information was unclear (either 
by corresponding with member countries, further searching on participating country health 
websites, or through the academic literature). What emerges is a picture of considerable 
complexity. While generally established as government public health initiatives, there is a 
combination of public and private providers. The private sector plays a role in screening in a 
number of countries, with sole responsibility for parts of countries such as England and 
New Zealand. Objectives for participation are generally set at a national level (generally 70% 
of the total population, but 80% in England) with regions or specific services having 
operational responsibility. This brief description of the selected policy settings, with 
particular emphasis on the age at which screening is recommended or available, and where 
the information is available, the strategies for recruitment, highlights the differences in 
approach that exist both within and between different countries  
Australia 
Australia has a national government that determines policy but operational responsibility 
for service delivery is devolved to State/Territory governments. Screening is free of charge 
for women attending through the national program. In most (but not all) States/Territories, 
women aged 50-69 years are invited to attend screening at 2 year intervals. Invitations are 
based on the electoral roll (elections are compulsory in Australia); where access to the 
electoral roll is not possible, women are encouraged to attend for screening through 
advertising. In 2004-05, the participation rate for women in the 50-69 years target group was 
56.2% (with variation between Australian states) (Australian Institute of Health and 
Welfare, 2008). Women aged 40-49 years can attend for screening, but whether, having 
attended, they will be invited back at 2 year intervals varies between individual states. 
Canada  
The Public Health Agency oversees the Canadian Breast Cancer Screening Initiative (Public 
Health Agency of Canada, 2008), but has less of a leadership role than other countries where 
national governments establish programs and devolve operational responsibility. 
Responsibility for mammography programs is devolved to the 12 Provinces/Territories, all 
of whom provide screening for women aged 50-69 years every two years. It is estimated that 
approximately 60% of women aged 50-69 years age group have had at least one 
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mammogram (Hanson et al., 2009). All but three Provinces/Territories allow women to 
access the program from age 40 years. All programs allow women aged over 70 years to be 
screened. A range of strategies are used to invite women to participate – letters of invitation, 
media campaigns and referral from medical doctors. Policy documents indicate a reliance on 
doctors referring those women outside of the eligible age groups. In five of the 
Provinces/Territories, women aged 40-49 years are reinvited for screening on an annual 
basis; the remainder do not reinvite women in this age group. 
England 
England has a nationally coordinated screening program, but screening services are 
devolved to individual screening units in National Health Service (NHS) regions. Women 
aged 50-70 years are invited to attend and in 2004-05 overall 75% of women invited to 
screening attended (NHS, 2006). The invitations are based on general practice registers. 
Women are screened at three year intervals. Women aged over 70 years are able to continue 
to participate in the program if they wish to do so. From 2012, following the ‘Age Trial’ 
(Moss et al., 2006), that investigated the age at which screening should commence, women 
will be invited to attend screening from age 47 years. 
Finland 
Finland has a unitary government that provides an organised screening program based on a 
national population register. The target age group is 50-69 years and women are invited to 
attend screening when they turn age 50 years of age. In Finland there has been debate about 
the age range for mammography screening. Initially women aged 50-59 years received 
regular invitations to screening, and women aged 60-69 received ‘irregular’ invitations 
(depending on the municipality); from 2007 all women aged 50-69 have been invited to the 
free screening program. Participation in screening by the target population is very high, 
with 87.9% of women invited to screening in the past three years having participated 
(Palencia et al, 2010). 
Ireland 
In Northern Ireland women aged 50-70 years are invited to attend the screening program every 
three years. In the Republic of Ireland, women aged 50-69 years are invited every two years. Both 
programs are free. The register of eligible women is compiled using government and private 
health sources in addition to individual women registering. There is approximately a 73-75% 
acceptance of screening invitations in both Northern Ireland and the Republic of Ireland (Kinnear 
et al, 2010). Screening is provided via mobile and fixed site services. 
Italy 
With guidelines set at the national level, Italian mammography programs invite women 
aged 50-69 years to screening. The mammography programs are devolved to the 21 
geographical regions and there are a total of 130 screening programs – 64 in the North, 39 in 
the Centre and 27 in the South and Islands. Some programs include women aged over 70 
years.  Since the commencement of screening programs some facilities include women aged 
45-49 years as the national government has provided free biennial mammography for 
women in this age group.  There are large differences in population participation between 
the regions, partially attributed to the fact that some programs in the Central and Southern 
regions have only recently been established, and due to dispersed populations some regions 
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mammogram (Hanson et al., 2009). All but three Provinces/Territories allow women to 
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screened. A range of strategies are used to invite women to participate – letters of invitation, 
media campaigns and referral from medical doctors. Policy documents indicate a reliance on 
doctors referring those women outside of the eligible age groups. In five of the 
Provinces/Territories, women aged 40-49 years are reinvited for screening on an annual 
basis; the remainder do not reinvite women in this age group. 
England 
England has a nationally coordinated screening program, but screening services are 
devolved to individual screening units in National Health Service (NHS) regions. Women 
aged 50-70 years are invited to attend and in 2004-05 overall 75% of women invited to 
screening attended (NHS, 2006). The invitations are based on general practice registers. 
Women are screened at three year intervals. Women aged over 70 years are able to continue 
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(depending on the municipality); from 2007 all women aged 50-69 have been invited to the 
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(Palencia et al, 2010). 
Ireland 
In Northern Ireland women aged 50-70 years are invited to attend the screening program every 
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programs are free. The register of eligible women is compiled using government and private 
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With guidelines set at the national level, Italian mammography programs invite women 
aged 50-69 years to screening. The mammography programs are devolved to the 21 
geographical regions and there are a total of 130 screening programs – 64 in the North, 39 in 
the Centre and 27 in the South and Islands. Some programs include women aged over 70 
years.  Since the commencement of screening programs some facilities include women aged 
45-49 years as the national government has provided free biennial mammography for 
women in this age group.  There are large differences in population participation between 
the regions, partially attributed to the fact that some programs in the Central and Southern 
regions have only recently been established, and due to dispersed populations some regions 
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struggle to provide a biennial service to all women in the target age groups (Georgi et al., 
2009). 
Netherlands 
Mammography is provided for all women aged 50-75 years of age. Women outside this age 
group may still access mammography, but the out-of-pocket expenses to do so will depend 
on their health insurance arrangements (all citizens are required to have health insurance). 
Approximately 84% of women invited to screening attend (Palencia et al, 2010). 
New Zealand 
Women aged 45-69 years are eligible to participate in screening in New Zealand, although 
the publicity materials emphasise that the greatest benefit is for women aged 50-69 years. 
For the two years up to December 2006, 60% of women aged 50-64 years had participated in 
screening, below the target of 70% and with high variation in participation between 
population groups (Thomson, Crengle & Lawrenson, 2009). Service delivery is devolved to 
eight regionally based lead providers, with funding responsibility the role of the central 
government. The private sector plays a key role in providing services. Women register for 
screening by phone or online. In some areas women are identified through general practice 
registers and are invited to screening. 
Norway 
Women aged 50-69 years are invited to be screened every two years. There are 26 stationary 
and 4 mobile screening units. The Central Population Registry of Norway is used to identify 
eligible women. Invitations are mailed to each eligible woman, suggesting a time for an 
appointment. Approximately 77% of all women invited participate do so (Kalager, et al, 
2010).  
Sweden 
Sweden’s central government has established mammography screening with delivery of 
mammography programs devolved to the 20 counties. While the two year screening interval 
is consistently applied, counties vary in whether women aged 40-49 years can access the 
program. The majority of counties invite women aged between 40-74 years to screening; six 
provinces invite women aged 50-69 years, and in a few cases the age range is slightly 
different again. Eligibility is based on the national population register. Screening is low cost, 
with women making a small co-payment for the service. The participation rate for women 
invited to screening is approximately 80% (Palencia et al, 2010). 
United States of America 
Guidelines for mammography screening in the Unites States of America emphasise the 
importance of clinical breast examination as well as mammography screening. While the 
Food and Drug Administration sets standards for mammography facilities, arrangements 
for screening are indicative of the health system more generally – where insurance coverage 
dictates recruitment and participation, and there is no organised national program beyond 
the setting of quality standards and guidelines for women. The United States Preventive 
TaskForce (2009) recommends mammography screening for women each two years 
commencing at age 50 years. Like the Australian policy context, the Taskforce emphasises 
that the decision to be screened between ages 40-49 years is an individual woman’s decision 
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and should be made taking account of personal beliefs about the benefits and harms. 
Various other stakeholders disagree with this advice and recommend screening from age 40 
years. Women participate in screening through their health maintenance or health insurance 
organisations (although most states mandate that insurance companies reimburse all or part 
of the cost of mammography for their members). Uninsured and low income women aged 
over 40 years who qualify for Medicare health insurance are able to access a screening 
mammogram each year (with eligibility for a baseline mammogram between 35-39 years) 
(National Cancer Institute, 2010).  
The selected international cases highlight the differences in policy in different health care 
settings. What is surprising is the level of scientific contention around the evidence 
particularly in relation to the magnitude of benefit for aged under 50 years. This plays out in 
differences within policy settings about women’s participation in mammography screening. 
This is illustrated more clearly in the following section which reports on interview studies 
with women in three different policy settings who chose to participate in mammography 
screening.  
4. Women’s choice to be screened – different policy settings, different 
choices? 
As previously stated, the age at which screening begins is a key site of policy difference, 
with the links between scientific evidence and policy knowledge unclear. The rest of this 
chapter focuses on this issue and explores the perspective of those women in different policy 
settings who have participated in screening programs while aged between 40-49 years. The 
aim is to highlight how embedded the policy context is in shaping what appears to be 
individual behaviour. Three policy settings have been chosen because their policy context 
differs for women aged 40-49 years. These three settings are two states in Australia and one 
county in Sweden. The first site is Tasmania. This island state is geographically isolated 
from the rest of Australia. It is a decentralised state. Of a total population of approximately 
476,000 people, approximately 60% live outside the capital city of Hobart. The second site is 
the state of Victoria. Less decentralised than Tasmania, it has a population of 5.1 million 
people with 3.7 million people living in the capital city of Melbourne, but an extensive 
regional and rural hinterland that comprises 1.4 million people. The third site is Uppsala, 
Sweden. With a total population of approximately 336,000 people, Uppsala is also quite 
decentralised, with 40% of the population residing outside its major municipality. 
The key difference between policy settings in Australia is whether they re-invite women in 
the 40-49 year age group once women have chosen to attend. As stated earlier, the 
Australian policy on screening targets women aged 50-69 years but allows women aged 40-
49 years to make an individual decision about whether to participate in screening. Tasmania 
has a policy of reinviting women once they have attended once. In the more populous state 
of Victoria, women are not reinvited – rather they must make the decision themselves as to 
whether they continue to participate in screening while they are in the 40-49 year age group. 
Another key difference between these two states, relates to jurisdictional issues. Health 
providers in Tasmania are unable to access the electoral roll to call women to screening once 
they turn 50 years of age, relying on public information campaigns to encourage women to 
participate, whereas Victoria recruits women using the electoral roll. In both Tasmania and 
Victoria, mammogram facilities are provided both at fixed sites and through mobile services 
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struggle to provide a biennial service to all women in the target age groups (Georgi et al., 
2009). 
Netherlands 
Mammography is provided for all women aged 50-75 years of age. Women outside this age 
group may still access mammography, but the out-of-pocket expenses to do so will depend 
on their health insurance arrangements (all citizens are required to have health insurance). 
Approximately 84% of women invited to screening attend (Palencia et al, 2010). 
New Zealand 
Women aged 45-69 years are eligible to participate in screening in New Zealand, although 
the publicity materials emphasise that the greatest benefit is for women aged 50-69 years. 
For the two years up to December 2006, 60% of women aged 50-64 years had participated in 
screening, below the target of 70% and with high variation in participation between 
population groups (Thomson, Crengle & Lawrenson, 2009). Service delivery is devolved to 
eight regionally based lead providers, with funding responsibility the role of the central 
government. The private sector plays a key role in providing services. Women register for 
screening by phone or online. In some areas women are identified through general practice 
registers and are invited to screening. 
Norway 
Women aged 50-69 years are invited to be screened every two years. There are 26 stationary 
and 4 mobile screening units. The Central Population Registry of Norway is used to identify 
eligible women. Invitations are mailed to each eligible woman, suggesting a time for an 
appointment. Approximately 77% of all women invited participate do so (Kalager, et al, 
2010).  
Sweden 
Sweden’s central government has established mammography screening with delivery of 
mammography programs devolved to the 20 counties. While the two year screening interval 
is consistently applied, counties vary in whether women aged 40-49 years can access the 
program. The majority of counties invite women aged between 40-74 years to screening; six 
provinces invite women aged 50-69 years, and in a few cases the age range is slightly 
different again. Eligibility is based on the national population register. Screening is low cost, 
with women making a small co-payment for the service. The participation rate for women 
invited to screening is approximately 80% (Palencia et al, 2010). 
United States of America 
Guidelines for mammography screening in the Unites States of America emphasise the 
importance of clinical breast examination as well as mammography screening. While the 
Food and Drug Administration sets standards for mammography facilities, arrangements 
for screening are indicative of the health system more generally – where insurance coverage 
dictates recruitment and participation, and there is no organised national program beyond 
the setting of quality standards and guidelines for women. The United States Preventive 
TaskForce (2009) recommends mammography screening for women each two years 
commencing at age 50 years. Like the Australian policy context, the Taskforce emphasises 
that the decision to be screened between ages 40-49 years is an individual woman’s decision 
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and should be made taking account of personal beliefs about the benefits and harms. 
Various other stakeholders disagree with this advice and recommend screening from age 40 
years. Women participate in screening through their health maintenance or health insurance 
organisations (although most states mandate that insurance companies reimburse all or part 
of the cost of mammography for their members). Uninsured and low income women aged 
over 40 years who qualify for Medicare health insurance are able to access a screening 
mammogram each year (with eligibility for a baseline mammogram between 35-39 years) 
(National Cancer Institute, 2010).  
The selected international cases highlight the differences in policy in different health care 
settings. What is surprising is the level of scientific contention around the evidence 
particularly in relation to the magnitude of benefit for aged under 50 years. This plays out in 
differences within policy settings about women’s participation in mammography screening. 
This is illustrated more clearly in the following section which reports on interview studies 
with women in three different policy settings who chose to participate in mammography 
screening.  
4. Women’s choice to be screened – different policy settings, different 
choices? 
As previously stated, the age at which screening begins is a key site of policy difference, 
with the links between scientific evidence and policy knowledge unclear. The rest of this 
chapter focuses on this issue and explores the perspective of those women in different policy 
settings who have participated in screening programs while aged between 40-49 years. The 
aim is to highlight how embedded the policy context is in shaping what appears to be 
individual behaviour. Three policy settings have been chosen because their policy context 
differs for women aged 40-49 years. These three settings are two states in Australia and one 
county in Sweden. The first site is Tasmania. This island state is geographically isolated 
from the rest of Australia. It is a decentralised state. Of a total population of approximately 
476,000 people, approximately 60% live outside the capital city of Hobart. The second site is 
the state of Victoria. Less decentralised than Tasmania, it has a population of 5.1 million 
people with 3.7 million people living in the capital city of Melbourne, but an extensive 
regional and rural hinterland that comprises 1.4 million people. The third site is Uppsala, 
Sweden. With a total population of approximately 336,000 people, Uppsala is also quite 
decentralised, with 40% of the population residing outside its major municipality. 
The key difference between policy settings in Australia is whether they re-invite women in 
the 40-49 year age group once women have chosen to attend. As stated earlier, the 
Australian policy on screening targets women aged 50-69 years but allows women aged 40-
49 years to make an individual decision about whether to participate in screening. Tasmania 
has a policy of reinviting women once they have attended once. In the more populous state 
of Victoria, women are not reinvited – rather they must make the decision themselves as to 
whether they continue to participate in screening while they are in the 40-49 year age group. 
Another key difference between these two states, relates to jurisdictional issues. Health 
providers in Tasmania are unable to access the electoral roll to call women to screening once 
they turn 50 years of age, relying on public information campaigns to encourage women to 
participate, whereas Victoria recruits women using the electoral roll. In both Tasmania and 
Victoria, mammogram facilities are provided both at fixed sites and through mobile services 
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to rural areas. By contrast, the Swedish county of Uppsala actively invites women to 
screening at age 40 years, with a recruitment letter giving an appointment date and time for 
individual women to attend.  
Of particular interest in this study was the decision making that rural women participated in 
when they decided to have a mammogram when aged 40-49 years. Rurality has been linked 
with poorer health outcomes and a key concern to policy makers in decentralised countries 
is how to best serve small populations in rural areas (Palmer and Short, 2010: 274). In each of 
the three policy settings examined, an emphasis has been placed on encouraging rural 
women’s access either through mobile services (Tasmania and Victoria) or by locating 
mammography at smaller regional centres (Uppsala). Exploratory research in Tasmania 
found that screening rates in the 40-49 year age group were substantially above those 
estimated by BreastScreen Australia and in the Victorian setting were significantly lower. 
This indicates that perhaps some other factors related to rurality and the provision of 
services might be important in understanding women’s decisions about mammography.  
In order to examine women’s decision making about mammography screening in these 
three different contexts, a qualitative study was designed. Using an interpretive 
methodological approach and a purposive sampling strategy, semi-structured interviews 
were conducted with women who had participated in mammography screening between 
the ages of 40-49 years. The interview schedule was in four sections. First, demographic 
information was obtained. Women were then asked about their ideas about health generally 
– the importance of health, and whether they took steps to maintain health. They were then 
asked about their screening history, their reasons for choosing to be screened, their ideas 
about mammography screening and their knowledge of contemporary debates about the 
age at which screening should commence. Finally, they were presented with some 
statements about mammography screening and asked whether they agreed or disagreed 
with them. These Likert questions were derived from the exploratory study originally 
carried out with women in the Tasmanian site (Willis and Baxter, 2003). While all questions 
(apart from the Likert scale questions) were open-ended enabling participants to reveal as 
much or as little as they wished, the schedule was designed to elicit responses from the 
broad ideas about health to specific information about their screening experiences. Where 
answers were unclear, additional probing questions were asked.  
The interviews were audiotaped and transcribed verbatim. Analysis commenced with 
transcription of the first interview, ensuring that interviews were flexible enough to capture 
the important issues at each site. This was particularly important for those interviews 
carried out in Uppsala (see below). In both the Australian settings, the Chief Investigator 
interviewed all participants. In the Swedish study, the process differed a little because of the 
reliance on a Swedish interviewer (five interviews were conducted in English) and 
translation into English. This required attention to the ways that words and phrases are 
given meaning in the Swedish cultural context and how they could be best understood in 
English. 
Interviews were analysed using a thematic analytical approach that incorporated both 
inductive and deductive elements. As the interview schedule had specific questions 
(outlined above), themes relating to reasons for attending were initially deductively derived 
from the data, but the contextual information presented by participants then allowed 
inductive exploration of these themes. Following transcription, each transcript was read, re-
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read and sections coded. Transcripts were then compared to find similarities and differences 
between responses. This then enabled the sorting of responses into categories. Further 
immersion in the data enabled the identification of themes relating to social and cultural 
ideas about knowledge and trust. 
Ethics approval for the study was obtained from the Human Research Ethics Committee, 
University of Tasmania for the Tasmanian and Victorian cohorts and the Research Ethics 
Committee, Uppsala University for the Swedish cohort. 
Study Site 1: Tasmania, Australia 
This research was informed by findings from a pilot study of 14 women in small rural sites 
on the east coast of Tasmania (Willis and Baxter, 2003). The Tasmanian cohort comprised 22 
women located at four small rural sites on the north west coast of Tasmania - a 
geographically isolated area of Tasmania. These small geographic locations are serviced 
each two years by a mobile breast screening service. Women were recruited to the study 
through advertising in local newspapers and posters at local health centres. Characteristics 
of the women who chose to participate in this study have been reported elsewhere (Willis, 
2004). Women were aged between 43 and 52 years at the time of the interview. All had 
participated in screening prior to turning 50 years of age. All but four had been re-screened 
at least once. Of the four who had not been re-screened, two had decided against screening 
at least until they were age 50, one was not due to be re-screened, and one was currently 
unable to access the problem as she was receiving treatment for breast cancer (detected 
through the screening program).  
In exploring the key reasons for deciding to be screened, participants were categorised into 
two groups, each with equal numbers. Women in the first group were characterised as ‘high 
risk/high fear’. They perceived they were at elevated risk of breast cancer and this was a 
key factor in choosing to participate in mammography screening. Five participants believed 
this was the case because they had ‘cancer in the family’, five other participants had a 
previous history of benign breast conditions and saw themselves as higher risk of breast 
cancer, and one participant was included in this group because she was ‘just terrified of 
getting breast cancer’. 
The second group were those participants characterised as ‘low risk/low fear’. This group of 
women saw themselves as having low or no risk of breast cancer but believed it was 
important to take advantage of the screening service anyway. They were most likely to see 
the service as providing an important health opportunity and it was their responsibility to 
take advantage of it. The opportunistic decision can be encapsulated in this quote:  
Well, its a free test and I might as well use it. I’ll do anything if its concerned with health ... I thought 
I might as well get in early. 
Participants in this ‘low risk/low fear’ group did not see themselves as at high risk of 
getting cancer. In fact many of them stated that they didn’t think they would ever get 
cancer. However, they argued that it was important to take any precaution that was 
available to them. For some, screening was a way of ‘exercising control’ over their health.  
Across both groups two key themes were important. These were the high level of ‘trust in 
technology’ and the notion of ‘individual responsibility’. Inherent in this latter theme was 
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to rural areas. By contrast, the Swedish county of Uppsala actively invites women to 
screening at age 40 years, with a recruitment letter giving an appointment date and time for 
individual women to attend.  
Of particular interest in this study was the decision making that rural women participated in 
when they decided to have a mammogram when aged 40-49 years. Rurality has been linked 
with poorer health outcomes and a key concern to policy makers in decentralised countries 
is how to best serve small populations in rural areas (Palmer and Short, 2010: 274). In each of 
the three policy settings examined, an emphasis has been placed on encouraging rural 
women’s access either through mobile services (Tasmania and Victoria) or by locating 
mammography at smaller regional centres (Uppsala). Exploratory research in Tasmania 
found that screening rates in the 40-49 year age group were substantially above those 
estimated by BreastScreen Australia and in the Victorian setting were significantly lower. 
This indicates that perhaps some other factors related to rurality and the provision of 
services might be important in understanding women’s decisions about mammography.  
In order to examine women’s decision making about mammography screening in these 
three different contexts, a qualitative study was designed. Using an interpretive 
methodological approach and a purposive sampling strategy, semi-structured interviews 
were conducted with women who had participated in mammography screening between 
the ages of 40-49 years. The interview schedule was in four sections. First, demographic 
information was obtained. Women were then asked about their ideas about health generally 
– the importance of health, and whether they took steps to maintain health. They were then 
asked about their screening history, their reasons for choosing to be screened, their ideas 
about mammography screening and their knowledge of contemporary debates about the 
age at which screening should commence. Finally, they were presented with some 
statements about mammography screening and asked whether they agreed or disagreed 
with them. These Likert questions were derived from the exploratory study originally 
carried out with women in the Tasmanian site (Willis and Baxter, 2003). While all questions 
(apart from the Likert scale questions) were open-ended enabling participants to reveal as 
much or as little as they wished, the schedule was designed to elicit responses from the 
broad ideas about health to specific information about their screening experiences. Where 
answers were unclear, additional probing questions were asked.  
The interviews were audiotaped and transcribed verbatim. Analysis commenced with 
transcription of the first interview, ensuring that interviews were flexible enough to capture 
the important issues at each site. This was particularly important for those interviews 
carried out in Uppsala (see below). In both the Australian settings, the Chief Investigator 
interviewed all participants. In the Swedish study, the process differed a little because of the 
reliance on a Swedish interviewer (five interviews were conducted in English) and 
translation into English. This required attention to the ways that words and phrases are 
given meaning in the Swedish cultural context and how they could be best understood in 
English. 
Interviews were analysed using a thematic analytical approach that incorporated both 
inductive and deductive elements. As the interview schedule had specific questions 
(outlined above), themes relating to reasons for attending were initially deductively derived 
from the data, but the contextual information presented by participants then allowed 
inductive exploration of these themes. Following transcription, each transcript was read, re-
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read and sections coded. Transcripts were then compared to find similarities and differences 
between responses. This then enabled the sorting of responses into categories. Further 
immersion in the data enabled the identification of themes relating to social and cultural 
ideas about knowledge and trust. 
Ethics approval for the study was obtained from the Human Research Ethics Committee, 
University of Tasmania for the Tasmanian and Victorian cohorts and the Research Ethics 
Committee, Uppsala University for the Swedish cohort. 
Study Site 1: Tasmania, Australia 
This research was informed by findings from a pilot study of 14 women in small rural sites 
on the east coast of Tasmania (Willis and Baxter, 2003). The Tasmanian cohort comprised 22 
women located at four small rural sites on the north west coast of Tasmania - a 
geographically isolated area of Tasmania. These small geographic locations are serviced 
each two years by a mobile breast screening service. Women were recruited to the study 
through advertising in local newspapers and posters at local health centres. Characteristics 
of the women who chose to participate in this study have been reported elsewhere (Willis, 
2004). Women were aged between 43 and 52 years at the time of the interview. All had 
participated in screening prior to turning 50 years of age. All but four had been re-screened 
at least once. Of the four who had not been re-screened, two had decided against screening 
at least until they were age 50, one was not due to be re-screened, and one was currently 
unable to access the problem as she was receiving treatment for breast cancer (detected 
through the screening program).  
In exploring the key reasons for deciding to be screened, participants were categorised into 
two groups, each with equal numbers. Women in the first group were characterised as ‘high 
risk/high fear’. They perceived they were at elevated risk of breast cancer and this was a 
key factor in choosing to participate in mammography screening. Five participants believed 
this was the case because they had ‘cancer in the family’, five other participants had a 
previous history of benign breast conditions and saw themselves as higher risk of breast 
cancer, and one participant was included in this group because she was ‘just terrified of 
getting breast cancer’. 
The second group were those participants characterised as ‘low risk/low fear’. This group of 
women saw themselves as having low or no risk of breast cancer but believed it was 
important to take advantage of the screening service anyway. They were most likely to see 
the service as providing an important health opportunity and it was their responsibility to 
take advantage of it. The opportunistic decision can be encapsulated in this quote:  
Well, its a free test and I might as well use it. I’ll do anything if its concerned with health ... I thought 
I might as well get in early. 
Participants in this ‘low risk/low fear’ group did not see themselves as at high risk of 
getting cancer. In fact many of them stated that they didn’t think they would ever get 
cancer. However, they argued that it was important to take any precaution that was 
available to them. For some, screening was a way of ‘exercising control’ over their health.  
Across both groups two key themes were important. These were the high level of ‘trust in 
technology’ and the notion of ‘individual responsibility’. Inherent in this latter theme was 
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the importance of having ‘good health habits’ with mammography being seen as something 
that should become a health habit in taking responsibility for health and wellbeing.  
In indicating a high level of trust in technology, some women drew on their lack of 
confidence in their capacity to perform breast self examination, and this was a factor in 
deciding to participate in screening. Having a test and using technology were presented as 
unproblematic and, generally, certain ways of defining one’s health status. The view of 
technology and testing that is portrayed through these interviews is of a benign test with the 
main benefit of confirming one’s healthy state. Only three of the participants discussed 
whether the technology could be fallible. Participants indicated that they had a high level of 
trust in the technology as a means by which they could obtain reassurance and confirmation 
of their good health. As one participant said: 
The good thing about having the mammogram is that its reassuring. It tells us of any change, if its 
fine, you know its fine... I never think of it as having a down-side because the results are too 
important  
Even where participants reflected on the possibility of having additional testing due to a 
false positive mammography result, the prevailing view was that such testing was essential 
in the process of confirming one’s healthy state. 
Participants also saw themselves as taking responsibility for their health. They saw the 
choice to be screened as part of their ‘good health practices’ that were important indicators 
that they were taking care of themself. Mammography co-existed with a range of practices 
they engaged in, from their annual check up with their general practitioner, to ensuring that 
they got sufficient exercise and had a healthy diet, to low levels of ‘risk behaviours’ such as 
smoking or excessive alcohol consumption. They thus saw themselves as engaging in a 
‘good health habit’ and that it was important to get into this habit before the age of 50. 
Participants believed that they were more in tune with their bodies at a younger age, and 
that it would be more difficult to ‘get into the habit’ once they were older. If it was a routine 
aspect of their health care that was entrenched in their health practices, this was seen as 
beneficial. For example: 
I thought, I’ll get started now and it won’t be so scary when I am 50... Yes, getting myself into the 
habit so that once I was 50 at least I was already in that habit, it wasn’t something that I had to 
consciously take that other decision and another step to go along. 
It’s good to get into a routine ... Because it means it becomes a part of your life, rather than just 
something you remember maybe three years later ... it becomes a routine, it becomes part of your life. 
It’s a safety net, I suppose.  
In discussing why they had chosen to be screened even though the target group was from 
age 50-69 years, participants discussed their belief that there was an increased number of 
younger women getting cancer, and that the age limit should be lowered. Indeed, what they 
perceived as the arbitrary nature of the age limit also meant that they should be able to 
exercise choice. Participants emphasised the importance of ‘making up their own minds’ 
about participation.  
It depends whose opinion you listen to ... I’ll just follow my own thoughts... Its a service thats there 
for me every two years and I am not interested in different opinions and different flavours of the day 
because of the changes on a weekly basis... I suppose the chance of women over 50 getting cancer [is 
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higher] ... I don’t know what they base their figures on. Women younger than that are getting breast 
cancer. So I don’t know whether they should have an age. I think they should make it free for all if you 
want to have the screening done. That’s the service there for you irrespective of your age and it should 
be free. 
Study Site 2: Victoria, Australia 
The notion of choice in the decision to be screened has a different dimension for women in 
the state of Victoria. Because they are not re-invited once they have participated, women 
aged 40-49 years at this policy site must ‘re-make’ the decision to be screened each two years 
until they turn 50 years of age. The Victorian participants in this study comprised 28 women 
located at two regional sites in rural Victoria. The average participation rate for women in 
this age group choosing to attend for screening is low in comparison with the Tasmanian 
study sites (at the time of this study between 10% and 13%). Two regional sites where there 
were sufficient numbers of women to gain a diverse sample aged between 40-49 years who 
had participated in screening were identified. These regional centres were located 
approximately 100 kilometres from the capital city. Local media and health services were 
enlisted to advertise the project and women contacted the researcher directly if they wished 
to participate in the interview study.  
While most of the Tasmanian cohort emphasised choice and were opportunistic in their 
reasons for attending screening, differences in the Victorian cohort were readily apparent. 
With a much lower percentage of women in this age group attending for screening than the 
population centres in Tasmania, what emerged are clear reasons for concern about breast 
cancer and the need to exercise their right to be screened. That this was a political decision 
was evident in one participant’s account of seeing a poster advertising the mobile service for 
women aged 50 years and above and someone had crossed out 50 and replaced it with ‘40’, 
thus alerting her to the possibility that she could also attend.  
The two categories of risk perception and decision making found in the Tasmanian cohort 
did not adequately capture this more complex decision making in this policy context. Thus, 
in terms of primary reason for attending mammography screening there were four 
categories that encapsulate this initial decision.  
1. Opportunistic – similar to the low risk/low fear group in the Tasmanian cohort, six 
women described initially attending because the service was available and so they 
believed they should use it. Of these participants, 1 also participated because she was 
‘close in age to 50 years’ and one also discussed having a family member who had 
experienced a benign growth removed from her breast. While they had attended the 
screening service because it was available, these two participants also discussed these 
factors as contributing to their decision.  
2. Family history and fear of cancer – For seven women the fact that they had a ‘family 
history’ of cancer (not necessarily breast cancer) was the primary reason that they 
decided to attend for screening. This was the only group that perceived themselves as 
‘high risk’ of cancer themselves, and thus were similar to the ‘high risk/high fear group 
in the Tasmanian cohort. 
3. Having indirect experience of cancer through knowing a close friend who had 
experienced breast cancer prompted three women to attend for screening when it was 
available. They did not believe that they were at high risk of getting breast cancer, but 
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the importance of having ‘good health habits’ with mammography being seen as something 
that should become a health habit in taking responsibility for health and wellbeing.  
In indicating a high level of trust in technology, some women drew on their lack of 
confidence in their capacity to perform breast self examination, and this was a factor in 
deciding to participate in screening. Having a test and using technology were presented as 
unproblematic and, generally, certain ways of defining one’s health status. The view of 
technology and testing that is portrayed through these interviews is of a benign test with the 
main benefit of confirming one’s healthy state. Only three of the participants discussed 
whether the technology could be fallible. Participants indicated that they had a high level of 
trust in the technology as a means by which they could obtain reassurance and confirmation 
of their good health. As one participant said: 
The good thing about having the mammogram is that its reassuring. It tells us of any change, if its 
fine, you know its fine... I never think of it as having a down-side because the results are too 
important  
Even where participants reflected on the possibility of having additional testing due to a 
false positive mammography result, the prevailing view was that such testing was essential 
in the process of confirming one’s healthy state. 
Participants also saw themselves as taking responsibility for their health. They saw the 
choice to be screened as part of their ‘good health practices’ that were important indicators 
that they were taking care of themself. Mammography co-existed with a range of practices 
they engaged in, from their annual check up with their general practitioner, to ensuring that 
they got sufficient exercise and had a healthy diet, to low levels of ‘risk behaviours’ such as 
smoking or excessive alcohol consumption. They thus saw themselves as engaging in a 
‘good health habit’ and that it was important to get into this habit before the age of 50. 
Participants believed that they were more in tune with their bodies at a younger age, and 
that it would be more difficult to ‘get into the habit’ once they were older. If it was a routine 
aspect of their health care that was entrenched in their health practices, this was seen as 
beneficial. For example: 
I thought, I’ll get started now and it won’t be so scary when I am 50... Yes, getting myself into the 
habit so that once I was 50 at least I was already in that habit, it wasn’t something that I had to 
consciously take that other decision and another step to go along. 
It’s good to get into a routine ... Because it means it becomes a part of your life, rather than just 
something you remember maybe three years later ... it becomes a routine, it becomes part of your life. 
It’s a safety net, I suppose.  
In discussing why they had chosen to be screened even though the target group was from 
age 50-69 years, participants discussed their belief that there was an increased number of 
younger women getting cancer, and that the age limit should be lowered. Indeed, what they 
perceived as the arbitrary nature of the age limit also meant that they should be able to 
exercise choice. Participants emphasised the importance of ‘making up their own minds’ 
about participation.  
It depends whose opinion you listen to ... I’ll just follow my own thoughts... Its a service thats there 
for me every two years and I am not interested in different opinions and different flavours of the day 
because of the changes on a weekly basis... I suppose the chance of women over 50 getting cancer [is 
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higher] ... I don’t know what they base their figures on. Women younger than that are getting breast 
cancer. So I don’t know whether they should have an age. I think they should make it free for all if you 
want to have the screening done. That’s the service there for you irrespective of your age and it should 
be free. 
Study Site 2: Victoria, Australia 
The notion of choice in the decision to be screened has a different dimension for women in 
the state of Victoria. Because they are not re-invited once they have participated, women 
aged 40-49 years at this policy site must ‘re-make’ the decision to be screened each two years 
until they turn 50 years of age. The Victorian participants in this study comprised 28 women 
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women described initially attending because the service was available and so they 
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3. Having indirect experience of cancer through knowing a close friend who had 
experienced breast cancer prompted three women to attend for screening when it was 
available. They did not believe that they were at high risk of getting breast cancer, but 
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knowing someone who had experienced the disease heightened their awareness of the 
importance of screening tests such as mammography. 
4. The largest group were those who had previously had mammograms for diagnostic 
reasons. Twelve women had either had a prior history of benign breast conditions or 
they had other symptoms that had required a mammogram, and when the screening 
service was available in their region after these events, they took the opportunity to be 
screened while still in their 40s. Many women in this group had also participated in 
‘well women’s checks’ run by a private screening service at the capital city, and this had 
included mammography, so they had a high awareness of being screened for breast 
cancer. Most interestingly and in contrast to the Tasmanian participants, this group also 
did not perceive that they were at high risk of breast cancer, despite their having had 
previous breast problems. 
As with the Tasmanian participants, in this group there were also strong views about the 
power of technology. Mammography was viewed as preferable to breast self examination or 
a clinical examination by a medical professional. For example:  
I think the visual thing is more comforting and reassuring than someone doing a breast examination 
on you and saying you’re fine. That’s their opinion, but if its in an x-ray, you can actually see it and 
somebody’s looked at it, and if you’re give the all clear, well you think, that’s peace of mind.  
Just peace of mind, I suppose. It’s something that you can do quickly and cheaply and it lets you off 
the hook. You think, oh well, I’m OK, I’ve had that test done. I don’t need to bother doing the arm up 
behind my head [breast self examination].  
Reassurance and peace of mind were the key advantages of mammography discussed by 
participants. Almost all participants used these words to describe how they felt about 
mammography.  
With regard to policy differences (and the fact that the policy in Victoria required women to 
take responsibility each two years to participate in screening), participants generally 
believed that women should take responsibility for their health, but also added and ‘it 
would be nice to be notified’ when they were due for rescreening. With regard to women’s 
responsibility, illustrative statements include:  
Women should be interested enough in their own bodies to want to remember.  
I would imagine that women who are concerned about their health would at least make some sort of 
note of when they’d be due again and do it themselves without having to be reminded 
The complexity of a policy focused on age as defining eligibility was problematised by 
women. When asked if they knew why the screening program targeted women aged 50 
years and over, about half the group had some awareness of the links between cancer and 
age. Many, however, believed that cancer and age were not necessarily related, but that 
women of any age could get breast cancer. Moreover of those women who mentioned the 
links between cancer and age, some expressed some uncertainty about this link as it 
contradicted their experiential knowledge gained through local communities and the media. 
There was some discussion of media coverage of young celebrities who had breast cancer, 
contributing to the belief that breast cancer is also a young women’s disease. The ideas 
about age and risk were encapsulated in statements such as:  
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There is no firm statistic to say it is always over 50 years that you get breast cancer. I mean there are 
women in their 20s getting it. And age holds no barrier on this.  
It doesn’t have to be any particular age, it can be any age that you can get breast cancer. You can be 
in your 20s, 30s or 50s whatever… Breast cancer is something that can happen any time. 
But I still think it should be encouraged for women who are under 40 because I think that some of 
those ones…could have a problem picked up earlier. It might be too late by the time they’re 50. 
Study Site 3: Uppsala, Sweden 
The Swedish cohort comprised 32 women attending for screening at two rural sites in 
Uppsala. All women aged between 40-49 years who were scheduled to attend 
mammography screening at two decentralised centres in Uppsala county in a one week 
period in August 2003 were invited to participate in the study. Women were advised about 
the study with an additional insert in their recruitment to screening letter. Participants 
ranged in age from 40 to 50 years.  
Most women had attended mammography screening three or more times, some having 
attended prior turning 40 years of age (for diagnostic reasons). Four participants from one of 
the two sites were attending for the first time, having turned 40 years of age during the past 
year. Participants were asked their reason for attending. The key initial finding that relates 
to the policy context was that, unlike the two other settings, participants did not and could 
not discuss participation in mammography screening as a matter of choice. Hence the title of 
the main findings paper from this part of the study ‘I come because I was called’ (Willis, 
2008). This was, in essence, the reason why they had participated – the health authorities 
had called them to attend and they did so. Twenty-seven of the 32 participants included this 
reason in their response to the question about why they first attended. They described this 
in terms of a ‘good offer’. The way participants felt about being called can be summarised by 
the response of one participant: 
I got called and then, in my opinion, there was nothing to decide about. It was just to go there. This is 
the sort of thing, make sure to go when you get such a chance. That’s how I think. There’s nothing to 
discuss really. 
As this response started to emerge as a consistent trend, participants were asked: ‘if you 
were not called, would you attend?’ Most women replied that they would not attend unless 
they thought they had a symptom that should be investigated, for example, a lump in the 
breast. Those participants who answered that they would attend without being called drew 
on reason such as family history of or being ‘that kind of personality that likes to take 
control’. These responses illustrate how an organised and targeted program for women 
works in a policy setting where there is a high degree of trust in medical authorities. In a 
climate of trust, people are happier for those in authority to make decisions. Some women 
described themselves, and the Swedish culture, as being obeying. So if the call to be 
screened came, women did not have to think about the decision. Even the fact that they did 
not have to make the appointment time themselves was important.  
Again women’s risk perception did not really affect their decision to attend. All but four 
believed that they were at low risk of having breast cancer, although, unlike the other 
cohorts, they were more likely to acknowledge the uncertainty of risk assessment. For 
example, participants made comments such as:  
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With regard to policy differences (and the fact that the policy in Victoria required women to 
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believed that women should take responsibility for their health, but also added and ‘it 
would be nice to be notified’ when they were due for rescreening. With regard to women’s 
responsibility, illustrative statements include:  
Women should be interested enough in their own bodies to want to remember.  
I would imagine that women who are concerned about their health would at least make some sort of 
note of when they’d be due again and do it themselves without having to be reminded 
The complexity of a policy focused on age as defining eligibility was problematised by 
women. When asked if they knew why the screening program targeted women aged 50 
years and over, about half the group had some awareness of the links between cancer and 
age. Many, however, believed that cancer and age were not necessarily related, but that 
women of any age could get breast cancer. Moreover of those women who mentioned the 
links between cancer and age, some expressed some uncertainty about this link as it 
contradicted their experiential knowledge gained through local communities and the media. 
There was some discussion of media coverage of young celebrities who had breast cancer, 
contributing to the belief that breast cancer is also a young women’s disease. The ideas 
about age and risk were encapsulated in statements such as:  
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There is no firm statistic to say it is always over 50 years that you get breast cancer. I mean there are 
women in their 20s getting it. And age holds no barrier on this.  
It doesn’t have to be any particular age, it can be any age that you can get breast cancer. You can be 
in your 20s, 30s or 50s whatever… Breast cancer is something that can happen any time. 
But I still think it should be encouraged for women who are under 40 because I think that some of 
those ones…could have a problem picked up earlier. It might be too late by the time they’re 50. 
Study Site 3: Uppsala, Sweden 
The Swedish cohort comprised 32 women attending for screening at two rural sites in 
Uppsala. All women aged between 40-49 years who were scheduled to attend 
mammography screening at two decentralised centres in Uppsala county in a one week 
period in August 2003 were invited to participate in the study. Women were advised about 
the study with an additional insert in their recruitment to screening letter. Participants 
ranged in age from 40 to 50 years.  
Most women had attended mammography screening three or more times, some having 
attended prior turning 40 years of age (for diagnostic reasons). Four participants from one of 
the two sites were attending for the first time, having turned 40 years of age during the past 
year. Participants were asked their reason for attending. The key initial finding that relates 
to the policy context was that, unlike the two other settings, participants did not and could 
not discuss participation in mammography screening as a matter of choice. Hence the title of 
the main findings paper from this part of the study ‘I come because I was called’ (Willis, 
2008). This was, in essence, the reason why they had participated – the health authorities 
had called them to attend and they did so. Twenty-seven of the 32 participants included this 
reason in their response to the question about why they first attended. They described this 
in terms of a ‘good offer’. The way participants felt about being called can be summarised by 
the response of one participant: 
I got called and then, in my opinion, there was nothing to decide about. It was just to go there. This is 
the sort of thing, make sure to go when you get such a chance. That’s how I think. There’s nothing to 
discuss really. 
As this response started to emerge as a consistent trend, participants were asked: ‘if you 
were not called, would you attend?’ Most women replied that they would not attend unless 
they thought they had a symptom that should be investigated, for example, a lump in the 
breast. Those participants who answered that they would attend without being called drew 
on reason such as family history of or being ‘that kind of personality that likes to take 
control’. These responses illustrate how an organised and targeted program for women 
works in a policy setting where there is a high degree of trust in medical authorities. In a 
climate of trust, people are happier for those in authority to make decisions. Some women 
described themselves, and the Swedish culture, as being obeying. So if the call to be 
screened came, women did not have to think about the decision. Even the fact that they did 
not have to make the appointment time themselves was important.  
Again women’s risk perception did not really affect their decision to attend. All but four 
believed that they were at low risk of having breast cancer, although, unlike the other 
cohorts, they were more likely to acknowledge the uncertainty of risk assessment. For 
example, participants made comments such as:  
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I think I am at low, risk, but you never know. 
I don’t think I am [at risk], but you never know. My mother hasn’t got it. But of course, I could get it 
anyway’.  
Family history was perceived as being the most common indicator of high risk, so responses 
to questions about risk tended to be discussed in this way. For example, when talking about 
the links between being at low risk and family history, participants made comments such as:  
I don’t know, but not on my parents, or grandmother, nobody has breast cancer.  
No, no, in our family, we have more cervical cancer. 
When asked about the best thing about having a mammogram, participants in this cohort 
also differed slightly from the two Australian cohorts where the key response was ‘peace of 
mind that there was no breast cancer’. While the theme of ‘peace of mind’ (expressed as 
reassurance, or safety/security in this group) was identified as important, women in this 
cohort were more likely to identify that the best thing about mammography was the 
possibility of having breast cancer detected earlier, and therefore there was greater potential 
for treatment and cure’.  As the following participants said: 
You get to know if you have breast cancer. 
If something has happened you get to know it at an early stage.  
Women were asked about their awareness of the policy differences between different 
counties. The interviewer presented this difference as follows: ‘Uppsala calls women when 
they are aged 40, but Stockholm calls women when they are aged 50 – do you know why 
this might be the case?’. Sixteen participants were not aware of the debates about age and 
were quite shocked, didn’t believe that such a difference existed or were appreciative of the 
policy as enacted in their own community. Indicative responses are as follows: 
I think its crazy that they don’t have the same focus on women under 50, the earlier the better. 
I knew that everyone is called when you get 40, its all of Sweden I think. 
Oh, I didn’t know that. Then we’re really spoiled here.   
Ten participants discussed being aware that there had been some debates in the media 
about the age debate with four of these discussing that this may be because the risk of breast 
cancer increases with age, but even then comments were made such as: 
Probably you are at higher risk when you are older. I guess that’s a fact, but it can’t hurt to start 
earlier. 
This discussion was reiterated by 12 other participants who argued that the age should be 
lower, primarily because they had known someone under 50 years with breast cancer with 
some participants arguing that breast cancer was ‘spreading down in age’. Others 
mentioned that the decision must be purely based on economic reasons (9 participants) and 
were concerned that women in this age group weren’t being screened.   
5. Discussion - key ideas and policy discourses 
Sociological ideas about choice, risk and trust can shed light on the participation decisions 
that women make about attending for mammography screening. The notion of ‘choice’ is 
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particularly relevant in the Australian context, because the policy for women aged 40-49 
years is predicated on individual women making the choice about whether to participate in 
screening. Here the emphasis is on women being well informed and having the capacity to 
make choice, in contrast to women aged 50-69 years where the state takes more of a role in 
facilitating their participation in screening. It is interesting to reflect on this policy emphasis 
on choice, as the state takes more of a passive role because of the much higher level of 
uncertainty about evidence of benefit, handing the decision back to individuals.  
These ideas are particularly relevant in considering the scientific and public uncertainty 
about screening in this age group, the popular discourse that the incidence of breast cancer 
is rising in this age group, and media coverage of young women’s battles with breast cancer 
(in Australia, Kylie Minogue, a celebrity figure was diagnosed with breast cancer in her 30s; 
similarly, actress Belinda Emmett died from the illness, and Jane McGrath, the wife of 
popular cricketer, Glenn McGrath, died from the illness, but has remained in the public eye 
through media coverage of her husband’s commitment to raising funds for better care of 
women with breast cancer).  
While the key themes of trust, risk and choice emerge across all three cohorts in this study 
they are differently emphasised according to the policy settings. Perceptions of risk alone 
cannot explain why different factors emerge in differing policy sectors. Alongside ‘system 
trust’ which was important in the Swedish example, there is also the emergence of 
uncertainty about age and breast cancer. This is important in the two Australian sites, but 
particularly in relation to the Victorian case. Here in the context of uncertainty women need 
to draw on a rights-based discourse in order to protect their entitlement to be screened. The 
ideas around choice and community action are particularly important in the Tasmanian 
context – they are re-invited each two years once they have decided to attend, so their 
entitlement to the service is less fragile than their Victorian counterparts, but they are aware 
of the social consequences for choosing or not choosing to use the service. The importance of 
the local service emerged as a theme across each of the settings.  
The presence of the breast screening mobile service is highly visible and the service is well 
advertised through local networks and local media, suggesting that there becomes a strong 
social encouragement among the community networks to attend while it is there. This was 
evident in both the Tasmanian and Victorian cohorts. Women were asked about what advice 
they would give to a friend and the strength of their answers was surprising with all but 
four participants in the Tasmanian cohort stating that they would actively encourage their 
friends to attend. For example, women in the Tasmania cohort said: 
Essential. As soon as someone turns 40 I tell them to go. 
Since I’ve been going for screening, I’ve been jumping on people to do that as well. 
Yes, I’d say, “Come on, we’ll go together and we’ll do lunch”. I’d encourage them. 
Location in a rural setting was linked to participation for women across all three cohorts. In 
this way, participation was screening was identified as a community action. People in rural 
centres are acutely aware that when services are provided they must use them, otherwise 
they risk losing them. As one Victorian participant stated when asked if it was important to 
use services like the mobile screening van:  
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on choice, as the state takes more of a passive role because of the much higher level of 
uncertainty about evidence of benefit, handing the decision back to individuals.  
These ideas are particularly relevant in considering the scientific and public uncertainty 
about screening in this age group, the popular discourse that the incidence of breast cancer 
is rising in this age group, and media coverage of young women’s battles with breast cancer 
(in Australia, Kylie Minogue, a celebrity figure was diagnosed with breast cancer in her 30s; 
similarly, actress Belinda Emmett died from the illness, and Jane McGrath, the wife of 
popular cricketer, Glenn McGrath, died from the illness, but has remained in the public eye 
through media coverage of her husband’s commitment to raising funds for better care of 
women with breast cancer).  
While the key themes of trust, risk and choice emerge across all three cohorts in this study 
they are differently emphasised according to the policy settings. Perceptions of risk alone 
cannot explain why different factors emerge in differing policy sectors. Alongside ‘system 
trust’ which was important in the Swedish example, there is also the emergence of 
uncertainty about age and breast cancer. This is important in the two Australian sites, but 
particularly in relation to the Victorian case. Here in the context of uncertainty women need 
to draw on a rights-based discourse in order to protect their entitlement to be screened. The 
ideas around choice and community action are particularly important in the Tasmanian 
context – they are re-invited each two years once they have decided to attend, so their 
entitlement to the service is less fragile than their Victorian counterparts, but they are aware 
of the social consequences for choosing or not choosing to use the service. The importance of 
the local service emerged as a theme across each of the settings.  
The presence of the breast screening mobile service is highly visible and the service is well 
advertised through local networks and local media, suggesting that there becomes a strong 
social encouragement among the community networks to attend while it is there. This was 
evident in both the Tasmanian and Victorian cohorts. Women were asked about what advice 
they would give to a friend and the strength of their answers was surprising with all but 
four participants in the Tasmanian cohort stating that they would actively encourage their 
friends to attend. For example, women in the Tasmania cohort said: 
Essential. As soon as someone turns 40 I tell them to go. 
Since I’ve been going for screening, I’ve been jumping on people to do that as well. 
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Definitely because they’ll keep coming. We’re pretty disadvantaged with lots of things and it’s great 
to see something come and basically the idiom is if you don’t use it, you lose it, so yes, I think its 
important. 
While the perceptions of individual risk remained low, women in the study identified the 
importance of using the service provided because it may help other women. This is 
powerfully encapsulated by one of the women from the Tasmanian cohort who points to the 
fact that she decided to participate in breast cancer screening primarily for community 
reasons, not because she believed that it would benefit her personally: 
At the time the bus was very new. It was the first time it had ever come [here], and it advertised for 
women over 50. You could go as a choice thing and I thought I had absolutely no person in my family 
with breast cancer at all. But I thought if I didn’t go, and all the people didn’t go, the bus wouldn’t 
come back again. So I went really to make sure the bus would come back again. Because it mightn’t be 
me it helps, but it could be someone else. Because it costs nothing and its only a few minutes of 
inconvenience and paid... I’m positive that I will never have breast cancer. 
In Victoria, the mobile service served as a reminder for women to attend the service, in the 
absence of formal reminder letters. This was also one way that the screening staff 
encouraged women to re-attend. For example, one woman said she was told by staff that 
she wouldn’t be re-invited until she turned 50, but that the service was well advertised in 
the local area and so she would know that she was due to be rescreened because the service 
would come back in two years. So all she had to do was to phone and make an appointment. 
Additionally, in the Swedish cohort, the use of a local service was also seen as a political 
action – that of reminding decision makers that ‘we are many women here as well’, and that 
services should not be centralised. It was in this setting that women were more likely to 
state that they would not use the service if they had to travel further distances. This perhaps 
indicates that trust in authorities  is easily broken - as these women had not actively made 
the choice to participate in screening, their commitment to it was dependent on the 
provision of adequate arrangements for screening by health service authorities. 
The provision of information to this age group is problematic. The scientific disagreement 
about the efficacy for women younger than 50 years, combined with the difficulty of 
translating epidemiological knowledge to the decision making processes at the clinical or 
individual level, means that clear information provision to assist informed choice is difficult 
to achieve. Across the three cohorts, there was some knowledge that the risk of breast cancer 
increases with age, but there was also uncertainty about this and confusion about whether 
this was the case. Many women talked of younger women who had been diagnosed with 
breast cancer and this subjective knowledge was sufficient to argue that the age at which 
screening should commence should be lower. In this way, screening was presented as a 
largely unproblematic solution to the problem of breast cancer. Only a few women 
mentioned that it may not be entirely accurate.  
It has been suggested that modelling the outcomes of screening mammography can provide 
women with the information they need when deciding whether to be screened. Barrett et al 
(2005) argue that a clear statement of the risks and the benefits of screening can be modelled 
and thus provide more balanced information to women. Hersch et al (2011) problematise the 
mismatch between women’s beliefs and values and the need to ensure informed consent in 
the context of ‘widely held positive attitudes and often uncritical support for 
 
Choice, Trust and Risk - The Policy Context and Mammography Screening  
 
21 
mammography and sreening generally’. In a study of Canadian woman, Vahabi and 
Gastaldo (2003: 253) note that women ‘are basing their decision on incomplete information’. 
It is also claimed that ‘the messages that women are receiving about mammography are 
skewed in favor of screening’ (Silverman, et al. 2001: 239) in part because population based 
programs such as mammography require large numbers of women to participate in order to 
show efficacy. However, while the push for balanced information is important, information 
provision in itself is, I argue, insufficient as the sole source of knowledge that should be 
taken into account in the decision to be screened. Social ideas and values are likely to 
influence the way that apparently neutral information is received and acted on. This is 
where ideas about trust may be useful. With close attention to the role of trust in health care 
encounters, there must also be attention to how trust occurs in situations where the 
information is inadequate. While some theorists argue that what is required is a ‘leap of 
faith’ in such situations, others argue that trust emerges from taking account of available 
information (see, Meyer et al., 2008) – thus, those women who draw on experiential 
knowledge, knowledge of living in a rural community, and on dominant discourses about 
cancer may have incomplete epidemiological knowledge but draw the evidence that is 
available to them. It is not surprising that such evidence results in a high level of trust  in the 
technological response to cancer, through mammography, and in the health authorities who 
provide the service. This notion of trust is very different to that envisaged by some policy 
makers who may prefer to believe in the objective and rational consumer carefully 
considering how the scientific evidence will play out in an individual risk assessment. The 
policy setting cannot be divorced from such considerations. 
6. Conclusion and policy implications 
The research reported in this chapter goes some way to understanding how policy impacts 
on women’s decision to participate in breast cancer screening. This research can be 
contrasted with dominant understandings of women’s behaviour in two key ways. First, 
most research in this area focuses on why women don’t participate and aims to understand 
how best to reach ‘non-compliant’ or under-served populations. Second, research tends to 
draw on individualised models of behaviour to understand women’s decision making. This 
research aims to connect the policy context with the decisions that women make about 
participation in breast cancer screening. What is evident from the brief international review 
of selected countries is that there isn’t a clear message for women aged 40-49 years to draw 
on in their decision making. The policy advice that this should be an individual risk 
assessment decision by women themselves is at odds with all of the scientific evidence 
which is aimed at a population based approach. As clinicians well know, population based 
evidence is difficult, or impossible, to translate into a message about individual benefit. For 
women at the three policy sites investigated for the qualitative study, the different policy 
settings did affect how they understood the decision to be screened, and identified a range 
of factors that cannot be individualised – decisions about health care are made within a 
social context where dominant ideas about cancer meet health service provision. This is 
particularly relevant when considering how the impact of the social affects rural women’s 
decisions to be screened. As Pasick and Burke (2008: 358) argue, we need an understanding 
of mammography use “that is not abstracted from daily life and all its variations, our theory 
must reflect a more complex an nuanced approach to the socio-cultural and behavioural 
mechanisms involved“. 
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Definitely because they’ll keep coming. We’re pretty disadvantaged with lots of things and it’s great 
to see something come and basically the idiom is if you don’t use it, you lose it, so yes, I think its 
important. 
While the perceptions of individual risk remained low, women in the study identified the 
importance of using the service provided because it may help other women. This is 
powerfully encapsulated by one of the women from the Tasmanian cohort who points to the 
fact that she decided to participate in breast cancer screening primarily for community 
reasons, not because she believed that it would benefit her personally: 
At the time the bus was very new. It was the first time it had ever come [here], and it advertised for 
women over 50. You could go as a choice thing and I thought I had absolutely no person in my family 
with breast cancer at all. But I thought if I didn’t go, and all the people didn’t go, the bus wouldn’t 
come back again. So I went really to make sure the bus would come back again. Because it mightn’t be 
me it helps, but it could be someone else. Because it costs nothing and its only a few minutes of 
inconvenience and paid... I’m positive that I will never have breast cancer. 
In Victoria, the mobile service served as a reminder for women to attend the service, in the 
absence of formal reminder letters. This was also one way that the screening staff 
encouraged women to re-attend. For example, one woman said she was told by staff that 
she wouldn’t be re-invited until she turned 50, but that the service was well advertised in 
the local area and so she would know that she was due to be rescreened because the service 
would come back in two years. So all she had to do was to phone and make an appointment. 
Additionally, in the Swedish cohort, the use of a local service was also seen as a political 
action – that of reminding decision makers that ‘we are many women here as well’, and that 
services should not be centralised. It was in this setting that women were more likely to 
state that they would not use the service if they had to travel further distances. This perhaps 
indicates that trust in authorities  is easily broken - as these women had not actively made 
the choice to participate in screening, their commitment to it was dependent on the 
provision of adequate arrangements for screening by health service authorities. 
The provision of information to this age group is problematic. The scientific disagreement 
about the efficacy for women younger than 50 years, combined with the difficulty of 
translating epidemiological knowledge to the decision making processes at the clinical or 
individual level, means that clear information provision to assist informed choice is difficult 
to achieve. Across the three cohorts, there was some knowledge that the risk of breast cancer 
increases with age, but there was also uncertainty about this and confusion about whether 
this was the case. Many women talked of younger women who had been diagnosed with 
breast cancer and this subjective knowledge was sufficient to argue that the age at which 
screening should commence should be lower. In this way, screening was presented as a 
largely unproblematic solution to the problem of breast cancer. Only a few women 
mentioned that it may not be entirely accurate.  
It has been suggested that modelling the outcomes of screening mammography can provide 
women with the information they need when deciding whether to be screened. Barrett et al 
(2005) argue that a clear statement of the risks and the benefits of screening can be modelled 
and thus provide more balanced information to women. Hersch et al (2011) problematise the 
mismatch between women’s beliefs and values and the need to ensure informed consent in 
the context of ‘widely held positive attitudes and often uncritical support for 
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provision in itself is, I argue, insufficient as the sole source of knowledge that should be 
taken into account in the decision to be screened. Social ideas and values are likely to 
influence the way that apparently neutral information is received and acted on. This is 
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encounters, there must also be attention to how trust occurs in situations where the 
information is inadequate. While some theorists argue that what is required is a ‘leap of 
faith’ in such situations, others argue that trust emerges from taking account of available 
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makers who may prefer to believe in the objective and rational consumer carefully 
considering how the scientific evidence will play out in an individual risk assessment. The 
policy setting cannot be divorced from such considerations. 
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on women’s decision to participate in breast cancer screening. This research can be 
contrasted with dominant understandings of women’s behaviour in two key ways. First, 
most research in this area focuses on why women don’t participate and aims to understand 
how best to reach ‘non-compliant’ or under-served populations. Second, research tends to 
draw on individualised models of behaviour to understand women’s decision making. This 
research aims to connect the policy context with the decisions that women make about 
participation in breast cancer screening. What is evident from the brief international review 
of selected countries is that there isn’t a clear message for women aged 40-49 years to draw 
on in their decision making. The policy advice that this should be an individual risk 
assessment decision by women themselves is at odds with all of the scientific evidence 
which is aimed at a population based approach. As clinicians well know, population based 
evidence is difficult, or impossible, to translate into a message about individual benefit. For 
women at the three policy sites investigated for the qualitative study, the different policy 
settings did affect how they understood the decision to be screened, and identified a range 
of factors that cannot be individualised – decisions about health care are made within a 
social context where dominant ideas about cancer meet health service provision. This is 
particularly relevant when considering how the impact of the social affects rural women’s 
decisions to be screened. As Pasick and Burke (2008: 358) argue, we need an understanding 
of mammography use “that is not abstracted from daily life and all its variations, our theory 
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1. Introduction  
Women from minority groups live at a disproportionately higher risk of chronic illnesses 
and cancer increasing their morbidity and mortality.(Newman, 2010) The shocking 
disproportion could be explained by the genetic makeup, family history, behavioral choices 
of food and low physical activity. Our behavior about cancer and breast cancer prevention 
depends on our cultural background because the social environment and culture determine 
the values of the patient and the provider.(Dein, 2004) Individual and access issues reduces 
the likelihood of obtaining screening mammography particularly among minority women, 
for instance, lack of physician’s recommendation, not having a regular provider and lack of 
health insurance. Factors associated with increasing the risk of not obtaining mammography 
screening include a disadvantaged background, low socioeconomic class, low education, 
smoking, older age and lack of physician access. (Curtis, Quale, Haggstrom, & Smith-
Bindman, 2008) Minority women often have a disadvantaged background. SEER data 1986-
2001 demonstrated lower screening mammography rates for various minority groups 
compared to white women: 50.6% for non-Hispanic whites, 40.5% for African-American, 
34.7% for Asian-American, 36.3% for Hispanic, and 12.5% for Native-American 
women.(Kagay, Quale, & Smith-Bindman, 2006) Mammography use varies by race and 
ethnicity of the women.  
Numerous interventions have been investigated to increase mammography use. Vernon 
reported that reminder-only studies would predict mammography uptake when compared 
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compared to white women: 50.6% for non-Hispanic whites, 40.5% for African-American, 
34.7% for Asian-American, 36.3% for Hispanic, and 12.5% for Native-American 
women.(Kagay, Quale, & Smith-Bindman, 2006) Mammography use varies by race and 
ethnicity of the women.  
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1999) Han performed a meta-analysis of mammography interventions for minority women 
demonstrating an average of 7.8% increase in the rate of mammography.(Han et al., 2009) 
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efficacious than others cannot be ascertained. Han reported that social networks 
(interventions made by lay health workers and promotoras) would actually lower the use of 
mammography, raising questions about the effectiveness of culturally sensitive (CS) 
education delivered by a lay health worker.(Han et al., 2009) 
Minorities fear losing confidentiality, thus programs increasing the awareness of the benefits 
of early detection could ameliorate this problem.(Wu, Colby, Iongi-Filiaga, & Maskarinec, 
2010) This is important because lack of regular screening among African American and 
Hispanic women is associated with late stage of breast cancer diagnosis.(Henry et al., 2011) 
Whether health promotion programs to increase mammography uptake should invest in CS 
education, particularly, using lay health workers remains unclear. The purpose of this meta-
analysis is to assess the effectiveness of culturally sensitive programs to increase 
mammography use by minority women when compared to: 1) usual care, and, 2) delivery 
through a lay health worker, 3) diverse racial/ethnic groups, such as, differences between 
Latina versus Asian Pacific descent versus Black women, 4) rural versus urban location. 
2. Methods  
The search strategy searched published materials. First, a limited search of Medline and 
CINAHL was conducted to identify relevant keywords contained in the title, abstract and 
subject descriptors. Second, terms identified in this way and the synonyms used by 
respective databases are used in the extensive search of the literature and, searching from 
the reference lists and bibliographies of the articles. The abstract is reviewed first, if it met 
criteria then, the article was reviewed. 
2.1 Study selection 
This systematic review considered studies of minority women at risk of breast cancer that 
were recent immigrants or that spoke English as a second language or were foreign born. 
The intervention of interest is an educational program culturally sensitive compared to 
usual care to increase compliance with mammography. The outcome variable is 
mammography uptake determined by the patient’s self-report or by record review. Study 
types included are randomized, clinical trials or comparative analysis. Studies conducted 
with languages other than English are excluded. When there was a discrepancy, two 
investigators looked at the article and finally, the study was admitted if it met design 
specifications and all other study inclusion criteria.  
2.2 Search strategy 
Ovid and CINAHL collections were retrieved with the following search terms used in 
various combinations: “intervention studies” or “patient education” as topic or “cooperative 
behavior” or “social change” or “interventions” AND “mammography” or 
“ultrasonography, mammary” or “mass screening” or “early detection of cancer” and 
“breast neoplasm” AND “Asian Americans” or “African Americans” or “Hispanic 
Americans” or “Minority groups”. Then, limits were placed to humans, female, English, all 
adult: 19+ years. The first collection had 109 articles. After scanning the abstracts, only 29 
were appropriate for further analysis due to outcome was not mammography or the 
research was geared to follow up mammography instead of screening mammography, or 
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the intervention was not considered culturally sensitive, or comparison was between two 
interventions other than usual care. In CINAHL we only found 2 additional articles and 
these were not appropriate for this analysis. After reading the selected articles, only 22 
articles were appropriate for further analysis. Only 14 studies from 10 publications were 
appropriate for meta-analysis (Figure 1), 2 additional studies with CS educational 
intervention among minority women were included for separate analysis due to having a 
different design (Table 5a and b). 
2.3 Data abstraction 
The reviewer abstracted data on study design, database, intervention, sample size, age, 
compliance with mammography, analysis and external validity into standardized data 
abstraction forms. The quality of the study is assessed using a quality form based on the 
methods developed by the University of Oxford titled Centre for Evidence Based 
Medicine critical appraisal tool specifically RCT Appraisal sheet. A grading system for the 
quality of the data was developed for a total score of 10 points. Studies that scored 
between 4-10 points were selected allowing flexibility to include studies in the low range. 
Inclusion criteria included studies with the following variables: 1) women of minority 
origin grouping all ethnic background into one larger group, 2) age greater than 40 years 
following the indications for mammography set by the American Cancer Society 
recommending yearly screening for women > 40 years, 3) education programs specifically 
designed to have an intervention described as cultural sensitive or using the same 
language spoken by the minority group in question, 4) mammography outcome expressed 
as % mammography excluding any study not reporting %, 5) studies designed as pre and 
post intervention, prospective randomized intervention, controlled randomized trials, 
clustered randomized trials, and studies of repeated measures, 6) location included 
minority women from countries other than United States because all countries have 
minority groups presenting socioeconomic disadvantages that can contribute to health 
disparities. Subgroups of racial/ethnic women were Latinas, African American and Asian 
/Middle East. Local health workers (LHW) were considered as intervention type when 
the article stated it, if the intervention required phone use, training a woman to deliver 
the information and or when the LHW was expected to intervene verbally in addition to 
complementing the education with printed materials. Printed materials were considered 
when sending or giving out tailored letters, culturally based printed material, and 
behavior based printed material. Whether the rates differ by geographic location, rural 
versus urban location was abstracted from the text. If the analysis was performed in a 
major city, it was assumed that urban was the correct location and not rural unless the 
authors specifically assigned a rural population in the sample. Studies that scored 
between 4-10 points were selected. Inclusion criteria included studies of: 1) women of 
minority origin, 2) age greater than 40 years, 3) education programs specifically designed 
to have an intervention described as cultural sensitive or using the same language as the 
minority group, 4) mammography outcome expressed as % mammography, 5) studies 
designed as pre and post intervention, prospective randomized intervention, controlled 
randomized trials, clustered randomized trials, and studies of repeated measures, 6) 
location included minority women in other countries. 
Exclusion criteria included studies where the intervention was: 1) not CS education, 2) if the 
outcome was not expressed as percent mammography or could not be converted to a 
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criteria then, the article was reviewed. 
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with languages other than English are excluded. When there was a discrepancy, two 
investigators looked at the article and finally, the study was admitted if it met design 
specifications and all other study inclusion criteria.  
2.2 Search strategy 
Ovid and CINAHL collections were retrieved with the following search terms used in 
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the intervention was not considered culturally sensitive, or comparison was between two 
interventions other than usual care. In CINAHL we only found 2 additional articles and 
these were not appropriate for this analysis. After reading the selected articles, only 22 
articles were appropriate for further analysis. Only 14 studies from 10 publications were 
appropriate for meta-analysis (Figure 1), 2 additional studies with CS educational 
intervention among minority women were included for separate analysis due to having a 
different design (Table 5a and b). 
2.3 Data abstraction 
The reviewer abstracted data on study design, database, intervention, sample size, age, 
compliance with mammography, analysis and external validity into standardized data 
abstraction forms. The quality of the study is assessed using a quality form based on the 
methods developed by the University of Oxford titled Centre for Evidence Based 
Medicine critical appraisal tool specifically RCT Appraisal sheet. A grading system for the 
quality of the data was developed for a total score of 10 points. Studies that scored 
between 4-10 points were selected allowing flexibility to include studies in the low range. 
Inclusion criteria included studies with the following variables: 1) women of minority 
origin grouping all ethnic background into one larger group, 2) age greater than 40 years 
following the indications for mammography set by the American Cancer Society 
recommending yearly screening for women > 40 years, 3) education programs specifically 
designed to have an intervention described as cultural sensitive or using the same 
language spoken by the minority group in question, 4) mammography outcome expressed 
as % mammography excluding any study not reporting %, 5) studies designed as pre and 
post intervention, prospective randomized intervention, controlled randomized trials, 
clustered randomized trials, and studies of repeated measures, 6) location included 
minority women from countries other than United States because all countries have 
minority groups presenting socioeconomic disadvantages that can contribute to health 
disparities. Subgroups of racial/ethnic women were Latinas, African American and Asian 
/Middle East. Local health workers (LHW) were considered as intervention type when 
the article stated it, if the intervention required phone use, training a woman to deliver 
the information and or when the LHW was expected to intervene verbally in addition to 
complementing the education with printed materials. Printed materials were considered 
when sending or giving out tailored letters, culturally based printed material, and 
behavior based printed material. Whether the rates differ by geographic location, rural 
versus urban location was abstracted from the text. If the analysis was performed in a 
major city, it was assumed that urban was the correct location and not rural unless the 
authors specifically assigned a rural population in the sample. Studies that scored 
between 4-10 points were selected. Inclusion criteria included studies of: 1) women of 
minority origin, 2) age greater than 40 years, 3) education programs specifically designed 
to have an intervention described as cultural sensitive or using the same language as the 
minority group, 4) mammography outcome expressed as % mammography, 5) studies 
designed as pre and post intervention, prospective randomized intervention, controlled 
randomized trials, clustered randomized trials, and studies of repeated measures, 6) 
location included minority women in other countries. 
Exclusion criteria included studies where the intervention was: 1) not CS education, 2) if the 
outcome was not expressed as percent mammography or could not be converted to a 
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mammography rate, 3) the women were not of minority origin, 4) if data did not include the 
years 1990 to the present, 4) study design was review, case report, case control but not an 
intervention, 5) quality rated <4. 
2.4 Statistical analysis 
The effectiveness of an educational intervention culturally sensitive to increase 
mammography use is estimated using meta-analysis with Comprehensive Meta-analysis 
software, version 2 and will be considered significant with P value <0.05. Random effects 
models were selected a priori to estimate combined study effects. Moreover, statistical 
heterogeneity of the studies was indicated based on Q=14.983, df =13, p=.002 in the initial 
analysis (Table 2). In the random effects model, variance is partitioned into within study and 
between studies variance. The weight assigned to each study was estimated by 
1/(variance+tau-squared), C>0, then tau squared = (Q-df)/C and tau-squared is the 
between studies variance. The triangular shape of the funnel plot of the standard error by 
log odds ratio suggested acceptable publication bias (Figure 1). 
2.5 Intervention and how it might work 
There is no standard definition of cultural sensitivity but it is important because culture 
influences how minorities view, understand and how they explain cancer. Minority patients 
value feeling respected. Respect results from dialogue, attention, curiosity, healing, 
empowerment and self-respect. Cultural sensitivity consists of being responsive to the 
attitudes, beliefs, feelings and position of minority groups who share common racial, 
national, religious or cultural traditions.(Hoffman-Goetz & Friedman, 2006; American 
Association of Diabetes Educators, 2007) Cultural sensitivity encompasses superficial and 
deep dimensions.  The superficial dimension considers observable behaviors, such as, 
people, places, language, music, clothing, product brands and food. The deep structure 
covers intangible factors, for instance, understanding the culture, historical events, social 
and environmental factors that influence health behaviors. Cultural competence, 
multicultural, cultural tailoring, racial identity and ethnic identity are all aspects of cultural 
sensitivity accepted in this review as determinants of the effectiveness of promoting 
mammography education among minority women. (U.S.Department of Health and Human 
ServicesOffice of Minority Health, 2001) 
3. Results 
3.1 Description of the population 
The population consisted of women of minority origin in the United States and abroad. 
Included were African American, Latina, Asian Pacific and Middle Eastern origin. (Figure 2) 
The age for mammography testing was older than 40 years for most studies (Table 1). From 
the two additional studies of different design described separately, Dignan presents the 
response from Native American Indian women (Table 5a) and Grindel presents a 
longitudinal study of African American women (Table 5b). An additional study with cluster 
randomized trial described Asian women response to CS education (Table 5c). Six studies 
were conducted in rural areas (Table 6). 
 











Fig. 1. Medline articles & added references included and excluded* by study design, 
total 108. 
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multicultural, cultural tailoring, racial identity and ethnic identity are all aspects of cultural 
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The population consisted of women of minority origin in the United States and abroad. 
Included were African American, Latina, Asian Pacific and Middle Eastern origin. (Figure 2) 
The age for mammography testing was older than 40 years for most studies (Table 1). From 
the two additional studies of different design described separately, Dignan presents the 
response from Native American Indian women (Table 5a) and Grindel presents a 
longitudinal study of African American women (Table 5b). An additional study with cluster 
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Funnel Plot of Standard Error by Log odds ratio
 
Fig. 2. Triangular shape of the funnel plot of the meta-analysis using CS education program 
to increase mammography uptake.  
3.2 Usual care versus culturally sensitive education 
The odds ratio (OR) of obtaining mammography were almost 1.5 times more likely for 
minority women who participated in CS education program than from usual care (OR=1.440 
(95% CI=1.164-1.780), p<0.001)) (Table 2).  
3.2.1 Lay health workers 
One question was if delivery of CS education through lay health workers compared to usual 
care increased mammography uptake? The odds that minority women would engaged in 
screening mammography after receiving CS education through a lay health worker 
increases 1.7 times than with usual care alone (OR=1.655 (95% CI=1.207 -2.267)) (Table 3). 
3.2.2 Racial/ethnic groups 
Our next question tested whether the effect size of CS education was homogeneous through 
all racial/ethnic groups (Table 4). When analyzing the odds of screening mammography 
after CS education by racial ethnic group, the odds of receiving screening was 1.569 higher 
than with usual care (OR=1.569 (95% CI=1.310-1.838)). All minority women responded 
positively to CS education. Latinas were more likely to obtain screening mammography 
after a CS education program than without it (OR=1.74 (95% CI=1.43-2.10)).  African 
American women have 1.2 higher odds of obtaining screening mammography after CS 
education program than with only usual care (OR 1.156 (95% CI=0.834 -1.601), but there was 
great variability within studies. Asian and Middle Eastern women have 1.6 higher odds of 
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obtaining screening with CS education than with usual care R/E, race/ethnicity; AA, 
African-American; RCT, randomized controlled trial; prosp interv, prospective 
interventional; LHW, lay health worker; (OR=1.64, 95% CI=0.98-2.80). Looking closely at 
Nguyen’s study, he used a combination including media campaign, and the women with 
higher number of exposures were more likely to obtain mammography. We have no way of 
adjusting for number of exposures with these data, therefore, Nguyen’s study was removed 
and the effect size is in favor of CS education  modestly increasing in favor of obtaining 
screening mammography when compared to usual care (OR=1.83, 95% CI (1.44-2.33). In 
summary, the racial ethnic groups in this meta-analysis have similar effects (p=0.28), the 
higher Latinas odds ratio is not statistically different from other racial/ethnic groups. 
 
Table 1. Description of studies included in meta-analysis, 10 publications, 14 studies. 
Dignan (2005) reported that among the American Indian population a telephone call using a 
lay health worker (Dignan et al., 2005) demonstrated higher odds than face-to-face CS 
education to obtain screening mammography (Table 5a).(Dignan et al., 2005) Using either 
one of those interventions would have 1.66 higher odds of obtaining mammography than 
not intervening (OR=1.66 (95% CI: 1.293-2.134). Of interest, Grindel’s study was assessed 
separately because is a longitudinal design using same woman at baseline as the pre-
intervention (Table 5b). The study demonstrated a strong effect size where African 
American women had 2.2 higher odds ratio of obtaining screening mammography given a 
program of CS education compared to their baseline (pre-intervention). A cluster 
randomized trial corroborates a similar effect size to the meta-analysis of the 10 studies 
(Table 5c). The odds ratio of obtaining screening mammography after the intervention was 
1.5 times that of usual care. Again, we can observe more variability in the African American 
women group but this could be related to power due to the small sample size used 
compared to the Jenkins study of Vietnamese women. This study had among the lowest 
standard error and would have created statistical problems if treated as un-clustered studies 
because the within study error would be underestimated.  
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c) Effect size of mammography uptake after intervention in minority women, cluster 
randomized trials. 
Table 5. Additional studies with different design presenting minority population of women 
subjected to CS education and their mammography uptake: a) American Indian b) African 
American. 
3.2.3 Rural versus urban location 
The odds ratio that minority women living in a rural area would obtain screening 
mammography after CS education were not statistically improved compared to usual care 
(OR=1.08 (95% CI= 0.75-1.56)) (Table 6). The odds that minority women living in urban 
areas would obtain screening mammography after CS education were 1.7 higher than for 
those without the intervention (OR=1.66 (95% CI=1.21-2.27)). Also, it depends on the type of 
intervention, thus lay health workers or promotoras present greater odds of obtaining 
screening mammography among rural minority women (OR=1.3 (95% CI=1.06-1.75)) than 
usual care. However, the effect of lay health workers was limited to one article among those 
living in urban areas (OR=3.14(95% CI=1.9-5.2)). 
 




Table 6. Effect size of culturally sensitive education on mammography uptake by location: 
urban versus rural. 
4. Discussion 
Culturally sensitive education programs are effective interventions to increase 
mammography uptake among minority women. Delivery of culturally sensitive 
intervention by lay health workers increase modestly mammography uptake among 
minority women. However, delivery of CS education by lay health workers was more 
effective than usual care. 
Effective interventions to increase mammography uptake include mailed educational 
materials, letters of invitation with phone calls, training and direct reminders to women, 
and home visits(Legler et al., 2002),(Nguyen et al., 2006) just as for cervical screenings. Asian 
women preferred women physicians performing the evaluation perhaps because of 
modesty, sexual behavior and the fear of losing confidentiality, in other words, having 
others know of the potential breast cancer diagnosis.(Nguyen, McPhee, Nguyen, Lam, & 
Mock, 2002), (Remennick, 2006) Nowadays minorities who do not have documented 
citizenship fear deportation avoiding preventive cancer care.  
Our meta-analysis confirms that delivery of CS education through a lay health worker 
compared to usual care alone increases the likelihood of obtaining screening. CS 
interventions other than educational could have a greater impact depending on the barrier 
impeding mammography uptake. Lay health workers that share cultural and linguistic 
characteristics communicating the breast cancer prevention message may reduce an 
important proportion of the disparity but not the entire multifaceted disparity. For instance, 
access enhancing, individual and system directed and combinations of effective 
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interventions may remove important barriers that cannot be addressed by an educational 
intervention. In other words, educational interventions increase the awareness and 
knowledge of screening behaviors but cannot remove barriers related to lack of health 
insurance, lack of regular provider or a physician recommending the test.(Peek & Han, 2004) 
Furthermore, Legler recommended measuring the individual components of an effective 
combination of interventions.(Legler et al., 2002) This is somewhat complicated because 
multiple interventions may have interaction potentiating the effect of one of the variables or 
the effect may vary according to the environmental elements present.  
The effect of removing linguistic barriers is unequal to almost any other CS intervention 
among Latinas and lay health workers. Phone counseling can invariably improve 
effectiveness in communication. Much harder is to effectively intervene to mitigate mistrust 
in the health care system that is rampant among minority women.(Peek & Han, 
2004),(Samsudeen, Douglas, & Bhopal, 2011) Alleviating healthcare mistrust through social 
networks and delivery through lay health workers could have a greater impact in changing 
health behavior towards cancer prevention compared to usual care or other interventions 
akin to tailored letters or printed materials.  
For women living in rural areas, we can see less benefit from CS education than for women 
in urban areas. In part, studies from rural areas had flaws based on limitations from lack of 
facilities in the area of the intervention, low response rates due to many being migrant 
farmers lost to follow up and approaching minority women who rarely or never access 
health services. However, the odds ratios range widely and some studies such as Fernandez 
and Erwin reported positive effectiveness of CS education among minority women in rural 
areas. In particular, delivering CS education through lay health workers suggests that rural 
minority women face problems beyond lack of awareness. Some of these barriers comprise 
access issues, for instance, lack of health insurance, regular provider and the manpower 
providing the services in rural areas. 
Some limitations of this meta-analysis include the variance caused by having all races and 
ethnicities combined together as minority women. However, considering that many 
minority women share a disadvantage background makes ground to compile their data 
together. Another limitation is the low quality of most randomized controlled trials (RCT) 
impacting the sample size thus the power that may underestimate differences between the 
intervention and usual care groups. Additionally, most data from RCT is self-reported by 
the women, a source of recall bias. Another limitation is that LHW complement their work 
by providing booklets and other printed materials limiting the assessment of the effect of 
LHW only or printed material only. In this study, the intervention LHW considered 
providing printed materials to educate minority women. 
5. Conclusion 
CS education is more effective than usual care to increase screening mammography 
behaviors among minority women. These data support that minority women are likely to 
increase mammography uptake after this intervention regardless of the racial/ethnic 
group. Delivering CS education through a lay health worker is more effective than usual 
care alone. 
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TO POLICY MAKERS: Minority women benefit from culturally sensitive education to 
increase screening mammography uptake. Investing in culturally sensitive education 
through a lay health worker is an effective intervention to reduce the disproportion of 
screening mammography uptake among minority women. 
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How to Optimize Population Screening Programs
for Breast Cancer Using Mathematical Models
Montserrat Rue et al.1
Research Group on Economic Evaluation and Health, Universities of
Lleida and Rovira i Virgili
Spain
1. Introduction
Breast cancer (BC) mortality in Western countries has followed a downward trend since the
early 1990s. However, BC remains the most common cancer in women worldwide and the
leading cause of premature mortality in women aged 35 to 64 years (Ferlay et al. (2007)).
Despite the widespread use of mammography, there is an intense debate in the scientific
community about the benefits and harms of screening for BC (Autier et al. (2011); Duffy et al.
(2010); Jorgensen & Gotzsche (2009); Tabar et al. (2003)). The guidelines of the US Prevention
Services Task Force in 2009 recommending biennial screening starting at age 50 (USPSTF
(2009)) originated dissension within the scientific community and BC interest groups. At
present, the screening recommendations reflect this dissent (ACOG (2011); Schousboe et al.
(2011)).
There is a need to consider optimization because, over time, technological improvements
allow access to programs that provide better results in exchange for higher costs. In an
environment where resources are scarce, policy makers face the possibility of their budget
being allocated to different programs, and need information on how to optimally allocate
resources. Economic evaluation helps them in decision making. One of the methods used
in economic evaluation -efficiency analysis- aims to maximize quality-adjusted life years
(QALYs) subject to the constraint of a fixed budget or the amount that society is willing to
pay per QALY (Abellán et al. (2008)). The QALYs take account of both the positive effects of
each technology as well as the adverse effects.
Evaluating the impact and costs of early detection programs using experimental designs is
not feasible. The randomised controlled trials currently have strong limitations, such as
sample size, long follow-up times and group contamination. It is difficult to use randomized
controlled trials to determine optimal ages and periodicities or to customize screening to
different BC risk groups. Although mathematical models have advantages and drawbacks,
they allow to include efficiency principles in the analysis.
Mathematical models can be used to design an optimal strategy for BC screening. Benefits,
adverse effects and the costs of screening and treatment over time need to be considered.
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mortality in the period 1975/2000, showed that each intervention contributed about equally
to this decline (Berry et al. (2005); Cronin et al. (2006); Feuer (2006)).
In a study about the effectiveness of early detection on mortality reduction in Catalonia
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minimize the frequency of adverse events while maintaining or even increasing benefits.
Figure 1 presents a flow chart of a population screening program.
Some of the adverse effects of screening mammograms are:
• False positive (FP) results. These occur when the mammogram is abnormal but no cancer is
actually present. Abnormal mammograms are followed up with additional tests, in some
cases invasive tests. FP are the consequence of a lack of specificity of mammography. In
Spain, Roman et al. (2011a) examined how protocol-related and women’s characteristics
affect the cumulative risk of FP over 10 sequential mammograms in a retrospective cohort
of 1,565,364 women, from 1990 to 2006. The cumulative FP risk for a woman who starts
screening at age 50 was 20%, ranging from 7% to 51% in the lowest and highest risk profiles,
respectively. The cumulative risk for invasive procedures was 1.8%, ranging from 1.6% to
12%.
Mandelblatt et al. (2009) found that more FP results occur in strategies that initiate
screening at age 40 than in those that initiate screening at age 50 or later and in those
strategies that include annual screening rather than biennial screening. Annual screening
























Fig. 1. Flow chart of a population screening program.2
yields almost twice as many FP results as biennial screening and many more women
undergo unnecessary biopsies under annual screening than biennial screening.
An FP result can cause anxiety and discomfort in affected women. FP can increase
adherence to a screening program (if there are concerns about changes, anxiety, etc.) or
they can reduce the confidence of participants in the diagnostic test and, consequently,
reduce their adherence to the program. Roman et al. (2011b) found that reattendance
rate at the second screening was 79% for women with a FP result versus 85% for women
2 In a given population, women within an age interval are offered a screening mammogram with certain
periodicity. Each time a women is offered a mammography exam, she can accept or refuse it. Women
who participate have a mammogram exam, which in case of a positive result leads to a diagnostic exam
that may include additional non-invasive or invasive tests. In the case of a positive result, women
are diagnosed and treated for BC. During this process, the group of women with negative screening
exams consists of true negative cases (TN) and false negative cases (FN), while the group of women
with positive screening exams and negative diagnostic exams defines the group of false positive cases
(FP). If they are still candidates, these three groups of women together with the rest of population
within program age range, will be offered a periodic new mammogram unless, before the next call to
participate, they either develop an interval cancer and go straight to a diagnostic exam, or die. Women
with a diagnosis of BC consist of true positive (TP) and overdiagnosed (OD) cases.
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without a FP result. These differences disappeared over time; in the seventh screening
they were 95% versus 96%. Risk factors for non-attendance to subsequent screenings were
age, non-attendance to the first scheduled screening, and previous invasive procedures.
Either a familial history of BC or the use of hormone replacement therapy were significant
protective factors against non-attendance.
• False negative (FN) results. These occur when the mammogram result is negative even
though BC is present. FN are a consequence of the lack of sensitivity of the mammography.
A FN result can lead to a delay in cancer diagnosis due to a false sense of security, and in
consequence to more aggressive treatment. High rates of FN indicate poor quality in the
screening program.
• Interval cancers (IC). These are diagnosed in the interval between two screening exams.
IC have a tumor growth rate higher than screen-detected tumors. IC are an important
measure of screening effectiveness because they reflect screening sensitivity. A shorter time
between exams could decrease the rates of IC, but would increase the risk of FP results and
overdiagnosis. In Spain, Bare et al. (2008) found that 35% of 57 interval cancers were true
IC (26%) or occult in the previous mammogram (9%) and 14% were FN. The remaining
51% presented minimal signs in the previous mammogram (18%) or were unclassifiable
(33%).
The incidence of interval cancer increases with age, breast density, hormone use, and
family history (Lowery et al. (2011)). These women’s characteristics could be used
to develop risk profiles that may benefit from more intensive screening. In addition,
Domingo et al. (2010) found that a more aggresive molecular phenotype, the triple
negative, was more frequent in true interval cancers than in screen-detected cancers.
• Overdiagnosis and overtreatment (OD). These occur when tumors that never would be
diagnosed during an individual’s life are diagnosed by screening. Overdiagnosis has a
greater chance of occuring in older women, since other causes of death are competing with
BC incidence. But they may also affect women of any age when tumors grow slowly or
spontaneously regress (Zahl et al. (2008)).
Overdiagnosis affects the estimates of sensitivity, specificity, predictive values and
incidence of cancer. Overdiagnosis estimates of BC are highly variable, as are the methods
to estimate it. Jorgensen & Gotzsche (2009), in a systematic review of BC incidence before
and after the introduction of screening, estimated that one in three screen detected BCs is
overdiagnosed. Our estimates of overdiagnosis in Catalonia ranged from 0.4% to 46.6%
for women born around 1935 and 1950, respectively (Martinez-Alonso et al. (2010)).
2.3 The lead-time and length biases of survival time
Since screening mammography for early BC detection was introduced, assessing
improvements in the survival from the time of diagnosis misrepresents the benefit because
it is confounded by two biases specific to screening.
BC-specific survival is measured from the time of diagnosis to the time of death. If a BC is
screen-detected before symptoms, then the lead time in diagnosis equals the length of time
between screening detection and when the first signs/symptoms would have appeared. Even
if early treatment had no benefit, the survival of screened individuals is longer simply by
the addition of the lead time (Figure 2). The observed survival time Z after the diagnosis by
screening is defined as
Z = X + Y, (1)
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Fig. 2. Lead time bias. (Adapted from the National Cancer Institute)
• Y: the lead-time.
• X: the post-lead-time survival, the time from clinical detection to death or the end of study.
Length bias arises because the cancers detected in screening examinations are more likely
to have slower growth than cases detected in the intervals between examinations and other
groups of cancer cases not detected by screening. Patients with screen-detected cancers
survive longer in part because the screened cancers are more indolent, but the improved
survival cannot be accurately attributed to the early treatment (Figure 3). It is important to
Fig. 3. Length bias.
take the lead-time and length biases into account when assessing the impact of screening.
Different authors have developed methods to obtain non-biased survival time estimates
Mahnken et al. (2008); Xu & Prorok (1995); Zelen & Feinleib (1969); Zelen & Lee (2002). The
mathematical models, developed by Lee & Zelen (2008), that we use to assess the impact of
early detection provide lead-time and lenght unbiased estimates.
2.4 Economic evaluation
Economic evaluation aims to provide health care decision makers with information on costs
and outcomes of alternative interventions (Drummond et al. (1997)). To take economically
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efficient decisions one needs to compare costs and benefits of all technically efficient options.
The basic tool is the cost-benefit analysis. Given the difficulty of assessing health in monetary
terms, alternatively, in health economics, cost-effectiveness analysis is used. The result of the
cost-effectiveness analysis is presented using a ratio between incremental costs and outcomes.
The costs are measured in monetary units and the outcomes in years of life gained. However,
the consideration that health outcomes are often multidimensional (e.g life expectancy and
quality of life) has lead to the use of the QALYs in the denominator of the cost-effectiveness
ratio. Then cost-effectiveness becomes a cost-utility analysis, and the values that are used to
weigh life years gained in terms of quality reflect the preferences of individuals in relation to
the different health states.
Oostenbrink et al. (2002) introduced a six-step procedure for estimating costs. These steps
include 1) the perspective of the study; 2) the choice of cost categories; 3) the identification
of units; 4) the measurement of resource use; 5) the monetary valuation of units; and 6)
the calculation of unit costs. In addition, they mentioned several key issues regarding the
standardisation of costs, e.g. methods for measurement and valuation or the reporting of
outcomes.
Different types of costs must be included in the study based on the decision taken at Step 1. If
the social perspective is taken, this involves estimating all the consequences of implementing
a new intervention taking into account all the agents involved (thus it includes all costs and all
benefits). However, many recent works have only the payer’s perspective. If a study assesses
both the social perspective and the payer’s perspective, both results should be presented
separately.
The choice of cost categories (Step 2) introduces the distinction between different cost items.
In the literature there is no single classification of costs. Table 1 shows one of the most common
classifications. Steps 3 to 6: identify the components of costs and measure the resources
Direct health care costs Costs directly related to prevention and treatment
Direct non health care
costs 1,2
Travel costs of patients and caregivers
Time costs of patients and caregivers
Indirect health care costs Productivity losses, paid and unpaid, of caregivers and patients
caused by death or disability
Leisure time of patients and caregivers
Table 1. Example of cost categories. Classifications where most authors agree
1 Weinstein (1990) includes in this section the costs of special education and juridical costs.
Oostenbrink et al. (2002) included these items in indirect costs.
2 Oliva et al. (2004) include in this section the costs of paid caregivers.
used. Once the resources are identified, the unit values need to be estimated. This step is
often difficult. Studies of economic efficiency attempt to examine real unitary costs for each
resource. But these studies often use the charges as a proxy for cost. However, this equivalence
is not recommended because costs and charges have a very different economic significance
(Finkler (1982)) and it calls into question the cost analysis. Also, in this case, the "bottom-up"
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calculation, despite being the most appropriate, is more complex because it needs individual
information on each item and it is nearly impossible to obtain all the data.
Despite economic evaluation studies being performed in a structured way, some issues remain
controversial. One of the weaknesses of economic evaluation studies is the lack of systematic
analysis of the costs which precludes a correct comparison of different studies. The two most
important points of disagreement, among others, are the lack of consensus on how to take
account of the indirect costs and the costs of the years of life gained.
A. Methods to estimate indirect costs
1. Human capital
The Human capital theory is based on the decisions of the individuals with respect to
their investment preferences (Becker (1964)). Many individuals do not enter the labor
market and continue studying, anticipating that in some years they will get higher
revenues. In terms of health, it can be reasoned that individuals follow healthier
lifestyles to increase their health. In both cases, in the future, individuals increase their
productivity and contribute to economic growth.
The method of human capital presents some limitations. On the one hand, the
calculation of indirect costs as the production loss due to mortality and morbidity is
less than the social welfare loss. On the other hand, when individuals improve their
health but do not return to the labor market the expenditure on health can not be
considered an investment (e.g. retired individuals). However, as Sala-i-Martin (1992)
and González-Páramo (1994) said, the contribution of these groups to social cohesion
and positive externalities over the production makes it possible to consider the health
expenditure as an investment
Puig-Junoy & Pinto (2001), concluded that, in general, the human capital method may
present strong inequities in the treatment given to individuals not included in the labor
market, for various reasons. The method neither considers unpaid productivity losses
(domestic productivity) nor the value of leisure time.
2. Frictional costs and the QALYs approach
These two methods are the principal alternatives to the human capital method. The
frictional costs method considers the costs of replacing the sick worker to be indirect,
and these costs are inversely related to unemployment. The QALY approach only
includes temporal costs (travel and waiting time) and the additional costs of training a
substitute in the work place as indirect costs (Oliva (1999)).
Lopez-Bastida et al. (2003) showed that indirect costs can represent between 20% (frictional
cost method) and 70% (human capital method) of the total cost of cancer. Antoñanzas et al.
(2006) estimated the direct and indirect costs of cancer in Spanish regions for a five years
follow-up, using the human hapital method. They did not include the costs of prevention
or early detection. In Catalonia, direct costs of BC accounted for 53.7 % of the total costs
and indirect costs for 46.3 %.
B. Costs incurred as a result of years of life gained
The future costs may be due to treatments applied, new health problems or those that
cause diseases not related, as well as other expenses of daily life. The key question is how
to measure future costs. The definition of related diseases may be arbitrary and there is no
consensus on the limits of what is understood by "other costs".
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Most papers include costs related to the disease throughout life. However, Meltzer (1997)
stated that the clear theoretical implication from a model of lifetime utility maximization
is that cost-effectiveness analyses should include all future costs, whether medical or
nonmedical.
Meanwhile, Cutler (2007) introduced another element to the discussion when relating the
introduction of an intervention to the health stock. Interventions that reduce disability
could lower lifetime spending. If the intervention results in fewer lifetime years spent
disabled, or if death occurs at a later age and the end-of-life care is cheaper, the total costs
of care may decrease.
With regard to information provided to health policy makers by the cost-effectiveness
analysis, it is important to note that the use of "lifetime costs" can influence the results
substantially, particularly when the studied intervention adds years of life but not quality
of life.
3. Mathematical optimization
According to Lee & Zelen (1998), planning a screening program for early BC detection requires
determining a) the individual characteristics that indicate when participation should start, b)
the periodicity of the subsequent exams, and c) recommendations for high-risk individuals.
An "optimal screening program" should take into account the benefits of screening, adverse
effects and costs. More screenings at shorter intervals would make it possible to detect more
tumors at initial stages, but part of this benefit would be counterbalanced by more false
positive results, overdiagnosis and costs.
Mathematical optimization refers to the selection of a best element from some set of available
alternatives. In early detection of BC, mathematical optimization can help finding the "best
available" values of the objective function (for example number of QALYs) given a defined
domain or set of inputs. Multiobjective optimization deals with having more than one
objective -sometimes in conflict- in an optimization problem. For example, there is a screening
strategy that produces the maximum number of QALYs, another that has the minimum cost
-not necessarily the no screening strategy- and an infinite number of alternatives that are some
combination of QALYs and costs.
3.1 The One size fits all BC screening
In 2009, the USPSTF (2009) updated the previous 2002 recommendation which supported
screening mammography every 1-2 years for all women older than 40 years. The 2009
USPSTF guidelines recommended against routine screening of women aged 40-49 years and
recommended biennial screening mammography for all women aged 50-74 year. Also, the
USPSTF recommended against teaching breast self-examination and assessed as insufficient
the evidence for clinical breast examination.
The USPSTF recommendations were based on the joint modeling work of Mandelblatt
et al. (2009) for the CISNET, which provided estimates of the average benefits and harms
expected across a cohort of contemporary women. The outcome meaures were the number
of mammograms, reduction in deaths from BC or life-years gained, false-positive results,
unnecessary biopsies, and overdiagnosis. The conclusion of the modeling analysis was that
screening at biennial intervals is more efficient and provides a better balance of benefits and
harms than screening at annual intervals. The USPSTF recommendations caused an intense
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discussion that lead to an update of their recommendation for women under 50 years of age.
The new wording was: The decision to start regular, biennial screening mammography before the age
of 50 years should be an individual one and take patient context into account, including the patient’s
values regarding specific benefits and harms.
In June 2011, the American College of Obstetricians and Gynecologists (ACOG) announced
new BC screening guidelines, annual mammography screening beginning at age 40, that
conflicts with the USPSTF recommendations (ACOG (2011)). The ACOG argument was the
high incidence of BC in the US and the potential to reduce deaths from it when caught early.
It is important to note that neither the USPSTF nor the ACOG recommendations take into
account the cost-effectiveness of the recommendations.
3.2 The Risk based BC screening
3.2.1 Models that schedule exams based on BC risk
Several authors have proposed the use of BC risk to guide screening recommendations.
3.2.1.1 The risk-based threshold method
Lee & Zelen (1998) applied their modeling theory to scheduling the early detection exams.
Every time a woman has a mammogram and the result is negative, the risk of BC decreases,
and then starts to increase again as a function of age. Lee and Zelen introduced two basic ideas
that either individually or together allow to obtain satisfactory examination schedules. The
threshold method provides examination schedules so that the probability of an individual
being in the preclinical state is always bounded by a preselected value. The concept of
schedule sensitivity is the ratio of the expected number of BC cases diagnosed on scheduled
examinations to the expected total number of BC cases. Combining the threshold and schedule
sensitivity methods allows to compare different strategies and select the most appropriate.
They started setting the probability of being in the preclinical state, Sp, at age 50 years as a
threshold. When the woman’s probability of being in Sp reaches the threshold, it’s time to
have an exam. Since BC incidence increases with age, the intervals between the examinations
become smaller as women get older.
3.2.1.2 The Pareto-optimal criteria
Rauner et al. (2010) designed a dynamic disease policy model for selecting Pareto-optimal
screening strategies. They considered a rapidly progressing cancer in a high-risk group
(younger women) and a more slowly progressing cancer in a low-risk group (older women).
They applied the model to BC in Austria for a time horizon of 10 years. The problem of interest
was to identify screening policies that maximize the total number of QALYs and minimize
total costs, under selected budget constraints. The decision variables were optimized using
the Pareto ant colony optimization (P-ACO) paradigm and used a discrete time population
approach.
In the Rauner’s model, the population is categorized as healthy, latently sick and identified
sick individuals, with transition probabilities into the states and also to death. Effectiveness
and costs are obtained with detailed equations in each category of individuals. The P-ACO
algorithm is inspired by the search for food behavior of ant colonies. While walking, ants
release pheromones on the ground making a path that other ants may follow. Shorter paths
have a higher probability of being used as the scent of pheromones is stronger. This process
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algorithm is inspired by the search for food behavior of ant colonies. While walking, ants
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have a higher probability of being used as the scent of pheromones is stronger. This process
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can be simulated on the computer as an heuristic method to solve complex optimization
problems. It generates solutions by successively adding a solution component (an ant move)
to an initially empty set.
The Rauner’s model showed that, in the case of low budgets, mammography screening should
be exclusively directed to older women (aged 50-70 years) with infrequent, low screening
for women younger than 50 years. The fact that cancer incidence is higher in older women
dominates the effect of faster progressing cancers in younger women.
3.2.1.3 Cost-effectiveness based on individual BC risk
Schousboe et al. (2011) examined the health benefits and cost utility of mammography
performed at different time intervals in women with different profiles of BC risk based on
the Tice et al. (2008) model. According to the authors, the health benefits and cost utility of
screening mammography may be strongly influenced by a woman’s risk of BC, which can
be estimated from her age, breast density on an initial mammogram, history of breast biopsy,
and family history of BC. They used a Markov microsimulation model to compare the lifetime
costs and health benefits of having mammography annually, biennially, or every 3 to 4 years
or not having mammography. The data sources were the Surveillance, Epidemiology, and
End Results program (SEER), Breast Cancer Surveillance Consortium (BCSC), and the medical
literature. The time horizon was the lifetime and the authors assumed the perspective of the
national health payer. Two cost-effectiveness thresholds were considered: $100,000 or less and
$50,000 or less per QALY gained.
The results showed that the most cost-effective frequency of mammography depended on the
studied risk factors. The authors presented a schema of recommendations about the frequency
of mammography that differs from the more simplistic guidelines of 1 or 2 years starting at
age 40 or 50 in the USA or biennially starting at 50 in many countries in Europe, regardless of
risk factors. According to Schousboe et al. women may choose to have mammography at age
40 years, and those with average or low breast density and no other BC risk factors may start
periodic screening at age 50 (with reassessment of breast density and the other risk factors).
Or, women aged 50 to 79 years who have low breast density and no other BC risk factors, may
consider having mammography less frequently than every two years. The authors concluded
that mammography screening should be personalized on the basis of woman’s risk factors
and beliefs about the potential benefit and harms of screening.
Mandelblatt et al. (2011) mentioned several limitations of using the Schousboe et al.
recommendations to guide personalised risk-based screening. Among others, difficulties in
communicating to women and health providers or women that are left without guidance.
Mandelblatt also warns about the efforts that need to be taken to understand the links between
tumor types and risk factors and the mechanisms by which density is associated with BC.
3.2.2 Models for predicting individual risk for breast cancer
Population-based BC screening programs apply the same screening procedure to the entire
target population. Currently, age is the only risk factor used to identify women who will
be invited to participate. However, there are other risk factors like family history, genetic or
breast density that have shown a significant association with BC risk. A key point to propose
an "optimal screening program" is the individualized risk measurement. There are already
several predictive models for individual risk assessment which incorporate both population
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risk and personal or family medical history, reproductive, endocrine or genetic factors. The
incorporation of the risk measure in the organization of the screening program might allow
the design of a screening protocol based on individual risk.
So far, the most known and used model for predicting the BC risk was developed by Gail
et al. (1989). While previous models were aimed at specific populations such as relatives of
BC affected women, the Gail model was the first that attempted to estimate the BC risk for
women in the general population. The model was based on data from a case-control study
conducted in women participating in a BC early detection program between 1973 and 1980.
The risk factors used in the model were age at menarche, age at first live birth, number
of previous biopsies, and number of first degree relatives with BC. Individualized BC
probabilities were obtained from information on relative risks, the baseline hazard rate and
competing risks. The original Gail model, developed in the USA, included both invasive BC
and DCIS. There is another model, exclusive of invasive BC and known as the Gail-2 model,
that allows estimation of BC risk using an interactive web tool (Costantino et al. (1999)). In
general, the Gail models showed good calibration. Ratios between expected and observed BC
cases are above 0.80 in all evaluation studies and close to 1 for most of them (Cummings et al.
(2009)). However, the ability to discriminate who will or will not have BC is poor, with values
of the c-statistic3 ranging from 0.57 to 0.62. Despite these results, the Gail-2 model is the most
often used.
Since its publication, this model has undergone several changes with the inclusion or
exclusion of different risk factors. It is also the model with the largest number of performance
evaluations in women of different populations or races. Chen et al. (2006) modified the initial
Gail model, including breast density as a risk factor. The Chen’s model included age at first
birth, number of previous biopsies, number of first-degree relatives with BC, breast density
and weight. Compared to the initial Gail model, the Chen’s model did not include age at
menarche and some interaction terms of the Gail model.
Barlow et al. (2006) developed a model that incorporated breast density, hormone replacement
therapy, body mass index, and the results of previous mammography exams as predictors of
the risk of BC within one year of the screening mammogram. Race or ethnic group were also
included in this model. With the addition of breast density as a risk factor it was expected that
the Chen and the Barlow’s models would improve discrimination. The c-statistic became 0.64
for the Chen’s model and 0.63 and 0.62 for pre and post menopausal women, respectively, for
the Barlow’s model.
Tice et al. (2008) simplified the Barlow’s model and extended it to assess the 5-year risk of BC.
The Tice’s model included age, race or ethnicity, family history of BC, history of breast biopsy
and breast density. The model showed good calibration in major race and ethnic groups in
the USA. But, as in the previous risk models, it had a modest ability to discriminate between
women who will develop BC and those who will not (the c-statistic was 0.66). The authors
concluded that the accuracy of the model needed to be further evaluated in independent
populations before it could be recommended for clinical use.
3 The c-statistic measures the ability of the model to separate women who will develop BC from those
who will not. It estimates the proportion of pairs of women in which the woman with BC has a higher
predicted risk than the woman without BC. A c-statistic of 0.5 is equivalent to no discrimination, and a
c-statistic of 1.0 indicates perfect discrimination.
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age 40 or 50 in the USA or biennially starting at 50 in many countries in Europe, regardless of
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periodic screening at age 50 (with reassessment of breast density and the other risk factors).
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be invited to participate. However, there are other risk factors like family history, genetic or
breast density that have shown a significant association with BC risk. A key point to propose
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et al. (1989). While previous models were aimed at specific populations such as relatives of
BC affected women, the Gail model was the first that attempted to estimate the BC risk for
women in the general population. The model was based on data from a case-control study
conducted in women participating in a BC early detection program between 1973 and 1980.
The risk factors used in the model were age at menarche, age at first live birth, number
of previous biopsies, and number of first degree relatives with BC. Individualized BC
probabilities were obtained from information on relative risks, the baseline hazard rate and
competing risks. The original Gail model, developed in the USA, included both invasive BC
and DCIS. There is another model, exclusive of invasive BC and known as the Gail-2 model,
that allows estimation of BC risk using an interactive web tool (Costantino et al. (1999)). In
general, the Gail models showed good calibration. Ratios between expected and observed BC
cases are above 0.80 in all evaluation studies and close to 1 for most of them (Cummings et al.
(2009)). However, the ability to discriminate who will or will not have BC is poor, with values
of the c-statistic3 ranging from 0.57 to 0.62. Despite these results, the Gail-2 model is the most
often used.
Since its publication, this model has undergone several changes with the inclusion or
exclusion of different risk factors. It is also the model with the largest number of performance
evaluations in women of different populations or races. Chen et al. (2006) modified the initial
Gail model, including breast density as a risk factor. The Chen’s model included age at first
birth, number of previous biopsies, number of first-degree relatives with BC, breast density
and weight. Compared to the initial Gail model, the Chen’s model did not include age at
menarche and some interaction terms of the Gail model.
Barlow et al. (2006) developed a model that incorporated breast density, hormone replacement
therapy, body mass index, and the results of previous mammography exams as predictors of
the risk of BC within one year of the screening mammogram. Race or ethnic group were also
included in this model. With the addition of breast density as a risk factor it was expected that
the Chen and the Barlow’s models would improve discrimination. The c-statistic became 0.64
for the Chen’s model and 0.63 and 0.62 for pre and post menopausal women, respectively, for
the Barlow’s model.
Tice et al. (2008) simplified the Barlow’s model and extended it to assess the 5-year risk of BC.
The Tice’s model included age, race or ethnicity, family history of BC, history of breast biopsy
and breast density. The model showed good calibration in major race and ethnic groups in
the USA. But, as in the previous risk models, it had a modest ability to discriminate between
women who will develop BC and those who will not (the c-statistic was 0.66). The authors
concluded that the accuracy of the model needed to be further evaluated in independent
populations before it could be recommended for clinical use.
3 The c-statistic measures the ability of the model to separate women who will develop BC from those
who will not. It estimates the proportion of pairs of women in which the woman with BC has a higher
predicted risk than the woman without BC. A c-statistic of 0.5 is equivalent to no discrimination, and a
c-statistic of 1.0 indicates perfect discrimination.
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The more recent models contain genetic characteristics. According to Pauw et al. (2009), the
lifetime risk of developing BC in the general population is around 10%. In contrast, the risk
of BC at age 70 increases to 65% in women carrying the BRCA1 gene and up to 45% for
carriers of the BRCA2 gene (Antoniou et al. (2003)). The Claus et al. (1991) models, BRCAPRO
(Parmigiani et al. (1998)), BOADICEA (Antoniou et al. (2002)) and IBIS (Tyrer et al. (2004)),
for example, incorporate the probability of carrying a mutation in these genes based on the
individual’s personal and family medical history of BC and ovarian cancer. The information
needed to use these models makes their use difficult in clinical practice. Also, women with
genetic BC risk have specific recomendations and screening protocols.
Individual risk estimated using risk models has been used in some cases to recommend
screening to women aged 40-49 years, based on the estimated risk for 50 years old women
without any risk factor (Gail & Rimer (1998)). Since there is a wide variety of models, it is
important to better analyze their applicability and effectiveness to specific populations or
conditions, in order to select the most suitable. Besides, the application of statistical risk
models for estimating individual risk is limited by the uncertainty of the estimates, in the
case of a specific model, and the variability, in the case of different models.
One of the limitations of BC risk models is that the risk factors and their impact on risk
of developing BC have been determined from observational studies in specific population.
Therefore, the estimations obtained from these models may not be valid for other populations.
We are currently assessing the predictions of the Gail’s model, the Barlow’s model and the
Chen’s model in Catalan population. Preliminary results show that these models are not well
calibrated for the Catalan population.
4. Our work
4.1 Cost-effectiveness of different screeening strategies in Catalonia. One size fits all BC
screening
Our objective was to help Catalan policy planners decide which population screening
strategies were cost-effective while using limited public resources. We performed an economic
evaluation of 20 screening strategies taking into account the cost over time of screening and
subsequent medical costs, including diagnostic confirmation, initial treatment, follow-up and
advanced care. Part of the cost-effectiveness analysis presented in this section has been
published elsewhere (Carles et al. (2011)). Based on the literature, in the present work we have
added an estimation of overall indirect costs to the direct costs that we used in our previous
study.
We generated 20 possible screening strategies by varying the periodicity of screening exams
and the age intervals of women screened. Annual or biennial screening with age intervals
that started at 40, 45 and 50 years and ended at 69, 70, 74 and 79 years were combined. The
background or non-screening scenario was also included. The probabilistic model developed
by Lee & Zelen (2008) was used to estimate the costs and effect of each screening scenario over
time.
4.1.1 The Lee and Zelen probabilistic model
Lee and Zelen (LZ) developed a probabilistic model that predicts mortality as a function of
the early detection strategy. The LZ model was one of the seven models used to estimate
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the impact of adjuvant therapy and mammography on US mortality from 1975 to 2000
(Cronin et al. (2006)). The LZ model had been previously validated by comparing the model
predictions with the randomized breast cancer early detection trials. It is a flexible model that
can accommodate complex natural histories and interventions (Lee & Zelen (2006)).
The characteristics and assumptions of the LZ model are described in detail elsewhere (Lee
& Zelen (1998; 2003; 2008; 2006)). The assumptions of the LZ model are: (1) a four-state
progressive disease in which a subject may be in a disease-free state (S0), preclinical disease
state (Sp: capable of being diagnosed by a screening exam), clinical state (Sc: diagnosis by
symptomatic detection), and death from BC state (Sd); (2) age-dependent transitions into the
different states; (3) age-dependent examination sensitivity; (4) age-dependent sojourn times in
each state; and (5) exam-diagnosed cases have a stage-shift in the direction of more favorable
prognosis relative to the distribution of stages in symptomatic detection.









τ − x τ y
Where:
τ − x: Age entering Sp; τ: Age of incidence (entering Sc); y: Age at death.
The basic LZ model calculates the cumulative probability of death for a specific cohort
exposed to any screening program after T years of follow-up. Similarly, the cumulative
probability of death for the cohort group without screening can be calculated. These
probabilities were used to calculate the possible reduction in mortality from an early detection
program after T years of follow-up. We extended the model to estimate incidence and
prevalence and also to perform an economic evaluation of different screening strategies. The
inputs needed to model the Catalan data have been published elsewhere (Rue et al. (2008;
2009); Vilaprinyo et al. (2008; 2009)).
4.1.2 Measuring the effect of different screening scenarios
For each screening scenario and for the background, the effect of screening was measured
with the number of QALYs. QALYs were estimated by applying the weights derived from
the EuroQol EQ-5D utility scores that Stout et al. (2006) used in the USA. All the calculations
assumed an initial population of 100,000 women at birth. The incidence of BC and mortality
from other causes refer to the cohorts born in the period 1948-1952. The time horizon for the
study was 40-79 years of age.
4.1.3 Costs’ considerations
Direct and indirect healthcare costs were considered. The estimation of direct costs was
partitioned into four parts: screening and diagnosis confirmation, initial treatment, follow-up
and advanced care costs. Based on Antoñanzas et al. (2006), indirect costs were estimated as
46.3% of the total (direct+indirect) costs. All costs were valued in 2005 euros and both costs
and outcomes were discounted at an annual rate of 3%.
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the impact of adjuvant therapy and mammography on US mortality from 1975 to 2000
(Cronin et al. (2006)). The LZ model had been previously validated by comparing the model
predictions with the randomized breast cancer early detection trials. It is a flexible model that
can accommodate complex natural histories and interventions (Lee & Zelen (2006)).
The characteristics and assumptions of the LZ model are described in detail elsewhere (Lee
& Zelen (1998; 2003; 2008; 2006)). The assumptions of the LZ model are: (1) a four-state
progressive disease in which a subject may be in a disease-free state (S0), preclinical disease
state (Sp: capable of being diagnosed by a screening exam), clinical state (Sc: diagnosis by
symptomatic detection), and death from BC state (Sd); (2) age-dependent transitions into the
different states; (3) age-dependent examination sensitivity; (4) age-dependent sojourn times in
each state; and (5) exam-diagnosed cases have a stage-shift in the direction of more favorable
prognosis relative to the distribution of stages in symptomatic detection.









τ − x τ y
Where:
τ − x: Age entering Sp; τ: Age of incidence (entering Sc); y: Age at death.
The basic LZ model calculates the cumulative probability of death for a specific cohort
exposed to any screening program after T years of follow-up. Similarly, the cumulative
probability of death for the cohort group without screening can be calculated. These
probabilities were used to calculate the possible reduction in mortality from an early detection
program after T years of follow-up. We extended the model to estimate incidence and
prevalence and also to perform an economic evaluation of different screening strategies. The
inputs needed to model the Catalan data have been published elsewhere (Rue et al. (2008;
2009); Vilaprinyo et al. (2008; 2009)).
4.1.2 Measuring the effect of different screening scenarios
For each screening scenario and for the background, the effect of screening was measured
with the number of QALYs. QALYs were estimated by applying the weights derived from
the EuroQol EQ-5D utility scores that Stout et al. (2006) used in the USA. All the calculations
assumed an initial population of 100,000 women at birth. The incidence of BC and mortality
from other causes refer to the cohorts born in the period 1948-1952. The time horizon for the
study was 40-79 years of age.
4.1.3 Costs’ considerations
Direct and indirect healthcare costs were considered. The estimation of direct costs was
partitioned into four parts: screening and diagnosis confirmation, initial treatment, follow-up
and advanced care costs. Based on Antoñanzas et al. (2006), indirect costs were estimated as
46.3% of the total (direct+indirect) costs. All costs were valued in 2005 euros and both costs
and outcomes were discounted at an annual rate of 3%.
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The costs of screening mammograms, complementary tests and administrative expenses
were obtained from the Early Detection Program of IMAS in the city of Barcelona. Data
on treatment costs was obtained from a database that included 592 women consecutively
diagnosed and initially treated for BC at the IMAS-Hospital del Mar in Barcelona in the period
January 1st, 2000 - December 31, 2003. Details can be found in Carles et al. (2011).
4.1.4 Cost-effectiveness analysis
To compare the relative costs and outcomes of the different scenarios, we calculated the
incremental cost-effectiveness ratio (ICER). The ICER indicates the additional cost of obtaining
one additional unit of outcome when moving from one strategy to the next. Each scenario is
compared with the next most efficient alternative. Once dominated or extended dominated
strategies are excluded, the remaining strategies form the cost-effectiveness frontier, the
efficient alternatives for which no other alternative policy exists that results in better effects
for lower costs. When costs are plotted on the Y axis and outcomes on the X axis, a dominated
strategy lies above and to the left of the non-dominated strategy.
Usually there is a social threshold, or willingness to pay, that constrains the choice between
efficient strategies. But, finally, a rational decision maker has to decide whether or not to move
up the efficiency frontier. Sacristan et al. (2002) and Pinto (2001) pointed to 30,000 e/ QALY
as the threshold of reference for the public funding of health services in Spain. Ortún et al.
(2004) indicated that this value is above the per capita income and above the average cost of a
QALY in Spain in 2003. In any case, the most important fact is that health policy makers use
this threshold as an initial value that can be modified to achieve equity and move towards a
social welfare threshold.
Figure 4 presents the results of the cost-effectiveness analysis. The background scenario
was taken as the reference scenario. All the screening alternatives represented increased
effectiveness and costs with respect to the background scenario.
Fig. 4. Cost-effectiveness analysis of different screening strategies.
Figure 4 footnote: Cost per quality-adjusted life year (QALY). Empty figures correspond to annual
strategies and full figures to biennial. Screening start age: 40 (big), 45 (medium) and 50 (small). Screening
end age: 69 (circle), 70 (diamond), 74 (triangle), and 79 (square). The line joins the dominant scenarios.
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Table 2 shows the non-dominated or non-extended dominated alternatives. Six screening
scenarios, three biennial and three annual, were selected: B50-69, B45-69, B45-74, A45-69,
A40-69 and A40-74. Compared with the current public screening strategy, B50-69, all the
remaining selected scenarios started the exams earlier and two of them ended later. Given the
threshold accepted as willigness to pay, the three biennial alternatives could be considered for
implementation.
Scenario Cost Δ Cost QALY Δ QALY e/QALY
(×106 e) (×106 e)
Background 237.2 0
B 50-69 267.3 30.1 3,614 3,614 8,328
B 45-69 282.3 15.0 4,447 833 18,061
B 45-74 286.7 4.4 4,633 186 23,539
A 45-69 327.9 41.2 5,979 1,346 30,578
A 40-69 364.0 36.1 6,756 777 46,535
A 40-74 375.5 11.5 6,987 231 49,786
Table 2. Cost-effectiveness of mammography screening strategies in Catalonia (Spain).
Incremental cost per QALY assuming a cohort of 100,000 women at birth. Dominated or
extended-dominated strategies were not included.
4.1.5 Comment
A reduced number of screening strategies have been selected for consideration by researchers,
decision makers and policy planners. Mathematical models are useful to assess the impact and
costs of BC screening in a specific geographical area.
Variability in the methodologies, patient characteristics, perspectives and time horizons used
by different authors is high. Some characteristics that are common to most of the studies
are the acceptance of increasing costs of advanced cancer care over time and the substantial
weight of hospitalization costs. A major challenge is to estimate the costs of advanced disease.
Even though clinical practice guidelines provide standard treatment for advanced disease,
very often treatments are customized according to the tumor or the patient’s characteristics
and the response to each treatment line.
Our previous work on cost-effectiveness (Carles et al. (2011) included an analysis of direct
health costs based on a very detailed mathematical model. In the present work, indirect costs
have been estimated according to the relation between total an indirect costs described by
Antoñanzas et al. (2006), as was mentioned in the Costs’considerations section. The order of the
non-dominated alternatives was the same using either direct or direct+indirect costs. But the
inclusion of indirect costs changed the absolute value of the cost per QALY, allows a discussion
based on the significance of the efficiency threshold used and changes the possibilities of
implementing the efficient alternatives. In summary, the results of the economic evaluation
provide information on the rank of efficient alternatives. The implementation of these
alternatives depends on economic policy.
4.2 A risk based scheduling of mammograms
We compared the risk-based threshold method proposed by Lee & Zelen (1998) with the
personalized screening according to risk factors presented by Schousboe et al. (2011). As we
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implementing the efficient alternatives. In summary, the results of the economic evaluation
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4.2 A risk based scheduling of mammograms
We compared the risk-based threshold method proposed by Lee & Zelen (1998) with the
personalized screening according to risk factors presented by Schousboe et al. (2011). As we
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mentioned earlier, the risk-based threshold method consists on having a mammogram every
time that the probability of being in the pre-clinical state is an a priori fixed value. As Lee
and Zelen did in their work, we chose as threshold the probability of being in the pre-clinical
state at age 50. Schousboe et al. performed a cost-effectiveness analysis with two thresholds,
$100,000 or $50,000 per QALY, to propose the risk individualized screening strategy.
We used the incidence model that Schousboe et al. (2011) estimated using the 1975-2005 SEER
data. We used the relative risks of breast density, family history and previous biopsies, for the
white US population, that Tice et al. (2008) determined. Figure 5 shows the incidence rates
by age, according to the sixteen BC risk groups defined combining breast density (4 BI-RADS
categories), family history (yes/no) and previous biopsies (yes/no). The bottom incidence
curve refers to women with BI-RADS density 1 and neither family history nor previous
biopsies whereas the top incidence curve corresponds to women with BI-RADS density 4 and
both family history and previous biopsies.
Fig. 5. Breast cancer incidence according to breast density, family history of BC and previous
biopsies. F: family history, B: previous biopsies.
Given that different combinations of risk factors produce similar incidence functions, we
decided to consider four BC risk groups, as an example. From low to very high risk:
1. Low : BI-RADS 1 with 0 or 1 risk factor, and BI-RADS 2 with 0 risk factors.
2. Intermediate: BI-RADS 1 with 2 risk factors, BI-RADS 2 with 1 risk factor, and BI-RADS 3-4
with 0 risk factors.
3. High: BI-RADS 2 with 2 risk factors, and BI-RADS 3-4 with 1 risk factor.
4. Very high: BI-RADS 3-4 with 2 risk factors
Figure 6 shows the probability of being in the pre-clinical state, Sp, in four different categories
of women, each one of them belonging to one of the above defined risk groups. Figure 6
a) correspond to the low, b) to the intermediate, c) to the high and d) to the very high risk
groups. Following Schousboe’s recommendations, in all cases, there are mammograms at
ages 40, 50, 60 and 70 years. The horizontal dotted line indicates the risk of being in Sp at
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age 50 in the general population, 0.00126. On one hand, the intervals between exams become
smaller as women get older. On the other hand, the number of exams increases as the risk of
BC increases. The periodicity becomes approximately annual and every 6 months for women
older than 60 years in categories c) and d), respectively.
(a) BI-RADS 1 and 0 risk factors (b) BI-RADS 2 and 0 risk factors
(c) BI-RADS 3 and 1 risk factors (d) BI-RADS 3 and 2 risk factors
Fig. 6. Examination schedule with age at initial examination=40 and reassessment at ages 50,
60 and 70. Examinations are scheduled whenever the probability of being in the preclinical
state reaches the same value as at age 50. Adapted from Lee & Zelen (1998).
Table 3 compares the screening recommendations based on the cost-effectiveness threshold
and the BC risk-based threshod methods. For women in category a) both methods give a
pattern of occasional mammograms. In category b) (intermediate risk) there is agreement for
women aged 40-49 and a similar pattern for women 50-59. For women older than 60 years,
the risk-based threshold method gives a higher number of exams. For women in categories c)
and d) the risk-based method results in a higher number of exams, except for women 40-49
years in category c). It is important to note that the risk-based method would result in very
high cost per QALY. The frequent exams in older women would cause low benefits in terms
of QALY and high adverse effects (high rate of overdiagnosis) and therefore, these strategies
would be dominated by less frequent strategies as Schousboe et al. proposed.
Figure 7 shows the probability of being in Sp in the same four categories as Figure 6. Here the
exams correspond to the periodicity recommended by Schousboe. The dotted horizontal line
indicates the threshold. Women in category a) would receive most of their mammograms
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high cost per QALY. The frequent exams in older women would cause low benefits in terms
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Age Cost-effectiveness threshold BC risk based
threshold method
$ 50,000 per QALY $ 100,000 per QALY Exams at ages
a) BI-RADS 1, no family history and no previous biopsies
40-49 None until age 50 None until age 50 40
50-59 None until age 60 Every 3-4 yr, Reassess at 60 50
60-69 Every 3-4 yr, Reassess at 70 Every 3-4 yr, Reassess at 70 60, 68
70-79 Every 3-4 yr Every 3-4 yr 72, 75, 79
b) BI-RADS 2, family history and no previous biopsies
40-49 None until age 50 40
50-59 Every 2 yr, Reassess at 60 50, 53, 56, 58
60-69 Every 2 yr, Reassess at 70 Every 1.5 yr
70-79 Every 2 yr Annually
c) BI-RADS 3, family history and no previous biopsies
40-49 Every 2 yr, Reassess at 50 40, 47, 49
50-59 Every 2 yr, Reassess at 60 Every 1.5 yr
60-69 Every 2 yr, Reassess at 70 Annually
70-79 Every 2 yr Annually
d) BI-RADS 3, family history and previous biopsies
40-49 Every 2 yr, Reassess at 50 40, 44, 46, 47.5, 49
50-59 Every 2 yr, Reassess at 60 Annually
60-69 Every 2 yr, Reassess at 70 Every 6 months
70-79 Every 2 yr Every 6 months
Table 3. Screening recommendations and scheduling of exams.
at probabilities of being in Sp lower than the threshold, indicating that they would be
overscreened. Figures 7 b), c) and d) indicate that as BC risk increases, the periodicities
recommended by Schousboe et al. result in an increased distance between the probability
of being in Sp and the threshold. In other words, in each exam the risk of BC is higher than
in the previous exam. Considering that the benefit in terms of QALY decreases as women get
older, as mentioned before, the more frequent strategies would become dominated by the less
frequent.
The next step would be to perform an economic evaluation of One size fits all strategies and BC
risk personalized strategies. A cost-effectiveness analysis, as the one we performed in section
4.1, would provide valuable information to guide in the selection of an optimal strategy.
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(a) BI-RADS 1 and 0 risk factors (b) BI-RADS 2 and 0 risk factors
(c) BI-RADS 3 and 1 risk factors (d) BI-RADS 3 and 2 risk factors
Fig. 7. Examination schedule with age at initial examination=40 and reassessment at ages 50,
60 and 70. Examinations are scheduled according the Schousboe et al. (2011)
recommendations. The horizontal dotted line corresponds to the probability of being in Sp at
age 50.
5. Conclusions and future research
BC screening has brought benefits, but the costs have not been low. We are beginning to have
information on the undesirable effects of population screening programs. Overdiagnosis,
overtreatment, anxiety and unnecessary tests need to be addressed adequately. Is there
enough evidence to justify changing to a new, evidence-based system? It seems clear that
the current One size fits all paradigm is inadequate in light of current BC research. Screening
with fixed periodicity results in some women being screened too much and others not being
screened often enough. Using what we know now about the natural history of BC and the
characteristics of current screening technologies, it is possible to develop better systems that
are more cost-effective and better tailored to the patient’s needs.
Change is always difficult in health care provision systems. The process of spreading
knowledge has its own rules and requires time and leaders who believe in change. Many
examples show that the gap between evidence and its use in clinical practice is enormous,
despite the high cost and harmful consequences of not using evidence. Professionals
working in the field of screening may be resistant to new methods, but the current long-term
economic crisis makes it necessary to review health care interventions to ensure that they
are maximizing their return on scarce resources, especially those interventions designed to
prevent or to detect diseases early.
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The theoretical advantages of a new approach require a careful, practical evaluation of how to
put it into effect. How would such a change be initiated and managed? According to Berwick
(2005; 2003) the translation of a new technology into improved patient outcomes involves at
least three overlapping processes: (1) decisions by a healthcare delivery organizations to adopt
these new technologies that are based on assessment of the efficacy and cost-effectiveness
of the technologies, (2) implementing these technologies within the complex organizational
structure of healthcare providers, and (3) monitoring the use of these new technologies.
What areas are the highest priority for ongoing research? There are some suggestions below:
1. Improvement of tools to measure BC risk. Dynamic evaluations are important, to the
extent that relevant information becomes available to incorporate into an individual risk
profile. Changes in breast density, family history, exposure to hormone replacement and
previous biopsies are examples of characteristics that should be considered to re-adjust
previous measurements of BC risk.
2. Conduct pilot studies of individualized screening. Assess benefits, adverse effects, costs
and difficulties in implementing them.
3. Investigate biological markers that help predict BC risk and risk of in situ tumors becoming
invasive.
4. Investigate indolent disease markers. Apply watchful waiting protocols instead of
aggressive interventions (mastectomies, chemotherapy).
5. Communicate facts (benefits and harms) about BC screening to women more effectively.
6. Improve information systems used to assess the effectiveness of interventions and
opportunities to make improvements. This calls for shared databases that integrate basic,
clinical and epidemiological research.
New technologies or interventions can certainly increase both life expectancy and quality of
life. However, the benefits may not exceed the costs when costs are considered in the broadest
sense: direct, indirect and intangible. Thus, as stated by Ortún et al. (2004), the overuse,
underuse and poor use exist in any health system and this negatively impacts the health of
the population. Understanding and analyzing effectiveness, beyond efficacy, is essential to
optimize the allocation of scarce resources and maximize the objective function that includes
both life expectancy and quality of life.
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least three overlapping processes: (1) decisions by a healthcare delivery organizations to adopt
these new technologies that are based on assessment of the efficacy and cost-effectiveness
of the technologies, (2) implementing these technologies within the complex organizational
structure of healthcare providers, and (3) monitoring the use of these new technologies.
What areas are the highest priority for ongoing research? There are some suggestions below:
1. Improvement of tools to measure BC risk. Dynamic evaluations are important, to the
extent that relevant information becomes available to incorporate into an individual risk
profile. Changes in breast density, family history, exposure to hormone replacement and
previous biopsies are examples of characteristics that should be considered to re-adjust
previous measurements of BC risk.
2. Conduct pilot studies of individualized screening. Assess benefits, adverse effects, costs
and difficulties in implementing them.
3. Investigate biological markers that help predict BC risk and risk of in situ tumors becoming
invasive.
4. Investigate indolent disease markers. Apply watchful waiting protocols instead of
aggressive interventions (mastectomies, chemotherapy).
5. Communicate facts (benefits and harms) about BC screening to women more effectively.
6. Improve information systems used to assess the effectiveness of interventions and
opportunities to make improvements. This calls for shared databases that integrate basic,
clinical and epidemiological research.
New technologies or interventions can certainly increase both life expectancy and quality of
life. However, the benefits may not exceed the costs when costs are considered in the broadest
sense: direct, indirect and intangible. Thus, as stated by Ortún et al. (2004), the overuse,
underuse and poor use exist in any health system and this negatively impacts the health of
the population. Understanding and analyzing effectiveness, beyond efficacy, is essential to
optimize the allocation of scarce resources and maximize the objective function that includes
both life expectancy and quality of life.
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1. Introduction  
Breast cancer has been reported as the highest cause of cancer deaths amongst women 
worldwide. The incidence and prevalence of cancer is rapidly increasing in the developed 
and developing countries. More than 10 million people are diagnosed with cancer every 
year. It is estimated that there will be 15 million new cases every year by 2020 (Horton, 2006) 
Rising incidence of breast cancer as well as earlier age of presentation has been reported in 
developing countries. Since no cure has been found for breast cancer, early diagnosis and 
early treatment have been found to yield a better survival rate. 
There is now strong evidence that an individual’s risk of developing cancer can be 
substantially reduced by healthy behavior such as participating in cancer screening 
according to recommended guidelines. The American Cancer Society posits that if we can 
effectively promote healthy behaviors, much of the suffering and death from cancer can be 
prevented or reduced (American Cancer Society, 2002). 
However, poor practice of breast cancer screening methods has been reported in many 
studies in Nigeria (Akhigbe & Omuemu, 2009; Okobia et al, 2006). Beyond poor knowledge, 
or ignorance, several other factors have been found to influence the practice of breast cancer 
screening in different countries, including Nigeria.  
In Nigeria, late presentation has been described as the hallmark of breast cancer and reasons 
given include poverty, under-education, lack of knowledge and poor access to care 
(Akhigbe & Omuemu, 2009; Okobia et al, 2006; Atoyebi et al, 1997). However, studies have 
shown that even when these factors are statistically controlled, African-Americans are still 
less likely to participate in cancer screening (Powe 1996). It was therefore concluded that 
other factors such as cultural values and beliefs may operate independent of variables such 
as poverty and education in affecting the decision to go for screening. 
Health beliefs differ from culture to culture. In Nigeria, beliefs are usually influenced by 
cultural and religious values, which in turn influence health behavior such as response to 
screening awareness campaigns. 
The Health Belief Model (HBM) has been used as a theoretical framework to study Breast 
Self-Examination and other breast cancer detection behaviors. The model stipulates that 
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health-related behavior is influenced by a person’s perception of the threat posed by a 
health problem and by the value associated with his or her action to reduce that threat 
(Champion et al, 1997). 
Cancer fatalism, the belief that death is inevitable when cancer is present has also been 
identified as a barrier to participation in cancer screening, detection and treatment. Cancer 
fatalism is believed to be the result of cultural, historical and socioeconomic factors that 
have influenced the lived experience of African-Americans (Powe, 1996). 
Nigeria is the most populous black African nation and breast cancer screening practice has 
been extremely poor. As has been found in other parts of the world, people of African origin 
are less likely to participate in cancer screening programs. (Powe, 1996) Breast cancer tends 
to be discovered in the later stages, when treatment options are limited and mortality rates 
increase, which is similar to reports in Nigeria. 
If we are to develop materials for educational intervention, they have to be culturally sensitive 
as the goal of such a drive will be to increase breast cancer knowledge, decrease cancer 
fatalism and improve participation in breast cancer screening among Nigerian women. 
Health beliefs and fatalism have been studied in various populations as means of 
identifying other strategies to help promote positive health behaviors, such as cancer 
screening. There is limited information concerning such a study in Nigeria.   
1.1 Health belief model 
The Health Belief Model (HBM) is by far the most commonly used theory in health 
education and health promotion (Glanz, Rimer, & Lewis, 2002). 
The HBM is a method used to evaluate and explain individual differences in preventative 
health behavior (Janz et al, 2002). The HBM has had the greatest influence in research related 
to prediction associated with breast cancer screening behaviors; several studies have used 
the HBM to understand breast cancer screening behaviors. The HBM model subscales 
measure six concepts, including perceived susceptibility, perceived seriousness, barriers, 
benefits, health motivation, and confidence (Champion 1999).  
1.1.1 Perceived susceptibility 
As the first component of the HBM, perceived susceptibility is defined as a subjective 
perception of the risk of an illness. One’s belief regarding the chances of being diagnosed 
with a medical condition can be applied by defining populations at risk and risk levels (Janz 
et al., 2002). Individual risk may be based on personal characteristics or behavior. 
Comparisons of perceived susceptibility with action risk can also be conducted (Janz et al., 
2002). Related to breast cancer screening behaviors, perceived susceptibility may include the 
risk of a breast cancer diagnosis in the long term or immediate future. 
1.1.2 Perceived severity 
Perceived severity, formerly called perceived “seriousness” is the second construct of the 
HBM. Perceived severity speaks to an individual’s belief about the severity or seriousness of 
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a disease and the sequence of events after diagnosis and personal feelings related to the 
consequences of a specific medical condition (Janz,Champion, & Stretcher, 2002). Possible 
medical consequences may include death, disability, and pain; possible social consequences 
consist of effects on work, family life, and social relations (Janz et al., 2002).The combination 
of perceived susceptibility and perceived severity has been labeled perceived threat. 
1.1.3 Perceived benefits 
The construct of perceived benefits is a person’s opinion of the value or usefulness of a new 
behavior in decreasing the risk of developing a disease. Also termed as perceived benefits of 
taking health action, the attitudes of health behavior changes are reliant on one’s view of the 
health benefits for performing a health action (Janz et al.,2002). Perceived benefits play a 
significant role in the adoption of secondary preventive behaviours, such as screenings. It is 
widely known and accepted that the earlier breast cancer is found, the greater the chances of 
survival. It is also known that breast self-examination (BSE), when done regularly, can be an 
effective means of early detection. But not all women do BSE regularly. They have to believe 
there is a benefit in adopting this behavior, which is exactly what was found to be true 
among black women: those who believed breast self-examinations were beneficial did them 
more frequently (Graham, 2002).  
1.1.4 Perceived barriers 
Perceived barriers refer to the potential negative aspects of or obstructions to taking a 
recommended health action. This is the belief about physical and psychological costs of 
taking health action (Janz et al., 2002). An internal cost benefit analysis occurs, weighing the 
health action’s expected effectiveness against perceptions that it may become an obstacle. 
Potential barriers may include financial expense, danger, pain, difficulty, upset, 
inconvenience, and time-consumption (Janz et al., 2002). Perceived barriers to performing 
breast cancer screening behaviors were emotional, social, and physical. 
Even when women know that breast cancer is a serious disease, and one for which women 
are at risk and one for which the perception of threat is high, the barriers to performing BSE 
exert a greater influence over the behavior than does the threat of cancer itself (Champion, 
1993; Champion & Menon, 1997; Umeh & Rogan-Gibson, 2001). Some of these barriers 
include difficulty with starting a new behavior or developing a new habit, fear of not being 
able to perform BSE correctly, having to give up things in order to do BSE, and 
embarrassment (Umeh & Rogan-Gibson, 2001). 
1.1.5 Self-efficacy 
Self-efficacy was added to the original four beliefs of the HBM in 1988 (Rosenstock, Strecher, 
& Becker, 1988). Self-efficacy is the belief in one’s own ability to do something (Bandura, 
1977). If a person believes a new behavior is useful (perceived benefit), but does not think he 
or she is capable of doing it (perceived barrier), chances are that it will not be tried. 
According to Umeh & Rogan-Gibson (2001), a significant factor in not performing BSE is 
fear of being unable to perform BSE correctly. In other words, unless a woman believes she 
is capable of performing BSE (that is, has BSE self-efficacy), this barrier will not be overcome 
and BSE will not be done. 
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1.1.6 Cues to action 
Cues to action, formerly known as motivation, are events, people, or things that move 
people to change their behavior. Examples of cues include media reports about preventing 
breast cancer, illness of a family member, and perceived benefits (Graham, 2002).  
1.2 Cancer fatalism 
Studies have revealed that fatalism may be a deterrent to participation in health promoting 
behaviours. Fatalism is the belief that all things in the world are under the control of some 
invisible force, and we are powerless to do anything about it. Fatalism is in general the view 
which holds that all events in the history of the world, and, in particular, the actions and 
incidents which make up the story of each individual life are determined by fate (Knight, 
2003). Fatalism is the belief that situations, such as illnesses or catastrophic events, happen 
because of a higher power (such as God), or they are just meant to happen, and cannot be 
avoided (Talbert PY, 2008). Indeed, fatalism has a strong tie with religion. 
Religious beliefs are particularly dominant among Nigerians, and together with a passionate 
confidence in God are such beliefs in fatalism, magic, witchcraft, and demons. Although 
Christianity and Islam have replaced traditional religions, the thoughts of the people about 
life, and their attitude to it, are still shaped by the old worldview. They exhibit this in their 
day-to-day interpersonal interactions (Jegede, 2002). These beliefs therefore remain, even in 
educated people long after their possible conversion to Christianity or Islam. As a result, 
fatalism remains a part of the average Nigerian's worldview. Worldview may be defined as 
the mental grid through which one sees the world (Sarma, 2007).  
Cancer fatalism is a situational manifestation of fatalism in which individuals may feel 
powerless in the face of cancer and may view a diagnosis of cancer as a struggle against 
insurmountable odds (Powe & Johnson, 1995).  
This study therefore seeks to understand the perception of Nigerian women about breast 
cancer screening using the health beliefs model with the subscales of perceived 
susceptibility, perceived severity, perceived benefits and barriers as well as self-efficacy and 
cues to action, including cancer fatalism.  
1.3 Hypotheses 
1. There is no significant relationship between the practice of breast self-examination and 
perceived barriers. 
2. There is no significant relationship between participants’ use of mammography and 
perceived barriers. 
3. There is no significant association between breast cancer fatalism and breast self-
examination. 
2. Methodology 
This study employed a descriptive correlation design, with health beliefs and cancer 
fatalism operationalized by the participants’ responses to Champion’s Health Belief Model 
Scale and Powe’s Cancer Fatalism Scale respectively. 
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The study evaluated the effects of health belief and cancer fatalism on the practice of breast 
cancer screening among educated Nigerian women. The dependent variables were breast 
self-examination and mammography. The independent variables were the components of 
the health belief model, and cancer fatalism. 
2.1 Data collection 
Purposive sampling was employed in recruiting two hundred and twenty five participants 
from among female health professionals (consisting of medical doctors, nurses, pharmacists 
and radiographers) in the Teaching Hospital and female teachers in secondary schools in the 
Benin City metropolis, aged between 30 and 60. The choice of purposive sampling technique 
“ensures that only elements relevant to the research are included and guarantees that extra 
care is taken to select those elements that satisfy the requirements of the research” (Nworgu, 
1991). Informed consent was obtained and participants were assured confidentiality of 
responses. Participation meant responding to a questionnaire soliciting demographic 
information as well as the Champion’s Health Belief Model Scale and the Powe Cancer 
Fatalism Scale. 
2.2 Instruments 
Champion’s Health Belief Model Scale: HBM scales for measuring beliefs related to breast 
cancer were assessed for content validity by a panel of three health educators who are 
familiar with the HBM and breast cancer screenings. It was agreed that the first item in the 
subscale of perceived susceptibility (It is extremely likely I will get breast cancer in the future) 
might meet with a strong denial by the average Nigerian woman. A pilot testing of the 
instrument subsequently revealed two items in the Health Belief Model scale that 
considerably lowered the internal consistency of the subscales. Together with an item in the 
Cues to action subscale (I have regular health check-ups even when I am not sick), these two items 
were excluded. All HBM scales were measured on a five-point Likert type scale with the 
following coding: strongly disagree (1); disagree (2); neutral (3); agree (4); and strongly 
agree (5). 
Powe Cancer Fatalism Scale: Participants’ level of breast cancer fatalism was assessed with the 
Powe Cancer Fatalism Scale (Powe, 1995). The Inventory is a 15-item questionnaire based on 
the philosophic origins and attributes of cancer fatalism (fear, predetermination, pessimism, 
inevitable death), with a Yes or No response. Each “Yes” response was scored as one point 
and a “No” response as zero, giving the possible range of scores from 0 to 15.  
Higher scores on the Powe Scale reflect higher degrees of fatalism. A score of zero to five 
indicates a low degree of fatalism, scores from six to ten indicate a moderate degree of 
fatalism, and scores from eleven to fifteen reflect a high degree of fatalism. In a study aimed 
at differentiating higher versus lower levels of cancer fatalism among a sample of African 
American women, Powe (2001) selected a mean score of 8 as a cut-off point, coding scores of 
0 to 8  as low cancer fatalism and scores 9 to 15 as high cancer fatalism. In this study, a cut-
off point determined by median split was used to classify participants as “High” and “Low” 
Breast Cancer Fatalism individuals. Participants with scores equal to or greater than 13 were 
categorized as “High Fatalism" individuals and those whose scores on this scale were below 
13 were classified as “Low Fatalism” individuals. 
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1.1.6 Cues to action 
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day-to-day interpersonal interactions (Jegede, 2002). These beliefs therefore remain, even in 
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insurmountable odds (Powe & Johnson, 1995).  
This study therefore seeks to understand the perception of Nigerian women about breast 
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1.3 Hypotheses 
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2. Methodology 
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fatalism operationalized by the participants’ responses to Champion’s Health Belief Model 
Scale and Powe’s Cancer Fatalism Scale respectively. 
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The Statistical Package for the Social Science (SPSS) computer software programme (version 
16 for Windows) was used to conduct frequency analyses and correlations. 
3. Results 
Cronbach’s alpha tests of reliabilities, conducted to assess the internal consistency of the six 
HBM subscales (i.e., susceptibility, severity, benefits, barriers, self-efficacy, and cues to 
action) and the fatalism scale are presented in Table 1. All alpha coefficients were in the .82 







Susceptibility .90 4 
Severity .82 5 
Benefits BSE .85 4 
Benefits MAMMO .82 5 
Barriers BSE .97 11 
Barriers MAMMO .93 11 
Cues to action  .94 4 
Self-Efficacy .82 7 
Powe Fatalism Scale         .94 15 
Table 1. Cronbach’s Alpha Reliabilities. 
Demographic data 
The survey population consisted of 225 women aged between 30 and 60 years who 
completed the survey instrument. Majority of the respondents (83.1%) were between 30 – 49 
years of age. Most (95.1%) were married. 
Educationally, 55.1% had completed University education while 44.9% had post-secondary 
but not university education. Post-secondary education includes training schools for 
nursing, medical laboratory science, radiography as well as colleges of education. Until 
recently, most of these schools offered certificate or diploma courses. Their products work as 
nurses, laboratory scientists, radiographers and teachers in primary and junior secondary 
schools. Health professionals, including doctors, pharmacists, nurses, medical laboratory 
scientists and radiographers accounted for 24.9% of the study population, while the 
remaining 75.1% were secondary school teachers. Nigeria is a multi-ethnic nation and Benin 
City is the capital of Edo State where the Binis and Ishans constitute a sizable proportion of 
the population. The Binis/Ishans constitute 56.4% with the Igbos and Yorubas together with 
a string of closely related ethnic groups contributing almost equally to the study population. 
The southern part of Nigeria is predominantly Christian, hence 88.4% professed Christianity 
as their religion. 
None of the respondents has ever been diagnosed with breast cancer but 7.1% reported that 
a family member or friend has experienced breast cancer. 35.6% of the respondents regularly 
do breast self-examination while 64.4% do not. Only a minute proportion of the study 
population (6.7%) has ever had a mammogram done, an overwhelming percentage has 
never had a mammogram done. 
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N = 225 
Percent 
Age (Years)   
       30-34 59 26.2 
       35-39 46 20.4 
       40-44 52 23.1 
       45-49 30 13.3 
       50-54 20 8.9 
       55-59 18 8.0 
Marital Status   
      Single 34 15.1 
      Married 180 80.0 
      Divorced 5 2.2 
      Separated 2 .9 
      Widowed 4 1.8 
Ethnicity   
Bini/Ishan 127 56.4 
     Igbo 31 13.8 
     Yoruba 35 15.6 
Urhobo/Itsekiri/Isoko 32 14.2 
Education   
    Secondary 101 44.9 
    Post-secondary/University 124 55.1 
Occupation   
   Health Professional 56 24.9 
   Teacher 169 75.1 
Religion   
   Christian 199 88.4 
   Muslim 26 11.6 
Has a family member or friend experienced breast cancer?   
     Yes 16 7.1 
     No 209 92.9 
Do you regularly do breast self-examination?   
     Yes 80 35.6 
     No 145 64.4 
Have you ever had a mammogram done?   
     Yes 15 6.7 
     No 210 93.3 
Table 2. Demographic Characteristics of Study Respondents (n = 225). 
3.1 Health belief model characteristics  
Participants were asked to indicate the degree to which they agreed or disagreed with 
statements related to perceived susceptibility, perceived severity, perceived benefits, 
perceived barriers, cues to action and self-efficacy of breast cancer screening. 
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3.1.1 Perceived susceptibility 
Majority of the respondents had high scores on the Perceived Susceptibility subscale. 79.5% 
either agreed or strongly agreed that their chances of getting breast cancer in the next few 
years are great. Similarly, majority either agreed or strongly agreed they feel they will get 
breast cancer sometime in their lifetime (77.3%), and concerned about the likelihood of 
developing breast cancer (53.3%). Table 3 shows a profile of perceived susceptibility.  
3.1.2 Perceived severity 
Although majority of participants agreed with the statements: Breast cancer would threaten a 
relationship with my boyfriend, husband or partner (39.6%); and If I developed breast cancer, I 
would not live longer than 5 years (69.3%), many neither agreed nor disagreed with most of the 
perceived severity subscale items.  
3.1.3 Perceived benefits of breast self-examination 
An overwhelming majority of the participants either disagreed or strongly disagreed with 
the statements: When I do breast self-examination, I am doing something to take care of myself 
(75.5%); Completing breast self-examination each month may help me to find breast lumps early 
(77.1%); Completing breast self-examination each month may decrease my chances of dying from 
breast cancer (68%); and If I find a lump early through breast self-examination, my treatment for 
breast cancer may not be as bad (69.3%). This reflects low perceived benefits to all the items in 
this subscale. 
3.1.4 Perceived benefits of mammogram 
Majority of the respondents do not agree that mammography has benefits as follows: When I 
get a recommended mammogram or x-ray of the breast, I feel good about myself (54.3%); When I get a 
mammogram or x-ray of the breast, I don’t worry as much about breast cancer (52.9%); Having a 
mammogram or x-ray of the breast will help me find lumps early (60.9%); Having a mammogram or 
x-ray of the breast will decrease my chance of dying from breast cancer (51.5%); and Having a 
mammogram will help me find a lump before it can be felt by me or a health professional (58.2%). 
Very few participants agreed with the statements, while many others neither agreed nor 
disagreed, as seen in Table 4 
3.1.5 Perceived barriers to BSE 
Participants were asked to indicate to what degree they agreed or disagreed with statements 
related to perceived barriers of breast cancer screening. On all the items in this subscale, 
participants were more in agreement with each statement. However, five  items received 
remarkably higher agreement: I do not feel I can do breast self-examination correctly (50.2%); 
Doing breast self-examination will make me worry about what is wrong with my breast (52.3%); My 
breasts are too large for me to complete breast self-examination (83.1%); My breasts are too lumpy for 
me to complete breast examination (81.8%); and I have other problems more important than doing 
breast self-examination (57.8%).  
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 N % N % N % 
Susceptibility       
My chances of getting breast cancer in the 
next few years are great. 
37 16.4 9 4.0 179 79.5 
I feel I will get breast cancer sometime 
during my life. 
49 21.8 2 0.9 174 77.3 
Developing breast cancer is currently a 
possibility for me 
38 16.9 33 14.7 154 68.4 
I am concerned about the likelihood of 
developing breast cancer. 
67 29.8 38 16.9 120 53.3 
Severity       
I am afraid to think about breast cancer. 81 36.0 65 28.9 79 35.1 
Problems I would experience with breast 
cancer would last a long time. 
72 32.0 63 28.0 90 40.0 
Breast cancer would threaten a 
relationship with my boyfriend, husband 
or partner. 
57 25.3 79 35.1 89 39.6 
If I had breast cancer my whole life would 
change. 
86 38.2 63 28.0 76 33.8 
If I developed breast cancer, I would not 
live longer than 5 years. 
 
42 18.7 27 12.0 156 69.3 
 
Table 3. Frequency and Percentages of Participants Susceptibility and Severity Responses. 
3.1.6 Perceived barriers to mammogram 
Majority of respondents agree or strongly agree with most of the statements in this subscale 
but those who neither agree nor disagree were in the majority on the following: It is difficult 
to get transportation for a mammogram or X-ray of the breast (50.2%); Having a mammogram or X-
ray of the breast costs too much money (42.2%); I cannot remember to schedule an appointment for a 
mammogram or X-ray of the breast (57.3%).  
3.1.7 Self-efficacy 
Majority of the participants disagreed with the following statements: I am sure of the steps to 
follow for doing breast self-examination (44.9%); I am able to tell something is wrong with my breasts 
when doing breast self-examination (49.7%); and I can use the correct part of my fingers when 
examining my breasts (50.7%). Fifty-four percent neither agree nor disagree that they could 
find a breast lump by performing breast self-examination (54.2%). 
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 N % N % N % 
Benefits of Breast Self-Examination       
When I do breast self-examination, I am doing 
something to take care of myself 
170 75.6 36 16.0 19 8.4 
Completing breast self-examination each 
month may help me to find breast lumps early. 
196 87.1 8 3.6 21 9.3 
Completing breast self-examination each 
month may decrease my chances of dying from 
breast cancer. 
153 68.0 30 13.3 42 18.7 
If I find a lump early through breast self-
examination, my treatment for breast cancer 
may not be as bad. 
156 69.3 43 19.1 26 11.6 
Benefits of Mammography       
When I get a recommended mammogram or x-
ray of the breast, I feel good about myself. 
122 54.2 71 31.6 32 14.2 
When I get a mammogram or x-ray of the 
breast, I don’t worry as much about breast 
cancer. 
119 52.9 79 35.1 27 12.0 
Having a mammogram or x-ray of the breast 
will help me find lumps early. 
137 60.9 66 29.3 22 9.8 
Having a mammogram or x-ray of the breast 
will decrease my chance of dying from breast 
cancer. 
116 51.6 77 34.2 32 14.2 
Having a mammogram will help me find a 
lump before it can be felt by [me] or a health 
professional. 
131 58.2 47 20.9 47 20.9 
 
Table 4. Frequency and Percentages of Participants Perceived Benefits Responses. 
3.1.8 Cues to action 
An overwhelming majority of the participants disagreed or strongly disagreed with all the 
statements in Cues to action subscale: I want to discover health problems early (71.5%); 
Maintaining good health is extremely important to me (80.5%); I search for new information to 
improve my health (85%); and I feel it is important to carry out activities which will improve my 
health (75.1%).  
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 N % N % N % 
Barriers of Breast Self-Examination       
I do not feel I can do breast self-examination 
correctly. 
50 22.2 62 27.6 113 50.2 
Doing breast self-examination will make me 
worry about what is wrong with my breast. 
88 39.1 42 18.7 95 42.2 
Breast self-examination is embarrassing to me.  88 39.1 42 18.7 95 42.2 
Breast self-examination takes too much time. 91 40.4 56 24.9 78 34.7 
It is hard to remember to do breast 
examination. 
103 45.8 40 17.8 82 36.4 
I don’t have enough privacy to do breast 
examination. 
64 28.4 61 27.1 100 44.4 
Breast self-examination is not necessary if you 
have a breast exam by a health professional. 
43 19.1 79 35.1 103 45.8 
Breast self-examination is not necessary if you 
have a routine mammogram.  
62 27.6 68 30.2 95 42.2 
My breasts are too large for me to complete 
breast self-examination. 
22 9.8 16 7.1 187 83.1 
My breasts are too lumpy for me to complete 
breast examination. 
12 5.3 29 12.9 184 81.8 
I have other problems more important than 
doing breast self-examination.  
86 38.2 9 4.0 130 57.8 
Barriers of Mammography       
I am afraid to find out there is something 
wrong when I have a mammogram or X-ray of 
the breast. 
68 30.2 47 20.9 110 48.9 
I am afraid to have a mammogram or X-ray of 
the breast because I don’t understand what 
will be done. 
38 16.9 56 24.9 131 58.2 
I don’t know how to go about scheduling a 
mammogram or X-ray of the breast 
20 8.9 81 36.0 124 55.1 
Having a mammogram or X-ray of the breast 
would be embarrassing. 
25 11.1 67 29.8 133 59.1 
Having a mammogram or X-ray of the breast 
would take too much time. 
27 12.0 78 34.7 120 53.3 
Having a mammogram or X-ray of the breast 
would be painful. 
39 17.3 86 38.2 100 44.4 
Having a mammogram or X-ray of the breast 
would expose me to unnecessary radiation. 
58 25.8 82 36.4 85 37.8 
It is difficult to get transportation for a 
mammogram or X-ray of the breast. 
21 9.3 113 50.2 91 40.4 
I have other problems more important than 
getting a mammogram or X-ray of the breast. 
44 19.6 72 32.0 109 48.4 
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Table 4. Frequency and Percentages of Participants Perceived Benefits Responses. 
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Having a mammogram or X-ray of the breast 
costs too much money. 
67 29.8 95 42.2 63 28.0 
I cannot remember to schedule an 
appointment for a mammogram or X-ray of 
the breast 
26 11.6 129 57.3 70 31.1 
Table 5. Frequency and Percentages of Participants Perceived Barriers Responses. 
 
Questions 










 N % N % N % 
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I know how to perform breast self-examination 94 41.8 66 29.3 65 28.9 
I can perform breast self-examination correctly. 65 28.9 76 33.8 84 37.3 
I could find a breast lump by performing breast 
self-examination 
63 28.0 122 54.2 40 17.8 
I am sure of the steps to follow for doing breast 
self-examination. 
101 44.9 51 22.7 73 32.4 
I am able to tell something is wrong with my 
breasts when doing breast self-examination. 
112 49.8 31 13.8 82 36.4 
I am able to tell something is wrong with my 
breasts when I look in the mirror. 
92 40.9 56 24.9 77 34.2 
I can use the correct part of my fingers when 
examining my breasts. 
114 50.7 60 26.7 51 22.7 
Cues to Action       
I want to discover health problems early. 161 71.6 53 23.6 11 4.9 
Maintaining good health is extremely important 
to me. 
181 80.4 41 18.2 3 1.3 
I search for new information to improve my 
health. 
193 85.8 32 14.2 0 0 
I feel it is important to carry out activities which 
will improve my health. 
169 75.1 36 16.0 20 8.9 
Table 6. Frequency and Percentages of Participants Self efficacy and Cues to action 
Responses. 
3.2 Fatalism scores 
Majority of the participants were in agreement with all the items of the fatalism scale, with 
the following items having seventy-five percentile “Yes” scores: I believe if someone is meant to 
have cancer, it doesn't matter what they eat, they will get cancer anyway (69.3%); I believe cancer 
will kill most people who get it (76.4%); I believe someone can smoke all their life, and if they are not 
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meant to get cancer, they won't get it (77.8%);and I believe some people don't want to know if they 
have cancer because they don't want to know they may be dying from it (82.2%). Total scores on 
the Fatalism Scale ranged from 0 -15, with means of 10.82 (SD = 4.35). Table 7 shows a 







 ITEM (N = 225) YES NO 
  N % N % 
1 I believe if someone is meant to have cancer, it doesn't 
matter what they eat, they will get cancer anyway.     
156 69.3 69 30.7 
2 I believe if someone has cancer, it is already too late to 
do anything about it. 
135 60.0 90 40.0 
3 I believe someone can smoke all their life, and if they 
are not meant to get cancer, they won't get it. 
175 77.8 50 22.2 
4 I believe if someone is meant to get cancer, they will get 
it no matter what they do.  
146 64.9 79 35.1 
5 I believe if someone gets cancer, it was meant to be. 138 61.3 87 38.7 
6 I believe if someone gets cancer, their time to die is 
near. 
115 51.1 110 48.9 
7 I believe if someone gets cancer, that's the way they 
were meant to die. 
105 46.7 120 53.3 
8 I believe getting checked for cancer makes people think 
about dying. 
136 60.4 89 39.6 
9 I believe if someone is meant to have cancer, they will 
have cancer. 
146 64.9 79 35.1 
10 I believe some people don't want to know if they have 
cancer because they don't want to know they may be 
dying from it. 
185 82.2 40 17.8 
11 I believe if someone gets cancer, it doesn't matter when 
they find out about it, they will still die from it. 
155 68.9 70 31.1 
12 I believe if someone gets cancer a lot of different 
treatments won't make any difference. 
144 64.0 81 36.0 
13 I believe if someone was meant to have cancer, it 
doesn't matter what the doctor tells them to do, they 
will get cancer anyway. 
143 63.6 82 36.4 
14 I believe if someone is meant to have cancer, it doesn't 
matter if they eat healthy foods, they will still get 
cancer. 
153 68.0 72 32.0 




Table 7. Scores on the Fatalism Scale. 
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Model R R Square
Adjusted 
R Square






Change df1 df2 
Sig. F 
Change 
1 .478a .229 .189 .43206 .229 5.744 11 213 .000 
Table 8. Summary of regression analysis on breast self-examination and perceived barriers.  
From Table 8 r = .478, f = 5.744, p > .001. This indicates a significant correlation. Therefore 
the hypothesis which stated that perceived barriers will have no effect on breast self-













Change df1 df2 
Sig. F 
Change 
1 .415a .172 .129 .23330 .172 4.020 11 213 .000 
Table 9. Summary of regression analysis on mammography practice and perceived barriers.  
From Table 9 r = .415, f = 4.020, p > .001. This indicates a significant correlation. Therefore 
the hypothesis which stated that perceived barriers will have no effect on mammography 
practice is rejected. 
Lastly, there is no significant association between breast cancer fatalism and the practice of 
breast self-examination. These results indicate that there is no statistically significant 
relationship between breast cancer fatalism and breast self-examination practice Χ2 (1, n = 
225) = 2.39, p = .122, phi = .113 There is no association between breast cancer fatalism and 
breast self-examination. 
4. Discussion 
Majority of women see themselves as susceptible to having breast cancer and yet an 
abysmally low proportion does nothing to prevent breast cancer by adopting the standard 
screening practices. Lack of knowledge about preventative measures has been a frequent 
finding from studies in this environment (Akhigbe & Omuemu, 2009).  
The scores on the perceived benefits of breast self-examination subscale reflect low 
perceived benefits. A low knowledge of screening methods for breast cancer, even among 
final year medical students had been reported in this environment (Akhigbe et al, 2009). The 
finding of low perceived benefits in the present study is therefore not surprising. 
Participants generally do not recognise the perceived benefits of screening mammography. 
This may explain why mammography use is very low in the study population (6.7%). 
Previous studies (Odusanya & Tayo, 2001; Akhigbe & Omuemu, 2009; Akhigbe & 
Igbinedion 2010) have confirmed this low mammography usage in other populations in 
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Nigeria. There is as yet no national health policy concerning breast cancer screening but 
several health and advocacy groups have been calling on the relevant health authorities to 
formulate and implement such a policy. However, appropriate health policy even with 
government funding will not necessarily increase mammography usage; awareness has to 
be created and populaton at risk have to know what benefits they stand to gain from having 
screening mammography done. 
The present study has revealed a high level of breast cancer fatalism among Nigerian 
women. It is therefore not surprising that the respondents who have shown high levels of 
perceived susceptibility still do not take preventative measures. It is like ‘If it will happen, 
nothing can stop it from happening’. Powe (1996) observed that many factors affect a 
person’s decision to participate in cancer screening; poor access to care, poverty, under-
education, and lack of knowledge regarding cancer have a negative relationship to 
participation in cancer screening. Studies have shown that being African American is 
positively correlated with these factors, and that even when these factors are statistically 
controlled, African Americans are still less likely to participate in cancer screening. Could 
the findings among African Americans be a ‘cultural carry-over’ from their roots? 
The present study appears to be highly supportive of the preceding conclusion. The 
academic and professional background of the study participants is clearly remarkable and 
above average, all of them working as either health professionals or secondary school 
teachers. They however have high scores in perceived susceptibility subscale of the HBM 
and very low score in the perceived benefits subscale; besides the practice of BSE and 
mammography is pitiably low. This poses a problem for working out appropriate, culturally 
relevant educational protocol for increasing breast cancer screening practices among 
Nigerian women. Having adequate knowledge of breast cancer and breast cancer screening 
methods is clearly not enough. Cultural barriers such as breast cancer fatalism will need to 
be overcome using appropriate educational intervention. 
Three hypotheses were tested. The rejection of the first hypothesis shows that perceived 
barriers have a direct negative effect on the practice of breast self-examination among the 
study population. Previous studies have noted poor knowledge of breast self-examination 
practice as a screening method among Nigerian women irrespective of their level of 
education or professional status (Odusanya & Tayo 2001; Akhigbe & Omuemu 2009). From 
the item responses on the perceived barrier subscale, such factors as large breast size and 
inadequate self-efficacy in performing a breast self-examination constitute major barriers. 
Focused educational intervention remains the obvious solution. 
The rejection of the second hypothesis shows that perceived barriers have a direct 
negative effect on mammography practice among the study population. There is a 
technology requirement for mammography practice. This makes economic consideration a 
veritable factor to overcoming this barrier. Unfortunately, health professional do not seem 
to fare better in their knowledge and practice of mammography, as this study and 
previous studies have consistently shown. There is therefore an urgent need for a review 
of training curricula by health institutions to include cancer awareness and screening 
methods. This may positively impact on the health behavior of those who are expected to 
teach others. 
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The third hypothesis was accepted, that is, there is no significant relationship between 
cancer fatalism and the practice of breast self-examination. Cancer fatalism is deeply rooted 
in ethno religious beliefs of the people. The individual, having resigned herself to fate or 
luck does nothing as prevention. Cancer fatalism, however, is a complex phenomenon with 
far-reaching implications (Powe & Finnie, 2003). 
5. Conclusion 
There is paucity of research publications on the effects of health belief model and cancer 
fatalism with regards to breast cancer among Nigerian women.  
There is need to for us to understand the psychological and psychosocial barriers that deter 
Nigerian women from having adequate breast cancer awareness as well as routine 
screening. Such information will be useful in putting together culturally relevant awareness 
literature and media content that address these barriers.  
From the health belief model, there are significant barriers that impact negatively on the 
practice of the two main screening methods, breast self-examination for which no tools or 
economic input is required, and screening mammography with the obvious advantages. 
Another significant finding is the high level of breast cancer fatalism among the study 
population. This represents a helpless resignation to accepting whatever the “death 
sentence” of breast cancer brings to the afflicted. Fatalism has remained a major cultural 
setback in this setting.  
This study therefore represents preliminary findings that should form the basis for further 
research. 
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research. 
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1. Introduction 
There is a widening Black:White breast cancer mortality disparity in Chicago (Figure 1). In 
1980 the mortality rates were equal; by 2005 Black women were nearly twice as likely to die 
from breast cancer (Ansell et al, 2009; Whitman et al, 2011). This disparity has been 
increasing since the early 1990’s because the breast cancer mortality rates for Black women 
in Chicago have remained constant while the rates for White women have decreased 
substantially (Whitman et al, 2011). Additionally, this disparity in Chicago is unusually 
high. For example, in 2005 the breast cancer mortality rate for Black women in Chicago was 
43.2 per 100,000 population and the rate for White women was 21.8 per 100,000 population 
(Whitman et al, 2011). This equates to a rate ratio of 1.98 (43.2/21.8) which is interpreted by 
stating that in 2005 Black women were 98% more likely to die from breast cancer than White 
women in Chicago. More recent data suggests that Black women in Chicago are 62% more 
likely to die from breast cancer using the 2005-2007 three-year average (38.3/23.6=1.62) 
(Figure 1). Disparities are seen in other cities as well. For example, in New York City the 
Black:White breast cancer disparity in 2005 was 37% (Whitman et al, 2011). These data 
suggest that Black women in Chicago are not benefiting from the technological 
advancements that have been made in early detection and treatment over the last two 
decades (Berry et al, 2005; Smith-Bindman et al, 2006; Tehranifar et al, 2009).   
In response to such data, health care providers, researchers, community leaders, educators, 
administrators and breast cancer survivors joined efforts to devise a strategy to eliminate the 
breast cancer mortality disparity in the Chicago area. As a result of a call to action, 111 
individuals from 74 local institutions formed three working groups focusing on access to 
mammography, quality of the diagnostic process, and access and quality of breast cancer 
treatment.  These three groups formed the Metropolitan Chicago Breast Cancer Task Force 
and outlined a plan consisting of 37 actionable recommendations to decrease breast cancer 
mortality for the metropolitan area of Chicago (Ansell et al, 2009; Metropolitan Chicago 
Breast Cancer Task Force [Task Force], 2007). 
One of the three main goals of the Task Force was to implement interventions to increase the 
number of age-eligible women in Chicago who obtain regular screening mammograms. At  
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Fig. 1. Age Adjusted Female Breast Cancer Mortality Rates, Chicago, By Race, 1981-2007. 
an early point we asked ourselves:  If our efforts were successful in increasing the number of 
women who wanted to obtain mammograms, would there be adequate capacity?  We thus 
began an inquiry to determine what this capacity was in Chicago. Researchers in the city did 
not know the answer to this question. Neither did advocacy groups. We were surprised that 
such a number was not even partially established for Chicago so we turned to other large 
cities. We were then more surprised that we were not able to find even one city that had an 
estimate of mammography capacity that might be useful in understanding the situation in 
Chicago.  
Given this general lack of information the Task Force thus decided to undertake a study of 
mammography screening capacity in Chicago. The purpose of this chapter is to report the 
results from a survey of such mammography facilities in order to estimate and compare 
potential need for screening mammography, utilization, and current capacity for screening 
mammography in the third largest city in the United States. To our knowledge this is the 
first such analysis of capacity for a major urban area in the United States. 
2. Methods 
2.1 The survey instrument 
The mammography capacity survey, which was conducted July – September 2007, 
contained 31 questions (Figure 2.), and was designed to take about 10 minutes to complete 
for someone familiar with the information. We asked facilities to provide information 
related to 2007 capacity, including the number of screening and diagnostic mammograms 
performed per month, hours of operation, number of machines, number of imaging 
technologists and radiologists interpreting mammograms, and the level of difficulty 
maintaining staffing.  
Screening Mammography Need, Utilization and Capacity  
in Chicago: Can We Fulfill Our Mission and Our Promises? 
 
91 
2.2 Recruitment of mammography centers 
In order to determine what mammography facilities existed in Chicago, we compiled a list 
of certified mammography facilities (U.S. Food and Drug Administration [FDA], 2007). We 
searched the FDA website by zip codes beginning with “606” which designates the city of 
Chicago. At the time of the survey there were no operating mobile mammography units, 
thus none were surveyed.  
Each facility received a cover letter stating the purpose of the Task Force, the purpose of the 
survey and the expectation of confidentiality. We mailed the letter along with a copy of the 
survey and waited two weeks. As expected few centers responded to an unsolicited letter 
requesting information about their mammography facility. For facilities that did not 
respond within the 2 weeks, we recruited partners in the Task Force to distribute the survey 
to their contacts or colleagues in the radiology departments on the list.  This round of efforts 
improved the response rate substantially but still not enough. We next solicited the help of 
three prominent health care leaders in the city who also serve as the co-chairs of the Task 
Force. They were able to stimulate several more institutions to complete the surveys.  
In the end we identified and attempted to survey all 49 FDA certified mammography 
centers located in Chicago. The overall response rate was 88% (43 out of 49). Every major 
institution responded. There were 6 non-responding sites according to state inspection 
records obtained by the authors each of which operated a single licensed mammography 
machine. 
2.3 Estimating potential need for screening mammography 
We estimated potential need for screening mammography as a function of the estimated 
number of female residents of Chicago aged 40 or older  according to the 2000 United States 
Census (http://factfinder.census.gov) (577,609) (Unites States Census Bureau, n.d.), and 
current guidelines which typically recommend a screening mammogram every year or 
every other year for women aged 40 and above (American Cancer Society, 2009; Lee et al, 
2010; Humphrey et al, 2002; U.S. Preventive Services Task Force, 2009). Need according to 
the recommendation for annual mammography was simply the number of age-eligible 
women residing in Chicago, and need according to biennial recommendation was equal to 
the number of age-eligible women divided by two.  
2.4 Estimating mammography utilization (volume) 
Facilities were asked to report separately on the number of screening and diagnostic 
mammograms performed in an average month. For the six non-responding Chicago sites, 
we estimated the numbers of screening and diagnostic mammograms based on the mean 
values for participating facilities obtained after excluding the larger academic centers.  
Mammography volume was calculated based on the responses to the question: “How many 
screening mammograms does this facility perform approximately per month?” This number 
was then divided by the site specific number of days open for mammograms. Consistent 
with previous reports, volume was then sub-divided into 3 categories:  High, Medium and 
Low. High Volume was defined as 15 or more mammograms performed each day, Medium 
Volume was 5-14 mammograms per day and Low Volume included centers that performed 
4 or fewer mammograms per day (Houn & Brown, 1994; Hendrick et al, 2005).   
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2.5 Estimating mammography maximum capacity   
We estimated each facility’s maximum capacity by using the 2006 Government 
Accountability Office (GAO) definition of maximum capacity that assumes that three 
mammograms can be performed per machine per operating hour (U.S. Government 
Accountability Office [GAO], 2006). We defined “maximum GAO screening capacity” as 
three times the number of mammography machines, times the number of hours open, 
multiplied by the proportion of all mammograms that were for screening. For non-
responding facilities, we estimated the number of machines, number of hours open, and 
maximum capacity based on information available on participating non-academic facilities. 
2.6 Staffing difficulties 
Our survey also asked questions about difficulties in staffing open positions in imaging. 
Difficulty was categorized as such:  much, moderate, none, and did not have to recruit new 
staff).  
2.7 Classifying mammography centers 
We asked the affiliation of every site filling out the survey. Sites were classified as academic 
if they reported a university affiliation with a medical school. Academic institutions in 
Chicago are larger and may have more resources than non-academic institutions due to 
grant opportunities, endowments, payer mix, etc. The survey also requested information on 
whether each facility made available a variety of breast screening and diagnostic 
procedures, imaging staff, the ability to interpret mammograms on site, the ability to offer 
same day results or procedures and general demographics of patients such as insurance 
status and race/ethnicity. 
2.8 Statistical analysis 
Data were entered into a Microsoft Access database and then analyzed in SAS (v. 9.0).  
3. Results 
In most cases (77%) the surveys were completed by staff members who were directly 
involved with the day to day workings of the imaging departments. Of the n=43 completed 
surveys, 12% of the sites (n=5) had senior management, consisting of executive directors and 
department heads, complete the survey. Forty-seven percent were directors or managers of 
breast imaging or general imaging (n=20), 14% were either radiologists or nurse 
practitioners (n=6), 9% were lead technologists (n=4), 7% were non-lead technologists (n=3), 
and 12% were data analysts or clerks (n=5). (Data not Shown). 
3.1 Potential need for screening mammography 
According to the 2000 U.S. Census, there were approximately 578,000 female residents of 
Chicago aged 40 or older. In order for every age-eligible woman in Chicago to obtain annual 
screening mammography there would need to be 578,000 screening mammography slots or 
appointments available, and one half of that or 289,000 slots or appointments in order for 
every age-eligible woman in Chicago to obtain a mammogram every two years. 
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 Total For Chicago 
Number of Centers 49 a 
Annual Screening Mammographic Need b 577,609 
Biennial Screening Mammographic Need c 288,805 
Number of Screening Mammograms (Utilization/Volume) 176,214 
Number of Total Mammograms (Utilization/Volume) 254,850 
Maximum Capacity for Screening using GAO (2006) Estimation d 492,879 
a 43 facilities responded to the survey; totals for the remaining 6 were estimated  
b defined as female residents of Chicago aged 40 and over 
c defined as female residents of Chicago aged 40 and over divided by 2 
d Government Accountability Office  
Table 1. Estimated Mammography Utilization, Capacity, and Need for Chicago, 2007. 
3.2 Mammography utilization (volume) compared with potential need   
Table 1 presents the screening mammography need, utilization, and capacity. In 2007, an 
estimated 176,214 screening mammograms were provided by Chicago facilities. If one 
assumes, consistent with several recommendations (American Cancer Society, 2009; Lee et 
al, 2010), that all women 40 years of age and older should have an annual mammogram then 
the estimated screening mammography volume (176,214) represents 31% of eligible women 
or “need” (577,609). If one instead assumes, consistent with other recommendations 
(Humphrey et al, 2002), that all women age 40 and over should have a mammogram every 
two years then the “need” is halved (288,805) and the estimated screening mammography 
volume represents 71% of eligible women or “need”.  
3.3 Mammography capacity compared with potential need   
According to the GAO-defined maximum capacity based on their 2006 revised definition 
that assumes 3 mammograms can be performed on one machine in an hour (GAO, 2006), 
there are 492,879 available screening mammography slots or appointments in the City of 
Chicago. This represents roughly 85% the “need” or number of age-eligible for annual 
screening (women 40 and over) women in Chicago (approximately 578,000) and 170% of the 
“need” or age eligible women for biennial screening (all women 40 and over divided by 2).  
3.4 Difficulty recruiting mammography staff 
More than one third (37%) of all facilities reported some difficulty in recruiting 
mammography technologists or radiologists, corresponding to one third (32%) of screening 
mammograms performed across these facilities (Table 2). One quarter of facilities 
representing one of every five screening mammograms reported difficulty hiring 
technologists, while a fifth of all facilities representing one quarter of screening 
mammograms reported difficulty hiring radiologists. Most notably, while only 1 in 10 
facilities reported difficulties recruiting breast imaging specialists, they accounted for nearly 
one of every 5 mammograms performed (Table 2). 
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one of every 5 mammograms performed (Table 2). 
 




Fig. 2. Mammography Facility Survey. 
A city wide task force was assembled in March of this year to address the unacceptable 
disparity in breast cancer mortality by race in Chicago.  This task force is compiling a 
list of recommendations to be released on October 17, 2007 to address the issues related 
to Access to and Quality of Mammography as well as Access and Quality of Treatment 
for breast cancer. In order to ensure that our recommendations are in line with 
mammography capacity in Chicago we need your help. We are asking you or someone 
knowledgeable within your institution to complete this brief survey and return this 
form as soon as possible. 
These data will be used to further guide our recommendations to improve breast health 
for all women in Chicago. We will not present or publish information from individual 
facilities or institutions either as part of the task force or elsewhere. Your name and the 
names of any colleagues will not be published in this report and will remain 
confidential.  We will only use your name and contact information if we have further 
follow-up questions.   
Thank you in advance for helping to fill in this important picture of access to 
mammography in Chicago. 
Instructions: Please fill out ONE form for EACH mammography facility at your 
institution, for your convenience we have typed in the names of the facilities which 
we are interested in learning more about. 
Facility name: __________________________________________________________  
Address: _______________________________________________________________  
City:_______________________________________   ZIP: ______________________  
Institution affiliation (if any):  _____________________________________________  
Name of person(s) completing this questionnaire: ___________________________  
Position or title(s):_______________________________________________________  
Capacity: 
1. How many hours is this facility open Monday-Friday? _________ 
2. How many hours is this facility open on the weekend? _________ 
3. How many mammography machines do you have at this facility? _________ 
4. How many imaging techs do you have who are dedicated to mammography 
(>75% of time spent on mammograms)? _________ 
5. How many imaging techs does this facility have who spend <75% of their time on 
mammography? _________ 
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_________ 
8. How many screening mammograms does this facility perform:   
9. approximately ______ per month? 
10. How many diagnostic mammograms does this facility perform:   
approximately ______ per month?
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Fig. 2. Mammography Facility Survey (continued). 
11. Roughly what percentage of your patients have private insurance? 
<25% 25-49% 50-75%  >75% 
12. Roughly what percentage of your patients are African American?  
 <25% 25-49%  50-75%  >75% 
13. Roughly what percentage of your patients are Latina/Hispanic? 
<25%  25-49%  50-75%  >75% 
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 <25%  25-49%  50-74%  75-89%  90-99% 100% 
 
Does your facility routinely Never Rarely Sometimes Often Always 
15. Read mammograms on site at your facility?      
16. Read films on the same day so that the 
patient can leave with the results?      
17. Routinely double-read mammograms with 
suspicious findings?      
18. Routinely double-read all mammograms?      
19. Provide computer-aided detection (CAD) for 
suspicious mammograms findings?      
20. Provide computer-aided detection (CAD) 
for all screening mammograms?      
Does your facility offer: 
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22.  Breast ultrasound?    Yes  No 
23.  Digital mammography?   Yes  No 
24.  Breast magnetic resonance imaging?  Yes  No 
25.  Breast nuclear medicine scanning?  Yes  No 
26.  Biopsies after a diagnostic mammogram? Yes  No 
27.  Biopsies carried out during the same visit? Yes  No 
Over the last year how much difficulty 











28. Dedicated mammography technicians     
29. X-ray technicians who perform some 
mammograms     
30. Dedicated mammography 
radiologists     
31. General Radiologists who read 
mammograms     
If we need to ask follow-up questions, please provide the name and phone number of 
the person we should contact: 
Name:________________________________Phone number:________________________ 
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Mammography Technicians or Radiologists 37 32 
Mammography Technicians 26 19 
Dedicated Mammography Technicians 12 10 
General Mammography  Technicians 23 12 
Breast Radiologists 19 26 
Dedicated Breast Radiologists 10 19 
General Breast Radiologists 14 13 
a Difficulty defined as much/moderate difficulty vs. no difficulty/did not need to recruit staff. 
b Does not include non-responding sites (n=6) 
Table 2. Difficultya Recruiting Mammography Staff for Chicago, 2007. 
3.5 Characteristics of mammography centers 
Table 3 presents the characteristics of the Chicago facilities with completed surveys and 
also demonstrates how these characteristics are distributed according to facility volume 
(Low, Medium, High; see Methods). Because the number of facilities in each category is 
small we omit tests of significance. However, several of the trends suggest strong 
relationships.  
As Table 3 indicates, in 2007 the 43 responding Chicago facilities (out of a total of 49) 
performed about 160,000 screening mammograms. Sixty-eight percent of the mammograms 
performed by the 43 responding Chicago facilities were performed at High Volume 
facilities. On average the High Volume centers performed 8,400 screening mammograms per 
site, whereas the Medium Volume centers performed 2,704 and the Low Volume centers 
performed 785.   
The facilities are open for an average of 45 hours per week (range = 4 hrs – 90 hrs) and more 
than half offer weekend hours. They reported employing a total of 160 radiologists who 
read screening mammograms, of whom 36% are dedicated mammography radiologists 
(interpreting mammograms or conducting breast procedures for >75% of working hours). 
The mean number of dedicated radiologists per institution (1.3 overall) was highest for High 
Volume facilities (2.6). These institutions reported the use of 84 mammography machines 
with the highest average per institution again being for High Volume facilities.  
About 16% of these facilities reported an academic affiliation, more than half of them 
occurring at High Volume facilities. A majority of facilities offer diagnostic services (67%) 
and interpret mammograms on site (79%) while smaller proportions offer same day results 
(23%) or same day biopsies (30%).  
About a quarter of these facilities serve a high proportion (>75%) of patients with private 
insurance, including almost half of the High Volume facilities. Forty-two percent of the 
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facilities serve a majority Black population and this proportion is highest at Low Volume 
facilities. Nineteen percent of the facilities serve a majority Hispanic population and this 
proportion is highest at Medium Volume facilities. 
4. Discussion  
The results of this unique survey show that the current available capacity for screening 
mammography in Chicago, as measured in terms of available mammography machines, is 
not adequate to meet the need of screening all Chicago residents (Table 1). In addition, there 
appear to be substantial issues pertaining to recruitment of staff needed to perform activities 
necessary to achieve this capacity (Table 2). 
The other important set of observations (Table 3) revolves around the many differences in 
the characteristics of Low, Medium and High Volume facilities. High Volume facilities 
(those doing > 15 screening mammograms/day) were different in many ways from Low 
(<4/day) and Medium (5-14/day) Volume facilities (Table 2). High Volume facilities are 
open more hours, have a greater proportion of radiologists who are dedicated to 
mammography, more often have academic affiliations and serve a greater proportion of 
patients with private insurance. They are also less likely to serve patient populations who 
are majority Black or Hispanic. These differences are most stark when comparing High 
Volume facilities with Low Volume (< 4/day) facilities. Literature suggests that both 
volume and academic affiliation may be associated with higher quality (Esserman et al, 
2002; Barlow et al, 2004; Woodward et al, 2002; Sickels et al, 2002; Miglioretti et al, 2007). 
There is some confusion in vocabulary in the few existing capacity studies and we would 
thus like to spell out some concepts and terminology before proceeding with a 
contextualization of our findings. Need for screening mammography is both a function of the 
number of women aged 40 or over (which is a function of the size of the population and its 
age structure), the screening rate and the accepted recommendation for the frequency of 
screening mammography (e.g., every year or every two years). Utilization (Volume) is in turn 
a function of capacity, education and outreach, geographic distribution of machines, 
financial barriers and opportunities, etc. (Etling et al, 2009; Elkin et al, 2010; Schueler et al, 
2008; Masi et al, 2008). Finally, Capacity refers to the potential supply of screening 
mammography and is a function of the number of available machines, the technology of the 
machines (e.g., analog or digital), and the numbers of available technologists and 
interpreters. Curiously, the number of mammography facilities is a frequently studied topic 
(Etling et al, 2009) but this is irrelevant to capacity and would be subsumed by consideration 
of the available number of machines. 
Given this terminology let us examine in greater detail the screening mammography 
situation in Chicago. In 2007, 206,000 women received (utilized) screening mammograms. 
Depending upon which screening frequency recommendation one employs, this number 
may be compared with a potential annual need of 578,000 mammograms or 289,000 
mammograms (Table 1). We see that the utilization of screening mammography in Chicago 
is far less than what is theoretically possible given that Chicago facilities can perform 
approximately 493,000 mammograms at full capacity. 
We have been able to locate only a few peer-reviewed journal articles on the topic of 
capacity and utilization of screening mammography. Brown and colleagues published an 
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economic analysis which was conducted in 1990 (Brown et al, 1990). This study concluded 
that there was an excess supply of mammograms for the utilization at that time. However, 
two major events occurred since this publication that affect capacity. First, the 
Mammography Quality Standards Act (MQSA) was enacted in 1993 creating an 
infrastructure for quality (FDA, 2002). After the enactment of MQSA several facilities closed 
due to not being able to keep up with the standards (Eastern Research Group, 2001). Second, 
insurance companies began covering screening mammograms as part of routine care. Thus, 
mammography became available to more women (Institute of Medicine, 2005). The 
conclusion of this study is now 20 years old and has only decreasing relevance to the field.  
The most prominent studies of capacity data revolve around the two main reports on this 
topic which are authored by the Government Accountability Office (GAO) in formats 
prepared for Congress. In 2002 the GAO (GAO-2002) prepared a report that evaluated 
capacity for the U.S. as a whole between 1998 and 2001 following the enactment of the 
Mammography Quality Standards Act (MQSA) (FDA, 2002). 
The GAO-2002 report noted that even while the number of mammography facilities had 
decreased during this interval the number of technologists and machines had increased 
(GAO, 2002). At the same time the GAO cited signs that these increases were coming to a 
halt. The GAO also noted, “Although mammography services are generally available, 
women have problems obtaining timely mammography services in some locations. Most of 
the availability problems are in certain metropolitan areas . . .” (GAO, 2002, pp. 3). Chicago 
may be one of these areas but that remains unknown since the GAO did not present any 
estimates for cities.   
The GAO issued the second report in 2006 (GAO-2006) to evaluate the potential capacity 
issues with possible facility closures related to MQSA that may have occurred between 2001 
and 2004 and found that capacity was adequate in most places (GAO, 2006). In the GAO-
2006 report facilities performing mammography, machines, and staff had all decreased since 
2001 yet capacity remained sufficient (GAO, 2006). In addition, the GAO-2006 report noted 
that Illinois, and Cook County (which contains Chicago) in particular, was one of the areas 
which had significant facility closures. The reports conclude that low-income women may 
be most affected by these closures.  
The picture painted in this report was more pessimistic than its predecessor. It noted that, 
“The numbers of mammography facilities, machines, radiologic technologists, and 
interpreting physicians decreased from 2001 to 2004” (GAO, 2006, pp. 4) even as the number of 
women seeking and receiving mammograms increased. The declines were 4% for machines, 
3% for technologists, and 5% for physician mammogram interpreters, “usually radiologists.”  
The report thus notes: “Although experts believe the nation’s current overall capacity to 
provide mammography services is adequate, they are concerned that the numbers of 
radiologic technologists and radiologists entering the field might not be sufficient to serve the 
increasing population that will need mammography services” (GAO, 2006, pp. 21). 
Indeed, other research has shown evidence of a shortage of radiologists who interpret 
mammograms and mammography technicians (D’Orsi et al, 2005; Lewis et al, 2006; D’Orsi, 
2004). Our survey indicates that there was substantial difficulty filling open positions in 
breast imaging. For instance, nearly 20% of the responding facilities had difficulty filling 
open positions for any type of radiologist, 10% had some difficulty hiring dedicated 
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radiologists and 14% had difficulty hiring general radiologists. In addition, nearly 30% of 
the sites had difficulty filling open positions for dedicated mammography technicians or x-
ray technicians (Table 2).  
Although there are few studies in this field some have recently emerged in the literature 
indicating a potential growing interest in the topic. For instance Etling and colleagues 
conducted a study in Texas. This group researched mammography facility proximity by 
county and the correlates of self-reported mammography utilization and reported that there 
was unequal distribution of mammography facilities in Texas counties which impacted 
utilization of screening mammography in some areas (Etling et al, 2009).  In Texas, the rural 
counties had fewer facilities within them and this in turn was correlated with higher late-
stage breast cancers (Etling et al, 2009). The main limitations to this study are that the 
researchers did not analyze machine availability, just facilities, and the results are mainly 
applicable to a more rural population. Although the methods are different this study does 
illuminate a potential capacity issue locally. 
Another way to examine Chicago’s capacity for screening mammograms comes from a 
study by Elkin and colleagues. This study concludes that in order to have adequate capacity 
to meet the recommendation of annual screenings there needs to be more than 1.7 
mammography machines for every 10,000 age-eligible women. The study further estimated 
that if the screening rate of 70% of the target population is the goal (per Healthy People 
2010) then 1.2 machines per 10,000 age eligible women would be needed (Elkin et al, 2010; 
U.S. Department of Health and Human Services, 2001). As Table 3 indicates, there are 84 
mammography machines serving Chicago. In addition, there are approximately 578,000 age 
eligible women in Chicago equating to 58 groups of 10,000 women (578,000/10,000=57.8). In 
order to provide mammograms to 100% of the age eligible women Chicago would need 99 
machines (58*1.7 machines). If Chicago were to accomplish screening 70% of age eligible 
women (which is recommended by the U.S. Healthy People 2010) then 70 machines (58*1.2) 
would be needed according to Elkin and colleagues’ calculations (U.S. Department of Health 
and Human Services, 2001; Elkin et al, 2010). If one assumes that all age eligible women 
should receive mammograms annually, then it seems clear that the current capacity in 
Chicago is not adequate. If however, one assumes biennial mammography for age eligible 
women, then capacity in Chicago is adequate. 
Of course in this chapter we have only been analyzing the issue of capacity. Even if there 
were adequate capacity to screen all women in Chicago, and our findings suggest that there 
is not, many other questions arise with respect to utilization.  These include issues of health 
insurance, outreach, education, etc. All in all the breast cancer screening capabilities seem 
hardly up to the task of accommodating all women for screening, which is the goal of many 
advocates and physicians in the city. 
The question must then be posed whether we will soon be doing a disservice to women by 
urging them to obtain a mammogram only to be turned away because there are no 
appointments available for several months. The problem is already at hand in some cases in 
Chicago. For example, the waiting time for a screening mammogram appointment at one of 
the most prominent academic medical centers in the city is between 7-10 months (Deardorff, 
2008a, 2008b). At the same time the city’s only public hospital has stopped doing screening 
mammograms altogether, a loss of about 10,000 mammograms per year which were 
obtained by the most vulnerable women in the city. Access is thus being challenged at both 
ends of the socioeconomic spectrum. 
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obtained by the most vulnerable women in the city. Access is thus being challenged at both 
ends of the socioeconomic spectrum. 
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There are some methodological limitations to consider. First, we had to estimate important 
measures for non-responders such as mammography volume and capacity indicators (e.g., 
machines and hours of operation). However, the non-response accounted for only 9% of the 
Chicago screening volume. In addition, all non-responding sites were smaller community 
based hospitals (e.g., none were larger academic institutions). Thus, our estimation 
techniques could not have affected the contours of our analysis. 
Second, all surveys were self-reported by facility representatives. There was thus a chance 
that some of the questions may have been interpreted in an idiosyncratic manner but it is 
not obvious how the summation of these interpretations would have influenced our results. 
4.2 Recommendations for further consideration 
It has been suggested that with looming staff shortages in the field of mammography, one 
may need to begin looking for ways to improve quality or efficiency. Some possible areas to 
explore are as follows: 
 The Metropolitan Chicago Breast Cancer Task Force recommends that the state of 
Illinois offer some tuition reimbursement for the medical training of physicians willing 
to practice radiology, and specifically mammography, in underserved communities, 
where fellowship trained radiologists are lacking. Perhaps an incentive for repaying 
medical school loans for physicians choosing to practice in underserved areas in 
mammography may increase the dwindling mammography workforce (Bärnighausen 
& Bloom, 2009).  
 Literature notes that independent double reading of mammograms improves the 
performance of a screening mammography program (Harvey et al, 2001). However, in 
the United States, it has been suggested that there is a radiologist shortage willing to 
interpret screening mammograms (D’Orsi et al, 2005; D’Orsi, 2004). One way to increase 
the workforce in mammography and improve quality is to increase the use of physician 
assistants, trained breast cancer nurses or highly skilled mammography technologists 
into a mammography practice. The literature suggests that these staff could be used as 
second readers or to complete administrative work such as communicating results with 
primary care clinics or following up with patients who have abnormal findings under 
the supervision of a radiologist (IOM, 2005; Duijum, 2007; Tonita, 1999). These staff may 
be able to increase the time a radiologist has to interpret mammograms and perform 
breast procedures, thus allowing each site to provide more mammograms. 
 Centralizing or regionalizing either interpreting radiologists and/or a film library may 
begin to solve some of the bottlenecks in Chicago, thus freeing up machine space for 
more mammograms. Having radiologists interpreting mammograms in a centralized 
location allows sites that do not have access to a fellowship trained radiologist to have 
their mammograms interpreted by the best possible radiologist. In addition, having a 
universal film library will allow sites to gain access to their patients’ prior films. Having 
prior films available for comparison to current films could prevent unneeded additional 
imaging (Burnside et al, 2002).  
 Some facilities have reputations for high quality care and thus have high demand for all 
services they provide, including mammograms. This can lead to long wait times at 
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facilities to obtain a simple screening mammogram. In Chicago those wait times have 
been as high as 10 months for a screening mammogram appointment. A way to combat 
this problem is to have a centralized scheduling database that allows referring 
physicians to find open appointments for mammograms across the city. Although it is 
not ideal to have women obtain mammograms at multiple sites, coupled with 
centralized interpretations and storage this should make it easier on both physicians 
and patients. In addition, mammograms can be distributed throughout the city rather 
than clustered at a few facilities, thus utilizing all available capacity throughout 
Chicago.  
 The only public hospital system in the Cook County area no longer provides screening 
mammograms due to budget cuts. This leaves about 10,000 uninsured and 
underinsured women without a mammogram. In addition, public clinics operated by 
the city of Chicago are not nearing capacity. If they do operate at capacity an additional 
25,000 mammograms could become available to the most underserved women in 
Chicago and Cook County. Safety-net providers have stepped up to absorb the 
uninsured women into their routine screening population. However this places a large 
financial burden on these facilities, rather than spreading the burden to other area 
facilities. We propose that the Cook County public hospital system reopen screening 
mammograms for its patients and that other public facilities begin to operate at 
capacity. In addition, other area facilities must also begin managing these patients for 
breast and other services. 
 Finally, insurance carriers reimburse at various rates, and most hover around the cost of 
the image. Public insurances also differ in how they reimburse for mammograms. 
Medicare, the insurance plan that older Americans use, reimburses slightly below the 
cost of a mammogram, whereas Medicaid, the insurance provided to the poorest 
Americans, reimburses at about half to three-quarters of the cost. For those who have 
no insurance, either the facility must enroll them in a state program which reimburses 
at the Medicaid rate or the facility must absorb the total cost. Most mammography 
facilities operate in a deficit or break even, thus leaving little room for upgrades or 
departmental improvements including upgrading equipment, elective training for staff 
or hiring assistants (Chen et al, 2004). All insurance carriers (including government 
insurance plans) must reimburse for the costs of these services so that these 
departments can be profitable enough to improve care and efficiency. Once 
mammography facilities become more fiscally sustainable, they may be able to absorb 
more patients without health insurance and thus provide more mammograms. 
Without testing or implementing some of these strategies, we will constantly run up against 
limited capacity as a barrier to receiving mammograms. 
5. Conclusions 
The findings in this chapter suggest that there is currently inadequate screening 
mammography capacity in Chicago to screen all age eligible women annually. However 
there is adequate capacity to screen all age eligible women biennially. Given the existence of 
programs to increase access and the work of the Metropolitan Chicago Breast Cancer Task 
Force and other advocacy organizations seeking to increase education and outreach, women 
may continue to confront barriers when scheduling their annual mammograms.  
Screening Mammography Need, Utilization and Capacity  
in Chicago: Can We Fulfill Our Mission and Our Promises? 
 
103 
This brings us back to the motivation for this survey – the large and growing racial disparity 
in breast cancer mortality in the city. There may be two driving forces with respect to 
screening mammography that are perpetuating this disparity. First, women may be 
delaying care for various reasons (usually financial or lack of insurance) leading to larger 
tumors being discovered at screening mammography (Rauscher et al, 2010). Not having 
insurance may also lead to women waiting for diagnostic services because they have no 
other choice. The second is that facilities may not have enough appointments available for 
the demand. As noted above, we know that two major institutions are already experiencing 
such problems. Community-based organizations and other agencies spend a lot of time and 
money navigating women to screening and working towards women receiving routine 
breast services. There are things facilities can do to promote regular screening and some 
facilities employ these tactics. However, these efforts will fail unless there are enough 
appointments available for women to get timely mammography services. 
The chicken and egg relationship between supply and demand must be understood in this 
context. Is utilization as low as it is because women do not yet desire screening 
mammograms or is it because they have pursued them and been turned away because of 
insurance difficulties? Or is it because of very long waits? Are we indeed inadvertently 
limiting utilization by limiting capacity? These are questions that require answers. More 
generally, this is a problem that demands a solution.   
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In Poland, the number of new installations of FFDM (Full – Field Digital Mammography) 
units is increasing every year. These increasing numbers of digital mammography systems 
(DR systems) were possible to be evaluated on the basis of the data provided by the facilities 
taking part in the mammography screening program organized by the Polish Ministry of 
Health. 
In 2006, in the framework of the “Polish National Breast Cancer Early Detection Program for 
Women aged from 50 to 69” was initiated. In order to create a structure for administration of 
the screening program of the Ministry of Health, 16 regional Coordination Centres, covering 
the administrative regions of the country, were created. Also, a Central Coordination 
Centre, located at the Centre of Oncology in Warsaw was set up. Thanks to such 
organization it was possible to contact all mammography facilities involved in the screening 
program, to receive the necessary data from them and to evaluate their equipment. 
Furthermore, it was possible to curry out control of physical and technical parameters of the 
mammography equipment and to collect data concerning the individual woman exposures. 
The data, in the range necessary to calculate the doses received by the women during the 
examinations were collected. On this basis it was possible to evaluate that in 2007 in the 
whole country there were 320 mammography units used in the mammography screening 
program, and among them there were only 5 DR systems. On the other hand in 2010 and in 
2011 only in the Mazovia region the screening was carried out with 7 (out of 48) and 9 (out 
of 51) DR mammography systems respectively. Two of them were installed at the Centre of 
Oncology in Warsaw. However, the increase of the DR systems in Poland is limited by the 
relatively high costs of such installations as compared with the screen – film mammography 
systems (SFM systems). Moreover, the facilities equipped with mammography systems 
complying with the quality control requirements, are replacing SFM systems with computed 
radiography systems (CR systems). 
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The literature data indicate the evident advantages of the application of digital detectors in 
mammography. Apart from advantages linked with much simpler procedures of computer 
systems as far as processing, presentation, archiving and transmission of digital images are 
concerned there are more important advantages of DR systems over SMF systems namely: 
better image quality and lower doses of radiation received by the examined women. 
According to the published data (Gennaro, 2004, 2006; Gosch, 2006; Hermann, 2002; 
Lawinski, 2008) the average glandular doses are within 2.0 mGy per exposure allowing for 
detection of the objects of 0.1 mm diameter which is very satisfying. However, the results of 
some authors (Fischmann et al., 2005) indicate that the doses received by women examined 
with the systems equipped with digital detector are higher than those when the screen - film 
detector is used. These discrepancies in the results called for further analysis of absorbed 
doses and image quality in mammography with DR systems. The authors of this chapter 
analysed and evaluated the values of absorbed doses received by women undergoing 
screening mammography examinations at 8 facilities in Poland equipped with DR systems 
from 4 different manufacturers. This made possible a comparison of the performance of 
different DR systems as far as image quality is concerned.  
2. Doses in mammography 
2.1 Average glandular dose 
According to “Dosimetry in Diagnostic Radiology: An International Code of Practice” by 
International Atomic Energy Agency the average glandular dose (later called AGD) is the 
mean absorbed dose in the glandular tissue (excluding skin) in a uniformly compressed 
breast. The absorbed dose is the mean energy imparted to matter of mass. The unit of 
absorbed dose is gray (Gy). 
The higher the AGD value the higher the probability of inducing a cancer in examined 
women. It is especially important in case of mammography screening when probably 
healthy women are examined. For this reason the determination of this dose is one of the 
elements of quality control of the mammography equipment. The direct determination of 
the AGD is rather impossible, therefore it is determined in practice by the multiplication of 
the air kerma at the upper surface of the breast (without taking into account the scattered 
radiation) by the appropriate conversion factors according to the following formula: 
 AGD = Kgcs  (1) 
where: 
AGD – average glandular dose, in mGy; 
K - entrance surface air kerma (ESAK), in mGy; 
g – factor taking into account breast thickness after compression, dependent on the half 
value layer of the X-ray beam;  
c – factor taking into account the breast tissue composition, dependent on the  half value 
layer of the X-ray beam and on the breast  thickness after compression; 
s – factor taking into account the X–ray spectrum, dependent on the anode material and on 
the additional filter.   
The values of the above mentioned factors have been calculated by Dance using Monte 
Carlo methods for simple breast model and various X–ray spectra in mammography. They 
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were presented, in the form of tables, in “Additional factors for the estimation of mean 
glandular breast dose using the UK mammography dosimetry protocol” by Dance et al. In 
this paper it was assumed that the breast tissue composition is dependent on the breast 
thickness after compression according to the following formula: 
 y = t3 + t2 + t +    (2)  
where: 
y – glandular tissue content of the breast, in %; 
t - breast thickness after compression, in mm; 
, , ,  – coefficients dependent on the age of women in two age groups:  40 -  49 years and 
50 - 64 years, given in Table 1.  
 
Coefficient Age 40 to 49 Age 50 to 64 
 0,00005209 -0,0001118 
 0,00125494 0,03932 
 -1,988 -4,544 
 138,8 176,0 
Table 1. Coefficients for polynomial fit of glandularity of breast, dependent on the age of 
women in two age groups:  40 -  49 years and 50 - 64 years (according to “Additional factors 
for the estimation of mean glandular breast dose using the UK mammography dosimetry 
protocol”). 
The above mentioned method of AGD determination is limited to the central part of the 
breast above the ionization chamber of the Automatic Exposure Control (AEC) system (in 
the SFM systems) and above the main region of detector of the AEC system (in DR systems). 
The measurement of ESAK during the exposure requires the use of very small detectors 
such as thermoluminescence dosimeters which would be visible on mammography images. 
However, the thermoluminescence dosimeters require complicated and well calibrated 
read-out systems. Simpler method of determining of the ESAK, not influencing the 
mammography image, is the measurement of the dose with a dosimeter of larger 
dimensions than the TLDs at the tube voltage (in kV) and a combination of anode/filter 
(such as for the breast exposure during examination) with arbitrary tube load (in mAs) and 
focus-dosimeter distance. Subsequently, assuming the linear dependence of dose in air on 
tube load and inverse dependence on focus-detector distance squared, it is possible to 
calculate the ESAK on the basis of the measured dose for an exposure of the breast of 
determined thickness after compression and taking into account the parameters of the 
exposure. Therefore, in order to calculate the doses received by women during 
mammography examinations the following parameters have to be known: anode/filter 
combination, tube voltage, tube load, breast thickness after compression, and also the 
woman age. Subsequently, the measurements of the half-value layer and the air kerma for 
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every tube voltage value and anode/filter combination used during examinations should be 
performed. On the basis of gathered data and performed measurements the values of AGD 
for single exposure for individual woman may be determined, later called the clinical breast 
dose. 
For the maximal uncertainty of the AGD determination a value of 14% suggested in the 
„Patient dose in digital mammography” by Chevalier et al. may be adopted. 
2.2 Doses for typical breast 
According to „European guidelines for quality assurance in breast cancer screening and 
diagnosis Fourth edition” by European Commission, in the frame of quality control tests the 
AGD values for typical breast, simulated by the homogenous PMMA plates should be 
determined. The PMMA plates from 2.0 cm to 7.0 cm thick are equivalent to typical breast 
from 2.1 cm to 9.0 cm thick, as it is shown in Table 2. During the quality control tests the 
exposures of PMMA plates should be performed with the same settings as during the 
clinical exposures (the same choice of the AEC mode, the same choice of the anode and 
additional filters, the same exposure control step). Subsequently, the AGD values for the 
different PMMA thicknesses exposures should be determined as for the exposure of 
equivalent breast (as described in 2.1 above). The AGD values obtained in such way may be 
compared to the limiting values. In Table 2, two types of such limiting values are listed for 
various PMMA thicknesses and equivalent breast thicknesses after compression. The first 
one, acceptable level, is a minimum requirement which has to be fulfilled by every 
mammography system. The second one, achievable level, more restrictive, should be the 








Maximum AGD for equivalent breast [mGy] 
Acceptable level Achievable level 
2.0 2.1 < 1.0 < 0.6 
3.0 3.2 < 1.5 < 1.0 
4.0 4.5 < 2.0 < 1.6 
4.5 5.3 < 2.5 < 2.0 
5.0 6.0 < 3.0 < 2.4 
6.0 7.5 < 4.5 < 3.6 
7.0 9.0 < 6.5 < 5.1 
 
Table 2. AGD limiting values for equivalent breast thicknesses according to “European 
guidelines for quality assurance in breast cancer screening and diagnosis Fourth edition”. 
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2.3 Clinical breast doses 
The authors of this chapter had an opportunity to determine the AGD values for exposures 
of individual women (clinical breast doses). These doses were determined for women 
examined with 10 mammography units equipped with full-field digital detectors (DR 
systems), installed at facilities taking part in the screening program in Poland.  
Determination of the clinical breast doses required the collection of all exposure parameters 
for examined women. The collected data included the following parameters: anode material, 
additional filter type, tube potential value, tube load value, birth year of a woman and 
breast thickness after compression. For every mammography unit the data for 200 exposures 
(examination of 50 women) were collected.  Subsequently, for every mammography unit the 
measurements of air kerma were performed (taking into account the linear dependence of 
air kerma on tube load) and also the measurement necessary for determination of half value 
layer for all tube potential values used during the exposures. The measurement were 
performed with a multimeter Piranha from RTI Electronics AB (type: 305; uncertainty: ± 5%) 
and with aluminium filters from Gammex (6x: 0.10 mm thickness and Al purity ≥ 99.9%). 
According to the methodology described in 2.1 above, the AGD values were calculated for 
every exposure.  In this way the values of clinical breast doses were determined for 500 
women (2000 exposures).  
Subsequently, the estimated values of clinical breast doses for each exposure were compared 
to the levels listed in Table 2. To determine the clinical breast dose limit for each breast 
thickness after compression the second-degree polynomial, based on data contained in Table 
2, was fitted. The polynomial for acceptable level is given by the formula (3), and for the 
achievable level by the formula (4):  
 y = 0.091x2 – 0.2326x + 1.1786   (3) 
 y = 0.059x2 – 0.012x + 0.402   (4) 
where: 
y – the clinical breast dose limit for each breast thickness, in mGy; 
x – breast thickness after compression, in cm. 
The correlation coefficient R2 between the values given by the above formulas and the values 
listed in Table 2 was higher than 0.99 in every case.  
In Table 3, for each of 10 DR systems (from 4 manufacturers indicated by consecutive 
numbers) the following parameters are given: material of image detector, the percentage of 
exposures performed with given anode/filter combination, the percentage of exposures for 
which the clinical breast doses did not exceed the acceptable an achievable limits. The 
presented results indicate that the maximal percentage of exposures for which clinical breast 
doses met the acceptable and achievable limits for DR systems for which all exposures were 
performed with the W/Rh combination. However, the case of the mammography unit 8 
does not confirm it. Furthermore, the analysis of the results of mammography units 2, 3, 6, 8 
(from the same manufacturer) indicate that the doses received by the women depend not 
only on the type of the unit and the manufacturer of the unit but first of all on that how the 
particular mammography system was calibrated by manufacturer service. 
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Unit 1 / 
Manufacturer 1 
amorphous 
selenium 100.0 (W/Rh) 99.0 89.0 





16.0 (Mo/Rh) 49.0 32.0 





92.5 (Mo/Rh) 80.5 47.0 
Unit 4 / 
Manufacturer 3 
amorphous 
selenium 100.0 (W/Rh) 92.0 85.5 













49.5 (Mo/Rh) 76.5 57.0 
Unit 7 / 
Manufacturer 1 
amorphous 
selenium 100.0 (W/Rh) 99.5 97.0 





35.5 (Mo/Rh) 97.5 92.05 
Unit 9 / 
Manufacturer 3 
amorphous 
selenium 100.0 (W/Rh) 100.0 100.0 
Unit 10 / 
Manufacturer 3 
amorphous 
selenium 100.0 (W/Rh) 100.0 99.0 
Table 3. Material of image detector, the percentage of exposures performed with given 
anode/filter combination, the percentage of exposures for which the clinical breast doses 
did not exceed the acceptable and achievable limits for 10 DR systems. 
The results of clinical breast dose calculated for 10 mammography units equipped with DR 
systems are presented in Fig. 1. in a form of a histogram in grey. These dose values range 
from 0.12 mGy to 5.80 mGy with the mean value of 1.78 mGy. They do not exceed the limit 
values for typical breasts at the acceptable level in 87.4% of cases and at the achievable level 
in 65.2% of cases. For comparison, in Fig. 1 a histogram, in black, of clinical breast doses 
calculated for 50 women examined with the use of one SFM unit is presented. This 
mammography unit was installed in the Coordination Centre of the Screening Program in 
Poland in 2007. The mammography unit and the accessories (film processor, viewing box, 
amplifying screens and films) were of good quality. They were systematically controlled 
and fulfilled all quality criteria given in „European guidelines for quality assurance in breast 
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cancer screening and diagnosis Fourth edition”. The clinical breast dose values determined 
for the SFM unit ranged from 0.40 mGy to 4.22 mGy with the mean value of 1.68 mGy. They 
did not exceed the limit values for typical breasts at the acceptable level in 98% of cases and 
at the achievable level in 95% of cases.  
The comparison of two histograms in Fig. 1 shows that the frequently cited opinion that the 
women examined with the use of DR mammography systems receive smaller doses of 
radiation than the women examined with SFM systems is not generally true. Furthermore, 
the SFM system presented here generated small clinical breast doses with simultaneous 
fulfilling the quality requirements formulated by the „European guidelines for quality 
assurance in breast cancer screening and diagnosis Fourth edition”. 
 
Fig. 1. The histograms of the clinical breast doses received by the women examined with the 
use of ten mammography units equipped with DR systems (in grey) and received by the 
women examined with the use of one SFM unit (in black).  
2.4 The modifications in DR systems and the clinical breast doses 
During the exploitation of the DR systems the manufacturer service upgrades the software 
of mammography unit, performs the calibration of the image detector and, in particular 
situations, replaces the image detector. Upgrade of the mammography unit software means 
changes of AEC area setting, exposure parameters setting and calibration setting. The 
replacement of the image detector is associated with the calibration of new image detector. 
All these activities should not influence the dose received by the examined women. 
However, the authors of this chapter noticed that the service actions in this area result in the 
increase of the clinical breast doses. For three mammography units (units 2, 3 and 4 are the 
same as in Table 3) the manufacturer service performed alterations of the image detector 
and the mammography system software. For the mammography units 2 and 3 the clinical 
breast doses were recalculated three times: directly after the installation of mammography 
unit, after the replacement of the image detector and the upgrade of the software, and for 
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the mammography unit 4 twice: after the installation of mammography unit and before the 
calibration of the image detector. The data concerning the minimum, maximum and mean 
values for established clinical breast doses and the percentage of exposures meeting the 
acceptable and achievable limits are presented in Table 4. 
The data analysis indicate that the mean values of clinical breast doses for the 
mammography unit 3 after the replacement of the image detector and after the upgrade of 
the software increased by about 44% and 50% in the relation to the mean value of clinical 
breast doses determined after installation of mammography unit. At the same time the 
number of exposures meeting the acceptable limit diminished from 22% to 1% and those 
meeting the achievable limit from 1% to 0%. In the case of the mammography unit 2 the 
mean clinical breast dose value after the upgrade of the software decreased by about 4% as 
compared to the mean value of clinical breast dose determined after the installation of the 
unit. On the other hand, after the replacement of the image detector mean value of the 
clinical breast dose increased by 8% in relation to the mean value of clinical breast doses 
calculated after the installation of the unit. The percentage values of exposures fulfilling the 
acceptable limits decreased after consecutive changes from 66% to 38% and 23% and for the 
achievable limits from 41% to 13% and 12%. For mammography unit 4 the mean value of 
clinical breast doses before the calibration of the image detector increased by about 9% in 
relation to clinical breast doses established just after the installation of the mammography 
unit and the small decrease of the number of exposures meeting the acceptable and 
achievable limits was observed.  
Taking into account the three DR systems, two from the same manufacturer, it is possible to 
conclude that during the upgrade of the software, calibration and exchange of the image 
detector (made by the manufacturer services) changes are introducing which, as a 
consequence, induce increase of the doses received by the women during examinations 
(which was observed in the case of the mammography unit 3). The manufacturer service 
staff claimed that they were carefully following the manufacturer indications. It might 
suggest that these were minimal indications, which leave a lot of freedom in service 
activities. Therefore, it is reasonable to determine the clinical breast doses values after every 
manufacturer service intervention into the software and the image detector in order to be 
able, in case of increased doses, to optimize the exposure parameters.  
Monitoring of the doses received by the women during mammography examinations, 
especially during screening, is necessary in order to protect potentially healthy population 
against additional irradiation. The values of AGD, calculated by the DR systems after every 
exposure and displayed on every mammography image would help the task. The accuracy 
of these values was tested during the clinical breast dose determination for the cases 
described above. For every exposure, the displayed AGD values were compared with 
clinical breast doses values calculated on the basis of exposure parameters. The percentage 
of the cases when the displayed AGD value agreeded with calculated one was established. 
As the criterion of the agreement between displayed and calculated values it was adopted 
that differences between these values could not be bigger than ±14% of calculated clinical 
breast doses values (i.e. the uncertainty of clinical breast dose value determination). The 
results of the comparisons are presented in Table 4. They indicate the discrepancies between 
the displayed and calculated values. The best agreement, for 71%exposures, was for 
mammography unit 2 just after its installation. The actions of manufacturer service resulted 
Comparison of Individual Doses During Mammography Screening Examinations  




Table 4. The values of clinical breast doses (minimal, maximal and mean), percentage of 
exposures fulfilling acceptable and achievable limits of doses, percentage of calculated 
clinical breast doses values complied with AGD values displayed after exposure and 
percentage of exposures for which displayed values were lower than calculated values, after 
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systems (units 2, 3 and 4 are the same as in Table 3). 
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in diminishing of this agreement in every case. Additionally, in the majority of cases the 
displayed doses were lower than the calculated ones. It was not possible to establish the 
reason of such discrepancies between the displayed values and the values calculated 
according to recommendations of the „European guidelines for quality assurance in breast 
cancer screening and diagnosis Fourth edition”. In any case, the displayed values could not 
be used for the evaluation of the radiation doses received by the examined women. 
3. Optimization of exposure parameters  
The significant increase of clinical breast dose values after the intervention of manufacturer 
service in mammography unit 3 (Table 4) forced the authors of this chapter into the attempt 
of exposure parameters optimization in order to reduce the doses received by the examined 
women. However, such dose reduction should not affect the image quality and the 
functioning of the automatic exposure control (AEC) system. The main parameter of image 
quality is the visibility of very small objects at the contrast threshold level. The functioning 
of AEC system is evaluated by a parameter linked to contrast handling by the system. This 
parameter is called the contrast to noise ratio (CNR) calculated for the objects of various 
thicknesses simulating typical breasts. 
3.1 Contrast threshold level of the image  
In mammography it is important to visualize and distinguish objects of low contrast and small 
dimensions on the image. The threshold contrast visibility is determined for circular objects of 
diameters from 0.1 mm to 2.0 mm placed in the homogenous PMMA plates of 4.5 cm total 
thickness. The small objects are made of gold, and the radiation contrast variability is attained 
by their various thicknesses. One of the phantoms suitable for contrast threshold 
determination is the CDMAM phantom manufactured by Artinis (Fig. 2). This phantom is 
composed of an aluminium plate type Al 1050 (99.5% purity) of 0.5 mm thickness with 
embedded golden discs (Au 99.9999 purity) of various thicknesses (from 0.03 m to 2.00 m) 
and various diameters (from 0.06 mm to 2.00 mm). The golden discs are placed in a matrix of 
16 lines and 16 columns which is turned by 45 in relation to the phantom longer side (in order 
to minimize the so called heel-effect1 on the image quality). Every matrix element contains two 
identical discs, one in the middle of the element and the other one in one of the corners of the 
element. The reason of the placement of the second disc in an arbitrarily selected corner is to 
not allow the observer analysing the images to memorize the disc positions. The aluminium 
plate is placed in the homogenous PMMA plate of 0.5 cm thickness. In the phantom set there 
are additional four PMMA plates (each 1.0 cm thick). The phantom dimensions are adapted to 
the dimensions of the standard mammography films (18 cm x 24 cm). 
According to the recommendations of the manufacturer of the CDMAM phantom (“Manual 
Contrast Detail Phantom CDMAM 3.4. & CDMAM Analyser software V1.2.”) the evaluation 
of objects visibility should be done on the basis of the analysis of the unprocessed (by 
mammography system software) image. On this kind of image (Fig. 3a) the observer is not 
able to detect any object, even the largest discs of 2.0 mm diameter. For comparison, in 
                                                 
1 Heel – effect: The non-uniform distribution of air kerma rate and of the beam hardness in an X-ray 
beam in planes perpendicular to the beam axis and in the direction cathode to anode (according to 
“Dosimetry in Diagnostic Radiology: An International Code of Practice” by International Atomic 
Energy Agency). 
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Fig. 3b the processed (by mammography system software) CDMAM phantom image is 
presented. 
 
Fig. 2. CDMAM phantom manufactured by Artinis. 
  
Fig. 3. Unprocessed image (a) and processed image (b) of CDMAM phantom for 
mammography unit 10 (unit 10 is the same as in Table 3).  
              a       b 
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1 Heel – effect: The non-uniform distribution of air kerma rate and of the beam hardness in an X-ray 
beam in planes perpendicular to the beam axis and in the direction cathode to anode (according to 
“Dosimetry in Diagnostic Radiology: An International Code of Practice” by International Atomic 
Energy Agency). 
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Fig. 3b the processed (by mammography system software) CDMAM phantom image is 
presented. 
 
Fig. 2. CDMAM phantom manufactured by Artinis. 
  
Fig. 3. Unprocessed image (a) and processed image (b) of CDMAM phantom for 
mammography unit 10 (unit 10 is the same as in Table 3).  
              a       b 
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The unprocessed image is transferred from workstation of mammography unit to the separate 
computer software provided by the manufacturer of the CDMAM phantom (i.e. CDMAM 
Analyser software) in order to analyse this image. Thicknesses of the objects of worst visibility for 
every object diameter are the final result of the computer analysis. As an example, in Table 5 the 
results of the image computer analysis for one of the DR systems are presented. Diameters 
of the objects are given in mm and thicknesses of the objects are given in m. 
 
Diameter: 0.060 0.080 0.100 0.130 0.160 0.200 0.250 0.310 0.400 0.500 0.630 0.800 1.000 1.250 1.600 2.000 
Thickness: 2.500 0.992 0.525 0.429 0.334 0.152 0.125 0.079 0.067 0.068 0.038 0.030 0.030 0.030 0.030 0.040 
Table 5. The results of the image analysis with CDMAM Analyser software V1.2. 
In order to get reliable results at least eight images should be analysed. In Fig. 4 the Contrast 
Detail Curves for a single image and for eight images are presented. It may be easily notice 
that the curves differ considerably, especially for discs of 0.13 mm and of 1.00 m diameter. 
The analysis of larger number of images is necessary to avoid random errors.  
 
Fig. 4. Contrast Detail Curves for a single image (left) and for eight images of the same series 
(right) for mammography unit 2 (unit 2 is the same as in Table 3). 
The CDMAM Analyser software does not provide the contrast values for structures 
contained in the CDMAM phantom. Therefore the next step after the plotting of the 
Contrast Detail Curve is to determine the threshold contrast on the basis of determined 
object thicknesses. The threshold contrast values of the object for several selected 
thicknesses are given in the “European guidelines for quality assurance in breast cancer 
screening and diagnosis Fourth edition”. These values were calculated for X-ray spectrum 
of 28 kV, molybdenum anode and additional filtration of 0.03 mm Mo on the basis of the 
data from the „Catalogue of diagnostic X – ray spectra & other data” (IPEM report 78) 
published by the  British Institute of Physics and Engineering in Medicine. In digital 
mammography various anode/filter combinations are employed, different from Mo/Mo, 
for example W/Rh (Table 3), and therefore the X-ray spectra differ considerably (for 
example the HVL) from the Mo/Mo spectrum at 28 kV. In theory, the data contained in 
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the „Catalogue of diagnostic X – ray spectra & other data” may be used for calculation of 
contrasts for different spectra. The software included in the catalogue allows for the 
generation of pre-attenuated spectra with additional filtration, and for calculation of tube 
output for such spectra (expressed as air kerma value per tube load value at 75 cm distance 
from the focal spot). The CDMAM phantom, with 4.0 cm of PMMA added, can be here 
treated as an additional filter consisting of 4.3 cm of PMMA, 0.5 mm aluminium, and 0.03-
2.00 μm of gold. Only the phantom is taken into account, attenuation caused by elements 
of the mammography unit (compression plate, breast support table, anti scatter grid, etc) 
is omitted. The radiation contrast can be defined as the percentage difference between the 
intensity of the beam passing through the phantom with a structure and beam passing 
through the phantom without the structure. However, the „Catalogue of diagnostic X – 
ray spectra & other data” contains only a limited range of spectra.  The spectra for 
molybdenum and rhodium targets are available for tube voltage values from 25 kV to 
32 kV, and spectra for a tungsten target are only available for tube voltage values from 
30 kV to 150 kV, while in mammography the tube voltage values beyond these ranges are 
also used.  Beam spectra for all target materials and wider range of tube voltage values (18 
kV to 40 kV) can be generated using polynomial models (“Molybdenum, rhodium, and 
tungsten anode spectral models using interpolating polynomials with application to 
mammography”). An Excel spreadsheet was written that generates such spectra, 
calculates their attenuation by filter material (e.g., Mo or Rh) and by the CDMAM 
phantom (similarly as in the software included with IPEM report 78), and calculates 
radiation contrast of the structures. Linear attenuation coefficients and photon to 
kerma-in-air conversion factors taken from „Catalogue of diagnostic X – ray spectra & 
other data” are used in the calculations. The spreadsheet allows the user to calculate 
radiation contrast for virtually any beam quality used in digital mammography. 
In Table 6, the values of threshold contrast in the case of the exposures at W/Rh 
combination of the CDMAM phantom for mammography units 4 and 10 are presented. The 
contrast values for the phantom structures were calculated following two methods. In the 
first one the catalogue of spectra from IPEM report 78 was used and adopted the same 
spectrum (Mo/0.03 mm Mo, 28 kV) as per „European guidelines for quality assurance in 
breast cancer screening and diagnosis Fourth edition”. In the second one the contrast was 
calculated for the actual spectrum, in this case the W/0.05 mm Rh and 28 kV with the use of 
the above described spreadsheet. For both mammography units the contrast values 
determined for beam Mo/0.03 mm Mo, 28 kV are higher than to the contrast values for the 
actual beam. It shows that the differences of 26% - 27% in calculation of threshold contrast 
exist for both methods for all diameters and thicknesses values. It must be taken into 
account during the evaluation of quality control tests and all kinds of comparisons. It may 
be expected that the differences of threshold contrast values may be larger if the tube 
voltage value of the actual spectrum differs from 28 kV.  
The values of the threshold contrast cannot exceed the limits given in the „European 
guidelines for quality assurance in breast cancer screening and diagnosis Fourth edition”. 
For every object diameter two limits were set up (acceptable and achievable) expressed by 
the thickness of the object and by the corresponding threshold contrast (Table 7). These 
limits were established with the use of the CDMAM phantom placed between two PMMA 
plates of 2.0 cm thick and for typical X-ray spectrum for tube voltage value 28 kV, 
molybdenum target material and 30 µm thick molybdenum filter. 
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Table 6. Values of the threshold contrast for the exposures at the W/Rh combination of the 
CDMAM phantom, determined with two methods for mammography unit 4 and 10 (units 4 
and 10 are the same as in Table 3). 
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0.10 1.68 23.00 1.10 15.80 
0.25 0.352 5.45 0.244 3.80 
0.50 0.150 2.35 0.103 1.60 
1.00 0.091 1.40 0.056 0.85 
2.00 0.069 1.05 0.038 0.55 
Table 7. Limiting values (acceptable and achievable levels) of the thickness of gold objects 
and corresponding value of threshold contrast for discs diameters from 0.10 mm to 2.00 mm 
according to the „European guidelines for quality assurance in breast cancer screening and 
diagnosis Fourth edition”. 
In Table 8 the examples of the image quality evaluation for four DR mammography units 
are presented. For the structures of the largest diameter (2.00 mm) on all images the 
structures of the same thicknesses were visible. The largest differences between the 
mammography units were seen for the low contrast objects of the smallest dimensions. 
While comparing the results of the analysis with the criteria given in the „European 
guidelines for quality assurance in breast cancer screening and diagnosis Fourth edition” 
(Table 7) one should consider mainly the visibility of the objects of specified thickness and 
not the specified contrast. The radiation contrast depends on the radiation quality used and 
does not characterize specifically the actual structure but the structure imaged with a given 
radiation beam. On the other hand the size of the structures visible on the phantom image is 




Diameter of detail [mm] 
0.10 0.25 0.50 1.00 2.00 
2 Gold thickness [m] 0.522 0.097 0.060 0.030 0.040 Threshold contrast [%] 8.74 1.69 1.05 0.53 0.70 
3 Gold thickness [m] 0.806 0.143 0.056 0.036 0.040 Threshold contrast [%] 11.93 2.24 0.88 0.57 0.63 
4 Gold thickness [m] 0.567 0.108 0.055 0.036 0.040 Threshold contrast [%] 7.36 1.43 0.75 0.49 0.62 
10 Gold thickness [m] 0.716 0.125 0.060 0.030 0.040 Threshold contrast [%] 9.17 1.69 0.82 0.41 0.55 
Table 8. The example of the golden objects thicknesses for particular diameters and 
corresponding values of threshold contrast values for unprocessed images for 
mammography units 2, 3, 4 and 10 (units 2, 3, 4 and 10 are the same as in Table 3).  
3.2 Contrast to noise ratio 
The contrast to noise ratio (CNR) is used for the evaluation of the functioning of the AEC 
systems (so called object thickness and tube voltage compensation) for a given 
mammography unit.  The functioning of the AEC systems should be controlled by 
exposures of PMMA plates of the thicknesses between 20 mm and 70 mm (10 mm step) with 
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The contrast to noise ratio (CNR) is used for the evaluation of the functioning of the AEC 
systems (so called object thickness and tube voltage compensation) for a given 
mammography unit.  The functioning of the AEC systems should be controlled by 
exposures of PMMA plates of the thicknesses between 20 mm and 70 mm (10 mm step) with 
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clinical settings of the AEC (tube voltage, target, filter, mode and exposure control step). 
During these exposures the compression paddle should be maximally pressed against the 
top surface of the plates.  On the PMMA plates an aluminium object of 0.2 mm thickness 
should be placed.  The dimensions of the object should be large enough to be able to mark 
on the image an area of 4 cm2 as a region-of-interest (ROI). The PMMA plates have to cover 
the whole image detector.  In Fig. 5 the positioning of the aluminium object on the PMMA 
plates and the position of the ROI (for which the mean pixel value and standard deviation 
are calculated) is indicated.  
 
Fig. 5. The positioning of the aluminium object on PMMA plates and the ROI delineation for 
the CNR measurement. 
The contrast to noise ratio (CNR) parameter should be calculated for a particular object 
according to the below presented formula from the „European guidelines for quality 
assurance in breast cancer screening and diagnosis Fourth edition”: 
    
   2 2
2
mean pixel value signal mean pixel value background
CNR




  (5) 
where: 
mean pixel value (signal) - mean pixel value for the ROI in position 2; 
mean pixel value (background) - mean pixel value for ROI in position 1; 
standard deviation (signal) – standard deviation for ROI in position 2; 
standard deviation (background) – standard deviation for ROI in position 1. 
On the basis of these data the CNR should be calculated according to the formula (5) for 
every PMMA plate from 20 mm to 70 mm thickness.  The calculated CNR values should be 
referred to the limiting value (CNRlimiting value) calculated according to the formula (6) below: 
 100%/5
CNRiCNR =i cm CNRlimiting value
     (6)  
where: 
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CNR i/5 cm – CNR  value for PMMA plates of 20 mm, 30 mm, 40 mm, 45 mm, 50 mm, 60 mm 
and 70 mm thicknesses referred to the CNR value for PMMA phantom of 50 mm thickness; 
CNRi – CNR value determined for PMMA plates of 20 mm, 30 mm, 40 mm, 45 mm, 50 mm, 
60 mm and 70 mm thickness; 
CNR limiting value – the value calculated according to the formula (7) below; 
 
 
Tresholdcontrast CNRmeasured measuredCNR limiting value Treshold contrast limiting value

    (7) 
where: 
Threshold contrastmeasured – the value of the threshold contrast determined for the golden 
object of 0.1 mm diameter placed in PMMA 50 mm thick (determined according to the 
methodology presented in 3.1); 
CNRmeasured – CNR value determined for 50 mm PMMA; 
Threshold contrastlimiting value – limiting value of threshold contrast for a golden object of 0.1 
mm diameter, equal to 23%. 
According to the „European guidelines for quality assurance in breast cancer screening and 
diagnosis Fourth edition” the CNR values relative to the CNR for 50 mm PMMA must be 
determined during every control of the AEC system, at least every six month. The 
exemplary results for three mammography DR systems are presented in Table 9. In Table 9 
in the second column the limiting values are listed.  All results met the tolerance limits. The 
CNR values established for 70 mm PMMA thicknesses relative to the CNR for 50 mm 
PMMA were about 2 times higher (for every system) than the limiting value. In the case of 
20 mm PMMA it was larger than the limiting value by about 3 to 4 times (depending on the 
system). This means that the AEC system setting by the manufacturer service is done to 
meet the minimum manufacturer requirements without trying to reach maximum values. 
This leads to the increased exposure of the image detector without taking into account the 





CNR limiting value 
Unit 2 / 
Manufacturer 2  




CNR  relative to CNR for 50 mm PMMA [%] 
20  115 420 467 305 
30  110 388 415 266 
40  105 322 345 249 
45  103 298 308 252 
50  100 259 270 238 
60  95 192 214 225 
70  90 178 194 209 
Table 9. The limiting values of the CNR relative to the CNR value for 50 mm PMMA for the 
objects of different thicknesses („European guidelines for quality assurance in breast cancer 
screening and diagnosis Fourth edition”) and the exemplary results of CNR values relative 
to CNR for 50 mm PMMA for mammography units 2, 3 and 4 (units 2, 3 and 4 are the same 
as in Table 3). 
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The user of the mammography system 3 did not agree to make exposures at the AEC system 
setting other than Auto-filter mode. The only way to introduce changes in exposure 
parameters setting was selecting different (than these which were used at that moment) 
service settings of the unit. For this particular unit the manufacturer service could select one 
of the available AEC system modes named in the mammography unit documentation as 
“Table 0”, “Table 1”, “Table 2” and “Table 3” (Table 10). The manufacturer described the 
way in which the AEC system adapts the tube voltage value to the breast thickness after 
compression. Before the optimization attempt the “Table 0” mode was set, for which the 
clinical breast doses did not fulfil the acceptance criteria. It was necessary to find out for 
which setting the clinical breast doses could be lowered to the acceptance limits without 
affecting the threshold contrast and CNR for various PMMA plates thicknesses.  
For each AEC mode: 
 AGD values were calculated for typical breasts (described in 2.2 above); 
 evaluation of threshold contrast for discs of various diameters was performed 
(described in 3.1 above); 
 CNR values were determined for exposures of the PMMA plates of the thickness in the 
range from 20 mm to 70 mm (10 mm step) and for 45 mm (described in. 3.2 above). 
All these activities were carried out with the exposure control step set to “0”, in Auto-filter 
mode and with the main region of detector of the AEC system manually set closest to the 
chest wall. The results are presented in Table 11 and Table 12. In Table 11, the values of tube 
voltage, tube load and anode/filter combination selected by the AEC system for various 
thicknesses of PMMA plates, CNR relative to CNR for 50 mm PMMA and the AGD values 
calculated for typical breasts for four possible settings of the mammography unit 3, are 
given. In Table 12, the thicknesses of golden objects of various diameters and corresponding 
values of threshold contrast for four settings of the mammography unit 3, are presented. 
When comparing the values in Tables 11 and 12 with limiting levels given in Tables 2, 7 and 
9 one can see that quality criteria at the acceptable levels concerning all parameters (AGD, 
threshold contrast and CNR) are met for modes “Table 1”, “Table 2” and “Table 3” with the 
lowest clinical breast doses for mode “Table 3”. For this particular mammography unit all 
routine mammography examinations, before the optimization of exposure parameters, were 
performed with the “Table 0”. For this mode the clinical breast doses were the highest and 
for PMMA plates of 4.0 cm and 4.5 cm thickness the AGD values exceed slightly the 
acceptable level, but the image quality was the best of the four modes.  For the “Table 2” 
mode the image quality was the worst.  Out of remaining two modes, “Table 1” and “Table 
3”, the “Table 3” mode was selected because of the lower clinical breast doses.   
With the AEC setting in mode “Table 3” the mammography examinations were performed 
and the quality of the images was accepted by the radiologists. The “Table 3” mode was set 
by the manufacturer service as the permanent option not to be changed. The exposure 
control step (“0”) wasn’t changed. At these settings of the mammography unit the 
examinations of women have been started. For the examined women the clinical breast 
doses were calculated according to the methodology given in 2.3 above. In Table 13, the 
minimum, maximum and mean values of clinical breast doses calculated for the women 
examined with the use of the mammography unit 3 before and after the optimization of  
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02 1.0 24 24 27 25 
03 1.5 24 24 27 25 
04 2.0 24 24 27 25 
05 2.5 24 24 27 26 
06 3.0 25 25 27 27 
07 3.5 26 25 28 28 
08 4.0 27 25 28 28 
09 4.5 28 26 28 29 
10 5.0 29 27 30 30 
11 5.5 30 28 31 30 
12 6.0 31 29 32 31 
13 6.5 32 29 32 31 
14 7.0 32 30 32 32 
15 7.5 32 31 33 32 
16 8.0 33 32 33 33 
17 8.5 33 33 33 33 
18 9.0 34 34 34 34 
19 9.5 34 34 35 34 
20 10.0 35 35 36 35 
21 10.5 35 35 37 36 
22 11.0 37 37 38 37 
23 11.5 38 38 39 38 
24 12.0 39 39 39 39 
25 12.5 39 39 39 39 
26 13.0 39 39 39 39 
27 13.5 39 39 39 39 
28 14.0 39 39 39 39 
29 14.5 39 39 39 39 
30 15.0 39 39 39 39 
31 15.5 39 39 39 39 
 
Table 10. Tube voltage selection scheme by the AEC system according to the breast thickness 
after compression – from technical documentation of the mammography unit 3. 
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Table 11. Tube voltage, tube load and anode/filter combination selected by the AEC system 
for PMMA plates of various thicknesses, CNR values relative to 5.0 cm PMMA and AGD 
values calculated for typical breasts for four operation modes of the AEC system for 
mammography unit 3. 
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AEC system Parameter 
Diameter of detail [mm] 
0.10 0.25 0.50 1.00 2.00 
“Table 0” 
Gold thickness  
[m] 0.525 0.125 0.068 0.030 0.040 
Threshold contrast 
[%] 8.758 2.173 1.189 0.526 0.701 
“Table 1” 
Gold thickness  
[m] 0.547 0.134 0.060 0.030 0.040 
Threshold contrast 
[%] 9.134 2.327 1.049 0.526 0.701 
“Table 2” 
Gold thickness  
[m] 0.753 0.138 0.081 0.037 0.040 
Threshold contrast 
[%] 12.333 2.396 1.414 0.649 0.701 
“Table 3” 
Gold thickness  
[m] 0.806 0.143 0.056 0.036 0.040 
Threshold contrast 
[%] 11.925 2.239 0.883 0.569 0.632 
Table 12. The thicknesses of golden objects of various diameters and corresponding values 





















































































































Before the optimization After the optimization
 
 
Fig. 6. Clinical breast doses calculated for two groups of women examined with the 
mammography unit 3: before the optimization of exposure parameters (in black) and after 
the optimization (in grey). 
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Before the optimization After the optimization
 
 
Fig. 6. Clinical breast doses calculated for two groups of women examined with the 
mammography unit 3: before the optimization of exposure parameters (in black) and after 
the optimization (in grey). 
 







clinical breast doses 












optimization 2.45 7.71 3.89 1 % 0 % 
After the 
optimization 1.16 3.64 1.80 80.5 % 47 % 
 
Table 13. Minimum, maximum and mean values of clinical breast doses calculated and the 
percentage of exposures, for which the clinical breast doses were below the acceptable and 
achievable level, before and after the optimization of exposure parameters for the 
mammography unit 3. 
exposure parameters, are presented. The percentage of exposures, for which the clinical 
breast dose values do not exceed the limiting values at the acceptable and achievable levels, 
are also given. The maximum, minimum and mean values of clinical breast doses after the 
optimization of exposure parameters were lower than these values before the optimization 
by about 53%. The values of clinical breast doses after the optimization of exposure 
parameters were below the acceptable level in 80.5% of cases and below the achievable level 
in 47% of cases. 
The decrease of the clinical breast dose values after setting the “Table 3” AEC mode on the 
mammography unit 3 is better presented in Fig. 6. Two histograms of clinical breast dose 
values, before the optimization of exposure parameters (in black) and after the optimization 
(in grey) are presented. They are clearly separated which means that the efforts to optimize 
the exposure parameters brought about a significant reduction of the clinical breast doses 
received by the women during examination. It should be noted that it was achieved at the 
cost of slight reduction of the visibility of the objects at the threshold contrast level, but it 
was accepted by the radiologists involved in image analysis in the mammography screening 
program. 
4. Conclusion 
The optimization procedure presented in this chapter is only a proposal of actions which 
could lead to the reduction of the doses received by the women during mammography 
examinations, especially in case of screening programs when probably healthy women are 
irradiated. The proposed approach has an advantage of not resigning of the system settings 
allowing for fully automatic of tube voltage and filter selection. Evidently, mammography 
units of various types and from different manufacturers have different capabilities but every 
capability should be first used for the optimization of exposure parameters and clinical 
breast doses reduction during mammography examinations.  
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1. Introduction  
Breast cancer is the most frequently diagnosed type of cancer nowadays and it is the leading 
cause of death caused by cancer in women (Jemal et al., 2011). It has become one of the main 
health problems both in developed and in developing countries. More than a million new 
cases of breast cancer are diagnosed every year all over the world (Ferlay et al., 2004). 
According to researches of the American Cancer Society (American Cancer Society, 2002), 
since 2002 breast cancer has been the second largest cause of death caused by cancer in 
women. According to a research conducted in 2007 in Korea, breast cancer was the second 
most frequently detected type of cancer in women (Kyu-Won et al., 2010). In 2008 there were 
3, 2 million (Ferlay et al., 2010) new cases of cancer in Europe out of which 421, 000 (13,1%) 
(Ferlay et al., 2010) cases were breast cancers. According to the mentioned research, after 
colorectal cancer (436, 000 cases) breast cancer is the second most frequently registered 
cancer in Europe (Ferlay et al., 2010). In Bosnia and Herzegovina 1600 new cases of breast 
cancer are registered every year (Saric, 2009). Nowadays, mammography represents the best 
diagnostic way for detection of breast cancer. This diagnostic medical discipline applies a 
specially designed roentgen apparatus for breast examination. A good topographic position 
and a high degree of mobility of the breast (Fajdic, 2001) enable a great number of early 
diagnosed breast cancers detected with mammography. Ultrasound breast diagnostic is 
often used as an additional method to classic mammography for breast cancer detection, 
especially identification of cysts in the breast (Fajdic, 2001). Nowadays there are classic 
(film-screen) and digital mammography. While digital mammography enables a superior 
contrast resolution, its spatial resolution is somewhat lower in regard to the standard 
technique (Kuzmiak et al., 2005). Advantages and disadvantages of these two types of 
mammography were compared in more than ten studies (Rosselli Del Turco et al., 2007; 
Skaane, 2009). One of the main arguments for giving priority to digital mammography in 
regard to classic mammography was the fact that digital systems cause less radiation during 
an examination (Hermann et al., 2002; Moran et al., 2005). The newest study shows that 
digital mammography cannot guarantee significantly lower patient doses in regard to 
classic mammography (Hauge et al., 2011). The objective of most studies about 
mammography is to define benefits and risks caused by application of radiation in 
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mammography. The size which best describes amount of risk for glandular tissue caused by 
application of radiation in mammography is called mean glandular dose (MGD). There are 
two critical age groups of patients in mammography: patients 40 to 49 years of age and 
patients 50 to 64 years of age. Naturally, patient doses have to be defined for all other 
patients who undergo mammographic diagnostic but do not belong to the mentioned age 
groups. Advantages of a routine mammography in timely diagnosing of breast diseases are 
great. Mammographic screening reduces mortality caused by breast cancer for women 39 to 
69 years of age (Heidi D. Nelson et al., 2009). This study aims to define patient doses and 
factors which influence them for all critical groups of patients in routine mammography. 
Since a mammographic examination of each breast consists of mediolateral and 
craniocaudal projection, it was necessary to define patient doses for  individual projections 
and for the complete mammographic examination. 
2. Materials and methods  
2.1 A procedure for measuring of measurable parameters in mammography  
Like any other study in diagnostic radiology, this one also aimed to first collect all 
measurable parameters during a routine mammography. It was necessary to collect not only 
physical but also technical, diagnostic and medical parameters.  
During mammographic diagnostic, it is necessary to note physical and technical parameters, 
and after completion of mammography also diagnostic and medical parameters which can 
be offered by a radiologist. On a basis of collected data about a patient (age, mass, height) 
and with an established body mass index (BMI), one can examine its relation with patient 
doses in mammography (Schubauer-Berigan et al., 2002; Jamal et al., 2003) and a frequency 
of patient’s going for a regular mammographic examination (Zhu et al., 2006). All 
experimental measuring of doses during diagnostic mammographic examinations was 
performed at the Department of Mammography of Public Health Institution Health Center 
Tuzla. For diagnostic examinations of patients we used a GE Healthcare Alpha ST (Mo/Mo) 
mammographic apparatus. In classic mammography (film-screen), Mo/Mo dominates as 
one of the most frequently used meta/filter combinations (Hauge et al., 2011), and many 
mammographic systems, such as Alpha ST, have a Mo/Mo meta/filter combination as their 
only choice. The measuring was done in the period from May 2008 to January 2011 and it 
involved  329 female patients between 40 and 64 years of age.   
The following data were recorded during a diagnostic examination: 
a. patient’s age, 
b. applied clinical spectrum (meta/filter combination), 
c. CBT (compressed breast thickness) and type of projection (CC, MLO) for each breast, 
d. exposition factors: charge I·t (mAs) and voltage (kVp), 
e. size of applied film ( 18 x 24 or 24 x 32), 
f. number of previous  mammographic examinations underwent by every patient, 
g. type of diagnostic examination: routine control examination,  post-operative control    
examination; an enlarged additional image of a certain projection is necessary; a 
repeated image because of insufficient sharpness.  
h. possible ultrasound control. 
An Analysis of Application of Mean Glandular Dose  
and Factors on Which It Depends to Patients of Various Age Groups 
 
135 
The mentioned data were used for calculation of strength of kerma in the air, filter half-
values and conversion factors for age groups. Mean glandular dose (MGD) for the breast 
was defined according to these parameters.  MGD doses were defined for every individual 
projection and for the complete mammographic examination. A statistical dependency 
(correlation) between compressed breast thickness and MGD dose was defined for every age 
group and for mediolateral and craniocaudal projection of every age group.  
A correlation between ultrasound and mammographic breast examination was found and it 
was confirmed that these two diagnostic disciplines complement each other excellently in 
early breast cancer prevention (Harlow et al., 1999; Kuhl et al., 2005). A combination of 
mammography and ultrasound with a possible ultrasound cytological puncture offers a 
basis for a reliable diagnosis of the smallest malignant formations in breasts (Mainiero, 
2010). A number of underwent mammographic examinations in a correlation with patient’s 
age gave an answer to many questions, such as: a level of information about breast cancer 
available to patients, need for a routine mammography in breast cancer prevention, 
importance of self-examination for women  and differences in psychological behavior of 
patients during the first and after several mammographic examinations. A type of 
diagnostic examination on a mammography unit and a way of its performance showed the 
importance of a role of a radiology technician and his/her direct communication with a 
patient during the process for obtaining a good quality of image in mammographic 
diagnostics.   
2.2 Quality control 
Quality control (Geise et al., 1988; Hendrick et al., 2002) in mammography contains a set of 
tests (Perry et al., 2006) which can be divided according to priority and a level of training of 
personnel who perform them. Some tests require usage of special equipment or special work 
conditions. That is why sometimes in some institutions there is a possibility of failure to 
implement a complete quality control of a mammography system. Regular quality controls 
of mammography units in some countries contributed to decreasing of patient doses and 
improvement of quality of mammographic images (Maccia et al., 1995; Zdesar, 2000; 
Vassileva et al., 2005; Ciraj-Bjelac et al., 2011) and improvement of functioning of a 
mammography unit (Zoetelief et al., 1992). The tests can be grouped in the following way: 
- Tests for mammographic device, 
- Tests for films, foil and processor, 
- Tests for quality of images,  
- Calculation of breast dose 
Quality control in mammography was regularly performed during a three-year period of 
data collection and its long-term strategy was to support reduction of mortality rate caused 
by breast cancer. A special attention was dedicated to tests for mammographic devices. 
Anode voltage value, dose reproducibility and filter half-value (HVL) without returnable 
radiation were measured for different settings of kVp and meta filter combination (a 
controlled mammography unit had only one meta filter combination Mo/Mo) following 
recommendations of the quality control protocol (Perry et al., 2006), which defines 
measuring methodology and frequency. When measuring half filter value (HVL) one used 
aluminium filters of extremely high purity (99,9%). First, measuring was done several times 
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without a filter in order to obtain an initial exposition value. Afterwards, sets of aluminium 
filters of various thicknesses were settled between the focus and detectors. Roentgen tube 
voltage ranged from 22 to 32 kVp  and every voltage value was measured several times in 
order to obtain half the dose in regard to the initial dose value on the detector. Possible HVL 
values in mammography range from 0,25 to 0,45 mmAl. All tests for mammographic device 
were done with Barracuda instrument. 
2.3 Dosimetry 
For every mammogram MGD was defined on a basis of conversion factors calculated by 
Dance et. al. (Dance et al., 2000) and a calculated K (entering air kerma measured freely in 
air without backscatter), using the following relation: 
 MGD = K g c s  
For every individual exposition K was calculated from post – exposure mAs (I  t) and 
output data for the x – ray set in μGy mAs-1 used in an exposition field. Conversion factors 
were calculated by Dance for a different clinical spectrum (target/filter combination), HVL, 
compressed breast thickness and breast glandularity. G  and c are conversion factors to 
account for both X-ray beam characteristics and breast composition  i.e., various percentages 
of fat and glandular tissue. Factor s includes a correction for applied type of the clinical 
spectrum and all screens were made using the same clinical spectra Mo/Mo. 
2.4 Statistical analysis   
The data were statistically processed in SPSS 17.0 and they were shown as standard 
deviation and confidence interval. Pearson´s coefficient was used for statistical significance 
of correlation between MGD and CBT. A value of p<0.05 was considered as indicative of 
significance. 
3. Results and discussion  
3.1 Age and compressed breast thickness 
Age of examined patients varied from 40 to 64.  The average age of the first group (40 – 49) 
was 45, 27 years (SD: 2,76) and of the second age group (50 – 64) it was 55,90 years (SD: 
4,20). The average age of all of the patients was 51,63 (SD: 6,39). Distribution of compressed 
breast thickness in mammography was symmetrical to patient’s age and it varied from 20 to 
100 mm.  Errors in defining compressed breast thickness varied in the range of  ± 1 mm. 
There was a good correlation between patient’s age and compressed breast thickness. A 
similar symmetry was noted in other works (Beckett & Kotre, 2000; Kunosic et al., 2010; 
Kunosic et al., 2011). Mean value of compressed breast  thickness of the complete sample 
was 42,24 mm (SD : 14,86). It is known that compressed breast thickness value shows a 
certain tendency of growth in younger patients and a tendency of decline in older patients 
(Law et al., 1994), which proved as true in our examined sample. Mean value of compressed 
breast thickness in mediolateral projection was 20 to 23 % higher than in craniocaudal 
projection. This information is very important for understanding of results and explanation 
of obtained glandular doses for the breast from Tables  4. and 5. 
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3.2 Quality control  
Accuracy of measured voltage in roentgen tube (maximum deviation) was  ± 0,89 kVp for 
voltage ranging from 22 to 32 kVp. Outgoing radiation (mGy/mAs)  was measured several 
times during this study and it was within the range of ± 4 % from the initial value.  The most 
frequently used voltage during performance of diagnostic examinations was 25 kVp (45,08 
%). This voltage was applied in cases when compressed breast thickness varied from 20 to 
28 mm, and sometimes with higher values of compressed breast thickness depending on age 
group to which a patient belongs.  
Voltage of 26 kVp (19,18 %) was applied in most cases when compressed breast thickness 
was 28 to 34 mm while voltage of 27 kVp (13,69 %) was mainly applied when compressed 
breast thickness varied from  35 to 45 mm. Percentage of utilization voltage of 25, 26 and 27 
kVp leads us to a conclusion that the greatest number of patients who underwent a routine 
mammography in this study had compressed breast thickness from 20 to 45 mm, if we 
assess utilization voltage. A significant percent of utilization was ascribed to voltage of 28 
kVp (10,57 %) and 29 kVp (8,03 %) when compresses breast thickness varied from 40 to 53 
mm and  54 to 63 mm, respectively. Voltage of 30 kVp (1,97 %) and 31 kVp (0,82 %) was 
applied for compressed breast thickness from 64 to 80 mm to make a compromise between 
mentioned values and obtain an image of  better quality. Voltage of 32 (0,49 %) and 33 (0,16 
%) kVp was used for extremely great values of compressed breast thickness from 81 to 100 
mm.   
 
Table 1. Statistical illustration of applied voltage per age groups for complete sample during 
mammographic diagnostics. 
When we analyze percentage of representation of voltage applied during diagnostic 
examinations per age groups we draw similar conclusions like for the complete sample, 
with a slight deviation. What is interesting to note here is that voltage of 30 – 33 kVp was 
not applied for the age group 40 – 49. Voltage of 25 kVp was mostly applied for this group 
while the difference in application of voltage of 26 and 27 kVp was insignificant. These three 
voltages were applied for about 80 % diagnostic examinations (Table 1.) of this age group. It 
is important to note that absence of application of extremely high voltage was compensated 
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with significant application of voltage of 28 and 29 kVp, which representation is greater in 
this age group in regard to the other age group (Table 1.). 
A tendency of application of voltage of 25 kVp and voltage of 26 kVp was retained in the 
age group 50 to 64 years of age (Table 1).  The difference in regard to the age group 40 – 49 
reflects in significantly less application of voltage of 27 and 28 kVp (Table 1.)  and greater 
utilization of voltage ranging from 30 to 33 kVp. This wide spectrum of voltage applied in 
the age group 50 – 64 was caused by a wide spectrum of compressed breast thickness. 
3.3 X – ray technique 
The greatest number of images taken during mammographic diagnostic was two for MLO 
and two for CC projection. The total number of images used for a complete diagnostic 
examination was 4. The same clinical spectrum (meta/filter) Mo/Mo was applied for all 
diagnostic examinations.  1220 images were taken to examine 329 patients (Table 2.), out of 
which 1172 images were taken for the complete mammographic examination of 293 (89,06 
%) patients (two images for each projection).  In this way both breasts were completely 
diagnostically processed (Hackshaw et al., 2000). 24 images were used for a routine control 
examination of one breast after a surgery or additional controls because of a certain doubt 
(one for each projection) to examine 12 (3,65 %) patients.  
Remaining 24 (7,29 %) patients were examined with application of 24 images mainly 
because of a need for an improved image (of better quality) for some of projections. 
 
Table 2. Statistical illustration of number of images taken and types of films applied for all 
age groups and  complete sample during mammographic diagnostic. 
Percentage of patients for whom taking two images was necessary for examination of one 
breast was 3,65 %, and it indicates a need for a routine mammographic control because it 
represents a percentage of patients in whom a timely routine control detected breast cancer. 
It is in common in all of developed countries of the world which have a developed program 
for early breast cancer detection to examine all patients with application of 4 images (two 
images for each projection) with a desire to obtain a complete clinical picture (Nelson et al., 
2002; Miller, 2005).  
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Such approach is a result of  routine mammography which is compulsory every third year 
in developed countries. As a result, there is a great number of patients with early detected 
breast cancer (Greenlee et al., 2000), which automatically influences a decrease of mortality 
caused by breast cancer (Tabar et al., 2003; Gøtzsche & Nielsen, 2006; Gøtzsche, 2011; D'Orsi 
&  Newell, 2011).  
 
Table 3. Statistical illustration of number of images taken depending on size of film applied 
for all age groups. 
An analysis of applied mammographic images per age categories (Table 3.) revealed new 
interesting information. Over  90% of complete mammographic examinations were 
performed in the first age group where belong younger patients (40 to 49 years of age). As 
expected, number of 18 x 24 images is greater because this is the population where the 
breast (Kopans et al., 2003), as a very dynamic organ, passes through a set of dynamic 
changes during its growth and development. Mammographic images 24 x 32 are mainly 
used for patients between 46 and 49. A percentage of control examinations after a surgery of 
one breast is small, not greater than  3,1 %. It is expected for this age category to have a lot of 
blur and unclearness in mammographic images, which sometimes cause repetition of one of 
diagnostic projections (1 image, CC or MLO). Percentage of repeated images is a bit smaller 
than 7 % (Table 3.), which is quite satisfactory for such huge population and adequate for a 
radiologist to obtain a clear clinical picture and to define a final diagnosis on a basis of an 
additional image. A complete mammographic examination was conducted in 44, 67 cases 
from the second age group  (50 - 64) with 18 x 24 film and in 43,65 % cases with 24 x 32 films. 
With this population, there is a tendency of increasing of a number of control examinations 
for 50% in regard to the younger age group. This is a confirmation of the tendency of growth 
of early breast cancer detection  in women who frequently undergo routine controls and 
self-examinations. Percentage trend of 7,62 % of repeated images in one projection is 
retained, although a number of diagnostically treated patients increased for 33% in regard to 
the previous group. A slight advantage for the benefit of usage of smaller 18 x 24 images in 
regard to bigger 24 x 32 images in a complete diagnostic examination corresponds to the  
average compressed breast thickness of diagnostically processed population (Table 5.). The 
mentioned data leads us to the conclusion that the average compressed breast thickness of 
the examined population with such great sample must be less than 50 mm, in comparison 
with other study (Kunosic et al., 2010). 
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regard to bigger 24 x 32 images in a complete diagnostic examination corresponds to the  
average compressed breast thickness of diagnostically processed population (Table 5.). The 
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the examined population with such great sample must be less than 50 mm, in comparison 
with other study (Kunosic et al., 2010). 
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3.4 Patient’s doses 
The most frequently used procedure in a routine mammography includes 2 images of every 
breast, craniocaudal and mediolateral. Even if there is a visible anomaly at one breast, it is 
necessary to perform a diagnostic mammographic examination of both breasts. Such 
procedure enables us to compare both breasts and to detect possible anomalies into details 
(Hackshaw et al., 2000). In the last 20 years a set of studies has been conducted in Europe 
with the objective to define MGD (Wall  & Roberts, 1992; Faulkner et al., 1995; Klein et al., 
1997; Beckett & Kotre, 2000; Adlien et al., 2005; Assiamah et al., 2005; Tsapaki et al., 2008; 
Kunosic et al., 2010; Ciraj-Bijelac et al., 2010). Similar researches were conducted on Thailand 
(Sookpeng & Ketted, 2006), in Iran (Bouzarjomehri et al., 2006), in the USA(Gentry & De 
Werd, 1996), Malaysia (Jamal et al., 2003), Australia (Heggie, 1996), Korea (Oh et al., 2003) 
and many other countries all over the world. Table 10.4. illustrates results regarding MGD 
for every individual projection and for the  complete  diagnostic examination of all patients 
during MLO and  CC diagnostic examinations. 
 
Table 4. Complete statistical illustration of voltage, compressed breast thickness,MGD for all 
patients and two different projections (CC, MLO). (MLO - Mediolateral oblique view; CC - 
Craniocaudal view; SD - Standard deviation, CI - Confidence interval for the mean of 95 %; 
CBT - Compressed breast thickness) 
Values of MGD and compressed breast thickness (CBT) were defined for a sample of 1220 
images (613 CC and 607 MLO projections). Mean value of a patient dose for the complete 
CC projection was 1,66 mGy and for MLO projection 1,92 mGy. A significant difference 
(Table 4.) between the mentioned doses (according to calculated values) was caused by 
compressed breast thickness and it was 13,54 %. Similar results were noted in works of other 
authors (Gentry & De Werd, 1996; Heggie, 1996; Young, 2000; Jamal et al., 2003; Oh et al., 
2003; Bouzarjomehri et al., 2006; Sookpeng & Ketted, 2006; Tsapaki et al., 2008; Kunosic et 
al., 2010). A sample of a significant increase of doses in MLO in regard to CC projection can 
be explained with the fact that pectoral muscle (Helvie et al., 1994; Young, 2000) is involved 
in MLO projection which causes an increase of thickness of compressed tissue and requires 
greater exposition for an image of a better quality. The total dose for a complete 
mammographic examination was 3,58 mGy, which is much less than  4 mGy which is the 
ceiling for mammography. In comparison with other studies (based on a principle of a great 
sample) the obtained patient dose is less in regard to a study conducted in Sweden (Eklund 
et al., 1993) which involved a sample of 1350 patients and in regard to a study conducted on  
490 patients in Australia (Heggie, 1996), and it correlates well with results of studies  from  
Korea (Oh et al., 2003) and  Greece (Tsapaki et al., 2008). A study conducted in Iran included 
246 patients (Bouzarjomehri et al., 2006) and showed that an obtained MGD dose for a  
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complete mammographic examination  in that country was 5,57 mGy, which is significantly 
more in regard to this study and which, most probably, is a consequence of a quality control 
system which was established late and differences in compressed breast thickness. The 
mentioned studies did not use conversion factors according to Dance (which are used in this 
study), but in Austra, Korea and Malaysia one used conversion factors according to  Wu 
(Wu et al., 1991), in Sweden  according to Rosenstein and in Iran according to Sobol (Sobol & 
Wu, 1997). Values of  MGD dose for a complete mammographic examination in Bosnia and 
Herzegovina are 5,0 % higher in regard to results obtained from 300 patients in Malaysia 
(Jamal et al., 2003) and 7,8 % higher in regard to the most complete study (Young & Burch, 
2000) conducted in the Great Britain which included  8745 patients. More than 70 % of all of 
mammographic diagnostic examinations was done with doses less than 3,2 mGy. According 
to a correlation analysis (Picture 10.2.), there was a considerable significance (Fig. 1.) 
between MGD and CBT (r = 0,689, p<0,01). 
 
Fig. 1. Correlation between MGD and CBT. 
A similar positive correlation between MGD and  CBT was noted on a much smaller sample 
of Bosnian patients (Kunosic et al., 2010). An influence of CBT on patient doses during 
mammographic diagnostic examinations was confirmed by other authors in their researches 
(Wall  & Roberts, 1992; Gentry & De Werd, 1996; Dance et al, 2000; Kruger et al, 2001; Oh et 
al., 2003; Bouzarjomehri et al., 2006; Sookpeng & Ketted, 2006; Bor et al, 2008; Robinson & 
Kotre, 2008) and some authors used this dependency to predict patient doses through 
training of artificial neural networks (Ceke et al., 2009). The number of previously 
conducted mammographic examinations for the complete group was 1,80 (SD: 0,66) while 
more than 75 % of patients underwent at least 2 mammographic examinations in their lives. 
All patients underwent an ultrasound breast examination. 
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3.5 Patient's doses for two different age groups 
It is extremely important to examine a relation between projections (craniocaudal and 
mediolateral projection) during a mammographic diagnostic, compressed breast thickness 
and mean glandular dose received by a patient during one exposition and during the 
complete examination for two different age groups (Wall  & Roberts, 1992; Gentry & De 
Werd, 1996; Heggie, 1996; Klein et al., 1997; Young, 2000; Young & Burch, 2000; Oh et al., 
2003; Jamal et al., 2003; Sookpeng & Ketted, 2006; Bouzarjomehri et al., 2006; Tsapaki et 
al., 2008; Ciraj-Bijelac et al., 2010; Kunosic et al., 2010). Patients are divided into a group of 
younger patients (40 - 49) and a group of older patients (50 - 64), according to the 
European Protocol for Dosimetry in Mammography (Perry, et al., 2006). Table 5. 
illustrates results regarding MGD doses for every individual projection (MLO and CC) 
and for the complete mammographic examination of the mentioned  projections. The first 
age group (40 – 49) consisted of 132 patients for whose examination 493 mammographic 
images were taken. Mean value of compressed breast thickness was 41,15 mm (SD:  
15,06).  
 
Table 5. Complete statistical illustration for voltage, compressed breast thickness, MGD for 
three different age groups and two different  projections (CC, MLO). (MLO - Mediolateral 
oblique view; CC - Craniocaudal view; SD - Standard deviation, CI - Confidence interval for 
the mean of 95 %; CBT - Compressed breast thickness). 
A slight tendency of increasing of compressed breast thickness with aging was noted with 
this age group (Klein et al., 1997; Moore et al., 2005). Compressed breast thickness in MLO 
projection was 21,53 %  higher than the one noted in CC projection. Doses in MLO and CC 
projection were 1,88 mGy and 1,64 mGy, respectively. The mentioned values of doses are 
within the frame of results promoted by K.C.Young (Young, 2000) for the age group 40 to 
48. A considerable significance was noted between MGD and CBT (Fig. 2.) with this age 
group (r = 0,689 ; p < 0,01).  More than 75 % of doses for individual (one) image in CC 
projection was less than  0,88 mGy while more than 75% of individual images in MLO 
projection was below 1,05 mGy. Doses received in an individual MLO projection were for 
about 12,76 % higher than in CC projection, which is mostly contributed by a difference in 
compressed breast thickness in the mentioned projections. The number of performed 
mammographic examinations for this age group as of now is 1,68 (SD: 0,60) while more than 
75 % of patients underwent at least 2 mammographic examinations in their lives, which is a 
good average considering the fact that this is the youngest group and bearing in mind a very 
bad economic status of the country. 
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Fig. 2. Correlation between MGD and CBT for age group  40 – 49. 
The second age group, 50 – 64 years of age, involved  197 patients for whose mammographic 
examination one made 727 images (Table 10.9.). Mean compressed breast thickness was 
42,98 mm (SD: 14,69). Compressed breast thickness in MLO projection was 23,35 % higher 
than in CC projection. Patient doses for the complete MLO and CC image were 1,96 mGy 
and 1,66 mGy, respectively. These results comply well with results from the work of Burch 
and Goodman (Burch  & Goodman, 1998). A patient dose in CC projection is something 
higher in regard to a study conducted in the USA (Gentry & De Werd, 1996) where one 
measured mean compressed breast thickness of 4,5 cm and  MGD of 1,5 mGy for the 
mentioned projection. What is interesting is that values of doses decreased with an increase 
of patients’ age in this group (Beckett & Kotre, 2000; Bouzarjomehri et al., 2006), probably 
because of a change (decrease) of breast glandularity (Eklund et al., 1993; Heggie, 1996). 
More than  75 % of doses for an individual (one) image in CC projection was less than 0,91 
mGy while more than 75% of individual images in MLO projection was below 1,12 mGy. 
Doses received during an individual MLO projection were for 15,31 % higher than in CC 
projection, which is mostly contributed by a difference in compressed breast thickness in the 
mentioned projections. A correlation analysis of this age group showed a considerable 
significance between MGD and CBT (r = 0,692; p < 0,01). The number of performed 
mammographic examinations for this age group as of now is 1,88 (SD: 0,69) and more than 
75 % of patients underwent less than 2 mammographic examinations in their lives. This 
information is discouraging since the number of examinations performed as of now in 
comparison with the number in developed countries should be much greater. Possible 
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causes would be an insufficient number of mammographic apparatuses, lack of information, 
poor social status of this age category and lack of a program and measures for prevention 
and detection of breast cancer at the state level. 
 
Fig. 3. Correlation between MGD and CBT for age group 50 – 64. 
4. Conclusion 
This work analyzes application of patient doses for various age groups of patients during a 
routine mammographic examination. One examined and analyzed factors on which patients 
doses depend. A correlation between patient doses and a complete spectrum of technical, 
physical, clinical and diagnostic parameters on which mammographic examination depends 
was established. The total dose for a complete mammographic examination was 3,58 mGy, 
which is significantly less than 4 mGy which is the ceiling for mammography. A slight 
tendency of compressed breast thickness increasing with age was noted for the age group  
40 – 49. In the second age group, 50 – 64, it was noted that values of doses decreased with an 
increase of patients’ age. It was defined that mean glandular dose depended on compressed 
breast thickness and that there was a positive correlation between these two sizes. More 
than 75 % of treated patients underwent at least 2 mammographic examinations in their 
lives. All patients underwent an ultrasound breast examination. 
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Najlaa Almazrouei 
Dubai Health Authority (DHA)–Medical Physics Section 
United Arab Emirates 
1. Introduction 
X-ray mammography is the most reliable method of detecting breast cancer. It is the method 
of choice for the Breast Screening Program in a variety of developed countries In order to 
obtain high quality mammograms at an acceptable breast dose, it is essential to use the 
correct equipment. 
In the United Arab Emirates (UAE), the number of mammography examinations has been 
rising steadily the past few years due to the rapid economic growth of the country and the 
increasing use of computed and digital radiography systems, as film based mammography 
systems are being abandoned progressively.  
At present, there is a growing concern about the radiation doses incurred by patients when 
undergoing breast examinations. For this reason, the UAE has decided to join the IAEA Task4 
project to undertake a survey of patient exposure in digital mammography in several Hospitals.  
The objectives of this work are 
- Achieve consistently high quality mammograms. 
- Limit radiation dose by determine the Average Glandular Dose (DG) resulting cranio-
caudal -  projections. 
- IAEA guidance was used for measuring the Entrance Surface Air Kerma (Ka,e) and 
EUREF - guidelines DG calculations. 
- Minimize the number of supplementary and repeat examinations. 
- Minimize the number of unnecessary invasive procedures. 
- The main objective of this work was to evaluate the Average Glandular Dose (DG) 
resulting from exposure to mammographic X-rays while the ultimate aim of the project 
remains the establishment of Dose Reference Levels (DRL) in the UAE. 
It is worth noting that the quantities and symbols used in this presentation are those 
suggested by the International Commission on radiation Units and Measurements (ICRU) in 
its publication 74. 
The Total numbers of mammography system in Dubai are 26 facilities both in Governmental 
and Privet sector, the Average number of patients per year were 528, the number of CR 
system 18, the DR system 5 and the screen film 3. 
There are some factors affecting the visibility of the objects:  
Size, Contrast & Noise (from different sources) 
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Also the following Exposure parameters: 
Anode (Mo, Rh, W...) => contrast, (resolution) 
Filter (Mo, Rh, Al...) => contrast 
Tube voltage (kV) => contrast 
Dose or tube loading (mAs) => noise 
Radiation dose to the breast is affected by the following parameter 
 The breast composition and thickness 
 The photon energy 
 The sensitivity of the image receptor 
 The breast composition has a significant influence on the dose 
 The area of the compressed breast has a small influence on the dose 
 Majority of the interactions are photoelectric 
A Quality Control program should ensure: 
 The best image quality 
 With the minimum dose to the breast 
 Hence regular check of important parameters 
2. Methodology, equipment and tools used to perform the study 
For tube quality 
- Victoreen NERO mAx 8000 multimeter + Fluke Biomedical Detector  
- Gamex test tool 
- Unfors kit (as a substitute when Victoreen was not available) 
For checking image quality 
- ToRMAX-316 (Leeds Test Object) for Detailed Image (total thickness 7 cm) 
- ACR phantom for general image 
For measuring the Contrast-to-Noise-Ratio (CNR) 
- ToRMAX-316 (Leeds Test Object)  
- 2 cm x 2 cm piece of aluminum of thickness 0.2 mm 
- ACR phantom  
For the measurement of ESAK 
- Victoreen NeroMax 8000 multimeter + Victoreen cylindrical Ion chamber 3.3 cc or  
- Unfors kit (as a substitute when Victoreen was not available)  
2.1 Quality control of the mammography machines 
All parameters relevant to X-ray beam (mainly kVp, HVL & light field collimation) should 
be checked. 
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2.1.1 KVp accuracy 
Method: 
- Turn on the Victoreen NERO Max 8000 and select the Mammography option then press 
enter.  
- Place the Victoreen NERO mAx 8000 Detector on the table. 
- Insert 22-35 filters to the detector. 
- Give exposure and write down the effective KVp and Dose.                         




- Turn on the Victoreen NERO Max 8000 and select the Mammography option then    
press  enter.  
- Place the Victoreen NERO mAx 8000 Detector on the table. 
- Insert 22-35 filters to the detector. 
- Give exposure and fill down the table.                         
- Action Limit: if the coefficient of variation exceeds 0.02, then seek service  
correction. 
- Formula used for calculation: 
 SD = √ [n ∑ x² - (∑ x) ² / n (n – 1)]      (1) 
 CV = SD / Mean     (2) 
2.1.3 Beam quality test (HVL) 
Method: 
1. Raise the compression paddle to its highest position. Mount the 6000-529 ionization 
chamber on a ring stand so there is approximately 5 cm of space between the bottom of 
the chamber and table. The chamber should be centered in the beam laterally, and 
approximately 4 cm from the chest wall. 
2. Collimate the beam, using the light field, so that the entire chamber is included in the 
beam. The field should be approximately 6 cm x 6 cm. If necessary, relocate the 
chamber such that it is centered in the field. 
3.  Set the kVp selector at a kVp setting that is frequently used for making  
mammograms.  
4. Connect the chamber to the Nero Max8000 device. 
5. Make an exposure. Note the reading and label it X0.  
6. Place a sheet of aluminum 0.2 mm thick on the compression paddle. Using the 
collimator light, be sure the entire ionization chamber is in the shadow of the aluminum 
sheet. Make an exposure. Record the reading and label it X1; also record the thickness of 
aluminum used to make the exposure. Label it t1. 
7. Place an additional 0.01 mm of aluminum on top of the aluminum absorbers) already in 
place. Make an exposure. Record the reading, labeling it with sequential indices. Also, 
record the total thickness of aluminum used in making the measurement, labeling it as 
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tN where N is the total number of filtered exposures taken so far. If XN is less than one 
half of X0 proceed to step 7, otherwise, repeat step  
8. It is now assumed that you have compiled a list of data pairs, labeled "ti" and "Xi"- If N 
is the total number of filtered exposures, then the half-value layer may then be 
calculated using the following formula: 
    
 
t 1n   t 1n
0 0N 2XN 1 / x  N  1 2XN / xHVL





2.2 Image quality 
For general image, we use the ACR mammography phantom contains test objects that are 
similar to microcalcifications, fibers, and masses 
- Image quality tests were performed at clinical settings to ensure that the X-ray 
machines were functioning properly, in accordance to the manufacturer’s specifications. 
- Place the phantom on the image receptor surface in the same position as a breast. The 
nipple indent marker should be positioned away from the chest wall, just as the nipple 
of the patient’s breast would be positioned.  
- Position the x-ray tube and compression device as you would for a craniocaudal 
examination of a patient’s breast.  
- Choose the kVp and mAs factors as you would use for an average 4.5 cm breast and 
make an exposure.  
- The image will represent the imaging abilities of your machine using these clinical  
factors. 
- If the image is over or under exposed, make a suitable adjustment in your factors and 
repeat the exposure.  
- This is an indication that adjustments may be necessary for patient imaging of these 
compressed breast thicknesses and should be checked. 
Use the ToRMAX-316 (Leeds Test Object) for Detailed Image (total thickness 7 cm) and 
repeat the pervious step for each breast thickness.  
 
   
Image 1. ToRMAX-316 (Leeds Test Object).           Image.2 
 




Image 3. this image reflect the image that we got from the phantom after exposure. 
2.3 Contrast-to-Noise Ratio (CNR) 
- The Contrast-to-Noise Ratio (CNR) was determined by placing a square-shaped 2 cm x 
2 cm piece of aluminum of thickness 0.2 mm on the PMMA phantom, 6 cm from the     
edge of the phantom and table, in the centre of the phantom. 
- Two ROIs of 4 cm2 were selected in the saved image to calculate the mean (S) and the         
standard deviation (σ).  













2.4 Average Glandular Dose, DG 
The AGD cannot be measured directly but it is derived from measurements with the 
standard phantom for the actual technique set-up of the mammographic equipment. 
The measurements of the Entrance Surface Air Kerma Ka,e were performed in two steps, 
First 
1. Set up the x-ray machine for a typical mammographic technique. Place a loaded cassette 
in the cassette holder, of the size and type consistent with the examination being 
simulated. Set the machine in the AEC mode and set the density control to the position 
most commonly used for the examination. 
2. Place a mammographic LTO phantom on the cassette holder assembly at the position        
normally occupied by the breast. Be sure the phantom completely covers the AEC 
sensor. 
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3. The LTO phantom was exposed to X-ray beams using automatic mode to get the kVp,   
mAs, and target/filter combination used.   
4. Then, remove the phantom and a similar exposure will perform in manual mode with 
no phantom.  
Second 
1. Now, place the Model 6000-529 ionization chamber in the center of the phantom. 
2. Lower the compression paddle until it contacts the chamber. Take care not to put any 
mechanical stress on the chamber. 
3. Connect the chamber cable to an NERO max8000; Follow the instructions 
accompanying the instrument for details of instrument operation. 
4. Make an exposure. Record the reading from the electrometer. Apply whatever 
corrections are necessary to yield an accurate exposure reading.  
5. Repeat step 4 three more times. Average all four results. The final result is the breast 
entrance exposure. You should now repeat the procedure for all other clinically used 
techniques. The value of Ka, e, the Entrance Surface Air Kerma (ESAK) is  
deduced 
 Ka, e = Od PIt (dsd / (dsd – T)) 2         (5) 
Od =   Tube output at level of detector 
Pit=    Tube current exposure time product (mAs) 
dsd=   Source to detector distance 
T=    Thickness of compressed breast (CBT) 
Conversion factors from incident air kerma to average glandular dose have been obtained 
using Monte Carlo transport calculations in simple breast models e.g. Dance et al  
(2000) 
The Average Glandular Dose DG is calculated as:   
  DG= Ka,e  . g. c. s  (6) 
- Where Ka,e is the entrance surface air kerma (without backscatter) calculated at the 
upper surface of the PMMA. 
- The factor g, corresponds to a glandularity of 50%, and is derived from the values 
calculated by Dance et al 2000 and is shown in table.1 for a range of HVL. 
- The c-factor corrects for the difference in composition of typical breasts from 50% 
glandularity [Dance et al 2000] and is given here for typical breasts in the age range 50 
to 64 in table.2. 
- Typical values of HVL for various spectra are given in table.3. The factor s shown in 
table 4 corrects for differences due to the choice of X-ray spectrum (Dance et al  
2000). 
Note that the c and g-factors applied are those for the corresponding thickness of typical 
breast rather than the thickness of PMMA block used. Where necessary interpolation may be 
made for different values of HVL. 
The dose should be determined using the usual clinically selected exposure factors 
including any automatic selection of kV and target/filter combination. 
 











g-factors (mGy/mGy)                                             
HVL (mmAl) 
0.25 0.30 0.35 0.40 0.45 0.50 0.55 0.60 
20 21 0.329 0.378 0.421 0.460 0.496 0.529 0.559 0.585 
30 32 0.222 0.261 0.294 0.326 0.357 0.388 0.419 0.448 
40 45 0.155 0.183 0.208 0.232 0.258 0.285 0.311 0.339 
45 53 0.130 0.155 0.177 0.198 0.220 0.245 0.272 0.295 
50 60 0.112 0.135 0.154 0.172 0.192 0.214 0.236 0.261 
60 75 0.088 0.106 0.121 0.136 0.152 0.166 0.189 0.210 
70 90 0.086 0.098 0.111 0.123 0.136 0.154 0.172 
80 103 0.074 0.085 0.096 0.106 0.117 0.133 0.149 















c-factors (mGy/mGy)                                     
HVL (mmAl) 
0.30 0.35 0.40 0.45 0.50 0.55 0.60 
20 21 97 0.889 0.895 0.903 0.908 0.912 0.917 0.921 
30 32 67 0.940 0.943 0.945 0.946 0.949 0.952 0.953 
40 45 41 1.043 1.041 1.040 1.039 1.037 1.035 1.034 
45 53 29 1.109 1.105 1.102 1.099 1.096 1.091 1.088 
50 60 20 1.164 1.160 1.151 1.150 1.144 1.139 1.134 
60 75 9 1.254 1.245 1.235 1.231 1.225 1.217 1.207 
70 90 4 1.299 1.292 1.282 1.275 1.270 1.260 1.249 
80 103 3 1.307 1.299 1.292 1.287 1.283 1.273 1.262 
Table 2. c-factors for breast simulated with PMMA. 
 
HVL (mm Al) for target filter combination 
Kv 
Mo + 30 μm 
Mo 
Mo +25 μm 
Rh 
 Rh +25 μm 
Rh 
 W +50 μm 
Rh 
 W +0.45 μm 
Al22 
25 0.33 ± .02  0.40 ± .02  0.38 ± .02  0.52 ± .03  0.31 ± .03 
28 0.36 ± .02  0.42 ± .02  0.43 ± .02  0.54 ± .03  0.37 ± .03 
31 0.39 ± .02  0.44 ± .02 0.48 ± .02 0.56 ± .03   0.42 ± .03 
34   0.47 ± .02   0.59 ± .03 0.47 ± .03 
37   0.50 ± .02     0.51 ± .03 
* Some compression paddles are made of Lexan, the HVL values with this type of 
compression plate are 0.01 mm Al lower compared with the values in the table. 
Table 3. Typical HVL measurements for different tube voltage and target filter 
combinations. (Data includes the effect on measured HVL of attenuation by a PMMA 
compression plate*.) 
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*This value is not given in the paper of Dance et al. The value in the table has been 
estimated using the S-values of other spectra. 
 
Table 4. s-factors for clinically used spectra [Dance et al. 2000]. 
The recommended achievable and limiting dose values in the European guidelines for the 
same PMMA thickness (van Engen et al 2006) are 0.6, 1, 1.6, 2, 2.4, 3.6, 5.1 mGy  and 1, 1.5, 2, 
2.5, 3, 4.5, 6.5 mGy respectively for 2, 3, 4, 4.5, 5, 6 and 7 cm of PMMA.  
In our survey we use the limiting dose values to compare our date with it, as it will be 













Table.5. European guild line for limit AGD (mGy) for at different PMMA thickness (cm).                  
3. Discussion 
The Results of the measured Average Glandular Dose (AGD) were performed on different 
breast thickness, we chose 2cm breast thickens, 4.5 cm breast thickens which simulate the 
standard breast thickens and the third thickens was 7 cm, so in our survey we were covered 
the small, medium and large breast thickness. 
We inspected (21 facilities), and 4 of them have a DR mammography, 13 CR mammography 
and 3 screen film mammography. 
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Results of the DR Mammography system 
 
 
Fig. 1. ((DR) AGD vs. Hospital at 2cm BT), shows that one hospital (H.C Mo\Mo) is 
exceeding the acceptable limits, it was a test to observe the differences between the different 
Anode\Filter combinations that their machine have, and they are using the automatic mode 
(Auto-Kv mode) to acquire their images. 
 
Fig. 2. ((DR) AGD vs. Hospital at 4.5cm BT),  we observe that all hospital were within the 
AGD acceptable limit, all theses hospital are using the automatic mode to acquire their 
images, Except hospital A & B, the technician control the Kv parameter depending on the 
breast thickness. 
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Results of the DR Mammography system 
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AGD acceptable limit, all theses hospital are using the automatic mode to acquire their 
images, Except hospital A & B, the technician control the Kv parameter depending on the 
breast thickness. 
 




Fig. 3. ((DR) AGD vs. Hospital at 7cm BT), shows that all hospitals are below the AGD 
acceptable limit, all theses hospital are using the automatic setting to acquire their images, 
Except hospital A & B, the technician use the  manual setting for the Kv parameter 
depending on the breast thickness. 
Result of 13 Computed Mammography machine 
 
Fig. 4. ((CR) AGD vs. Hospital at 2cm BT), we observe from this figure that there are 3 
hospitals were exceeding the AGD acceptable limit, which they are H6, H11&H13 with 
different anode\filter combination. H6: they are using the automatic mode, H11: they only 
have one Anode\Filter combination they use manual setting for Kv and automatic setting 
for mAs they were advice to change their setting to reduce the dose. H13: the technician 
were use the manual mode for acquiring their images , they were advised to fix call the 
service to fix their machine on the same time their cassette also were old and it was need to 
be changed. Regarding the other hospitals the most of them were fully automatic and the 
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Results of the Three Screen Film Mammography machine 
 
Fig. 7.( (Screen film) AGD vs. Hospital at 4.5 cm BT), shows that all hospitals were below the 
AGD acceptable limit. All of these hospitals were using the manual setting for acquiring 
their images, their images were acceptable to their physician, for H3 the parameters used 
was Kv=28 & mAs=25. 
Comparison between Calculated Average Glandular Dose (AGD) & System AGD 
In most facilities, the difference between AGD values measured by the Physicist and those 
generated by the system were found acceptable, thus justifying a survey of patient doses on 
the basis of the AGD recorded by the system. 
 
Fig. 8. Comparison between Calculated AGD & System AGD for 2 cm Breast Thickens. 
 













Fig. 10. Comparison between Calculated AGD & System AGD for 7 cm Breast Thickness. 
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Result of the Contrast to Noise Ratio results (CNR) 
 
Fig. 11. the Contrast to Noise Ratio (CNR) –CR system. 
 
Fig. 12. the Contrast to Noise Ratio (CNR) –DR system. 
4. Conclusion 
This study on radiation exposure in mammography concerned number of facilities in Dubai 
region and will be extended to a larger number of facilities in the near future.  
The results obtained show that quality control and patient Dosimetry are crucially needed in 
order to ensure a safe and efficient use of mammographic X-rays on patients whether for 
routine diagnosis or breast screening. 
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Also , we found that the value of the CNR is depend on the specification of the  manufacture 
for each mammography machine , so we can’t compare the value measured of the hospitals 
to each other because they are from different manufactures  
5. Acknowledgment 
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6. Appendix: The forms used to collect the data 
Quality Control Findings – Mammography/ ------ 
 
 
Hospital: --------------------------------------------------- Done on: ------------------------   
X-ray Tube  Operation machine 
Manufacture:  
X-ray unit name: 
Model Number: 









  Radiographic projection:                 Cranio-caudal/lateral/oblique 
   Anode material:                              Mo/W/Rh 
  Inherent filtration material:            
  Inherent filtration thickness:                                                                   mm 
  Additional filtration material: 
  Additional filtration thickness:                                                               mm 
  Focus to film distance:                                                                            cm 
  Grid used:                                                                     Yes/No 
  Automatic exposure control used:                                Yes/No 
 Tube potential:                kVp            ;                 Tube charge:            mAs 
Frequency: Acceptance, yearly and after tube or collimator repair/exchange. 
6.1 Collimation assessment 
Source to image receptor distance (SID) ---------- cm 
Deviation between X-ray field and light field 
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Target material  Mo Mo 
Collimator (cm)  18x24 24x30 
Left edge deviation    
Right edge deviation    
Sum of left and right edge deviations    
Sum as % of SID    
Anterior edge deviation    
Chest edge deviation    
Sum of anterior and chest edge deviations    
Sum as % of SID    
ACTION LIMIT: ACR/MQSA - If sum of left plus right edge deviations or anterior plus 
chest edge deviations exceeds 2% of SID, seek service adjustment. 
Deviation between X-ray field and edges of the image receptor 
 
Left edge deviation        
% of SID (retain sign)        
Right edge deviation        
% of SID (retain sign)        
Anterior edge deviation        
% of SID (retain sign)        
Chest edge deviation        
% of SID (retain sign)        
ACTION LIMIT: ACR/MQSA - If X-ray field exceeds image receptor at any side by more 
than 2% of SID or if  X-ray field falls within image receptor on the chest wall side, seek 
service adjustment. 
ACR - If X-ray field falls within image receptor by more than -2% on the left and right sides 
or by more than -4% on the anterior side, seek service adjustment. 
Alignment of chest-wall edges of compression paddle and film 
 
Difference between paddle edge and film            
Difference as % of SID            
ACTION LIMIT: ACR/MQSA -If chest-wall edge of compression paddle is within the 
image receptor or projects beyond the chest-wall edge of the image receptor by more than 
1% of SID, seek service correction. 
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6.2 Kvp accuracy/reproducibility 




 Set 1 Set 2 Set 3 Set 4 
Nominal kVp setting     
Focal spot L L L L 
Exposure time (sec)     
mA     
mAs 50 50 50 50 
Measured kVp values 
 
 
1      
2      
3      
4      
Mean kVp      
Standard deviation (SD)      
Mean kVp - Nominal kVp      
0.05 X Nominal kVp      
% Error      
Coefficient of variation      
Pass/Fail Results      
% Error Pass/Fail Criterion 5.00% CV Pass/Fail Criterion 0.02 
 
ACTION LIMIT: ACR/MQSA - If the mean kVp differs from the nominal by more than 
+5% of the nominal kVp, or if the coefficient of variation exceeds 0.02, then seek service 
correction. 
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6.3 Beam quality (HVL) measurement 
Dosimetry system used----------------- 
 
 
Nominal Kvp setting  30 30 30 
Target material     
Filter     
mA        
Time        
mAs  50 50 50 
No aluminum filtration, E(0a)       
0.2 mm of added aluminum, E(2)        
0.3 mm of added aluminum, E(3)        
0.4 mm of added aluminum, E(4)        
0.5 mm of added aluminum, E(5)        
0.6 mm of added aluminum, E(6)        
No aluminum filtration, E(0b)        
Average E(0)        
Average E(0)/2        
Calculated HVL (mm Al)        
 
 
MQSA X-Ray Tube Voltage and Minimum HVL 




6.4 Image quality 
Using ACR Phantom: 
Anode/Filter: ---------------------  
The exposure factors were kV=     mAs=            ESAK=               AGD=  
 




NO. Region Materials Visible 
1 1.56 mm nylon fiber  
2 1.12 mm nylon fiber  
3 0.89 mm nylon fiber  
4 0.75 mm nylon fiber  
5 0.54 mm nylon fiber  
6 0.40 mm nylon fiber  
7 0.54 mm simulated micro-calcification  
8 0.40 mm simulated micro-calcification  
9 0.32 mm simulated micro-calcification  
10 0.24 mm simulated micro-calcification  
11 0.16 mm simulated micro-calcification  
12 2.00 mm tumor-like mass  
13 1.00 mm tumor-like mass  
14 0.75 mm tumor-like mass  
15 0.50 mm tumor-like mass  
16 0.25 mm tumor-like mass  
6.5 Using TOR MAX phantom 
Anode/Filter: --------------------- 
BT = 2cm, Exposure factor:    kV=     mAs=            ESAK=             AGD=  
BT = 4.5cm, Exposure factor: kV=     mAs=            ESAK=             AGD=  
BT =7cm, Exposure factor:     kV=     mAs=            ESAK=             AGD=  
 












BT Groups Line pairs/mm 
2   
5   
7   
LHS  Grating 
 
BT Groups Line pairs/mm 
2   
5   
7   
Low Contrast Bar Patterns 
BT Groups Line pairs/mm 
2   
5   
7   
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BT No. detected Threshold Contrast
2   
5   
7   
Small Detail Visibility: 
 
 
0.5  mm details: 
 
BT No. detected Threshold Contrast 
2   
5   
7   
0.25  mm details: 
BT No. detected Threshold Contrast 
2   
5   






6.6 Contrast to noise ratio measurement 
Exposure conditions   
 
  Radiographic projection:                                                             Cranio-caudal 
   Anode material:                              Mo/W/Rh 
  Inherent filtration material:            
  Inherent filtration thickness:                                                                           mm 
  Additional filtration material: 
  Additional filtration thickness:                                                                      mm 
  Focus to film distance:                                                                                   cm 
  Grid used:                                       Yes/No 




















/Filter kV mAs 
AGD 
(mGy) 
Under Al object 
Sal       SDal 
Side to Al 
object 
S       SD 
CNR 
2          
3          
4          
4.5          
5          
6          
7          
ACR 
Phantom          
6.7 Dose measurement 
CBT = 2 cm 
Exposure conditions 
Focus-Chamber Distance (cm):   
FBD Focus-Bucky Distance (cm): 
 nKi @FBD = Ki (FCD/FBD)2 /mAs    nKe=nKi*BF  
Note, BF=1.09; Ki should be correct for calibration factors, temperature and pressure 
 





s) Auto Manu Auto Manu 
        
        
        
ESAK calculation for clinical exposures 
Ke=nKe*mAs*(FBD/(FBD-BT))2 
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Is Mammographic Density a Biomarker to Study 
the Molecular Causes of Breast Cancer? 
Hanna Mirette and Diorio Caroline 
Université Laval/Unité de Recherche en Santé des Populations 
Canada 
1. Introduction 
Breast cancer is the most common cancer affecting females worldwide. It accounts for 31% 
of all new cancer cases diagnosed in females with 23% of cases diagnosed in women 
younger than 50 years old (Jemal et al., 2002; Smigal et al., 2006). Being the second cause of 
cancer deaths after lung cancer (Jemal et al., 2002), enormous scientific efforts have been 
done aiming to better understand, treat and prevent breast cancer. Despite these research 
efforts, breast cancer remains a major health problem. 
Since their implementation, the mammographic screening programs have resulted in breast 
cancer detection at an earlier stage and consequently have contributed to a greater reduction 
in the breast cancer mortality rate (Lebovic et al., 2010). Routine screening mammograms 
usually target women aged from 50 to 69 years old (Bryant & Mai, 2011). However, many 
studies have identified 40 years old as an appropriate age to begin annual mammographic 
screening (Bryant & Mai, 2011; Lebovic et al., 2010). Besides being a screening and 
diagnostic device, the mammography is also used as a research tool.  
Variations in the mammographic appearance of the breast referred to as “mammographic 
density”, reveal histological changes in breast tissue composition. Nowadays, elevated 
mammographic density is proven to be one of the strongest risk factors for breast cancer. 
Whatever the method used to classify mammographic density, all have shown a substantial 
increased breast cancer risk associated with increased mammographic density (McCormack 
& dos Santos Silva, 2006). Mammographic density has been consistently associated with 
increased risk of hyperplasia, atypical hyperplasia and carcinoma in situ (Boyd et al., 2000). 
In addition, several recognized risk factors for breast cancer (such as number of full-term 
pregnancies, age at first full-term pregnancy, family history of breast cancer, personal 
history of breast biopsies and use of hormone replacement therapy) are also associated with 
mammographic density (Boyd et al., 2010; Heine & Malhotra, 2002). Mammographic density 
is related to levels of hormonal and growth factors involved in cellular proliferation, 
differentiation and apoptosis (Diorio et al., 2005b; Greendale et al., 2005; Howard & 
Gusterson, 2000) which have established roles in the etiology of breast cancer (Imagawa et 
al., 2002; Shekhar et al., 2003). 
Mammographic density reflects the proportion of the breast occupied by epithelial and 
stromal tissues. Therefore, mammographic density is hypothesized to reflect the quantity of 
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non-adipose breast tissue (Boyd et al., 2010; Li et al., 2005), representing the population of 
breast cells at risk of carcinogenic transformation (Trichopoulos et al., 2005). Breast cancer 
generally arises from epithelial cells (Russo et al., 1990), and an increase in the overall 
epithelial cell number is believed to increase the risk of breast cancer (Preston-Martin et al., 
1990). However, there is also growing evidence that stroma plays an important role, not 
only in mammary gland development, but also in breast carcinogenesis (Imagawa et al., 
2002; Shekhar et al., 2003; Woodward et al., 1998). Stroma is a major component of the breast 
(Imagawa et al., 2002; Page & Winfield, 1986; Shekhar et al., 2003) and variations in 
mammographic density may be more sensitive to changes in the stroma than to those in the 
epithelium (Warren & Lakhani, 2003). Knowledge of molecular markers (such as proteins 
and genes expression) in normal breast epithelium and stroma that are associated with 
mammographic density may provide important clues regarding breast cancer etiology. 
Studying the influence of such genes/proteins on mammographic density used as an end 
point in epidemiological studies may reduce the long term follow-up period needed to 
detect their effects on breast cancer incidence, thus providing an easier and more economic 
way to study the pathogenesis of breast cancer. A better understanding of molecular 
markers influencing mammographic density may also help to identify preventive targets.  
In this review, we intend to shed light on the possibility of using mammographic density as 
an intermediate biomarker to study the molecular causes of breast cancer. We hypothesize 
that if breast cancer biomarkers ultimately exert their influence on mammographic density 
in the same direction as they influence breast cancer risk, then mammographic density could 
be considered as an intermediate biomarker for breast cancer rather than just a risk factor. 
An overview with emphasis on changes in genes and proteins expression in normal breast 
tissue and their relationship with mammographic density is provided.  
2. Mammographic density 
The breast is composed mainly of fibroglandular tissue and adipose tissue at different 
proportions. These constituents differ in their X-ray attenuation characteristics. 
Fibroglandular tissue, mainly composed of epithelial cells and supporting stroma, 
attenuates more X-rays and thus appears white on mammograms, while adipose tissue, 
which is radiolucent, appears dark on mammograms. Hence, variations in the radiological 
appearance of the breast on a mammogram reflect variations in breast tissue composition.  
Mammographic density represents the proportion of the breast occupied by radiologically 
dense tissue. Results from Li’s study show that elevated mammographic density is 
associated with a greater nuclear area of both epithelial and non-epithelial cells, as well as 
with a greater proportion of collagen and a greater area of glandular structures (Li et al., 
2005). It is believed that elevated mammographic density reflects the effects of mitogens and 
mutagens which influence cellular proliferation and genetic damage of these cells (Martin & 
Boyd, 2008). This provides a potential mechanism by which elevated mammographic 
density could influence the risk of breast cancer. Moreover, it has been suggested that 
mammographic density is more related to stromal changes rather than epithelial changes 
(Heine & Malhotra, 2002; Warren & Lakhani, 2003). This is consistent with Lin and 
colleagues findings who reported a higher number of stromal cells but not epithelial cells in 
high mammographic density regions when compared to low mammographic density 
regions within the same woman (p for trend < 0.01) (Lin et al., 2011). 
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3. Assessment and classifications of mammographic density 
In 1976, Wolfe first described a method for classifying variations in the mammographic 
appearance of the breast into four categories based on the visual assessment of the extent of 
dense breast tissue on the mammogram as well as of characteristics of densities seen 
(prominent ducts and dysplasia). The four categories correlate with breast cancer risk, 
where breasts with the densest pattern were associated with the highest risk of developing 
breast cancer (Wolfe, 1976). Later, the Wolfe categories have been largely replaced by the 
American College of Radiology’s Breast Imaging Reporting and Data System (BI-RADS). 
The BI-RADS, which is still frequently in use, also classifies mammographic density into 
four categories: 1 = almost entirely fatty breast, 2 = breast containing scattered densities, 3 = 
heterogeneously dense breast and 4 = extremely dense breast. Since then, several methods 
have been developed seeking to provide a quantitative and continuous measure of 
mammographic density. In 1995, Boyd proposed a six-category scale based on the visual 
estimation by a radiologist of the proportion of the breast occupied by radiologically dense 
tissue. The six categories are: 0%, < 10%, 10%-< 25%, 25%-< 50%, 50%-< 75%, ≥ 75% (Boyd et 
al., 1995). These previously mentioned methods depend on the visual assessment and are 
thus subjected to bias (Warren, 2004). Mammographic density is now often measured by a 
computer-assisted method on digitized images allowing the quantitative assessment of 
mammographic density. Results from such a method are expressed as absolute area of 
mammographic density in square centimeters or in percentage of mammographic density. 
The computer-assisted method is known to have a high degree of reliability and 
reproducibility for determining mammographic density (Boyd et al., 1995; Boyd et al., 2010). 
The limitation of this method is that it does not take into account the gradual transition from 
dense to non-dense breast tissue. Generally, the quantitative approaches have the advantage 
over the qualitative categorical approaches in providing a continuous measure of 
mammographic density. However, quantitative methods do not consider the breast volume; 
instead they take into account the breast area. Nonetheless, quantitative approaches give a 
more consistent estimate of the associated breast cancer risk and this risk persists after 
adjustment for other risk factors. 
4. Mammographic density and breast cancer risk 
The association between elevated mammographic density and increased breast cancer risk 
was investigated in many studies. In order to confirm this association, McCormak and dos 
Santos Silva conducted a systematic meta-analysis on 42 previously published studies 
(McCormack & dos Santos Silva, 2006). They included 14,000 women with breast cancer and 
226,000 women without breast cancer. They concluded that elevated mammographic 
density, regardless of the type of assessment, was consistently positively associated with an 
increased risk of breast cancer. Women with the most dense breast (> 75%) have 3-5 fold 
greater risk of developing breast cancer compared to women with the least dense breast      
(< 5%). The authors also reported that the associations were stronger when mammographic 
density was measured in percent mammographic density rather than categorized according 
to Wolfe scale. Thus, it is well established that high mammographic density constitutes an 
independent risk factor for breast cancer and that it accounts for a large proportion of the 
disease incidence (Boyd et al., 2010). It has been recently shown that women who 
experienced a decrease in mammographic density of at least one BI-RADS category over a 
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non-adipose breast tissue (Boyd et al., 2010; Li et al., 2005), representing the population of 
breast cells at risk of carcinogenic transformation (Trichopoulos et al., 2005). Breast cancer 
generally arises from epithelial cells (Russo et al., 1990), and an increase in the overall 
epithelial cell number is believed to increase the risk of breast cancer (Preston-Martin et al., 
1990). However, there is also growing evidence that stroma plays an important role, not 
only in mammary gland development, but also in breast carcinogenesis (Imagawa et al., 
2002; Shekhar et al., 2003; Woodward et al., 1998). Stroma is a major component of the breast 
(Imagawa et al., 2002; Page & Winfield, 1986; Shekhar et al., 2003) and variations in 
mammographic density may be more sensitive to changes in the stroma than to those in the 
epithelium (Warren & Lakhani, 2003). Knowledge of molecular markers (such as proteins 
and genes expression) in normal breast epithelium and stroma that are associated with 
mammographic density may provide important clues regarding breast cancer etiology. 
Studying the influence of such genes/proteins on mammographic density used as an end 
point in epidemiological studies may reduce the long term follow-up period needed to 
detect their effects on breast cancer incidence, thus providing an easier and more economic 
way to study the pathogenesis of breast cancer. A better understanding of molecular 
markers influencing mammographic density may also help to identify preventive targets.  
In this review, we intend to shed light on the possibility of using mammographic density as 
an intermediate biomarker to study the molecular causes of breast cancer. We hypothesize 
that if breast cancer biomarkers ultimately exert their influence on mammographic density 
in the same direction as they influence breast cancer risk, then mammographic density could 
be considered as an intermediate biomarker for breast cancer rather than just a risk factor. 
An overview with emphasis on changes in genes and proteins expression in normal breast 
tissue and their relationship with mammographic density is provided.  
2. Mammographic density 
The breast is composed mainly of fibroglandular tissue and adipose tissue at different 
proportions. These constituents differ in their X-ray attenuation characteristics. 
Fibroglandular tissue, mainly composed of epithelial cells and supporting stroma, 
attenuates more X-rays and thus appears white on mammograms, while adipose tissue, 
which is radiolucent, appears dark on mammograms. Hence, variations in the radiological 
appearance of the breast on a mammogram reflect variations in breast tissue composition.  
Mammographic density represents the proportion of the breast occupied by radiologically 
dense tissue. Results from Li’s study show that elevated mammographic density is 
associated with a greater nuclear area of both epithelial and non-epithelial cells, as well as 
with a greater proportion of collagen and a greater area of glandular structures (Li et al., 
2005). It is believed that elevated mammographic density reflects the effects of mitogens and 
mutagens which influence cellular proliferation and genetic damage of these cells (Martin & 
Boyd, 2008). This provides a potential mechanism by which elevated mammographic 
density could influence the risk of breast cancer. Moreover, it has been suggested that 
mammographic density is more related to stromal changes rather than epithelial changes 
(Heine & Malhotra, 2002; Warren & Lakhani, 2003). This is consistent with Lin and 
colleagues findings who reported a higher number of stromal cells but not epithelial cells in 
high mammographic density regions when compared to low mammographic density 
regions within the same woman (p for trend < 0.01) (Lin et al., 2011). 
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3. Assessment and classifications of mammographic density 
In 1976, Wolfe first described a method for classifying variations in the mammographic 
appearance of the breast into four categories based on the visual assessment of the extent of 
dense breast tissue on the mammogram as well as of characteristics of densities seen 
(prominent ducts and dysplasia). The four categories correlate with breast cancer risk, 
where breasts with the densest pattern were associated with the highest risk of developing 
breast cancer (Wolfe, 1976). Later, the Wolfe categories have been largely replaced by the 
American College of Radiology’s Breast Imaging Reporting and Data System (BI-RADS). 
The BI-RADS, which is still frequently in use, also classifies mammographic density into 
four categories: 1 = almost entirely fatty breast, 2 = breast containing scattered densities, 3 = 
heterogeneously dense breast and 4 = extremely dense breast. Since then, several methods 
have been developed seeking to provide a quantitative and continuous measure of 
mammographic density. In 1995, Boyd proposed a six-category scale based on the visual 
estimation by a radiologist of the proportion of the breast occupied by radiologically dense 
tissue. The six categories are: 0%, < 10%, 10%-< 25%, 25%-< 50%, 50%-< 75%, ≥ 75% (Boyd et 
al., 1995). These previously mentioned methods depend on the visual assessment and are 
thus subjected to bias (Warren, 2004). Mammographic density is now often measured by a 
computer-assisted method on digitized images allowing the quantitative assessment of 
mammographic density. Results from such a method are expressed as absolute area of 
mammographic density in square centimeters or in percentage of mammographic density. 
The computer-assisted method is known to have a high degree of reliability and 
reproducibility for determining mammographic density (Boyd et al., 1995; Boyd et al., 2010). 
The limitation of this method is that it does not take into account the gradual transition from 
dense to non-dense breast tissue. Generally, the quantitative approaches have the advantage 
over the qualitative categorical approaches in providing a continuous measure of 
mammographic density. However, quantitative methods do not consider the breast volume; 
instead they take into account the breast area. Nonetheless, quantitative approaches give a 
more consistent estimate of the associated breast cancer risk and this risk persists after 
adjustment for other risk factors. 
4. Mammographic density and breast cancer risk 
The association between elevated mammographic density and increased breast cancer risk 
was investigated in many studies. In order to confirm this association, McCormak and dos 
Santos Silva conducted a systematic meta-analysis on 42 previously published studies 
(McCormack & dos Santos Silva, 2006). They included 14,000 women with breast cancer and 
226,000 women without breast cancer. They concluded that elevated mammographic 
density, regardless of the type of assessment, was consistently positively associated with an 
increased risk of breast cancer. Women with the most dense breast (> 75%) have 3-5 fold 
greater risk of developing breast cancer compared to women with the least dense breast      
(< 5%). The authors also reported that the associations were stronger when mammographic 
density was measured in percent mammographic density rather than categorized according 
to Wolfe scale. Thus, it is well established that high mammographic density constitutes an 
independent risk factor for breast cancer and that it accounts for a large proportion of the 
disease incidence (Boyd et al., 2010). It has been recently shown that women who 
experienced a decrease in mammographic density of at least one BI-RADS category over a 
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period of six years had a 28% lower breast cancer risk compared to women whose 
mammographic density was unchanged (Tanne, 2010).  
5. Breast cancer risk factors associated to mammographic density 
Mammographic density is not constant throughout life. It declines with increasing age 
reflecting the age-related changes in breast tissue composition. These age-related changes, 
referred to as involution, reveal the reduction of the epithelium and stroma within the breast 
and the simultaneous increase in fat. Premenopausal women have consistently been found to 
have more elevated mammographic density than postmenopausal women. It might be slightly 
confusing knowing that mammographic density, which constitutes a breast cancer risk factor, 
decreases with age while breast cancer incidence increases with advanced age. This apparent 
paradox can be resolved by the breast cancer incidence model proposed by Pike (Pike et al., 
2004). Pike based his model on the concept that the relevant measure to describe the age-
specific incidence of breast cancer is the cumulative breast tissue exposure rather than the 
chronological age. The breast tissue exposure reflects the cumulative exposure of mammary 
cells to hormones and growth factors and the accumulation of genetic damage. According to 
Pike’s model, breast tissue exposure is at its peak at menarche, and then it decreases gradually 
during pregnancy, until it reaches its lowest values during the postmenopausal period. Thus, 
the incidence of breast cancer and the cumulative exposure of breast tissue both increase with 
age (Henson & Tarone, 1994; Pike et al., 2004). 
Several known risk factors for breast cancer; hormonal, reproductive and anthropometric 
variables, are also associated with variations in mammographic density. The strongest 
associations are observed with body weight. Mammographic density is inversely associated 
with body mass index (Brisson et al., 1984; Diorio et al., 2005a). This is consistent with the 
inverse association between body mass index or weight and breast cancer risk among 
premenopausal, but inconsistent with the positive association among postmenopausal 
women (Hunter & Willett, 1993; Trentham-Dietz et al., 1997). Height, which is proven to be 
positively associated with an increased risk of breast cancer among pre- and 
postmenopausal women, is also positively associated with increased mammographic 
density (Brisson et al., 1984; Trentham-Dietz et al., 1997).  
Moreover, hormonal-related breast cancer risk factors such as nulliparity, low number of 
live births, late age at first birth and combined hormone replacement therapy are positively 
associated with increased percent mammographic density (Boyd et al., 2010; El-Bastawissi et 
al., 2000). However, the association of circulating estrogen levels (known to be strongly 
positively associated with breast cancer risk) with mammographic density has so far been 
inconsistent (Boyd et al., 2002c; Greendale et al., 2005). It is believed that the exposure to 
endogenous and exogenous hormones accompanying reproductive and hormonal changes 
increases mammographic density by affecting the proliferative activity and the quantity of 
stroma and epithelium in breast tissue (Boyd et al., 2010). Furthermore, menopause was 
found to be associated with a reduction in dense areas accompanied by an increase in non-
dense areas. These changes in mammographic density due to menopausal status are not 
fully explained by the effect of age on density (Boyd et al., 2002a). 
However, all these epidemiological risk factors explain only about 20%-40% of the 
variability in percent mammographic density (Vachon et al., 2000). It seems that genetic 
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factors (heritability) could be responsible for greater variations in mammographic density. 
Current evidence shows that mammographic density is highly heritable and is inherited as a 
quantitative trait (Boyd et al., 2002b; Ursin et al., 2009). Heritability accounts for 50%-60% of 
the variation in mammographic density. Heritability of mammographic density may 
explain, at least in part, the familial aggregation pattern of breast cancer. Women with 
elevated percent mammographic density are more likely to have a first-degree relative with 
a history of breast cancer (Ziv et al., 2003).  
Recently, it has been demonstrated that tamoxifen, which reduces the extent of 
mammographic density, also decreases the burden of invasive breast cancer (Cuzick et al., 
2011). In that trial, for the 46% of women in the tamoxifen arm whose density was reduced 
by 10% or more, the risk of breast cancer was reduced by 63% relative to the control group 
(odds ratio (OR) = 0.37, p = 0.002) while for the 54% of women whose density was reduced 
by less than 10%, there was no reduction in breast cancer risk (OR = 1.13, p = 0.60). The 
action of tamoxifen is mediated through its effects on several gene products including 
insulin-like growth factor-1 (IGF-1) (Pollak et al., 1990), a protein that is believed to play a 
role in mammographic density (Diorio et al., 2005b) and breast cancer development  
(Schernhammer et al., 2005). This action can therefore be schematized as follow:  
 
The number of proteins / genes that can be measured in breast tissue rather than in the 
circulation is rapidly increasing because of new molecular technologies. Given that some 
preventive agents can decrease mammographic density and consequently breast cancer risk 
through their modifying effects on several proteins and/or genes, it seems important to 
study proteins/genes that could influence mammographic density. These proteins/genes 
may be further used as preventive targets in future breast cancer intervention studies.  
6. Proteins expression in breast tissue associated to mammographic density 
6.1 Insulin-like growth factors 
Knowing that mammographic density declines gradually with age and that circulating 
levels of IGF-1 also decrease with age and that both are related to an increased risk of breast 
cancer, it might be of great importance to study the relationship between the two. A pioneer 
study investigated the association between IGF-1 expression in breast tissue and 
mammographic density among women aged 45-55 years old who underwent breast biopsies 
with a final diagnosis of benign lesions (Guo et al., 2001). They used 92 formalin-fixed 
paraffin blocks of breast tissues surrounding benign lesions obtained from women with 
little (< 25%, n = 46) or extensive (> 50%, n = 46) mammographic density matched according 
to age at time of biopsy. In this study, tissue levels of IGF-1 from nuclear areas were 
analysed by immunohistochemistry and quantified using quantitative microscopy. Guo and 
colleagues found that breast tissue from subjects with extensive mammographic density had 
a greater IGF-1 staining when compared to subjects with little mammographic density (p = 
0.02). After stratification by age, this association was significant only for subjects less than 50 
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period of six years had a 28% lower breast cancer risk compared to women whose 
mammographic density was unchanged (Tanne, 2010).  
5. Breast cancer risk factors associated to mammographic density 
Mammographic density is not constant throughout life. It declines with increasing age 
reflecting the age-related changes in breast tissue composition. These age-related changes, 
referred to as involution, reveal the reduction of the epithelium and stroma within the breast 
and the simultaneous increase in fat. Premenopausal women have consistently been found to 
have more elevated mammographic density than postmenopausal women. It might be slightly 
confusing knowing that mammographic density, which constitutes a breast cancer risk factor, 
decreases with age while breast cancer incidence increases with advanced age. This apparent 
paradox can be resolved by the breast cancer incidence model proposed by Pike (Pike et al., 
2004). Pike based his model on the concept that the relevant measure to describe the age-
specific incidence of breast cancer is the cumulative breast tissue exposure rather than the 
chronological age. The breast tissue exposure reflects the cumulative exposure of mammary 
cells to hormones and growth factors and the accumulation of genetic damage. According to 
Pike’s model, breast tissue exposure is at its peak at menarche, and then it decreases gradually 
during pregnancy, until it reaches its lowest values during the postmenopausal period. Thus, 
the incidence of breast cancer and the cumulative exposure of breast tissue both increase with 
age (Henson & Tarone, 1994; Pike et al., 2004). 
Several known risk factors for breast cancer; hormonal, reproductive and anthropometric 
variables, are also associated with variations in mammographic density. The strongest 
associations are observed with body weight. Mammographic density is inversely associated 
with body mass index (Brisson et al., 1984; Diorio et al., 2005a). This is consistent with the 
inverse association between body mass index or weight and breast cancer risk among 
premenopausal, but inconsistent with the positive association among postmenopausal 
women (Hunter & Willett, 1993; Trentham-Dietz et al., 1997). Height, which is proven to be 
positively associated with an increased risk of breast cancer among pre- and 
postmenopausal women, is also positively associated with increased mammographic 
density (Brisson et al., 1984; Trentham-Dietz et al., 1997).  
Moreover, hormonal-related breast cancer risk factors such as nulliparity, low number of 
live births, late age at first birth and combined hormone replacement therapy are positively 
associated with increased percent mammographic density (Boyd et al., 2010; El-Bastawissi et 
al., 2000). However, the association of circulating estrogen levels (known to be strongly 
positively associated with breast cancer risk) with mammographic density has so far been 
inconsistent (Boyd et al., 2002c; Greendale et al., 2005). It is believed that the exposure to 
endogenous and exogenous hormones accompanying reproductive and hormonal changes 
increases mammographic density by affecting the proliferative activity and the quantity of 
stroma and epithelium in breast tissue (Boyd et al., 2010). Furthermore, menopause was 
found to be associated with a reduction in dense areas accompanied by an increase in non-
dense areas. These changes in mammographic density due to menopausal status are not 
fully explained by the effect of age on density (Boyd et al., 2002a). 
However, all these epidemiological risk factors explain only about 20%-40% of the 
variability in percent mammographic density (Vachon et al., 2000). It seems that genetic 
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factors (heritability) could be responsible for greater variations in mammographic density. 
Current evidence shows that mammographic density is highly heritable and is inherited as a 
quantitative trait (Boyd et al., 2002b; Ursin et al., 2009). Heritability accounts for 50%-60% of 
the variation in mammographic density. Heritability of mammographic density may 
explain, at least in part, the familial aggregation pattern of breast cancer. Women with 
elevated percent mammographic density are more likely to have a first-degree relative with 
a history of breast cancer (Ziv et al., 2003).  
Recently, it has been demonstrated that tamoxifen, which reduces the extent of 
mammographic density, also decreases the burden of invasive breast cancer (Cuzick et al., 
2011). In that trial, for the 46% of women in the tamoxifen arm whose density was reduced 
by 10% or more, the risk of breast cancer was reduced by 63% relative to the control group 
(odds ratio (OR) = 0.37, p = 0.002) while for the 54% of women whose density was reduced 
by less than 10%, there was no reduction in breast cancer risk (OR = 1.13, p = 0.60). The 
action of tamoxifen is mediated through its effects on several gene products including 
insulin-like growth factor-1 (IGF-1) (Pollak et al., 1990), a protein that is believed to play a 
role in mammographic density (Diorio et al., 2005b) and breast cancer development  
(Schernhammer et al., 2005). This action can therefore be schematized as follow:  
 
The number of proteins / genes that can be measured in breast tissue rather than in the 
circulation is rapidly increasing because of new molecular technologies. Given that some 
preventive agents can decrease mammographic density and consequently breast cancer risk 
through their modifying effects on several proteins and/or genes, it seems important to 
study proteins/genes that could influence mammographic density. These proteins/genes 
may be further used as preventive targets in future breast cancer intervention studies.  
6. Proteins expression in breast tissue associated to mammographic density 
6.1 Insulin-like growth factors 
Knowing that mammographic density declines gradually with age and that circulating 
levels of IGF-1 also decrease with age and that both are related to an increased risk of breast 
cancer, it might be of great importance to study the relationship between the two. A pioneer 
study investigated the association between IGF-1 expression in breast tissue and 
mammographic density among women aged 45-55 years old who underwent breast biopsies 
with a final diagnosis of benign lesions (Guo et al., 2001). They used 92 formalin-fixed 
paraffin blocks of breast tissues surrounding benign lesions obtained from women with 
little (< 25%, n = 46) or extensive (> 50%, n = 46) mammographic density matched according 
to age at time of biopsy. In this study, tissue levels of IGF-1 from nuclear areas were 
analysed by immunohistochemistry and quantified using quantitative microscopy. Guo and 
colleagues found that breast tissue from subjects with extensive mammographic density had 
a greater IGF-1 staining when compared to subjects with little mammographic density (p = 
0.02). After stratification by age, this association was significant only for subjects less than 50 
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with high mammographic density compared to blocks from women with low 
mammographic density among subjects less than 50 years of age (p = 0.0009). A main pitfall 
of Guo’s study was the lack of information regarding the menopausal status of the 
participants. Nonetheless, data from laboratory and epidemiological studies seem to 
support these findings.    
The IGF-1 is a member of a superfamily of multifunctional peptides. The majority of 
circulating IGFs are produced by the liver in response to growth hormone, but many other 
tissues including the breast tissue can also express IGFs. IGF-1 plays a crucial role in 
regulating many cellular functions such as cell proliferation, differentiation and apoptosis. It 
is well known that IGF-1 is essential for normal mammary cells development (Marshman & 
Streuli, 2002). Strange and colleagues have demonstrated that IGF-1 increases the 
proliferative activity of cultured mammary cells and hence the risk of breast cancer. They 
added that IGF-1 is able to stimulate the growth of cultured human breast epithelial and 
stromal cells in a dose-dependent manner (Strange et al., 2002; Strange et al., 2004). Several 
epidemiological studies have provided evidence that elevated circulating levels of IGF-1 are 
associated with increased breast cancer risk in pre- but not postmenopausal women 
(Hankinson et al., 1998; Krajcik et al., 2002; Schernhammer et al., 2005; Toniolo et al., 2000). 
This is in line with the positive association between increased circulating levels of IGF-1 and 
percent mammographic density among pre- (p = 0.02) but not postmenopausal women (p = 
0.37) that was observed in our large study specifically designed to confirm what other 
studies of smaller sample size had observed (Diorio et al., 2005b). More recently, we showed 
that single nucleotide polymorphisms (SNPs) located on IGF-1 gene were also associated 
with premenopausal mammographic density, and this association remained after 
adjustment for IGF-1 levels (Diorio et al., 2008). Although circulating levels of IGF-1, mainly 
produced in the liver, have been linked to breast morphogenesis and breast cancer risk, our 
results support the idea that IGF-1 at tissue levels are important in this respect, at least 
among premenopausal women. This association only found among premenopausal women 
may reflect a cross-talk between IGF-1 and steroid hormones. In fact, a previous study has 
observed a strong evidence of a cross-talk between IGF-1 and estrogen in breast tissue 
(Martin & Stoica, 2002). Estrogen induces IGF-1 expression through binding to estrogen 
receptor-α (ERα), and IGF-1, by binding to its receptor, initiates a cascade of 
phosphorylation that ends by activating ERα. This estrogen-IGF-1 cross-talk may induce 
mammary epithelial cells proliferation and possibly tumor development.  
6.2 Hormone receptors 
Since mammographic density reflects the cumulative effect of steroid hormones on breast 
tissue and blood estradiol level is a risk factor for breast cancer, then mammographic 
density is expected to be associated to hormone receptors in breast tissue. So far, two studies 
assessed the association between the two subtypes of ER, ERα and ERβ, separately and 
mammographic density (Lundstrom et al., 2006; Verheus et al., 2009), while two others 
assessed the association between ER, with no mention of the subtype, and mammographic 
density (Harvey et al., 2008; Yang et al., 2010). Among these, three groups also assessed the 
association between the progesterone receptor (PgR) and mammographic density (Harvey 
et al., 2008; Verheus et al., 2009; Yang et al., 2010).  
Lundstrom and colleagues obtained normal tissue specimens from 28 postmenopausal 
women aged ≥ 52 years old undergoing surgery for breast cancer as first treatment. 
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Radiological examination was performed on tissue blocks, and pair-wise samples of dense 
and non-dense tissue were selected. They analysed semi-quantitatively ERα and ERβ in 
glandular epithelium by immunohistochemical staining intensity. They observed a higher 
ERα staining in glandular epithelium in mammographically dense compared to non-dense 
breast tissue (2.4 ± 0.2 versus 1.6 ± 0.2; p < 0.01). Conversely, there was no significant 
association between ERβ and mammographic density (2.2 ± 0.2 versus 1.9 ± 0.3; p > 0.05 for 
dense and non-dense tissue respectively) (Lundstrom et al., 2006). The major strengths of 
Lunstrom’s study were the measurement of the two subtypes of ER separately and the 
usage of paired samples of dense and non-dense normal breast tissue at a distance of at least 
2 cm from the tumor from each patient. The small sample size, the lack of premenopausal 
women included in the study sample and the usage of normal breast tissue obtained from 
breast cancer patients which may not be completely representative of normal breast tissue 
were the main limitations of this study.  
In the study conducted by Verheus and colleagues, they assessed the epithelial expression of 
ERα, ERβ, and PgR in relation to mammographic density among 159 pre- and 
postmenopausal women having breast cancer, 60 years old on average, and of different 
ethnicities. They prepared tissue microarrays (TMAs) from benign breast tissue samples 
obtained from tumor blocks (mean = 1.7 specimens per woman). The TMAs were then 
immunostained for ERα, ERβ and PgR, which were measured by quantitative microscopy 
and categorized as < 10% or ≥ 10% of staining. Mammographic density from the 
craniocaudal views before breast cancer diagnosis was assessed using a computer-assisted 
method. None of the markers measured in breast tissue was significantly associated with 
percent or absolute mammographic density among the whole study population or among 
Japanese women. However, they observed a negative association between ERα expression 
and percent mammographic density (p = 0.04), a positive association between ERβ and 
percent mammographic density (p = 0.05) and a positive association between PgR and 
absolute mammographic density (p = 0.03) among Caucasian women (Verheus et al., 2009). 
Assessment of ERα and ERβ separately, the usage of TMA approach which allows the 
assessment of several markers expression in a large number of samples under the same 
staining conditions, the classification of mammographic density by a computer-assisted 
method and the adjustment for several potential confounders in the analysis were the main 
advantages of Verheus’ study. However, the usage of benign breast tissue obtained from 
tumor blocks may not be fully representative of normal breast tissue and markers 
expression in benign tissue could have been influenced by potential paracrine effects of the 
adjacent tumors.  
Harvey and colleagues included in their study 56 postmenopausal women aged from 45 to 
85 years old having a surgical treatment for breast cancer. Mammographic density of the 
contralateral breast was assessed by a computer-assisted method. The ER and PgR content 
in ducts, lobules and fibrous stroma was measured by immunohistochemistry performed on 
tissue blocks free from cancer, and the intensity of staining, as negative or positive, was 
visually estimated. Contrary to what one might have expected, the authors did not find any 
significant association between ER or PgR and mammographic density after adjustment for 
hormonal replacement therapy use and age (Harvey et al., 2008). The small sample size, the 
lack of premenopausal women among the study population, the usage of tissue blocks from 
mastectomy specimens which might not be completely free from foci of carcinoma in 
addition to be sampled in densest areas of the breast and the lack of adjustment for potential 
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with high mammographic density compared to blocks from women with low 
mammographic density among subjects less than 50 years of age (p = 0.0009). A main pitfall 
of Guo’s study was the lack of information regarding the menopausal status of the 
participants. Nonetheless, data from laboratory and epidemiological studies seem to 
support these findings.    
The IGF-1 is a member of a superfamily of multifunctional peptides. The majority of 
circulating IGFs are produced by the liver in response to growth hormone, but many other 
tissues including the breast tissue can also express IGFs. IGF-1 plays a crucial role in 
regulating many cellular functions such as cell proliferation, differentiation and apoptosis. It 
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6.2 Hormone receptors 
Since mammographic density reflects the cumulative effect of steroid hormones on breast 
tissue and blood estradiol level is a risk factor for breast cancer, then mammographic 
density is expected to be associated to hormone receptors in breast tissue. So far, two studies 
assessed the association between the two subtypes of ER, ERα and ERβ, separately and 
mammographic density (Lundstrom et al., 2006; Verheus et al., 2009), while two others 
assessed the association between ER, with no mention of the subtype, and mammographic 
density (Harvey et al., 2008; Yang et al., 2010). Among these, three groups also assessed the 
association between the progesterone receptor (PgR) and mammographic density (Harvey 
et al., 2008; Verheus et al., 2009; Yang et al., 2010).  
Lundstrom and colleagues obtained normal tissue specimens from 28 postmenopausal 
women aged ≥ 52 years old undergoing surgery for breast cancer as first treatment. 
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Radiological examination was performed on tissue blocks, and pair-wise samples of dense 
and non-dense tissue were selected. They analysed semi-quantitatively ERα and ERβ in 
glandular epithelium by immunohistochemical staining intensity. They observed a higher 
ERα staining in glandular epithelium in mammographically dense compared to non-dense 
breast tissue (2.4 ± 0.2 versus 1.6 ± 0.2; p < 0.01). Conversely, there was no significant 
association between ERβ and mammographic density (2.2 ± 0.2 versus 1.9 ± 0.3; p > 0.05 for 
dense and non-dense tissue respectively) (Lundstrom et al., 2006). The major strengths of 
Lunstrom’s study were the measurement of the two subtypes of ER separately and the 
usage of paired samples of dense and non-dense normal breast tissue at a distance of at least 
2 cm from the tumor from each patient. The small sample size, the lack of premenopausal 
women included in the study sample and the usage of normal breast tissue obtained from 
breast cancer patients which may not be completely representative of normal breast tissue 
were the main limitations of this study.  
In the study conducted by Verheus and colleagues, they assessed the epithelial expression of 
ERα, ERβ, and PgR in relation to mammographic density among 159 pre- and 
postmenopausal women having breast cancer, 60 years old on average, and of different 
ethnicities. They prepared tissue microarrays (TMAs) from benign breast tissue samples 
obtained from tumor blocks (mean = 1.7 specimens per woman). The TMAs were then 
immunostained for ERα, ERβ and PgR, which were measured by quantitative microscopy 
and categorized as < 10% or ≥ 10% of staining. Mammographic density from the 
craniocaudal views before breast cancer diagnosis was assessed using a computer-assisted 
method. None of the markers measured in breast tissue was significantly associated with 
percent or absolute mammographic density among the whole study population or among 
Japanese women. However, they observed a negative association between ERα expression 
and percent mammographic density (p = 0.04), a positive association between ERβ and 
percent mammographic density (p = 0.05) and a positive association between PgR and 
absolute mammographic density (p = 0.03) among Caucasian women (Verheus et al., 2009). 
Assessment of ERα and ERβ separately, the usage of TMA approach which allows the 
assessment of several markers expression in a large number of samples under the same 
staining conditions, the classification of mammographic density by a computer-assisted 
method and the adjustment for several potential confounders in the analysis were the main 
advantages of Verheus’ study. However, the usage of benign breast tissue obtained from 
tumor blocks may not be fully representative of normal breast tissue and markers 
expression in benign tissue could have been influenced by potential paracrine effects of the 
adjacent tumors.  
Harvey and colleagues included in their study 56 postmenopausal women aged from 45 to 
85 years old having a surgical treatment for breast cancer. Mammographic density of the 
contralateral breast was assessed by a computer-assisted method. The ER and PgR content 
in ducts, lobules and fibrous stroma was measured by immunohistochemistry performed on 
tissue blocks free from cancer, and the intensity of staining, as negative or positive, was 
visually estimated. Contrary to what one might have expected, the authors did not find any 
significant association between ER or PgR and mammographic density after adjustment for 
hormonal replacement therapy use and age (Harvey et al., 2008). The small sample size, the 
lack of premenopausal women among the study population, the usage of tissue blocks from 
mastectomy specimens which might not be completely free from foci of carcinoma in 
addition to be sampled in densest areas of the breast and the lack of adjustment for potential 
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confounding factors may explain the absence of association. The major strength of this study 
was the use of a computer-assisted method providing a continuous and reproducible 
measure of mammographic density. 
For their study, Yang and colleagues identified 27 premenopausal women and 39 
postmenopausal women (29-88 years old) who underwent surgery for breast cancer as first 
treatment. These women had low (BI-RADS 1 or 2, n = 28) or high (BI-RADS 3 or 4, n = 38) 
mammographic density. They analysed ER and PgR expression immunohistochemically in 
stroma and epithelium separately, from normal frozen breast tissue located at least 5 cm 
away from the tumor. The Allred scoring system was used by a breast pathologist to 
measure each marker. In this study, the authors did not find any significant positive 
association between ER or PgR and mammographic density in univariate models (Yang et 
al., 2010). Unfortunately, their small sample size did not allow analysis stratified by 
menopausal status. As in the above studies, they used normal breast tissue obtained from 
breast cancer patients which may not truly represent normal breast tissue.  
Therefore, out of the studies that analysed the association between specified subtypes of ER 
expression in breast tissue and mammographic density, one study observed a positive 
association between epithelial ERα expression and mammographic density among 
postmenopausal women (Lundstrom et al., 2006), while another study observed an inverse 
association among pre- and postmenopausal Caucasian women (Verheus et al., 2009). In this 
latter population, a positive association of ERβ and PgR expression in breast tissue with 
mammographic density was also observed (Verheus et al., 2009). However, none of the 
other two studies that assessed PgR found any significant association among pre- and/or 
postmenopausal women (Harvey et al., 2008; Yang et al., 2010). 
It is well known that ovarian steroid hormones play a critical role in normal mammary cell 
development, proliferation and differentiation (Graham & Clarke, 1997; Nilsson et al., 2001). 
While most of the studies agree that estrogen increases the risk of breast cancer, the effect of 
progesterone on this risk remains a subject of controversy (Hankinson & Eliassen, 2007). In 
fact, PgR could be considered a marker of both estrogen and progesterone actions in the 
mammary gland, since PgR expression is regulated by estrogen (Shyamala et al., 2002). 
Estrogen exerts its biological activity on mammary cells particularly through nuclear ERs. 
ERs are further subdivided into two subtypes; ERα and ERβ, having different expression 
levels in normal and malignant breast tissues. ERα and ERβ, encoded by different genes, 
exert different biological actions on breast tissue cells. Activation of ERα increases the rate of 
breast cells proliferation by up-regulating several genes involved in cellular proliferation 
such as cyclin D (Liu et al., 2002b), while down-regulating other genes known to inhibit 
proliferation such as transforming growth factor-β (TGF-β) (Chang et al., 2006). In a recent 
study, Woolcott and colleagues observed that ERα levels were higher in nonneoplastic 
epithelium obtained from breast cancer cases when compared to control biopsies obtained 
from women free from breast cancer (OR = 2.6; 95% CI 1.1-6.2). However, there was no 
significant difference between PgR expression in nonneoplastic epithelium obtained from 
breast cancer cases and that obtained from control women (OR = 0.7; 95% CI 0.4-1.3) 
(Woolcott et al., 2008). The ERα-induced breast cells proliferation is consistent with 
Lundstrom’s finding (Lundstrom et al., 2006) of increased epithelial ERα expression in 
dense breast tissue compared to non-dense tissue. These results suggest that breast tissue 
could be influenced by increased ERα expression, leading to increased mammographic 
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density and finally to increased breast cancer risk at least among postmenopausal women. 
On the other hand, the overexpression of ERβ decreases ERα transcriptional activity. ERβ 
has been found to modulate the expression of many ERα regulated genes involved in cell 
proliferation such as cyclin D and TGF-β genes (Chang et al., 2006; Liu et al., 2002b). Also, 
ERβ down-regulates the ERα protein level (Chang et al., 2006). Furthermore, ERβ staining 
was inversely correlated with the Ki67, marker of cellular proliferation, in normal breast 
tissue and preinvasive mammary tumor (Roger et al., 2001). This suggests that ERβ acts as a 
tumor suppressor (Bardin et al., 2004). Thus, it is evident that the ratio between both 
subtypes is the most important determinant of the overall response. The increased 
expression of ERα concomitant with decreased ERβ expression was found to take place in 
early breast cancer stages (Leygue et al., 1998a; Roger et al., 2001). Knowing that ER 
subtypes have opposite actions on breast tissue could provide further explanation regarding 
the opposite associations found in Verheus and colleagues study, who did not consider the 
ratio or the mutual adjustment of both subtypes in their analysis since both subtypes were 
associated to mammographic density. 
6.3 Aromatase enzyme 
A recent study assessed the association between breast tissue aromatase expression, a rate-
limiting enzyme in the estrogen pathway, and mammographic density (Vachon et al., 2011). 
They looked for this association among 49 healthy Caucasian women aged from 40-82 years 
old. Mammographic density was visually assessed using the mammographic films and 
identifying areas of low and high mammographic density. They applied a fine-needle 
guided ultrasound to obtain tissue biopsies from dense and from non-dense breast areas for 
each woman. Biopsies were analysed by immunohistochemistry, and immunostaining for 
aromatase was scored visually in terms of extent and intensity of staining for each cell type 
(stroma, epithelium and adipocytes) using a modified H-score (Santen et al., 1994). They 
observed greater aromatase staining in dense breast tissue when compared to non-dense 
tissue (p < 0.0003). This result was consistent for pre- and postmenopausal women when 
assessed separately. The aromatase staining was higher in both stromal and epithelial cells 
from dense tissue compared to those from non-dense tissue (both p < 0.01). Conversely, it 
was lower in adipocytes from dense tissue versus non-dense tissue (p < 0.01). Concerning 
dense breast tissue, aromatase staining in stromal cells was threefold higher than that in 
epithelial cells. The major strengths of Vachon’s study were the paired samples of dense and 
non-dense normal breast tissue taken from healthy subjects and the scoring of aromatase 
using both the extent and the intensity of staining. To our knowledge, this is the only study 
assessing the association between breast tissue aromatase level and mammographic density 
and therefore further larger studies are recommended to confirm these promising findings. 
The aromatase enzyme catalyzes the conversion of androgens, androstenedione and 
testosterone to estrogen, estrone and estradiol. Thus, it is largely responsible for estrogen 
levels in breast tissue, especially after menopause, when the in situ production of estrogen in 
mammary adipose tissue takes the upper hand following the cessation of ovarian estrogen 
synthesis. Increased aromatase expression would result in higher estrogen levels and 
subsequently greater breast tissue exposure to estrogen. Irahara and colleagues observed an 
elevated level of aromatase mRNA in breast cancer cells when compared to normal breast 
tissue (Irahara et al., 2006). Furthermore, aromatase has been shown to stimulate the growth 
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confounding factors may explain the absence of association. The major strength of this study 
was the use of a computer-assisted method providing a continuous and reproducible 
measure of mammographic density. 
For their study, Yang and colleagues identified 27 premenopausal women and 39 
postmenopausal women (29-88 years old) who underwent surgery for breast cancer as first 
treatment. These women had low (BI-RADS 1 or 2, n = 28) or high (BI-RADS 3 or 4, n = 38) 
mammographic density. They analysed ER and PgR expression immunohistochemically in 
stroma and epithelium separately, from normal frozen breast tissue located at least 5 cm 
away from the tumor. The Allred scoring system was used by a breast pathologist to 
measure each marker. In this study, the authors did not find any significant positive 
association between ER or PgR and mammographic density in univariate models (Yang et 
al., 2010). Unfortunately, their small sample size did not allow analysis stratified by 
menopausal status. As in the above studies, they used normal breast tissue obtained from 
breast cancer patients which may not truly represent normal breast tissue.  
Therefore, out of the studies that analysed the association between specified subtypes of ER 
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association between epithelial ERα expression and mammographic density among 
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mammographic density was also observed (Verheus et al., 2009). However, none of the 
other two studies that assessed PgR found any significant association among pre- and/or 
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While most of the studies agree that estrogen increases the risk of breast cancer, the effect of 
progesterone on this risk remains a subject of controversy (Hankinson & Eliassen, 2007). In 
fact, PgR could be considered a marker of both estrogen and progesterone actions in the 
mammary gland, since PgR expression is regulated by estrogen (Shyamala et al., 2002). 
Estrogen exerts its biological activity on mammary cells particularly through nuclear ERs. 
ERs are further subdivided into two subtypes; ERα and ERβ, having different expression 
levels in normal and malignant breast tissues. ERα and ERβ, encoded by different genes, 
exert different biological actions on breast tissue cells. Activation of ERα increases the rate of 
breast cells proliferation by up-regulating several genes involved in cellular proliferation 
such as cyclin D (Liu et al., 2002b), while down-regulating other genes known to inhibit 
proliferation such as transforming growth factor-β (TGF-β) (Chang et al., 2006). In a recent 
study, Woolcott and colleagues observed that ERα levels were higher in nonneoplastic 
epithelium obtained from breast cancer cases when compared to control biopsies obtained 
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density and finally to increased breast cancer risk at least among postmenopausal women. 
On the other hand, the overexpression of ERβ decreases ERα transcriptional activity. ERβ 
has been found to modulate the expression of many ERα regulated genes involved in cell 
proliferation such as cyclin D and TGF-β genes (Chang et al., 2006; Liu et al., 2002b). Also, 
ERβ down-regulates the ERα protein level (Chang et al., 2006). Furthermore, ERβ staining 
was inversely correlated with the Ki67, marker of cellular proliferation, in normal breast 
tissue and preinvasive mammary tumor (Roger et al., 2001). This suggests that ERβ acts as a 
tumor suppressor (Bardin et al., 2004). Thus, it is evident that the ratio between both 
subtypes is the most important determinant of the overall response. The increased 
expression of ERα concomitant with decreased ERβ expression was found to take place in 
early breast cancer stages (Leygue et al., 1998a; Roger et al., 2001). Knowing that ER 
subtypes have opposite actions on breast tissue could provide further explanation regarding 
the opposite associations found in Verheus and colleagues study, who did not consider the 
ratio or the mutual adjustment of both subtypes in their analysis since both subtypes were 
associated to mammographic density. 
6.3 Aromatase enzyme 
A recent study assessed the association between breast tissue aromatase expression, a rate-
limiting enzyme in the estrogen pathway, and mammographic density (Vachon et al., 2011). 
They looked for this association among 49 healthy Caucasian women aged from 40-82 years 
old. Mammographic density was visually assessed using the mammographic films and 
identifying areas of low and high mammographic density. They applied a fine-needle 
guided ultrasound to obtain tissue biopsies from dense and from non-dense breast areas for 
each woman. Biopsies were analysed by immunohistochemistry, and immunostaining for 
aromatase was scored visually in terms of extent and intensity of staining for each cell type 
(stroma, epithelium and adipocytes) using a modified H-score (Santen et al., 1994). They 
observed greater aromatase staining in dense breast tissue when compared to non-dense 
tissue (p < 0.0003). This result was consistent for pre- and postmenopausal women when 
assessed separately. The aromatase staining was higher in both stromal and epithelial cells 
from dense tissue compared to those from non-dense tissue (both p < 0.01). Conversely, it 
was lower in adipocytes from dense tissue versus non-dense tissue (p < 0.01). Concerning 
dense breast tissue, aromatase staining in stromal cells was threefold higher than that in 
epithelial cells. The major strengths of Vachon’s study were the paired samples of dense and 
non-dense normal breast tissue taken from healthy subjects and the scoring of aromatase 
using both the extent and the intensity of staining. To our knowledge, this is the only study 
assessing the association between breast tissue aromatase level and mammographic density 
and therefore further larger studies are recommended to confirm these promising findings. 
The aromatase enzyme catalyzes the conversion of androgens, androstenedione and 
testosterone to estrogen, estrone and estradiol. Thus, it is largely responsible for estrogen 
levels in breast tissue, especially after menopause, when the in situ production of estrogen in 
mammary adipose tissue takes the upper hand following the cessation of ovarian estrogen 
synthesis. Increased aromatase expression would result in higher estrogen levels and 
subsequently greater breast tissue exposure to estrogen. Irahara and colleagues observed an 
elevated level of aromatase mRNA in breast cancer cells when compared to normal breast 
tissue (Irahara et al., 2006). Furthermore, aromatase has been shown to stimulate the growth 
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of breast cancer cells in vitro (Macaulay et al., 1994). The aromatase is the product of the 
CYP19 gene which is a member of the cytochrome P450 enzymes family. A comprehensive 
haplotype analysis of CYP19 and breast cancer risk reveals that a common specific long-
range haplotype is associated with an increased risk of breast cancer (OR = 1.31; 95% CI 
1.11-1.54) (Haiman et al., 2003). In contrast, no association has been observed in a recent 
comprehensive examination of CYP19 variants and mammographic density (Olson et al., 
2007). However, the common long-range haplotype associated with breast cancer risk has 
not been assessed by Olson and colleagues. The identification of causal variants associated 
with the CYP19 long-range haplotype should be investigated. 
6.4 Epidermal growth factors 
Among the complete family of epidermal growth factor receptors and their ligands expressed 
in breast tissue, human epidermal growth factor receptor-2 (HER-2) and transforming growth 
factor-α (TGF-α) have been evaluated for their association with mammographic density. 
In the study conducted by Verheus and colleagues described earlier (Verheus et al., 2009), the 
authors also measured the expression of HER-2 in breast tissue. They observed no association 
between HER-2 staining and mammographic density among the whole study population (p = 
0.82 and p = 0.74 for percent and absolute mammographic density respectively), among 
Caucasian women (p = 0.38 and p = 0.99 for percent and absolute mammographic density 
respectively) or among Japanese women (p = 0.57 and p = 0.73 for percent and absolute 
mammographic density respectively). HER-2 belongs to the human epidermal growth factor 
receptor family which is involved in the regulation of normal breast growth and development. 
In fact, HER-2 is overexpressed in 20-30% of cases of breast cancer (Cho et al., 2008). When 
HER-2 is overexpressed, it sends signals to the nucleus to proliferate, resulting in increased 
cellular multiplication and consequently malignant growth (Yarden, 2001). A recent meta-
analysis found that the functional SNP Ile655Val of HER-2 is associated to breast cancer risk 
among Asian women but not among Caucasian nor European women (Tao et al., 2009). 
Moreover, no association has been observed between HER-2 Ile655Val SNP and 
mammographic density among Australian women (Stone et al., 2007). The Ile655Val is 
believed to destabilize the active HER-2 reducing its activation (Fleishman et al., 2002).  
In the study previously considered, Guo and colleagues also quantified TGF-α staining, and 
found no association with mammographic density before or after stratification for age (all p 
> 0.30) (Guo et al., 2001). The influence of TGF-α, a member of the epidermal growth factor 
family of peptides, on breast cancer incidence is not fully explored. However, a previous 
laboratory study has demonstrated that TGF-α enhances the growth of normal mouse 
mammary epithelial cell line (Casey et al., 2007). Furthermore, TGF-α can act as a mitogen 
and differentiation factor in mammary epithelium inducing multifocal hyperplastic and 
malignant lesions in an animal model (Smith et al., 1995).  
Additional research will be needed to clarify the role of epidermal growth factor family in 
breast morphogenesis and breast cancer risk. 
6.5 Matrix metalloproteinases 
In a recent study, Steude and colleagues attempted to assess the association between matrix 
metalloproteinases (MMPs) 1, 3, 9, 12 and their inhibitor (TIMP-3) in breast tissue and 
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mammographic density (Steude et al., 2009). Their study population was composed of 75 
premenopausal and 202 postmenopausal breast cancer patients with mainly Caucasian and 
Japanese ancestry. To achieve their goal, they prepared TMAs with up to 4 cores from areas 
representing benign breast tissues (mean = 2.9 cores per woman). The expression of MMPs 
and TIMP-3 was immunohistochemically measured and visually classified in the stroma as 
no versus any stain (available for 169 women) and in the epithelium as no, weak or strong 
stain intensity (available for 259 women) separately. A computer-assisted method was 
applied for the evaluation of mammographic density from prediagnostic digitized 
mammograms from the craniocaudal views. Because the expression of MMP-3 and MMP-9 
was observed in less than 20% of epithelial and less than 5% of stromal breast tissue, the 
authors did not examine their associations with percent mammographic density. Contrary 
to what was expected, MMP-1, MMP-12 and TIMP-3 analysed in stromal and in epithelial 
tissue were not significantly related to percent mammographic density after adjustment for 
confounders among the whole study population or across ethnic groups.  
Although Guo and colleagues did not measure MMPs, they assayed TIMP-3 in addition to 
IGF-1 and TGF-α reported earlier (Guo et al., 2001). They found that TIMP-3 expression was 
higher in tissue from subjects with extensive mammographic density compared to age-
matched subjects with little mammographic density (p = 0.08). Moreover, this association 
was statistically significant for women less than 50 years old (p = 0.004), but not for women 
50 years old or more (p = 0.48). Guo and colleagues hypothesized that TIMP-3 may influence 
epithelial and stromal proliferation contributing to higher mammographic density and 
subsequently increased breast cancer risk. The discrepancy between Steude and Guo’s 
studies could be due to different means used in classifying mammographic density, 
different immunostaining techniques applied, and different study population regarding 
their breast diseases, ethnicity and mean age. In particular, participants in Guo’s study were 
younger (ranging from 45-55 years old) than those recruited in Steude’s study (mean age = 
60.2 ± 8.7 years old) suggesting that the association between TIMP-3 and breast density 
could be limited to young women. A further larger study, stratifying analyses according to 
menopausal status, will be needed to clarify these observations.  
The MMPs are proteases responsible for cleaving proteins of the extracellular matrix. MMPs 
regulate a wide range of biological functions such as cell death, proliferation, differentiation, 
tumor associated angiogenesis and malignant conversion (Coussens et al., 2002). They can 
also induce tumor invasion and metastasis (Balduyck et al., 2000). MMPs have been found to 
be greatly expressed in malignant breast tissue when compared to the surrounding normal 
breast tissue (Bartsch et al., 2003; Garbett et al., 2000). However, their roles in breast cancer 
development are unclear. According to Shin and colleagues, none of the two common SNPs 
in the MMP-12 gene (A-82G in the promoter region and A1082G in the exon) was associated 
with breast cancer risk among pre- and postmenopausal Chinese women (Shin et al., 2005). 
A recently published meta-analysis, looked for the association between MMP-1 (rs1799750), 
MMP-2 (rs243865), MMP-3 (rs3025058) and MMP-9 (rs3918242) SNPs and breast cancer risk 
(Zhou et al., 2011). They selected 9 case-control studies including 2,597 cases and 2,618 
controls, and found only an association between MMP-2 SNP and breast cancer risk. 
However, MMP-2 expression in breast tissue has not yet been examined in association with 
mammographic density. 
TIMP-3 was found able to induce cellular apoptosis (Baker et al., 1999; Jiang et al., 2002). 
However, an increased TIMP-3 expression was observed in breast cancer (Byrne et al., 1995; 
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of breast cancer cells in vitro (Macaulay et al., 1994). The aromatase is the product of the 
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mammographic density (Steude et al., 2009). Their study population was composed of 75 
premenopausal and 202 postmenopausal breast cancer patients with mainly Caucasian and 
Japanese ancestry. To achieve their goal, they prepared TMAs with up to 4 cores from areas 
representing benign breast tissues (mean = 2.9 cores per woman). The expression of MMPs 
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applied for the evaluation of mammographic density from prediagnostic digitized 
mammograms from the craniocaudal views. Because the expression of MMP-3 and MMP-9 
was observed in less than 20% of epithelial and less than 5% of stromal breast tissue, the 
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to what was expected, MMP-1, MMP-12 and TIMP-3 analysed in stromal and in epithelial 
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matched subjects with little mammographic density (p = 0.08). Moreover, this association 
was statistically significant for women less than 50 years old (p = 0.004), but not for women 
50 years old or more (p = 0.48). Guo and colleagues hypothesized that TIMP-3 may influence 
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their breast diseases, ethnicity and mean age. In particular, participants in Guo’s study were 
younger (ranging from 45-55 years old) than those recruited in Steude’s study (mean age = 
60.2 ± 8.7 years old) suggesting that the association between TIMP-3 and breast density 
could be limited to young women. A further larger study, stratifying analyses according to 
menopausal status, will be needed to clarify these observations.  
The MMPs are proteases responsible for cleaving proteins of the extracellular matrix. MMPs 
regulate a wide range of biological functions such as cell death, proliferation, differentiation, 
tumor associated angiogenesis and malignant conversion (Coussens et al., 2002). They can 
also induce tumor invasion and metastasis (Balduyck et al., 2000). MMPs have been found to 
be greatly expressed in malignant breast tissue when compared to the surrounding normal 
breast tissue (Bartsch et al., 2003; Garbett et al., 2000). However, their roles in breast cancer 
development are unclear. According to Shin and colleagues, none of the two common SNPs 
in the MMP-12 gene (A-82G in the promoter region and A1082G in the exon) was associated 
with breast cancer risk among pre- and postmenopausal Chinese women (Shin et al., 2005). 
A recently published meta-analysis, looked for the association between MMP-1 (rs1799750), 
MMP-2 (rs243865), MMP-3 (rs3025058) and MMP-9 (rs3918242) SNPs and breast cancer risk 
(Zhou et al., 2011). They selected 9 case-control studies including 2,597 cases and 2,618 
controls, and found only an association between MMP-2 SNP and breast cancer risk. 
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TIMP-3 was found able to induce cellular apoptosis (Baker et al., 1999; Jiang et al., 2002). 
However, an increased TIMP-3 expression was observed in breast cancer (Byrne et al., 1995; 
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Uria et al., 1994). This is in line with Guo’s observation who suggested that TIMP-3 might 
increase the risk of premenopausal breast cancer through its effect on epithelial and stromal 
cells proliferation. According to Peterson, who evaluated the association between 19 SNPs of 
TIMP-3 and breast cancer risk among 1,062 Chinese women with breast cancer and 1,069 
without, women with the rs9609643 AA genotype had 60% lower risk of developing breast 
cancer when compared to women with GG genotype (OR = 0.4, 95% CI 0.2-1.0). Whereas, 
women with the rs8136803 TT genotype were 5 times more at risk of developing breast 
cancer when compared to women with the GG genotype (OR = 5.1, 95% CI 1.1-24.3) 
(Peterson et al., 2009). However, it is still unknown if these SNPs have a functional 
relevance. Lei and colleagues observed a moderately increased breast cancer risk for the C 
allele carriers of the TIMP-3 rs9619311 SNP (OR = 1.25, 95%CI 1.05-1.50) among Swedish 
women (Lei et al., 2007). A similar non-significant association was also observed in 
Peterson’s study (OR = 1.2, 95%CI 0.9-1.5). Since TIMP-3 rs9619311 SNP is located in the 
promoter region, it is possible that it may affect transcription binding sites. Further studies 
will be needed to confirm if TIMP-3 is associated with mammographic density and breast 
cancer risk.    
6.6 Proteoglycans 
Two groups examined the association between the expression of some proteoglycans in 
breast tissue and mammographic density (Alowami et al., 2003; Lundstrom et al., 2006). In 
the study conducted by Alowami and colleagues, they assessed the association between the 
expression of small leucine-rich proteoglycans, lumican and decorin in breast tissue and 
percent mammographic density. In their study, they included 62 women aged 54-75 years 
old diagnosed with benign or preinvasive breast diseases. Immunohistochemical analysis of 
lumican and decorin was performed on tissue blocks obtained from resection margins 
distant from the lesion, and immunostainings were scored visually in terms of extent and 
intensity of staining. Following the localization of biopsies on previous screening 
mammograms, the authors assessed mammographic density of the surrounding breast 
tissue distant from the lesion using the six-category Boyd scale. For this study, they 
excluded all women whose mammographic density score ranged from 25%-50% and 
subdivided all remaining participants into low (< 25%, n = 35) and high (> 50%, n = 27) 
mammographic density subgroups. They observed that the expression of lumican and 
decorin was restricted to the stroma surrounding the epithelium. The median value of the 
expression of both lumican and decorin was 2-3 times higher in specimens from women 
with high mammographic density compared to those with low mammographic density 
(both with p < 0.0001). No adjustment for age has been made, but women in the categories of 
low and high mammographic density had similar range of age (54-74 and 54-75 years old, 
respectively). In their study, Alowami and colleagues included mainly postmenopausal 
women thus reducing the proportion of cases with high mammographic density and 
limiting the generalizability of their results.  
The study considered earlier in the ERα-related section also compared the expression of 
syndecan-1, a cell surface heparan proteoglycan, in pair-wise samples of dense and non-
dense normal breast tissue from 28 postmenopausal women undergoing surgery for breast 
cancer (Lundstrom et al., 2006). They performed an immunohistochemical staining to assess 
syndecan-1 intensity semi-quantitatively in stroma, stromal cells, ductal and lobular 
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epithelium. They found that syndecan-1 expression was significantly higher in dense than 
non-dense normal breast tissue (p = 0.004, p = 0.02, p = 0.008 and p = 0.02 for stroma, stromal 
cells, ductal and lobular epithelium respectively). Moreover, syndecan-1 expression was 
higher in stroma than in epithelial tissue (p < 0.01). They concluded that the redistribution of 
syndecan-1 from epithelium to stroma maybe a key step in increased mammographic 
density. 
The main proteoglycan synthesis inducer in breast tissue remains unknown. In addition, the 
role of proteoglycans in tumorigenesis has not been sufficiently explored. Previous studies 
have demonstrated an increased lumican expression in stroma from invasive breast 
carcinoma compared to stroma from adjacent normal breast tissue (Leygue et al., 1998b; 
Leygue et al., 2000). However, the exact mechanism by which lumican can induce cellular 
proliferation is not known. Contrary to lumican, decorin is believed to suppress cellular 
growth through epidermal growth factor receptor activation and p21 cell-cycle inhibitor 
induction (Moscatello et al., 1998; Santra et al., 1997). This is in line with Leygue’s findings, 
who reported a decreased decorin expression in stroma from neoplastic breast tissue 
compared to stroma from normal adjacent breast tissue (Leygue et al., 2000). Kelemen and 
colleagues investigated the association between 14 common SNPs in the lumican (LUM) and 
decorin (DCN) genes among 1641 Caucasian women (798 breast cancer cases and 843 
controls). Then, SNPs showing the strongest associations (one SNP per gene) were assessed 
among 4,470 breast cancer cases and 4,560 controls from England. The authors identified 
three SNPs in LUM (rs2268578, rs10859110 and rs17018765) and three SNPs in DCN (rs7441, 
rs516115 and rs3138165) which were each associated with increased breast cancer risk 
among their first study population. However, only LUM rs2268578 SNP was associated with 
increased breast cancer risk among pooled studies, but did not reach statistical significance 
among English women only (Kelemen et al., 2008). Since this SNP is located in an intron, 
more research will be needed to identify a functional SNP in LUM gene with an effect on 
mammographic density and breast cancer risk.  
Proteoglycans are present either free in the extracellular compartment or attached to the cell 
surface as syndecans and glypicans (Liu et al., 2002a). The heparin sulphate proteoglycans 
(HSPG) play a crucial role in normal developmental processes, such as embryogenesis, as 
well as pathological conditions such as tumorigenesis (Liu et al., 2002a; Perrimon & 
Bernfield, 2000). In particular, syndecan-1 plays a critical role in the regulation of cellular 
adhesion, migration and proliferation. Syndecan-1 is expressed in stroma of breast cancer 
tissue as well as in normal epithelium but less in normal breast tissue stroma (Maeda et al., 
2004). This suggests that syndecan-1 is redistributed in cancerous tissue (Lofgren et al., 
2007). Syndecan-1 expression in stromal cells seems to promote growth of breast carcinoma 
cells in direct coculture by inducing cell proliferation rather than reducing its apoptosis. It is 
thought that the expression of syndecan-1 in stroma of tumors is a sort of oncofetal reaction 
of a regulatory pathway. Syndecan-1 exerts its biological action on the cell, through binding 
to various extracellular proteins, growth factors and cytokines via the heparan sulphate 
chain (Lofgren et al., 2007; Maeda et al., 2004). Syndecan-1 forms a complex with fibroblast 
growth factor (FGF-2), FGF-2/HSPG/FGF receptor-1, determining breast cancer cells 
response to FGFs in vitro (Mundhenke et al., 2002). Knowing that syndecan-1 is more 
abundantly expressed in stroma of malignant breast tissue and that it can promote cellular 
proliferation, one may hypothesize that syndecan-1 can affect mammographic density by 
promoting cellular proliferation and subsequently increasing the risk of breast cancer. 
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epithelium. They found that syndecan-1 expression was significantly higher in dense than 
non-dense normal breast tissue (p = 0.004, p = 0.02, p = 0.008 and p = 0.02 for stroma, stromal 
cells, ductal and lobular epithelium respectively). Moreover, syndecan-1 expression was 
higher in stroma than in epithelial tissue (p < 0.01). They concluded that the redistribution of 
syndecan-1 from epithelium to stroma maybe a key step in increased mammographic 
density. 
The main proteoglycan synthesis inducer in breast tissue remains unknown. In addition, the 
role of proteoglycans in tumorigenesis has not been sufficiently explored. Previous studies 
have demonstrated an increased lumican expression in stroma from invasive breast 
carcinoma compared to stroma from adjacent normal breast tissue (Leygue et al., 1998b; 
Leygue et al., 2000). However, the exact mechanism by which lumican can induce cellular 
proliferation is not known. Contrary to lumican, decorin is believed to suppress cellular 
growth through epidermal growth factor receptor activation and p21 cell-cycle inhibitor 
induction (Moscatello et al., 1998; Santra et al., 1997). This is in line with Leygue’s findings, 
who reported a decreased decorin expression in stroma from neoplastic breast tissue 
compared to stroma from normal adjacent breast tissue (Leygue et al., 2000). Kelemen and 
colleagues investigated the association between 14 common SNPs in the lumican (LUM) and 
decorin (DCN) genes among 1641 Caucasian women (798 breast cancer cases and 843 
controls). Then, SNPs showing the strongest associations (one SNP per gene) were assessed 
among 4,470 breast cancer cases and 4,560 controls from England. The authors identified 
three SNPs in LUM (rs2268578, rs10859110 and rs17018765) and three SNPs in DCN (rs7441, 
rs516115 and rs3138165) which were each associated with increased breast cancer risk 
among their first study population. However, only LUM rs2268578 SNP was associated with 
increased breast cancer risk among pooled studies, but did not reach statistical significance 
among English women only (Kelemen et al., 2008). Since this SNP is located in an intron, 
more research will be needed to identify a functional SNP in LUM gene with an effect on 
mammographic density and breast cancer risk.  
Proteoglycans are present either free in the extracellular compartment or attached to the cell 
surface as syndecans and glypicans (Liu et al., 2002a). The heparin sulphate proteoglycans 
(HSPG) play a crucial role in normal developmental processes, such as embryogenesis, as 
well as pathological conditions such as tumorigenesis (Liu et al., 2002a; Perrimon & 
Bernfield, 2000). In particular, syndecan-1 plays a critical role in the regulation of cellular 
adhesion, migration and proliferation. Syndecan-1 is expressed in stroma of breast cancer 
tissue as well as in normal epithelium but less in normal breast tissue stroma (Maeda et al., 
2004). This suggests that syndecan-1 is redistributed in cancerous tissue (Lofgren et al., 
2007). Syndecan-1 expression in stromal cells seems to promote growth of breast carcinoma 
cells in direct coculture by inducing cell proliferation rather than reducing its apoptosis. It is 
thought that the expression of syndecan-1 in stroma of tumors is a sort of oncofetal reaction 
of a regulatory pathway. Syndecan-1 exerts its biological action on the cell, through binding 
to various extracellular proteins, growth factors and cytokines via the heparan sulphate 
chain (Lofgren et al., 2007; Maeda et al., 2004). Syndecan-1 forms a complex with fibroblast 
growth factor (FGF-2), FGF-2/HSPG/FGF receptor-1, determining breast cancer cells 
response to FGFs in vitro (Mundhenke et al., 2002). Knowing that syndecan-1 is more 
abundantly expressed in stroma of malignant breast tissue and that it can promote cellular 
proliferation, one may hypothesize that syndecan-1 can affect mammographic density by 
promoting cellular proliferation and subsequently increasing the risk of breast cancer. 
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Recently, Menashe and colleagues conducted a pathway analysis of breast cancer genome-
wide association study (Menashe et al., 2010). In their study, they included 69,525 SNPs 
representing 421 pathways and 3,962 genes, and performed the analysis on 1,145 
postmenopausal women of European ancestry with invasive breast cancer and 1,142 
controls. They observed that genetic alterations associated with three pathways, including 
the top ranked “syndecan-1 signaling”, may contribute to breast cancer susceptibility. The 
pathway related to “syndecan-1 signaling” namely “FGF signaling” was ranked 10th in this 
study. The “syndecan-1 signaling” pathway contains 13 genes involved in different cellular 
processes mediated by syndecan-1. In this study, syndecan-1 rs7563245 SNP was moderately 
associated with increased breast cancer risk (p for trend = 0.019). 
6.7 Cyclooxygenase-2 
One study investigated the cyclooxygenase-2 (COX-2) enzyme expression in breast tissue 
from 66 women aged 29-88 years old with dense or non-dense breasts according to BI-RADS 
categories (Yang et al., 2010). In addition to hormone receptors previously described, they 
analysed COX-2 expression immunohistochemically in stroma and epithelium of normal 
breast tissue obtained from mastectomy specimens, and quantified immunostainings using 
the Allred scoring system. In their study, Yang and colleagues observed higher COX-2 
expression in stroma (p < 0.001) and epithelium (p < 0.02) from dense breasts compared to 
non-dense breasts. However, after inclusion of all immunohistochemical factors in the 
model, only COX-2 expression in the stroma was statistically significant (p < 0.01). 
The COX enzymes influence cellular proliferation by catalyzing the formation of 
prostaglandins (Soslow et al., 2000). Growing evidence supports the role of COX-2 in 
promoting tumorigenesis by catalyzing the synthesis of several prostaglandins, mainly 
prostaglandin E2, which in turn stimulates angiogenesis and inhibits the immune 
surveillance (Ben-Av et al., 1995; Soslow et al., 2000). By inducing prostaglandin E2 
synthesis, COX-2 can also promote increased aromatase activity and mRNA production in 
the mammary gland and thereby augment estrogen production (Subbaramaiah et al., 2008; 
Zhao et al., 1996). Nevertheless, COX-2 has been shown to inhibit TGF-β which is known to 
reduce mammary epithelial cell proliferation (Studer & Chu, 2005; Yang et al., 2010). In 
support of this, COX-2 has been found to be up-regulated in 41% and 80% of invasive breast 
tumors and ductal carcinoma in situ respectively, which is significantly different from the 
negligible expression in nonneoplastic epithelium (p < 0.0001) (Soslow et al., 2000). In an 
effort to better assess the association between COX-2 and breast cancer risk, Yu and 
colleagues conducted a meta-analysis on the relationship between common SNPs in the 
COX-2 gene and breast cancer risk (Yu et al., 2010). In their meta-analysis, they found no 
clear association of rs5275, rs5277 or rs20417 SNPs with breast cancer risk in any model 
(codominant, dominant or recessive model). However, a novel SNP located in exon 2 (169 C 
> G) of the COX-2 gene has been recently associated to breast cancer risk (OR (GG vs. CC) = 
1.76, 95% CI 1.20-3.05) (Li et al., 2009). Because of its location in an exon, the role of this SNP 
on the COX-2 expression should be investigated. 
7. Genes expression in breast tissue associated to mammographic density 
The hypothesis that specific genetic pathways could influence mammographic density was 
tested by two research groups (Haakensen et al., 2010; Yang et al., 2010). The first study, 
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described above (Yang et al., 2010), used RNA isolated from frozen biopsy specimens from 
normal breast tissue containing at least 60% epithelial content and obtained at a distance of 
more than 5 cm from the primary tumor. The authors compared about 34,000 different genes 
expression in tissues from women with high (n = 28) and low (n = 38) mammographic 
densities. They identified 73 genes differentially expressed by ≥ 1.5 folds with a p < 0.001 
(false discovery rate (FDR) < 0.10). Of those, 26 genes were up-regulated in dense breast 
tissue versus non-dense tissue, and 47 genes were down-regulated in dense tissue when 
compared to non-dense tissue. Consistent with the link between stroma and mammographic 
density, the biological functions analysis revealed that the differentially expressed genes 
were involved in tissue morphology, connective tissue development, function and 
disorders, developmental, skeletal and muscular disorders and tumor morphology. It was 
also found from both network and canonical pathways analysis that decreased TGF-β 
signaling was related to mammographic density, including the identification of the TGF-β 
receptor II (TGFBR2) as being lowly expressed in breast tissue of women with high 
compared to low mammographic density.  
In addition to increased COX-2 enzyme expression (an inhibitor of TGF-β), Yang and 
colleagues observed a decreased signaling of TGF-β in dense versus non-dense breast 
tissue (Yang et al., 2010). Growing evidence suggests a dual action of TGF-β, shifting from 
tumor suppressor in early tumor initiation steps to tumor growth promoter in advanced 
malignant stages. The dual action of TGF-β is mediated through two opposing receptors, 
the antiangiogenic receptor ALK5 (TGFBR1) and the proangiogenic receptor ALK1. The 
balance between the two pathways determines the net result. TGF-β exerts its protective 
effect against breast cancer by inducing cell cycle arrest and promoting apoptosis of 
normal mammary epithelial cells (Casey et al., 2007). Data from 6,703 cases and 6,840 
controls have been assessed in a recent meta-analysis performed by Scollen and 
colleagues in attempt to better understand the association between TGF-β and breast 
cancer risk (Scollen et al., 2011). The authors identified the most common variants in 17 
genes comprising both arms of TGF-β signaling pathways. The minor G allele of SNP 
rs10512263 of the TGFBR1 gene and the G allele of SNP rs4522809 of the TGFBR2 gene had 
a protective effect (OR (G vs. A) = 0.87, 95% CI 0.81-0.95, p = 0.001 and OR (G vs. A) = 
0.95, 95% CI 0.91-0.99, p = 0.02, respectively). The TGFBR1 rs10512263 SNP, located in 
intron 1, is either a causal variant of unknown function or marking the causal SNP, while 
rs4522809 SNP located in intron 2 of the TGFBR2 gene is most likely marking a putative 
causal variant. Conversely, for rs1982073 SNP located in TGFB1 gene, there was a dose-
dependent association between the proline-encoding allele and increased breast cancer 
risk (OR (Pro vs. Leu) = 1.05, 95% CI 1.02-1.09, p = 0.002). The Pro allele induces TGFB1 
secretion in vitro compared to the Leu allele. The authors observed no detectable effect of 
SNPs on genes that regulate the proangiogenic pathway.  
The second study that examined genes differentially expressed in breast tissue according to 
mammographic density included 79 healthy women (Haakensen et al., 2010). They assessed 
percent mammographic density using a computer-assisted method from digitized 
craniocaudal mammograms of both breasts. In this study, they used RNA isolated from 
biopsies that were taken from areas with no visible pathology, but with some 
mammographic density in order to obtain sufficient RNA amount. They tested 9,767 
different probes expression for their associations with percent mammographic density, and 
identified 25 probes representing 24 genes of decreased expression associated with 
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balance between the two pathways determines the net result. TGF-β exerts its protective 
effect against breast cancer by inducing cell cycle arrest and promoting apoptosis of 
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controls have been assessed in a recent meta-analysis performed by Scollen and 
colleagues in attempt to better understand the association between TGF-β and breast 
cancer risk (Scollen et al., 2011). The authors identified the most common variants in 17 
genes comprising both arms of TGF-β signaling pathways. The minor G allele of SNP 
rs10512263 of the TGFBR1 gene and the G allele of SNP rs4522809 of the TGFBR2 gene had 
a protective effect (OR (G vs. A) = 0.87, 95% CI 0.81-0.95, p = 0.001 and OR (G vs. A) = 
0.95, 95% CI 0.91-0.99, p = 0.02, respectively). The TGFBR1 rs10512263 SNP, located in 
intron 1, is either a causal variant of unknown function or marking the causal SNP, while 
rs4522809 SNP located in intron 2 of the TGFBR2 gene is most likely marking a putative 
causal variant. Conversely, for rs1982073 SNP located in TGFB1 gene, there was a dose-
dependent association between the proline-encoding allele and increased breast cancer 
risk (OR (Pro vs. Leu) = 1.05, 95% CI 1.02-1.09, p = 0.002). The Pro allele induces TGFB1 
secretion in vitro compared to the Leu allele. The authors observed no detectable effect of 
SNPs on genes that regulate the proangiogenic pathway.  
The second study that examined genes differentially expressed in breast tissue according to 
mammographic density included 79 healthy women (Haakensen et al., 2010). They assessed 
percent mammographic density using a computer-assisted method from digitized 
craniocaudal mammograms of both breasts. In this study, they used RNA isolated from 
biopsies that were taken from areas with no visible pathology, but with some 
mammographic density in order to obtain sufficient RNA amount. They tested 9,767 
different probes expression for their associations with percent mammographic density, and 
identified 25 probes representing 24 genes of decreased expression associated with 
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increased mammographic density (FDR < 0.25). No particular biological function or 
pathway was found to be associated to this set of genes. Among identified genes, 
Haakensen and colleagues found that three uridine 5’-diphospho-glucuronosyltransferase 
genes (UGT2B7, UGT2B10 and UGT2B11) and the ERα gene were down-regulated in tissues 
with high mammographic density compared to those with low mammographic density. 
When the expressions of these genes were in models taking into account age and body mass 
index, only UGT2B10 expression among women younger than 50 years old and ERα 
expression among women 50 years or older remained statistically significant. Inclusion of 
healthy women was the major strength of this study.   
The UGT genes encode enzymes responsible for the inactivation of several compounds, 
including sex hormones. They catalyse the glucuronidation of sex hormones to less active 
compounds (Guillemette et al., 2004). Like UGT2B7, UGT2B10 is capable of estrone 
conjugation. A study has demonstrated that the mRNA and activity of both UGT were 
down-regulated in cancerous breast tissue when compared to normal breast tissue 
(Starlard-Davenport et al., 2008). The mRNA expression of UGT2B7 and UGT2B10 were 
decreased by almost four folds and more than eight folds respectively in cancerous breast 
tissue biopsies compared to normal breast tissue (p = 0.01 and p = 0.04, respectively). 
Moreover, estrogen glucuronidation, which is considered as an index of UGT activity, was 
reduced by two folds in cancerous breast tissue compared to normal tissue. These results 
suggest that UGT2B7 and UGT2B10 have a protective role for breast tissue against 
estrogen metabolites and that decreased UGT2B7 and UGT2B10 expressions can promote 
breast carcinogenesis. This finding is consistent with that of Haakenssen and colleagues 
who observed decreased UGT2B7 and UGT2B10 expressions in mammographically dense 
breast tissue. The association between UGT variants or levels and breast cancer risk is not 
yet reported.  
Contrary to what one would expect, Haakensen and colleagues found that the expression 
of ERα gene was significantly down-regulated in breasts with higher mammographic 
density among women 50 years or older. According to the authors, this decrease in ERα 
expression in dense breast tissue could be explained, at least in part, by the increased 
estrogen levels in postmenopausal breast tissue (Borras et al., 1994; Saceda et al., 1988). 
However, as stated previously, measurement of both ERα and ERβ expressions according 
to menopausal status may be required to evaluate the link between these receptors and 
mammographic density.     
There was no overlap in lists of genes up-regulated or down-regulated according to 
mammographic density between both studies. The divergence between Yang and 
Haakensen results could be attributed to different means used to evaluate mammographic 
density (BI-RADS vs. computer-assisted method) and genes expression (Affymetrix 
U133Plus 2 Gene chip vs. Agilent Human Whole genome Oligo Microarrays G4110A 
platform), as well as the selection of normal breast tissue (≥ 60% epithelial content from 
breast cancer patient vs. mammographically dense tissue from healthy women). The main 
pitfall of both studies was the use of breast tissue specimens containing various proportions 
of types of cells (epithelial, stromal, adipocyte, etc.) We believe that it is important to 
distinguish tissue types, like epithelium from stroma, because it has been clearly determined 
that these two tissues exhibit distinct expression profiles (Finak et al., 2006). This is also in 
line with results from our previous sections.  
 




In summary, some candidate proteins and genes in normal breast tissue such as IGF-1, 
TIMP3, TGF-β, UGT, stromal COX-2 and stromal and epithelial aromatase among pre- and 
postmenopausal women and epithelial ERα, stromal lumican and decorin, and epithelial 
and stromal syndecan-1 among postmenopausal women have been found to be associated 
with mammographic density. Among these, IGF-1, ERα, aromatase, TIMP3, lumican, 
syndecan-1, COX-2, TGF-β and UGT have also been related to breast cancer risk in the same 
direction of their association with mammographic density. However, the small number of 
studies that examined each protein/gene limited the conclusions that could be drawn.  
Nonetheless, these data provide some support to the hypothesis that mammographic 
density could be used as an intermediate biomarker of breast cancer. Mammographic 
density promises a relatively quick exploration of the effect of several mitogens on breast 
tissue eliminating the long period of time elapsing between exposure to mitogen and the 
detection of their effect on breast tissue. Future investigations incorporating both pre- and 
postmenopausal women and examining the association of various molecular markers 
(proteins and genes expression) on epithelial and stromal breast tissue separately with 
mammographic density are therefore required to confirm the above findings and to identify 
new promising ones. The identification of molecular markers influencing mammographic 
density may provide important clues regarding the molecular causes of breast cancer. 
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1. Introduction   
Mammographic screening is the only important intervention for the early detection of breast 
cancer. The ability of mammography to detect incipient breast cancer depends on breast 
density. Hormonal treatments, affecting the breast radiological density, are an important 
risk factor interfering mammography. In the same time, mammographic density is currently 
being explored as a biomarker of response in primary and secondary prevention trials. 
Important considerations for chemoprevention studies include maximizing intrareader 
reliability and minimizing variance resulting from technical and physiologic factors (Fabian 
& Kimler, 2006). While technical factors for maximizing intrareader reliability and 
minimizing variance depend on classifications and technology, it is also important to 
evaluate the impact of physiologic and pharmacological factors  
2. Classifications of breast mammographic density   
Mammographic breast density reflects mammary gland development and structure. From 
the multiple methods that have been developed to assess mammographic density, Wolfe`s 
classification identified four categories: N1, P1, P2 and DY (Wolfe), with density increasing 
from N1 to DY, the greatest relative risk being associated with the DY pattern (Wolfe, 1976). 
The BIRADS system developed by the American College of Radiology classifies breasts as 1) 
almost entirely fatty, 2) scattered fibronodular tissue, 3) heterogeneously dense and 4) 
extremely dense (American College of Radiology [ACR], 1993). The proportion of women 
having BIRADS category 3 and 4 dramatically decreases with age. BIRADS semiquantitative 
classification has a suboptimal intrareader reliability (Fabian & Kimler, 2006). For greater 
intraobserver reliability, continuous, computer assisted measurements have a better 
performance, being more suitable for prevention studies (Fabian & Kimler, 2006). 
Byrne, using the mammograms from the Breast Cancer Detection Demonstration Project, 
developed a continuous density measurement system, in which the area of the breast 
occupied by increased density was measured relative to the total area of the breast (Byrne et 
al., 1995). Byrne`s classification has 5 categories of relative areas of increased 
mammographic density and give a better assessment of relative risk for breast cancer than 
the 4-category Wolfe classification. The authors observed that the area of increased density 
is a risk factor, while the total breast area is not. 
 
Mammography – Recent Advances 
 
198 
cancer risk: a meta-analysis. Breast Cancer Res Treat, Vol.122, No.1, pp.251-257, ISSN 
1573-7217  
Zhao, Y.; Agarwal, V. R.; Mendelson, C. R. & Simpson, E. R. (1996). Estrogen biosynthesis 
proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to 
activation of promoter II of the CYP19 (aromatase) gene. Endocrinology, Vol.137, 
No.12, pp.5739-5742, ISSN 0013-7227  
Zhou, P.; Du, L. F.; Lv, G. Q.; Yu, X. M.; Gu, Y. L.; Li, J. P. & Zhang, C. (2011). Current 
evidence on the relationship between four polymorphisms in the matrix 
metalloproteinases (MMP) gene and breast cancer risk: a meta-analysis. Breast 
Cancer Res Treat, Vol.127, No.3, pp.813-818, ISSN 1573-7217  
Ziv, E.; Shepherd, J.; Smith-Bindman, R. & Kerlikowske, K. (2003). Mammographic breast 
density and family history of breast cancer. J Natl Cancer Inst, Vol.95, No.7, pp.556-
558, ISSN 0027-8874  
10 
Mammographic Density Under Hormonal  
and Hormone-Like Treatments 
Şerban Nastasia 
University of Medicine and Pharmacy “Carol Davila” Bucharest 
Romania 
1. Introduction   
Mammographic screening is the only important intervention for the early detection of breast 
cancer. The ability of mammography to detect incipient breast cancer depends on breast 
density. Hormonal treatments, affecting the breast radiological density, are an important 
risk factor interfering mammography. In the same time, mammographic density is currently 
being explored as a biomarker of response in primary and secondary prevention trials. 
Important considerations for chemoprevention studies include maximizing intrareader 
reliability and minimizing variance resulting from technical and physiologic factors (Fabian 
& Kimler, 2006). While technical factors for maximizing intrareader reliability and 
minimizing variance depend on classifications and technology, it is also important to 
evaluate the impact of physiologic and pharmacological factors  
2. Classifications of breast mammographic density   
Mammographic breast density reflects mammary gland development and structure. From 
the multiple methods that have been developed to assess mammographic density, Wolfe`s 
classification identified four categories: N1, P1, P2 and DY (Wolfe), with density increasing 
from N1 to DY, the greatest relative risk being associated with the DY pattern (Wolfe, 1976). 
The BIRADS system developed by the American College of Radiology classifies breasts as 1) 
almost entirely fatty, 2) scattered fibronodular tissue, 3) heterogeneously dense and 4) 
extremely dense (American College of Radiology [ACR], 1993). The proportion of women 
having BIRADS category 3 and 4 dramatically decreases with age. BIRADS semiquantitative 
classification has a suboptimal intrareader reliability (Fabian & Kimler, 2006). For greater 
intraobserver reliability, continuous, computer assisted measurements have a better 
performance, being more suitable for prevention studies (Fabian & Kimler, 2006). 
Byrne, using the mammograms from the Breast Cancer Detection Demonstration Project, 
developed a continuous density measurement system, in which the area of the breast 
occupied by increased density was measured relative to the total area of the breast (Byrne et 
al., 1995). Byrne`s classification has 5 categories of relative areas of increased 
mammographic density and give a better assessment of relative risk for breast cancer than 
the 4-category Wolfe classification. The authors observed that the area of increased density 
is a risk factor, while the total breast area is not. 
 
Mammography – Recent Advances 
 
200 
Boyd et al divided breast density measurements into 6 categories similar to those of Byrne, 
using a similar computer-assisted system for detection of mammographic density (Boyd et 
al., 1995). 
Continuous density measurement system studies reported that the 10% of women who had 
>75% increased breast density had a 4 to 5-fold greater risk of breast cancer than women 
with no areas of increased breast density, after corrections for weight, reproductive and 
family history (Byrne et al.,1995; Boyd et al., 1995). Women with 50–75% area of density 
have a 2.5 to 3.0-fold increase in risk. Boyd et al. have suggested that the increase in relative 
risk estimates resulting from a breast density measurement lasts at least a decade (Fabian & 
Kimler, 2006; Boyd et al., 2002). 
This long-lasting influence of breast density further justifies the interest in evaluation of the 
impact of physiologic and pharmacological factors on mammografic breast density. 
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23-33.9 cm2 34-52.9 cm2 > 53 cm2 
Boyd None < 10 % 10- <25 % 25- <50 % 50- <75 % ≥ 75 % 
 
Wolfe  
Percent of women 
exhibiting breast 
density patterns 
12 % 28 % 48 % 12 % 




Control group divided in six approximately equal groups 






































Boyd (all ages) 1.0 1.2 2.2 2.4 3.4 5.3 
Table 1. Risk of breast cancer development associated with mammographic density in 
Wolfe`s (Wolfe, 1976), Byrne`s (Byrne et al., 1995) and Boyd`s (Boyd et al., 1995) 
classifications (adapted from Fabian & Kimler, 2006). 
3. Endogenous influences on breast mammographic density   
Mammographic parenchymal patterns are a function of breast development. The 
development of breast is the sum of ducts and lobules genetic-induced development, under 
the control of endogenous factors, mainly endocrine. Estrogens are responsible for growth 
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and developments of the ducts, while the maturation of the breast acinus is progesteron-
dependent. Progesteron is responsible for water accumulation at the end of menstrual cycle, 
increasing the breast density and whiteness on mammography. Declining in levels of 
estrogens and progesteron in menopause is associated with a decrease in breast density, 
making it easier to be examined by mammography. 
4. Exogenous influences on breast mammographic density   
Exogenous hormonal influences on mammografic breast density are best reflected by 
positive associations of mammografic breast density with postmenopausal hormone 
replacement therapy (HRT) and inverse associations with tamoxifen (Ghosh & Vachon, 
2010).  
4.1 Hormone replacement therapy 
Hormone replacement therapy (HRT) increase the breast density (glandular tissue), which 
appears as white areas on a mammography, making microcalcifications and breast masses 
more difficult to detect, since breast abnormalities also appear as white areas on a 
mammography. 
HRT is used by perimenopausal and early postmenopausal women, in the age group in 
which the incidence of breast cancer is maximum. As HRT contains a wide range of 
therapeutic interventions, its effects on mammography will vary according to several 
variables: HRT users versus non-users, age and window of opportunity, duration and dose 
of therapy, estrogen versus estrogen+progestin therapy, continuos combined versus 
sequential HRT, type of progestin, transdermal versus oral HRT. 
The impact of HRT on mammographic screening is decreasing its sensibility, current use of 
HRT being associated with reduced sensitivity and specificity of mammographic breast 
cancer screening (Banks, 2001). Many studies suggest that current HRT users are more likely 
than non-users to have interval breast cancer (cancer occurring in the interval between 
screenings) (Banks, 2001; Cohen, 1997; Rosenberg et al., Litherland et al., 1999). Therefore, 
the benefit of mammographic screening may be reduced in HRT users, in terms of breast 
cancer mortality reduction, compared with non-users. Regarding the specificity of 
mammographic screening, many studies showed a lower specificity for current HRT users 
(Laya et al., 1996; Thurfjell et al., 1997), who may experience more false positive recall, 
compared with non-users (recalled for assessment after initial mammography, but found 
not to have breast cancer) (Clemons & Goss, 2001). Thurfjell et al (Thurfjell et al., 1997) 
divided current HRT users into three categories: less than 3 years of use, 3-6 years of use and 
more than 6 years of use. They reported specificities of 95%, 95%, and 92% respectively 
(p=0.046), revealing a trend for false positive recalls with increasing duration of use of HRT. 
These data are consistent with the study of Sala et al, who found that starting HRT pre- or 
perimenopausally and > 5 years of use will increase the probability of a high-risk 
mammographic density pattern, more difficult to evaluate (Sala et al., 2000). 
Current HRT users have an increased probability of having a high risk pattern of breast 
density (Sala et al., 2000; Persson et al., 1997; McTiernan et al., 2005; Greendale et al., 2003; 
Chlebowski et al., 2003; Boyd et al., 2006). Current estrogen + progestin therapy users and 
current estrogen-only therapy users had greater odds of having dense breasts (98% [1.87–
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2.09]) and 71%, respectively [1.56–1.87]), compared to never users (Aiello et al., 2006). Type 
of HRT regimen is an important factor, influencing breast mammographic density. 
Lundstrom E et al (Lundstrom E et al., 1999) found that increase in mammographic density 
was much more common among women receiving continuous estrogen + progestin HRT 
(52%) than among those receiving estrogen + progestin HRT (13%) and estrogen-only (18%) 
treatment. The increase in density was apparent already at first visit after the start of 
hormone replacement therapy. There was little change in mammographic status during 
long-term follow-up (Lundstrom E et al., 1999). 
Transdermal HRT use is associated with a significantly lower incidence of increased 
mammographic breast density and breast tenderness compared with oral HRT (Harvey et 
al., 2005). In Harvey`s study (2005), 202 postmenopausal women were randomized to 
transdermal (estradiol+norethindrone) or oral (estradion+norethistron acetate) HRT. 
Significantly fewer women using transdermal HRT had an increase in mammographic 
breast density or breast tenderness compared to oral HRT. Of the women using transdermal 
HRT, 39.1% had no change in breast density compared to 15.7% for women using oral HRT. 
Only 4% of women using transdermal HRT had a marked increase in density (>25%) 
compared to 15.7% of women using oral HRT. 
 
 
Fig. 1. Increase in mammographic breast density in a 53 years old patient on sequential 
combined hormonal therapy (1,5 mg estradiol transdermally+20 mg dydrogesterone orally). 
Left – mammography at baseline; right – mammography after 1 year of treatment. 
Procentual mammographic density raised from 23% to 55% (Russu et al., 2008). 
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The randomized, double-blinded PEPI trial (Greendale et al., 1999) compared the 
mammography before and after twelve months of treatment, for HRT patients versus 
placebo. Twenty percent of HRT patients had increased mammographic density, as 
compared to 0 % in placebo group. There was no difference in breast densities between 
continuous combined and sequential HRT groups. There was also no difference in breast 
densities with different progestins. Patients with estrogen-only therapy had a very small 
increase in breast density. 
The WHI Study (Chlebowski et al., 2003) found that, after one year of estrogen plus 
progestin therapy, the percent of abnormal mammography was higher in estrogen plus 
progestin therapy group, compared with placebo group (9,4% vs 5,4%; P<0.001), and the 
difference was maintained throughout the duration of the study. In each year thereafter, the 
percentage of women with abnormal mammograms was significantly higher in the estrogen 
plus progestin group vs the placebo group. For the whole study, 31.5% of women in the 
estrogen plus progestin group had at least 1 abnormal mammogram vs 21.2% of women in 
the placebo group (P<.001). Thus, even short-term estrogen plus progestin use resulted in a 
substantial increase in abnormal mammograms requiring medical evaluation. The risk for 
breast cancer parallels the percentage of abnormal mammography. The authors concluded 
that E+P therapy increased the number of breast cancer and the number of not necessary 
interventions for false positive mammography in this group. However, most of the studies 
found a lower mortality for HRT users compared with non-users. 
The Million Women Study showed that current users of HRT at recruitment were more 
likely than never users to develop breast cancer (adjusted relative risk 1.66 [95% CI 1.58-
1.75], p<0.0001) and die from it (1.22 [1.00-1.48], p=0.05). Stopping HRT reduces breast 
cancer risk, as demonstrated in WHI study (Chlebowski et al., 2003), where the authors 
found that past users of HRT were not at an increased risk of incident or fatal disease (1.01 
[0.94-1.09] and 1.05 [0.82-1.34], respectively). 
Patients with estrogen-only therapy tend to have a small increase in breast density and 
lower risk for invasive breast cancer. In WHI study follow-up (La Croix et al., 2011), after 6 
years of equine estrogens use and a mean 10,7 years after baseline, estrogen-only therapy 
was associated with a lower risk for invasive breast cancer than the placebo group (hazard 
ratio, 0.77; 95% confidence interval, 0.62–0.95); moreover, among younger women, estrogen 
use was associated with lower risk for CHD (HR, 0.59; 95% CI, 0.38–0.90). However, this 
does not imply that estrogen-only therapy should be recommended at this time for breast 
cancer chemoprophylaxis (Beral et al., 2003; Kaunitz, 2011; Jungheim & Colditz, 2011). 
Progestin-releasing intrauterine devices are a type of hormone therapy addressed to women 
younger than 50 years of age, especially with associated uterine pathology (e.g., fibroids, 
menorrhagia).  
A retrospective, population-based, case-control study (Dinger et al., 2011), performed on 
25565 women (5113 breast cancer cases and 20452 controls) failed to observe any increase of 
breast cancer risk in levonorgestrel intrauterine device users.  
Combination of levonorgestrel intrauterine device and low-dose oral estradiol valerate 
was associated with a slight increase in mammographic breast density. Lundstrom et al 
(Lundstrom et al., 2006) assessed 20 healthy patients with levonorgestrel intrauterine 
device and 2 mg oral estradiol valerate and they found an apparent increase in breast 
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does not imply that estrogen-only therapy should be recommended at this time for breast 
cancer chemoprophylaxis (Beral et al., 2003; Kaunitz, 2011; Jungheim & Colditz, 2011). 
Progestin-releasing intrauterine devices are a type of hormone therapy addressed to women 
younger than 50 years of age, especially with associated uterine pathology (e.g., fibroids, 
menorrhagia).  
A retrospective, population-based, case-control study (Dinger et al., 2011), performed on 
25565 women (5113 breast cancer cases and 20452 controls) failed to observe any increase of 
breast cancer risk in levonorgestrel intrauterine device users.  
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was associated with a slight increase in mammographic breast density. Lundstrom et al 
(Lundstrom et al., 2006) assessed 20 healthy patients with levonorgestrel intrauterine 
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density in only 3 women (15%). However, there was no increase in proliferation, as 
expressed by the percentage of MIB-1-positive breast cells in fine-needle aspiration 
biopsies. Given the small number of cases, these results need to be confirmed by larger 
studies. 
Timing of HRT initiation influences the mammographic parenchymal patterns. Analizing a 
subgroup from EPIC-Norfolk cohort, Sala et al (Sala et al., 2000) found that women who are 
starting HRT, while still menstruating, were more likely to have a high-risk breast density 
pattern compared to women not exposed to HRT or to those who started HRT after 
menopause. A recent Million Women Study analysis update (Beral et al., 2011) focused on 
the influence of timing on breast cancer risk for the different treatment regimens. Relative 
risks were found to be higher if therapy was started before or soon after menopause than in 
the case of a longer interval between menopause and starting HRT (p < 0.001). Among 
current users of estrogen-only therapy, there was little or no increase in risk if use began 5 
years or more after menopause (RR 1.05, 95% CI 0.89–1.24), whereas risk was increased if 
use began before or within 5 years after menopause (RR 1.43, 95% CI 1.35–1.51). A similar 
pattern was seen for users of E+P (RR 1.53, 95% CI 1.38–1.70 vs. RR 2.04, 95% CI 1.95–2.14). 
The timing of initiation of HRT relative to that of menopause appears to be an important 
factor that modulates the risk of breast cancer. 
HRT effects on breast and mammography are reversible. After discontinuing hormone 
therapy, breast density decrease rapidly. Discontinuation of HRT a few weeks prior to 
mammography may improve mammographic performances. The rapid decrease in breast 
density after stopping HRT suggest that increased breast density in HRT users is different 
from increased breast density in non-users. Increased breast density in non-users reflects a 
genetic increased quantity of glandular and fibrous tissue, whereas increased breast density 
in HRT users may suggest a water retention at breast level, probably due to stromal 
changes, under hormonal influence (Alowami et al., 2003). In a retrospective study, Harvey 
at al analyzed breast density modifications after stopping HRT (Harvey et al., 1997). HRT-
induced mammographic changes disappeared two weeks after HRT discontinuation. 
However, twelve patients in their study did not experienced mammographic reversal after 
HRT discontinuation, and, on biopsy, one case of atypical hyperplasia and one case of 
ductal invasive carcinoma were found. More recent studies failed to observe an 
improvement in mammographic diagnostic accuracy, following HRT suspension. The 
Buist`s randomised trial revealed that HT suspension was associated with small changes in 
breast density and did not affect recall rates. There was no evidence to support short-term 
HT suspension before mammography (Buist et al., 2009). 
A few studies addressed the issue of reducing breast cancer risk in HRT population. Adding 
aromatase inhibitors to HRT may lower mammographic breast density in postmenopausal 
women. A small retrospective study (Mousa et al., 2008) demonstrated a statistically 
significant reduction in mammographic breast density occurred in the women who received 
hormone therapy plus an aromatase inhibitor letrozole, whereas no significant change was 
observed in the women receiving hormone therapy alone. Aromatase inhibitors could be 
good candidates for primary chemoprevention of breast cancer in postmenopausal women 
using hormone therapy (Mousa et al., 2008). 
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4.2 Oral contraceptive 
A special type of exogenous hormonal therapy is oral contraceptive (OC) use. Modern OC 
consist in a combination of ethinilestradiol (20µg or 30 µg) and different types of progestins. 
Oral contraceptive use is an issue of young women, mostly before age of 40, a time when 
mammographic screening begins. Therefore, studies evaluating the impact of COC on 
mammographic breast density are lacking.  
A Norwegian study (Gram et al., 2002) examined the relationship between oral 
contraceptive ever use and mammographic patterns among 3218 women, aged 40-56 years, 
who fulfilled a questionnaire about ever OC use, duration, and starting age of OC. Women 
ever having used OCs had an increased risk for high-risk mammographic patterns [OR 1.27; 
95% CI (1.0-1.6)], compared with those reporting never having used OCs. There was no 
relationship between different types of OC use (different doses) and high-risk patterns. 
Nulliparous women, who ever used OCs, were four times more likely [OR 4.65; 95% CI (2.1-
10.3)] to have high-risk patterns, compared with never users. 
Breast cancer lifetime-risk of oral contraceptive use was addressed in a large study (Hunter 
et al., 2010), performed on 116.608 female nurses, aged 25 to 42 years at enrollment in 1989, 
among which 1.344 cases of invasive breast cancer were diagnosed until 2001. There was no 
relationship between past use of any oral contraceptive and breast cancer risk [RR= 1.12; 
95% confidence interval (0.95-1.33)]. Current use of any oral contraceptive was only 
marginally related to a higher risk of breast cancer [RR=1.33; 95% confidence interval (1.03-
1.73)]. However, users of triphasic oral contraceptive, with levonorgestrel as the progestin, 
were exposed to an excess risk of breast cancer, as high as 3.05 [95% confidence interval 
(2.00-4.66); P < 0.0001]. The authors (Hunter et al., 2010) concluded that current use of oral 
contraceptives is associated with an excess risk of breast cancer, levonorgestrel-based 
triphasic contraceptives accounting for this risk elevation. 
4.3 Gonadotropin-releasing hormone agonists  
Gonadotropin-releasing hormone agonist (GnRHA) suppress ovarian function, decreasing 
circulating levels of estrogens, so it could be assumed that their administration would 
influence breast density. A special designed contraceptive study (Spicer et al., 1994) 
randomly assigned 21 patients, 27–40 years of age, with a 5-fold greater than normal risk of 
breast cancer, in a 2:1 ratio to special contraceptive group (14 women who received GnRHA 
(leucoprolide acetate) plus very low doses add-back conjugated estrogen and medroxy-
progesterone acetate) or to a control group (7 women). The authors found that women on 
the contraceptive regimen showed significant (P = 0.039) reduction in mammographic 
densities between the baseline and 1-year mammograms, compared with control group. In a 
follow-up of this study (Spicer et al., 1994), 12 months after completion of treatment, the 
mean percentage of mammographic density in the treated group was no different from that 
at baseline (P = 0.73). Reductions in mammographic density for this special contraceptive 
regimen (GnRHA plus low-dose add-back estrogen-progestin) persist only during treatment 
period. The densities return to baseline when the women resume normal menstrual cycles. 
A more recent study (Weitzel et al., 2007) performed on BRCA1 mutation high-risk patients, 
using GnRHA deslorelin, confirmed these data. Twelve months treatment with deslorelin, 
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density in only 3 women (15%). However, there was no increase in proliferation, as 
expressed by the percentage of MIB-1-positive breast cells in fine-needle aspiration 
biopsies. Given the small number of cases, these results need to be confirmed by larger 
studies. 
Timing of HRT initiation influences the mammographic parenchymal patterns. Analizing a 
subgroup from EPIC-Norfolk cohort, Sala et al (Sala et al., 2000) found that women who are 
starting HRT, while still menstruating, were more likely to have a high-risk breast density 
pattern compared to women not exposed to HRT or to those who started HRT after 
menopause. A recent Million Women Study analysis update (Beral et al., 2011) focused on 
the influence of timing on breast cancer risk for the different treatment regimens. Relative 
risks were found to be higher if therapy was started before or soon after menopause than in 
the case of a longer interval between menopause and starting HRT (p < 0.001). Among 
current users of estrogen-only therapy, there was little or no increase in risk if use began 5 
years or more after menopause (RR 1.05, 95% CI 0.89–1.24), whereas risk was increased if 
use began before or within 5 years after menopause (RR 1.43, 95% CI 1.35–1.51). A similar 
pattern was seen for users of E+P (RR 1.53, 95% CI 1.38–1.70 vs. RR 2.04, 95% CI 1.95–2.14). 
The timing of initiation of HRT relative to that of menopause appears to be an important 
factor that modulates the risk of breast cancer. 
HRT effects on breast and mammography are reversible. After discontinuing hormone 
therapy, breast density decrease rapidly. Discontinuation of HRT a few weeks prior to 
mammography may improve mammographic performances. The rapid decrease in breast 
density after stopping HRT suggest that increased breast density in HRT users is different 
from increased breast density in non-users. Increased breast density in non-users reflects a 
genetic increased quantity of glandular and fibrous tissue, whereas increased breast density 
in HRT users may suggest a water retention at breast level, probably due to stromal 
changes, under hormonal influence (Alowami et al., 2003). In a retrospective study, Harvey 
at al analyzed breast density modifications after stopping HRT (Harvey et al., 1997). HRT-
induced mammographic changes disappeared two weeks after HRT discontinuation. 
However, twelve patients in their study did not experienced mammographic reversal after 
HRT discontinuation, and, on biopsy, one case of atypical hyperplasia and one case of 
ductal invasive carcinoma were found. More recent studies failed to observe an 
improvement in mammographic diagnostic accuracy, following HRT suspension. The 
Buist`s randomised trial revealed that HT suspension was associated with small changes in 
breast density and did not affect recall rates. There was no evidence to support short-term 
HT suspension before mammography (Buist et al., 2009). 
A few studies addressed the issue of reducing breast cancer risk in HRT population. Adding 
aromatase inhibitors to HRT may lower mammographic breast density in postmenopausal 
women. A small retrospective study (Mousa et al., 2008) demonstrated a statistically 
significant reduction in mammographic breast density occurred in the women who received 
hormone therapy plus an aromatase inhibitor letrozole, whereas no significant change was 
observed in the women receiving hormone therapy alone. Aromatase inhibitors could be 
good candidates for primary chemoprevention of breast cancer in postmenopausal women 
using hormone therapy (Mousa et al., 2008). 
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Oral contraceptive use is an issue of young women, mostly before age of 40, a time when 
mammographic screening begins. Therefore, studies evaluating the impact of COC on 
mammographic breast density are lacking.  
A Norwegian study (Gram et al., 2002) examined the relationship between oral 
contraceptive ever use and mammographic patterns among 3218 women, aged 40-56 years, 
who fulfilled a questionnaire about ever OC use, duration, and starting age of OC. Women 
ever having used OCs had an increased risk for high-risk mammographic patterns [OR 1.27; 
95% CI (1.0-1.6)], compared with those reporting never having used OCs. There was no 
relationship between different types of OC use (different doses) and high-risk patterns. 
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were exposed to an excess risk of breast cancer, as high as 3.05 [95% confidence interval 
(2.00-4.66); P < 0.0001]. The authors (Hunter et al., 2010) concluded that current use of oral 
contraceptives is associated with an excess risk of breast cancer, levonorgestrel-based 
triphasic contraceptives accounting for this risk elevation. 
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Gonadotropin-releasing hormone agonist (GnRHA) suppress ovarian function, decreasing 
circulating levels of estrogens, so it could be assumed that their administration would 
influence breast density. A special designed contraceptive study (Spicer et al., 1994) 
randomly assigned 21 patients, 27–40 years of age, with a 5-fold greater than normal risk of 
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regimen (GnRHA plus low-dose add-back estrogen-progestin) persist only during treatment 
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A more recent study (Weitzel et al., 2007) performed on BRCA1 mutation high-risk patients, 
using GnRHA deslorelin, confirmed these data. Twelve months treatment with deslorelin, 
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plus low-dose add-back steroids, significantly decreased mammographic percent density in 
BRCA1 mutation carriers. This regimen may reduce breast cancer risk and improve the 
usefulness of mammographic surveillance by reducing density. 
4.4 Selective tissue estrogenic activity regulator   
Other forms of sistemic therapy for relief of climacteric symptoms and prevention of 
osteoporosis in postmenopausal women include selective tissue estrogenic activity regulator 
(STEAR), the most known being tibolone. Tibolone, a tissue-specific compound, constitutes 
an alternative for treatment in postmenopausal women (Moore, 1999).   
It appears that tibolone exerts minimal effects of the breast tissue and mammographic 
density. In a prospective, randomized, double-blind, placebo-controlled study (Lundström 
et al., 2002), breast density was increased in 46-50% of oral continuous combined HRT users, 
as opposed to only 2-6% in oral tibolone users and 0% in placebo group. The authors 
concluded that in contrast to estrogen/progestogen treatment, tibolone seems to exert little 
stimulation of breast tissue. 
According to Asia Pacific Tibolone Consensus Group, symptomatic HRT users with 
increased breast density that result in an unreadable mammogram could be switched on 
tibolone, in order to decrease mammographic density without losing the beneficial effects of 
HRT (Huang & Baber, 2010). 
However, the relationship between tibolone use and increased risk of breast cancer remains 
inconclusive (Opatrny et al., 2008). A population-based case-control study, GPRD database 
(Opatrny et al., 2008), found that tibolone do not increase the risk for breast cancer in 
postmenopausal women (RR 0.86; 95% CI 0.65-1.13). Even more, LIFT trial (Cummings et al., 
2008), which included 4538 osteoporotic postmenopausal women with no history of breast 
cancer, treated with tibolone, 1,25 mg/day, demonstrated a decreased risk of invasive breast 
cancer (RR = 0.32; 95% CI, 0.13 to 0.80; P=0.02).  
However, in women with a history of breast cancer, data from the LIBERATE (Kenemans et 
al., 2009) study show that tibolone (2,5 mg/day) does increase the risk of breast cancer 
recurrence. LIBERATE population of women is mostly using adjuvant systemic therapy, 
67% of women being on tamoxifen and 6.5% on aromatase inhibitors. Tibolone may interfere 
with the protective action of these agents, especially with the aromatase inhibitors, through 
an estrogen-agonistic action on dormant tumor cells. To date, tibolone should be 
contraindicated for women with a history of breast cancer. 
Although comparison is not possible between LIFT and LIBERATE study, dose seems to be 
an important issue with respect to breast cancer risk, when using tibolone for vasomotor 
symptoms relief and osteoporosis treatment. 
4.5 Selective estrogen-receptor modulators   
Selective estrogen-receptor modulators (SERMs), previously called antiestrogens, are drugs 
that competitively inhibit estrogen binding to estrogen receptors (ERs), and have mixed 
agonist and antagonist activity (depending on the target tissue). SERMs affect a variety of 
biologic processes regulated by activated estrogen receptor. Depending on the target tissue, 
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levels and types of ERs, and their structure, SERMs may exhibit either estrogen antagonist 
or estrogen agonist effects (Fabian & Kimler, 2005).  
Tamoxifen is a SERM with estrogen antagonist effects in the breast, weak estrogen agonist 
activity in the bone, cardiovascular system and CNS, and important estrogen agonist effects 
in the uterus, liver, and vagina.  
Most of the data regarding tamoxifen effects on mammographic breast density came from 
prevention studies, performed on populations at high-risk for breast cancer or with a history 
of breast cancer. In the National Surgical Adjuvant Breast and Bowel Project (NSABP) 
randomized clinical trial of high-risk women, 5 years of tamoxifen therapy was shown to 
reduce invasive breast cancer risk by 49% and noninvasive breast cancer risk by 50% com-
pared with placebo (Fisher et al., 1998). 
Treatment with tamoxifen is associated with a reduction in breast density in both 
premenopausal and postmenopausal women (Ursin et al., 1996). However, the reduction in 
breast density in association with these factors has not yet been correlated with the 
reduction in the risk of breast cancer. 
Slanetz (Slanetz et al., 2004) described mammographic density decrease on tamoxifen and 
return to the baseline density following termination of the drug, so they postulated that 
decrease in breast density could reflect the sensitivity to tamoxifen and be a marker of 
therapeutic benefit associated with tamoxifen. The more radiolucent pattern by tamoxifen 
allow enhanced mammographic detection and may further add benefit for women. After 
discontinuation of tamoxifen, breast density is returning to its initial pattern. The clinical 
significance of resumption of a dense breast pattern following discontinuation of tamoxifen 
remains to be determined (Ursin et al., 1996). 
In high-risk populations (women with known breast cancer on adjuvant tamoxifen or 
women at high risk for breast cancer on tamoxifen for chemoprevention), tamoxifen 
produced a statistically significant reduction in mammmographic breast density and this 
reduction occurred more frequent in premenopausal than in postmenopausal women (54). 
In a study (Son & Oh, 1999), performed on breast cancer patients who have undergone 
surgery, 87% of premenopausal women with breast cancer had a decrease in parenchymal 
area with tamoxifen use, whereas only 29% of postmenopausal women experienced a 
decrease. 
A similar trend was observed in the Brisson`s study, performed on women with high-risk 
for breast cancer. Women younger than 50 experienced a decrease in parenchymal pattern 
classification in 67% of cases compared with 13% of postmenopausal women aged 50 or 
older (Brisson et al., 2000). 
The duration of tamoxifen treatment is important. In a nested case-control study performed 
for IBIS-1 participants, Cuzick et al. noticed that the reduction in dense area for women 
treated for 4,5 years with tamoxifen is double compared with women given placebo (Cuzick 
et al., 2004). The majority of breast density reduction occurred in the first 18 months of 
treatment. There was a significant interaction with age such that a minimal decrease in area 
of density was observed for women over 55 treated with tamoxifen, that is, 1% compared to 
13% for women younger than 45 (Cuzick et al., 2004). Importantly, reduction in breast 
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plus low-dose add-back steroids, significantly decreased mammographic percent density in 
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67% of women being on tamoxifen and 6.5% on aromatase inhibitors. Tibolone may interfere 
with the protective action of these agents, especially with the aromatase inhibitors, through 
an estrogen-agonistic action on dormant tumor cells. To date, tibolone should be 
contraindicated for women with a history of breast cancer. 
Although comparison is not possible between LIFT and LIBERATE study, dose seems to be 
an important issue with respect to breast cancer risk, when using tibolone for vasomotor 
symptoms relief and osteoporosis treatment. 
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that competitively inhibit estrogen binding to estrogen receptors (ERs), and have mixed 
agonist and antagonist activity (depending on the target tissue). SERMs affect a variety of 
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Tamoxifen is a SERM with estrogen antagonist effects in the breast, weak estrogen agonist 
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in the uterus, liver, and vagina.  
Most of the data regarding tamoxifen effects on mammographic breast density came from 
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therapeutic benefit associated with tamoxifen. The more radiolucent pattern by tamoxifen 
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reduction occurred more frequent in premenopausal than in postmenopausal women (54). 
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treated for 4,5 years with tamoxifen is double compared with women given placebo (Cuzick 
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treatment. There was a significant interaction with age such that a minimal decrease in area 
of density was observed for women over 55 treated with tamoxifen, that is, 1% compared to 
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density predicted only one-third of the reduction in breast cancer incidence seen in 
prevention trials. 
While tamoxifen is mostly recommended by the oncologists, both for curative or preventive 
breast cancer treatment, other SERM`s, like raloxifen, are largely recommended by general 
practitioners for the treatment of postmenopausal osteoporosis. Raloxifene has higher 
affinity for estrogen receptor and more intense antagonistic effects (by blocking ER-
activating function domains, AF-1 and AF-2), than tamoxifen (which blocks only AF-2, but 
not AF-1) (Howell et al., 2001; Katzenellenbogen et al., 1996). 
In the STAR trial (Vogel et al., 2006), tamoxifen and raloxifene had equivalent effects in 
reducing risk of invasive breast cancer in all examined subgroups, including women with a 
history of atypical hyperplasia or LCIS, who had the highest annual rates of invasive breast 
cancer. Most of the STAR cases were diagnosed as a result of mammograms demonstrating 
increasing calcifications, in conditions of reducted breast density. Because the lesions were 
early detected and small, most were treated surgically with lumpectomy. 
In a retrospective analysis, performed on a subset of women enrolled in a multicenter, 
double-blind, randomized, placebo- and active-controlled phase 3 trial evaluating 
bazedoxifene for the treatment of postmenopausal osteoporosis, Harvey et al found that the 
changes in breast density with the newer SERM bazedoxifene 20 or 40 mg were similar to 
those with raloxifene 60 mg or placebo (Harvey et al., 2009). 
The analysis of extraskeletal outcomes (Gennari et al., 2009) of PEARL study indicated that 
lasofoxifene 0.25 mg and 0.5 mg reduces the risk of ER positive breast cancer (by 84% and 
67%, respectively). This effect was also evident for all breast cancers (a composite endpoint 
consisting of ER+, ER–, invasive, and ductal cancer in situ) with lasofoxifene 0.5 mg dose 
(65% and 79% risk reduction compared to placebo through 3 and 5 years, respectively) 
(Cummings et al., 2008). 
4.6 Aromatase inhibitors    
The aromatase inhibitors reduce breast and circulating estrogen levels in postmenopausal 
women. As a consequence, aromatase inhibitors may reduce mammographic breast density. 
Vachon et al randomized 106 postmenopausal women to either aromatase inhibitor letrozole 
or placebo after 5 years of tamoxifen (Vachon et al., 2007). After 9 to 15 months, no 
difference breast mammographic density was found between the 2 groups.  
MAP1 was a multicenter, randomized, double-blind, placebo-controlled, feasibility trial in 
which postmenopausal women with or without prior invasive breast cancer were 
randomized in a 2:1 ratio of letrozole (2.5 mg daily) or placebo for 12 months and followed 
for a total of 24 months. After one year treatment, letrozole does not appear to have a 
significant effect on mammographic percent breast density, compared with placebo (Cigler 
et al., 2010). Same author performed MAP 2 trial (Cigler et al., 2011) randomizing healthy 
postmenopausal women to exemestan (25 mg daily) or placebo for 12 months and followed 
them for a total of 24 months. The primary endpoint was change in percent breast density 
between the baseline and 12-month mammograms. For exemestan-treated patients, there 
was no significant difference in percent breast density from baseline to 6, 12, or 24 months; 
in the same time, there was no difference between exemestan and placebo group.  
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It was postulated that aromatase inhibitors could reduce mammographic breast density in 
women taking HRT. Two studies examined the influence of letrozole on MBD among 
postmenopausal women taking HRT: one found no change in percent MBD among 42 high-
risk women on either estrogen alone or combination HRT (estrogen and progestins) after 
taking 2.5 mg letrozole per day for 6 months (64), whereas the other study found a reduction 
among women on low-dose combination therapy who were taking letrozole (2.5 mg) 3 times 
weekly for a median of 24 (range, 2-63) months (6.8% vs 1.4% reduction) (Mousa et al., 2008). 
The effects of aromatase inhibitors on breast density, as well as on breast cancer risk, still 
require further investigation (Becker & Kaas, 2009). 
4.7 Phytoestrogens    
Phytoestrogens are plant derived substances that are structurally and functionally similar to 
estrogens and are found in many foods. They exhibit both weak estrogen and anti-
estrogenic activity; therefore, they act as natural SERMs. There are 3 classes of 
phytoestrogens: isoflavonoids, coumestans and ligans (Malik & Prakash, 2004).  
Maskarinec et al randomly assigned 220 premenopausal women, aged 39 – 46 years old, to 
soy intake intervention group or control group (Maskarinec et al., 2004). After 2 years of 
intervention, the authors observed no significant differences in mammographic densities by 
intervention status. 
Association between regular green tea intake and high soy intake may have beneficial 
effects on the breast density. Wu, Ursin et al assessed the effects of the effects of regular 
green tea and soy intake on mammographic density, in a cross-sectional study performed on 
3315 Chinese women in Singapore (Wu et al., 2008). For daily green tea drinkers, percent 
mammographic density was statistically significantly lower than for non-tea drinkers (19.5 
% versus 21.7%; P = 0.002), even after adjustment for soy (P = 0.002). There was no 
association between black tea intake and percent mammographic density. Very high soy 
intake was associated with lower percent density only among postmenopausal women 
(compared normal or low soy intake; 18.9% versus 20.5%, P = 0.035); however, after 
adjustment for green tea intake, this association was no longer statistically significant (P = 
0.52). 
5. Conclusion  
Mammographic density is a well-known risk factor for breast cancer, although the 
biologic basis of the relationship between breast cancer risk and increased mammographic 
density is not yet completely understood. Nor is the mechanism by which hormonal 
therapy influences mammographic breast density. Despite the beneficial effects on 
menopausal symptoms and osteoporosis, it is the fear of breast cancer that make 
menopausal women reluctant to take hormone therapy. Characterizing the association 
between breast density and hormonal influences may enhance the understanding of how 
mammographic density influences breast cancer risk for both pre- and postmenopausal 
women. Mammographic density reflecting directly the changes at the breast level, the 
influences generated by the associated therapies should be taken into account in screening 
and diagnostic programs.  
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density predicted only one-third of the reduction in breast cancer incidence seen in 
prevention trials. 
While tamoxifen is mostly recommended by the oncologists, both for curative or preventive 
breast cancer treatment, other SERM`s, like raloxifen, are largely recommended by general 
practitioners for the treatment of postmenopausal osteoporosis. Raloxifene has higher 
affinity for estrogen receptor and more intense antagonistic effects (by blocking ER-
activating function domains, AF-1 and AF-2), than tamoxifen (which blocks only AF-2, but 
not AF-1) (Howell et al., 2001; Katzenellenbogen et al., 1996). 
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cancer. Most of the STAR cases were diagnosed as a result of mammograms demonstrating 
increasing calcifications, in conditions of reducted breast density. Because the lesions were 
early detected and small, most were treated surgically with lumpectomy. 
In a retrospective analysis, performed on a subset of women enrolled in a multicenter, 
double-blind, randomized, placebo- and active-controlled phase 3 trial evaluating 
bazedoxifene for the treatment of postmenopausal osteoporosis, Harvey et al found that the 
changes in breast density with the newer SERM bazedoxifene 20 or 40 mg were similar to 
those with raloxifene 60 mg or placebo (Harvey et al., 2009). 
The analysis of extraskeletal outcomes (Gennari et al., 2009) of PEARL study indicated that 
lasofoxifene 0.25 mg and 0.5 mg reduces the risk of ER positive breast cancer (by 84% and 
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(65% and 79% risk reduction compared to placebo through 3 and 5 years, respectively) 
(Cummings et al., 2008). 
4.6 Aromatase inhibitors    
The aromatase inhibitors reduce breast and circulating estrogen levels in postmenopausal 
women. As a consequence, aromatase inhibitors may reduce mammographic breast density. 
Vachon et al randomized 106 postmenopausal women to either aromatase inhibitor letrozole 
or placebo after 5 years of tamoxifen (Vachon et al., 2007). After 9 to 15 months, no 
difference breast mammographic density was found between the 2 groups.  
MAP1 was a multicenter, randomized, double-blind, placebo-controlled, feasibility trial in 
which postmenopausal women with or without prior invasive breast cancer were 
randomized in a 2:1 ratio of letrozole (2.5 mg daily) or placebo for 12 months and followed 
for a total of 24 months. After one year treatment, letrozole does not appear to have a 
significant effect on mammographic percent breast density, compared with placebo (Cigler 
et al., 2010). Same author performed MAP 2 trial (Cigler et al., 2011) randomizing healthy 
postmenopausal women to exemestan (25 mg daily) or placebo for 12 months and followed 
them for a total of 24 months. The primary endpoint was change in percent breast density 
between the baseline and 12-month mammograms. For exemestan-treated patients, there 
was no significant difference in percent breast density from baseline to 6, 12, or 24 months; 
in the same time, there was no difference between exemestan and placebo group.  
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(compared normal or low soy intake; 18.9% versus 20.5%, P = 0.035); however, after 
adjustment for green tea intake, this association was no longer statistically significant (P = 
0.52). 
5. Conclusion  
Mammographic density is a well-known risk factor for breast cancer, although the 
biologic basis of the relationship between breast cancer risk and increased mammographic 
density is not yet completely understood. Nor is the mechanism by which hormonal 
therapy influences mammographic breast density. Despite the beneficial effects on 
menopausal symptoms and osteoporosis, it is the fear of breast cancer that make 
menopausal women reluctant to take hormone therapy. Characterizing the association 
between breast density and hormonal influences may enhance the understanding of how 
mammographic density influences breast cancer risk for both pre- and postmenopausal 
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1. Introduction
This chapter evaluates recently proposed computer vision methodologies for mammographic
segmentation and risk classification based on Tabár tissue modelling (Tabár et al., 2004). The
overall objective is to bridge the gap between the theoretical work and their clinical usefulness,
with respect to mammographic risk assessment for early breast cancer detection.
In the computer vision literature, there are two lines of scientific investigation into automated
mammographic risk assessment. The first focuses on the correlation between mammographic
risk and the parenchymal; and the second focuses on the correlation with the overall
breast density. In addition, the sensitivity of mammography is significantly reduced by
increased breast density which can mask some tumours due to dense fibroglandular tissue
(Sickles, 2007). Whilst computer aided mammographic density estimation has been widely
investigated as a two-class (i.e. dense and non-dense breast tissue) problem, Tabár breast
components composition estimation as a four-class (i.e. nodular, linear, homogeneous
densities and radiolucent) problem seems to be overlooked in computer aided mammography.
Despite the current standard which is favouring breast density based risk estimation, clinical
evidence has shown that the mammographic parenchymal appearances (e.g. distribution of
various breast tissues) may provide more information than percent density alone (Astley,
2004).
2. Background
Breast density varies from one woman to another. These variations are related to the
risk of developing breast cancer; the denser the breast appearance the higher the risk.
Mammographic breast density also has a strong association with mammographic screening
sensitivity (Couto et al., 2001). Women with high risk density patterns are advised to undergo
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2.1 Mammographic risk assessment
To assess breast cancer risk, different methods have been developed to measure
mammographic density patterns. Two most frequently used classification methods for
measuring breast density include Wolfe’s mammographic parenchymal patterns (Wolfe,
1976a), and the percentage of the breast densities (Brisson et al., 2003). In Wolfe’s scheme,
breast cancer risk (i.e. N1, P1, P2 and DY) is assessed based on four mammographic features,
including the extent of dense breast tissue in the mammogram, and characteristics of densities
(e.g. shape and texture). Several other classification methods use parenchymal patterns,
including BIRADS classification (i.e. BIRADS I-IV) proposed by the American College of
Radiology (American College of Radiology, 2004), and Tabár’s scheme (i.e. Tabár I-V) (see
Section 2.2). Breast percentage density based scheme, such as Boyd’s six-class categories
(Boyd et al., 1995) assesses the extent of fibroglandular breast densities in the mammogram,
without taking into account the various types of fibroglandular densities, and is expressed by
the percentage of the breast showing dense tissue (Boyd et al., 2006).
Experts’ subjective appraisal of mammograms can lead to inter and intra observer variability.
Automated mammographic risk assessment may be beneficial in a clinical environment,
because computerised processes can produce unbiased and consistent results as a means of
aiding diagnosis.
2.2 Tabár tissue modelling
In mammographic risk assessment, Tabár et al. have proposed a mixture model of four
mammographic building blocks, representing nodular, linear, homogeneous and radiolucent
tissues (Tabár et al., 2004). These four building blocks compose the normal breast anatomy.
Nodular densities mainly correspond to Terminal Ductal Lobular Units (TDLUs). Linear
structures correspond to either ducts, fibrous tissue or blood vessels. Homogeneous
structureless densities correspond to fibrous tissues which appearance could hide the
underlying normal TDLUs and ducts, as well as their alterations due to hyperplastic breast
changes. Radiolucent areas are related to adipose fatty tissues, which appear as dark areas in
mammographic images (Tabár et al., 2004).
Tabár’s tissue modelling is strongly influenced by Wolfe’s original work, which divided
mammograms, using parenchymal patterns, into four classes (Wolfe, 1976b). For Tabár’s risk
assessment model, the relative proportions of the tissues belonging to the four building blocks
are used to subdivide mammograms into five risk classes. Patterns I to V indicate low to high
mammographic risk. The relative composition of the four building blocks, nodular, linear,
homogeneous and radiolucent (in that order) are as follows:
• Pattern I has composition [25%, 15%, 35%, 25%]. This pattern is the most common
mammographic pattern in premenopausal woman (Tabár et al., 2004). All four building
blocks are fairly equally distributed in this pattern. However, with involution, pattern I
will change to either pattern II or pattern III; on the other hand, hormone-replacement therapy
often reverses the process of involution. Mammograms of pattern I show normal fibroglandular
tissue with partial fatty replacement, and pathological changes can be easily perceived in pattern
I, although these breasts can be radiologically “dense” (Tabár et al., 2004). This pattern is
considered the lowest mammographic risk.
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Fig. 1. Mammographic risk patterns with respect to Tabár’s risk classification. From left to
right showing patterns I-V, corresponding from low to high mammographic risk.
• Pattern II has composition [2%, 14%, 2%, 82%]. This pattern represents the end results of
the process of involution, and is characterised by the over representation of radiolucent
fatty tissue, which provides excellent background for radiologists to visualise any process
of disease (Tabár et al., 2004). Therefore, the detection of abnormalities in mammograms
of pattern II is relatively easier.
• Pattern III is similar in composition to pattern II. In this pattern the retroareolar prominent
ducts are often associated with periductal fibrosis (Tabár et al., 2004). Neither of these
patterns (i.e. patterns II and III) has nodular densities or diffuse fibrosis; the over representation
of radiolucent fatty tissue makes pathological lesions being detected relatively easier on the
mammogram (Tabár et al., 2004).
• Pattern IV has composition [49%, 19%, 15%, 17%]. This pattern is dominated by prominent
nodular and linear densities. Their presence often makes perception of pathological lesions
difficult. Also this pattern appears to be resistant to the process of involution (Tabár et al., 2004).
This pattern is considered higher mammographic risk.
• Pattern V has composition [2%, 2%, 89%, 7%]. This patten is dominated by extensive
fibrosis. The overwhelming dominance of this homogeneous, structureless fibrous tissue limits the
capabilities of mammography to demonstrate the details of normal anatomy and to reveal small
pathological lesions. The radiology reports often state such a mammogram as “extensive fibrosis",
which is the only demonstrable feature (Tabár et al., 2004). This pattern is considered the
highest mammographic risk.
Fig. 1 shows example mammographic images with respect to Tabár’s five mammographic
risk patterns.
3. Literature review
Automatic mammographic risk assessment is expected to play a significant role in
the development of breast screening programs and computer-aided detection/diagnosis
systems. As mentioned, strong evidence has indicated a correlation between mammographic
parenchymal patterns and mammographic risk. This section reviews the existing
representative methodologies used for mammographic risk assessment, and related
techniques used in computer-aided mammography, with discussions of their merits and
shortcomings.
219
Evaluation of Mammographic Segmentation
and Risk Classif atio  Based on Tabár Ti sue Modelling
2 Will-be-set-by-IN-TECH
2.1 Mammographic risk assessment
To assess breast cancer risk, different methods have been developed to measure
mammographic density patterns. Two most frequently used classification methods for
measuring breast density include Wolfe’s mammographic parenchymal patterns (Wolfe,
1976a), and the percentage of the breast densities (Brisson et al., 2003). In Wolfe’s scheme,
breast cancer risk (i.e. N1, P1, P2 and DY) is assessed based on four mammographic features,
including the extent of dense breast tissue in the mammogram, and characteristics of densities
(e.g. shape and texture). Several other classification methods use parenchymal patterns,
including BIRADS classification (i.e. BIRADS I-IV) proposed by the American College of
Radiology (American College of Radiology, 2004), and Tabár’s scheme (i.e. Tabár I-V) (see
Section 2.2). Breast percentage density based scheme, such as Boyd’s six-class categories
(Boyd et al., 1995) assesses the extent of fibroglandular breast densities in the mammogram,
without taking into account the various types of fibroglandular densities, and is expressed by
the percentage of the breast showing dense tissue (Boyd et al., 2006).
Experts’ subjective appraisal of mammograms can lead to inter and intra observer variability.
Automated mammographic risk assessment may be beneficial in a clinical environment,
because computerised processes can produce unbiased and consistent results as a means of
aiding diagnosis.
2.2 Tabár tissue modelling
In mammographic risk assessment, Tabár et al. have proposed a mixture model of four
mammographic building blocks, representing nodular, linear, homogeneous and radiolucent
tissues (Tabár et al., 2004). These four building blocks compose the normal breast anatomy.
Nodular densities mainly correspond to Terminal Ductal Lobular Units (TDLUs). Linear
structures correspond to either ducts, fibrous tissue or blood vessels. Homogeneous
structureless densities correspond to fibrous tissues which appearance could hide the
underlying normal TDLUs and ducts, as well as their alterations due to hyperplastic breast
changes. Radiolucent areas are related to adipose fatty tissues, which appear as dark areas in
mammographic images (Tabár et al., 2004).
Tabár’s tissue modelling is strongly influenced by Wolfe’s original work, which divided
mammograms, using parenchymal patterns, into four classes (Wolfe, 1976b). For Tabár’s risk
assessment model, the relative proportions of the tissues belonging to the four building blocks
are used to subdivide mammograms into five risk classes. Patterns I to V indicate low to high
mammographic risk. The relative composition of the four building blocks, nodular, linear,
homogeneous and radiolucent (in that order) are as follows:
• Pattern I has composition [25%, 15%, 35%, 25%]. This pattern is the most common
mammographic pattern in premenopausal woman (Tabár et al., 2004). All four building
blocks are fairly equally distributed in this pattern. However, with involution, pattern I
will change to either pattern II or pattern III; on the other hand, hormone-replacement therapy
often reverses the process of involution. Mammograms of pattern I show normal fibroglandular
tissue with partial fatty replacement, and pathological changes can be easily perceived in pattern
I, although these breasts can be radiologically “dense” (Tabár et al., 2004). This pattern is
considered the lowest mammographic risk.
18 Mammography – Recent Advances Evaluation of Mammographic Segmentation and Risk Classification Based on Tabár Tissue Modelling 3
Fig. 1. Mammographic risk patterns with respect to Tabár’s risk classification. From left to
right showing patterns I-V, corresponding from low to high mammographic risk.
• Pattern II has composition [2%, 14%, 2%, 82%]. This pattern represents the end results of
the process of involution, and is characterised by the over representation of radiolucent
fatty tissue, which provides excellent background for radiologists to visualise any process
of disease (Tabár et al., 2004). Therefore, the detection of abnormalities in mammograms
of pattern II is relatively easier.
• Pattern III is similar in composition to pattern II. In this pattern the retroareolar prominent
ducts are often associated with periductal fibrosis (Tabár et al., 2004). Neither of these
patterns (i.e. patterns II and III) has nodular densities or diffuse fibrosis; the over representation
of radiolucent fatty tissue makes pathological lesions being detected relatively easier on the
mammogram (Tabár et al., 2004).
• Pattern IV has composition [49%, 19%, 15%, 17%]. This pattern is dominated by prominent
nodular and linear densities. Their presence often makes perception of pathological lesions
difficult. Also this pattern appears to be resistant to the process of involution (Tabár et al., 2004).
This pattern is considered higher mammographic risk.
• Pattern V has composition [2%, 2%, 89%, 7%]. This patten is dominated by extensive
fibrosis. The overwhelming dominance of this homogeneous, structureless fibrous tissue limits the
capabilities of mammography to demonstrate the details of normal anatomy and to reveal small
pathological lesions. The radiology reports often state such a mammogram as “extensive fibrosis",
which is the only demonstrable feature (Tabár et al., 2004). This pattern is considered the
highest mammographic risk.
Fig. 1 shows example mammographic images with respect to Tabár’s five mammographic
risk patterns.
3. Literature review
Automatic mammographic risk assessment is expected to play a significant role in
the development of breast screening programs and computer-aided detection/diagnosis
systems. As mentioned, strong evidence has indicated a correlation between mammographic
parenchymal patterns and mammographic risk. This section reviews the existing
representative methodologies used for mammographic risk assessment, and related
techniques used in computer-aided mammography, with discussions of their merits and
shortcomings.
219
Evaluation of Mammographic Segmentation
and Risk Classif atio  Based on Tabár Ti sue Modelling
4 Will-be-set-by-IN-TECH
3.1 Textons representation
Recent research has demonstrated the use of textons (Varma & Zisserman, 2004) based
mammographic segmentation. Petroudi et al. (Petroudi et al., 2003) applied such a technique
directly to mammographic images for risk classification. A total of 40 textons were generated
via clustering over the filter response space; that is 10 textons for each of the four BIRADS
categories. Mammograms were modelled as texton frequency histograms; and by comparing
the texton distribution of a mammogram to the learned models using the χ2 (chi-square)
method, the mammographic risk was determined as the BIRADS risk category corresponding
to the nearest neighbour model. The evaluation was conducted on a small Oxford database
(not publicly available) (Evertsz et al., 2000), the exact agreement with the ground truth was
76% accuracy.
Gong et al. (Gong et al., 2006) used a similar statistical approach for mammographic
segmentation and risk classification. Instead of using image filtering to obtain the feature
vectors, the raw pixel intensities of a N × N square neighbourhood image patch around
a pixel were taken and row reordered, to form a N2 dimensional feature vector. Four
mammographic risk classes were learned based on Wolfe’s scheme (Wolfe, 1976b). The same
processes used in (Petroudi et al., 2003) were employed for the texton generation, mapping,
and risk classification. The Oxford database was again used in the evaluation, and an average
classification accuracy of 87% was achieved for 43 randomly selected mammograms.
The statistical texture based classification method (Petroudi et al., 2003) was combined with
the multi-vector Markov random fields based approach (Gong et al., 2006) in (Petroudi &
Brady, 2006), to perform mammographic density segmentation using textural and structural
information based on Wolfe’s scheme. At the evaluation stage, 32 mammograms were
selected from the Oxford database. The segmentation results show a strong correspondence
between the texture variations and the radiologists perception of the different breast density
patterns. Despite the use of a small dataset, the breast density segmentation is considered
anatomically plausible from an expert radiologist’s point of view. It is concluded that texton
based statistical modelling is able to generalise the data, and overcome noise issues related to
image acquisition and involution of the breast.
Muhimmah et al. (Muhimmah et al., 2007) applied a texton related technique for
mammographic segmentation based on Tabár’s tissue modelling; a texton selection strategy
is incorporated using a combination of visual assessment (probability maps) and minimum
spanning tree topological information. The initial number of textons (cluster centres) for each
tissue type (i.e. nodular, linear, homogeneous and radiolucent) was empirically chosen to
be 25. In the texton selection process, the (Euclidean) minimum spanning tree was used to
indicate a topologically probable correct connectivity, in high dimensional spaces. Distinct
textons (higher discriminative power) tend to be situated towards the outer edges of the tree;
common texture, noise and intensity aspects tend to be modelled by textons in the central part
of the tree. A visual assessment was employed to determine the appropriate textons, based
on the distinctiveness of the textons spatial displacements. Subsequently, a model driven
based mammographic segmentation was performed based on the selected textons. A similar
approach was applied in (He et al., 2008) with an alternative texton selection process. Both
studies have shown realistic segmentation results, but no risk classification experiments were
conducted.
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3.2 Co-occurrence matrix representation
Arnau et al. (Oliver et al., 2007) applied co-occurrence matrices as a means of extracting
texture features directly from mammographic images for automatic classification of breast
density. A total of 216 features were computed from the co-occurrence matrices and
used at the classification stage. The classification accuracy achieved was 78% using a
K-Nearest-Neighbour (K = 3) classifier over the complete set of the MIAS database
(Suckling et al., 1994). Further improvement was made in (Oliver et al., 2008) based on
the same methodology, where 10 additional morphological features for the fatty and dense
tissue regions were calculated. At the classification stage a combined Bayesian classifier
was developed based on the K-Nearest-Neighbour and ID3 Decision Tree; the combined
classifier achieved 86% and 77% correct classification for the MIAS and DDSM (Heath et al.,
1998) database, respectively. The investigation indicated that classification accuracies can
be improved by increasing the combination of the orientations and step intervals of the
co-occurrence matrices (as well as additional features). However, the dimensionality of the
feature space was increased.
Zwiggelaar et al. (Zwiggelaar et al., 2003) introduced set-permutation-occurrence matrices
(a set of co-occurrence matrices) as texture feature vectors for texture segmentation of
mammographic density. The novel texture modelling approach incorporated spatial
information implicitly. The segmentation results were used for automatic mammographic
risk assessment. Further improvement was made in (Zwiggelaar & Denton, 2004), where
a transportation algorithm (Hitchcock, 1941) was used to select the appropriate set of
co-occurrence matrices for the segmentation of mammographic density. It should be noted
that using the transportation algorithm can lead to a very computational intensive task
(Andoni et al., 2008); therefore it may not be practical for use in a clinical environment.
3.3 Moments representation
As breast cancer develops/progresses, statistical information can be gathered with respect
to shape related texture (e.g. various types of tumours), which may have significant
implication for the staging of breast cancer. Inspired by medical diagnosis of malignant
breast cancer, where mammogram masses are classified based on the presence of spicular
lesions or diffuse stellate appearance (Tavassoly, 1992); Soares et al. (Soares et al., 1998) have
shown that moment techniques can be used for shape related texture analysis in digitised
mammograms. Specifically, moments were used as features for automated classification of
masses in mammography (Soares et al., 1998). It is a logical approach to use moments as shape
features for mass classification, because stellate tumours can be characterised as an irregular
shape with radiating spicules. A similar technique was used in (Mencattini et al., 2007), and
additional texture features (i.e. Haralick features (Haralick et al., 1973)) are incorporated
for mass classification. Other types of moments, such as discrete orthogonal Chebyshev
moments were employed in (Vyas & Priti, 2007) for malignancy texture classification in
digitised mammograms. Eisa et al. (Eisa et al., 2009) combined moments with texture
features to improve content-based image retrieval in mammography. For an image a set of
geometric moments (spatial moments) of different orders are computed, as a global shape
descriptor to describe different spatial characteristics of the image intensity distribution.
The results indicated that the mixture of features is more discriminative than the texture
or moments based features alone. Tucceryan (Tucceryan, 1994) demonstrated the efficiency
of obtaining texture features by computing moments over local image regions. A set of
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features with respect to specific texture properties of the image, can be used to derive a
set of spatial moments from the second and third-order moments. The spatial moments
based texture features are able to capture orientation sensitive texture properties, as well as
more complicated textural properties. Substantial evidence has shown that moments based
techniques are feasible for texture modelling in mammography. It is especially true when
modelling Tabár’s mammographic building blocks (i.e. nodular, linear, homogeneous and
radiolucent) as different breast tissue types have texture patterns related to not only their
periodicity but also shape features.
3.4 Signatures representation
In the computer vision literature, signature (2D histogram) techniques have been applied
to texture analysis in mammography as a means of detection and recognition. Guliato
et al. (Guliato et al., 2008) used signature of a turning angle function to encode features
(e.g. roughness, complexity) that characterise the contours of masses for breast tumour
classification, because malignant breast tumours and benign masses can be distinguished
by their shape characteristics. Zwiggelaar et al. (Zwiggelaar, 2002; Zwiggelaar et al.,
1999) investigated abnormality (e.g. the central mass of spiculated lesions) detection in
mammography using scale-orientation signatures. Such signatures have been described as
rich descriptors of the neighbourhood around each image pixel, and were used to label
structures in images, to classify the pixels into linear structures, blob-like structures or
background texture. Therefore, signature techniques are also capable of modelling shape
related texture.
4. Materials
The Mammographic Image Analysis Society (MIAS) database consists of 322 mammographic
images in mediolateral views. The mammographic films were digitised to 50 micron ×
50 micron resolution with a Joyce-Loebl scanning microdensitometer, a device linear in
the optical density range 0-3.2 and representing each pixel with an 8-bit word (Suckling
et al., 1994). The database provides {x, y} image-coordinates for the centre of a circle, its
approximate radius (in pixels) that encloses the abnormalities, the information about their
severities (i.e. benign and malignant), and the abnormality types (e.g. calcification, masses,
architectural distortion and asymmetry). Ground truth for breast density is classed into
three categories (i.e. fatty, glandular, and dense). The ground truth for mammographic risk
classification with respect to Tabár and BIRADS was provided by an expert radiologist.
4.1 Mammographic image patches
In order to facilitate the texture modelling and training process, a set of randomly selected
mammograms from the MIAS database were subsampled by an expert mammographic
screening radiologist to obtain samples representing Tabár’s mammographic building blocks,
resulting in patches containing (199) nodular, (253) linear, (70) homogeneous and (121)
radiolucent tissue examples (Muhimmah et al., 2007). The collection of patches (See Fig.
2 for examples) covers the various mammographic risk classifications. In addition, for 98
subsampled mammographic patches detailed manual annotations were provided by the same
radiologist covering (21) nodular, (27) linear structure, (28) homogeneous and (22) radiolucent
regions.
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Fig. 2. Subsampled mammographic patches in the top and bottom row belong to the same
tissue type. From left to right: nodular, linear, homogeneous, and radiolucent. It should be
noted that intra class variation can be seen as large variation in intensity and texture patterns
within the same tissue types (Tabár’s mammographic building blocks).
5. Methodologies
With respect to mammographic risk assessment using computer vision techniques, there
are a few approaches to mammographic segmentation and risk classification using Tabár’s
scheme, probably because BIRADS is currently more wildly used. However, in computer
aided mammography, it is plausible to perform risk assessment based on Tabár’s tissue
modelling. This section describes two recently developed approaches (He et al., 2009;
2010) for mammographic segmentation and risk estimation based on modelling of various
breast components (i.e. nodular, linear, homogeneous and radiolucent tissue) as seen in
mammograms. To develop an automated, accurate and repeatable mammographic risk
estimation approach based on Tabár’s tissue modelling, the major challenge is to segment
a given mammographic image according to Tabár’s mammographic building blocks, so that
the characteristic mixture of these building blocks can be determined, the mammographic
risk can be estimated, and the relative proportions of different breast tissue patterns can be
quantified. This process is illustrated in Fig. 3.
5.1 Moments based approach
Mammographic segmentation based on spatial moments and prior information (e.g. shape
related texture features) of mammographic building blocks was investigated. The developed
methodology is capable of modelling complex mammographic images and can deal with intra
class variation and noise aspects.
5.1.1 Local moments calculation
Moments up to order four are computed within a small local window centred at each pixel
(i, j) in an image. This number of moments is capable of capturing sufficient texture geometry
information on a low dimensional feature. The coordinates of a local window, with size
equal to W × W (with W being odd so that the pixel (i, j) is at the centre of the window)
are normalised to be in the [-1, 1] range. The size of the local window was determined by
estimating the position of the first side-band in Fourier space, using Fourier analysis on local
patches (Gonzales & Woods, 1992). A series of investigations was conducted on parameter
settings based on the full range of anatomical objects; the chosen sampling regions consisted
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the characteristic mixture of these building blocks can be determined, the mammographic
risk can be estimated, and the relative proportions of different breast tissue patterns can be
quantified. This process is illustrated in Fig. 3.
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related texture features) of mammographic building blocks was investigated. The developed
methodology is capable of modelling complex mammographic images and can deal with intra
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5.1.1 Local moments calculation
Moments up to order four are computed within a small local window centred at each pixel
(i, j) in an image. This number of moments is capable of capturing sufficient texture geometry
information on a low dimensional feature. The coordinates of a local window, with size
equal to W × W (with W being odd so that the pixel (i, j) is at the centre of the window)
are normalised to be in the [-1, 1] range. The size of the local window was determined by
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Fig. 3. A flowchart of mammographic segmentation and risk classification methodology.
Note that mammographic patches are used at the training (modelling) stage, but full
mammographic images are used at the testing (segmentation) stage.
of four square windows with W = {7, 13, 33, 63}, where the lower limit indicates the feature
extraction of small structures (e.g. small diameter nodular tissue, thin linear structures), and
the upper limit indicates the feature extraction of larger structures. For a pixel (m, n) which
falls within the local window f (m, n), the normalised coordinates (xm, yn) are defined as
xm = (m − i)/(W/2) and yn = (n − j)/(W/2). The (p + q)th order moments within the
window centred at pixel (i, j) are computed by a discrete sum approximation, which uses the










n f (m, n). (1)
The lower-order moments (p + q ≤ 1) have well defined geometric interpretations. The
higher-order moments (p + q ≥ 2) give more detailed shape characteristics of the polygons
(Tucceryan, 1994). The m00 moment is used to identify concentrated density (compact
high-intensity) at a point, which can be interpreted as a centre of mass detector. The two
first order moments, m10 and m01 are used to identify image pixels at which the brightness
changes sharply or has a discontinuity, which can be interpreted as edge or contrast detectors,
respectively. The second order moment m11 is used to identify image pixels brightness
discontinuities at cross like junctions, which can be interpreted as a cross detector. Local
moments are inherently integral-based features, which can reduce the effect of uncorrelated
noise. The computation of local moments can be interpreted as a convolution of an image with
a set of masks (Tucceryan, 1994), this has been illustrated in Fig. 4. The x and y coordinates
of the centre of mass can be computed as x̄ = m10/m00 and ȳ = m01/m00 with respect to
the normalised coordinates. The central moments are computed for each pixel in the local
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Fig. 4. In both rows, from left to right: original input image, m10 moment image, m01 moment
image, and m11 moment image. The local window sizes used were 13 (top) and 63 (bottom).








(xm − x̄)p (yn − ȳ)q f (m, n). (2)
5.1.2 Deriving local image properties
Local image properties are derived from higher order moments (Awcock & Thomas, 1996; Eisa
et al., 2009), and determined as
• Variance Vxy (spreading) around the centre of mass with respect to the x-axis and y-axis











where Vx and Vy are the variances with respect to the x-axis and y-axis, respectively.
• Skewness (symmetry) around the centre of mass can be characterised by the normalised








Skewness values of S = 0, S < 0 and S > 0 can be interpreted as a Gaussian
(normal) distribution, flatter than a normal distribution, and more peaked than a normal
distribution, respectively.
• Kurtosis (peakedness) around the centre of mass can be computed from the normalised 4th




− 3 and Ky = μ04
(μ00Vy)2
− 3. (5)
Kurtosis values of K = 0, K < 0, K > 0 and K < −1.2 can be interpreted as a
Gaussian (normal) distribution, flatter than normal distribution, more peaked than normal
distribution, and bimodal (multi-modal) distribution, respectively.
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• The ratio of the longest to the shortest distance vectors from the centroid of the local
window to its boundaries is considered as a measure of elongation of the region and is
defined as
elongation =
(μ20 − μ02)2 + 4μ112
μ00
. (6)
• For elongated objects, the orientation θ (in degrees) of the major (‘long’) direction with










For each pixel, 12 attributes were obtained to form a feature vector (i.e. μ00, m10, m01, x̄, ȳ,
m11, elongation, θ, Sx, Sy, Kx, Ky) at four scales; this gives a total of 48 features to represent
each pixel.
5.1.3 Feature transformation
A nonlinear transformation, namely a hyperbolic tangent function (Caelli & Oguztoreli, 1987),





| tanh(σ(Mk(a, b)− Mk))|, (8)
where ωij is an L × L (L = 55) averaging window centred at location (i, j), finer textures
require a smaller window to detect smaller features, whereas coarser textures require a larger
window; the value σ = 0.01 controls the shape of the logistic function; and k = {1, 2, ..., 12}.
The parameter values were empirically determined to achieve optimal results, and no
significant effect on the results were caused by small variations. Fig. 5 shows example moment
images before and after transformation; before the nonlinear transformation, the extracted
feature images can be interpreted visually as line detection with different orientations and
scales. The enhanced feature images show increased differentiation on tissue specific areas.
This is expected to lead to more discriminative feature vectors.
5.1.4 Mammographic model generation
Once the transformed feature vectors were obtained, Tabár mammographic building blocks
can be modelled using K-means clustering (K = 10). A total of 40 cluster centres were
generated to represent nodular, linear, homogeneous and radiolucent tissue (10 for each of
the four tissue types). The number of cluster centres (K value) was determined empirically
based on the assumption that each mammographic building block contains at least 4 to 6
texture primitives according to their visual appearance covering different orientations and
scales. A smaller number of cluster centres can lead to less discriminative models; conversely,
too many cluster centres can lead to many similar models and redundancy. Visual assessment
of the segmentation of mammographic patches using the manual annotations (e.g. outlined
tissue specific areas) provided by the expert radiologist, was used to heuristically decide the
number of cluster centres. It should be noted that there is no rigorous way to determine
exactly how many texture primitives should be used for complex texture patterns as seen
in mammographic images. However, it is expected that the set of features describes all
mammographic anatomical aspects covering lines and regions at various scales.
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Fig. 5. Example moment images Mk and the corresponding transformed feature images Fk,
where k = 1, 2, ..., 12. The original linear structure patch is the same as in Fig. 4. The local
window W = 13.
5.1.5 Model driven segmentation
At the segmentation stage, for each pixel of a mammographic image, the same procedure
was applied to obtain transformed feature vectors. For each pixel, the resultant feature
vector was compared to the distribution of all the mammographic building block models. A
distance weighted K-Nearest-Neighbour (KNN) classifier (K = 9) was used, to assign a Tabár
mammographic building block class to each pixel, which weighted the contribution of each
of the K nearest neighbours with the Mahalanobis distance (Mahalanobis, 1936) to the query
point, giving greater weight to closer neighbours to reduce misclassification. The K value was
determined empirically, but variation in these parameter indicated robustness.
It is indicated in the computer vision literature that a low intensity background (e.g. low or
zero grey level values) can lead to meaningless moments (Tucceryan, 1994). When performing
texture analysis in mammographic images, this can happen when extracting features of
homogeneous regions have high intensity background, and can cause misclassification
between high density homogeneous tissue and low density radiolucent tissue. The intensity
of homogeneous and radiolucent areas may vary between different mammographic risk
patterns; and image normalisation can alter the intensity distribution. To tackle the
problem of misclassification due to meaningless moments between high intensity tissues
(e.g. homogeneous and nodular) and low intensity tissues (e.g. radiolucent), a threshold
post-processing is incorporated into the classifier to reduce classification errors. This involves
reclassifying tissue that is initially classified as radiolucent, but has a very high intensity,
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Fig. 5. Example moment images Mk and the corresponding transformed feature images Fk,
where k = 1, 2, ..., 12. The original linear structure patch is the same as in Fig. 4. The local
window W = 13.
5.1.5 Model driven segmentation
At the segmentation stage, for each pixel of a mammographic image, the same procedure
was applied to obtain transformed feature vectors. For each pixel, the resultant feature
vector was compared to the distribution of all the mammographic building block models. A
distance weighted K-Nearest-Neighbour (KNN) classifier (K = 9) was used, to assign a Tabár
mammographic building block class to each pixel, which weighted the contribution of each
of the K nearest neighbours with the Mahalanobis distance (Mahalanobis, 1936) to the query
point, giving greater weight to closer neighbours to reduce misclassification. The K value was
determined empirically, but variation in these parameter indicated robustness.
It is indicated in the computer vision literature that a low intensity background (e.g. low or
zero grey level values) can lead to meaningless moments (Tucceryan, 1994). When performing
texture analysis in mammographic images, this can happen when extracting features of
homogeneous regions have high intensity background, and can cause misclassification
between high density homogeneous tissue and low density radiolucent tissue. The intensity
of homogeneous and radiolucent areas may vary between different mammographic risk
patterns; and image normalisation can alter the intensity distribution. To tackle the
problem of misclassification due to meaningless moments between high intensity tissues
(e.g. homogeneous and nodular) and low intensity tissues (e.g. radiolucent), a threshold
post-processing is incorporated into the classifier to reduce classification errors. This involves
reclassifying tissue that is initially classified as radiolucent, but has a very high intensity,
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to homogeneous or nodular tissue. The threshold values were determined based on prior
knowledge of the intensity distribution and variation of mammographic images across the
whole MIAS database, and were defined as the mean values of homogenous and nodular
tissues from the collection of annotated mammographic patches. It should be noted that
in practice, mammographic images may be obtained through different image acquisition
processes. Therefore, for an alternative database, the threshold values may need to be
re-evaluated using training images obtained from a specific image acquisition process.
5.2 Texture signatures based approach
Mammographic segmentation using texture signatures based methodology was developed in
an attempt to incorporate spatial (e.g. textons based techniques) and geometric (e.g. moments
based techniques) texture features.
For each pixel, a texture signature is generated, consisting of three distinct signatures. Each
signature of size L × L was computed within a local window C, to encode different texture
features. To ensure computational correctness, it is necessary to use a circular window instead
of a more conventional square window to compute local image features. This is because
the proposed methodology uses the distance between a pixel and the centre pixel within the
sampling window C as a parameter. The upper limit of the parameter is defined as the value
of the max distance between these two points, and the radial distance for any point on a circle
to the centre has the same max value. A series of investigations was conducted on parameter
settings; covering the full range of anatomical objects. Fourier analysis was used to estimate
the first side-band (Gonzales & Woods, 1992) which indicated a circular window of 63 pixels
in diameter for feature extraction. Whilst, texture signature size was empirically defined in a
dimension of 25 × 25 pixels, which is expected to be able to encode sufficient mammographic
features. A significant amount of randomly sampled points (≥ 60,000) from 78 patches (e.g.
16 nodular, 22 linear structure, 23 homogeneous and 17 radiolucent) were used at the training
stage, regardless of the associated risk class for the original mammogram.
A texture signature is effectively a stack of three 2D histograms, encoding directional texture
features (e.g. intensity, orientation and elongation variation).
5.2.1 Texture signature - Part I
The first part of a texture signature consists of a cumulative histogram based on the radial
distance between the centre pixel and grey-level intensity within the circular window C.
The signature’s y-axis represents the grey-level intensity, and the x-axis represents the radial
distance to the centre pixel. The occurrence values at any {x, y} position within the signature
are multiplied with the relevant grey-level value. In the grey-level spatial distribution space,
the first part of the texture signature represents the roughness of a given circular texture
region. The signature configuration varies rapidly with distance in coarse textures (e.g.
nodular tissues in Fig. 6 A(a)), and steady with distance in fine textures (e.g. homogeneous
tissues in Fig. 6 C(a)); the accumulated grey-level close to the top of the signature indicates
dominance of low intensity pixel presence (e.g. radiolucent fatty tissues in Fig. 6 D(a)), whilst
the accumulated grey-level close to the bottom of the signature indicates dominance of high
intensity pixel presence (e.g. homogeneous tissues in Fig. 6 C(a)).
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5.2.2 Texture signature - Part II
The second part of a texture signature is a cumulative histogram based on the angle between
the tangent at each segment and grey-level intensity within the circular window C. The angle
θ = 0 ◦ is defined when a pixel lies on the positive side of the y-axis of the circular window C,
and increases counterclockwise. The signature’s y-axis represents the grey-level intensity, and
the x-axis represents the tangent at segment within the circular window C. The occurrence
values at any {x, y} position within the signature are multiplied with the relevant grey-level
value. The accumulated grey-level values change with the orientation of the linear structures.
Visually speaking, texture signature containing many rough peaks indicate the presence of
lines (e.g. linear structure in Fig. 6 B(b)). A thick band with spreading tendency appearing
in the texture signature indicates the presence of nodular tissues (e.g. Fig. 6 A(b)). Note
that the linear structure patches may contain noise, and have very low contrast between
the foreground and background. These issues make it difficult to extract the related linear
structure features. However, the spikes as seen in the corresponding signatures indicate the
presence of linear structures and their approximate orientations.
5.2.3 Texture signature - Part III
A texture image may contain repeated occurrence of some grey-level configurations, which
vary rapidly in fine textures, and slowly in coarse textures (Haralick et al., 1973). These
changes can be encoded in co-occurrence matrices. A co-occurrence matrix is constructed
by describing how frequently two pixels, separated by a distance d, with grey-level x1
and x2 appear. The occurrence of a grey-level configuration may be described by matrices
of relative frequencies. The third part of a texture signature is a modified co-occurrence
matrix with d = 1 and θ = 90 ◦. In this case, the x and y-axes of the signature represent
grey-level information. Note that other configurations are possible, but the experimental
results indicated variations in these are not significant. Given a pair of values for the x and
y-axis, the absolute value of the intensity difference between two pixels is accumulated, and
used as the corresponding histogram value. The statistical variations such as the frequency
of some grey-level configurations, and the magnitude of the variance of the configurations,
can be used to discriminate breast components with different texture properties (e.g. Fig. 6
A(c)-D(c)).
5.2.4 Texture signature - combined (I + II + III)
Finally, all the values in the signature were normalised to zero mean and unit variance. The x
and y-axes were normalised to L, to ensure the constructed texture signature has a consistent
size of L × L for the three parts. Fig. 6 shows normalised individual signatures, and the
resulting combined texture signatures.
5.2.5 Model generation, selection and reduction
Texture signatures generated from the mammographic patches vary due to mammographic
images taken under various exposure conditions, linear structures at different orientations,
and stochastic parenchymal patterns in nodular tissue. K-means clustering was used to
establish initial models based on the assumption that similar models are closely clustered
in the feature space, and can be combined through a clustering process. Initially, 30
cluster centres were empirically defined for each mammographic building block. Note
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to homogeneous or nodular tissue. The threshold values were determined based on prior
knowledge of the intensity distribution and variation of mammographic images across the
whole MIAS database, and were defined as the mean values of homogenous and nodular
tissues from the collection of annotated mammographic patches. It should be noted that
in practice, mammographic images may be obtained through different image acquisition
processes. Therefore, for an alternative database, the threshold values may need to be
re-evaluated using training images obtained from a specific image acquisition process.
5.2 Texture signatures based approach
Mammographic segmentation using texture signatures based methodology was developed in
an attempt to incorporate spatial (e.g. textons based techniques) and geometric (e.g. moments
based techniques) texture features.
For each pixel, a texture signature is generated, consisting of three distinct signatures. Each
signature of size L × L was computed within a local window C, to encode different texture
features. To ensure computational correctness, it is necessary to use a circular window instead
of a more conventional square window to compute local image features. This is because
the proposed methodology uses the distance between a pixel and the centre pixel within the
sampling window C as a parameter. The upper limit of the parameter is defined as the value
of the max distance between these two points, and the radial distance for any point on a circle
to the centre has the same max value. A series of investigations was conducted on parameter
settings; covering the full range of anatomical objects. Fourier analysis was used to estimate
the first side-band (Gonzales & Woods, 1992) which indicated a circular window of 63 pixels
in diameter for feature extraction. Whilst, texture signature size was empirically defined in a
dimension of 25 × 25 pixels, which is expected to be able to encode sufficient mammographic
features. A significant amount of randomly sampled points (≥ 60,000) from 78 patches (e.g.
16 nodular, 22 linear structure, 23 homogeneous and 17 radiolucent) were used at the training
stage, regardless of the associated risk class for the original mammogram.
A texture signature is effectively a stack of three 2D histograms, encoding directional texture
features (e.g. intensity, orientation and elongation variation).
5.2.1 Texture signature - Part I
The first part of a texture signature consists of a cumulative histogram based on the radial
distance between the centre pixel and grey-level intensity within the circular window C.
The signature’s y-axis represents the grey-level intensity, and the x-axis represents the radial
distance to the centre pixel. The occurrence values at any {x, y} position within the signature
are multiplied with the relevant grey-level value. In the grey-level spatial distribution space,
the first part of the texture signature represents the roughness of a given circular texture
region. The signature configuration varies rapidly with distance in coarse textures (e.g.
nodular tissues in Fig. 6 A(a)), and steady with distance in fine textures (e.g. homogeneous
tissues in Fig. 6 C(a)); the accumulated grey-level close to the top of the signature indicates
dominance of low intensity pixel presence (e.g. radiolucent fatty tissues in Fig. 6 D(a)), whilst
the accumulated grey-level close to the bottom of the signature indicates dominance of high
intensity pixel presence (e.g. homogeneous tissues in Fig. 6 C(a)).
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5.2.2 Texture signature - Part II
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values at any {x, y} position within the signature are multiplied with the relevant grey-level
value. The accumulated grey-level values change with the orientation of the linear structures.
Visually speaking, texture signature containing many rough peaks indicate the presence of
lines (e.g. linear structure in Fig. 6 B(b)). A thick band with spreading tendency appearing
in the texture signature indicates the presence of nodular tissues (e.g. Fig. 6 A(b)). Note
that the linear structure patches may contain noise, and have very low contrast between
the foreground and background. These issues make it difficult to extract the related linear
structure features. However, the spikes as seen in the corresponding signatures indicate the
presence of linear structures and their approximate orientations.
5.2.3 Texture signature - Part III
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vary rapidly in fine textures, and slowly in coarse textures (Haralick et al., 1973). These
changes can be encoded in co-occurrence matrices. A co-occurrence matrix is constructed
by describing how frequently two pixels, separated by a distance d, with grey-level x1
and x2 appear. The occurrence of a grey-level configuration may be described by matrices
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results indicated variations in these are not significant. Given a pair of values for the x and
y-axis, the absolute value of the intensity difference between two pixels is accumulated, and
used as the corresponding histogram value. The statistical variations such as the frequency
of some grey-level configurations, and the magnitude of the variance of the configurations,
can be used to discriminate breast components with different texture properties (e.g. Fig. 6
A(c)-D(c)).
5.2.4 Texture signature - combined (I + II + III)
Finally, all the values in the signature were normalised to zero mean and unit variance. The x
and y-axes were normalised to L, to ensure the constructed texture signature has a consistent
size of L × L for the three parts. Fig. 6 shows normalised individual signatures, and the
resulting combined texture signatures.
5.2.5 Model generation, selection and reduction
Texture signatures generated from the mammographic patches vary due to mammographic
images taken under various exposure conditions, linear structures at different orientations,
and stochastic parenchymal patterns in nodular tissue. K-means clustering was used to
establish initial models based on the assumption that similar models are closely clustered
in the feature space, and can be combined through a clustering process. Initially, 30
cluster centres were empirically defined for each mammographic building block. Note
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Fig. 6. From top to bottom showing mammographic patches containing nodular, linear
structure, homogeneous and radiolucent tissue, respectively. For each row, from left to right
showing an mammographic patch, three individual signatures, and the texture signature.
that to predetermine the appropriate number of cluster centres may prove challenging for
complicated breast anatomic components. Therefore, the initial number of cluster centres was
over-estimated deliberately to facilitate further model selection and reduction. This model
generation by clustering resulted in a total of 120 (30 × 4) cluster centres to represent four
types of mammographic building blocks. For each mammographic building block model
Mi (i ∈ 1, 2, ...120), a cross voting process was employed to achieve the optimal model
subsets, by determining whether it is the nearest neighbour (in a Euclidean sense) of the
other models of the same type of mammographic building block. For instance, if model Mi
receives votes from a subset of models Ms, it can be interpreted as to be representative of
the mammographic building block. Models receiving no or few votes may be outliers, and
are removed. The outlier bounds (threshold values) were determined empirically through a
series of tests on mammographic patch segmentation. The threshold values for nodular and
homogeneous tissue models, were defined as half of the largest standard deviation values of
the corresponding models; whereas for linear and radiolucent tissue models, the threshold
values were defined as half of the smallest standard deviation values of the corresponding
models. As a result, a total of 42 models (i.e. 12 for nodular tissue, 15 for linear tissue, 8 for
homogeneous tissue, and 7 for radiolucent tissue) were selected from the initial 120 models.
5.2.6 Model driven segmentation
At the segmentation stage, the same procedure was used to generate a texture signature at
each pixel. The resultant texture signatures were compared to the 42 selected mammographic
building block models. A distance weighted K-Nearest-Neighbour (KNN) classification (K =
3) was used in the Euclidean space, to assign a mammographic building block to each pixel,
which weighted the contribution of each of the K nearest neighbours with the distance to
the query point, giving greater weight to closer neighbours to reduce misclassification. The
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K value was determined empirically, but variation in this parameter indicated robustness,
in terms of the number of correctly classified pixels and visual correctness of the segmented
tissue specific areas.
6. Evaluation
A comparative evaluation of two mammographic segmentation methods was conducted;
evaluation aspects include: 1) mammographic segmentation using the MIAS database, 2)
quantitative and qualitatively measurement on the derived tissue compositions from the
segmented images, 3) mammographic risk classification based on the tissue compositions,
and 4) clinical evaluation of the segmentation to assess the realistic and practical use of the
proposed methodologies in a clinical environment.
Customised software was developed for evaluation, to determine the effectiveness
of the segmentation methodologies and the potential clinical utilisation for screening
mammography or computer aided diagnosis systems. An expert consultant radiologist
performed the evaluation by grading a given mammographic segmentation from five
available options (i.e. unacceptable, poor, acceptable, good and very good). In addition, the grades
can be combined and referred to as principal grades; the first two grades were considered
as clinically unacceptable (CUA), the remaining three were considered as clinically acceptable
(CA)). The statistical results are presented as percentages with respect to the five grades and
principal grades, and associated with all Tabár and BIRADS risk classification, as well as the
corresponding low and high risk categories. Expert feedback was collected and incorporated
in the investigation, including the segmentation accuracy on the tissue specific areas, and
the misclassified breast tissues associated with the segmentation methodology issues. All the
clinical evaluation aspects were taken into account to conclude the relationship between the
risk classification and clinical practice satisfaction.
7. Results and discussion
This section compares the experimental results, and is arranged in line with the evaluation
stages described in Section 6. With respect to the mammographic risk classification, both
Tabár and BIRADS risk categories are included, in order to facilitate the classification accuracy
comparison achieved using existing work in the literature.
7.1 Mammographic segmentation
Mammographic segmentation was performed on the MIAS database using both the moments
and texture signatures based methods. Visually speaking, comparing the results achieved
using a filter bank based texton approach in (He et al., 2008), the segmentation results
produced by both the methods show significant improvements with respect to segmentation
on tissue specific areas (see Fig. 7 for examples). In terms of mammographic segmentation
accuracy, pectoral muscle and upper abdominal fat are often misclassified as nodular or
homogeneous fat within nodular tissues. With respect to segmentation produced using
the moments based method, dense areas are often misclassified as radiolucent tissue.
Misclassified tissues between nodular and homogeneous classes may be caused by under
exposed films. This indicated the lack of discriminative modelling between nodular and
homogeneous tissues, as well as between nodular and radiolucent tissues. The segmentation
results indicated that both the moments and texture signatures based methods are capable of
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Fig. 6. From top to bottom showing mammographic patches containing nodular, linear
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receives votes from a subset of models Ms, it can be interpreted as to be representative of
the mammographic building block. Models receiving no or few votes may be outliers, and
are removed. The outlier bounds (threshold values) were determined empirically through a
series of tests on mammographic patch segmentation. The threshold values for nodular and
homogeneous tissue models, were defined as half of the largest standard deviation values of
the corresponding models; whereas for linear and radiolucent tissue models, the threshold
values were defined as half of the smallest standard deviation values of the corresponding
models. As a result, a total of 42 models (i.e. 12 for nodular tissue, 15 for linear tissue, 8 for
homogeneous tissue, and 7 for radiolucent tissue) were selected from the initial 120 models.
5.2.6 Model driven segmentation
At the segmentation stage, the same procedure was used to generate a texture signature at
each pixel. The resultant texture signatures were compared to the 42 selected mammographic
building block models. A distance weighted K-Nearest-Neighbour (KNN) classification (K =
3) was used in the Euclidean space, to assign a mammographic building block to each pixel,
which weighted the contribution of each of the K nearest neighbours with the distance to
the query point, giving greater weight to closer neighbours to reduce misclassification. The
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K value was determined empirically, but variation in this parameter indicated robustness,
in terms of the number of correctly classified pixels and visual correctness of the segmented
tissue specific areas.
6. Evaluation
A comparative evaluation of two mammographic segmentation methods was conducted;
evaluation aspects include: 1) mammographic segmentation using the MIAS database, 2)
quantitative and qualitatively measurement on the derived tissue compositions from the
segmented images, 3) mammographic risk classification based on the tissue compositions,
and 4) clinical evaluation of the segmentation to assess the realistic and practical use of the
proposed methodologies in a clinical environment.
Customised software was developed for evaluation, to determine the effectiveness
of the segmentation methodologies and the potential clinical utilisation for screening
mammography or computer aided diagnosis systems. An expert consultant radiologist
performed the evaluation by grading a given mammographic segmentation from five
available options (i.e. unacceptable, poor, acceptable, good and very good). In addition, the grades
can be combined and referred to as principal grades; the first two grades were considered
as clinically unacceptable (CUA), the remaining three were considered as clinically acceptable
(CA)). The statistical results are presented as percentages with respect to the five grades and
principal grades, and associated with all Tabár and BIRADS risk classification, as well as the
corresponding low and high risk categories. Expert feedback was collected and incorporated
in the investigation, including the segmentation accuracy on the tissue specific areas, and
the misclassified breast tissues associated with the segmentation methodology issues. All the
clinical evaluation aspects were taken into account to conclude the relationship between the
risk classification and clinical practice satisfaction.
7. Results and discussion
This section compares the experimental results, and is arranged in line with the evaluation
stages described in Section 6. With respect to the mammographic risk classification, both
Tabár and BIRADS risk categories are included, in order to facilitate the classification accuracy
comparison achieved using existing work in the literature.
7.1 Mammographic segmentation
Mammographic segmentation was performed on the MIAS database using both the moments
and texture signatures based methods. Visually speaking, comparing the results achieved
using a filter bank based texton approach in (He et al., 2008), the segmentation results
produced by both the methods show significant improvements with respect to segmentation
on tissue specific areas (see Fig. 7 for examples). In terms of mammographic segmentation
accuracy, pectoral muscle and upper abdominal fat are often misclassified as nodular or
homogeneous fat within nodular tissues. With respect to segmentation produced using
the moments based method, dense areas are often misclassified as radiolucent tissue.
Misclassified tissues between nodular and homogeneous classes may be caused by under
exposed films. This indicated the lack of discriminative modelling between nodular and
homogeneous tissues, as well as between nodular and radiolucent tissues. The segmentation
results indicated that both the moments and texture signatures based methods are capable of
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Fig. 7. Example mammographic segmentation. Tabár risk pattern IV; BIRADS risk pattern III.
This shows the original mammographic image (left) and the segmentation produced using
the moments (middle) and texture signatures (right) based methodologies. The tissue specific
areas are: nodular (red), linear (green), homogeneous (blue) and radiolucent (yellow). Note
that nodular tissue was over-segmented when using the moments based method.
incorporating shape related texture features during the Tabár tissue modelling. Although the
segmentation seems to be less accurate on extremely larger tissue structures. This is due to
the use of sampling windows at the feature extraction stage, as the encompassed region for
a local window may not be sufficiently large to capture these structures. However, using a
larger window can compromise computational efficiency.
With respect to the moments based approach, some of the misclassified pixels within low
contrast regions (e.g. radiolucent tissue) may be caused by meaningless moments. High
intensity homogeneous density regions (e.g. homogeneous tissue) can lead to a similar
problem. This indicates that the currently used texture features may miss out some
discriminative intensity information. It seems necessary to have an approach designed
specifically for dealing with intensity variation as seen on digitised mammograms; the zero
mean normalisation method used may be too generalised, and can have a direct effect on
the model generation. A threshold based post-processing step was used to reduce the false
positives using prior knowledge. This process is effective but may require tuning for an
alternative database (e.g. DDSM (Heath et al., 1998)), because the mammographic image
intensity distribution can be affected, due to a different image acquisition process.
7.2 Tissue composition
Table 1 shows the average tissue compositions (the relative proportions of the four
mammographic building blocks) achieved, based on the developed segmentation approaches.
The differences between the achieved and proposed tissue compositions (see Section 2.2)
were measured by the Euclidean distance (ED). The smaller the distance, the more similar
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Nodular Linear Homogeneous Radiolucent ED
Tabár pattern I
Tabár et al. (Tabár et al., 2004) 25 15 35 25
Moment 27±18 15±5 26±17 32±21 11.6
Texture Signature 19±5.8 14±5.3 26±15.6 41±16.3 19.3
Tabár pattern II/III
Tabár et al. (Tabár et al., 2004) 2 14 2 82
Moment 14±10 9±4 21±20 56±23 34.7
Texture Signature 10±9.4 12±4.2 10±18.8 68±21.6 18.1
Tabár pattern IV
Tabár et al. (Tabár et al., 2004) 49 19 15 17
Moment 38±19 12±5 26±15 24±14 18.4
Texture Signature 44±11.7 11±4.3 13±11.5 32±12.4 17.8
Tabár pattern V
Tabár et al. (Tabár et al., 2004) 2 2 89 7
Moment 12±18 4±4 67±27 17±13 26.2
Texture Signature 11±3.3 7 ±4.4 64±11.0 18±10.9 29.2
Table 1. The relative proportions of the four mammographic building blocks and their
standard deviations, obtained using the developed mammographic segmentation
approaches. The Euclidean distances between the achieved and the tissue compositions
proposed by Tabár are shown in the column ‘ED’.
the achieved and proposed tissue composition, which also reflects the effectiveness of the
developed mammographic segmentation approaches. The ED results indicated that the
agreement between the proposed tissue compositions are closer to those achieved using the
texture signatures based approach, compared to the moments based approach. The average
values of the summations of the variances for the risk patterns for the moments and texture
signatures based approach are 90.9 and 84.4, respectively. The smaller average total variance
can be linked to the satisfactory classification accuracies achieved using texture signatures
based mammographic segmentation (see Sections 7.3 and 7.4).
The resultant tissue composition from each segmented mammographic image was used as
a feature vector for the risk classification. With respect to Tabár based risk classification,
the feature vectors were compared with Tabár models (risk patterns) and using a
Euclidean distance. Whilst BIRADS based risk classification was performed using leave-one
(mammographic image)-out methodology. The ground truth was provided by an expert
radiologist.
7.3 Risk classification - Tabár’s risk categories
In the computer vision literature, very few investigations were conducted with respect to
mammographic risk classification based on Tabár’s risk categories. These classification results
are summarised and compared in Table 3. Details of risk classification confusion matrices
are shown in Table 2. A direct comparison with existing mammographic risk assessment
methods is not always possible due to differences in databases choice. Jamal et al. (Jamal et al.,
2006) used 122 mammograms, 30, 21, 20, 27 and 24 for patterns I to IV, respectively. It should
be noted that the used dataset is much smaller than the MIAS database and not publicly
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Fig. 7. Example mammographic segmentation. Tabár risk pattern IV; BIRADS risk pattern III.
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that nodular tissue was over-segmented when using the moments based method.
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segmentation seems to be less accurate on extremely larger tissue structures. This is due to
the use of sampling windows at the feature extraction stage, as the encompassed region for
a local window may not be sufficiently large to capture these structures. However, using a
larger window can compromise computational efficiency.
With respect to the moments based approach, some of the misclassified pixels within low
contrast regions (e.g. radiolucent tissue) may be caused by meaningless moments. High
intensity homogeneous density regions (e.g. homogeneous tissue) can lead to a similar
problem. This indicates that the currently used texture features may miss out some
discriminative intensity information. It seems necessary to have an approach designed
specifically for dealing with intensity variation as seen on digitised mammograms; the zero
mean normalisation method used may be too generalised, and can have a direct effect on
the model generation. A threshold based post-processing step was used to reduce the false
positives using prior knowledge. This process is effective but may require tuning for an
alternative database (e.g. DDSM (Heath et al., 1998)), because the mammographic image
intensity distribution can be affected, due to a different image acquisition process.
7.2 Tissue composition
Table 1 shows the average tissue compositions (the relative proportions of the four
mammographic building blocks) achieved, based on the developed segmentation approaches.
The differences between the achieved and proposed tissue compositions (see Section 2.2)
were measured by the Euclidean distance (ED). The smaller the distance, the more similar
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Table 1. The relative proportions of the four mammographic building blocks and their
standard deviations, obtained using the developed mammographic segmentation
approaches. The Euclidean distances between the achieved and the tissue compositions
proposed by Tabár are shown in the column ‘ED’.
the achieved and proposed tissue composition, which also reflects the effectiveness of the
developed mammographic segmentation approaches. The ED results indicated that the
agreement between the proposed tissue compositions are closer to those achieved using the
texture signatures based approach, compared to the moments based approach. The average
values of the summations of the variances for the risk patterns for the moments and texture
signatures based approach are 90.9 and 84.4, respectively. The smaller average total variance
can be linked to the satisfactory classification accuracies achieved using texture signatures
based mammographic segmentation (see Sections 7.3 and 7.4).
The resultant tissue composition from each segmented mammographic image was used as
a feature vector for the risk classification. With respect to Tabár based risk classification,
the feature vectors were compared with Tabár models (risk patterns) and using a
Euclidean distance. Whilst BIRADS based risk classification was performed using leave-one
(mammographic image)-out methodology. The ground truth was provided by an expert
radiologist.
7.3 Risk classification - Tabár’s risk categories
In the computer vision literature, very few investigations were conducted with respect to
mammographic risk classification based on Tabár’s risk categories. These classification results
are summarised and compared in Table 3. Details of risk classification confusion matrices
are shown in Table 2. A direct comparison with existing mammographic risk assessment
methods is not always possible due to differences in databases choice. Jamal et al. (Jamal et al.,
2006) used 122 mammograms, 30, 21, 20, 27 and 24 for patterns I to IV, respectively. It should
be noted that the used dataset is much smaller than the MIAS database and not publicly
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Automatic




I 33 36 41 9 28%
II/III 14 66 5 8 71%
IV 22 6 50 2 63%
V 1 1 5 21 75%
Automatic




s I 102 16 1 0 86%
II/III 7 61 11 14 66%
IV 9 5 65 1 81%
V 1 4 0 23 82%
Table 2. Classification confusion matrices based on Tabár risk categories. With respect to the
moments based method (left), total accuracy was 53%, κ = 0.36 (fair agreement). Total
accuracy for low and high categories was 71%, κ = 0.40 (fair agreement). With respect to the
texture signatures (right) based method, total accuracy was 78%, κ = 0.7 (substantial
agreement). Total accuracy for low and high categories was 86%, κ = 0.69 (substantial
agreement).
Database I II/III IV V Total1 Low High Total2
Jamal (Jamal et al., 2006) 73 90 74 88 83
MIAS He_M (He et al., 2009) 28 71 63 75 53 70 72 71He_TS (He et al., 2010) 86 66 81 82 78 88 82 86
Table 3. Mammographic risk classification based on Tabár’s risk categories. He_M (He et al.,
2009) used the developed moments based approach. He_TS (He et al., 2010) used the
developed texture signatures based approach.
available. Therefore, the distribution over the inter and intra class variations are expected
to be different, which can effect the classification results. With respect to the classification
achieved using the developed methods, strong correlation was found between the precision of
mammographic segmentation and subsequent risk classification. The segmentation accuracy
is particular critical when performing risk classification based on Tabár tissue modelling,
because tissue compositions for the segmented images were used as feature vectors at the
risk classification stage. The results show overall good classification accuracies, except for
Tabár pattern I results achieved using the moments based approach. It should be noted that
the latter aspect can be linked to previous published results (Muhimmah et al., 2006), which
indicated that Tabár Patten I shows weak correlation between BIRADS and Tabár risk models.
7.4 Risk classification - BIRADS risk categories
The majority of the investigations with respect to mammographic risk classification are based
on BIRADS risk categories. The classification results are summarised and compared in Table
5. Details of risk classification confusion matrices are shown in Table 4. Note that Bovis et
al. (Bovis & Singh, 2002) used mammographic images for 377 patients from DDSM. Petroudi
et al. (Petroudi et al., 2003) used 132 images selected from the Oxford database (not publicly
available). A direct comparison with Oliver et al. (Oliver et al., 2008) is probably the closest
option. Oliver et al. (Oliver et al., 2008) shows divergence in the opinion of three expert
radiologists, and the inter observer variation is dealt with using the majority vote from the
three radiologists. In the experiment, the consensus classification was used and superior
classification was achieved. It should be noted that the inter observer variation seems to be
minimised by using the consensus classification. In (Oliver et al., 2008) the MIAS database
was used, and 82% correct classification was obtained based on ‘expert C’ (Oliver et al., 2008).
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Automatic




I 65 10 1 11 75%
II 0 71 21 11 69%
III 0 18 63 12 68%
IV 0 5 7 25 68%
Automatic




s I 41 5 10 3 70%
II 1 68 12 5 79%
III 0 11 101 29 71%
IV 0 0 5 29 85%
Table 4. Classification confusion matrices based on BIRADS risk categories. With respect to
the moments based method (left), total accuracy was 70%, κ = 0.59 (moderate agreement).
Total accuracy for low and high categories was 79%, κ = 0.58 (moderate agreement). With
respect to the texture signatures (right) based method, total accuracy was 75%, κ = 0.75
(substantial agreement). Total accuracy for low and high categories was 87%, κ = 0.74
(substantial agreement).
Database I II III IV Total1 Low High Total2
MIAS
Oliver(A) (Oliver et al., 2008) 80 60 67 46 66 79 77 79
Oliver(B) (Oliver et al., 2008) 89 75 69 59 75 92 77 85
Oliver(C) (Oliver et al., 2008) 91 84 89 73 86 89 94 91
He_M (He et al., 2009) 47 73 87 65 73 73 91 83
He_TS (He et al., 2010) 70 79 72 85 75 79 94 87
DDSM Oliver (Oliver et al., 2008) 55 88 77 69 77 89 79 84Bovis (Bovis & Singh, 2002) 71 97
Oxford Petroudi (Petroudi et al., 2003) 91 64 70 78 76 91 94
Table 5. Mammographic risk classification based on BIRADS risk categories and comparison
with existing work using: Oliver(A), the segmentation and feature extraction are described in
(Karssemeijer, 1998); Oliver(B), the segmentation approach is described in (Karssemeijer,
1998) and the feature extraction is used in (Oliver et al., 2008); Oliver(C), both the
segmentation and feature extraction are described in (Oliver et al., 2008). He_M (He et al.,
2009) used the developed moments based approach. He_TS (He et al., 2010) used the
developed texture signatures based approach.
It should be noted that the proposed mammographic segmentation is specifically designed
with respect to Tabár mammographic parenchymal patterns, and has fundamental differences
to density based segmentation described in (Oliver et al., 2008). In this study, BIRADS risk
classification was obtained to facilitate the classification performance evaluation when using
different risk models (i.e. Tabár and BIRADS), as using mammographic parenchymal patterns
rather than density information alone.
7.5 Clinical evaluation
The risk classification results (see Tables 2 and 4) show both Tabár and BIRADS related aspects,
and indicate that the results for the high risk mammograms are significantly better than
those for the low risk mammograms; also show a clear correlation between the Tabár and
BIRADS results, and is in line with previous published work (Muhimmah et al., 2006). Table
6 shows the segmentation assessment results with respect to the moments based approach, in
which for Tabár II/III and BIRADS I, at about 41%, are especially low. The other individual
235
Evaluation of Mammographic Segmentation
and Risk Classif atio  Based on Tabár Ti sue Modelling
18 Will-be-set-by-IN-TECH
Automatic




I 33 36 41 9 28%
II/III 14 66 5 8 71%
IV 22 6 50 2 63%
V 1 1 5 21 75%
Automatic




s I 102 16 1 0 86%
II/III 7 61 11 14 66%
IV 9 5 65 1 81%
V 1 4 0 23 82%
Table 2. Classification confusion matrices based on Tabár risk categories. With respect to the
moments based method (left), total accuracy was 53%, κ = 0.36 (fair agreement). Total
accuracy for low and high categories was 71%, κ = 0.40 (fair agreement). With respect to the
texture signatures (right) based method, total accuracy was 78%, κ = 0.7 (substantial
agreement). Total accuracy for low and high categories was 86%, κ = 0.69 (substantial
agreement).
Database I II/III IV V Total1 Low High Total2
Jamal (Jamal et al., 2006) 73 90 74 88 83
MIAS He_M (He et al., 2009) 28 71 63 75 53 70 72 71He_TS (He et al., 2010) 86 66 81 82 78 88 82 86
Table 3. Mammographic risk classification based on Tabár’s risk categories. He_M (He et al.,
2009) used the developed moments based approach. He_TS (He et al., 2010) used the
developed texture signatures based approach.
available. Therefore, the distribution over the inter and intra class variations are expected
to be different, which can effect the classification results. With respect to the classification
achieved using the developed methods, strong correlation was found between the precision of
mammographic segmentation and subsequent risk classification. The segmentation accuracy
is particular critical when performing risk classification based on Tabár tissue modelling,
because tissue compositions for the segmented images were used as feature vectors at the
risk classification stage. The results show overall good classification accuracies, except for
Tabár pattern I results achieved using the moments based approach. It should be noted that
the latter aspect can be linked to previous published results (Muhimmah et al., 2006), which
indicated that Tabár Patten I shows weak correlation between BIRADS and Tabár risk models.
7.4 Risk classification - BIRADS risk categories
The majority of the investigations with respect to mammographic risk classification are based
on BIRADS risk categories. The classification results are summarised and compared in Table
5. Details of risk classification confusion matrices are shown in Table 4. Note that Bovis et
al. (Bovis & Singh, 2002) used mammographic images for 377 patients from DDSM. Petroudi
et al. (Petroudi et al., 2003) used 132 images selected from the Oxford database (not publicly
available). A direct comparison with Oliver et al. (Oliver et al., 2008) is probably the closest
option. Oliver et al. (Oliver et al., 2008) shows divergence in the opinion of three expert
radiologists, and the inter observer variation is dealt with using the majority vote from the
three radiologists. In the experiment, the consensus classification was used and superior
classification was achieved. It should be noted that the inter observer variation seems to be
minimised by using the consensus classification. In (Oliver et al., 2008) the MIAS database
was used, and 82% correct classification was obtained based on ‘expert C’ (Oliver et al., 2008).
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I 65 10 1 11 75%
II 0 71 21 11 69%
III 0 18 63 12 68%
IV 0 5 7 25 68%
Automatic




s I 41 5 10 3 70%
II 1 68 12 5 79%
III 0 11 101 29 71%
IV 0 0 5 29 85%
Table 4. Classification confusion matrices based on BIRADS risk categories. With respect to
the moments based method (left), total accuracy was 70%, κ = 0.59 (moderate agreement).
Total accuracy for low and high categories was 79%, κ = 0.58 (moderate agreement). With
respect to the texture signatures (right) based method, total accuracy was 75%, κ = 0.75
(substantial agreement). Total accuracy for low and high categories was 87%, κ = 0.74
(substantial agreement).
Database I II III IV Total1 Low High Total2
MIAS
Oliver(A) (Oliver et al., 2008) 80 60 67 46 66 79 77 79
Oliver(B) (Oliver et al., 2008) 89 75 69 59 75 92 77 85
Oliver(C) (Oliver et al., 2008) 91 84 89 73 86 89 94 91
He_M (He et al., 2009) 47 73 87 65 73 73 91 83
He_TS (He et al., 2010) 70 79 72 85 75 79 94 87
DDSM Oliver (Oliver et al., 2008) 55 88 77 69 77 89 79 84Bovis (Bovis & Singh, 2002) 71 97
Oxford Petroudi (Petroudi et al., 2003) 91 64 70 78 76 91 94
Table 5. Mammographic risk classification based on BIRADS risk categories and comparison
with existing work using: Oliver(A), the segmentation and feature extraction are described in
(Karssemeijer, 1998); Oliver(B), the segmentation approach is described in (Karssemeijer,
1998) and the feature extraction is used in (Oliver et al., 2008); Oliver(C), both the
segmentation and feature extraction are described in (Oliver et al., 2008). He_M (He et al.,
2009) used the developed moments based approach. He_TS (He et al., 2010) used the
developed texture signatures based approach.
It should be noted that the proposed mammographic segmentation is specifically designed
with respect to Tabár mammographic parenchymal patterns, and has fundamental differences
to density based segmentation described in (Oliver et al., 2008). In this study, BIRADS risk
classification was obtained to facilitate the classification performance evaluation when using
different risk models (i.e. Tabár and BIRADS), as using mammographic parenchymal patterns
rather than density information alone.
7.5 Clinical evaluation
The risk classification results (see Tables 2 and 4) show both Tabár and BIRADS related aspects,
and indicate that the results for the high risk mammograms are significantly better than
those for the low risk mammograms; also show a clear correlation between the Tabár and
BIRADS results, and is in line with previous published work (Muhimmah et al., 2006). Table
6 shows the segmentation assessment results with respect to the moments based approach, in
which for Tabár II/III and BIRADS I, at about 41%, are especially low. The other individual
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classes are encouraging, with the Tabár V and BIRADS IV classes reaching 100% clinical
acceptable results (note that the number of samples for Tabár V or BIRADS IV are small).
The segmentation assessment results based on all the images in both Tabár and BIRADS
risk categories indicate the robustness of the segmentation methodology, as both achieved
70% clinical acceptable results. Further details of the segmentation assessment results can be
found in Table 7, where the classification results were correlated from the risk classification
confusion matrices (see Tables 2 (left) and 4 (left)) and Table 6. Table 7 shows the number of
cases which were correctly classified (e.g. all the cases on the diagonal of a confusion matrix) in
the original mammographic risk assessment experiment against the clinical evaluation of the
segmentation results. The results for mammographic risk assessment that were misclassified
by a single, two and three classes (e.g. +/- 1 to II would be I and III) are also included (it
should be noted that the misclassification by three classes only happens with a few cases).
The same clinical satisfaction study was conducted with respect to the results obtained using
the texture signatures based approach. Table 8 shows the segmentation assessment results,
which for Tabár I, at 42% is especially low; however, the clinical acceptable rate increases as
the risk level gets higher which is particularly encouraging, with the Tabár V class reaching
over 96% clinical acceptable results. For BIRADS risk classes I-III, the clinical acceptable rate
for segmentation is about 55%; and 92% clinical acceptable rate is achieved for BIRADS risk
class IV. It should be noted that the number of samples for Tabár V or BIRADS IV are small.
These aspects are also clear for the low/high risk results, which show a relative better clinical
acceptable result for high risk categories, where the high risk results based on Tabár risk
modelling are promising as over 76% are considered clinically acceptable results. Further
details of the segmentation assessment results can be found in Table 9, where the classification
results from the risk classification confusion matrices (see Tables 2 (right) and 4 (right)) and
Table 8 are correlated. Table 9 shows the number of cases which were correctly classified (e.g.
all the cases on the diagonal of a confusion matrix) in the mammographic risk assessment
experiments against the clinical evaluation of the segmentation results.
The results in Tables 7 and 9 show strong correlations between the level of correctness of
the mammographic risk classification and clinical evaluation of the segmentation results:
i.e. correct mammographic risk classification is associated with the good and very good
segmentation results, whilst misclassification by two and three classes is mainly associated
with the poor and unacceptable segmentation results. This is especially true for the BIRADS
based results, where the (almost) correctly classified images each have a clinical acceptable
segmentation, as opposed to only a few cases that are in the clinical acceptable segmentation
category for the images associated with significant misclassification for mammographic risk
assessment.
The decreasing accuracies in all the individual low risk classes indicates the precision of
the segmentation are not all up to the clinical standard. From a clinical point of view,
a mathematically correct risk classification (possibly due to a robust classifier), does not
necessarily reflect the correctness of the associated segmentation. Even though, the clinical
evaluation still show strong positive correlations with the automatic risk classification. It
is interesting to see the accuracies increased in the individual high risk classes. This
seems to indicate an apparent difference between the way in which radiologists perceive
mammographic risk and how the segmentation performs, with especially the segmentation
of radiolucent tissues maybe less robust. However, in associating the correct classification
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Tabár images U P A G VG CA
I 119 8% 11% 14% 29% 37% 81 %
II/III 93 32% 24% 8% 9% 28% 44 %
IV 80 5% 20% 14% 20% 41% 75 %
V 28 0% 0% 4% 43% 54% 100 %
Low 212 19% 17% 11% 20% 33% 65 %
High 108 4% 15% 11% 26% 44% 81 %
BIRADS images U P A G VG CA
I 59 35% 24% 11% 8% 22% 41 %
II 86 20% 20% 9% 19% 32% 60 %
III 141 4% 14% 15% 26% 41% 82 %
IV 34 0% 0% 3% 38% 59% 100 %
Low 145 26% 22% 10% 14% 28% 52 %
High 175 3% 12% 13% 29% 43% 85 %
Table 6. Clinical grading of satisfaction regarding the mammographic segmentation using
the moments approach. ‘U’, ‘P’, ‘A’, ‘G’ and ‘VG’ denote unacceptable, poor, acceptable, good
and very good, respectively.
Tabár images U P A G VG CA
correct 251 8% 17% 13% 25% 37% 75%
+/- 1 40 28% 20% 3% 5% 45% 53%
+/- 2 28 46% 4% 7% 18% 25% 50%
+/- 3 1 0% 0% 0% 100% 0% 100%
(LH) correct 275 9% 16% 12% 24% 39% 75%
(LH) incorrect 45 42% 13% 4% 13% 27% 44%
BIRADS images U P A G VG CA
correct 239 9% 18% 10% 23% 40% 73%
+/- 1 63 14% 8% 16% 25% 37% 78%
+/- 2 15 80% 13% 7% 0% 0% 7%
+/- 3 3 33% 67% 0% 0% 0% 0%
(LH) correct 279 9% 16% 12% 24% 38% 75%
(LH) incorrect 41 46% 12% 5% 10% 27% 41%
Table 7. Clinical grading of satisfaction regarding the mammographic segmentation using
the moments approach, associated with the level of the automatic mammographic risk
classification. ‘LH’ denotes low and high risk.
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classes are encouraging, with the Tabár V and BIRADS IV classes reaching 100% clinical
acceptable results (note that the number of samples for Tabár V or BIRADS IV are small).
The segmentation assessment results based on all the images in both Tabár and BIRADS
risk categories indicate the robustness of the segmentation methodology, as both achieved
70% clinical acceptable results. Further details of the segmentation assessment results can be
found in Table 7, where the classification results were correlated from the risk classification
confusion matrices (see Tables 2 (left) and 4 (left)) and Table 6. Table 7 shows the number of
cases which were correctly classified (e.g. all the cases on the diagonal of a confusion matrix) in
the original mammographic risk assessment experiment against the clinical evaluation of the
segmentation results. The results for mammographic risk assessment that were misclassified
by a single, two and three classes (e.g. +/- 1 to II would be I and III) are also included (it
should be noted that the misclassification by three classes only happens with a few cases).
The same clinical satisfaction study was conducted with respect to the results obtained using
the texture signatures based approach. Table 8 shows the segmentation assessment results,
which for Tabár I, at 42% is especially low; however, the clinical acceptable rate increases as
the risk level gets higher which is particularly encouraging, with the Tabár V class reaching
over 96% clinical acceptable results. For BIRADS risk classes I-III, the clinical acceptable rate
for segmentation is about 55%; and 92% clinical acceptable rate is achieved for BIRADS risk
class IV. It should be noted that the number of samples for Tabár V or BIRADS IV are small.
These aspects are also clear for the low/high risk results, which show a relative better clinical
acceptable result for high risk categories, where the high risk results based on Tabár risk
modelling are promising as over 76% are considered clinically acceptable results. Further
details of the segmentation assessment results can be found in Table 9, where the classification
results from the risk classification confusion matrices (see Tables 2 (right) and 4 (right)) and
Table 8 are correlated. Table 9 shows the number of cases which were correctly classified (e.g.
all the cases on the diagonal of a confusion matrix) in the mammographic risk assessment
experiments against the clinical evaluation of the segmentation results.
The results in Tables 7 and 9 show strong correlations between the level of correctness of
the mammographic risk classification and clinical evaluation of the segmentation results:
i.e. correct mammographic risk classification is associated with the good and very good
segmentation results, whilst misclassification by two and three classes is mainly associated
with the poor and unacceptable segmentation results. This is especially true for the BIRADS
based results, where the (almost) correctly classified images each have a clinical acceptable
segmentation, as opposed to only a few cases that are in the clinical acceptable segmentation
category for the images associated with significant misclassification for mammographic risk
assessment.
The decreasing accuracies in all the individual low risk classes indicates the precision of
the segmentation are not all up to the clinical standard. From a clinical point of view,
a mathematically correct risk classification (possibly due to a robust classifier), does not
necessarily reflect the correctness of the associated segmentation. Even though, the clinical
evaluation still show strong positive correlations with the automatic risk classification. It
is interesting to see the accuracies increased in the individual high risk classes. This
seems to indicate an apparent difference between the way in which radiologists perceive
mammographic risk and how the segmentation performs, with especially the segmentation
of radiolucent tissues maybe less robust. However, in associating the correct classification
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Tabár images U P A G VG CA
I 119 8% 11% 14% 29% 37% 81 %
II/III 93 32% 24% 8% 9% 28% 44 %
IV 80 5% 20% 14% 20% 41% 75 %
V 28 0% 0% 4% 43% 54% 100 %
Low 212 19% 17% 11% 20% 33% 65 %
High 108 4% 15% 11% 26% 44% 81 %
BIRADS images U P A G VG CA
I 59 35% 24% 11% 8% 22% 41 %
II 86 20% 20% 9% 19% 32% 60 %
III 141 4% 14% 15% 26% 41% 82 %
IV 34 0% 0% 3% 38% 59% 100 %
Low 145 26% 22% 10% 14% 28% 52 %
High 175 3% 12% 13% 29% 43% 85 %
Table 6. Clinical grading of satisfaction regarding the mammographic segmentation using
the moments approach. ‘U’, ‘P’, ‘A’, ‘G’ and ‘VG’ denote unacceptable, poor, acceptable, good
and very good, respectively.
Tabár images U P A G VG CA
correct 251 8% 17% 13% 25% 37% 75%
+/- 1 40 28% 20% 3% 5% 45% 53%
+/- 2 28 46% 4% 7% 18% 25% 50%
+/- 3 1 0% 0% 0% 100% 0% 100%
(LH) correct 275 9% 16% 12% 24% 39% 75%
(LH) incorrect 45 42% 13% 4% 13% 27% 44%
BIRADS images U P A G VG CA
correct 239 9% 18% 10% 23% 40% 73%
+/- 1 63 14% 8% 16% 25% 37% 78%
+/- 2 15 80% 13% 7% 0% 0% 7%
+/- 3 3 33% 67% 0% 0% 0% 0%
(LH) correct 279 9% 16% 12% 24% 38% 75%
(LH) incorrect 41 46% 12% 5% 10% 27% 41%
Table 7. Clinical grading of satisfaction regarding the mammographic segmentation using
the moments approach, associated with the level of the automatic mammographic risk
classification. ‘LH’ denotes low and high risk.
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Tabár imgs U P A G VG CA
I 119 31% 27% 16% 18% 8% 42 %
II/III 93 23% 19% 22% 22% 14% 58 %
IV 80 14% 17% 24% 25% 20% 69 %
V 28 4% 0% 14% 21% 61% 96 %
Low 212 27% 24% 19% 19% 11% 49 %
High 108 11% 13% 21% 24% 31% 76 %
BIRADS imgs U P A G VG CA
I 87 19% 24% 29% 25% 3% 57 %
II 103 28% 16% 20% 17% 19% 56 %
III 93 24% 24% 16% 21% 15% 52 %
IV 37 2% 6% 21% 21% 50% 92 %
Low 190 24% 19% 23% 22% 12% 57 %
High 130 20% 20% 17% 21% 22% 60 %
Table 8. Clinical grading of satisfaction regarding the mammographic segmentation using
the texture signatures approach. ‘U’, ‘P’, ‘A’, ‘G’ and ‘VG’ denote unacceptable, poor, acceptable,
good and very good, respectively.
Tabár imgs U P A G VG CA
correct 170 11% 21% 22% 24% 22% 68%
+/- 1 68 16% 13% 22% 29% 20% 71%
+/- 2 72 50% 21% 14% 8% 7% 29%
+/- 3 10 40% 40% 20% 0% 0% 20%
(LH) correct 227 11% 20% 22% 26% 21% 69%
(LH) incorrect 93 48% 20% 13% 10% 9% 32%
BIRADS imgs U P A G VG CA
correct 224 16% 16% 23% 25% 20% 68%
+/- 1 68 24% 32% 13% 15% 16% 44%
+/- 2 17 58% 24% 12% 0% 6% 18%
+/- 3 11 82% 9% 9% 0% 0% 9%
(LH) correct 253 15% 19% 22% 25% 19% 66%
(LH) incorrect 67 48% 25% 10% 7% 10% 27%
Table 9. Clinical grading of satisfaction regarding the mammographic segmentation using
the texture signatures approach, associated with the level of automatic mammographic risk
classification. ‘LH’ denotes low and high risk.
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of mammograms with the assessment of the segmentation results, Tables 7 and 9 indicated a
strong correlation between these. This might also indicate that the tissue modelling associated
with the segmentation process, does not cover the various tissue classes appropriately, and
there might be a strong non-linear component in the expert assessment (e.g. when the areas of
dense tissues are significant, the areas of linear and radiolucent tissues play a less important
role), which is not present in the tissue modelling approach. It is encouraging to see in Table
8 that the accuracies increased in high risk classes (i.e. Tabár V and BIRADS IV). It is also
interesting to notice small classification variation between BIRADS risk classes I, II and III.
This may indicate that the presented methodology is able to discriminate mammographic
parenchymal patterns well based on Tabár risk modelling, but less robust in extracting density
information (possible due to meaningless moments) based on BIRADS risk models.
The major concerns from the radiologist who participated in the clinical evaluation include: 1)
pectoral muscle and upper abdominal fat are often misclassified as nodular or homogeneous
fat within nodular tissues; 2) radiolucent areas are often misclassified as dense tissue; and
3) misclassification of tissue between nodular and homogeneous classes may be caused
by (apparently) under exposed films. Clinical feedback indicates some segmentation
methodology issues, such as the lack of discriminative modelling between nodular and
homogeneous tissues, as well as between nodular and radiolucent tissues. Intra and inter
observer variation is noticeable; however, it should be noted that the issue of experts’
subjective assignment of risk classification can be dealt with using multiple readers, and the
majority risk classifications can be considered as ‘final’, but full evaluation of these aspects is
seen as future work. For automatic mammographic risk assessment based on parenchymal
pattern segmentation, it is encouraging that applying advanced machine learning techniques
achieves an improved risk classification. At the same time, a follow up clinical evaluation
linking the risk classification and segmentation should be emphasised, to ensure a realistic
practical usage in a clinical environment.
8. Conclusions
It is possible to use computer vision techniques to estimate the mammographic risk based
on the composition of the four mammographic building blocks (i.e. nodular, linear,
homogeneous and radiolucent) described by Tabár. The presented results using the moments
and texture signatures based methodologies show realistic segmentation on tissue specific
areas, improved estimation of the relative proportions of the four building blocks when
compared to the results achieved using the textons based approach (He et al., 2008), and
leading to promising mammographic risk classification results. The presented clinical
evaluation, both quantitative and qualitative, confirms that the technical evaluation of
an automatic risk classification based on Tabár’s tissue modelling, may not reflect the
effectiveness of the methodology in a clinical setting. Even though, the clinical evaluation
still shows strong positive correlations with the automatic risk classification. In addition,
the segmentation assessment is linked to the correct/incorrect automatic mammographic
risk classification, which indicated that anatomically correct segmentation results tend to
lead to correct mammographic risk estimation. However, work towards a robust automatic
mammographic segmentation using Tabár’s tissue modelling is still on going; such an
application is expected to be useful as a means of aiding radiologists’ diagnosis and treatment
planning prior to biopsies.
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Tabár imgs U P A G VG CA
I 119 31% 27% 16% 18% 8% 42 %
II/III 93 23% 19% 22% 22% 14% 58 %
IV 80 14% 17% 24% 25% 20% 69 %
V 28 4% 0% 14% 21% 61% 96 %
Low 212 27% 24% 19% 19% 11% 49 %
High 108 11% 13% 21% 24% 31% 76 %
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I 87 19% 24% 29% 25% 3% 57 %
II 103 28% 16% 20% 17% 19% 56 %
III 93 24% 24% 16% 21% 15% 52 %
IV 37 2% 6% 21% 21% 50% 92 %
Low 190 24% 19% 23% 22% 12% 57 %
High 130 20% 20% 17% 21% 22% 60 %
Table 8. Clinical grading of satisfaction regarding the mammographic segmentation using
the texture signatures approach. ‘U’, ‘P’, ‘A’, ‘G’ and ‘VG’ denote unacceptable, poor, acceptable,
good and very good, respectively.
Tabár imgs U P A G VG CA
correct 170 11% 21% 22% 24% 22% 68%
+/- 1 68 16% 13% 22% 29% 20% 71%
+/- 2 72 50% 21% 14% 8% 7% 29%
+/- 3 10 40% 40% 20% 0% 0% 20%
(LH) correct 227 11% 20% 22% 26% 21% 69%
(LH) incorrect 93 48% 20% 13% 10% 9% 32%
BIRADS imgs U P A G VG CA
correct 224 16% 16% 23% 25% 20% 68%
+/- 1 68 24% 32% 13% 15% 16% 44%
+/- 2 17 58% 24% 12% 0% 6% 18%
+/- 3 11 82% 9% 9% 0% 0% 9%
(LH) correct 253 15% 19% 22% 25% 19% 66%
(LH) incorrect 67 48% 25% 10% 7% 10% 27%
Table 9. Clinical grading of satisfaction regarding the mammographic segmentation using
the texture signatures approach, associated with the level of automatic mammographic risk
classification. ‘LH’ denotes low and high risk.
38 Mammography – Recent Advances Evaluation of Mammographic Segmentation and Risk Classification Based on Tabár Tissue Modelling 23
of mammograms with the assessment of the segmentation results, Tables 7 and 9 indicated a
strong correlation between these. This might also indicate that the tissue modelling associated
with the segmentation process, does not cover the various tissue classes appropriately, and
there might be a strong non-linear component in the expert assessment (e.g. when the areas of
dense tissues are significant, the areas of linear and radiolucent tissues play a less important
role), which is not present in the tissue modelling approach. It is encouraging to see in Table
8 that the accuracies increased in high risk classes (i.e. Tabár V and BIRADS IV). It is also
interesting to notice small classification variation between BIRADS risk classes I, II and III.
This may indicate that the presented methodology is able to discriminate mammographic
parenchymal patterns well based on Tabár risk modelling, but less robust in extracting density
information (possible due to meaningless moments) based on BIRADS risk models.
The major concerns from the radiologist who participated in the clinical evaluation include: 1)
pectoral muscle and upper abdominal fat are often misclassified as nodular or homogeneous
fat within nodular tissues; 2) radiolucent areas are often misclassified as dense tissue; and
3) misclassification of tissue between nodular and homogeneous classes may be caused
by (apparently) under exposed films. Clinical feedback indicates some segmentation
methodology issues, such as the lack of discriminative modelling between nodular and
homogeneous tissues, as well as between nodular and radiolucent tissues. Intra and inter
observer variation is noticeable; however, it should be noted that the issue of experts’
subjective assignment of risk classification can be dealt with using multiple readers, and the
majority risk classifications can be considered as ‘final’, but full evaluation of these aspects is
seen as future work. For automatic mammographic risk assessment based on parenchymal
pattern segmentation, it is encouraging that applying advanced machine learning techniques
achieves an improved risk classification. At the same time, a follow up clinical evaluation
linking the risk classification and segmentation should be emphasised, to ensure a realistic
practical usage in a clinical environment.
8. Conclusions
It is possible to use computer vision techniques to estimate the mammographic risk based
on the composition of the four mammographic building blocks (i.e. nodular, linear,
homogeneous and radiolucent) described by Tabár. The presented results using the moments
and texture signatures based methodologies show realistic segmentation on tissue specific
areas, improved estimation of the relative proportions of the four building blocks when
compared to the results achieved using the textons based approach (He et al., 2008), and
leading to promising mammographic risk classification results. The presented clinical
evaluation, both quantitative and qualitative, confirms that the technical evaluation of
an automatic risk classification based on Tabár’s tissue modelling, may not reflect the
effectiveness of the methodology in a clinical setting. Even though, the clinical evaluation
still shows strong positive correlations with the automatic risk classification. In addition,
the segmentation assessment is linked to the correct/incorrect automatic mammographic
risk classification, which indicated that anatomically correct segmentation results tend to
lead to correct mammographic risk estimation. However, work towards a robust automatic
mammographic segmentation using Tabár’s tissue modelling is still on going; such an
application is expected to be useful as a means of aiding radiologists’ diagnosis and treatment
planning prior to biopsies.
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1. Introduction
The CAD (Computer-aided Diagnosis) systems have been experiencing an exponential
growth in the last decades. Since the mid-1980s of time consuming film digitization
on a limited number of cases to its present status on large FFDM (Full-Field Digital
Mammography) databases Giger et al. (2008). The current usage of CAD systems has brought
about the need for breast cancer detection and classification efficient mechanisms. The CAD
algorithm sensitivity and specificity are influenced directly by database characteristics such
as image size, lesion distribution, and location of the lesion, biopsy results, BI-RADS™
classification and consensus opinion Giger et al. (2008). The use of existing mammographic
databases such as DDSM (Digital Database for Screening Mammography) Heath et al.
(2001b) with female patients mainly from the Massachusetts General Hospital mammography
program with the statistics of 56.18% (whites), 30.34% (unknown races), 2.06% (asians), 4.12%
(blacks), 6.55% (spanish surnames), 0.75% (other races), to tune the CAD algorithms can
avoid time consuming and expensive achievement but on the other hand can bias the CAD
algorithm to a women population not reflected in the image database, therefore causing
a ripple effect in the results Heath et al. (2001a). In the current study, we developed
an unprecedented database, the MIDAS (Mammographic Image Database for Automated
Analysis) covering a sample of Brazilian women population - such sample is primarily based
on FFDM images and whereas the population are not divides by races but on the other hand
are formed by a Brazilian unique mixing of indian south american, africans and european
populations along with genetic informations. The initial database contains about 600 digital
mammograms including two images of each breast, associated patient information, masses,
architectural distortion, special cases, calcification, associated findings, breast composition,
BI-RADS™ categories and overall impression. The MIDAS mammogram images are obtained
from the Janice Lamas Radiology Clinic.
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1.1 The Janice Lamas Radiology Clinic
The Janice Lamas Radiology Clinic is a image diagnosis clinic founded in 1993 that performs
mammography exams for diagnosis and screening, general ultrasound exams, biopsies and
bone densitometry exams. The medical director is Janice Magalhães Lamas, M.D., PhD. and
her clinical interests include all aspects of breast imaging and intervention including digital
mammography with the use of CAD systems, breast ultrasound and dedicated breast MRI
(Magnetic Resonance Imaging). Dr. Janice’s expertise is requested regularly to speak at
brazilian meetings dedicated to radiology. In addition to her speaking engagements, she has
developing scientific research in breast cancer area and bone mineral density evaluation, and
she has published numerous articles on breast imaging. The clinic is also certified by the
Brazilian College of Radiology and Image Diagnosis.
1.2 The MIDAS approach
Unlike the others well established mammographic databases, the MIDAS database approach
includes all mammogram images covering a sample of Brazilian women population, patient
genome sequences data, open source image processing algorithms available, open access and
open collaborative environment. The unique characteristic of containing mammographic
imagens covering the Brazilian women population associated with the genomic
sequences is a brand new inovation that enhances the scientific research and discovery.
The MIDAS database also welcomes existing and new open source image processing
algorithms that allow the tests and validation on the mammographic images. All scientists
worldwide can participate in the MIDAS database with new algorithms and tools in a open
and collaborative environment.
1.3 Motivation
The lack of a genuine brazilian mammographic database and the collaborative and open use
and test of new CAD tools are the main motivation for MIDAS project. The MIDAS database
is an innovative database that integrates phenotypes - the mammograms and increasingly
their respective genotypes, according to patient biopsy and subsequent genome sequencing.
Complex studies for mapping the effect of distinct genes and their results in the mammogram
image pattern will enable the discovery of unknown cancer genes and help to understand
their pathways of behavior. The BI-RADS™ assessment for all mammograms is an additive
factor that enables better algorithm tunning.
2. Mammography screening
Screening to control chronic-degenerative diseases and diseases of neoplastic nature can be
defined as an examination on asymptomatic women, carried out with the intent of classifying
them as likely or unlikely to develop the disease Morrison (1992). The goal of screening is to
define women with preclinical disease as positive and women without preclinical disease as
negative. The result from the screening - positive or negative definition - reflects the efficacy
of the test in showing the signs of preclinical disease as well as correct interpretation of the
findings. An error, i.e. a positive definition for someone without preclinical disease, or a
negative definition for someone with the condition, can result from either low test efficacy or
incorrect interpretation Morrison (1992) Barratt et al. (2005). In a screening test, the matter that
is under investigation is the capability to correctly distinguish between diseased and healthy
individuals. Thus, to be certain that the disease is really present or absent, it is frequently
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the case that elaborate, expensive or risky tests, such as biopsies, surgical exploration or
autopsy, must be carried out Fletcher et al. (1996). Estimation of diagnostic test validity in
relation to a standard is certified by knowing the proportions of right diagnoses (true positives
and true negatives) and wrong ones (false positives and false negatives) Pereira (2000b).
In relation to mammography, the level of logic validity is based on consensus and expert
opinions Basset et al. (1994) Fletcher & Elmore (2005), and evaluations of accuracy are based
on histopathological examination of the suspected lesion. The ability of mammography to
define women with preclinical diseases as positive is referred to as its sensitivity. If measured,
it is around 78 to 85%. The specificity of the test is its ability to define as negative women
who do not have the disease. If measured, it should be greater than 90% Morrison (1992).
The sensitivity of the screening test is a determining factor for disease control programs and
the specificity directly influences the costs and feasibility of the screening program Morrison
(1992) Fletcher et al. (1996) Basset et al. (1994). All mammograms must be categorized as one
of the alternatives below Basset et al. (1994):
• True Positive: when cancer is diagnosed within a one-year period after a biopsy is
recommended.
• True Negative: when no cancer is diagnosed up to one year after a normal mammogram is
reported.
• False Positive: when no cancer is diagnosed within a one-year period after an abnormal
mammogram from which a biopsy is recommended; and when there is a benign finding
in a biopsy within a one-year period after an abnormal mammogram Fletcher & Elmore
(2005).
• False Negative: when cancer is diagnosed within a one-year period after a normal
mammogram is reported.
• Positive Predictive Value: refers to diferent rates, depending on the definition of
false positive. Based on an abnormal screening examination: 5-10%. Based on a
recommendation for biopsy or surgery: 25-40%. Based on the result from biopsies carried
out at the clinic, from an abnormal mammogram or from another diagnostic procedure
carried out on the breast, after a negative mammogram Basset et al. (1994); Sickles et al.
(2002).
2.1 Prevalence and incidence
A program for early detection and treatment is applicable in the case of diseases that present
a preclinical phase that cannot be diagnosed but is detectable, and for which the treatment
must offer some advantage over late treatment. The proportion of the population that has a
detectable preclinical phase is the prevalence. Prevalence depends, primarily, on the incidence
rate of the condition, which, in turn, reflects the action of causal factors. Prevalence varies
with the length of the preclinical phase. The greater the duration is, greater the proportion of
affected women will be Pereira (1996) Fletcher & Wagner (1996). Finally, prevalence depends
on whether or not previous screenings have been carried out Morrison (1992). A screening
test with greater sensitivity can detect tumors at the beginning of this phase. Prevalence
represents the stock of cases, new and old, and usually expresses damage of a chronic nature
Fletcher & Wagner (1996), such as breast cancer. Incidence is recognized as the most important
measurement in epidemiology because it relates to the dynamics of occurrence of a certain
event, over a specific observation time Pereira (1996). For example, among asymptomatic
women with previous mammography examinations that showed no suspicious signs of
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negative definition for someone with the condition, can result from either low test efficacy or
incorrect interpretation Morrison (1992) Barratt et al. (2005). In a screening test, the matter that
is under investigation is the capability to correctly distinguish between diseased and healthy
individuals. Thus, to be certain that the disease is really present or absent, it is frequently
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the case that elaborate, expensive or risky tests, such as biopsies, surgical exploration or
autopsy, must be carried out Fletcher et al. (1996). Estimation of diagnostic test validity in
relation to a standard is certified by knowing the proportions of right diagnoses (true positives
and true negatives) and wrong ones (false positives and false negatives) Pereira (2000b).
In relation to mammography, the level of logic validity is based on consensus and expert
opinions Basset et al. (1994) Fletcher & Elmore (2005), and evaluations of accuracy are based
on histopathological examination of the suspected lesion. The ability of mammography to
define women with preclinical diseases as positive is referred to as its sensitivity. If measured,
it is around 78 to 85%. The specificity of the test is its ability to define as negative women
who do not have the disease. If measured, it should be greater than 90% Morrison (1992).
The sensitivity of the screening test is a determining factor for disease control programs and
the specificity directly influences the costs and feasibility of the screening program Morrison
(1992) Fletcher et al. (1996) Basset et al. (1994). All mammograms must be categorized as one
of the alternatives below Basset et al. (1994):
• True Positive: when cancer is diagnosed within a one-year period after a biopsy is
recommended.
• True Negative: when no cancer is diagnosed up to one year after a normal mammogram is
reported.
• False Positive: when no cancer is diagnosed within a one-year period after an abnormal
mammogram from which a biopsy is recommended; and when there is a benign finding
in a biopsy within a one-year period after an abnormal mammogram Fletcher & Elmore
(2005).
• False Negative: when cancer is diagnosed within a one-year period after a normal
mammogram is reported.
• Positive Predictive Value: refers to diferent rates, depending on the definition of
false positive. Based on an abnormal screening examination: 5-10%. Based on a
recommendation for biopsy or surgery: 25-40%. Based on the result from biopsies carried
out at the clinic, from an abnormal mammogram or from another diagnostic procedure
carried out on the breast, after a negative mammogram Basset et al. (1994); Sickles et al.
(2002).
2.1 Prevalence and incidence
A program for early detection and treatment is applicable in the case of diseases that present
a preclinical phase that cannot be diagnosed but is detectable, and for which the treatment
must offer some advantage over late treatment. The proportion of the population that has a
detectable preclinical phase is the prevalence. Prevalence depends, primarily, on the incidence
rate of the condition, which, in turn, reflects the action of causal factors. Prevalence varies
with the length of the preclinical phase. The greater the duration is, greater the proportion of
affected women will be Pereira (1996) Fletcher & Wagner (1996). Finally, prevalence depends
on whether or not previous screenings have been carried out Morrison (1992). A screening
test with greater sensitivity can detect tumors at the beginning of this phase. Prevalence
represents the stock of cases, new and old, and usually expresses damage of a chronic nature
Fletcher & Wagner (1996), such as breast cancer. Incidence is recognized as the most important
measurement in epidemiology because it relates to the dynamics of occurrence of a certain
event, over a specific observation time Pereira (1996). For example, among asymptomatic
women with previous mammography examinations that showed no suspicious signs of
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malignancy, it informs how many of them present subclinical breast cancer. Incidence is one
of the determining factors of prevalence Fletcher & Wagner (1996). In reality, estimation of
both incidence and prevalence enables better knowledge of the situation and consequently
enables adequate orientation of actions, with regard to implementation of new programs.
Implementation of an early detection program for breast cancer by means of mammography
must be preceded by studies that can evaluate the existing situation. Thus, before the possible
beneficial impact on mortality of early detection of malignant but asymptomatic lesions can be
measured, it is important to ascertain the breast cancer rate among women who are apparently
healthy Warren-Burhenne (1996). In Brazil, there are few reports measuring the distribution of
malignant lesions detected by mammography screening among asymptomatic women Koch
(1998) Lamas & Pereira (1998).
2.2 Factors related to detection of breast cancer
Several factors influence early detection through mammography or delayed diagnosis of
malignant lesions among apparently normal women. Among these are the biological behavior
of the tumor, the type of equipment used, the technical ability of those who produce
and interpret the mammograms, the time interval between subsequent screenings and the
existence of a quality control program at the clinic Koch (1998) Sickles (1995). Technological
advances and greater knowledge of breast radiology have made it possible to identify
breast lesions with suspected malignancy earlier on Haus et al. (1990) Taplin et al. (2004).
The biological behavior of the tumor, which is inherent to each type of neoplasia and the
relationships established with the human organism, is one of the factors that determine the
length of the subclinical phase and hence favors or hinders early detection Taplin et al. (2004).
Length bias The growth speed of the tumor is a crucial matter, since the likelihood of cancer
detection during the preclinical phase depends on the length of this phase. There is little
chance of detecting tumors with a short preclinical phase before they are manifested clinically.
On the other hand, tumors with preclinical phases that last for years are more likely to be
discovered through screening Morrison (1992). Studies have shown that the mean duration of
the preclinical phase of cases diagnosed through mammography screening tends to be longer
than the mean duration of the cases that are routinely identified through the appearance of
symptoms Warren-Burhenne (1996) and that tumors that grow slowly during the preclinical
phase have the same behavior when symptomatic. Thus, screening would tend to detect
tumors with good prognoses, as a result of the bias from the length of the preclinical phase,
regardless of how much time is gained through early detection or how much benefit comes
from early treatment Black & Ling (1990) Zelen (1976). Prevalence bias Breast cancer has
faster growth among young women and slower growth among older women. It can remain
in the subclinical phase for an indeterminate length of time Moskowitz (1986). Research has
indicated that older women, aged over 50 years, have a longer preclinical phase of the disease,
compared with women aged less than 50 years, in whom the biological behavior of the tumor
is more aggressive Baker (1982) Kopans (1995).
However, mammography examinations contribute towards elevation of the prevalence rate,
through indiscriminately detecting tumors with progressive growth and those that may
remain without clinical manifestation for indeterminate periods Morrison (1992). This
constitutes a distortion, known as prevalence bias, caused by excessive representation of
long-duration cases and can occur in cross-sectional studies Fletcher & Wagner (1996).
Although these distortions can contribute towards high prevalence of subclinical lesions,
these rates have not been shown to be statistically different at ages of under and over 50
years in Brazil, which seems to indicate that prevalence bias is not the only explanation for
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the measurement found, especially among younger women Lamas & Pereira (1998). These
results are consistent with some other studies that observed that there was no drastic change
in cancer rates from under to over the age of 50 years Kopans (1995). Since the duration
of subclinical disease is greater among older women, it is expected that there will be a
proportionally greater number of affected women over the age of 50 years, represented by the
prevalence rates. The data from Brazil do not show statistically significant differences in the
proportion of women with cancer at the subclinical phase, at an initial stage of development,
comparing women under and over 50 years of age (P = 0.52). These studies in Brazil indicate
that detection of a greater number of tumors with slow growth and good prognostics is
not, in this particular case, related to age Lamas (2000). By contributing towards a higher
detection rate for malignant tumors, mammography includes lesions of different biological
behavior with distinguishing between them: lesions with rapid growth and those with slow
development Liff et al. (1991). The latter may remain asymptomatic for an indeterminate
period of time Feuer & Wun (1992). Regarding the frequency of malignant lesions, there is
a consensus that the tumor prevalence rate among asymptomatic women is between six and
ten cases per thousand women screened using mammography Warren-Burhenne & Burhenne
(1992) . Rates lower than this standard range indicate that mammography is adding little
to clinical examination of breasts, in which case there could be many false negatives. In
Brazil, the data indicate high rates, in relation to population-based studies Vizcaíno et al.
(1998) Thurfjell & Lindgren (1994). The measurements are similar to the rates observed by
some institutional studies in developed countries at the beginning of their early detection
programs Warren-Burhenne & Burhenne (1992) Maya et al. (2006). Proposals that are feasible
for the public healthcare system need to be drawn up from quantitative data on disease
frequency. Such knowledge provides information on the magnitude and importance of the
damage to health Pereira (1996). The decision on whether it is appropriate or not to begin
mammography screening as a secondary prevention strategy must be based on relevant
measurements of breast cancer frequency among asymptomatic women.
2.3 Limitation of epidemiological studies
The variation in morbidity due to breast cancer, for which there are multiple causal factors and
some are still little known, limits epidemiological studies, even in populations with similar
characteristics, which may invalidate comparisons between studies Pereira (1996) Sickles
(1992). It has to be borne in mind, regarding the distribution of morbidity, that the disease
affects women who are less favored in socioeconomic terms. As also seen with infectious
diseases, chronic-degenerative diseases and especially the advanced stages of breast cancer
are a greater scourge among less favored individuals. In Brazil, breast cancer is diagnosed
at advanced stages: more than 70 % of the cases are found in stages II to VI, a situation
in which the chances of cure are much smaller Maya et al. (2006) . According to data from
the National Cancer Institute, the estimated risk is 50 cases of this disease for every 100,000
women, including asymptomatic and symptomatic patients. It is therefore important to have
public policies that establish nationwide strategies for diagnosing breast cancer, such as the
breast cancer information system (SISMAMA) that has been implemented since 2008, and
the Mammography Quality Program. There are still flaws in screening for breast cancer in
Brazil. SISMAMA has not yet been implemented in all public clinics, and the quality control
program is not available in all clinics. However, some important tools for implementing public
policy regarding breast cancer prevention have been developed within the Brazilian National
Health System (SUS) . Higher social classes are better informed about primary and secondary
prevention mechanisms, as well as having greater access to health services, which influences
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malignancy, it informs how many of them present subclinical breast cancer. Incidence is one
of the determining factors of prevalence Fletcher & Wagner (1996). In reality, estimation of
both incidence and prevalence enables better knowledge of the situation and consequently
enables adequate orientation of actions, with regard to implementation of new programs.
Implementation of an early detection program for breast cancer by means of mammography
must be preceded by studies that can evaluate the existing situation. Thus, before the possible
beneficial impact on mortality of early detection of malignant but asymptomatic lesions can be
measured, it is important to ascertain the breast cancer rate among women who are apparently
healthy Warren-Burhenne (1996). In Brazil, there are few reports measuring the distribution of
malignant lesions detected by mammography screening among asymptomatic women Koch
(1998) Lamas & Pereira (1998).
2.2 Factors related to detection of breast cancer
Several factors influence early detection through mammography or delayed diagnosis of
malignant lesions among apparently normal women. Among these are the biological behavior
of the tumor, the type of equipment used, the technical ability of those who produce
and interpret the mammograms, the time interval between subsequent screenings and the
existence of a quality control program at the clinic Koch (1998) Sickles (1995). Technological
advances and greater knowledge of breast radiology have made it possible to identify
breast lesions with suspected malignancy earlier on Haus et al. (1990) Taplin et al. (2004).
The biological behavior of the tumor, which is inherent to each type of neoplasia and the
relationships established with the human organism, is one of the factors that determine the
length of the subclinical phase and hence favors or hinders early detection Taplin et al. (2004).
Length bias The growth speed of the tumor is a crucial matter, since the likelihood of cancer
detection during the preclinical phase depends on the length of this phase. There is little
chance of detecting tumors with a short preclinical phase before they are manifested clinically.
On the other hand, tumors with preclinical phases that last for years are more likely to be
discovered through screening Morrison (1992). Studies have shown that the mean duration of
the preclinical phase of cases diagnosed through mammography screening tends to be longer
than the mean duration of the cases that are routinely identified through the appearance of
symptoms Warren-Burhenne (1996) and that tumors that grow slowly during the preclinical
phase have the same behavior when symptomatic. Thus, screening would tend to detect
tumors with good prognoses, as a result of the bias from the length of the preclinical phase,
regardless of how much time is gained through early detection or how much benefit comes
from early treatment Black & Ling (1990) Zelen (1976). Prevalence bias Breast cancer has
faster growth among young women and slower growth among older women. It can remain
in the subclinical phase for an indeterminate length of time Moskowitz (1986). Research has
indicated that older women, aged over 50 years, have a longer preclinical phase of the disease,
compared with women aged less than 50 years, in whom the biological behavior of the tumor
is more aggressive Baker (1982) Kopans (1995).
However, mammography examinations contribute towards elevation of the prevalence rate,
through indiscriminately detecting tumors with progressive growth and those that may
remain without clinical manifestation for indeterminate periods Morrison (1992). This
constitutes a distortion, known as prevalence bias, caused by excessive representation of
long-duration cases and can occur in cross-sectional studies Fletcher & Wagner (1996).
Although these distortions can contribute towards high prevalence of subclinical lesions,
these rates have not been shown to be statistically different at ages of under and over 50
years in Brazil, which seems to indicate that prevalence bias is not the only explanation for
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the measurement found, especially among younger women Lamas & Pereira (1998). These
results are consistent with some other studies that observed that there was no drastic change
in cancer rates from under to over the age of 50 years Kopans (1995). Since the duration
of subclinical disease is greater among older women, it is expected that there will be a
proportionally greater number of affected women over the age of 50 years, represented by the
prevalence rates. The data from Brazil do not show statistically significant differences in the
proportion of women with cancer at the subclinical phase, at an initial stage of development,
comparing women under and over 50 years of age (P = 0.52). These studies in Brazil indicate
that detection of a greater number of tumors with slow growth and good prognostics is
not, in this particular case, related to age Lamas (2000). By contributing towards a higher
detection rate for malignant tumors, mammography includes lesions of different biological
behavior with distinguishing between them: lesions with rapid growth and those with slow
development Liff et al. (1991). The latter may remain asymptomatic for an indeterminate
period of time Feuer & Wun (1992). Regarding the frequency of malignant lesions, there is
a consensus that the tumor prevalence rate among asymptomatic women is between six and
ten cases per thousand women screened using mammography Warren-Burhenne & Burhenne
(1992) . Rates lower than this standard range indicate that mammography is adding little
to clinical examination of breasts, in which case there could be many false negatives. In
Brazil, the data indicate high rates, in relation to population-based studies Vizcaíno et al.
(1998) Thurfjell & Lindgren (1994). The measurements are similar to the rates observed by
some institutional studies in developed countries at the beginning of their early detection
programs Warren-Burhenne & Burhenne (1992) Maya et al. (2006). Proposals that are feasible
for the public healthcare system need to be drawn up from quantitative data on disease
frequency. Such knowledge provides information on the magnitude and importance of the
damage to health Pereira (1996). The decision on whether it is appropriate or not to begin
mammography screening as a secondary prevention strategy must be based on relevant
measurements of breast cancer frequency among asymptomatic women.
2.3 Limitation of epidemiological studies
The variation in morbidity due to breast cancer, for which there are multiple causal factors and
some are still little known, limits epidemiological studies, even in populations with similar
characteristics, which may invalidate comparisons between studies Pereira (1996) Sickles
(1992). It has to be borne in mind, regarding the distribution of morbidity, that the disease
affects women who are less favored in socioeconomic terms. As also seen with infectious
diseases, chronic-degenerative diseases and especially the advanced stages of breast cancer
are a greater scourge among less favored individuals. In Brazil, breast cancer is diagnosed
at advanced stages: more than 70 % of the cases are found in stages II to VI, a situation
in which the chances of cure are much smaller Maya et al. (2006) . According to data from
the National Cancer Institute, the estimated risk is 50 cases of this disease for every 100,000
women, including asymptomatic and symptomatic patients. It is therefore important to have
public policies that establish nationwide strategies for diagnosing breast cancer, such as the
breast cancer information system (SISMAMA) that has been implemented since 2008, and
the Mammography Quality Program. There are still flaws in screening for breast cancer in
Brazil. SISMAMA has not yet been implemented in all public clinics, and the quality control
program is not available in all clinics. However, some important tools for implementing public
policy regarding breast cancer prevention have been developed within the Brazilian National
Health System (SUS) . Higher social classes are better informed about primary and secondary
prevention mechanisms, as well as having greater access to health services, which influences
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morbidity Pereira (1996). This unequal access is in addition to unequal quality at diagnostic
centers, which is another condition responsible for the distorted picture of morbidity.
Screening attracts people who are more conscious about healthcare, among whom the disease
tends to take a more favorable clinical course, regardless of the time gained through early
detection or the benefit of timely treatment. This might not have such an influence on
the results if all members of the population were screened. One important point that also
influences the measurement of prevalence is sample selection. Samples composed by women
who seek medical care or are referred to a clinic dedicated to mammography do not constitute
a random sample, but rather, attendance of the demand. One important point to be discussed
in investigations from which the aim is to extrapolate the results is the use of randomization
for selection of elements for a sample. Age, social levels and ethnic characteristics are factors
associated with diseases, and thus, comparisons between groups with different characteristics
will be biased. Differences relating to sample selection The institutional nature of some
studies may introduce distortions and be responsible for differences in rates, because they
constitute attendance of the demand. To minimize this sample selection bias, one option is
to use women who undergo mammography examinations as periodic routine examinations
required by the companies in which they work. The higher breast cancer prevalence rate at
clinics that attend to the demand Sickles (1995) is explained by the greater incidence of the
disease in such groups, which expresses the presence of causal factors Kopans (1995) Lopes
et al. (1996). There is evidence that women exposed to a greater number of risk factors more
frequently seek specialized clinics, which explains some of the differences in the frequencies of
breast cancer between populations Smith (1993) Colditz et al. (1993). Women from privileged
economic classes are exposed to a greater number of risk situations, such as stress, lack
of breastfeeding, use of hormones, nulliparity and use of oral contraceptives, as well as
other factors that are associated with greater risk of developing other diseases, including
diets rich in animal fat and alcohol, among other factors Koch (1998) MacPherson et al.
(1983). These conditions are associated with greater risk of having breast cancer, and personal
antecedents of this neoplasia are the factor most strongly related to the disease Roubidoux
et al. (1997). Atypical hyperplasia, also known as a high-risk type of lesion, is similarly
strongly associated, and it has been estimated that the risk of developing in situ carcinoma
or subsequent invasive carcinoma is five to ten times greater Dupont et al. (1993) Boecker
et al. (2002). To affirm the causal relationship between the two events, it is necessary to
rule out alternative explanations, in order to avoid erroneous conclusions. Confounding
factors are one of these explanations, and therefore should be a matter of constant concern
during the development of a study: in its planning, in the statistical analysis and in the
interpretation of the results Pereira (1996). Differences relating to the existence of previous
screenings Another factor that influences the results is the absence of previous screenings. In
Brazil, unlike what is found in developed countries, there is no early detection program on a
national scale, and only recently has there been any encouragement for asymptomatic women
to undergo periodic mammography examinations, as a form of secondary prevention. This
explains the small percentage of women who had already undergone screening in the samples
of studies published on this issue. The yield from a screening test decreases proportionally
as it is repeated among a given group of people Chamberlain (1984). Prevalence studies
may differ in relation to the proportion of the women in the sample who had already
undergone mammography examinations, since the prevalence measurement includes both
new and old cases. The length bias that was described by some English authors Smith
(1995) Fletcher & Wagner (1996) may contribute to the high cancer rate found in samples
composed predominantly by older women, a situation in which the tumor presents slow
growth. Length bias is greater among the cases detected through the initial screening, a
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situation in which the prevalence of the tumors in this phase is predominantly represented by
lesions that have long preclinical phases. As the control examinations are repeated, especially
at short intervals, the distribution of the preclinical phase duration among the detected
subclinical cases becomes more similar to the distribution routinely diagnosed in a population
that did not undergo screening. In these circumstances, it could be that the length bias is less
important in the selection of the prognostic factors. However, if the preclinical phase of the
disease is short, continuous screenings would be necessary to reach the objective of detecting
lesions at these stages Morrison (1992). Differences relating to the measurement procedures
Methodological errors can give false interpretations to the results. Although the possibility is
smaller, the prevalence rate may be altered by distortions introduced into the measurement of
the procedures. Thus, in frequency investigations, these measurement biases appear when the
findings obtained from the sample data differ from those of the population, simply through
measurement problems. These deviations can occur when the event lacks definition, when
poorly elaborated questionnaires are used, when uncalibrated low-resolution equipment is
used, and when several data-gatherers, interviewers or observers are used, among other
situations Pereira (2000a) Sickles et al. (2002). Randomized clinical trials are considered to be
the standard of excellence, because they produce direct and unequivocal evidence to explain
a cause-effect relationship between two events Pereira (1996).
2.4 Comparative efficacy of self-examination, clinical breast examination and
mammography in screening for breast cancer
There is no way to separate the effects of mammography and clinical breast examination in
relation to reduction of mortality. Even with technological advances, there are no reasons to
suppose that a mammography screening program, in isolation from a clinical examination,
would have the same effect as when they are combined. Since the time of the first randomized
study, which began in 1960, a time at which the equipment used had low resolution,
mammography has been shown to be 1.6 times more sensitive than the examination carried
out separately, for mammography screening Baker (1982). It is important to emphasize that
clinical examination has been recommended as an early detection method for breast cancer .
Clinical breast examination is important for ruling out clinically evident tumors that do
not have a corresponding mammographic configuration. Although mammography is more
sensitive than clinical breast examination, 9% of tumors are only detected through palpation
Baker (1982). Nevertheless, with the technological evolution of mammography equipment,
some studies have observed a decrease in the rate of negative mammograms among patients
with palpable nodules . In these cases, non-visualization of the tumor through mammography
may result from a variety of factors, but in most cases is a consequence of increased breast
density Tabár (1993) Kopans et al. (1996) Fitzgerald (2001). There is evidence that clinical
breast examination contributes towards the screening of suspected lesions Baker (1982) Miller
et al. (1992) Chu & Connor (1991). However, on a larger scale, it does not have an impact
relating to decreased risk of mortality due to cancer Humphrey et al. (2002).
3. Database image and data aquisition
All images are generated in DICOM format by digital mammography equipments at Janice
Lamas Radiology Clinic. At first moment the MIDAS database is available to general public
containing about 100 mammograms and 600 images and an image sample is shown in
Figure 1. The high definition images are available under personal request, after MIDAS
team approval. The low definition images are freely available to the general public. All
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morbidity Pereira (1996). This unequal access is in addition to unequal quality at diagnostic
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Screening attracts people who are more conscious about healthcare, among whom the disease
tends to take a more favorable clinical course, regardless of the time gained through early
detection or the benefit of timely treatment. This might not have such an influence on
the results if all members of the population were screened. One important point that also
influences the measurement of prevalence is sample selection. Samples composed by women
who seek medical care or are referred to a clinic dedicated to mammography do not constitute
a random sample, but rather, attendance of the demand. One important point to be discussed
in investigations from which the aim is to extrapolate the results is the use of randomization
for selection of elements for a sample. Age, social levels and ethnic characteristics are factors
associated with diseases, and thus, comparisons between groups with different characteristics
will be biased. Differences relating to sample selection The institutional nature of some
studies may introduce distortions and be responsible for differences in rates, because they
constitute attendance of the demand. To minimize this sample selection bias, one option is
to use women who undergo mammography examinations as periodic routine examinations
required by the companies in which they work. The higher breast cancer prevalence rate at
clinics that attend to the demand Sickles (1995) is explained by the greater incidence of the
disease in such groups, which expresses the presence of causal factors Kopans (1995) Lopes
et al. (1996). There is evidence that women exposed to a greater number of risk factors more
frequently seek specialized clinics, which explains some of the differences in the frequencies of
breast cancer between populations Smith (1993) Colditz et al. (1993). Women from privileged
economic classes are exposed to a greater number of risk situations, such as stress, lack
of breastfeeding, use of hormones, nulliparity and use of oral contraceptives, as well as
other factors that are associated with greater risk of developing other diseases, including
diets rich in animal fat and alcohol, among other factors Koch (1998) MacPherson et al.
(1983). These conditions are associated with greater risk of having breast cancer, and personal
antecedents of this neoplasia are the factor most strongly related to the disease Roubidoux
et al. (1997). Atypical hyperplasia, also known as a high-risk type of lesion, is similarly
strongly associated, and it has been estimated that the risk of developing in situ carcinoma
or subsequent invasive carcinoma is five to ten times greater Dupont et al. (1993) Boecker
et al. (2002). To affirm the causal relationship between the two events, it is necessary to
rule out alternative explanations, in order to avoid erroneous conclusions. Confounding
factors are one of these explanations, and therefore should be a matter of constant concern
during the development of a study: in its planning, in the statistical analysis and in the
interpretation of the results Pereira (1996). Differences relating to the existence of previous
screenings Another factor that influences the results is the absence of previous screenings. In
Brazil, unlike what is found in developed countries, there is no early detection program on a
national scale, and only recently has there been any encouragement for asymptomatic women
to undergo periodic mammography examinations, as a form of secondary prevention. This
explains the small percentage of women who had already undergone screening in the samples
of studies published on this issue. The yield from a screening test decreases proportionally
as it is repeated among a given group of people Chamberlain (1984). Prevalence studies
may differ in relation to the proportion of the women in the sample who had already
undergone mammography examinations, since the prevalence measurement includes both
new and old cases. The length bias that was described by some English authors Smith
(1995) Fletcher & Wagner (1996) may contribute to the high cancer rate found in samples
composed predominantly by older women, a situation in which the tumor presents slow
growth. Length bias is greater among the cases detected through the initial screening, a
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subclinical cases becomes more similar to the distribution routinely diagnosed in a population
that did not undergo screening. In these circumstances, it could be that the length bias is less
important in the selection of the prognostic factors. However, if the preclinical phase of the
disease is short, continuous screenings would be necessary to reach the objective of detecting
lesions at these stages Morrison (1992). Differences relating to the measurement procedures
Methodological errors can give false interpretations to the results. Although the possibility is
smaller, the prevalence rate may be altered by distortions introduced into the measurement of
the procedures. Thus, in frequency investigations, these measurement biases appear when the
findings obtained from the sample data differ from those of the population, simply through
measurement problems. These deviations can occur when the event lacks definition, when
poorly elaborated questionnaires are used, when uncalibrated low-resolution equipment is
used, and when several data-gatherers, interviewers or observers are used, among other
situations Pereira (2000a) Sickles et al. (2002). Randomized clinical trials are considered to be
the standard of excellence, because they produce direct and unequivocal evidence to explain
a cause-effect relationship between two events Pereira (1996).
2.4 Comparative efficacy of self-examination, clinical breast examination and
mammography in screening for breast cancer
There is no way to separate the effects of mammography and clinical breast examination in
relation to reduction of mortality. Even with technological advances, there are no reasons to
suppose that a mammography screening program, in isolation from a clinical examination,
would have the same effect as when they are combined. Since the time of the first randomized
study, which began in 1960, a time at which the equipment used had low resolution,
mammography has been shown to be 1.6 times more sensitive than the examination carried
out separately, for mammography screening Baker (1982). It is important to emphasize that
clinical examination has been recommended as an early detection method for breast cancer .
Clinical breast examination is important for ruling out clinically evident tumors that do
not have a corresponding mammographic configuration. Although mammography is more
sensitive than clinical breast examination, 9% of tumors are only detected through palpation
Baker (1982). Nevertheless, with the technological evolution of mammography equipment,
some studies have observed a decrease in the rate of negative mammograms among patients
with palpable nodules . In these cases, non-visualization of the tumor through mammography
may result from a variety of factors, but in most cases is a consequence of increased breast
density Tabár (1993) Kopans et al. (1996) Fitzgerald (2001). There is evidence that clinical
breast examination contributes towards the screening of suspected lesions Baker (1982) Miller
et al. (1992) Chu & Connor (1991). However, on a larger scale, it does not have an impact
relating to decreased risk of mortality due to cancer Humphrey et al. (2002).
3. Database image and data aquisition
All images are generated in DICOM format by digital mammography equipments at Janice
Lamas Radiology Clinic. At first moment the MIDAS database is available to general public
containing about 100 mammograms and 600 images and an image sample is shown in
Figure 1. The high definition images are available under personal request, after MIDAS
team approval. The low definition images are freely available to the general public. All
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Fig. 1. A Reduced Example of MIDAS Dicom Image
the genomic information will be extracted after breasts biopsies and genomic sequencing at
Genome Analyser Illumina GAIIx. All the images are obtained from the following equipment:
• Equipment: Mammomat Inspiration
• Voltage: 23 Kv to 35 Kv
• Large focus: 0.3 mm and small focus: 0.15 mm
• Pixel size: 85 μm and 70 μm
• Samples per pixel: 1
• Image size 2082 x 2800
• Bits allocated: 16
• Photometric interpretation: monochrome-1
The DBMS open source object-relational database system PostgreSQL is used to receive the
MIDAS database. The database conceptual modeling is presented in Figure 2.
4. Software tools
We provide a Web application (Midas-Web) for getting access to the database content and
for manipulating the database’ images through several digital image processing algorithms.
Therefore, at a high-level point of view, Midas-Web is both an information system (with
CRUD1 operations for the mammography database) as well as an extensible environment for
1 In the software community, CRUD operations correspond to basic functions that allow users to create,
update, delete, and query data base content
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playing with and experimenting digital image processing algorithms. Some goals have been
used to guide the design and development of Midas-Web:
• Basic mechanisms for authentication and authorization.
• Rapid application development cycle
• Extensible set of algorithms for digital image processing and interpretation
We realize three main usage profiles within the Midas-Web context. First, medical
practitioners might access Midas-Web to compare, through analogy, their diagnosis with
existing BI-RADS™ diagnosis present in the Midas database. Such a comparison is useful
for the purpose of increasing diagnosis’ confidence and teaching. Another usage profile
also corresponds to medical practitioners who want to share their findings, introducing new
cases in the Midas database. This usage profile is restricted by security policies, and Midas
administrators analyze all requests related to the introduction of new cases before making
them publicly available. Another usage profile correspond to researchers that want to apply
their algorithms for digital image processing and interpretation using the Midas database
images.
In the remaining of this section we detail some design decisions related to the Midas-Web
architecture, database schema and extensibility support for introducing new algorithms for
digital image processing.
4.1 Architecture
Midas-Web follows a standard web based architecture, in which the system is decomposed in
three principal layers Fowler (2002): the web layer, the business logic layer and the data source
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layer. The web layer provides the presentation logic, processing the user requests, calling
business operations, and forwarding to a proper graphical user interface (GUI) component that
should render the results of a user request.
The business logic layer is responsible for implementing the application transactional logic,
which usually involves algorithms for data validation and calculation. Actually, in the case of
Midas-Web, this layer is really thin, once Midas-Web basically provides CRUD operations to
the Midas database. Nevertheless, it is still important to consider this layer in the architecture,
since it increases the opportunities for code reuse.
Finally, the data source layer provides an abstraction over the underlying Midas database
system. Therefore, components in this layer implement services for accessing the database, in
such a way that we are able to evolve the database (for instance from a SQL based to a non
SQL database) without breaking the upper layers of the Midas-Web application.
Figure 3 presents the logical view of the Midas-Web architecture. In order to reduce the
development cycle, and also motivated by the low complexity of the business logic, we
developed Midas-Web using Grails Smith & Ledbrook (2009). Grails (or Groovy on Rails)
is a web development framework focused on productivity gains through the confluence of
the Groovy dynamic language Koenig et al. (2007) and the prevalence of source code structure
convention over configuration through XML files. The main components of a Grails application
are: (a) the Controller Classes, which handle user inputs and forward business’ responses to
suitable views; (b) The Grails Server Pages, which renders the graphical user interface; (c)
the Service Classes, which implements the business logic; and (d) the Domain Classes, which
describe the domain concepts and implement the data access layer to perform queries and
updates into the database.
Fig. 3. Logical view of the Midas-Web architecture
Grails offers a powerful integration with the Java language, so that it is possible to call existing
Java code from Grails, as well as Grails applications are package as a standard Java Web
Archive (WAR) and, as such, they could be deployed into Java Application Servers (like Tom
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Cat or JBOSS). The Java integration is useful because it supports the extensible architecture
for digital image processing, one of the contributions of Midas-Web (Section 4.3).
4.2 Database structure
The Midas database schema was influenced, at a great extent, by the BI-RADS™
classification D’Osri et al. (2003). For this reason, each patient, whose identity must
be preserved, might be associated with different studies (representing clinical cases or
investigations); and each study has properties such as:
• breast composition
• histology
• date in which the exam was conducted
• the main findings of the exam
In addition, and also according to the BI-RADS™ classification, each study must provide a
lesion description and at least four images (mammograms). Table 1 shows the attributes used




























Table 1. Attributes of a lesion description according to BI-RADS™
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Fig. 4. Core relations of the Midas database schema
4.3 Extensibility support and collaborative environment
The MIDAS project group is a collaborative effort between Instituto Federal de Brasília,
University of Brasília Computer Science Department, University of Brasília Post-Graduate
Program in Biomedical Engineering, Catholic University of Brasília Post-Graduate Program
in Knowledge Management and Information Technology and Janice Lamas Radiology
Clinic. The MIDAS open and collaborative environment allows the users and developers to
participate in the research process. After MIDAS team validating all new image processing
algorithms, artifical intelligence tools, pattern recognition tools, and new findings can be
added to MIDAS database.
5. Assessment and automated analysis
5.1 MIDAS assessment
The MIDAS database and application has been tested during the startup process and along
its business life. The Information Technology infrastructure provided to MIDAS includes a
Cyber Data Center host service and hardware usage monitoring. All the image processing
algorithms and pattern recognition tools has been tested by Janice Lamas Radiology Clinic
experts and reports will be generated in order to improve the software tools.
5.2 Automated analysis: Breast cancer image assessment using an adaptive
network-based fuzzy inference system
The MIDAS database provides an ANFIS model algorithm Fernandes et al. (2010) for
automated analysis through every 600 mammogram images. This algorithm presents
an ANFIS model for a CAD (Computer Aided Diagnosis) prototype system to classify
calcifications in mammograms, in order to aid the medical expert in breast cancer diagnosis.
The proposed model embodies pre processing, detection, features extraction and classification
phases, which proved adequate for the study domain, obtaining similar results to the
indicated in the literature. This approach might be complemented with micro calcification
shape analysis and image segmentation techniques. The neuro fuzzy ANFIS model, utilized
in the mammogram ROI’s classification phase, reached a maximum accuracy rate of 99.75%
with Mini MIAS database and now can be tested with MIDAS database. This can be observed
in the results presented by Fernandes et al. (2010), when the sigmoidal membership function
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PSIGMF was chosen, with the training algorithm in back propagation, employing small values
for epochs. The other membership functions analyzed also showed satisfactory accuracy rates,
however they were not the best ones. The cross validation method allowed a higher formalism
in the division of entry data (estimation, validation and test sets), which is necessary due
to the small quantity of images with calcifications available in the database Mini MIAS, to
prevent excessive training of the network and, consequently, a better generalization of the
system. The proposed system is available as a knowledge management tool. This allows the
dissemination of tacit and explicit knowledge of medical experts and their past experience in
the field, allowing still a better performance in the evaluation of routine exams by means of a
graphical tool.
6. Related work
The Mammographic Image Analysis Society (MIAS) is a database of digital mammograms
where the films are from the U.K. National Breast Screening Programme and they have
been digitised to 50 micron pixel edge with a Joyce-Loebl scanning microdensitometer, a
device linear in the optical density range 0-3.2 and representing each pixel with an 8-bit
word Suckling et al. (1994). The database contains 322 digitised films and it also includes
radiologist’s "truth"-markings on the locations of any abnormalities that can be present.
The database has been reduced to a 200 micron pixel edge and padded/clipped so that
all the images are 1024x1024 Suckling et al. (1994). The Digital Database for Screening
Mammography (DDSM) is a collaborative effort between Massachusetts General Hospital,
Sandia National Laboratories and the University of South Florida Computer Science and
Engineering Department. The database contains approximately 2,500 mammograms each
includes two images of each breast, along with some associated patient information (age at
time of study, ACR breast density rating, subtlety rating for abnormalities, ACR keyword
description of abnormalities) and image information. Images containing suspicious areas
have associated pixel-level "ground truth" information about the locations and types of
suspicious regions. The DDSM also provides software for accessing the mammogram
and truth images and for calculating performance figures for automated image analysis
algorithms Heath et al. (2001b).
7. Future work
7.1 Genotypes and phenotypes
The search of new genes of cancer and its epigenomics implications are the main areas
of future investigation. Discovering the human genomic variability and its complexes
phenotypes are the major obstacles and where the efforts will be concentrated. New image
processing algorithms and also new artificial intelligence methods will be used in order to
offer the physicians more technical support in the breast cancer treatment.
7.2 Breast cancer visual modeling
7.2.1 Motivation
Visual characteristics of human body components are highly relevant as an input for a variety
of decisions on health concerning activities. One can promptly access and eventually perform
adjustments on information upon some injury or physiological change through user-friendly
devices, as a valuable resource for therapeutic procedures and specialized training too.
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One should remark that visualization is supposed to convey information compatible with
viewer’s perception and cognition skills Agrawala et al. (2011). Visual modeling of cells
growth is an instance of data visualization that allows a fast information analysis for problem
solving. This kind of data processing more and more becomes an efficient way to support
decision-making. Visualization can be understood as a low-cost human cognitive process to
create an image about a domain space. It enables insights about some context, say, qualitative
and quantitative answers to existing problems and facts recognition that were previously not
possible Fayyad & Grinstein (2002) Konofagou (2004). Although visual models are able to
express just part of the features of the real object, they are enough informative and useful
for an effective subsequent decision process. Typical instances of lesion that require visual
information for treatment are cells abnormal growth that may constitute cancerous tissues
as a result of an evolutionary process with genetic mutations Beckmann et al. (1997) Evan
& Vousden (2001) Lux et al. (2006). Images provide relevant information about size and
tonalities irregularities that may express different kinds of existing lesions. The availability
of a non-invasive and inexpensive computational technique to model evolutionary process of
breast cancer thus becomes highly relevant. Hence one expects to develop models of breast
cancer, to recognize their properties, for supporting therapeutic processes and decisions, with
experimental validation in mammography clinics. Its results should be suitable for actual use
in units of health care.
7.2.2 Visual modeling
A visualization system is developed according to the following steps Agrawala et al. (2011).
Initially, the principles of design-oriented field of interest are identified. Then the algorithms
are developed to implement these principles. Afterwards the results are validated based
on users’ perception of visually modeled information. Segmentation is based on certain
characteristic features that are common to the pixels that should make up each segment. If
the image contains multiple objects with similar characteristics, as in the case of breast duct
anatomy, the approximate tones of pixels belonging to the object are a segmentation criterion.
After properly separated and identified the object or region, it becomes possible to capture
information that can be used for subsequent classification according known categories. Thus
it is essential to know all the properties that are necessary and sufficient to characterize an
object. The image of an object is a projection of a three-dimensional object on a plane. Through
the image we might infer the size of the projection of the object and thus estimate the size of
the object. The position of the object is useful for the activation of devices able to perform
any procedure directly on the scene, for example, microsurgery or application of medication.
Each property should be able to unambiguously characterize the objects belonging to different
classes and at the same time be able to accommodate all the variations that can occur for
objects belonging to the same class. The decision about membership of an object to some class
can be deterministic or probabilistic. In fact the value of a property in a set of standards can be
a random variable with estimated mean and standard deviation. So such decision is based on
the membership of the measured property in a pattern to a range of the known model. More
accurate procedures for statistical classification also consider the cost of misclassification,
which can be quite relevant, for example, at diseases diagnosis based on recognition of images
of tissue samples. Concerning therapeutic procedures it is often necessary to recognize tissues
with different textures, in order to assess the extent of changes in these tissues. This is the case
of analysis of the development of breast cancer. Project activities are shown in Figure 5.
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Fig. 5. Visual Modeling Project flow adapted from Guadagnin et al. (2011)
7.2.3 Expected results
One expects to have a system for visual modeling of evolutionary process of breast tumorous
tissues. It will also identify the main requirements for training professionals in monitoring
and management of patients supposed an appropriate use of computing resources.
7.2.4 Perspectives
Simulations could be used to advise patients and professionals about cancerous lesions
evolution as well as to examine evolving response to specific treatments. The model could
be also adjusted to simulate different cells mutation types Bankhead & Heckendorn (2007).
The amount of image processing and analysis applications in medical diagnosis is very
extent. Otherwise there are several other areas where these techniques are useful or even
indispensable too, for instance, in computer-assisted surgery, post-surgery follow-up or
therapy and monitoring of potentially dangerous evolution. Simulated images are helpful
for healing supported by computational processes and medical diagnosis, and applications of
telemedicine.
8. Conclusions
The MIDAS (Mammographic Image Database for Automated Analysis) is an innovative
database containing mammogram images covering a sample of Brazilian women population,
patient genome sequences data, open source image processing algorithms, open access and
open collaborative environment. After its initial tunning and legal procedures it will be
available to the Internet to worldwide access and collaboration. The MIDAS database project
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aims to enhance the scientific activity regarding breast cancer research among brazilian
women population and therefore raising the health prognosis.
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aims to enhance the scientific activity regarding breast cancer research among brazilian
women population and therefore raising the health prognosis.
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1. Introduction
Over the past few years, the cancer has been one of the most responsible for the high number
of deaths, and could become one of the main responsible for most deaths in the next decades.
According to the World Health Organization, the number of deaths due to cancer, which was
just 13% in 2008, is currently having a significant increase and one estimates that this number
could reach approximately 12 million until 2030 (Tang et al., 2009).
Breast cancer is the second most common and leading cause of cancer death among women
in Brazil. The National Cancer Institute (INCA) reports more than 50,000 new cases of the
disease, with risk of 51 cases per 100,000 women. In the southeastern region of the country,
this number is about 34% higher than the national average, with an estimate of 68 new cases
per 100,000 women. For this reason, studies have shown that early detection is the key to
improve breast cancer prognosis (Brasil, 2009).
Some works have shown that early detection of disease is a crucial factor for
reducing mortality from breast cancer. Among the most important medical imaging
methods (for example, MRI, ultrasonography and screen/film mammography), screen/film
mammography is the method most easily accessible and has proved to be an effective aid for
radiologists in the early detection of breast cancers and in the reduction of mortality rates.
In this examination, four images are obtained, two corresponding to the right breast and
two to the left breast of the projections cranio-caudal (CC) and medio-lateral oblique (MLO).
The images acquisition improves visualization of breast tissue and increases the chances
for detecting signs that characterize the presence of non-palpable lesions such as nodules,
calcification, signs of bilateral asymmetry and architectural distortion (Rangayyan et al., 2007).
Retrospective evaluations of previous screening films of cancers, detected between screening
rounds (interval cancers), show evidence of abnormality in 16% among 27% of cases. Missed
cancers are due to many reasons: low disease prevalence, breast structure complexity, finding
subtleties, and radiologist fatigue. To improve the accuracy of mammography, radiologists
employed double reading of the same screening mammogram to increase the sensitivity rate
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1. Introduction
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mammography is the method most easily accessible and has proved to be an effective aid for
radiologists in the early detection of breast cancers and in the reduction of mortality rates.
In this examination, four images are obtained, two corresponding to the right breast and
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The images acquisition improves visualization of breast tissue and increases the chances
for detecting signs that characterize the presence of non-palpable lesions such as nodules,
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Retrospective evaluations of previous screening films of cancers, detected between screening
rounds (interval cancers), show evidence of abnormality in 16% among 27% of cases. Missed
cancers are due to many reasons: low disease prevalence, breast structure complexity, finding
subtleties, and radiologist fatigue. To improve the accuracy of mammography, radiologists
employed double reading of the same screening mammogram to increase the sensitivity rate
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(Kinoshita et al., 2007). Second reading of the screening mammograms by a human reader can
increase cancer detection rates (Thurfjell et al., 1994) (Warren & Duffy, 1995). Obviously, this
procedure is too expensive, complex, and time consuming particularly in screening programs
where a huge number of mammographic images have to be read (Mencattini et al., 2010).
The development of computerized systems as second readers represents an alternative.
Computer-Aided Detection (CADe) and Computer-Aided Diagnosis (CADx) systems have
been applied to mammographic images to assist radiologists on lesions analysis such as
microcalcification, mass and architectural distortions. Algorithms for image processing
together with artificial intelligence techniques, such as neural network and fuzzy logic,
are used in order to enhance, segment, extract features and classify abnormalities (Jiang
et al., 2007), (Balleyguier et al., 2007), (Doi et al., 1999). CADe schemes are systems that
automatically detect suspicious lesions in mammograms, being used as a localization task.
CADx systems extend the computer analysis to yield as output the characterization of a
region or the estimated probability of lesion malignancy. The present chapter is focused on
the classification task.
Although CADe and CADx systems have provided a large number of research and high rates
of sensitivity, the majority of these works analyzes the MLO and CC views independently.
In some situations, this system detects abnormalities in only one of the views. Radiologists
believe that there is an inconsistency if a particular lesion is similar in both views and the
system does not have the capability to find it. Studies have shown that these limitations have
changed their impressions and radiologists are ignoring the results provided by these systems
(Doi et al., 1999).
Several computer algorithms are used for identification of abnormalities in the breast
by extracting features directly from digitized mammograms. Typically, two classes of
features are extracted from mammograms with these algorithms, namely morphological and
non-morphological features. Morphological features are intended to describe information
related to the morphology of a lesion, such as lesion size and shape. Image texture
analysis is an important class that represents gray level properties of images used to describe
non-morphological features that are not easily interpreted by humans. This information can
be obtained through a variety of image processing algorithms, calculated using a variety
of statistical, structural and spectral techniques including co-occurrence matrices, fractal
dimensions and multiresolution techniques. Using a different space by special data transform
such as Fourier transform or wavelets transform could be helpful to separate a special data
that contain specific characteristics. Multiresolution analysis allows for the preservation of an
image according to certain level of resolution, i.e., it allows for the zooming in and out on the
underlying texture structure. Therefore, the texture extraction is not affected by the size of the
pixel neighborhood (Eltoukhy et al., 2010).
In this chapter, we present a method for extraction and selection of texture-related attributes
and classification using the fusion of information from both CC and MLO visions. In
the extraction stage, the wavelet transform method was applied to provide texture-related
attributes for the considered images. Following, the singular value decomposition (SVD)
technique was used to reduce the number of attributes. The application of analysis of variance
(ANOVA) was also conducted for further reduction of the attributes after the SVD application.
In the final step, we used the Random Forest and SVM classifiers to analyze mammogram
lesions. The overall performance of the proposed method was evaluated by means of the area
under the ROC curve.
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2. Materials and methods
2.1 Data set
The database used in this work encompasses mammographic screen/film digitized images
taken from the Digital Database for Screening Mammography (DDSM) (Balleyguier et al.,
2007). The DDSM project is a joint effort of researchers from the Massachusetts General
Hospital (D. Kopans, R Moore), the University of South Florida (K. Bowyer), and the Sandia
National Laboratories – EUA (P. Kegelmeyer). The DDSM database has been widely used as
a benchmark for numerous articles on the mammographic area, for being free of charge and
having a vast and diverse quantity of cases. It is constituted of mammographic images and
its corresponding technical and clinical information, including exam dates, age of patients,
digitalization equipment (as well as resolution, number of rows, pixels per row and bits per
pixel of the acquired images), lesion types (according to BIRADS®), and existent pathologies.
For the evaluation of the algorithms, a data set was used comprising 480 mammographic
images from 160 patients (being 80 with no lesions and 80 with malignant lesion) which
were randomly selected from DDSM dataset. These lesions have different sizes, densities,
and margins types. For each case, we used four mammograms, taken from the left and the
right breasts, obtained in CC and MLO views. We selected images digitized with a Lumisys
laser film scanner at 50 mm pixel size. Each image has a resolution of 4096 gray level tones.
The location and size of a mass, when it exists, were taken from the code-chain of the “.ics”
file available at the DDSM project and were used to automatically extract square sub-images
called regions of interest (ROIs) from the original image. The images used in the experiments
were cuttings of size 128×128 pixels done in the sub-image, whose centers correspond to the
centers of the presented abnormalities. An example of the cropping process that eliminates
image label and background is given in Figure 1. To obtain subimages with no mass, we have
followed the same procedure, except that the location was randomly taken from a healthy part
of the mammogram. With this approach, a total of 480 sub-images were acquired, and each of
these cropped images was used for texture feature extraction and subsequent classification.
2.2 Multiresolution analysis
Image analysis on multiple scales allows image resolution to be modified in order to process
as little data as possible. This is accomplished by selecting relevant details for a given task
(Mallat, 1996). The basic idea is to represent the image on several resolutions and analyse
them on frequency domain, through the application of function transforms. In this chapter,
we analyse the performance of wavelet transforms on a multiresolution environment. The
basics of wavelet transforms are presented as follows.
2.2.1 Wavelet transforms
For a given function f (x) ∈ R, the wavelet transform W f (a, b) ∈ R is obtained from the inner
product of f (x) with a wavelet family, i.e.:
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(Kinoshita et al., 2007). Second reading of the screening mammograms by a human reader can
increase cancer detection rates (Thurfjell et al., 1994) (Warren & Duffy, 1995). Obviously, this
procedure is too expensive, complex, and time consuming particularly in screening programs
where a huge number of mammographic images have to be read (Mencattini et al., 2010).
The development of computerized systems as second readers represents an alternative.
Computer-Aided Detection (CADe) and Computer-Aided Diagnosis (CADx) systems have
been applied to mammographic images to assist radiologists on lesions analysis such as
microcalcification, mass and architectural distortions. Algorithms for image processing
together with artificial intelligence techniques, such as neural network and fuzzy logic,
are used in order to enhance, segment, extract features and classify abnormalities (Jiang
et al., 2007), (Balleyguier et al., 2007), (Doi et al., 1999). CADe schemes are systems that
automatically detect suspicious lesions in mammograms, being used as a localization task.
CADx systems extend the computer analysis to yield as output the characterization of a
region or the estimated probability of lesion malignancy. The present chapter is focused on
the classification task.
Although CADe and CADx systems have provided a large number of research and high rates
of sensitivity, the majority of these works analyzes the MLO and CC views independently.
In some situations, this system detects abnormalities in only one of the views. Radiologists
believe that there is an inconsistency if a particular lesion is similar in both views and the
system does not have the capability to find it. Studies have shown that these limitations have
changed their impressions and radiologists are ignoring the results provided by these systems
(Doi et al., 1999).
Several computer algorithms are used for identification of abnormalities in the breast
by extracting features directly from digitized mammograms. Typically, two classes of
features are extracted from mammograms with these algorithms, namely morphological and
non-morphological features. Morphological features are intended to describe information
related to the morphology of a lesion, such as lesion size and shape. Image texture
analysis is an important class that represents gray level properties of images used to describe
non-morphological features that are not easily interpreted by humans. This information can
be obtained through a variety of image processing algorithms, calculated using a variety
of statistical, structural and spectral techniques including co-occurrence matrices, fractal
dimensions and multiresolution techniques. Using a different space by special data transform
such as Fourier transform or wavelets transform could be helpful to separate a special data
that contain specific characteristics. Multiresolution analysis allows for the preservation of an
image according to certain level of resolution, i.e., it allows for the zooming in and out on the
underlying texture structure. Therefore, the texture extraction is not affected by the size of the
pixel neighborhood (Eltoukhy et al., 2010).
In this chapter, we present a method for extraction and selection of texture-related attributes
and classification using the fusion of information from both CC and MLO visions. In
the extraction stage, the wavelet transform method was applied to provide texture-related
attributes for the considered images. Following, the singular value decomposition (SVD)
technique was used to reduce the number of attributes. The application of analysis of variance
(ANOVA) was also conducted for further reduction of the attributes after the SVD application.
In the final step, we used the Random Forest and SVM classifiers to analyze mammogram
lesions. The overall performance of the proposed method was evaluated by means of the area
under the ROC curve.
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were cuttings of size 128×128 pixels done in the sub-image, whose centers correspond to the
centers of the presented abnormalities. An example of the cropping process that eliminates
image label and background is given in Figure 1. To obtain subimages with no mass, we have
followed the same procedure, except that the location was randomly taken from a healthy part
of the mammogram. With this approach, a total of 480 sub-images were acquired, and each of
these cropped images was used for texture feature extraction and subsequent classification.
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Image analysis on multiple scales allows image resolution to be modified in order to process
as little data as possible. This is accomplished by selecting relevant details for a given task
(Mallat, 1996). The basic idea is to represent the image on several resolutions and analyse
them on frequency domain, through the application of function transforms. In this chapter,
we analyse the performance of wavelet transforms on a multiresolution environment. The
basics of wavelet transforms are presented as follows.
2.2.1 Wavelet transforms
For a given function f (x) ∈ R, the wavelet transform W f (a, b) ∈ R is obtained from the inner
product of f (x) with a wavelet family, i.e.:
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Fig. 1. Procedure applied for the selection of ROI’s: images with malignant lesion and images
no lesions.
are wavelets obtained from scaling and time shifting operations on a mother wavelet ψ(x),
with a and b being the scaling and translation factors, respectively. The mother wavelet ψ(x)
is an integrable function with zero mean, i.e.:
∫ ∞
−∞
ψ(x)dx = 0 (3)
and centered in the neighborhood of x = 0. Examples of wavelets can be found on reference
(Mallat, 1998). The scale parameter a is referred to as the transform resolution level. When
W f (a, b) is known only for a < a0, to recover f (x) it is necessary a complement of information
corresponding to W f (a, b) for a > a0. This is obtained by introducing a scaling function φ(x),
from which an approximation of f (x) at scale a is achieved:












In this way, W f (a, b) and L f (a, b) are defined as the detail and approximation coefficients of
the wavelet transform, respectively.
To allow fast numerical implementations, it is common to impose that the scale and translation
parameters vary only along discrete values, the most common being the dyadic wavelet
decomposition, which is achieved when a = 2j and b = k 2j, for integers j and k. Therefore,
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which are orthonormal bases of some subspaces of L2(R) related to the resolution 2j. Many
families of wavelets have been developed, such as Haar, Daubechies, Coiflet, cubic splines,
among others.
For discrete signals, the discrete wavelet transform (DWT) is obtained by the discretization of
time as well as the translation and scale parameters. Mallat has proved that the dyadic DWT
of a signal is equivalent to its decomposition through high-pass and low-pass filter banks, as
many filters as is the desired resolution. The DWT achieves a multiresolution decomposition







aj,k g̃[n − 2jk] + ∑
k∈Z
dJ,kh̃[n − 2Jk] (7)
The sequences h̃[n] and g̃[n] are low-pass and high-pass synthesis filters, respectively. They
are called reconstruction filters.
The wavelet coefficients, namely the approximation coefficients aj,k and the detail coefficients
dJ,k, are obtained by the convolution operations:
aj,k = ∑
n
f [n]hj[n − 2jk] (8)
dJ,k = ∑
n
f [n]gJ [n − 2Jk] (9)
where hj[n] and gJ [n] are the analysis discrete filters, related to the approximation and detail
coefficients, respectively. They are called decomposition filters. Considering two filters, a
low-pass h[n] and a high-pass g[n], the analysis filters can be obtained iteratively as:
g1[n] = g[n] (10)
h1[n] = h[n] (11)
gj+1 = ∑
k
gj[k]h[n − 2k] (12)
hj+1 = ∑
k
hj[k]h[n − 2k] (13)
At each j-th resolution, the wavelet coefficients are obtained by convolving the previous one
with hj[n] and gJ [n] and taking every other sample of the convolution (downsampling the
result by a factor of 2), as illustrated by Figure 2. If the decomposition filter h[n] and the
Fig. 2. DWT analysis filter bank.
reconstruction filter h̃[n] are considered to be equal, this defines conjugate mirror filters and
h[n] and g[n] completely characterizes the dyadic DWT, with g[n] = (−1)nh[N − 1− n], where
N is the number of filter coefficients. In this case, as it can be seen, the filter h[n] plays an
important role for wavelet transforms.
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h[k]φ(t − k) (15)
As an example, the Daubechies wavelets are distinguished from each other by the number of
vanishing moments. The Daubechies with 3 vanishing moments, referred to as Db3, was used








Table 1. Daubechies filter for a wavelet with 3 vanishing moments.
In what concerns images, which are bidimensional (2D) signals, the DWT can be computed as
given by Figure 3, which shows an image decomposition from the j-th level to the (j + 1)-th
level of the DWT. The coefficients LLj represent the pixel values of the original image. Firstly,
the image is passed through a pair of filters on each row, followed by a downsampling of
2. The results are used as inputs of two filter banks, which are applied at the columns of
the image, followed by downsampling. Four sub-images are generated in this process: the
approximation LLj+1, which represents the original image with a smaller resolution, and the
details LHj+1, HLj+1, HHj+1, which represent the horizontal, vertical and diagonal directions,
respectively.
Fig. 3. Filter bank representing one DWT stage.
For each ROI, the 2D-DWT was applied using three different wavelet functions, Coiflet 5,
Daubechies 3 e Symlet 4, with 2 resolution levels. The application of the first decomposition
level yields the coefficient matrices LL1 ,LH1 ,HL1 and HH1. The second decompositon level
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applied in subband LL1 resulted in the coefficient matrices LL2 ,LH2 ,HL2 and HH2, and so on.
Once most of the information is contained in the detail coefficients, only the detail subimages
are evaluated in this work.
2.2.2 Nonlinearity operator
Implementation of discrete wavelet transformation involves linear convolution of images with
coefficients of filter meant for the wavelet basis function considered (Selvan & Ramakrishnan,
2007). However, linear convolution increases the size of subband images. This causes
distortions at boundaries of the image, when the image is reconstructed.
To overcome this problem, we applied the method proposed by Selvan and Ramakrishnan
to make the subband coefficients less sensitive to local variations (Selvan & Ramakrishnan,
2007). In this technique, each row and column of a Q × Q image is periodically extended
by R/2 pixels on both sides, where R is the number of filter coefficients. That results in a
(Q + R)× (Q + R) image. Addition of any value lower than R/2 will not yield the required
core samples, after removing excess samples on the boundaries. An addition of any value
higher than R/2 will lead to more number of samples than required. Hence, R/2 pixels are
added on all four sides of the image. Convolution of the (Q + R)× (Q + R) image, with filter
of length R, yields ((Q + R) + R − 1) samples in one dimension. Out of these samples, core
(Q + 2R − 1 − 2(R − 1)) = (Q + 1) samples are considered for decimation, which results in
[(Q + 1)/2] core samples after decimation. Hence, after one level of wavelet decomposition,
a Q × Q image yields four (Q/2)× (Q/2) subbands, resulting in nonexpansive samples. In
this case, the coefficient matrices were adjusted to the size 64× 64 for one decomposition level.
For two decompositon level, this method yieds subband matrices of size 32 × 32.
In order to make the subband coefficients less sensitive to local variations, nonlinearity
and smoothing operators must be applied on wavelet transformation coefficients, before
extracting the parameters. For nonlinearity and smoothing operations, the total energy of











where Ei is the overall energy in the i-th subband, wi(j, k) is the wavelet transformation
coefficient at locations (j, k) in the i-th subband, and P and Q are the number of rows and
columns of the i-th subband, respectively. Here, parameters P and Q have similar values.
In the present work, we also consider 3 × 3 neighborhoods, compute their average, and
normalize the average, as proposed by (Selvan & Ramakrishnan, 2007). At each location
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applied in subband LL1 resulted in the coefficient matrices LL2 ,LH2 ,HL2 and HH2, and so on.
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2007). However, linear convolution increases the size of subband images. This causes
distortions at boundaries of the image, when the image is reconstructed.
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to make the subband coefficients less sensitive to local variations (Selvan & Ramakrishnan,
2007). In this technique, each row and column of a Q × Q image is periodically extended
by R/2 pixels on both sides, where R is the number of filter coefficients. That results in a
(Q + R)× (Q + R) image. Addition of any value lower than R/2 will not yield the required
core samples, after removing excess samples on the boundaries. An addition of any value
higher than R/2 will lead to more number of samples than required. Hence, R/2 pixels are
added on all four sides of the image. Convolution of the (Q + R)× (Q + R) image, with filter
of length R, yields ((Q + R) + R − 1) samples in one dimension. Out of these samples, core
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The central wavelet coefficient from the 3 × 3 neighborhood was then replaced by the
corresponding normalized energy.
Figure 4 represents the process of wavelet decomposition for each ROI to obtain the wavelet
coefficient features.
Fig. 4. Ilustration Wavelet decomposition of a mammographic image.
This process produced 12,288 wavelet coefficients for the first decomposition (64 × 64 in 3
subimages) and 3,072 coefficients for the second decomposition (32 × 32 in 3 subimages).
Gathering together all detail coefficients from the subbands resulted on a feature vector of
15,360 attributes.
2.3 Singular value decomposition
In this work, the number of wavelet coefficients is very large and the estimation of model
parameters is computationally demanding. Singular value decomposition (SVD) based
method is a very powerful mathematical tool which is mainly used here to reduce a
large dataset to a dataset with significantly fewer values, still containing a large fraction
of the variability present in the original data. SVD is extraordinarily useful and has
many applications such as data analysis, signal processing, pattern recognition and image
compression (Pedrini & Schwartz, 2008). It is a linear algebra tool that allows for the
decomposition of a matrix into the product of three more simple matrices (Selvan &
Ramakrishnan, 2007) (Ramakrishnan & Selvan, 2007a) (Ramakrishnan & Selvan, 2007b).
To explain the aplication of SVD, consider the matrix Ii with size P × Q, whose entries are
the subband wavelet coefficients after the introduction of nonlinearity. The application of the




where Ui, with size P × Q, and Vi, with size Q × Q, are orthogonal matrices whose columns
are the eigenvectors of matrices IiITi and I
T
i Ii, respectively, and Si, with size Q × Q, is
a diagonal matrix whose non-zero entries are the singular values (square roots of the




σ1 0 0 · · · 0
0 σ2 0 · · · 0
. . .
0 0 · · · 0 σQ
⎤
⎥⎥⎥⎦ (20)
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where σi are the non-zero singular values, with σ1 ≥ σ2 ≥ ... ≥ σQ. Once the SVD is unique
for each matrix, the singular values completely represents the subband images.
A method of truncation of the lower singular values, which is equivalent to a filter based
approach, was applied to matrix Si for dimensionality reduction with images with noise. In
(Selvan & Ramakrishnan, 2007), the authors have shown that the effect of noise is more intense
on singular values with lower magnitudes. Therefore, the diagonal matrix can be truncated







where σn is the n-th singular value and σ1 is its highest value.
Since the wavelet transform in this work was considered for 2 resolution levels, there are
subband images with sizes 64 × 64 and 32 × 32 pixels, what leads to a different number
of truncated singular values (different K) for each mammogram. Therefore, Equation 21 was
used to get a value of Kr for each resolution level, and the overall K was obtained by averaging
the number of truncated singular values obtained. Having defined the average value K,
singular values were extracted from each of the eight wavelet subimages, resulting in a feature
vector of 6K elements representing texture characteristics of the original mammograms.
Figure 5 shows an example of the Si diagonal matrix obtained from the subband LH2 of
a Coiflet wavelet mother used for texture analysis. The values of the diagonal matrix was
truncated by the average value K, which corresponds to the attributes in the region marked in
green, representing the texture features.
Fig. 5. Matrix Si (32 × 32) of subband LH2 obtained by SVD from wavelet transform.
2.4 Attributes reduction
In order to verify the relevance of the attributes obtained after the SVD procedure, we applied
the technique of Analysis of Variance (ANOVA). This technique is a statistical model that
compares the means of two or more experiments. This evaluation is performed to the extent
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Figure 5 shows an example of the Si diagonal matrix obtained from the subband LH2 of
a Coiflet wavelet mother used for texture analysis. The values of the diagonal matrix was
truncated by the average value K, which corresponds to the attributes in the region marked in
green, representing the texture features.
Fig. 5. Matrix Si (32 × 32) of subband LH2 obtained by SVD from wavelet transform.
2.4 Attributes reduction
In order to verify the relevance of the attributes obtained after the SVD procedure, we applied
the technique of Analysis of Variance (ANOVA). This technique is a statistical model that
compares the means of two or more experiments. This evaluation is performed to the extent
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that the observed differences between the means are significant for the comparison of two
estimates Vieira (2006). For our experiments, this comparison was carried out on the mass
and normal mammographic images. Then, mean and standard deviation were calculated
for sets of texture data of the masses and normal images. This set was used to evaluate if
each attribute belonged to a particular class. However, when there are differences between
the attribute and these classes, this information was eliminated because they did not suit as
a reference in the definition of classes in the classification stage Pedrini & Schwartz (2008)
Susomboon et al. (2008).
The one-way ANOVA method was firstly applied on the singular values attributes generated
by the SVD procedure to determine the statistical significance of these values. In this method,
the null hypothesis is that all attribute means are the same. The alternative hypothesis is that
at least two of them are different. An F-test is applied to generate this test with a confidence
interval of p = 5%. The set with singular values was tested to evaluate if each attribute is
different from each other. If any two groups are statistically the same, both are discarded
since they do not contribute to the classification step.
In many cases, the alternative hypothesis is quite general and one needs some information
about which pairs of means are significantly different, and which are not. This is done with
a test called multiple comparison procedure. The multiple comparison method was applied
recurrently to determine a minimum value for the number of reduced attributes. This step
occurred with the change in the p value down to the value p = 1.10−16.
The selection of sets for ANOVA evaluation and a graphic with the analysis of the attributes
are illustrated in Figure 6
Fig. 6. Method of application of the ANOVA method on attribute 2.
2.5 Fusion of textural information
Several studies have demonstrated that the fusion of information extracted from two views,
CC and MLO, allow for the reduction of false positive compared to the use of a single image
Paquerault et al. (2002) Gupta et al. (2006).
For the process of fusion of information from two views, we applied the ANOVA technique
to analyze the characteristics that are relevant in both images, i.e., information that was
statistically different. The procedure resulted in an array of textural data with 50% of
information from vision CC and 50% from MLO view. Only the common characteristics of
the two views were used in the classification stage.
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Figure 7 shows the block diagram of the algorithm to fusion information from the
mammograms obtained in both CC and MLO view.
Fig. 7. Block diagram of the algorithm for obtaining the vector with the fusion of information
from mammograms.
2.6 Classification stage
As a final stage of the computerized algorithm, after the information fusion step, a
classification procedure was performed on the characteristic vectors outcome obtained from
both views. In this work, we used the Random Forest and SVM classifiers, separately, to
categorize the mammogram ROIs either as normal or abnomal tissues. These algorithms
were implemented in WEKA (Waikato Environment for Knowledge Analysis) software (Vibha
et al., 2006).
The Random Forest algorithm is built from a collection of classification trees. It is a concept of
regression trees, bootstrap samples induced by a set of training data, using features selected
in the random process of tree induction (Ramos & Nascimento, 2008).
The Support Vector Machine algorithm based on Sequential Minimal Optimization for
implementation (SMO) is a machine learning technique based on statistical learning theory,
which seeks to find a hyperplane with maximum separation between the classes, assuming
that the data are linearly separable. If not, the SVM maps the data using a kernel function in
a feature space of higher dimension, where the data becomes linearly separable (Osta et al.,
2008).
To train and test the proposed computerized method, a cross validation procedure was
performed on a dataset comprising 240 normal ROI (240 images) and 240 abnormal ROI (240
images). To obtain the performance for each classification we implemented a 10-fold cross
validation procedure, in which the dataset were split into N parts. N − 1 parts served as the
training data to fit the classification model. The remaining part was used as the test data for
the estimation of performance measures. Each of the N parts was used as test data in turn.
The resulting N estimates were averaged to obtain the final expected value. Figure 8 presents
the scheme of division into parts for the application of cross-validation procedure.
2.7 System evaluation
To give support to the performance evaluation of proposed method, we computed sensitivity
(true positive rate), specificity (true negative rate) and accuracy for each of the confusion
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CC and MLO, allow for the reduction of false positive compared to the use of a single image
Paquerault et al. (2002) Gupta et al. (2006).
For the process of fusion of information from two views, we applied the ANOVA technique
to analyze the characteristics that are relevant in both images, i.e., information that was
statistically different. The procedure resulted in an array of textural data with 50% of
information from vision CC and 50% from MLO view. Only the common characteristics of
the two views were used in the classification stage.
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mammograms obtained in both CC and MLO view.
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from mammograms.
2.6 Classification stage
As a final stage of the computerized algorithm, after the information fusion step, a
classification procedure was performed on the characteristic vectors outcome obtained from
both views. In this work, we used the Random Forest and SVM classifiers, separately, to
categorize the mammogram ROIs either as normal or abnomal tissues. These algorithms
were implemented in WEKA (Waikato Environment for Knowledge Analysis) software (Vibha
et al., 2006).
The Random Forest algorithm is built from a collection of classification trees. It is a concept of
regression trees, bootstrap samples induced by a set of training data, using features selected
in the random process of tree induction (Ramos & Nascimento, 2008).
The Support Vector Machine algorithm based on Sequential Minimal Optimization for
implementation (SMO) is a machine learning technique based on statistical learning theory,
which seeks to find a hyperplane with maximum separation between the classes, assuming
that the data are linearly separable. If not, the SVM maps the data using a kernel function in
a feature space of higher dimension, where the data becomes linearly separable (Osta et al.,
2008).
To train and test the proposed computerized method, a cross validation procedure was
performed on a dataset comprising 240 normal ROI (240 images) and 240 abnormal ROI (240
images). To obtain the performance for each classification we implemented a 10-fold cross
validation procedure, in which the dataset were split into N parts. N − 1 parts served as the
training data to fit the classification model. The remaining part was used as the test data for
the estimation of performance measures. Each of the N parts was used as test data in turn.
The resulting N estimates were averaged to obtain the final expected value. Figure 8 presents
the scheme of division into parts for the application of cross-validation procedure.
2.7 System evaluation
To give support to the performance evaluation of proposed method, we computed sensitivity
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Fig. 8. Division scheme for the application of training and test classification step.
matrices (Tsai & Lee, 2002). A confusion matrix shows the predicted and actual classifications
accomplished by a classifier. It has dimensions L × L, where L is the number of classes
evaluated by the classifier. In our case, L = 2 and the confusion matrix can be stated as
shown in Table2. The parameters employed for performance evaluation can be summarized
Class Positive Negative
Positive True Positive (TP) False Negative (FN)
Negative False Positive (FP) True Negative (TN)
Table 2. Confusion matrix for L = 2 classes.
in Table 3, which shows the most commonly used formulas. Specificity measures the
percentage of positive instances that were predicted as positives, while sensitivity measures
the percentage of negative instances that were predicted as negatives. Overall accuracy is the
probability that a diagnostic test is correctly performed.
Parameter Definition
Sensitivity TP / (TP + FN)
Specificity TN / (TN + FP)
Accuracy (TN + TP) / (TP + TN + FP + FN)
Table 3. Definition of performance evaluation parameters.
Performance evaluation was accomplished by means of the receiver operating characteristic
(ROC) curves. An ROC curve is a two-dimensional graph of test sensitivity, plotted on the
y-axis, versus its false positive rate (or 1 − specificity), plotted on the x-axis. An ROC graph
depicts relative trade-offs between benefits (TP) and costs (FP), and is produced by varying the
decision threshold of the classifier. Although it sometimes can lose some subtle information
on classification results, the area under the ROC curve (AUC) is a good accurate measure of a
given classifier performance. A test classification with an AUC of 1.0 is a perfect test and an
AUC of 0.0 results in a perfectly inaccurate test.
3. Results
3.1 Extraction and reduction from wavelet transform
In the proposed method, texture information was extracted by wavelet tranform application
and the SVD method was employed to reduce the number of coefficients before the
classification stage. These methods were applied to each ROI obtained in the CC and MLO
views. Table 4 shows the number of truncated singular values (K parameter) for the first
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and second levels of each subband image of each view, as well the resulting number of
attributes after SVD application. The resulting number of coefficients is obtained multiplying
the second and third rows of the table by 3 and summing the result, since it was employed
a two level decomposition that results in 3 subimages for each level. Once the wavelet
Mother wavelet K (64×64) K (32×32) Number of Coefficients
Coiflet 5 23 12 105
Daubechies 3 26 14 120
Symlets 4 23 13 108
Table 4. Value of truncated K parameter and resulting number of coefficients after reduction
for each subband image of each CC and MLO views.
transform is a natural filtering process derived from distinct discrete filters, the use of different
wavelet mothers conducted to a different number of coefficients, reflected in the truncated K
parameter, for each analyzed image. As seen in the previous table, in summary, the SVD
method can effectively reduce the number of coefficients obtained from wavelet subimages.
As stated before, each wavelet transformed ROI initially encompassed a total of 15,360 wavelet
coefficients extracted from a two-level decomposition procedure. The application of the SVD
method provided an average reduction of 99.3% on the number of attributes necessary for
evaluation of texture information. Comparing the different wavelet mothers evaluated, it can
be observed that the Coiflet 5 wavelet provided the smaller number of coefficients.
To reduce the number of attributes and provide a better separation of diseased and normal
classes, the method of analysis of variance (ANOVA) with significance level of 5% was applied
on the coefficients resulting from the SVD method. Table 5 shows the number of coefficients
resulting from the application of ANOVA method with a significance level of 0.05.
Type of Wavelet Mother CC MLO
Coiflet 5 51 48
Daubechies 3 62 48
Symlets 4 56 43
Table 5. Number of wavelet coefficients after application of ANOVA method with p = 0.05.
The procedure to determine the significance was applied again to determine a minimum value
in reducing the number of attributes. Table 6 presents the obtained results in relation to the
number of coefficients after the application of ANOVA method with the limiting value set to
p = 1.10−16 Applying the ANOVA method on the attributes resulting from the SVD method,
Type of Wavelet Mother CC MLO
Coiflet 5 7 14
Daubechies 3 5 11
Symlets 4 5 15
Table 6. Number of the wavelet coefficients after application of ANOVA method with p =
1 × 10−16.
it can be noticed that there is a significant reduction on the number of coefficients. These
values are even more expressive when the ANOVA was applied recursively with the limiting
significance level set to p = 1 × 10−16, which led to an average reduction of 81.34% compared
to the first application of ANOVA.
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decision threshold of the classifier. Although it sometimes can lose some subtle information
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AUC of 0.0 results in a perfectly inaccurate test.
3. Results
3.1 Extraction and reduction from wavelet transform
In the proposed method, texture information was extracted by wavelet tranform application
and the SVD method was employed to reduce the number of coefficients before the
classification stage. These methods were applied to each ROI obtained in the CC and MLO
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attributes after SVD application. The resulting number of coefficients is obtained multiplying
the second and third rows of the table by 3 and summing the result, since it was employed
a two level decomposition that results in 3 subimages for each level. Once the wavelet
Mother wavelet K (64×64) K (32×32) Number of Coefficients
Coiflet 5 23 12 105
Daubechies 3 26 14 120
Symlets 4 23 13 108
Table 4. Value of truncated K parameter and resulting number of coefficients after reduction
for each subband image of each CC and MLO views.
transform is a natural filtering process derived from distinct discrete filters, the use of different
wavelet mothers conducted to a different number of coefficients, reflected in the truncated K
parameter, for each analyzed image. As seen in the previous table, in summary, the SVD
method can effectively reduce the number of coefficients obtained from wavelet subimages.
As stated before, each wavelet transformed ROI initially encompassed a total of 15,360 wavelet
coefficients extracted from a two-level decomposition procedure. The application of the SVD
method provided an average reduction of 99.3% on the number of attributes necessary for
evaluation of texture information. Comparing the different wavelet mothers evaluated, it can
be observed that the Coiflet 5 wavelet provided the smaller number of coefficients.
To reduce the number of attributes and provide a better separation of diseased and normal
classes, the method of analysis of variance (ANOVA) with significance level of 5% was applied
on the coefficients resulting from the SVD method. Table 5 shows the number of coefficients
resulting from the application of ANOVA method with a significance level of 0.05.
Type of Wavelet Mother CC MLO
Coiflet 5 51 48
Daubechies 3 62 48
Symlets 4 56 43
Table 5. Number of wavelet coefficients after application of ANOVA method with p = 0.05.
The procedure to determine the significance was applied again to determine a minimum value
in reducing the number of attributes. Table 6 presents the obtained results in relation to the
number of coefficients after the application of ANOVA method with the limiting value set to
p = 1.10−16 Applying the ANOVA method on the attributes resulting from the SVD method,
Type of Wavelet Mother CC MLO
Coiflet 5 7 14
Daubechies 3 5 11
Symlets 4 5 15
Table 6. Number of the wavelet coefficients after application of ANOVA method with p =
1 × 10−16.
it can be noticed that there is a significant reduction on the number of coefficients. These
values are even more expressive when the ANOVA was applied recursively with the limiting
significance level set to p = 1 × 10−16, which led to an average reduction of 81.34% compared
to the first application of ANOVA.
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3.2 Classification of CC and MLO views independently
Tables 7 and 8 show the mean values of sensitivity,specificity, accuracy and standard deviation
(σ) for the Random Forest and SVM classifiers, respectively, for CC e MLO views independent
after the reduction process of wavelet coefficients. Sensitivity and specificity are the basic
Coiflet 5 Daubechies 3 Symlet 4
CC MLO CC MLO CC MLO
Sensitivity 74,17 76,04 75,83 77,50 74,44 77,78
Specificity 75,83 77,29 77,08 77,83 75,00 78,06
Accuracy 75,00 76,67 76,46 77,67 74,72 77,92
σ 16,20 15,18 14,83 14,65 15,89 14,54
Table 7. Measurements obtained with the Random Forest classifier for each view of
mammogram.
Coiflet 5 Daubechies 3 Symlet 4
CC MLO CC MLO CC MLO
Sensitivity 70,00 69,38 67,92 71,17 67,78 71,11
Specificity 81,67 85,63 83,33 86,33 84,44 87,22
Accuracy 75,83 77,50 75,63 78,75 76,11 79,17
σ 9,58 10,63 10,58 10,56 10,83 10,32
Table 8. Measurements obtained with the SVM classifier for each view of mammogram.
measures of the precision for a given diagnostic test. Observing the data on Tables 7 and 8
we can see a great variation on the results for the different wavelets considered. From Table
7, concerning the Random Forest classifier, it can be noticed that the MLO view provided
the best results for all three wavelet mothers used. Among the wavelet functions considered,
there is little difference on the results (approximately 1%), and the best results were obtained
with the application of the Symlet 4 wavelet mother.
A similar result can be observed for the SVM classifier, as it can be seen on Table 8 that shows
better results for the MLO views. Comparing the values for the MLO and CC views, the
first one resulted on average values 3% superior than the latter. These results show that an
inconsistency can occur if a particular lesion is similar in both views and the system does
not have the capability to find it. As stated in (Doi et al., 1999), studies have shown that
these limitations have been considered mistrusted and radiologists tend to ignoring the results
provided by these systems.
When comparing both classifiers, this inconsistency can also be noted, since there is a large
variability of results. The Random Forest presented better results for false positive rates than
the SVM classifier, but the latter, on average, performed better for the false negative tests.
Considering the accuracy results (overall system performace), the SVM classifier presented
the better results on average.
Those results are corroborated when considering the AUC as a measure of the system
performance. Figure 9 shows the results of AUC for the Random Forest classifier applied
to the CC and MLO views independently, after the reduction procedure, parameterized by
the different wavelet functions. In Figure 10, the same results of AUC are shown when
applying the SVM classifier. As it can be noticed, SVM performed better for almost all cases,
the exception being the Daubechies 3 wavelet on the CC view.
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Fig. 9. Results of AUC after application of the reduction methods for different wavelets and
Random Forest classifier.
Fig. 10. Results of AUC after application of the reduction methods for different wavelets and
SVM classifier.
3.3 Classification of two-view information fusion (CC and MLO)
Table 9 shows the number of texture data after application of the ANOVA technique in each
view separately and the number of attributes after the two-view attributes fusion for each type
of wavelet mother. Tables 10 and 11 show the mean values of sensitivity, specificity, accuracy
Type of Wavelet-Mother CC MLO CC + MLO
Coiflet 5 7 14 14
Daubechies 3 5 11 10
Symlets 4 5 15 10
Table 9. Number of relevant textural information after application of the ANOVA technique
with p = 1 × 10−16.
and standard deviation (σ) for the process of two-view information fusion, using the Random
Forest and SVM classifiers, respectively.
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Table 8. Measurements obtained with the SVM classifier for each view of mammogram.
measures of the precision for a given diagnostic test. Observing the data on Tables 7 and 8
we can see a great variation on the results for the different wavelets considered. From Table
7, concerning the Random Forest classifier, it can be noticed that the MLO view provided
the best results for all three wavelet mothers used. Among the wavelet functions considered,
there is little difference on the results (approximately 1%), and the best results were obtained
with the application of the Symlet 4 wavelet mother.
A similar result can be observed for the SVM classifier, as it can be seen on Table 8 that shows
better results for the MLO views. Comparing the values for the MLO and CC views, the
first one resulted on average values 3% superior than the latter. These results show that an
inconsistency can occur if a particular lesion is similar in both views and the system does
not have the capability to find it. As stated in (Doi et al., 1999), studies have shown that
these limitations have been considered mistrusted and radiologists tend to ignoring the results
provided by these systems.
When comparing both classifiers, this inconsistency can also be noted, since there is a large
variability of results. The Random Forest presented better results for false positive rates than
the SVM classifier, but the latter, on average, performed better for the false negative tests.
Considering the accuracy results (overall system performace), the SVM classifier presented
the better results on average.
Those results are corroborated when considering the AUC as a measure of the system
performance. Figure 9 shows the results of AUC for the Random Forest classifier applied
to the CC and MLO views independently, after the reduction procedure, parameterized by
the different wavelet functions. In Figure 10, the same results of AUC are shown when
applying the SVM classifier. As it can be noticed, SVM performed better for almost all cases,
the exception being the Daubechies 3 wavelet on the CC view.
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Fig. 9. Results of AUC after application of the reduction methods for different wavelets and
Random Forest classifier.
Fig. 10. Results of AUC after application of the reduction methods for different wavelets and
SVM classifier.
3.3 Classification of two-view information fusion (CC and MLO)
Table 9 shows the number of texture data after application of the ANOVA technique in each
view separately and the number of attributes after the two-view attributes fusion for each type
of wavelet mother. Tables 10 and 11 show the mean values of sensitivity, specificity, accuracy
Type of Wavelet-Mother CC MLO CC + MLO
Coiflet 5 7 14 14
Daubechies 3 5 11 10
Symlets 4 5 15 10
Table 9. Number of relevant textural information after application of the ANOVA technique
with p = 1 × 10−16.
and standard deviation (σ) for the process of two-view information fusion, using the Random
Forest and SVM classifiers, respectively.
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Coiflet 5 Daubechies 3 Symlet 4
CC + MLO CC + MLO CC + MLO
Sensitivity 82,50 83,33 82,50
Specificity 81,67 82,92 80,83
Accuracy 82,08 83,13 81,67
σ 12,43 11,74 13,20
Table 10. Results for two-view fusion obtained using the Random Forest classifier.
Coiflet 5 Daubechies 3 Symlet 4
CC + MLO CC + MLO CC + MLO
Sensitivity 75,83 77,08 75,00
Specificity 88,33 89,17 88,61
Accuracy 82,08 83,13 81,81
σ 10,77 9,89 9,94
Table 11. Results for two-view fusion obtained using the SVM classifier.
As seen on Tables 10 and 11, the results for the two classifiers using two-view CC and MLO
information fusion were increased for all wavelet functions considered. As an example, for
the Coiflet 5 wavelet, the fusion procedure led the sensitivity (fraction of the number of
regions detected as positive against those that actually have a mass) to be increased about
5% compared to the result of the same wavelet for individual visions. The same occurred
to the other two wavelets. Furthermore, the results also show an increase in the specificity
Fig. 11. Results of AUC after the two-view information fusion process for the Random Forest
and SVM classifiers.
and accuracy parameters due to the two-view information fusion procedure. The results on
the tables also show that the Daubechies 3 wavelet function have reached the best results
compared to the other two applied wavelets. Since accuracy reflects the relation between
sensitivity and specificity, that descriptor permited to note the similar overall performance
between the two classifiers. This result is also visible when evaluating the AUC performance
of the classifiers. Figure 11 shows the results of AUC after CC and MLO information fusion
for the three different types of wavelet mother and the Random Forest and SVM classifiers.
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4. Conclusion
In this work, we develop a method for extraction and selection of attributes using the
information fusion from both CC and MLO views for breast cancer classification of
mammogram images. Comparing the results of Tables 7 with 10 and 8 with 11, we observe
that the use of textural information, obtained from the fusion of the CC and MLO views, might
raise the rates of the descriptors evaluated.
Experimental results showed that the three types of wavelet mother had superior performance
over the area under the ROC curve for the SVM classifier. Performance evaluation was
conducted in relation to the AUC and the results obtained showed that the best classification
rates were obtained using the Daubechies wavelel, giving an AUC = 0.831 for the Support
Vector Machine classifiers. Future experiments may use other types of feature descriptors to
evaluate possible improvements in image classification.
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Coiflet 5 Daubechies 3 Symlet 4
CC + MLO CC + MLO CC + MLO
Sensitivity 82,50 83,33 82,50
Specificity 81,67 82,92 80,83
Accuracy 82,08 83,13 81,67
σ 12,43 11,74 13,20
Table 10. Results for two-view fusion obtained using the Random Forest classifier.
Coiflet 5 Daubechies 3 Symlet 4
CC + MLO CC + MLO CC + MLO
Sensitivity 75,83 77,08 75,00
Specificity 88,33 89,17 88,61
Accuracy 82,08 83,13 81,81
σ 10,77 9,89 9,94
Table 11. Results for two-view fusion obtained using the SVM classifier.
As seen on Tables 10 and 11, the results for the two classifiers using two-view CC and MLO
information fusion were increased for all wavelet functions considered. As an example, for
the Coiflet 5 wavelet, the fusion procedure led the sensitivity (fraction of the number of
regions detected as positive against those that actually have a mass) to be increased about
5% compared to the result of the same wavelet for individual visions. The same occurred
to the other two wavelets. Furthermore, the results also show an increase in the specificity
Fig. 11. Results of AUC after the two-view information fusion process for the Random Forest
and SVM classifiers.
and accuracy parameters due to the two-view information fusion procedure. The results on
the tables also show that the Daubechies 3 wavelet function have reached the best results
compared to the other two applied wavelets. Since accuracy reflects the relation between
sensitivity and specificity, that descriptor permited to note the similar overall performance
between the two classifiers. This result is also visible when evaluating the AUC performance
of the classifiers. Figure 11 shows the results of AUC after CC and MLO information fusion
for the three different types of wavelet mother and the Random Forest and SVM classifiers.
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4. Conclusion
In this work, we develop a method for extraction and selection of attributes using the
information fusion from both CC and MLO views for breast cancer classification of
mammogram images. Comparing the results of Tables 7 with 10 and 8 with 11, we observe
that the use of textural information, obtained from the fusion of the CC and MLO views, might
raise the rates of the descriptors evaluated.
Experimental results showed that the three types of wavelet mother had superior performance
over the area under the ROC curve for the SVM classifier. Performance evaluation was
conducted in relation to the AUC and the results obtained showed that the best classification
rates were obtained using the Daubechies wavelel, giving an AUC = 0.831 for the Support
Vector Machine classifiers. Future experiments may use other types of feature descriptors to
evaluate possible improvements in image classification.
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1. Introduction 
In this chapter, firstly, the author describes the differences between CAD for analog 
mammography and FFDM with reference to clinical workflow and physical characteristics, 
and secondly, addresses how the detection performance of CAD can differ in accordance 
with image quality utilizing different FFDM systems, including future possibilities of breast 
CAD. 
2. Difference between CAD with analog mammography and with digital 
mammography in clinical workflow 
With CAD and analog mammography the CAD device is a single, independent device 
(Figure 1). The quality and quantity of image data depends on the film and the digitizer. It is 
easy to collect and analyze digital data through a film digitizer and the CAD system is an 
independent machine mainly developed by a venture company. 
On the other hand, with CAD and digital mammography, it is necessary to collect so-called 
raw digital data from an acquisition system. To develop CAD software, it is necessary to 
work in conjunction with acquisition systems. Furthermore, CAD is an independent 
instrument with analog mammography; on the other hand, with digital mammography, 
CAD will be one of the interpretation functions of the reading workstation. For the most 
effective utilization, it is necessary to integrate CAD well with the reading workstation 
workflow.  
Therefore, to disseminate CAD with digital mammography, we should take into 
consideration how to organize complete systems, including acquisition systems, reading 
workstations, and network systems. If the acquisition system and the reading workstation 
are made by the same maker, we can transfer raw image data from the acquisition system to 
the CAD server, and indicate Structure Report (SR) on the monitors at the reading 
workstation without any problems. On the other hand, when the makers are different, it 
may be a problem (Figure 2). For most effective utilization, it is necessary to integrate CAD 
well into the reading workstation workflow [1]. 
 14 
Breast CAD (Computer Aided Detection)  
in FFDM (Full Field Digital Mammography) 
Nachiko Uchiyama 
Research Center for Cancer Prevention and Screening,  
National Cancer Center, Tsukiji,  
Chuo-Ku, Tokyo,  
Japan 
1. Introduction 
In this chapter, firstly, the author describes the differences between CAD for analog 
mammography and FFDM with reference to clinical workflow and physical characteristics, 
and secondly, addresses how the detection performance of CAD can differ in accordance 
with image quality utilizing different FFDM systems, including future possibilities of breast 
CAD. 
2. Difference between CAD with analog mammography and with digital 
mammography in clinical workflow 
With CAD and analog mammography the CAD device is a single, independent device 
(Figure 1). The quality and quantity of image data depends on the film and the digitizer. It is 
easy to collect and analyze digital data through a film digitizer and the CAD system is an 
independent machine mainly developed by a venture company. 
On the other hand, with CAD and digital mammography, it is necessary to collect so-called 
raw digital data from an acquisition system. To develop CAD software, it is necessary to 
work in conjunction with acquisition systems. Furthermore, CAD is an independent 
instrument with analog mammography; on the other hand, with digital mammography, 
CAD will be one of the interpretation functions of the reading workstation. For the most 
effective utilization, it is necessary to integrate CAD well with the reading workstation 
workflow.  
Therefore, to disseminate CAD with digital mammography, we should take into 
consideration how to organize complete systems, including acquisition systems, reading 
workstations, and network systems. If the acquisition system and the reading workstation 
are made by the same maker, we can transfer raw image data from the acquisition system to 
the CAD server, and indicate Structure Report (SR) on the monitors at the reading 
workstation without any problems. On the other hand, when the makers are different, it 
may be a problem (Figure 2). For most effective utilization, it is necessary to integrate CAD 
well into the reading workstation workflow [1]. 
 




Fig. 1. Example of the Workflow of the CAD System Using Analog Mammography. 
 
SR: Structure Report 
CAD analyzes raw data from the acquisition system in a CAD server and refers the indication of CAD 
results to a reading workstation. 
The quality and quantity of image data depends on the acquisition system. The operating system 
consists of three steps: (1) an acquisition system, (2) a CAD server, and (3) a reading work station. The 
number of makers of CAD systems that correspond to each acquisition system is limited. It is necessary 
to confirm before installation whether the reading workstation can display CAD analysis results.  
Fig. 2. Example of the Workflow of the CAD System Using Digital Mammography.  
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3. How can image quality affect the detection performance of breast CAD in 
FFDM? 
Purpose 
At present, CAD, dedicated to digital mammography, analyzes the raw imaging data and 
detects candidate lesions including masses and microcalcifications. As for the physical 
characteristics, regarding the linear attenuation coefficient for breast tissue, the differential 
value between breast tissue and calcification is larger than the differential value between 
breast tissue and mass. In the raw imaging data, mass lesions have relatively localized large 
areas with a smaller number of photon counts compared to surrounding breast tissue. CAD 
analyzes the characteristics and detects the area as a candidate mass lesion. The raw imaging 
data is inverted and the mass lesion is recognized clinically as a localized high density area 
compared to background breast tissue density. In the raw imaging data, on the other hand, 
the images with microcalcification lesions have localized small and clustered areas with a 
smaller number of photon counts compared to the background breast tissue. CAD analyzes 
the characteristics and detects the area as a candidate microcalcification lesion. The raw 
imaging data is inverted and the microcalcification lesions are recognized clinically as small 
and clustered areas with higher density compared to the background breast tissue density.  
According to the background, CAD, dedicated to FFDM, can be directly affected by the 
physical characteristics of the raw imaging data. Unlike the raw imaging data on hard copy, 
utilizing digitizers for CAD processing in the analog system by groups, in units of 8-10 bits, 
the raw imaging data for CAD processing in FFDM are analyzed by groups, in units of 12-14 
bits, which has a much more dynamic range compared to digitized hard copy data in the 
analog system. According to the background, in FFDM, there are more opportunities to 
apply a combination of anode/filters such as W/Rh that allows us to decrease the radiation 
dose while keeping higher image quality in CNR (Contrast to Noise Ratio), compared to the 
images using Mo/Mo and Mo/Rh in the analog system [2].The raw imaging data for CAD 
processing with FFDM can be more strongly influenced by the different contrast and image 
sharpness in clinical images, compared to the CAD dedicated to an analog system. 
Accordingly, the detection pattern in CAD can vary even in clinical cases. The author 
evaluated the variety of detection performance of CAD, utilizing two different FFDM 
systems with reference to analysis of physical characteristics such as CNR and spectral 
analysis of anode/filters. This study was conducted to retrospectively evaluate the variation 
of CAD performance according to different radiation exposure parameters [3,4] 
4. Materials and methods 
This study was conducted as part of research that was approved by the IRB at our institute 
on June 12th in 2007. All patients that were recruited for this study gave informed consent. 
The clinical cases in this study were selected from screening mammograms taken from June 
12th in 2007 to December 24th in 2009. Clinical image data were acquired by two different 
FFDM systems. One was an a-Se FFDM system with a spatial resolution of 70ìm (System A) 
and imaging data were acquired from June 12th in 2007 to November 24th in 2008. Another 
was an a-Se FFDM system with a spatial resolution of 85ìm (System B) and imaging data 
were acquired from December 7th in 2008 to December 24th in 2009. Mammograms were 
diagnosed as BI-RADS category 1 or 2 by double-reading and breast ultrasound was 
performed in each case and diagnosed as a normal or a benign case. The total number of 
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cases was 1140 cases in System A and 1178 cases in System B. The median patient age was 
59.8 years old (range 40-75 years old) in System A and 60.0 years old (range 40-88 years old) 
in System B. To optimize radiation exposure parameters in clinical images, we measured 
CNR (Contrast to Noise Ratio) in accordance with EUREF (European Guidelines for Quality 
Assurance in Breast Cancer Screening and Diagnosis) guide lines simulating breast 
thickness, utilizing PMMA phantoms (20-70mm) and radiation exposure parameters, kV 
(24-34kV) and combinations of anode/filters (Mo/Mo, Mo/ Rh, and W/Rh). In addition, we 
performed spectral analysis of anode/filters (Mo/Mo, Mo/ Rh, and W/Rh) regarding both 
FFDM systems. A CAD dedicated to the FFDM systems was applied for the purpose of 
review and was verified, regarding detection areas, with reference to the diagnostic reports 
of the mammogram and ultrasound. The same CAD algorithm was utilized for the two 
FFDM systems.  
5. Results 
We optimized radiation exposure parameters in a clinical setting with reference to the 
results of the CNR analysis and dosimetry in accordance with EUREF Guidelines [5] (Fig.3.). 
In System A, under 20mm breast thickness, the combination of 24kV with Mo/Mo was 
selected; from 21m to 30mm breast thickness, the combination of 26kV with Mo/Mo was 
selected; from 31mm to 40mm breast thickness, the combination of 28kV with Mo/Mo was 
selected; from 41to 60mm, the combination of 30kV with W/Rh was selected; from 61mm to 
70mm, the combination of 32kV with W/Rh was selected; and above 70mm, the 
combination of  34kV with W/Rh was selected (Fig.4-5). 
   
SD; Standard Deviation 
Fig. 3. CNR Measurements in Accordance with EUREF. 
 


























































































Fig. 5. CNR Analysis: 20mm,40mm,and 60mm Thick PMMA Phantoms in System B. 
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CAD detected relatively dense areas as false-positive masses at a rate of 9.8% (448/4560 
images) and fibrous tissue as false-positive microcalcifications at a rate of 0.7% (34/4560 
images).  
In the cases utilizing 24-28kV Mo/Mo, CAD detected masses as false positives more 
frequently at a rate of 12.7% (279/2196 images), compared to the cases utilizing 30-34 kV 
W/Rh which detected false positives at a rate of 7.1% (169/2364 images). There was a 
statistically significant difference (P=0.008<0.05) between the two different combinations of 
anode/filters. CAD detected more false-positive masses in the cases utilizing the 
combinations with Mo/Mo in comparison with the cases utilizing the combinations with 
W/Rh. On the other hand, in the cases utilizing 30-34kV W/Rh, CAD detected false-positive 
microcalcifications more frequently at a rate of 1.1% (26/2364 images), compared to 0.4 % 
(8/2196 images) detected utilizing 24-28kV Mo/Mo. There was a statistically significant 
difference (P=0.022<0.05) between the two combinations with different anode/filters. CAD 
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Fig. 7. Spectrum of W/Rh in System B. 
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 Linear Attenuation Coefficient(cm-1) 
Breast Tissue  0.8 
Fatty Tissue  0.45 
Skin  0.8 
Mass  0.85 
Calcification  12.5 
Table 2. Linear Attenuation Coefficient of Breast Tissue at 20keV [6]. 
characteristics and detects the area as a candidate mass lesion. The raw imaging data is 
inverted and the mass lesion is recognized clinically as a localized high density area 
compared to background breast tissue density. On the other hand, the images with 
microcalcification lesions have localized small and clustered areas with a smaller number of 
photon counts compared to the background breast tissue in the raw imaging data. CAD 
analyzes the characteristics and detects the area as a candidate microcalcification lesion. The 
raw imaging data is inverted and the microcalcification lesions are recognized clinically as 
small and clustered areas with higher density compared to the background breast tissue 
density.  According to the background, CAD dedicated to digital mammography can be 
directly affected by the physical characteristics of the raw imaging data. In this study, in 
System A, CAD detected more false positive masses with 24-28Kv Mo/Mo compared to 
those detected with 30-34Kv W/Rh. According to spectral analysis, Mo/Mo acquires a 
smaller number of photons compared to W/Rh . The raw imaging data with Mo/Mo has a 
relatively narrow range of photon counts and the differentials in the photon counts between 
background breast tissue and mass can be small. As a result, CAD can detect more false 
positive masses compared to imaging with W/Rh. On the other hand, CAD detected more 
false positive microcalcifications with 30-34Kv W/Rh compared to the number detected 
with 24-28Kv Mo/Mo (Fig.8-9). 
This could be a result of the characteristics of W/Rh which can acquire a larger number of 
photons compared to Mo/Mo. Images with W/Rh have a much wider range of photon 
counts and the differential value of photon counts between background breast tissue and 
microcalcifications is large. As a result, imaging data with W/Rh can detect candidate 
microcalcification lesions with more sensitivity than imaging with Mo/Mo. Even with the 
same combination of anode/filters, the CAD in System A with 30-34kV W/Rh detected 
more false positive masses compared to System B with 30-34kV W/Rh.CAD results may 
differ even when the same system is used, according to which combination of anode/filter is 
used. On the other hand, CAD results may differ when different systems are used, even 
though the same combination of anode/filter is used. According to spectral analysis, the 
spectrum of W/Rh used in System A shows greater similarity to the spectrum of Mo/Mo 
than the spectrum of W/Rh used in System B. As a result, CAD detected more false 
positives using W/Rh with System A compared to System B. The CAD performance was  
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Fig. 8. Example Case with a False Positive Mass Marked by CAD. 
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Fig. 9. An Example Case with False Positive Calcifications Marked by CAD. 
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affected by the difference in image quality produced by different radiation exposure 
parameters of the different anode/filters within one system and by differences in the two 
systems. In FFDM, CAD algorithms should be considered to vary depending on the image 
acquisition systems. In addition, recently, new breast image acquisition technologies, as well 
as digital breast tomosynthesis and dual-energy mammography, have been developed and 
have started to be acquired for breast diagnosis. These image acquisition approaches, 
utilizing new CAD techniques, will be capable of accurate volumetric measuring of breast 
density and microcalcifications, differently from conventional 2D images [7]-[9]. The results 
of this study imply that we should take into consideration the importance of analyzing 
physical characteristics with CAD, according to the different image quality with systems 
dedicated to new image acquisition technologies. 
7. Conclusion 
In this section, the author addresses the issue that CAD performance is affected by the 
difference in image quality produced by different radiation exposure parameters of the 
different anode/filters within one system and by differences in the two systems; also 
variations in CAD algorithms utilizing FFDM should be taken into account. 
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1. Introduction
Based on recent statistics from the International Agency for Research on Cancer (Ferlay et al.,
2010), breast cancer account for 10.9% of all cancers diagnosed and ranks as the fifth cause of
cancer death in the world. Although incidence rates are increasing, mortality rates are stable,
representing an improved survival rate. This improvement can be attributed to effective
means for the early detection as well as to significant improvement in treatment options,
exposure, etc. Mammography is, at present, the only viable method for detecting most of
tumors early enough for effective treatment, without unnecessary biopsies, or other invasive
procedures. Therefore, screening mammography in women aged 40 to 70 years is currently
the effective strategy to reduce breast cancer mortality. Early detection of invasive breast
cancers is associated with better prognosis than waiting for women to become symptomatic.
However, detecting the early signs of breast cancer is challenging because the cancerous
structures have many features in common with normal breast tissue. Moreover, the accuracy
of interpretation of screening mammograms is affected by several factors, such as image
quality, the radiologist’s level of expertise, and the high volume of cases. Recent statistics
show that in current breast cancer screenings 10% − 25% of the tumors are missed by the
radiologists (Burrell et al., 2001; Cheng, 2003; Nishikawa, 2007). Missed cancers are due
to many reasons: low disease prevalence, breast structure complexity, finding subtleties,
and radiologist fatigue. To accomplish with these difficulties, different methods have been
analyzed: first of all, double reading, which provides either double perception or double
interpretation of lesions. It has been demonstrated that a single radiologist is more accurate
when reading mammograms methodically than quickly and that two observers achieve an
improvement in detection rate of 5% − 15% (Mazzarella & Bazzocchi, 2007). Obviously, this
procedure is too expensive, complex, and time consuming especially in screening programs
where a huge number of mammographic images have to be read. The development of
computerized systems as second readers represents an alternative. Researchers have been
developing algorithms to detect mammographic abnormalities for more than 30 years with
the aim of either automating mammographic interpretation or providing a tool that could
enhance human film-reading accuracy. Computer-aided detection (CADe) and diagnosis
(CADx) systems are widely used in mammography, where signs of breast cancer are often
very subtle. Both systems involve the use of computer algorithms to detect patterns in
images associated with signs of disease and to assign them a malignancy index. This result
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should attract the clinicians’ attention to potentially abnormal regions in mammograms. In
the recent years, the authors have developed a CADe-CADx system (CAD in the following),
called Assisted Breast Cancer Diagnosis Environment (ABCDE) (Salmeri et al., 2009), to
assist radiologists in the early detection of breast cancer. Beside the development of specific
algorithms for the enhancement of abnormalities and the identification of pathological
structures, the performance evaluation of each block of the whole CAD system has been also
performed. In order to understand the actual complexity of the complete validation of a CAD
system in mammography, consider the left-hand part of the flowchart reported in Fig. 1 where
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Fig. 1. Flowchart of the whole CAD ABCDE system. The right part shows the issues related
to the uncertainty contributions handling and propagation through the blocks.
2. Motivations and objectives
This work stems from considerations of Wirth (Wirth, 2006) and Nishikawa (Nishikawa, 2007)
regarding the performance evaluation of a CADe system. One of the major limitations in the
design of novel computerized algorithms for breast cancer detection is related to the inherent
difficulty of proving their effectiveness and improvement with respect to existing methods. In
the context of performance evaluation a sequence of unresolved issues can be identified.
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- The assessment of the whole CAD system does not coincide with the testing of individual
components of the CAD system. The latter requires specific indicators according to each
block and its functionalities, while the former coincides with testing classification ability of
the system. In CADe systems, it means to test the capability of the system of discriminating
between normal and pathological tissue, while in CADx systems, it is related to the ability
of discriminating between malignant and benign abnormalities.
- In the literature, there are well-accepted characteristics needed to evaluate the performance
of each algorithm in the CAD system: sensitivity, robustness, adaptability, accuracy
and precision, reliability (or reproducibility), and efficiency. Each of them is defined in
compliance with the definitions contained in reference documents such as (International
vocabulary of metrology. Basic and general concepts and associated terms (VIM), 2008).
Unfortunately, exact limits beyond which the performance of the system is acceptable lack
and are often verbally reported.
- Receiver Operating Characteristic (ROC) and Free-Response ROC (FROC) analysis are
used to assess the classification performance of the whole CAD system. They plot
sensitivity versus specificity or false positives per image/case. Optimal operating points
can be derived based on the Youden-index, the distance from the ideal ROC curve, the
optimal clinically acceptable false-detection rate. Unfortunately, often this is a subjective
choice and depends on who is making the evaluation.
- Problems in the ROC analysis occur when more than two classes are used in the
classification process, as for example in the classification of the lesion margins and shapes,
or in algorithms used to automatically assess the breast tissue density.
- Standard ROC analysis does not implement the so called failure assessment, that is the
analysis of the circumstances under which an algorithm fails and the correction of the
failure causes. In some works, the authors verbally describe the specific cases where
the algorithm fails, as for example in (Ferrari et al., 2004), examining in details the False
Negatives produced by the algorithms and the possible causes.
- Datasets available is another important problem. Public databases such as MiniMIAS
and DDSM are quite old and do not contain all the informations needed to evaluate
the performance of a innovative CAD. In fact, modern issues in breast cancer detection
involves important aspects such as bilateral asymmetry, architectural distortion, prior
mammograms, interval cancers. The cited databases do not contain this kind of
abnormalities, except for those reported in case there is also a lesion. Moreover, a few
images are present with this kind of abnormalities and this limitation does not inspire full
confidence in the final results produced by the CAD.
- The comparison of the various existing methods and possibly the introduction of
improvements to one of them is extremely difficult if not impossible for two main reasons:
the first one is that the algorithms are not completely described or documented so that it
is not possible for authors to make a comparative analysis; secondly, the algorithms are
often black-boxes so that testing involves only inputs and outputs, but not the internal
decision-making process.
Many of the above mentioned problems can be partially solved or at least addressed
considering a further important aspect in the CAD performance evaluation and algorithms
testing, that is uncertainty sources modeling and propagation. In fact, considering all
the uncertainty sources that can be present in the considered context of mammography,
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should attract the clinicians’ attention to potentially abnormal regions in mammograms. In
the recent years, the authors have developed a CADe-CADx system (CAD in the following),
called Assisted Breast Cancer Diagnosis Environment (ABCDE) (Salmeri et al., 2009), to
assist radiologists in the early detection of breast cancer. Beside the development of specific
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performed. In order to understand the actual complexity of the complete validation of a CAD
system in mammography, consider the left-hand part of the flowchart reported in Fig. 1 where
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Fig. 1. Flowchart of the whole CAD ABCDE system. The right part shows the issues related
to the uncertainty contributions handling and propagation through the blocks.
2. Motivations and objectives
This work stems from considerations of Wirth (Wirth, 2006) and Nishikawa (Nishikawa, 2007)
regarding the performance evaluation of a CADe system. One of the major limitations in the
design of novel computerized algorithms for breast cancer detection is related to the inherent
difficulty of proving their effectiveness and improvement with respect to existing methods. In
the context of performance evaluation a sequence of unresolved issues can be identified.
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used to assess the classification performance of the whole CAD system. They plot
sensitivity versus specificity or false positives per image/case. Optimal operating points
can be derived based on the Youden-index, the distance from the ideal ROC curve, the
optimal clinically acceptable false-detection rate. Unfortunately, often this is a subjective
choice and depends on who is making the evaluation.
- Problems in the ROC analysis occur when more than two classes are used in the
classification process, as for example in the classification of the lesion margins and shapes,
or in algorithms used to automatically assess the breast tissue density.
- Standard ROC analysis does not implement the so called failure assessment, that is the
analysis of the circumstances under which an algorithm fails and the correction of the
failure causes. In some works, the authors verbally describe the specific cases where
the algorithm fails, as for example in (Ferrari et al., 2004), examining in details the False
Negatives produced by the algorithms and the possible causes.
- Datasets available is another important problem. Public databases such as MiniMIAS
and DDSM are quite old and do not contain all the informations needed to evaluate
the performance of a innovative CAD. In fact, modern issues in breast cancer detection
involves important aspects such as bilateral asymmetry, architectural distortion, prior
mammograms, interval cancers. The cited databases do not contain this kind of
abnormalities, except for those reported in case there is also a lesion. Moreover, a few
images are present with this kind of abnormalities and this limitation does not inspire full
confidence in the final results produced by the CAD.
- The comparison of the various existing methods and possibly the introduction of
improvements to one of them is extremely difficult if not impossible for two main reasons:
the first one is that the algorithms are not completely described or documented so that it
is not possible for authors to make a comparative analysis; secondly, the algorithms are
often black-boxes so that testing involves only inputs and outputs, but not the internal
decision-making process.
Many of the above mentioned problems can be partially solved or at least addressed
considering a further important aspect in the CAD performance evaluation and algorithms
testing, that is uncertainty sources modeling and propagation. In fact, considering all
the uncertainty sources that can be present in the considered context of mammography,
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performing a detailed modelization of each of them, constructing a dedicated propagation
procedure through each block of the CAD, according to the uncertainty nature, will allow us
to address the following topics:
- An analysis of sensitivity could be performed in order to extract the influence of each
uncertainty source on each algorithm parameter and on the final output value. In this
way, both the design and the testing steps will be improved and completed, allowing to
introduce corrective factors or change the algorithm, test the robustness of more systems.
- Extended ROC and FROC analysis could be performed, providing, for each decision point
(corresponding to a pair of values for the sensitivity and the specificity in the ROC curve for
example), a confidence interval given a certain coverage probability. In this way, a direct
failure analysis can be guided by this kind of analysis as will be shown in the following
sections.
- According to the context, screening programs or diagnostic mammography, requested
coverage probabilities can be different. Moreover, it can be interesting to assign a
confidence interval to each output of the CAD and of each block, for any coverage
probability, from an high sensitive choice (95%) to a more specific or operating case (80%).
The application of a Monte Carlo analysis, as that described in (JCGM, 2008), allows us
to simulate every kind of sensitivity analysis, starting from very few assumptions on
the nature of the uncertainty sources able to affect the CAD output. Specific estimation
procedures should be implemented to preliminary provide accurate modeling of the
uncertainty sources.
- Novel inference mechanisms, such as those based on fuzzy logic theory, would allow
us to transform a black-box system into a white-box system, where interaction with the
physician and with the developers is simple and constructive.
In light of this, we have already partially addressed some of the above cited issues:
breast masses automatic segmentation (Mencattini et al., 2011d; Rabottino et al., 2008)
and the uncertainty propagation through the algorithm (Mencattini et al., 2010b),
microcalcifications classification (Ferrero et al., 2010), performance evaluation of an automatic
tumoral masses identification algorithm (Mencattini et al., 2010a), uncertainty propagation
through the classification of breast masses (considering also the features extraction
and the feature selection procedures), the uncertainty propagation by Random Fuzzy
Variables (RFVs) through a denoising and enhancement procedure for the detection of
microcalcifications (Mencattini et al., 2009b), and the noise variance estimation results under
the assumption of signal-dependent noise (.Mencattini et al., 2007; Salmeri et al., 2008).
3. Materials
The digital mammographic image can be obtained using Full-Field Digital Mammography
(FFDM) or it can be obtained by digitizing a Screen Film Mammogram (SFM). The two kinds
of images exhibit very different properties in linearity (relationship between pixel intensity
and exposure to X-ray detector), contrast (contrast in SFM at low and high exposures is
reduced with respect to FFDM), spatial resolution (40 − 50 μm in SFM, 100 μm in FFDM),
and noise: in linear FFDM noise is proportional to the square root of the X-ray exposure,
while at low exposures electronic noise is dominant; conversely, for logarithmic FFDM noise
is proportional to the inverse of the square root of the X-ray exposure to the detector. The same
holds for SFM, but changed according to the characteristic curve. Owing to these differences,
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robust validation and testing procedures should consider images either from SFM and from
FFDM. In order to map gray-levels to optical density the calibration curve of each acquisition
system is used. Each acquisition system In particular, in this work we will consider three
databases: the Digital Database for Screening Mammography (DDSM) (Heath et al., 1998),
the Mammographic Image Database (MIAS) (Suckling et al., 1994), and a FFDM database
from the San Paolo Hospital in Bari (Mencattini et al., 2011d). In the following, we briefly
describe the characteristics of the three databases.
3.1 MiniMIAS database
The Mammographic Image Analysis Society (MIAS) is an organization of UK research groups
interested in the understanding of mammograms and has generated a public database of
digital mammograms available via the Pilot European Image Processing Archive (PEIPA)
of the University of Essex, at: http://peipa.essex.ac.uk/info/mias.html. Films taken from the
UK National Breast screening Programme have been digitized to 50 μm pixel edge with a
Joice-Loebl scanning microdensitometer, a device linear in the optical density range [0 − 3.2]
and representing each pixel with an 8-bit word. The original database has been reduced to
a 200 μm pixel edge and padded/clipped so that all the images are 1024 × 1024 and the
mammogram is centered in the matrix. Fig. 2 reports four examples of images taken from
MiniMIAS database.
Fig. 2. Examples of mammographic images from the MiniMIAS database. (Figures-left)
Normal case, right (mdb053) and left (mdb054) mammograms. (Figures-right) bilateral
asymmetry case, right (mdb081) and left (mdb082) mammograms.
3.2 DDSM database
The Digital Database for Screening Mammography (DDSM) (Heath et al., 1998) was
completed in 1999 and contains a total of 2620 cases. Primary support for this project
was a grant from the Breast Cancer Research Program of the U.S. Army Medical Research
and Materiel Command. The DDSM project is a collaborative effort involving co-p.i.s
at the Massachusetts General Hospital (D. Kopans, R. Moore), the University of South
Florida (K. Bowyer), and Sandia National Laboratories (P. Kegelmeyer). Additional cases
from Washington University School of Medicine were provided by Peter E. Shile, MD,
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of images exhibit very different properties in linearity (relationship between pixel intensity
and exposure to X-ray detector), contrast (contrast in SFM at low and high exposures is
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Assistant Professor of Radiology and Internal Medicine. Additional collaborating institutions
include Wake Forest University School of Medicine (Departments of Medical Engineering
and Radiology), Sacred Heart Hospital and ISMD, Incorporated. Each study includes two
images of each breast, along with some associated patient information (age at time of study,
ACR breast density rating, subtlety rating for abnormalities, ACR keyword description of
abnormalities) and image information (scanner, spatial resolution, bpp). Images containing
suspicious areas have associated pixel-level “ground truth” information about the locations
and types of suspicious regions. Unfortunately, lesion boundary drawn by radiologists are not
always reliable and often include also pixels from normal tissue. The images are digitized by
four different scanners (HOWTEK-A/D, LUMISYS, and DBA) using spatial resolution equal
to [43.5, 50, 42] μm and a pixel resolution equal to 12 bpp for scanners (HOWTEK-A/D and
LUMISYS) and equal to 16 bpp for scanner DBA. Each study contains four screening views,
left and right mediolateral oblique (MLO) and cranio-caudal views (CC). Figure 3 reports
three pairs of mammograms from DDSM, one for each scanner.
Fig. 3. Three pairs of DDSM images from three different scanners (a) DBA, (b) HOWTEK-A,
(c) LUMISYS.
Images from scanner HOWTEK-D presents the same characteristics of scanner HOWTEK-A
and are omitted.
3.3 FFDM database
Thanks to a collaboration with the San Paolo Hospital in Bari and with the Dept. of
Mathematics at the University of Bari, we have access to Full Field Digital Mammographic
(FFDM) images acquired using the Senograph 2000D ADS 17.3, GE Medical Systems, at a
spatial resolution of 94 μm and a pixel resolution of 12 bpp. Each study contains two relevant
series: a series including the four standard views (CC and MLO) for presentation state and
a series including, if present, a screen save image reporting the lesion boundary manually
drawn by radiologists. Currently, these images are used for the development and testing
of an algorithm for the automatic extraction of the lesions boundary in order to assign a
malignancy degree to each lesion detected by a radiologist. At the moment, the dataset
includes 196 mammograms containing one or more benign or malignant massive lesions. The
malignancy assessment is a part of the CADx section in ABCDE and is currently based on
fractal analysis (Giuliato & Rangayyan, 2011; Mencattini et al., 2011d; Raguso et al., 2010).
Figure 4 reports four FFDM images from San Paolo Hospital.
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Fig. 4. Four FFDM images containing a massive lesion whose boundary has been drawn by a
radiologist.
4. A Monte Carlo approach for CAD performance assessment
Recent reference documents (JCGM, 2008) revised almost totally the formal and practical
definitions concerning measurement uncertainty, its modelization and propagation, as a part
in the measurand estimation. There are two types of measurement error quantity that can
occur during a measurement process: systematic and random. A systematic error (an estimate
of which is known as a measurement bias) is associated with the fact that a measured quantity
value contains an offset (that can be unpredictable and uncontrollable). A random error relies
on the fact that when a measurement is repeated it will generally provide a measured quantity
value that is different from the previous value. It is random in that the next measured quantity
value cannot be predicted exactly from previous such values. The GUM (JCGM, 2008)
provided a different way of thinking about measurement and in how to express the perceived
quality of the result of a measurement. Rather than express the result of a measurement
by providing a best estimate of the measurand, along with information about systematic
and random error values (in the form of an “error analysis”), the GUM approach aims at
expressing the result of a measurement as a best estimate of the measurand, along with an
associated measurement uncertainty.
Let us denote with Xi any input quantities (measurands) and with Y the output quantity
about which information is required. The output Y should be related to the inputs X1, . . . , XN
by a measurement models that can be explicitly formulated Y = f (X1, . . . , XN) or implicitly
defined h(X1, . . . , XN , Y) = 0. Functions f (·) and h(·) should be estimated. The main stages
of uncertainty evaluation are formulation, propagation, and summarizing.
- The formulation stage consists on defining the output quantity Y, identifying the input
quantities on which Y depends (Xi), developing a measurement model relating Y to
the input quantities (functions f (·) and h(·)), and on the basis of available knowledge,
assigning probability distributions to the input quantities (or a joint probability
distribution to those input quantities that are not independent).
- The propagation stage consists of propagating the probability distributions for the input
quantities through the measurement model to obtain the probability distribution for the
output quantity Y. The propagation of distributions can be implemented in several
ways: analytical methods, i.e. methods that provide a mathematical representation of the
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probability density function (pdf) for Y; uncertainty propagation based on replacing the
model by a first-order Taylor series approximation (also called the the law of propagation
of uncertainty); numerical methods that implement the propagation of distributions,
specifically using Monte Carlo method, that will be described in the following.
- The summarizing step is them performed to extract from the Y probability distribution
the expectation of Y (the best estimation of Y), the standard deviation of Y (a measure of
dispersion of Y), a confidence interval containing Y with a specified coverage probability.
Monte Carlo method provides a general approach to obtain an approximate numerical
representation of the distribution function FY for Y. The heart of the approach is repeated
sampling from the pdfs for the Xi. The implementation of the method is summarized below:
a) select the number M of Monte Carlo trials to be made;
b) generate M vectors, by sampling from the assigned pdfs, as realizations of the (set of N)
input quantities Xi;
c) for each such vector, form the corresponding model value of Y, yielding M model values;
d) sort these M model values into strictly increasing order, using the sorted model values to
provide the estimation G of FY;
e) use G to form an estimate y of Y and the standard uncertainty u(y) associated with y.
f) use G to form an appropriate confidence interval for Y, for a stipulated coverage
probability p.
Step f) is crucial because it can be formulated as a constrained minimization problem. In fact,
given a coverage probability p, the associated confidence interval [y1, y2]p is obtained as the
minimum interval [a, b] such that G−1(b) − G−1(a) = p. When the pdf of Y is symmetric
the solution is trivial an equal to G−1((1 + p)/2) − G−1((1 − p)/2). Some relevant features
of Monte Carlo method are: a reduction in the analysis effort required for complicated or
non-linear models, especially since the partial derivatives of first- or higher-order of the model
are not needed; generally improved estimate of Y for non-linear models; improved standard
uncertainty associated with the estimate of Y for non-linear models, especially when the Xi
are assigned non-Gaussian (e.g. asymmetric) pdfs, without the need to provide derivatives
of higher order1; provision of a confidence interval corresponding to a stipulated coverage
probability when the pdf for Y cannot adequately be approximated by a Gaussian distribution
or a scaled and shifted t-distribution, i.e. when the central limit theorem does not apply.
Being the measurement uncertainty modeling a central part in the assessment of the CAD
performance, in the following section, we will describe the major sources of uncertainty that
can be identified in a CAD for mammography.
5. Uncertainty modeling in a CAD
Numerous sources of uncertainty have to be taken into account in a medical image processing
system for breast cancer detection and diagnosis, both in the system development step and in
the operating conditions. Keeping in mind the two different situations, here below, we recall
the most relevant sources of uncertainty subdividing them into five groups: instrumental
1 This point is crucial when an evident asymmetric pdf should be assigned to the input quantity such as
for photon noise.
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uncertainty, uncertainty sources related to the patient, model uncertainty related to the CAD
parameters selection, uncertainty sources related to the input provided by the radiologist
during the system development and validation steps (reference values etc.), the uncertainty
sources related to the possible interaction among the CAD and the physician who is manually
setting the algorithm parameters during the system operation.
• GROUP 1: image acquisition and digitalization process (i.e., spatial resolution, geometric
distortion, noise, pixel quantization, film degradation, artifacts introduction, etc.);
• GROUP 2: biological and patient variability (related to both pathological or normal cases);
intrinsic and unpredictable data variability (e.g., patient movement);
• GROUP 3: model uncertainty due to the unperfect or incomplete knowledge about
algorithm parameters values and their influence on the final results. Major concern should
be paid to algorithm with a random initialization, where some parameters are initially set
to a value randomly selected in a certain interval.
• GROUP 4: human observer subjective interpretation of the image according to his/her
experience, in providing reference boundary, malignancy degree, reference region of
investigation, useful for the CAD validation.
• GROUP 5: interaction between the human observer and the image data, in manually
enhancing the image contrast, selecting Region Of Interest, manually sectioning the breast
region for inspection etc., during the operation of the system.
Some of these sources of uncertainty (GROUPS 1 and 3) can be reasonably modelled and
considered in the uncertainty estimation process (Mazzarella & Bazzocchi, 2007), while some
other (GROUPS 2, 4, and 5) have unknown nature and are difficult to be embedded, even
if noteworthy. As a consequence of the large subjectivity in using the CAD system in this
context, a metrological validation of medical image processing approaches is required to
highlight the intrinsic characteristics and behavior of a method, to evaluate its performance
and limitations, and to compare the method with different existing approaches.
In the following sections, we will describe with more details a possible modelization of
the uncertainty contributions summarized above, providing examples taken from ABCDE’s
functionalities.
5.1 GROUP 1: Noise contribution in mammographic images
Each step that contributes to the final digital mammographic image influences the global
uncertainty in a different way: the formation process, based on X-ray exposure, introduces
a noise contribution that is intensity dependent (e.g., photon noise), the microscopic structure
of the impressed film introduces the so-called film grain noise, finally the digitalization process
when performed through scanner devices, introduces an uncertainty contribution that is
related to the number of bit per pixel (bpp) used in the conversion, or an uncertainty term that
presents systematic periodic patterns (Mencattini et al., 2009b) superimposed to the image.
Photon noise is the dominant random contribution in this context, since the bpp is usually
12 − 16, but other relevant noise contributions can be present at low and high exposures.
Consequently, as suggested in (Jain, 1989), we consider an heteroscedastic noise model for the
random contribution assuming that the noise variance depends on the intensity of each pixel,
and it is not constant within the image. The noise model can be represented as follows:
Ĩ(n, m) = I(n, m) + η1(n, m), (1)
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probability density function (pdf) for Y; uncertainty propagation based on replacing the
model by a first-order Taylor series approximation (also called the the law of propagation
of uncertainty); numerical methods that implement the propagation of distributions,
specifically using Monte Carlo method, that will be described in the following.
- The summarizing step is them performed to extract from the Y probability distribution
the expectation of Y (the best estimation of Y), the standard deviation of Y (a measure of
dispersion of Y), a confidence interval containing Y with a specified coverage probability.
Monte Carlo method provides a general approach to obtain an approximate numerical
representation of the distribution function FY for Y. The heart of the approach is repeated
sampling from the pdfs for the Xi. The implementation of the method is summarized below:
a) select the number M of Monte Carlo trials to be made;
b) generate M vectors, by sampling from the assigned pdfs, as realizations of the (set of N)
input quantities Xi;
c) for each such vector, form the corresponding model value of Y, yielding M model values;
d) sort these M model values into strictly increasing order, using the sorted model values to
provide the estimation G of FY;
e) use G to form an estimate y of Y and the standard uncertainty u(y) associated with y.
f) use G to form an appropriate confidence interval for Y, for a stipulated coverage
probability p.
Step f) is crucial because it can be formulated as a constrained minimization problem. In fact,
given a coverage probability p, the associated confidence interval [y1, y2]p is obtained as the
minimum interval [a, b] such that G−1(b) − G−1(a) = p. When the pdf of Y is symmetric
the solution is trivial an equal to G−1((1 + p)/2) − G−1((1 − p)/2). Some relevant features
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non-linear models, especially since the partial derivatives of first- or higher-order of the model
are not needed; generally improved estimate of Y for non-linear models; improved standard
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are assigned non-Gaussian (e.g. asymmetric) pdfs, without the need to provide derivatives
of higher order1; provision of a confidence interval corresponding to a stipulated coverage
probability when the pdf for Y cannot adequately be approximated by a Gaussian distribution
or a scaled and shifted t-distribution, i.e. when the central limit theorem does not apply.
Being the measurement uncertainty modeling a central part in the assessment of the CAD
performance, in the following section, we will describe the major sources of uncertainty that
can be identified in a CAD for mammography.
5. Uncertainty modeling in a CAD
Numerous sources of uncertainty have to be taken into account in a medical image processing
system for breast cancer detection and diagnosis, both in the system development step and in
the operating conditions. Keeping in mind the two different situations, here below, we recall
the most relevant sources of uncertainty subdividing them into five groups: instrumental
1 This point is crucial when an evident asymmetric pdf should be assigned to the input quantity such as
for photon noise.
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uncertainty, uncertainty sources related to the patient, model uncertainty related to the CAD
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during the system development and validation steps (reference values etc.), the uncertainty
sources related to the possible interaction among the CAD and the physician who is manually
setting the algorithm parameters during the system operation.
• GROUP 1: image acquisition and digitalization process (i.e., spatial resolution, geometric
distortion, noise, pixel quantization, film degradation, artifacts introduction, etc.);
• GROUP 2: biological and patient variability (related to both pathological or normal cases);
intrinsic and unpredictable data variability (e.g., patient movement);
• GROUP 3: model uncertainty due to the unperfect or incomplete knowledge about
algorithm parameters values and their influence on the final results. Major concern should
be paid to algorithm with a random initialization, where some parameters are initially set
to a value randomly selected in a certain interval.
• GROUP 4: human observer subjective interpretation of the image according to his/her
experience, in providing reference boundary, malignancy degree, reference region of
investigation, useful for the CAD validation.
• GROUP 5: interaction between the human observer and the image data, in manually
enhancing the image contrast, selecting Region Of Interest, manually sectioning the breast
region for inspection etc., during the operation of the system.
Some of these sources of uncertainty (GROUPS 1 and 3) can be reasonably modelled and
considered in the uncertainty estimation process (Mazzarella & Bazzocchi, 2007), while some
other (GROUPS 2, 4, and 5) have unknown nature and are difficult to be embedded, even
if noteworthy. As a consequence of the large subjectivity in using the CAD system in this
context, a metrological validation of medical image processing approaches is required to
highlight the intrinsic characteristics and behavior of a method, to evaluate its performance
and limitations, and to compare the method with different existing approaches.
In the following sections, we will describe with more details a possible modelization of
the uncertainty contributions summarized above, providing examples taken from ABCDE’s
functionalities.
5.1 GROUP 1: Noise contribution in mammographic images
Each step that contributes to the final digital mammographic image influences the global
uncertainty in a different way: the formation process, based on X-ray exposure, introduces
a noise contribution that is intensity dependent (e.g., photon noise), the microscopic structure
of the impressed film introduces the so-called film grain noise, finally the digitalization process
when performed through scanner devices, introduces an uncertainty contribution that is
related to the number of bit per pixel (bpp) used in the conversion, or an uncertainty term that
presents systematic periodic patterns (Mencattini et al., 2009b) superimposed to the image.
Photon noise is the dominant random contribution in this context, since the bpp is usually
12 − 16, but other relevant noise contributions can be present at low and high exposures.
Consequently, as suggested in (Jain, 1989), we consider an heteroscedastic noise model for the
random contribution assuming that the noise variance depends on the intensity of each pixel,
and it is not constant within the image. The noise model can be represented as follows:
Ĩ(n, m) = I(n, m) + η1(n, m), (1)
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where Ĩ(n, m) is the noisy image, I(n, m) is the noise-free image, η1(n, m) is a zero mean non
stationary random process given by η1(n, m) = η · σ(n, m) with η ∼ N (0, 1) a normal random
process with zero mean and unitary variance, and σ2(n, m) the spatial-dependent variance of
the process η1(n, m).
The assumption of a normal random process with non constant variance is fully justified (Jain,
1989) for luminance values in the subrange [0.2 − 0.8] that corresponds to what we are
interested in; actually, dark or very bright pixels are corrupted by a saturated gaussian noise
with cut tails. This problem could occasionally produce an underestimation of the noise
variance we perform, but involving regions far from the regions of interest.
It is well known that the noise variance σ2(n, m) depends on the intensity I(n, m). In
particular, we get that σ2(n, m) = αI(n, m)β for scanner devices and σ2(n, m) = γ ·
log10(I(n, m))− d0 for photographic films. Consequently, an estimation procedure is needed
in order to estimate the unknown dependence of the noise variance σ2(n, m) on the intensity
I(n, m). To do this, we implement the noise estimation introduced in (Gravel et al., 2004),
later extended and improved in (.Mencattini et al., 2007; Salmeri et al., 2008). The strength
of the estimation algorithm is that it can be applied to very different kind of medical
images (MRI, ultrasound images, etc.) where noise is signal dependent following different
probability distribution (Rician noise, Rayleigh, etc). In case of homoscedastic noise (where
noise variance is constant through the image) the estimation algorithm still provides an
accurate estimation of the noise variance, needed in many algorithms for image denoising
and enhancement (Mencattini et al., 2010b; 2008). Here below, we only report a sketch of the
whole estimation algorithm.
a) Extract low-frequency components from the image containing homogeneous regions. This
step is performed by applying a low pass gaussian filter to the original noisy image
obtaining a smoothed orignal image.
b) Evaluate the high frequency components of the image by the subtraction of the smoothed
image to the original one. Obviously this image contains both small details, boundaries,
and noise.
c) Eliminate edges by applying a robust edge detector to the original image. This further step
is needed in order to eliminate edges from the estimation procedure, that would decrease
noise variance estimation accuracy. Then, by thresholding we obtain a binary mask of
principal edges.
d) Build an histogram of relating each bin to the intensity of image considering pixels at the
same position in the smoothed image and in the noise image.
e) Evaluate the standard deviation of each bin by a Median Absolute Deviation (MAD)
estimator.
f) Perform a robust regression analysis by Cubic Smoothing Spline in order to fit the data
extracted at step (e).
A block diagram of the whole algorithm is reported in Fig. 5.
Unfortunately, uncertainty contribution do not embed only random effects, related to noise.
In fact, in medical diagnosis, it is often crucial to take into account also non random
contributions that can occur during the exposure, the acquisition and the digitalization
of the image. We refer for example to physiological movements of the patient (a few
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Fig. 5. The noise variance estimation algorithm.
seconds are needed in order to form a single mammographic image), to artifacts that can
be present in the final image, due to dust, fingerprints, scratch, and to the non random
contribution introduced by the scanner itself, such as the spatial non uniformity introduced
in the luminance. For example, the images database we consider, e.g., the Digital Database
for Screening Mammography (DDSM) (Heath et al., 1998) uses the three scanners DBA,
HOWTEK, and LUMISYS to digitalize more than 4000 mammographic images. We can notice
that the final images are corrupted by a periodic pattern contribution that we assumed to be
systematic. An example is shown in Fig. 6(a)-(b) where two regions are extracted from the
same mammographic image. Region A is dark and it is evident that there is an overlying
periodic pattern that here is also emphasized by an histogram stretching. On the contrary,
region B is corrupted by noise but the periodic pattern is much more subtle. In Fig. 6(c) the
two-dimensional Fourier Transforms of the two regions are also shown proving that there is a
unidirectional periodic pattern overlying region A and that the same does not hold for region
B with the same evidence.
It is well known that systematic effects have to be corrected before performing a reliable
uncertainty propagation of random effects (Santo et al., 2004). Unfortunately, as a consequence
of the previous considerations, this kind of contributions is both luminance and spatial
dependent so that it is very difficult to evaluate and correct it. Moreover, from both medical
and visual viewpoints, it could be dangerous to preliminarily correct the images from non
random contribution thus altering the final aspects of the images and falsifying the correct
diagnosis of microcalcifications. In this regard, the new version of International Vocabulary
of Metrology (VIM) (see (International vocabulary of metrology. Basic and general concepts and
associated terms (VIM), 2008) paragraph 2.26) states that Sometimes, estimated systematic effects
are not corrected for but, instead, associated measurement uncertainty components are incorporated.
Finally, scanner devices used in medical laboratories are not completely characterized from
a metrological point of view thus making the exact evaluation of these effects for correction
impossible. As a possible solution, we assume to treat non random contributions as systematic
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where Ĩ(n, m) is the noisy image, I(n, m) is the noise-free image, η1(n, m) is a zero mean non
stationary random process given by η1(n, m) = η · σ(n, m) with η ∼ N (0, 1) a normal random
process with zero mean and unitary variance, and σ2(n, m) the spatial-dependent variance of
the process η1(n, m).
The assumption of a normal random process with non constant variance is fully justified (Jain,
1989) for luminance values in the subrange [0.2 − 0.8] that corresponds to what we are
interested in; actually, dark or very bright pixels are corrupted by a saturated gaussian noise
with cut tails. This problem could occasionally produce an underestimation of the noise
variance we perform, but involving regions far from the regions of interest.
It is well known that the noise variance σ2(n, m) depends on the intensity I(n, m). In
particular, we get that σ2(n, m) = αI(n, m)β for scanner devices and σ2(n, m) = γ ·
log10(I(n, m))− d0 for photographic films. Consequently, an estimation procedure is needed
in order to estimate the unknown dependence of the noise variance σ2(n, m) on the intensity
I(n, m). To do this, we implement the noise estimation introduced in (Gravel et al., 2004),
later extended and improved in (.Mencattini et al., 2007; Salmeri et al., 2008). The strength
of the estimation algorithm is that it can be applied to very different kind of medical
images (MRI, ultrasound images, etc.) where noise is signal dependent following different
probability distribution (Rician noise, Rayleigh, etc). In case of homoscedastic noise (where
noise variance is constant through the image) the estimation algorithm still provides an
accurate estimation of the noise variance, needed in many algorithms for image denoising
and enhancement (Mencattini et al., 2010b; 2008). Here below, we only report a sketch of the
whole estimation algorithm.
a) Extract low-frequency components from the image containing homogeneous regions. This
step is performed by applying a low pass gaussian filter to the original noisy image
obtaining a smoothed orignal image.
b) Evaluate the high frequency components of the image by the subtraction of the smoothed
image to the original one. Obviously this image contains both small details, boundaries,
and noise.
c) Eliminate edges by applying a robust edge detector to the original image. This further step
is needed in order to eliminate edges from the estimation procedure, that would decrease
noise variance estimation accuracy. Then, by thresholding we obtain a binary mask of
principal edges.
d) Build an histogram of relating each bin to the intensity of image considering pixels at the
same position in the smoothed image and in the noise image.
e) Evaluate the standard deviation of each bin by a Median Absolute Deviation (MAD)
estimator.
f) Perform a robust regression analysis by Cubic Smoothing Spline in order to fit the data
extracted at step (e).
A block diagram of the whole algorithm is reported in Fig. 5.
Unfortunately, uncertainty contribution do not embed only random effects, related to noise.
In fact, in medical diagnosis, it is often crucial to take into account also non random
contributions that can occur during the exposure, the acquisition and the digitalization
of the image. We refer for example to physiological movements of the patient (a few
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seconds are needed in order to form a single mammographic image), to artifacts that can
be present in the final image, due to dust, fingerprints, scratch, and to the non random
contribution introduced by the scanner itself, such as the spatial non uniformity introduced
in the luminance. For example, the images database we consider, e.g., the Digital Database
for Screening Mammography (DDSM) (Heath et al., 1998) uses the three scanners DBA,
HOWTEK, and LUMISYS to digitalize more than 4000 mammographic images. We can notice
that the final images are corrupted by a periodic pattern contribution that we assumed to be
systematic. An example is shown in Fig. 6(a)-(b) where two regions are extracted from the
same mammographic image. Region A is dark and it is evident that there is an overlying
periodic pattern that here is also emphasized by an histogram stretching. On the contrary,
region B is corrupted by noise but the periodic pattern is much more subtle. In Fig. 6(c) the
two-dimensional Fourier Transforms of the two regions are also shown proving that there is a
unidirectional periodic pattern overlying region A and that the same does not hold for region
B with the same evidence.
It is well known that systematic effects have to be corrected before performing a reliable
uncertainty propagation of random effects (Santo et al., 2004). Unfortunately, as a consequence
of the previous considerations, this kind of contributions is both luminance and spatial
dependent so that it is very difficult to evaluate and correct it. Moreover, from both medical
and visual viewpoints, it could be dangerous to preliminarily correct the images from non
random contribution thus altering the final aspects of the images and falsifying the correct
diagnosis of microcalcifications. In this regard, the new version of International Vocabulary
of Metrology (VIM) (see (International vocabulary of metrology. Basic and general concepts and
associated terms (VIM), 2008) paragraph 2.26) states that Sometimes, estimated systematic effects
are not corrected for but, instead, associated measurement uncertainty components are incorporated.
Finally, scanner devices used in medical laboratories are not completely characterized from
a metrological point of view thus making the exact evaluation of these effects for correction
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Fig. 6. (a) A mammographic image with a dark region (A) exhibiting a periodic pattern and a
bright region (B) in which the same effect is much more subtle. (b) A zoom of the two regions
A and B. (c) The 2D-FFT of the regions A and B respectively.
effects and to embed them in a unified uncertainty model, implementing an uncertainty
propagation through a suitable method.
A viable solution is to use information extracted by the estimation procedure performed for
the noise variance modeling. In this way, by merging different images coming from the same
scanner or digitalization device, we are able to provide more accurate limits for the systematic
contribution. In the following, we will provide an example for the whole noise estimation
procedure considering the three different databases: MiniMIAS, DDSM, and San Paolo FFDM
images.
Fig. 7 reports the noise variance modeling considering DDSM images for the three different
scanners HOWTEK-A, LUMISYS, and DBA at different spatial and pixel resolution. Note
that for low luminance values electronic noise in HOWTEK-A and in DBA is the dominant
noise contribution, while photon noise due to X-ray exposure has a small variance at high
and low exposure. Noise variance related to photon noise has a maximum value in the
range [0.4 − 0.6] for scanners LUMISYS, HOWTEK-A, and DBA. Fig. 8(a) shows the noise
variance estimation for images from MiniMIAS database. Photon noise is low at high and
low exposure and the noise variance has a maximum value in the same range as above.
Both LUMISYS, HOWTEK-A, and MIAS scanning device have a linear characteristic curve.
Conversely, scanner DBA has a logarithmic response. Finally, Fig. 8(b) reports the noise
variance estimation performed on the FFDM images from the San Paolo Hospital. Also in
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Fig. 7. Noise variance modeling for scanners HOWTEK-A and LUMISYS (left) and DBA
(right). A Cubic Smoothing Spline regression is applied with a smoothing parameter equal to
0.9999 for scanners HOWTEK-A and LUMISYS and to 0.999 to scanner DBA. The systematic
noise variation is marked by the arrows.
this case, photon noise is the dominant contribution. The digital mammography device has a
logarithmic characteristic curve.




































Fig. 8. Noise variance modeling for Joice-Loebl scanning microdensitometer (a) and for GE
Senograph 2000D ADS 17.3 (b). A Cubic Smoothing Spline regression is applied with a
smoothing parameter equal to 0.999. The systematic noise variation is marked by the arrows.
It can be noted that the noise dependence from the pixel intensity strongly varies across
different digitalization devices, according to pixel quantization, spatial resolution, scanner
calibration curve, etc. Also, the systematic noise variation is different across the devices.
5.2 GROUP 2: biological and patient variability
Uncertainty sources due to biological and patient variability are probably the most difficult
kind of uncertainty to consider because it groups together unpredictable variations in patient
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effects and to embed them in a unified uncertainty model, implementing an uncertainty
propagation through a suitable method.
A viable solution is to use information extracted by the estimation procedure performed for
the noise variance modeling. In this way, by merging different images coming from the same
scanner or digitalization device, we are able to provide more accurate limits for the systematic
contribution. In the following, we will provide an example for the whole noise estimation
procedure considering the three different databases: MiniMIAS, DDSM, and San Paolo FFDM
images.
Fig. 7 reports the noise variance modeling considering DDSM images for the three different
scanners HOWTEK-A, LUMISYS, and DBA at different spatial and pixel resolution. Note
that for low luminance values electronic noise in HOWTEK-A and in DBA is the dominant
noise contribution, while photon noise due to X-ray exposure has a small variance at high
and low exposure. Noise variance related to photon noise has a maximum value in the
range [0.4 − 0.6] for scanners LUMISYS, HOWTEK-A, and DBA. Fig. 8(a) shows the noise
variance estimation for images from MiniMIAS database. Photon noise is low at high and
low exposure and the noise variance has a maximum value in the same range as above.
Both LUMISYS, HOWTEK-A, and MIAS scanning device have a linear characteristic curve.
Conversely, scanner DBA has a logarithmic response. Finally, Fig. 8(b) reports the noise
variance estimation performed on the FFDM images from the San Paolo Hospital. Also in
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Fig. 8. Noise variance modeling for Joice-Loebl scanning microdensitometer (a) and for GE
Senograph 2000D ADS 17.3 (b). A Cubic Smoothing Spline regression is applied with a
smoothing parameter equal to 0.999. The systematic noise variation is marked by the arrows.
It can be noted that the noise dependence from the pixel intensity strongly varies across
different digitalization devices, according to pixel quantization, spatial resolution, scanner
calibration curve, etc. Also, the systematic noise variation is different across the devices.
5.2 GROUP 2: biological and patient variability
Uncertainty sources due to biological and patient variability are probably the most difficult
kind of uncertainty to consider because it groups together unpredictable variations in patient
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physiological status and position. Fortunately, the protocol that regulates mammography
provides a set of rules that allow you to control many of these sources of uncertainty: the
breast is compressed and locked during exposure to X-rays, reducing the possible involuntary
movements also due to the simple respiratory motion; the hormonal changes that may
occur during the patient’s mammography are also controlled as much as possible through
detailed recommendations about the optimal time to perform the examination in relation to
the menstrual cycle. In any case, a complete and accurate CAD system should also provide
the possibility to receive and process information relating to the phase of the woman’s life: at
puberty, lactation, or menopause, in order to adapt algorithm parameters such as for example
those related to fibro-glandular disk extraction in bilateral asymmetry detection.
5.3 GROUP 3: model uncertainty
A CAD for mammography consists of several blocks, as already shown in the introduction.
The correct functioning and adaptation of each block involve the use of inline tuned
parameters that are initialized to a certain value (randomly or not) and can be changed during
the system functioning, according to the image characteristics (adaptation) or according to
pre-specified rules. The CAD developers identify these rules during the system development
and validation steps, using large datasets of mammographic images, but a complete
knowledge of the behavior of the selected parameters is not realistic. In light of this, a formal
way to deal with this incomplete knowledge is to perform an analysis of sensitivity, that,
considering a parameter at a time, introduces small perturbation of it and evaluate the final
effect on the block output. By an iterative procedure, the developer can assign an interval of
values to each block output with a dual effect: quantifying the most critical parameters that
most influence the output and modify the block in order to improve the robustness of the
whole system to unpredictable parameters variations.
The CAD elaboration units can be divided into three categories:
- direct computational blocks involving constant multiplicative coefficients and/or
nonlinear operators;
- iterative blocks involving adaptive thresholds and signal-dependent parameters that
change during the block functioning;
- conditional statements involving the comparison of input variables with thresholds (fixed
or changing during the functioning).
According to the typology, different kind of uncertainty modelling should be performed. Here
below, we provide some examples already investigated by the authors in previous works. In
Section 6 will be described in more detail a recent study in the context of the identification of
bilateral asymmetry.
5.3.1 Direct elaboration units
Context Handling and propagation of random and systematic uncertainty contributions
due to image noise through a wavelet-based enhancement and denoising procedure for
microcalcification detection (Mencattini et al., 2009b).
Materials DDSM Images containing malignant and benign calcifications.
Method Random Fuzzy Variables able to simultaneously represent and propagate through
dedicated mathematical operators random and systematic terms. The method has been
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developed by Ferrero and Salicone (Ferrero & Salicone, 2009; Salicone, 2007) and it is still
under investigation the possible application of the method to iterative and more complex
elaboration units.
5.3.2 Iterative elaboration units
Context Handling and propagation of random uncertainty contributions due to image noise
through the automatic segmentation and classification of massive lesions in mammographic
images (Mencattini et al., 2009a; 2010a; Rabottino et al., 2011).
Algorithm Segmentation is performed by an iris detection algorithm, an iterative
region-growing procedure is applied to extract the mass boundary, geometric and textural
(Haralick) features are computed for each segmented lesion, and finally a Bayes linear
classifier is applied to assign a malignancy degree to each lesion (Mencattini et al., 2009a).
Materials DDSM Images containing malignant and benign massive lesions.
Method Monte Carlo simulations using 50 trials on ROIs 1000 × 1000. The AUC-based
performance assessment has been performed. Fig. 9 reports the cumulative distribution
function and the histogram of the AUC obtained after the trials. Note that the AUC parameter
Fig. 9. AUC cumulative distribution function and histogram.
has a clear non-Gaussian probability distribution, such that the confidence interval for p = 0.9
is very different than the interval obtained under the assumption of normality.
Context and Algorithm An analogous study has been developed in collaboration with the San
Paolo Hospital and the Dept. of Mathematics University of Bari, using the active contour
algorithm developed by Chan and Vese (Chan & Vese, 2001) for the segmentation step, the
fractal analysis and support vector machines for the malignancy assessment. Preliminary
results can be found in (Mencattini et al., 2011d).
Materials San paolo FFDM Images and DDSM images containing malignant and benign
massive lesions histologically proven.
Method Monte Carlo simulations using 100 trials.
5.3.3 Conditional elaboration units
Context Conditional statements in a fuzzy logic inference system for pattern
classification (Ferrero et al., 2010; Mencattini & Salmeri, 2011a). The pattern classification
step is an important section of a CAD because it is use in many functionalities: in the
automatic identification of lesions a classifier is used to reduce false positive lesion candidates
discriminating them from true lesions; in the malignancy assessment a classification step
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breast is compressed and locked during exposure to X-rays, reducing the possible involuntary
movements also due to the simple respiratory motion; the hormonal changes that may
occur during the patient’s mammography are also controlled as much as possible through
detailed recommendations about the optimal time to perform the examination in relation to
the menstrual cycle. In any case, a complete and accurate CAD system should also provide
the possibility to receive and process information relating to the phase of the woman’s life: at
puberty, lactation, or menopause, in order to adapt algorithm parameters such as for example
those related to fibro-glandular disk extraction in bilateral asymmetry detection.
5.3 GROUP 3: model uncertainty
A CAD for mammography consists of several blocks, as already shown in the introduction.
The correct functioning and adaptation of each block involve the use of inline tuned
parameters that are initialized to a certain value (randomly or not) and can be changed during
the system functioning, according to the image characteristics (adaptation) or according to
pre-specified rules. The CAD developers identify these rules during the system development
and validation steps, using large datasets of mammographic images, but a complete
knowledge of the behavior of the selected parameters is not realistic. In light of this, a formal
way to deal with this incomplete knowledge is to perform an analysis of sensitivity, that,
considering a parameter at a time, introduces small perturbation of it and evaluate the final
effect on the block output. By an iterative procedure, the developer can assign an interval of
values to each block output with a dual effect: quantifying the most critical parameters that
most influence the output and modify the block in order to improve the robustness of the
whole system to unpredictable parameters variations.
The CAD elaboration units can be divided into three categories:
- direct computational blocks involving constant multiplicative coefficients and/or
nonlinear operators;
- iterative blocks involving adaptive thresholds and signal-dependent parameters that
change during the block functioning;
- conditional statements involving the comparison of input variables with thresholds (fixed
or changing during the functioning).
According to the typology, different kind of uncertainty modelling should be performed. Here
below, we provide some examples already investigated by the authors in previous works. In
Section 6 will be described in more detail a recent study in the context of the identification of
bilateral asymmetry.
5.3.1 Direct elaboration units
Context Handling and propagation of random and systematic uncertainty contributions
due to image noise through a wavelet-based enhancement and denoising procedure for
microcalcification detection (Mencattini et al., 2009b).
Materials DDSM Images containing malignant and benign calcifications.
Method Random Fuzzy Variables able to simultaneously represent and propagate through
dedicated mathematical operators random and systematic terms. The method has been
306 Mammography – Recent Advances Metrological Assessment of a CAD System for the Early Diagnosis of Breast Cancer in Digital Mammography 15
developed by Ferrero and Salicone (Ferrero & Salicone, 2009; Salicone, 2007) and it is still
under investigation the possible application of the method to iterative and more complex
elaboration units.
5.3.2 Iterative elaboration units
Context Handling and propagation of random uncertainty contributions due to image noise
through the automatic segmentation and classification of massive lesions in mammographic
images (Mencattini et al., 2009a; 2010a; Rabottino et al., 2011).
Algorithm Segmentation is performed by an iris detection algorithm, an iterative
region-growing procedure is applied to extract the mass boundary, geometric and textural
(Haralick) features are computed for each segmented lesion, and finally a Bayes linear
classifier is applied to assign a malignancy degree to each lesion (Mencattini et al., 2009a).
Materials DDSM Images containing malignant and benign massive lesions.
Method Monte Carlo simulations using 50 trials on ROIs 1000 × 1000. The AUC-based
performance assessment has been performed. Fig. 9 reports the cumulative distribution
function and the histogram of the AUC obtained after the trials. Note that the AUC parameter
Fig. 9. AUC cumulative distribution function and histogram.
has a clear non-Gaussian probability distribution, such that the confidence interval for p = 0.9
is very different than the interval obtained under the assumption of normality.
Context and Algorithm An analogous study has been developed in collaboration with the San
Paolo Hospital and the Dept. of Mathematics University of Bari, using the active contour
algorithm developed by Chan and Vese (Chan & Vese, 2001) for the segmentation step, the
fractal analysis and support vector machines for the malignancy assessment. Preliminary
results can be found in (Mencattini et al., 2011d).
Materials San paolo FFDM Images and DDSM images containing malignant and benign
massive lesions histologically proven.
Method Monte Carlo simulations using 100 trials.
5.3.3 Conditional elaboration units
Context Conditional statements in a fuzzy logic inference system for pattern
classification (Ferrero et al., 2010; Mencattini & Salmeri, 2011a). The pattern classification
step is an important section of a CAD because it is use in many functionalities: in the
automatic identification of lesions a classifier is used to reduce false positive lesion candidates
discriminating them from true lesions; in the malignancy assessment a classification step
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is used to assign the malignancy degree to each considered suspicious lesion; lastly, in the
identification of bilateral asymmetry the classifier assigns the asymmetry degree to each pair
of mammograms under test. Many different classifiers exist in the literature and have been
used in developing a CAD for mammography: Bayesian classifier, decision trees, artificial
neural networks, logistic regression, support vector machine, fuzzy logic inference systems
are the most popular approaches. Each of them has its own peculiarity. For example, SVM is
excellent for small training dataset, while artificial neural network has great flexibility to very
large datasets. However, most of them can be considered as completely black boxes able to
learn from examples and to produce a final class membership. None of them, excluding fuzzy
inference systems and decision trees, produces simple classification rules that can be easily
understood by physicians. Finally, only fuzzy inference systems can be directly modified
by physicians who can add classification rules, according to his/her experience. Algorithm
Since the method uses a non-standard fuzzy logic system, in the following we will provide
a brief introduction of the method. A Fuzzy Inference System (FIS) for medical diagnosis is
a nonstandard FIS firstly proposed by Andersson in (Andersson, 2007). The core of such a
system is a simple structure composed of three agents: the patient (the mammogram in our
context), the symptoms (in our context the features extracted to characterize the object to
be classified), and finally the diagnosis (in our context the class, normal or abnormal tissue,
benign or malignant lesions, normal or asymmetric breast, etc.). The architecture of such a FIS
involves three kind or relations: two input relationships (the relation Mammogram-Features
and the relation Features-Diagnosis) and a third relation (the Mammogram-Diagnosis
relation) that is derived by the first two relations using a specific inference process. The first
relation is built by physicians in the patient-history or anamnesis process, while is learnt by
the CAD during the features extraction and training steps. The second relation is derived
by the physician according to his/her experience, retrospective study and clinical trials in
which a symptom has been confirmed to be significant for a certain diagnosis (e.g., spiculated
margins of a mass represent the infiltrating properties of the lesion and a sign of possible
malignancy). Finally, the third relation assigns a final class membership to a mammogram or
simply to a region of interest (P in the following), according to the features extracted on it and
on their significance for a certain class. Such a system has been already applied in different
situations: the malignancy assessment of calcifications clusters (Ferrero et al., 2010), the false
positive reduction in the automatic mass identification (Mencattini & Salmeri, 2011b), the
development of a novel scoring system to measure the severity of illness of patients admitted
in Intensive Care Units (Mencattini et al., 2011e). In this section, we will consider in details
the malignancy assessment of calcifications.
A FIS rule has an IF-THEN structure, an example of two distinct rules is reported below.
IF number of calcifications in a cluster is HIGH in mammogram P AND number of calcifications is
HIGHLY significant for diagnosis MALIGNANT THEN mammogram P contains a MALIGNANT
cluster of calcifications
IF mean entropy of calcifications is HIGH in mammogram P AND mean entropy of calcifications is
HIGHLY significant for diagnosis BENIGN THEN mammogram P contains a BENIGN cluster of
calcifications
Each rule is preliminarily evaluated computing the two antecedents according to specific
mathematical fuzzy operators and then the rules are aggregated through a weighted average
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operator (Ferrero et al., 2010). The evaluation of the two antecedents, number of calcifications
in a cluster is HIGH and number of calcifications in a cluster is HIGHLY significant for diagnosis
MALIGNANT involves the definition of the fuzzy variable number of calcifications, and
consequently of the fuzzy sets HIGH number of calcifications and LOW number of calcifications.
This definition consists in the construction of two trapezoidal Membership Functions (MFs) as
those reported in Fig. 10 for the two symptoms number of calcifications (Sj) and mean entropy of

























Fig. 10. Examples of MF construction for symptom Sj (number of calcifications) and Sk (mean
entropy of calcifications). The magenta bars identify the class M while the blue bars
represent the class B.
for a certain value S̄J of the first symptom, the system assigns two degrees of membership
μMS̄j
and μBS̄j to the class MALIGNANT (M) and BENIGN (B) respectively. As long as the




toward zero. The opposite happens when Sj decreases from x2 to x1. It is evident that
each of the two MFs depends on the two parameters x1 and x2 which are extracted from
the distribution of the feature for the different classes. In particular, x1 is the maximum value
of Sj for benign cases such that all the Sj for malignant cases are greater than x1. Conversely,
x2 is the minimum value of Sj for malignant cases such that all the Sj values for benign cases
are smaller than x2. The evaluation of x1 and x2 is performed after outliers elimination on
each feature Sj. Parameters x1 and x2 influences the final class membership function and an
analysis of sensitivity should be implemented for them.
The second antecedent number of calcifications is HIGHLY significant for diagnosis MALIGNANT
involves the computation of what we called Incidence Level ILDiSj of a symptom Sj for a
diagnosis Di, where in the considered example Di is M or B. It represents the degree of
influence that a symptom Sj can have on a certain diagnosis Di and a degree of correlation
among them. This correlation is evaluated according to physician’s experience or again from
the distribution of the symptom’s values for each class. Two examples of this calculation are
reported in Fig. 11 for the number of calcifications in a cluster and for the mean entropy of
calcifications for the two classes Malignant and Benign. In particular, we get for symptom Sj
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is used to assign the malignancy degree to each considered suspicious lesion; lastly, in the
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of mammograms under test. Many different classifiers exist in the literature and have been
used in developing a CAD for mammography: Bayesian classifier, decision trees, artificial
neural networks, logistic regression, support vector machine, fuzzy logic inference systems
are the most popular approaches. Each of them has its own peculiarity. For example, SVM is
excellent for small training dataset, while artificial neural network has great flexibility to very
large datasets. However, most of them can be considered as completely black boxes able to
learn from examples and to produce a final class membership. None of them, excluding fuzzy
inference systems and decision trees, produces simple classification rules that can be easily
understood by physicians. Finally, only fuzzy inference systems can be directly modified
by physicians who can add classification rules, according to his/her experience. Algorithm
Since the method uses a non-standard fuzzy logic system, in the following we will provide
a brief introduction of the method. A Fuzzy Inference System (FIS) for medical diagnosis is
a nonstandard FIS firstly proposed by Andersson in (Andersson, 2007). The core of such a
system is a simple structure composed of three agents: the patient (the mammogram in our
context), the symptoms (in our context the features extracted to characterize the object to
be classified), and finally the diagnosis (in our context the class, normal or abnormal tissue,
benign or malignant lesions, normal or asymmetric breast, etc.). The architecture of such a FIS
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and the relation Features-Diagnosis) and a third relation (the Mammogram-Diagnosis
relation) that is derived by the first two relations using a specific inference process. The first
relation is built by physicians in the patient-history or anamnesis process, while is learnt by
the CAD during the features extraction and training steps. The second relation is derived
by the physician according to his/her experience, retrospective study and clinical trials in
which a symptom has been confirmed to be significant for a certain diagnosis (e.g., spiculated
margins of a mass represent the infiltrating properties of the lesion and a sign of possible
malignancy). Finally, the third relation assigns a final class membership to a mammogram or
simply to a region of interest (P in the following), according to the features extracted on it and
on their significance for a certain class. Such a system has been already applied in different
situations: the malignancy assessment of calcifications clusters (Ferrero et al., 2010), the false
positive reduction in the automatic mass identification (Mencattini & Salmeri, 2011b), the
development of a novel scoring system to measure the severity of illness of patients admitted
in Intensive Care Units (Mencattini et al., 2011e). In this section, we will consider in details
the malignancy assessment of calcifications.
A FIS rule has an IF-THEN structure, an example of two distinct rules is reported below.
IF number of calcifications in a cluster is HIGH in mammogram P AND number of calcifications is
HIGHLY significant for diagnosis MALIGNANT THEN mammogram P contains a MALIGNANT
cluster of calcifications
IF mean entropy of calcifications is HIGH in mammogram P AND mean entropy of calcifications is
HIGHLY significant for diagnosis BENIGN THEN mammogram P contains a BENIGN cluster of
calcifications
Each rule is preliminarily evaluated computing the two antecedents according to specific
mathematical fuzzy operators and then the rules are aggregated through a weighted average
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operator (Ferrero et al., 2010). The evaluation of the two antecedents, number of calcifications
in a cluster is HIGH and number of calcifications in a cluster is HIGHLY significant for diagnosis
MALIGNANT involves the definition of the fuzzy variable number of calcifications, and
consequently of the fuzzy sets HIGH number of calcifications and LOW number of calcifications.
This definition consists in the construction of two trapezoidal Membership Functions (MFs) as
those reported in Fig. 10 for the two symptoms number of calcifications (Sj) and mean entropy of

























Fig. 10. Examples of MF construction for symptom Sj (number of calcifications) and Sk (mean
entropy of calcifications). The magenta bars identify the class M while the blue bars
represent the class B.
for a certain value S̄J of the first symptom, the system assigns two degrees of membership
μMS̄j
and μBS̄j to the class MALIGNANT (M) and BENIGN (B) respectively. As long as the




toward zero. The opposite happens when Sj decreases from x2 to x1. It is evident that
each of the two MFs depends on the two parameters x1 and x2 which are extracted from
the distribution of the feature for the different classes. In particular, x1 is the maximum value
of Sj for benign cases such that all the Sj for malignant cases are greater than x1. Conversely,
x2 is the minimum value of Sj for malignant cases such that all the Sj values for benign cases
are smaller than x2. The evaluation of x1 and x2 is performed after outliers elimination on
each feature Sj. Parameters x1 and x2 influences the final class membership function and an
analysis of sensitivity should be implemented for them.
The second antecedent number of calcifications is HIGHLY significant for diagnosis MALIGNANT
involves the computation of what we called Incidence Level ILDiSj of a symptom Sj for a
diagnosis Di, where in the considered example Di is M or B. It represents the degree of
influence that a symptom Sj can have on a certain diagnosis Di and a degree of correlation
among them. This correlation is evaluated according to physician’s experience or again from
the distribution of the symptom’s values for each class. Two examples of this calculation are
reported in Fig. 11 for the number of calcifications in a cluster and for the mean entropy of
calcifications for the two classes Malignant and Benign. In particular, we get for symptom Sj
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Fig. 11. Examples of evaluation of the incidence level IL for symptom Sj (number of
calcifications) and Sk (mean entropy of calcifications). The gray bars identify those cases that
do not contribute to the calculation of the incidence levels.
(number of calcifications) that
ILMSj =
�{SMj |SMj > SBj }
�{SMj }
, ILBSj =
�{SBj |SBj < SMj }
�{SBj }
(2)
From equations (2) it is fully justified that the incidence level has a strong influence on the
final class membership and again a dedicated analysis of sensitivity should be performed. In
the considered context, seven features are used to assess the malignancy of the calcifications:
number of microcalcifications (S1), minimum area of the microcalcifications (S2), area of the
convex hull containing microcalcifications (S3), entropy of the cluster of microcalcifications
(S4), mean contrast of the microcalcifications (S5), mean entropy of the microcalcifications
(S6), Haralick parameter H8 (Sum Entropy) (S7).
Materials DDSM images, 119 benign and 122 malignant calcifications clusters.
Methods Recently, an innovative approach to propagate random and systematic uncertainty
contributions through a FIS has been implemented (Ferrero et al., 2010). In light of this, within
a collaboration with the Dept. of Electrical Engineering Politecnico of Milan, the method has
been applied to our context. Basically, the method assigns a Random Fuzzy Variable (RFV) to
each variable in order to model simultaneously random and systematic uncertainty terms.
From Fig. 12 (figure top-left) it can be noted that an RFV is an extended Fuzzy Variable,
whose Membership Function is composed of an inner and an outer standard MF. The inner
MF represents the systematic uncertainty contribution, usually it is a rectangular MF, as in
standard interval analysis; the outer part represents the random contribution and a direct
approach can be implemented to derive it from the pdf of the variable (Dubois et al., 2004).
Fig. 12 (figures right) reports the Random Fuzzy Variables (RFVs) for each feature used for
calcifications malignancy assessment considering one of the images taken from DDSM. In
this context, we assumed only systematic uncertainty contribution for discrete symptoms
S1, S2, S3 and only random contributions for symptom S4, . . . , S7 2. The corresponding
2 The random contributions in symptoms S1, . . . , S3 are considered to be small and totally embedded
in the systematic terms. On the contrary, we assumed that the systematic contribution in symptoms
S4, . . . , S7 was negligible with respect to random variations.
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histograms for features S4, . . . , S7 are reported on the left. Figure top-left reports the two RFVs
representing the benign and the malignancy degrees associated to the considered cluster. The
inner part results from the propagation of the systematic effects, while the outer part results
from the propagation of the random effects through the FIS.











































































Fig. 12. Figure Top-left: RFVs of the malignancy and the benign degrees for one test image.
Figure bottom-left: histogram of features S4 − S7. Figure right: RFVs of the features
extracted. Red plot: inner MFs of the RFVs; blue plot: outer MFs of the RFVs.
5.4 GROUP 4: radiologist-dependent CAD inputs
During the development step and the CAD validation procedure, one or more radiologists
should provide the ground truth needed as a reference to set the algorithm parameters.
i) During the validation of the breast region segmentation, radiologists provide the actual
breast skin line, the nipple position, the pectoral muscle profile. In particular, in case
of minoris, very obscure nipple, very dark uncompressed tissue, this reference strongly
depends on radiologist experience and more than one radiologist should be interpelled
using a voting procedure to select a final robust reference.
ii) During the validation of the automatic lesions identification, the radiologist is called to
identify the possible lesion, whose position is then confirmed by biopsy.
iii) Also, the boundary of the lesion can be drawn by the radiologist, or, more rarely, a core
and an external boundary are drawn, as in DDSM database. The core identifies the internal
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a collaboration with the Dept. of Electrical Engineering Politecnico of Milan, the method has
been applied to our context. Basically, the method assigns a Random Fuzzy Variable (RFV) to
each variable in order to model simultaneously random and systematic uncertainty terms.
From Fig. 12 (figure top-left) it can be noted that an RFV is an extended Fuzzy Variable,
whose Membership Function is composed of an inner and an outer standard MF. The inner
MF represents the systematic uncertainty contribution, usually it is a rectangular MF, as in
standard interval analysis; the outer part represents the random contribution and a direct
approach can be implemented to derive it from the pdf of the variable (Dubois et al., 2004).
Fig. 12 (figures right) reports the Random Fuzzy Variables (RFVs) for each feature used for
calcifications malignancy assessment considering one of the images taken from DDSM. In
this context, we assumed only systematic uncertainty contribution for discrete symptoms
S1, S2, S3 and only random contributions for symptom S4, . . . , S7 2. The corresponding
2 The random contributions in symptoms S1, . . . , S3 are considered to be small and totally embedded
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histograms for features S4, . . . , S7 are reported on the left. Figure top-left reports the two RFVs
representing the benign and the malignancy degrees associated to the considered cluster. The
inner part results from the propagation of the systematic effects, while the outer part results
from the propagation of the random effects through the FIS.











































































Fig. 12. Figure Top-left: RFVs of the malignancy and the benign degrees for one test image.
Figure bottom-left: histogram of features S4 − S7. Figure right: RFVs of the features
extracted. Red plot: inner MFs of the RFVs; blue plot: outer MFs of the RFVs.
5.4 GROUP 4: radiologist-dependent CAD inputs
During the development step and the CAD validation procedure, one or more radiologists
should provide the ground truth needed as a reference to set the algorithm parameters.
i) During the validation of the breast region segmentation, radiologists provide the actual
breast skin line, the nipple position, the pectoral muscle profile. In particular, in case
of minoris, very obscure nipple, very dark uncompressed tissue, this reference strongly
depends on radiologist experience and more than one radiologist should be interpelled
using a voting procedure to select a final robust reference.
ii) During the validation of the automatic lesions identification, the radiologist is called to
identify the possible lesion, whose position is then confirmed by biopsy.
iii) Also, the boundary of the lesion can be drawn by the radiologist, or, more rarely, a core
and an external boundary are drawn, as in DDSM database. The core identifies the internal
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portion of the lesion, while the boundary includes also the spicules and the structures that
radiate from the core.
iv) In some situations, the radiologist draws the boundary of a region representing a bilateral
asymmetry or locate the center of an architectural distortion. This situation is much more
radiologist’s dependent, because there is not any histological test that can confirm this
reference.
v) Finally, less frequently, the radiologist is called to provide additional information about the
breast tissue such as ACR tissue density or ACR subtlety rating. Both these parameters are
fundamental for the correct functioning of some algorithms such as bilateral asymmetry
identification (Casti, 2011). A recent preliminary study proved the effectiveness of a
procedure for the extraction of the fibro-glandular disk and of the oriented patterns in
the breast, tuned according to the ACR tissue density.
All of the information provided by the radiologist influence both the CAD learning capability
and the effectiveness of its operation. Each of them should be perturbated in order to evaluate
the actual influence on the final results produced by the CAD. In particular, in Section 6 we
will describe recent simulation results, obtained assuming a systematic perturbation of the
ACR density rating assessed by a single radiologist. Using a leave one out cross-validation
procedure, considering a pair of mammograms at a time, we assumed that the radiologist
assessed a density rating higher than the actual density. Such a bias, is then propagated
through the whole algorithm for the identification of bilateral asymmetry on a dataset
including 23 pairs of normal mammograms and 23 pairs if asymmetric mammograms taken
from MiniMIAS database. The same procedure has been implemented assuming that the
radiologist assigns to the pair of mammograms under test a density rating smaller than
the actual one. Doing so, the whole algorithm produces for each pair of mammograms an
asymmetry degree in absence of perturbation and two asymmetry degrees in presence of a
positive and a negative perturbation respectively. Further details will be provided later.
5.5 GROUP 5: CAD-radiologist interaction
A recent study by Nishikawa (Nishikawa, 2007) reports important considerations on the
evaluation of a CADe system. He recalls that a CADe system does not need to detect cancers,
but it needs to assist radiologist in doing this. This means that the real help is in detecting
tumors missed by the radiologist increasing the overall sensitivity of the radiologist-CADe
system. It is possible to have a CADe scheme with a sensitivity lower than 50% and still
be a useful aid. So, one of the crucial point is the interaction CADe-radiologist. If cancers
missed by the computer is too high then the radiologist will lose confidence in the ability
of the computer to detect cancers. On the other hand, false detections reduce radiologist’s
productivity because the radiologists must spend time reviewing all computer detections.
Conversely, a CAD could over-learn from available samples produced by the same apparatus
and reported by the same radiologist. Nishikawa observes that a positive bias can occur even
if training and test set are the same or if the dataset used for features selection and the training
set are the same. To reduce this bias and to reduce over-learning, more than one radiologist
should report the images used for development, validation, training, and test, using a voting
procedure to select one report for each case. Moreover, a separate dataset for each of the above
phase should be used, preferably extracted from different databases.
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6. A numerical example of uncertainty propagation through ABCDE: bilateral
asymmetry identification
For almost thirty years, methods have been developed to try to use computers as second
readers to make up for this potential loss of reliability. Almost all fields of image processing
and analysis have been explored but little attention has been paid to the identification of
bilateral asymmetry on mammograms. Asymmetric breast tissue is usually benign, but
an asymmetric area may indicate a developing mass or an underlying cancer. Thus, the
American College of Radiology (ACR) Breast Imaging Reporting and Data System (BI-RADS),
which has developed a standardized method for breast imaging reporting, describes bilateral
asymmetry as one of the four signs of breast cancer that radiologists have to detect. Some
commercial CAD systems have obtained the Food and Drug Administration (FDA) approval
and are beginning to be applied widely for the detection of masses and microcalcification on
mammograms, but none of them has been developed for bilateral asymmetry identification.
The paucity of works related to this topic may be due to the fact that bilateral asymmetries are
difficult to be identified for the following reasons:
1. it needs a comparison between the left and right views which is a difficult task owing to
the natural asymmetry of the breasts, and to the absence of good corresponding points to
perform matching;
2. distortion inherent to the manual position of the breast during X-ray exposure;
3. the wide range of appearance associated with differences between women in the amount
and distribution of fibroglandular tissue, which is also influenced by age and hormonal
status and whose asymmetry could also represents simply a physiological sign.
The authors are currently working on the development of an automatic bilateral asymmetry
identification procedure, one of the most innovative part of ABCDE (Casti, 2011; Mencattini
et al., 2011c). The aim is to improve the early diagnosis of breast cancer, especially in
screening test, providing clues about the presence of early signs of tumors like parenchymal
distortion, small asymmetric bright spots and contrast, that are not detected by other methods.
Asymmetric breasts could be reliable indicators of future breast disease in women and this
factor should be considered in a woman’s risk profile. The Breast Imaging Reporting and
Data System (BIRADS) defines bilateral asymmetry as an area of fibroglandular tissue that
is more extensive in one breast as compared to the contralateral one. Thus an asymmetric
finding can be represented by a difference in shape and distribution of the fibroglandular
tissues of the two breasts but also by a difference in the oriented pattern of the two disks.
The oriented features detectors used in this work is a set of real Gabor filters oriented at
different angles (spaced at angles of 18 degrees) (Rangayyan et al., 2008). Real Gabor filters,
in fact, yield good performances in terms of capability to detect the presence of oriented
features as well as in terms of accuracy in the estimation of the angle of the directional
components and are fundamental tools in image understanding where the information of
interest is displayed in the form of oriented features. The foregoing considerations guided
the choice to segment the fibroglandular tissue from the rest of the breast parenchyma using
Gaussian mixture modelling (Ferrari et al., 2004). Differences between the left and right
breasts in terms of directional and morphological features are then extracted and used to
assess the asymmetry degree of the patient. The idea is that the integration of measures
of shape and distribution of the fibroglandular tissue with measures of the oriented pattern
through a Gabor filtering analysis, can provide a better and accurate characterization of the
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portion of the lesion, while the boundary includes also the spicules and the structures that
radiate from the core.
iv) In some situations, the radiologist draws the boundary of a region representing a bilateral
asymmetry or locate the center of an architectural distortion. This situation is much more
radiologist’s dependent, because there is not any histological test that can confirm this
reference.
v) Finally, less frequently, the radiologist is called to provide additional information about the
breast tissue such as ACR tissue density or ACR subtlety rating. Both these parameters are
fundamental for the correct functioning of some algorithms such as bilateral asymmetry
identification (Casti, 2011). A recent preliminary study proved the effectiveness of a
procedure for the extraction of the fibro-glandular disk and of the oriented patterns in
the breast, tuned according to the ACR tissue density.
All of the information provided by the radiologist influence both the CAD learning capability
and the effectiveness of its operation. Each of them should be perturbated in order to evaluate
the actual influence on the final results produced by the CAD. In particular, in Section 6 we
will describe recent simulation results, obtained assuming a systematic perturbation of the
ACR density rating assessed by a single radiologist. Using a leave one out cross-validation
procedure, considering a pair of mammograms at a time, we assumed that the radiologist
assessed a density rating higher than the actual density. Such a bias, is then propagated
through the whole algorithm for the identification of bilateral asymmetry on a dataset
including 23 pairs of normal mammograms and 23 pairs if asymmetric mammograms taken
from MiniMIAS database. The same procedure has been implemented assuming that the
radiologist assigns to the pair of mammograms under test a density rating smaller than
the actual one. Doing so, the whole algorithm produces for each pair of mammograms an
asymmetry degree in absence of perturbation and two asymmetry degrees in presence of a
positive and a negative perturbation respectively. Further details will be provided later.
5.5 GROUP 5: CAD-radiologist interaction
A recent study by Nishikawa (Nishikawa, 2007) reports important considerations on the
evaluation of a CADe system. He recalls that a CADe system does not need to detect cancers,
but it needs to assist radiologist in doing this. This means that the real help is in detecting
tumors missed by the radiologist increasing the overall sensitivity of the radiologist-CADe
system. It is possible to have a CADe scheme with a sensitivity lower than 50% and still
be a useful aid. So, one of the crucial point is the interaction CADe-radiologist. If cancers
missed by the computer is too high then the radiologist will lose confidence in the ability
of the computer to detect cancers. On the other hand, false detections reduce radiologist’s
productivity because the radiologists must spend time reviewing all computer detections.
Conversely, a CAD could over-learn from available samples produced by the same apparatus
and reported by the same radiologist. Nishikawa observes that a positive bias can occur even
if training and test set are the same or if the dataset used for features selection and the training
set are the same. To reduce this bias and to reduce over-learning, more than one radiologist
should report the images used for development, validation, training, and test, using a voting
procedure to select one report for each case. Moreover, a separate dataset for each of the above
phase should be used, preferably extracted from different databases.
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6. A numerical example of uncertainty propagation through ABCDE: bilateral
asymmetry identification
For almost thirty years, methods have been developed to try to use computers as second
readers to make up for this potential loss of reliability. Almost all fields of image processing
and analysis have been explored but little attention has been paid to the identification of
bilateral asymmetry on mammograms. Asymmetric breast tissue is usually benign, but
an asymmetric area may indicate a developing mass or an underlying cancer. Thus, the
American College of Radiology (ACR) Breast Imaging Reporting and Data System (BI-RADS),
which has developed a standardized method for breast imaging reporting, describes bilateral
asymmetry as one of the four signs of breast cancer that radiologists have to detect. Some
commercial CAD systems have obtained the Food and Drug Administration (FDA) approval
and are beginning to be applied widely for the detection of masses and microcalcification on
mammograms, but none of them has been developed for bilateral asymmetry identification.
The paucity of works related to this topic may be due to the fact that bilateral asymmetries are
difficult to be identified for the following reasons:
1. it needs a comparison between the left and right views which is a difficult task owing to
the natural asymmetry of the breasts, and to the absence of good corresponding points to
perform matching;
2. distortion inherent to the manual position of the breast during X-ray exposure;
3. the wide range of appearance associated with differences between women in the amount
and distribution of fibroglandular tissue, which is also influenced by age and hormonal
status and whose asymmetry could also represents simply a physiological sign.
The authors are currently working on the development of an automatic bilateral asymmetry
identification procedure, one of the most innovative part of ABCDE (Casti, 2011; Mencattini
et al., 2011c). The aim is to improve the early diagnosis of breast cancer, especially in
screening test, providing clues about the presence of early signs of tumors like parenchymal
distortion, small asymmetric bright spots and contrast, that are not detected by other methods.
Asymmetric breasts could be reliable indicators of future breast disease in women and this
factor should be considered in a woman’s risk profile. The Breast Imaging Reporting and
Data System (BIRADS) defines bilateral asymmetry as an area of fibroglandular tissue that
is more extensive in one breast as compared to the contralateral one. Thus an asymmetric
finding can be represented by a difference in shape and distribution of the fibroglandular
tissues of the two breasts but also by a difference in the oriented pattern of the two disks.
The oriented features detectors used in this work is a set of real Gabor filters oriented at
different angles (spaced at angles of 18 degrees) (Rangayyan et al., 2008). Real Gabor filters,
in fact, yield good performances in terms of capability to detect the presence of oriented
features as well as in terms of accuracy in the estimation of the angle of the directional
components and are fundamental tools in image understanding where the information of
interest is displayed in the form of oriented features. The foregoing considerations guided
the choice to segment the fibroglandular tissue from the rest of the breast parenchyma using
Gaussian mixture modelling (Ferrari et al., 2004). Differences between the left and right
breasts in terms of directional and morphological features are then extracted and used to
assess the asymmetry degree of the patient. The idea is that the integration of measures
of shape and distribution of the fibroglandular tissue with measures of the oriented pattern
through a Gabor filtering analysis, can provide a better and accurate characterization of the
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tissue, allowing the detection of the asymmetric abnormalities eventually present on the
mammographic images. Once a numerical representation of the pairs of mammographic
images has been obtained, bilateral asymmetry identification has been performed by pattern
classification, based on a Support Vector Machine (SVM) classifier. Fig. 13 shows the flowchart
of the whole procedure. The highlighted block denotes the most innovative part of the
algorithm. It involves the tuning of the parameters of the algorithm according to the ACR





























Fig. 13. A flowchart of the whole algorithm for the identification of bilateral asymmetry.
clustering procedure inside the gaussian mixture model estimation depend on the tissue
density. This approach leads inevitably to a strong dependence on the density assigned to
the final result, i.e. the degree of asymmetry. Fig. 14 reports two examples taken from DDSM
images for an asymmetric and a normal pair of mammograms. The fibroglandular disks are
also included along with the oriented pattern derived using Gabor filters. Finally, the rose
diagram of the angular distribution of the left and right breast is reported. The considered
asymmetric case has a density equal to 4 (at least 90% of the breast is composed of dense
tissue), while the normal case has an assigned density equal to 3 (a portion in the range of
49% − 90% of the whole breast region is occupied by heterogeneously dense tissue).
The recent work has been devoted to the identification of the most relevant sources of
uncertainty in the described algorithm. Two uncertainty contributions, respectively random
and systematic, have been investigated:
1) the image power noise, estimated as described in previous sections;
2) subjective radiologist’s bias in assessing the ACR density category, simulated by the
assignment of a density value higher or lower than that assigned by the first radiologist.
The two different sources of uncertainty have to be separately considered and simulated, in
order to avoid the interactions of them, possible compensation effects, in order to perform an
individual failure analysis.
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Fig. 14. Figure left: a pair of mammograms from DDSM with an assigned bilateral
asymmetry (B − 3056 CC views). Figure right: a pair of normal symmetric mammograms
from DDSM (A − 0048 MLO views).
6.1 Random uncertainty contribution: image noise
The Monte Carlo Method (MCM) has been implemented to evaluate and propagate the
uncertainty contribution due to noise on the mammographic images. The implemented
procedure is described as follows:
i) represent the luminance of each pixel by a pdf of a normal random variable with mean
value taken from a smoothed version of the given image and standard deviation given by
the noise variance estimation;
ii) select the number M of Monte Carlo trials;
iii) generate M different noisy images, by sampling from the assigned pdf using the model in
(1), thus producing M realizations of the input mammographic image;
iv) apply the CADe algorithm to each of M image realizations and form the corresponding M
different asymmetry degrees for each image;
v) sort these M values into strictly increasing order and construct a discrete representation G
of the cumulative distribution function for the asymmetry degree;
vi) use G to derive an appropriate confidence interval for the asymmetry degree, for a given
coverage probability p.
vii)Repeat steps i)-vi) for any image in the test set, considering a smoothed version of the
remaining N − 1 original images for training, in a leave one out cross-validation testing
procedure, thus producing N × M different asymmetry degrees.
viii)Using the values in vii) compute two vectors of M sensitivities and M specificities, thus
producing extended ROC curves for each coverage probability.
Fig. 15 reports the asymmetry degrees for the asymmetric and normal cases taken from
MiniMIAS database. The confidence interval associated is for a coverage probability equal
to p = 0.90. The green circles identify the most critical pair of mammograms in terms of
noise influence among the asymmetric and the normal cases. Fig. 16(a) reports the extended
ROC curve accounting for the confidence intervals around the sensitivity and the specificity
computed by steps: i)-viii).
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tissue, allowing the detection of the asymmetric abnormalities eventually present on the
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images has been obtained, bilateral asymmetry identification has been performed by pattern
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of the whole procedure. The highlighted block denotes the most innovative part of the
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images for an asymmetric and a normal pair of mammograms. The fibroglandular disks are
also included along with the oriented pattern derived using Gabor filters. Finally, the rose
diagram of the angular distribution of the left and right breast is reported. The considered
asymmetric case has a density equal to 4 (at least 90% of the breast is composed of dense
tissue), while the normal case has an assigned density equal to 3 (a portion in the range of
49% − 90% of the whole breast region is occupied by heterogeneously dense tissue).
The recent work has been devoted to the identification of the most relevant sources of
uncertainty in the described algorithm. Two uncertainty contributions, respectively random
and systematic, have been investigated:
1) the image power noise, estimated as described in previous sections;
2) subjective radiologist’s bias in assessing the ACR density category, simulated by the
assignment of a density value higher or lower than that assigned by the first radiologist.
The two different sources of uncertainty have to be separately considered and simulated, in
order to avoid the interactions of them, possible compensation effects, in order to perform an
individual failure analysis.
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Fig. 14. Figure left: a pair of mammograms from DDSM with an assigned bilateral
asymmetry (B − 3056 CC views). Figure right: a pair of normal symmetric mammograms
from DDSM (A − 0048 MLO views).
6.1 Random uncertainty contribution: image noise
The Monte Carlo Method (MCM) has been implemented to evaluate and propagate the
uncertainty contribution due to noise on the mammographic images. The implemented
procedure is described as follows:
i) represent the luminance of each pixel by a pdf of a normal random variable with mean
value taken from a smoothed version of the given image and standard deviation given by
the noise variance estimation;
ii) select the number M of Monte Carlo trials;
iii) generate M different noisy images, by sampling from the assigned pdf using the model in
(1), thus producing M realizations of the input mammographic image;
iv) apply the CADe algorithm to each of M image realizations and form the corresponding M
different asymmetry degrees for each image;
v) sort these M values into strictly increasing order and construct a discrete representation G
of the cumulative distribution function for the asymmetry degree;
vi) use G to derive an appropriate confidence interval for the asymmetry degree, for a given
coverage probability p.
vii)Repeat steps i)-vi) for any image in the test set, considering a smoothed version of the
remaining N − 1 original images for training, in a leave one out cross-validation testing
procedure, thus producing N × M different asymmetry degrees.
viii)Using the values in vii) compute two vectors of M sensitivities and M specificities, thus
producing extended ROC curves for each coverage probability.
Fig. 15 reports the asymmetry degrees for the asymmetric and normal cases taken from
MiniMIAS database. The confidence interval associated is for a coverage probability equal
to p = 0.90. The green circles identify the most critical pair of mammograms in terms of
noise influence among the asymmetric and the normal cases. Fig. 16(a) reports the extended
ROC curve accounting for the confidence intervals around the sensitivity and the specificity
computed by steps: i)-viii).
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Fig. 15. Asymmetry degree for each case in the data set and the relative confidence interval,
due to the noise uncertainty contribution, with 90% coverage probability. (a) Asymmetric
cases. (b) Normal cases.
































































Fig. 16. ROC curve of the classifier (mean value in blue) with the uncertainty contribution
due to (a) image noise and (b) ACR density assessment bias propagated to the False Positive
Rate and to the True Positive Rate.
6.2 Systematic uncertainty contribution: density category assessment
As seen before, the assessment of the density ACR category plays an important role in the
whole algorithm. As a consequence, a different value assessed to the test image by the
radiolgist could lead to changes in the system performance, which instead was calibrated
using tree expert radiologists criterions and their experience. This kind of uncertainty
contribution however is not random but systematic. In fact, a radiologist can introduce a
subjective bias in assessing the ACR category to the mammographic image, which depends on
his/her personal experience or on the particular mammographic equipment he/she is using.
Therefore the CADe system has been tested using to different kind of bias:
1) a negative bias modeled as 3: ACRbiased = ACRunbiased − 1;
3 Obviously, in this case density rating equal to 1 remains unchanged.
316 Mammography – Recent Advances Metrological Assessment of a CAD System for the Early Diagnosis of Breast Cancer in Digital Mammography 25
2) a positive bias modeled as 4: ACRbiased = ACRunbiased + 1.
The following procedure has been implemented to perform the uncertainty propagation of
the two kinds of bias:
i) for each image of the dataset add a negative bias;
ii) test the CADe algorithm on each image obtained in i) and form the corresponding model
value of the output, yielding N output values (where N is again the number of images of
the dataset);
iii) for each image of the dataset add a positive bias;
iv) test the CADe algorithm on each image obtained in iii) and form the corresponding model
value of the output, yielding other N output values;
v) sort these 2N values into strictly increasing order, using the sorted values to provide a
discrete representation G of the distribution function for the asymmetry degree;
vi) use G to form an appropriate confidence interval for the asymmetry degree, for a given
coverage probability p.
Fig. 17 reports the asymmetry degrees for the asymmetric and normal cases taken from
MiniMIAS database. The confidence interval associated is for a coverage probability equal to
p = 0.90. The green circles identify the most critical pair of mammograms in terms of density
bias influence among the asymmetric and the normal cases. Fig. 16(b) shows the extended

















































































Fig. 17. Asymmetry degree for each case in the data set and the relative confidence interval,
due to the noise uncertainty contribution, with 90% coverage probability. (a) Asymmetric
cases. (b) Normal cases.
ROC curve accounting for the propagation of the ACR density assessment bias through the
whole identification algorithm. A failure analysis could be guided from this kind of validation
procedure.
7. Conclusions
This chapter has addressed the problem of metrological validation of a CAD system (both
CADe-CADx) in mammography. Guided by the work of Wirth and that of Nishikawa, we
4 Obviously, in this case density rating equal to 4 remains unchanged.
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Fig. 15. Asymmetry degree for each case in the data set and the relative confidence interval,
due to the noise uncertainty contribution, with 90% coverage probability. (a) Asymmetric
cases. (b) Normal cases.
































































Fig. 16. ROC curve of the classifier (mean value in blue) with the uncertainty contribution
due to (a) image noise and (b) ACR density assessment bias propagated to the False Positive
Rate and to the True Positive Rate.
6.2 Systematic uncertainty contribution: density category assessment
As seen before, the assessment of the density ACR category plays an important role in the
whole algorithm. As a consequence, a different value assessed to the test image by the
radiolgist could lead to changes in the system performance, which instead was calibrated
using tree expert radiologists criterions and their experience. This kind of uncertainty
contribution however is not random but systematic. In fact, a radiologist can introduce a
subjective bias in assessing the ACR category to the mammographic image, which depends on
his/her personal experience or on the particular mammographic equipment he/she is using.
Therefore the CADe system has been tested using to different kind of bias:
1) a negative bias modeled as 3: ACRbiased = ACRunbiased − 1;
3 Obviously, in this case density rating equal to 1 remains unchanged.
316 Mammography – Recent Advances Metrological Assessment of a CAD System for the Early Diagnosis of Breast Cancer in Digital Mammography 25
2) a positive bias modeled as 4: ACRbiased = ACRunbiased + 1.
The following procedure has been implemented to perform the uncertainty propagation of
the two kinds of bias:
i) for each image of the dataset add a negative bias;
ii) test the CADe algorithm on each image obtained in i) and form the corresponding model
value of the output, yielding N output values (where N is again the number of images of
the dataset);
iii) for each image of the dataset add a positive bias;
iv) test the CADe algorithm on each image obtained in iii) and form the corresponding model
value of the output, yielding other N output values;
v) sort these 2N values into strictly increasing order, using the sorted values to provide a
discrete representation G of the distribution function for the asymmetry degree;
vi) use G to form an appropriate confidence interval for the asymmetry degree, for a given
coverage probability p.
Fig. 17 reports the asymmetry degrees for the asymmetric and normal cases taken from
MiniMIAS database. The confidence interval associated is for a coverage probability equal to
p = 0.90. The green circles identify the most critical pair of mammograms in terms of density
bias influence among the asymmetric and the normal cases. Fig. 16(b) shows the extended

















































































Fig. 17. Asymmetry degree for each case in the data set and the relative confidence interval,
due to the noise uncertainty contribution, with 90% coverage probability. (a) Asymmetric
cases. (b) Normal cases.
ROC curve accounting for the propagation of the ACR density assessment bias through the
whole identification algorithm. A failure analysis could be guided from this kind of validation
procedure.
7. Conclusions
This chapter has addressed the problem of metrological validation of a CAD system (both
CADe-CADx) in mammography. Guided by the work of Wirth and that of Nishikawa, we
4 Obviously, in this case density rating equal to 4 remains unchanged.
317
Metrological Assessment of a CAD System
for the Early Diagnosis of Breast C cer in Digital Mammograp y
26 Will-be-set-by-IN-TECH
realized that there are still several open issues concerning the validation of CAD in this
context. Based on the experience gained in the context of modeling and propagation of
measurement uncertainty in the medical field, we have prepared this review providing some
guidelines to expand and improve the validation and performance evaluation of CAD. Several
examples have been inserted drawing inspiration from the CAD ABCDE that our research
team is developing, especially showing those points that are distinctive compared to other
commercial CAD already on the market. These points relate mainly to the metrological
assessment, to the adaptability to different databases (either analog and digital), to the
presence of new functional blocks relating to the identification of bilateral asymmetry, and
last but not least to the ability to interact with the radiologist who can add rules in the CAD
decision making process. This last functionality is allowed by the use of Fuzzy Inference
Systems. Finally, taking a cue from the considerations of Wirth, we have also provided some
hints on how to implement a failure assessment of the resulting False Negatives/Positives
produced by a CAD.
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1. Introduction 
Breast cancer is the second leading cause of cancer deaths in women today (after lung 
cancer) and is the most frequently diagnosed cancer among women, excluding skin cancers. 
According to the American Cancer Society, an estimated of 230,480 new cancer cases are 
expected to be diagnosed in 2011; about 2,140 new cases are expected in men. In addition to 
invasive breast cancer, 57,650 new cases of in situ breast cancer are expected to occur among 
women in 2011. Of these, approximately 85% will be ductal carcinoma in situ (DCIS). An 
estimated 39,970 breast cancer deaths (39,520 women, 450 men) are expected in 2011. Death 
rates for breast cancer have steadily decreased in women since 1990, with larger decreases in 
women younger than 50 (a decrease of 3.2% per year) than in those 50 and older (2.0% per 
year), representing progress in both earlier detection and improved treatment. 
Breast imaging has a key role in the early detection of breast cancer, which in conjunction 
with increased public awareness (prompting for monthly self-breast examination and 
annual examination by physician) yields the reduction in mortality from breast cancer.  
Screen-film (SF) mammography is currently the most effective imaging modality for the 
early detection of breast cancer, challenged however by the presence of dense breast 
parenchyma. Furthermore, radiologist accuracy in diagnostic task (discrimination of 
malignant from benign lesions) is relatively low and is also differentiated with respect to 
lesion type (masses versus microcalcifications) (Cole et al., 2003). Despite the advantages 
offered by digital mammography the diagnosis of indeterminate lesions is still a challenging 
task. Breast ultrasound and Dynamic Contrast Enhanced Magnetic Resonance Imaging 
(DCE-MRI) are significant adjuncts to mammography providing additional diagnostic 
information by exploiting 3D structural and functional tissue properties related to lesion 
angiogenesis.  
Computer-Aided Detection (CADe) and Computer-Aided Diagnosis (CADx) schemes have 
been proposed across breast imaging modalities to improve radiologist performance in 
detection and diagnosis tasks (Bassett, 2000; Cheng et al., 2003; Sampat et al., 2005; Chan et 
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(DCE-MRI) are significant adjuncts to mammography providing additional diagnostic 
information by exploiting 3D structural and functional tissue properties related to lesion 
angiogenesis.  
Computer-Aided Detection (CADe) and Computer-Aided Diagnosis (CADx) schemes have 
been proposed across breast imaging modalities to improve radiologist performance in 
detection and diagnosis tasks (Bassett, 2000; Cheng et al., 2003; Sampat et al., 2005; Chan et 
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al., 2005; Giger et al., 2008; Costaridou et al., 2008; Elter & Horsch, 2009). These schemes also 
aim to reduce intra- and inter-observer variability by quantifying information that the 
human observer can perceive but in an objective and reproducible way (“mimic the human 
eye”), or to further quantify any information that may not be readily perceived by human 
eyes. The challenges of the CADx approaches are differentiated across breast imaging 
modalities and lesion types.  
The American College of Radiology (ACR) Breast Imaging Reporting and Data System (BI-
RADS) lexicon (ACR BIRADS 2003) defines masses, microcalcification (MC) clusters, 
architectural distortion and bilateral asymmetry as the major breast cancer signs in X-ray 
mammography. A mass is a space occupying lesion seen at least in two different 
mammographic projections. If a mass is seen only in a single projection is called asymmetric 
density. When a focal area of breast tissue appears distorted with spiculations radiating 
from a common point and focal retraction at the edge of the parenchyma, while no central 
mass is definable, it is called architectural distortion. 
Calcifications are small deposits of calcium within the breast tissue and as masses are 
associated with both malignant and benign underlying biological processes (Kopans, 2007). 
Calcifications appear as high Signal-to-noise-ratio (SNR) bright structures, due to the high 
attenuation coefficient of calcium (higher than other breast constituents such as water, fat 
and glandular tissue). Calcifications can be large (>1mm) referred to as macro-calcifications 
and are commonly associated with benign conditions. MCs are tiny deposits of calcium in 
the breast with size ranging from 0.1mm to 1mm. A number of MCs grouped together is 
termed as a cluster and it may be a strong indication of cancer. A cluster is defined as at 
least three MCs within a 1 cm2 area. Benign MCs are usually larger and coarser with round 
and smooth contours. Malignant MCs tend to be numerous, clustered, small, varying in size 
and shape, angular, irregularly shaped and branching in orientation. 
In x-ray mammography, the automated interpretation of MCs is an open issue and more 
difficult than the corresponding task for masses (Cheng et al., 2003; Sampat et al., 2005). 
Difficulty in automated MCs interpretation is attributed to MCs fuzzy nature (varying size 
and shape), low contrast and low distinguishability from their surroundings (Cheng et al., 
2003) rendering the accurate segmentation of MCs a challenging task. CADx schemes for 
MC clusters can be categorized into two major approaches: morphology-based and texture-
based approaches. The morphology-based CADx schemes are highly dependent on the 
robustness of the employed segmentation algorithm. Texture-based CADx schemes assume 
that the presence of MCs alters the texture of the background tissue that MCs are embedded 
in; focused on extracting texture features from Regions of Interest (ROI) containing the 
cluster, these approaches do not depend on the robustness of a segmentation algorithm (i.e. 
the segmentation step is omitted). Since it is the breast tissue surrounding MCs that is 
subjected to histopathological analysis, to derive a malignant or a benign outcome, 
mammographic image texture analysis seems a more natural choice, while the bias induced 
by the presence of MCs on the texture pattern of the ROI being analyzed should also be 
considered (Thiele et al., 1996).  
The following sections provide the current state-of-the-art approaches towards computer-
aided diagnosis of MC clusters. Specifically, morphology-based and texture-based 
approaches are reviewed and an application paradigm focusing on their inter-comparison is 
provided. 
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2. Computer-aided detection and diagnosis of breast lesions in x-ray 
mammography 
While SF mammography is currently the most effective breast imaging modality for the 
early detection of breast cancer (detection of breast abnormalities/lesions), its specificity in 
differentiating malignant from benign lesions is relatively low resulting in a high number of 
unnecessary biopsies.  
Digital mammography allows the separation of image acquisition, processing, and display 
and represents a solution to many of the inherent limitations of SF mammography (Pissano, 
2000). The digital detector has a linear response to x-ray intensity, in contrast to the 
sigmoidal response of screen-film systems. As a result, use of a digital detector provides a 
broader dynamic range of densities and higher contrast resolution. Through image 
processing, display parameters may be chosen independently from image acquisition 
factors. Small differences in attenuation between normal and abnormal breast tissue can be 
amplified, rendering digital mammography most suitable for screening of dense breast. 
Despite the advantages offered by digital mammography, the radiologic interpretation of 
MCs still remains a major issue and is more challenging than the interpretation of breast 
masses. Studies have shown that the performance of radiologists in interpreting breast 
lesions is highly dependent on lesion type (masses vs. MCs) even with the use of image 
post-processing techniques (Cole et al., 2003). Specifically, it has been shown that radiologist 
performance in MCs interpretation is reduced as compared to masses interpretation, 
independent of the post-processing method used (Cole et al., 2003). Furthermore, inter- and 
intra-observer variability is higher in MCs interpretation as compared to masses 
interpretation (Skaane et al., 2008), and is also similar to observer variability in SF 
mammography (Baker et al., 1996;  Skaane et al., 2008). 
CADe and CADx schemes have a key role in detection and diagnosis of breast lesions 
aiming to improve radiologist performance, reduce observer variability and quantify lesion 
properties (Bassett, 2000; Cheng et al., 2003; Sampat et al., 2005; Chan et al., 2005; Costaridou 
et al., 2008; Costaridou, 2011). They were originally proposed and applied on digitized 
images with proven benefits, but as being better suited to digitally acquired images they are 
expected to cast further insights towards breast cancer detection and management. These 
systems act only as “second readers” and the final decision is made by the radiologist. The 
term “CADe/x” refers to formulating the clinical detection or diagnosis problem into the 
context of quantitative image feature extraction and pattern classification with the goal of 
solving it automatically (Duncan &Ayache, 2000). 
CADe schemes have been developed to improve radiologists’ performance in detecting 
breast lesions, by identifying suspicious regions of masses and MC clusters in an image (i.e. 
by placing prompts over areas of concern). The input to a CADe scheme is an image and the 
output is a location of a possible abnormality. Recent CADe schemes also provide the lesion 
boundary.  CADx schemes in breast imaging aim to assist radiologists in the diagnostic task 
of lesion characterization (malignancy vs. benignity), thus affecting patient management 
(follow-up vs. biopsy). The input to a CADx scheme is a ROI indicating a breast 
lesion/abnormality. The output of a CADx scheme is a probability of malignancy for the 
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lesion considered. Both CADe and CADx schemes share similar processing stages, such as 
segmentation, feature extraction and classification adjusted however to the specific task at 
hand. Figure 1 depicts the typical architecture of a CADe and a CADx scheme. 
The high performances achieved by CADe schemes for breast lesions in x-ray 
mammography have led to their incorporation in commercially available FDA approved 
systems. These systems have shown to improve the performance of radiologists in detecting 
breast lesions, however, the high rate of false positives reported by some studies arise 
controversies concerning their exact impact on radiologist interpretation (Gur et al., 2004, 
Fenton et al., 2007). On the other hand, the development of commercially available CADx 
systems is still ongoing (Sampat et al., 2005).  
 
Fig. 1. Flowchart depicting the typical architecture of a CADe and a CADx scheme. Optional 
steps are indicated with dashed line 
3. CADx schemes for MC clusters 
3.1 Morphology-based CADx schemes  
In the clinical practice the diagnosis of MC clusters in based on morphology (shape, size and 
intensity) properties and distribution properties of individual particles within a MC cluster, 
thus, most CADx schemes are also focused on the automated quantification of such 
properties (Cheng et al., 2003; Sampat et al., 2005; Costaridou et al., 2008; Elter & Horsch, 
2009; Costaridou, 2011). 
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A number of authors have utilized a wide range of quantitative individual MC morphology 
properties (Patrick et al., 1991; Shen et al., 1994; Papadopoulos et al., 2008; Sklansky et al., 
2000; Jiang et al., 1996). Specifically, size and shape features (area, perimeter, elongation, 
circularity, compactness, eccentricity, moment ratio, axis ratio, concavity index, effective 
thickness and volume as well as, shape signature) and MC intensity features (mean 
intensity, background intensity, contrast and edge strength) have been exploited.  
CADx schemes that classify MC clusters are based on two categories of cluster features: 
 Category I: Cluster features based on descriptive statistics (e.g. average, standard 
deviation, coefficient of variation, maximum, median, range) of individual MC 
morphology properties. 
 Category II: Cluster features describing cluster morphology considering the cluster as 
an entire object (cluster area, diameter, perimeter, circularity, eccentricity, elongation, 
solidity and cluster background intensity). In this category the spatial distribution of 
individual MC particles within a cluster is also considered (number of MCs, structural 
index, proximity to the nearest MC, cluster density, as well as distance to pectoral and 
breast edge). 
Table 1. summarizes morphology-based CADx schemes for MCs in terms of discriminant 
features (derived from Category I and/or Category II) including feature selection and 
classification techniques employed. Classification performance is also provided in terms of 
area under Receiver Operating Characteristic - ROC curve (Az index) on patient and cluster-
basis. Performance in patient-basis is derived by considering decision scores by both 
mammographic views (mediolateral oblique and craciocaudal). A disadvantage of these 
methods is that their performance is dependent on the accuracy of the segmentation method 
used. Specifically, the segmentation accuracy of less robust segmentation methods reduces 
the performance of morphology-based CADx schemes (Paquerault et al., 2004; Arikidis et 
al., 2008; Arikidis et al., 2009). 
3.2 Texture-based CADx schemes 
Another approach that overcomes limitations associated to segmentation issues is texture 
analysis applied on ROIs containing the MC cluster.  This approach is based on the 
hypothesis that a malignancy (e.g. the MC) would cause changes in the texture of tissue 
surrounding it. Aiming at capturing such tissue texture alterations, CADx schemes have 
exploited various texture feature sets as well as feature selection and classification 
algorithms (Cheng et al., 2003; Sampat et al., 2005; Elter & Horsch, 2009), summarized in 
Table 2. Table 2 also provides classification performance of reported CADx schemes in a 
cluster-basis. Since a direct comparison of the reported CADx methodologies is not feasible, 
mainly due to the heterogeneous datasets analyzed, the attempted comparisons in the 
following paragraphs are only indicative of existing trends in texture analysis.  
The grey level co-occurrence matrix (GLCM) characterizes the spatial distribution of grey 
levels in an image (Haralick et al., 1973). Features extracted from GLCMs provide 
information concerning image texture heterogeneity and coarseness, which is not 
necessarily visually perceived. The discriminating ability of GLCMs features, as extracted 
from original image ROIs containing MCs, has been demonstrated by most studies (Dhawan 
et al., 1996; Kocur et al., 1996; Kramer & Aghdasi 1999; Chan et al., 1997; Chan et al., 1998; 
Soltanian-Zadeh et al., 2004), with specific GLCMs feature combinations achieving an 
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lesion considered. Both CADe and CADx schemes share similar processing stages, such as 
segmentation, feature extraction and classification adjusted however to the specific task at 
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Fig. 1. Flowchart depicting the typical architecture of a CADe and a CADx scheme. Optional 
steps are indicated with dashed line 
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3.1 Morphology-based CADx schemes  
In the clinical practice the diagnosis of MC clusters in based on morphology (shape, size and 
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2009; Costaridou, 2011). 
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A number of authors have utilized a wide range of quantitative individual MC morphology 
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Table 1. Morphology-based CADx schemes for MC clusters 
Az of 0.88 in discriminating malignant from benign MC clusters (Chan et al., 1997). In 
addition, GLCMs feature have shown to be more effective than morphology-based features 
(Chan et al., 1998), while their combination can provide an even higher classification 
performance. Soltanian-Zadeh et al. (2004) demonstrated that GLCMs extracted from ROIs 
containing the MCs were superior to GLCMs extracted from segmented MCs and suggested 
that “there may be valuable texture information concerning the benignity or malignancy of 
the cluster in those areas that lie outside the MCs”. 
Aiming at capturing tissue texture alterations in multiscale representation, studies have also 
exploited first order statistics (FOS) (i.e. energy, entropy and square root of the coefficients 
norm) extracted from wavelet (Dhawan et al., 1996; Kocur et al., 1996; Soltanian-Zadeh et al., 
2004) or multi-wavelet (Soltanian-Zadeh et al., 2004 transform subimages. Wavelet/ 
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al., 2004  
 GLCMs features from 
segmented MCs and from 
ROIs containing the MCs 
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 Entropy, Energy (multi-wavelet, 
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et al., 2008 
 First order statistics 
 GLCMs features 
 Laws’ texture energy measures 
 Energy, Entropy (redundant 
DWT; B-spline)  
 Co-occurrence based 
(Decomposition: redundant 
DWT; Filter: B-spline; Levels: 
1-3)  
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*Performance provided in % classification accuracy; GLCMs: Grey-level co-occurrence matrices; SRN: 
Square Root of the Norm of coefficients; DWT: Discrete Wavelet Transform. 
Table 2. Texture-based CADx schemes for MC clusters 
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multiwavelet FOS have shown to be more effective than GLCMs features (Kocur et al., 
1996; Soltanian-Zadeh et al., 2004) and shape features (Soltanian-Zadeh et al., 2004) 
suggesting the advantages offered by the multiscale representation of the tissue analyzed. 
Dhawan et al. (1996) demonstrated that the combination of GLCMs with FOS wavelet 
features, representing global and local texture respectively, is superior to cluster features; 
however, best performance was achieved by a selected feature set including GLCMs, 
wavelet and cluster features. An obvious extension of wavelet FOS is the computation of 
co-occurrence matrix features from wavelet decomposed subimages, to describe 
coefficients second order statistics (Van de Wouwer et al., 1998). Kramer and Aghdasi 
(1999) demonstrated that co-occurrence matrices features extracted from wavelet 
decomposed subimages were superior to GLCMs and wavelet FOS in discriminating 
malignant from benign MC clusters. 
3.2.1 Texture analysis of the tissue surrounding MCs 
As opposed to the previously described CADx approaches which analyze the texture 
pattern of ROIs containing the MC cluster, the MCs surrounding tissue analysis approach 
focuses on the investigation of the “net texture pattern” of the underlying breast tissue 
removing any bias induced by the presence of MCs. 
The biological basis of the hypothesis is that as the tissue surrounding MCs is the one 
sampled and subjected to histopathological analysis to decide on benignity or malignancy, 
this tissue area should be subjected to texture analysis. The hypothesis was introduced by 
Thiele et al. (1996) who investigated texture properties of the tissue surrounding MCs on 
digital scout views acquired during the stereotactic biopsy procedure. The hypothesis was 
tested on a dataset of 54 cases (18 malignant/36 benign) exploiting GLCMs and fractal 
geometry based features and achieved a classification performance 85% (sensitivity 89%, 
specificity 83%) employing Linear and Logistic Discriminant analysis. Since its introduction 
on digital scout views, the feasibility of the MCs surrounding tissue analysis hypothesis has 
been further investigated on screening mammograms (Karahaliou et al., 2007a, 2007b, 2008).  
In the following sections (4.1, 4.2 and 4.3) the potential contribution of this approach in 
CADx of MC clusters  is investigated and compared to current state-of-the-art approaches, 
by means of a meta-analysis application paradigm of the sample analysed in (Karahaliou et 
al., 2007a, 2008; Arikidis et al., 2008). 
4. Application paradigm 
4.1 Texture vs. morphology analysis for MC cluster diagnosis 
Methods performance inter-comparison is tested on a pilot dataset of 92 MC clusters. 49 MC 
clusters were malignant (as proven by biopsy) while 43 MC clusters were benign (either 
biopsy proven or without call-back). Mammograms were originated from the Digital 
Database for Screening Mammography (DDSM) (Heath et al., 2000) and correspond to 
digitization with a single laser scanner (LUMISIS) at a pixel depth of 12 bits and 50 μm pixel 
resolution. Mammograms correspond to extremely dense and heterogeneously dense breast 
parenchyma (density 3 and 4 according to ACR BIRADS lexicon). Figure 2 depicts the 
distribution of the 92 MC clusters with respect to malignancy assessment. 
 




Fig. 2. Distribution of the dataset of 92 MC clusters with respect to malignancy rating 
provided in the DDSM. 1: negative, 2: benign, 3: probably benign, 4: suspicious abnormality, 
5: highly suggestive of malignancy 
a. Texture analysis of tissue surrounding MCs 
The “MCs surrounding tissue” area is provided by MC segmentation and subsequent 
“exclusion” of the segmented MC areas from the ROI containing the cluster (Figure 3).  As 
the approach requires only a “coarse” MC segmentation, requirements for accurate 
segmentation are relaxed, as compared to the corresponding ones of morphology-based 
CADx schemes. Wavelet based signatures (Van de Wouwer et al., 1998) were employed for 
quantification of the “net texture pattern” of the breast tissue. The specific texture feature 
category was selected due to its improved discriminating ability over three robust texture 
feature categories (first order statistics features (Gonzalez & Woods, 2000), Laws’ texture 
energy measures (Laws, 1979)) and grey level co-occurrence matrices (Haralick et al., 1973) 
previously adopted in CADx approaches for the differentiation of malignant form benign 
MC clusters.  
Wavelet coefficient co-occurrence matrices (WCCMs) (Van de Wouwer et al., 1998) features 
were generated employing the redundant dyadic wavelet transform whose wavelet filter is 
the first-order derivative of a cubic B-spline (Mallat & Zhong, 1992). The transform was 
implemented using the ‘algorithme `a trous’ (algorithm with holes), which does not involve 
down-sampling. The gradient magnitude coefficients of the 2nd and 3rd dyadic scale were 
considered for co-occurrence matrices feature extraction. Co-occurrence matrices were 
generated for 4 angles (0°, 45°, 90°,135°) and for various displacement vector values d. From 
each co-occurrence matrix 16 features were extracted. For each d, the mean and range value 
of each feature over the four co-occurrence matrices were calculated. In order to define the 
“MCs surrounding tissue” area, wavelet decomposition was performed on original 
mammogram ROIs (513x513 pixels) containing the MC clusters. To deal with contaminated 
pixels adjacent to MC areas, the “coarsely” segmented MC areas were dilated in proportion 
to the filter lengths used to derive wavelet gradient magnitude coefficients. Figure 4 
illustrates ST-ROIs on original mammogram and on gradient magnitude coefficients of the 
2nd and 3rd dyadic scale of the wavelet transform employed. 
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The Stepwise Discriminant Analysis (SDA) was then employed to select one single feature 
subset from extracted WCCMs features. The selected subset referred here in as WCCMs*, is 
comprised of 3 WCCMs features corresponding to: Mean of Shade (d=18, scale 2), Range of 
Difference Variance (d=14, scale 3) and Mean of Information Measure of Correlation 1 (d=18, 
scale 3).  
 
Fig. 3. Illustrative example of ST-ROI definition. (a) 513x513 pixel part of original 
mammogram containing a MC cluster (DDSM: volume cancer_09, case B_3406, RIGHT_CC). 
(b) Segmented MC areas (in black) of the cluster and 129x129 pixel ROI (black rectangle) 
containing the cluster. (c) Magnified ROI of figure (b). Surrounding tissue ROI (i.e. ST-ROI) 
corresponds to the area resulting from exclusion of segmented MC areas from the 129x129 
pixel ROI. Borders of excluded MC areas are indicated with solid line 
 
Fig. 4. ST-ROIs (129x129 pixels) on original (a) and wavelet gradient magnitude coefficients 
of the 2nd (b) and 3rd (c) dyadic scale. Borders of excluded MC areas are indicated with 
solid line 
b. Texture analysis of ROIs containing the MCs 
This approach is similar to the “MCs surrounding tissue” one with respect to texture feature 
extraction and classification without however requiring the “coarse” MC segmentation step. 
Specifically, 129x129 pixel ROIs centered at each cluster, identical to the ones employed in 
the “MC surrounding tissue” apporach, were subjected to texture feature extraction by 
means of wavelet based signatures. The SDA was then employed to select one single feature 
subset. The selected subset referred here in as WCCMs**, is comprised of 4 WCCMs features 
corresponding to: Range of Inverse Difference Moment (d=1, scale 2), Mean of Difference 
Variance (d=6, scale 2), Range of Prominence (d=6, scale 2) and Mean of Contrast (d=18, scale 2).  
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c. Morphology analysis of MCs 
A recently proposed segmentation algorithm was employed to segment individual MCs 
within each cluster, details of which can be found elsewhere (Arikidis et al., 2008). Briefly, 
the method is based on implementation of active rays on B-spline wavelet representation to 
identify MC contour point estimates in a coarse-to-fine strategy at two levels of analysis. An 
iterative region growing method is then used to delineate the final MC contour curve, with 
pixel aggregation constrained by the MC contour point estimates.  
Ten (10) individual MC features were extracted from each segmented MC corresponding to: 
area, length, eccentricity, compactness, radial standard deviation, relative contrast, 2 
regional moments (one related to the spread and one related to the eccentricity of object 
mass), one moment of region boundary and a shape roughness measure provided by 
Fourier descriptors. Twenty (20) MC cluster features were then generated by computing the 
mean and range of the above feature values over the entire cluster. The SDA was then 
employed to select one single feature subset from the 20 cluster features. The selected subset 
comprised of 3 cluster features corresponding to: mean of relative contrast, range of relative 
contrast and the regional moment related to object mass eccentricity.  
The discriminating ability of the three selected feature subsets was investigated using a least 
squares minimum distance (LSMD) classifier, using the Leave-One-Out (LOO) (Theodoridis 
& Koutroumbas 1999) training-testing methodology. Classification performance of the three 
feature subsets (morphology, WCCMs* and WCMMs**) was evaluated by means of the Az 
index (area under ROC curve).  
The morphology-based feature subset achieved an Az±standard error (SE) of 0.809±0.046 
with lower and upper 95% Confidence Interval (CI) values of 0.698 and 0.882, respectively. 
On the same dataset (of 92 MC clusters) the “MCs surrounding tissue texture analysis” 
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The Stepwise Discriminant Analysis (SDA) was then employed to select one single feature 
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c. Morphology analysis of MCs 
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 Az ± SE p-value 
Morphology vs.   WCCMs* 0.809±0.046   vs.   0.881±0.036 0.15 
Morphology vs.   WCCMs** 0.809±0.046   vs.   0.803±0.048 0.92 
WCCMs*    vs.    WCCMs** 0.881±0.036   vs.   0.803±0.048 0.11 
Table 3. p-values (z-test) for classification performance comparison among selected subsets 
from the three approaches 
4.2 Texture plus morphology analysis for MC cluster diagnosis 
In order to investigate the combined performance of texture- and morphology-based 
analysis two additional feature sets were generated by (a) merging the morphology-based 
selected subset with the WCCMs* subset and (b) merging the morphology-based selected 
subset with the WCCMs** subset. 
From each merged feature set one subset was generated by means of an exhaustive search 
procedure. Specifically, the LSMD classifier was designed with all possible feature 
combinations, from 2 up to 6 features, and for each combination the classifier performance 
was evaluated by means of the LOO training-testing methodology. The feature combination 
with the highest classification performance (by means of Az index) and the minimum 
number of features was selected. 
Table 4 summarizes classification performance of the two selected subsets by means of Az ± 
SE and 95% asymmetric CI values. No statistically significant difference was observed in 
classification performance of the two approaches (p>0.05). 
 
 Features included in subset Az ± SE [Lower, Upper] 95% 
asymmetric CI 
Morphology and  
WCCMs* 
Regional Moment (eccentricity) 0.899±0.035 [0.802, 0.950]  
Mean of Shade (d=18, scale 2) 
Range of Difference Variance (d=14, 
scale 3) 
Mean of Information Measure of 
Correlation 1 (d=18, scale 3)
Morphology and   
WCCMs** 
Mean of Relative Contrast 0.868±0.038 [0.771, 0.926] 
Range of Relative Contrast 
Regional Moment (eccentricity) 
Mean of Difference Variance (d=6, 
scale 2) 
Mean of Contrast (d=18, scale 2) 
Table 4. Classification performance of the two combined (texture and morphology) selected 
subsets by means Az ± SE and 95% asymmetric Confidence Interval (CI) values. WCCMs*: 
selected texture feature subset employing the “MCs surrounding tissue” approach. 
WCCMs**: selected texture feature subset employing the commonly adopted approach of 
analysing tissue ROIs containing the MCs 
 




Texture analysis is ultimately concerned with automated methods that can derive image 
information from a purely computational point of view. As such, is nothing than numeric 
manipulation of digital or digitized images to get quantitative measurements (Tourassi, 
1999). However, in contrast to morphology analysis, texture analysis can potentially 
improve decision making by capturing clues “beyond the human eye”. Morphology 
analysis based schemes quantify visually perceived properties, mimicking radiologist 
decision making in an objective and reproducible way. Texture analysis has a divergent role 
when considered in decision making. It can mimic radiologist perception of image texture 
(when texture differences are visually perceived) or it can augment the visual skills of the 
radiologists by extracting/quantifying image features that may be relevant to the diagnostic 
problem, but are not visually extractable.  
In case of CADx schemes based on morphology analysis of MCs the first approach is 
applicable. Specifically, image analysis approaches are employed to quantify individual 
MCs properties that are commonly assessed by the radiologist to provide a final decision 
concerning diagnosis and patient management. In case of CADx schemes based on texture 
analysis of ROIs including MCs the second approach is applicable. Specifically, image 
analysis approaches are employed to quantify the texture properties of ROIs, e.g. to capture 
the increased heterogeneity, due to presence of large number of MCs within ROI, but also 
capture texture alterations of tissue surrounding MCs. The first is visually perceived, and in 
a sense is also one of the diagnostic criteria adopted in clinical practice for MCs. The second 
(i.e. the MCs surrounding tissue heterogeneity) is not currently evaluated in the clinical 
practice but accounts for an approach worthy of being further exploited.  
Nonetheless, texture analysis is not a panacea for the diagnostic interpretation of 
radiographic images. As the pursuit of texture analysis is based on the hypothesis that the 
texture signature of an image is relevant to the diagnostic task at hand, the hypothesis 
should always be tested (Tourassi, 1999).  
In the current application paradigm, we tested the hypothesis that wavelet texture 
signatures of tissue surrounding MCs as depicted on screening mammograms is relevant to 
the diagnostic task. Results have demonstrated the feasibility of the “MCs surrounding 
tissue” texture analysis approach in the differentiation of malignant from benign MC 
clusters on screening mammograms, in support of the hypothesis originally formulated by 
(Thiele et al., 1996) on stereotactic scout views. While a direct comparison with the results of 
this study (Thiele et al., 1996) is not feasible, due to the different nature of the datasets 
analyzed, comparable performance is achieved.  
As compared to other texture-based CADx schemes analyzing ROIs containing the cluster 
(Dhawan et al., 1996; Kocur et al., 1996; Chan et al., 1997; Chan et al., 1998; Kramer & 
Aghdasi 1999; Soltanian-Zadeh et al., 2004), the performance achieved by the wavelet 
texture signatures, employing the MCs surrounding tissue approach, is also comparable. 
However, heterogeneity of the datasets analyzed renders direct comparison not feasible. 
As compared to the morphology-based CADx schemes, the “MCs surrounding tissue” 
texture analysis approach has the advantage of relaxing segmentation accuracy 
requirements. However, the current study demonstrated the advantages of combining 
wavelet texture signatures derived from the tissue surrounding MCs with morphology 
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features of MC clusters, in accordance to Chan et al. (1998) who combined GLCMs features 
(from ROIs containing the cluster) with morphology-based ones. 
While no statistically significant difference between the two texture-based approaches was 
observed, the results of this study demonstrate a trend in favour of the “MCs surrounding 
tissue” texture analysis approach over the commonly adopted one of analysing ROIs 
containing the MCs. We attribute this trend to the fact that the “MCs surrounding tissue 
texture analysis” allows an investigation of the net texture pattern of the underlying tissue, 
which is the one that generates the MCs, removing bias due to the number and distribution 
of MCs within the depicted tissue. 
Additional research efforts are required for validating/establishing the computer-extracted 
image features (morphology-based or texture-based) of MC clusters as diagnostic image-
based biomarkers for breast cancer. Specifically, research should be focused on investigating 
the relationship between quantitatively extracted features and histopathological indices.  
5. Migration to computer-aided prognosis 
Computer-aided diagnosis of mammographic MCs has also been extended from the task of 
differentiating malignant from benign MC clusters to prognostic tasks towards the 
identification of potential mammographic image-based prognostic markers. 
Specifically, morphology-based analysis of MC clusters applied on magnification 
mammograms has been exploited for the classification of 58 MC clusters into fibroadenoma, 
mastopathy, noninvasive carcinoma of the noncomedo type, noninvasive carcinoma of the 
comedo type and invasive carcinoma (Nakayama  et al., 2004). Features considered are (i) 
the variation in the size of microcalcifications within a cluster, (ii) the variation in pixel 
values of microcalcifications within a cluster, (iii) the shape irregularity of 
microcalcifications within a cluster, (iv) the extent of the linear and branching distribution of 
microcalcifications, and (v) the distribution of microcalcifications in the direction toward the 
nipple. The Bayes decision rule was employed for distinguishing between five histological 
categories demonstrating promising results. 
The potential contribution of follow-up mammograms in this specific prognostic task (i.e. in 
identifying the histological classification of clustered MCs) was also evaluated (Nakayama  
et al., 2006). Specifically, the previously defined five morphology features were extracted 
from previous and current magnification mammograms. The ten features were merged by 
means of a Modified Bayes discriminant function for the histological classification of 93 MC 
clusters (55 malignant and 38 benign).  
Classification results were improved by employing a nearest neighbor criterion and by 
augmenting the feature set (i.e. adding the number of microcalcifications within the cluster) 
(Nakayama  et al., 2007). 
The identification of potential image-based prognostic markers for breast cancer, i.e. 
quantitative image features capable of predicting biological behaviour and disease 
aggressiveness, accounts for an emerging research area, expected to have a significant 
impact on patient management and treatment response assessment. 
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6. Conclusions  
Only a few research efforts (Chan et al., 1998; Soltanian-Zadeh et al., 2004) have focused on 
comparing state-of-the-art approaches for computer-aided diagnosis of breast cancer, 
including the presented application paradigm which considered a pilot dataset. Thus, the 
systematic evaluation of proposed methods performance utilizing large and publicly 
available datasets is a necessity. Furthermore, method inter-comparison should consider 
testing on datasets generated by multicenter studies to ensure a large size, inclusion of 
varying case subsets with respect to lesion types (e.g. MCs of varying morphology and 
distribution) and image acquisition systems (i.e. digitized vs. FFDM). 
It is important to investigate the effect of reported CADx schemes on radiologist 
performance in breast cancer diagnosis task, by considering a radiologist’s diagnosis task 
aided by a specific CADx scheme and an un-aided corresponding one, also taking into 
account issues related to interaction of radiologist with a CADx scheme. The contribution 
of CADx schemes in reducing intra- and inter-observer variability should also be 
investigated. 
Advances in breast imaging have broadened the role of computer-based approaches in 
breast cancer diagnosis further suggesting multimodality and multi-parametric approaches. 
Multi-modality CADx schemes that combine features extracted from different imaging 
modalities, each one capturing additional tissue properties, may be advantageous to single-
modality CADx in the task of differentiating between malignant and benign lesions (Yuan et 
al., 2010), especially in the case of benign and malignant lesions with overlapping imaging 
features on a single imaging modality. Finally, the multi-modality approach has an 
increased potential towards identification of potential new diagnostic and prognostic 
biomarkers for breast cancer. 
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A.A. Kudryashov, A.G. Petrov and A.A. Telegin 
Institute for Radio Engineering and Electronics of Russian Academy of Sciences, 
Russia 
1. Introduction 
The short coming of the conventional film-screen systems arises from limited dynamic range 
due to the film latitude and Swank noise from the screen and film granularity that limits the 
system rather than quantum fluctuations. A thin intensifying screen is used to achieve better 
spatial resolution; however thin screens also have limited detector quantum efficiency. Most 
currently available digital X-ray systems use scanned-slit geometries to minimize tehe 
required detector area and minimize system complexity. Scanned-slit systems achieve also 
efficient rejection of Compton scattered X-rays by suffering significant X-ray tube loading in 
comparison to conventional large-field imaging geometries. There remains a significant 
clinical need in production of detection systems with sufficiently high spatial resolution and 
detection quantum efficiency. An improvement of digital radiography compared to 
conventional systems is the high dynamic range. Futhermore real-time data acquisition is 
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carriers (electron-hole pairs). These current carriers must be separated by the intrinsic 
electric field emerging in a heterogeneous semiconducting structure consisting of regions 
with different types of conductivity. There is some similarity between the X-ray detector and 
a solar cell based on GaAs (Jenny et al., 1956;Moizhes, 1960). But there is a difference too. 
The difference arises from higher operating energies of X-ray detector, that leads to the 
cecessity to solve more challenges. In the X-ray detector developed in our laboratory the 
photovoltaic effect is obtained in the p+-n-n’-n+ GaAs structure. 
2. Fabrication and characteristics of the photovoltaic GaAs detector 
The epitaxial p+-n-n'-n+ GaAs structures were grown by vapor-phase epitaxy (VPE), on Si-
doped n+ -GaAs(l00) substrates (n = 1018cm3), 2" diameter and 500 (µm thick. There were two 
basic problems solved by the fabrication of those structures: (i) growth of high-resistant n-
GaAs epitaxial layers of maximum thickness and (ii) creation of the depletion region all over 
this thickness. The growth of thick gallium arsenide epitaxial layers by VPE is complicated 
by low growth rates and by the imperfections on the surface of the growing layer, such as 
piramides of growth. For the epitaxial layer growth we have used the technology permitting 
to obtain n-GaAs epitaxial layer with low concentration of EL-2 defects. 
The epitaxial structure consists of three epitaxial layers: p + -GaAs top layer with a thickness 
of 1-2 µm and p ≈ 1018cm-3, n-GaAs epitaxial layer with a thickness of 60-100 (µm and 1011-
1013cm-3 and n'-GaAs buffer layer with a thickness of 2-3 µm and n’≈ 5 x 10l7cm-3. The ohmic 
contacts were prepared by vacuum deposition of Al/Cr and Ni/Ga/Au thin films on the 
front and rear surface of the structure, respectively.  
Investigations of the I-V characteristics of the photovoltaic X-ray detector have shown that 
those characteristics are similar to that of the conventional solar cells. The behavior of the 
reverse branch of I- V characteristic i0 (reverse saturation current) is of special importance, 
because it determines the detector dark current. Under illumination of the photovoltaic X-
ray detector by X-rays its I-V characteristics are shifted along the current axis. The typical I-
V characteristic of the photovoltaic X-ray detector without illumination is shown in Fig. 1. 
The small disturbance at approximately -3 V is caused by the fail of measuring system. 
The photovoltaic X-ray detector can be used in two operation modes: short circuit mode and 
open circuit mode. It is preferable to use the detector in short circuit operation mode 
because, then the response of the detector varies linearly with the X-ray intensity, while the 
response of the detector in the open circuit mode varies logarithmically. 
When the photovoltaic X-ray detector is illuminated, a short circuit current, isc, is generated 
in the n-GaAs epitaxial layer and the I- V characteristics are shifted along the current axis. 
The current generated in an ideal photovoltaic detector can be written as 
 isc = Ngq,  
where q is electron charge, Ng is the incident flux of all X-ray photons with the energy 
greater than the bandgap Eg upon the device. For GaAs Eg = 1.424 eV. Fig. 2 shows the short 
circuit current as a function of incident X-ray doze. One can see that the short circuit current 
varies linearly with the X-ray doze. 
 




Fig. 1. Typical I-V characteristic of photovoltaic X-ray detector. 
 
Fig. 2. Short-circuit current of X-ray detector as a function of X-ray dose rate. 
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The investigation of C-V characteristics has allowed us to control the depletion region in the 
epitaxial n-GaAs layer, to evaluate the carrier concentration n = Nd-Na (Nd is a donor 
concentration, Na is a acceptor concentration), to spot the profile of the built-in electric field 
in the depletion region and, at last, to spot the energetic diagram for GaAs(p+-n-n'-n+) 
photovoltaic detector. 
Fig. 3 shows the typical C-V characteristic of the photovoltaic X-ray detector. It can be seen 
that the capacitance is almost constant for reverse and forward biases up to 0.4 V. It is 
reasonable, therefore, to suppose that the depletion region extends over all the metallurgical 
thickness of the high resistant n-GaAs epitaxial layer. The presence of the depletion region 
over the entire thickness of a high-resistant n-GaAs is very important because it gives a 
opportunity to reduce the the long “tales”  of the detector signal due to the carrier 
generation in the regions where the built-in electric field is neat zero. 
 
 
Fig. 3. Typical C-V characteristic of photovoltaic X-ray detector. 
A high performance photovoltaic detector must efficiently collect the carriers generated. 
Maximum detector signal is obtained only when both electrons and holes created by x-ray 
irradiation in the depletion region are fully collected. 
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The charge collection efficiency is determined by the thickness of the depletion region and 
the collection length 
 Lc=(μnτn+ μpτp)·E ,  
where  μn and μp are electron and hole mobilities, τn and τp are electron and hole lifetimes, E 
is built-in electric field in the depletion region. The lifetime  of excess free charge carriers 
produced by x-ray irradiation in the depletion region is an important parameter for the high 
charge collection efficiency. Poor collection efficiency is caused by deep level traps which 
reduce the mobility-lifetime product in GaAs layer. Generally large mobility-lifetime 
product and high resistivity are required for good transport characteristics resulting in high 
charge collection efficiency. The long lifetimes (of order of 200 ns) in epitaxial GaAs were 
obtained by decreasing of EL-2 center concentration to less as 1013 cm-3 in the n-GaAs 
epitaxial layer. 
It should be noted that the carrier collection length decreases if forward bias voltage is 
applied to photovoltaic detector and transport of carriers via diffusion dominates as detector 
approaches the open-circuit mode. Let us now consider briefly the role of the depletion 
region. The concentrations of impurities and charge carriers out of the depletion region are 
balanced also charge density it is equal to zero. The depletion region almost doesn’t contain 
mobile charges therefore there is here the large gradient of electric field due to the charges of 
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where ε is the dielectric constant, e is the charge of an electron, NA and NB are 
concentrations of acceptors and donors in the p+ and n layers of the structure, V is the 
applied voltage and ΦB is the built-in voltage of the junction. The width of the depletion 
region can be controlled by the epitaxial technique used to prepare GaAs p+-n-n'-n+ 
structure or by the application of reverse bias to the junction. Electron-hole pairs generated 
in the depletion region are separated and accelerated by the built-in electric field and enter 
the region where they are the majority carriers. Charge carriers generated out of the 
depletion region but on distance of the mean diffusion length from it will diffuse into the 
depletion region and drift there. The charge collection efficiency is the most important factor 
in detector operation. It is defined by three factors, namely by the charge carriers mobility’s, 
by the charge carriers lifetimes and by the electric field in the p-n junction. 
The built-in electric field is the origin of photocurrent in the photovoltaic X-ray detector. In 
order to obtain a reasonable built-in electric field in the depletion region it is important to 
control accurately the total number of impurities. Direct measurements of the built-in 
electric field by the EBIC method were made to determine its profile in the epitaxial GaAs 
(p+-n-n’-n+) structure.  The junction structure was investigated by the use of Philips SEM 515 
scanning electron microscope. In the built-in electric field profile studies the electron beam is 
incident normal to the edge of epitaxial structure. The profile of built-in electric field in 
epitaxial GaAs (p+-n-n’-n+) structure with depletion region of 80 µm thickness is shown in 
Fig. 4. One can see here that the built-in electric field exists over the entire epitaxial n-GaAs 
layer. 
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Fig. 4. Profile of the built-in electric field. 
The response of the epitaxial GaAs (p+-n-n’-n+) detector to charged particles was 
investigated by the use of α-particles from radioisotope source. We have measured the 
charge collection efficiency and energy resolution.All measurements were made at room 
temperature. Registration of α-particles was performed at atmospheric pressure and in 
vacuum (p≈10-4Torr) at 0 and 17 V bias voltages. Epitaxial GaAs (p+-n-n’-n+) detectors were 
tested by α-particles from a three-component source U233[4824 keV]-Pu238[5499 keV]- 
Pu239[5156 keV]. The summary of the results is shown in table 1. 
Here Vbias is the bias voltage, Eα(keV) is the energy of the α-particles, Qtheor(e) is the 
theoretical charge in the detector (in thousands of electron-hole pairs), N(Ch) is the position 
of peak in ADC counts, σ of the peak is also in ADC counts, Qcol is the measured charge 
collected in detector and CCE is the charge collection efficiency. The energy resolution better 
than 1% is obtained at air pressure. One can see on the Table that the charge collection 
efficiency at zero bias voltage is lower than at 17 V bias. Since the high concentration of 
electron-hole pairs created by α-particles disturbs significantly the built-in electric field, the 
electron-hole pairs are not fully collected without a bias voltage. 
A photovoltaic X-ray detector was irradiated with 241Am(60 keV) photons. Measurements of 
the charge collection efficiency obtained with bias voltages of 0 and 17 V show charge 
collection efficiency of 93.4% and 93.6%, respectively. In this case, the charge collection 
efficiencies without bias voltage and with the bias of 17 V are the same. 
 






 Eα(keV) Qtheor N (Ch) σ (Ch) Qcol CCE (%) σ(e) 
Ebias=0 V 
P = 740 
mmHg 
4824 1148.571 317 9.92 873.165 76.0 17.3 
5156 1227.619 375 9.08 974.375 79.4 , 15.8 
5499 1309.286 431 7.72 1072.095 81.9 13.5 
Ebias= 17 V 
P = 740 
mmHg 
4824 1148.571 378 9.4 979.61 85.3 16.4 
5156 1227.619 448 7.98 1101.76 89.7 13.9 
5499 1309.286 515 7.9 1218.675 93.1 13.8 
Ebias=0 V 
P = 0 mmHg 
4824 1148.571 519 9.22 905.655 78.9 16.1 
5156 1227.619 561 8.69 978.945 79.7 15.2 
5499 1309.286 599 7.1 1045.255 79.8 12.4 
Ebias  = 17 V 
P = 0 mmHg 
4824 1148.571 622 5.1 1085.39 94.5 8.9 
5156 1227.619 675 4.71 1177.875 95.9 8.2 
5499 1309.286 729 5.2 1272.105 97.2 9.1 
 
Table 1. The summary of α-particle measurements. 
The quantum efficiency of the photovoltaic X-ray GaAs detector is limited by the thickness 
of the n-GaAs layer in the epitaxial structure. The use of a grazing incident angle geometry, 
which provides a larger absorption length for X-ray photons without increasing the actual 
thickness of the epitaxial layer, is the only way to increase the quantum efficiency of the 
photovoltaic GaAs X- ray detector. We have measured the sensitivity of the photovoltaic 







where Iph is the photocurrent, D is the X-ray dose and A is the sensitive surface area of the 
detector. The results are shown in Fig. 5. The function has a maximum at 35 keV. The mean 
sensitivityat this energy was about 30 µA·min/Gy·cm2. Above 35 keV, the detector 
sensitivity decreases but at a lower rate compared to the decrease in X-ray linear absorption 
coefficient in GaAs. It can probably be explained by the cascade processes in the epitaxial 
structure. 
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Fig. 5. Sensitivity of the photovoltaic GaAs detector as a function of effective energy. 
 
Fig. 6. Sensitivity of the photovoltaic GaAs X-ray detector as a function of the angle. 
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The quantum efficiency for the photovoltaic GaAs (p+-n-n’-n+) detector is limited by the 
thickness of the n’-GaAs epitaxial layer. To increase the sensitivity of the detector one can 
use the grazing-incident X-ray photons angle geometry which provides a larger absorption 
length in the depletion region without increasing the actual thickness. The measured 
sensitivity as a function of the angle is shown in Fig.6. 
3. Multielement X-ray detector made by the use of photolitography 
The scribing the channels on the depth greater than 100 µm to separate the pixels in active 
layer one from another made the linear detector very fragile if we want to decrease pixel 
size and pitch less than ~ 200 µm. So one cane make the pixel’s row by the lithography and 
separate the pixel’s photocurrent with the use of “guard” rings as it is shown in Fig. 7. In 
our case the pitch was 108 µm. 
 
 
Fig. 7. Intrinsic structure of GaAs (p+-n-n’-n+)  X-ray detector with guard rings. 
In distance of 30 µm between pixels  the aluminium conductor of a "guard" ring is 
located. The “guard” ring is connected to the full- wafer ohmic contact on n+ side for all 
detectors (cathode). In p+ layer and partially in n layer the grooves on depth of 8-10 µm 
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Fig. 8. Signal profiles on the three near-by contacts. 
4. Bilinear X-ray detector 
In order to increase the spatial resolution of the linear detector one can decrease the pitch 
and therefore the pixel size. But it leads to decreasing of the signal of the detector. To avoid 
this one can use a bilinear design of the detector. Let us see the difference between that two 
types of a detector. 
The single or linear multielement detector is a row of pixels (Fig. 9) located along an axis 0X 
with periodic distance between their geometrical centres: d. The recording of the image is 
carried out by its scanning in an axis 0Y. The double or bilinear staggered photosensors (Fig. 
9b,c) (Bosiers et al, 1995)  consist of two rows of linear pixels shifted by one of them in 
relation to another along an axis OX on the half of pixel's period: d/2, and with distance 
centre to centre of axes of two rows in d/2. The step of scanning of bilinear row along an 
axis 0Y is equal d/2. For bilinear row, submitted in Fig. 9 b, the photosensitivity of sensors is 
lower, as the surface area of the aperture is twice as low as that for viewed here by us  
(Fig. 9c). 
For harmonic intensity modulation in image the appropriate photosensor response, as it is 
easy to deduce from modulation transfer function (MTF), will correspond to 
 r(fx, fy, x, y) = SabMTF(fx,fy) cos[2π(fxx +fyy)]  
where S is the detector sensitivity, depending on absorbed photon energy and on detector 
matter; fx, fy are spatial frequencies of the image and a, b are geometrical sizes (apertures) of 
a rectangle on axes 0X and 0Y (Fig. 9). In a Fig. 10 the dependencies of response difference 
on value f for rectangular bilinear row with a step Δx = d/2 and Δy = fy = 0 for the 
photosensor moving in space with a step of scanning Δx, Δy, are shown: curve—1 (2a = d), 
curve—2 (2a/3 = d) and curve—3 (a= d;\ with Δy = b and Δx= fy= 0: curve—1; and linear 
row: curve —4 (Δx = a= d, Δy = 0, fy = 0) and (Δy = b = d, Δx = 0, fx= 0). For linear row  
 




Fig. 9. Kinds of pixel rows. 
response difference is higher at low spatial frequencies and lower (worse) at high spatial 
frequencies, than that for bilinear row. Minimum detectable contrast is evaluated from 
measurement of the smallest response difference (Munier et al., 1992). 
 
Fig. 10. Dependencies of detector response difference on spatial frequency for bilinear row 
(1,2,3)  and linear row (4). 
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The multielement detector was made of 2 x 512=1024 pixels with pitch of 0.8 mm in our 
case. The spatial resolution of double staggered sensor row is twice as high as the resolution 
of that of single sensor row with the same pitch. Measured spatial resolution is 1.2 line-
pairs/mm, contrast sensitivity not worse 1% and dynamic range defined as the ratio of 
maximum detectable X-ray signal to electronic noise level more than 2000 are received. 
Read-out operation of detector's signal was realized on near-to-short-circuit mode 
(Achmadullin et al., 2002). By combining the signal information from two linear rows of 
detectors a X-ray imaging with improved spatial resolution is received. One can see the X-
ray image of fishes as an example of the use of bilinear detector in Fig 11. For comparison in 
the same figure is placed the image of fish received by the pin-diode detector with a pitch of 
200 µm. The image is taken from the paper of G.I. Ayzenshtat et al.,2004. One can see that 




Fig. 11. The X-ray images of fishes. Left image is received by the bilinear detector with 800 
µm pitch, right image is received by the pin-diode detector with the 200 µm pitch. 
 




We have consicered here the basic features of the GaAs photovoltaic X-ray detector. The 
detector based on epitaxial p+-n-n’-n+ GaAs structures immediately converts  X-ray photons 
to a photocurrent without bias. It has fast response and low noise level. All the 
measurements described above were made in short-circuit operation mode for the 
simplicity. To decrease a dose (it is very important in medicine) the detector can operate in  
pulse-count mode. Photovoltaic GaAs X-ray detectors can find their application in medicine, 
non-destructive testing, custom houses and other branches. 
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1. Introduction 
Recent papers have reported the usefulness of DBT as the latest diagnostic modality for 
breast cancer [1]-[6]. In this chapter, the author describes clinical evaluation of the 
usefulness regarding DBT with reference to other diagnostic modalities such as Full Field 
Digital Mammography (FFDM), contrast-enhanced (CE) MRI, contrast-enhanced (CE) CT, 
and ultrasound (US) in accordance with preliminary experiences in breast cancer 
diagnosis. 
2. Diagnostic impact of adjunction of Digital Breast Tomosynthesis (DBT)  
to Full Field Digital Mammography (FFDM) and in comparison with Full Field 
Digital Mammography (FFDM) 
Purpose: To evaluate the diagnostic impact of adjunction of DBT to FFDM and in 
comparison with FFDM only, in accordance with pathological findings and breast density. 
Materials and Methods: This study was approved by the IRB at our institute. 303 women, 
having 333 lesions, (age 29-84, mean age 54.0 years old) that were recruited for this study 
gave informed consent. The images were taken as diagnostic mammograms from October in 
2009 to October in 2011. 45 cases were referred from other institutions by US and 258 cases 
were referred by MMG or palpation. Clinical image data were acquired by an a-Se FFDM 
system with a spatial resolution of 85μm (MAMMOMAT Inspiration, Siemens, 
Germany).Two-view DBT was performed with the same rotation angle (±25°) and 
compression pressure as the FFDM. With one-view DBT, the radiation dose was 1.5 times 
compared to one-view FFDM. The radiation dose, utilizing ACR 156 phantom by FFDM, 
was 1.20mGy. Images were reconstructed by the shift and add method and the filtered back 
projection (FBP) method. FFDM and reconstructed slice images of DBT were reviewed at a 
dedicated workstation (MAMMO Report, Siemens, Germany). Two radiologists and four 
breast surgeons evaluated the findings by FFDM only and the adjunction of DBT to FFDM 
before surgery in accordance with BIRADS categories; BIRADS1-2 (no findings or benign), 
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BIRADS 3 (probably benign, but short-term follow-up or additional diagnostic procedure 
necessary), and BIRADS 4-5(highly suspicious or definitely malignant and a biopsy 
necessary). All cases were operated on and confirmed as malignant or borderline lesions 
pathologically.  
Results: 181 cases were diagnosed as fatty or scattered (BIRADS density 1-2) and 122 cases 
were diagnosed as inhomogeneous dense or dense (BIRADS density 3-4). Of the 
pathological findings, 186 lesions were diagnosed as Invasive Ductal Carcinoma(IDC), 60 
lesions were diagnosed as Ductal Carcinoma in Situ(DCIS), 33 lesions were IDC 
predominantly Ductal Carcinoma in Situ(DCIS),16 lesions were diagnosed as Invasive 
Lobular Carcinoma(ILC), 7 lesions were diagnosed as Lobular Carcinoma in Situ (LCIS), 5 
lesions each were diagnosed as Mucinous Carcinoma (Muc Ca) and Intraductal Papilloma 
(IDP), 4 lesions were diagnosed as Apocrine Carcinoma, 3 lesions each were diagnosed as 
Mixed IDC+ILC and Intracystic Papillary Tumor(ICPT), two lesions each were diagnosed as 
Invasive Micropapillary Carcinoma(IMPC), DCIS with LCIS, and Phyllodes Tumor, and one 
lesion each was diagnosed as SCC, ILC with DCIS, ILC predominantly DCIS, ILC 
predominantly LCIS, and Muc Ca predominantly DCIS (Table1.). With FFDM only, the 
detection rate was 88.9% (176/198) for breasts with BIRADS density 1-2 and 83.7% (113/135) 
for breasts with BIRADS density 3-4. The findings by FFDM only were mass (n=142; 42.6%), 
Focal Asymmetry(FA) (n=31; 9.3%), distortion (n=15; 4.5%), microcalcifications (n=40; 
12.0%), microcalcifications with FA (n=8; 2.4%), microcalcifications with distortion (n=7; 
2.1%), microcalcifications with mass (n=46; 13.8%), and none (n=44; 13.2%). 
With adjunction of DBT to FFDM, the detection rate (BIRADS 3-5) was 97.4% (193/198) for 
breasts with BIRADS density 1-2 and 94.8% (128/135) for breasts with BIRADS density 3-4. 
The average detection rate was 86.8% by FFDM only and 96.4% by adjunction of DBT to 
FFDM. There was a statistically significant difference between the FFDM only and 
adjunction of DBT to FFDM among BIRADS density 1-2 and BIRADS density 3-4 (P<0.05). 
On the other hand, there was no statistically significant difference according to breast 
density (FFDM only: P=0.221, 3-4; adjunction of DBT to FFDM: P=0.202).By BIRADS 
category with FFDM only, 44 lesions (13.2%) were diagnosed as BIRADS 1 or 2, 75 lesions 
(22.5%) were diagnosed as BIRADS 3, 214 lesions (64.3%) were diagnosed as BIRADS 4 or 5; 
on the other hand, 12 lesions (3.6%) were diagnosed as BIRADS 1 or 2, 21 lesions (6.3%) 
were diagnosed as BIRADS 3, 300 lesions (90.1%) were diagnosed as BIRADS 4 or 5 (Table 
2.,Fig1).  
In addition, regarding radiological findings, diagnostic accuracy was improved in 96 lesions 
(BIRADS 1-2 to BIRADS 3-5 or BIRADS 3 to BIRADS 4-5). These included 93 mass-related 
lesions (mass, FA, or distortion) and 3 microcalcifications-related lesions 
(microcalcifications, microcalcifications and FA, or microcalcifications and distortion). 
However, diagnostic confidence was improved in cases of microcalcifications-related lesions 
owing to the presence of masses or focal dense areas with microcalcifications. In addition, 
by adjunction of DBT to FFDM, 32 more lesions were detected in comparison with FFDM 
only (Table 3.)  
Discussion. According to recent reports, DBT is a useful diagnostic procedure compared to 
2D mammography because breast structures are superimposed onto a two-dimensional (2D) 
image [6]. The outline of the lesion can be potentially obscured. Our preliminary results also 
indicated that adjunction of DBT to FFDM contributed not only to detecting the lesion, but 
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also to clarifying the diagnostic accuracy, especially with regard to mass-related lesions. On 
the other hand, regarding microcalcifications-related lesions, only using DBT slice image, it 
is difficult to recognize the overview of the clustered microcalcifications and analyze the 
morphology of each microcalcification’s outline at current settings for image acquisition and 
reconstruction. As a result, adjunction of DBT to FFDM is the best current option. 32 more 
lesions were detected by adjunction of DBT to FFDM. Not only 14 invasive cancers (IDC 
n=11, ILC n=2, ILC pred LCIS n=1), but also 18 non-invasive cancerous or borderline lesions 
(DCIS n=15, LCIS n=1, IDP n=2). 
Adjunction of DBT to FFDM was useful to detect early stage breast cancer and it is not 
affected by breast density. 
Conclusion. In this study, the results indicated that adjunction of DBT to FFDM was 
superior to FFDM only, regarding diagnostic performance.  
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FFDM Only Adjunction of DBT to FFDM
DCIS  n=22 n=7 
IDC   n=13 n=2 
LCIS  n=3 n=2 
ILC n=2 n=0 
IDP n=2 n=0 
ILC Pred LCIS n=1 n=0 
ICPC                          n=1                  n=1          
Total n=44 n=12 
Table 3. Missed Lesions in Pathological Findings by FFDM Only Vs. Adjunction of DBT to 
FFDM. 
   
                   a. FFDM image             b. DBT image 
 
c. US image 
Fig. 1. Radiological Findings of Adjunction of DBT and US images. 
 
Optimization of Digital Breast Tomosynthesis (DBT) for Breast Cancer Diagnosis 
 
359 
FFDM (Fig.1a) showed distortion only in the right breast by CC view (white arrow).DBT 
(Fig.1b) showed an irregularly shaped mass corresponding to the distortion shown by 
FFDM (white arrow). US (Fig.1c) showed hypo-echoic masses corresponding to the lesion 
shown by DBT (white arrow). The pathological diagnosis was IDC (Sci Ca). 
3. Evaluation of correlation between pathological size and diagnostic size  
Purpose 
To compare the diagnostic performance between combined Full Field Digital 
Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) in comparison with US 
and contrast enhanced MRI with regard to the extent of the lesion. 
Materials and methods 
This study was approved by the IRB at our institute. 196 women having 217 lesions (age 29-77, 
mean age 53.0 years old) that were recruited for this study, gave informed consent. The images 
of FFDM, DBT, US, and contrast enhanced MRI were taken for diagnosis before surgery from 
October, 2009 to October, 2011. Regarding FFDM and DBT, clinical image data were acquired 
by an a-Se FFDM system with a spatial resolution of 85μm (MAMMOMAT Inspiration, 
Siemens, Germany). Two-view DBT was performed with the same compression angle and 
compression pressure as the FFDM. With one-view DBT, the radiation dose was 1.5 times that 
of one-view FFDM. The radiation dose, utilizing ACR 156 phantom by FFDM, was 1.20mGy. 
FFDM and reconstructed slice images of DBT were reviewed at a dedicated workstation. 
Regarding contrast enhanced MRI, MIP images and MPR images (coronal, axial, sagittal) of 
3mm thickness reconstructed from dynamic MRI (four phases) at 3.0 tesla were evaluated. 
Two radiologists and three breast surgeons evaluated the findings regarding extent of the 
lesion by FFDM only, FFDM plus DBT, US, and contrast enhanced MRI in a non-blind 
consensus study before surgery, and compared the total size of the lesion with the actual 
pathological size of the lesion. The coefficient of correlation was analyzed by Pearson’s 
Product Moment Correlation Coefficient (SPSS Statistics 17.0, IBM, USA). 
Results 
Of the pathological findings, 125 lesions (57.6%) were diagnosed as IDC, 39 lesions (18.0%) 
were diagnosed as DCIS, 21 lesions (9.7%) were diagnosed as IDC predominantly DCIS, 11 
lesions (5.1%) were diagnosed as ILC, five lesions (2.3%) were diagnosed as LCIS, three 
lesions each (2.4%) were diagnosed as Muc ca and Apocrine Ca, two lesions each (0.9%) 
were diagnosed as Phyllodes Tumor and IMPC, one lesion (0.5%) each was diagnosed as 
ILC with DCIS, Mixed ILC and IDC, Muc Ca pred DCIS, and ICPC(Table1.).The sensitivity 
of the lesion was 0.908 (197/217) by MMG, 0.972(211/217) by adjunction of DBT to FFDM, 
0.927(201/217) by US, and 0.977 (212/217) by MRI.MMG missed 20 lesions (DCIS n=14, IDC 
n=5, and ICPC n=1), adjunction of DBT to FFDM missed 6 lesions ( DCIS n=5 and ICPC 
n=1), US missed 16 lesions ( DCIS n=12, IDC n=2, IDC pred DCIS n=1, and LCIS n=1) , and 
MRI missed 5 lesions (DCIS n=5). 
The coefficient of correlation between pathological diagnostic size and each modality was 
0.352 with FFDM (P<0.01), 0.586 with adjunction of DBT to FFDM (P<0.01), 0.472 with US 
(P<0.01), and 0.628 with MRI (P<0.01) regarding IDC and ILC (n=136; pathological size; 3-
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by an a-Se FFDM system with a spatial resolution of 85μm (MAMMOMAT Inspiration, 
Siemens, Germany). Two-view DBT was performed with the same compression angle and 
compression pressure as the FFDM. With one-view DBT, the radiation dose was 1.5 times that 
of one-view FFDM. The radiation dose, utilizing ACR 156 phantom by FFDM, was 1.20mGy. 
FFDM and reconstructed slice images of DBT were reviewed at a dedicated workstation. 
Regarding contrast enhanced MRI, MIP images and MPR images (coronal, axial, sagittal) of 
3mm thickness reconstructed from dynamic MRI (four phases) at 3.0 tesla were evaluated. 
Two radiologists and three breast surgeons evaluated the findings regarding extent of the 
lesion by FFDM only, FFDM plus DBT, US, and contrast enhanced MRI in a non-blind 
consensus study before surgery, and compared the total size of the lesion with the actual 
pathological size of the lesion. The coefficient of correlation was analyzed by Pearson’s 
Product Moment Correlation Coefficient (SPSS Statistics 17.0, IBM, USA). 
Results 
Of the pathological findings, 125 lesions (57.6%) were diagnosed as IDC, 39 lesions (18.0%) 
were diagnosed as DCIS, 21 lesions (9.7%) were diagnosed as IDC predominantly DCIS, 11 
lesions (5.1%) were diagnosed as ILC, five lesions (2.3%) were diagnosed as LCIS, three 
lesions each (2.4%) were diagnosed as Muc ca and Apocrine Ca, two lesions each (0.9%) 
were diagnosed as Phyllodes Tumor and IMPC, one lesion (0.5%) each was diagnosed as 
ILC with DCIS, Mixed ILC and IDC, Muc Ca pred DCIS, and ICPC(Table1.).The sensitivity 
of the lesion was 0.908 (197/217) by MMG, 0.972(211/217) by adjunction of DBT to FFDM, 
0.927(201/217) by US, and 0.977 (212/217) by MRI.MMG missed 20 lesions (DCIS n=14, IDC 
n=5, and ICPC n=1), adjunction of DBT to FFDM missed 6 lesions ( DCIS n=5 and ICPC 
n=1), US missed 16 lesions ( DCIS n=12, IDC n=2, IDC pred DCIS n=1, and LCIS n=1) , and 
MRI missed 5 lesions (DCIS n=5). 
The coefficient of correlation between pathological diagnostic size and each modality was 
0.352 with FFDM (P<0.01), 0.586 with adjunction of DBT to FFDM (P<0.01), 0.472 with US 
(P<0.01), and 0.628 with MRI (P<0.01) regarding IDC and ILC (n=136; pathological size; 3-
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108mm, average 35.4mm), 0.516 with FFDM (P<0.05), 0.590 with adjunction of DBT to FFDM 
(p<0.01), 0.375 with US (P>0.05), and 0.688 with MRI(P<0.01) regarding IDC predominantly 
DCIS (n=21; pathological size; 14-104mm, average 46.9mm), and 0.454 with FFDM (P<0.01), 
0.589 with adjunction of DBT to FFDM (P<0.01), 0.130 with US (P>0.05), and 0.558 (P<0.01) 
with MRI regarding DCIS(n=39; pathological size; 4-100mm, average 32.6mm) (Fig.2). 
Discussion 
According to recent reports, CE-MRI is sensitive in evaluating the extent of cancerous 
lesions; on the other hand, it involves the risk of overestimation of the size of the lesion [7]. 
In this study, we evaluated the sensitivity and the tumor size determined by FFDM only, 
adjunction of DBT to FFDM, US, and MRI compared with that determined by pathological 
diagnosis. In this study, regarding the sensitivity of the lesion, MRI showed the highest 
sensitivity and adjunction of FFDM to DBT showed comparable performance as well. 
Regarding the tumor size, MRI showed the strongest correlation with that determined by 
pathological diagnosis in IDC and ILC (r = 0.628) and IDC pred DCIS (r=0.688). The tumor 
size determined by adjunction of DBT to FFDM showed the second strongest correlation 
with that determined by pathological diagnosis in IDC and ILC (r = 0.586) and IDC pred 
DCIS (r=0.590) and the strongest correlation with that determined by pathological diagnosis 
in DCIS (r=0.589). By MRI, the lesions of DCIS were over-estimated compared with 
adjunction of DBT to FFDM (Fig.2c). In addition, the coefficient of correlation between 
adjunction of DBT to FFDM and MRI showed strong correlation compared to other 
diagnostic modalities, FFDM only and US. According to the results, the adjunction of DBT 
to FFDM combined with MRI can contribute to more accurate diagnosis with regard to 
evaluation of the extent of the lesion. 
Conclusion 
In this study, the results indicated that the adjunction of FFDM to DBT was superior 
compared with US or FFDM only, with regard to sensitivity and in evaluating the extent of 
the lesion. In addition, the adjunction of FFDM to DBT showed a strong correlation with 
MRI. 
 
 196 Cases 217 Lesions  
(29-77y.o.; Averag Age 53y.o) 
IDC  n=125 
ILC  n=11 
IDC Pred DCIS n=21 
DCIS n=39 
LCIS n=5 
Muc Ca n=3 
Apocrine Ca  n=3 
Phyllodes Tumor n=2 
IMPC n=2 
ILC with DCIS n=1 
Mixed ILC and IDC  n=1 
Muc Pred DCIS n=1 
ICPC                      n=1             
Total n=217
Table 4. Subtypes of Pathological Findings of the Lesions. 
 




Coefficient of Correlation  0.352**
Significant Probability P<0.001
*** FFDMDBT Pathology FFDM
Coefficient of Correlation  0.586**  0.632**
Significant Probability P<0.001 P<0.001
US Pathology FFDM FFDMDBT 
Coefficient of Correlation  0.472**  0.480**  0.583**
Significant Probability P<0.001 P<0.001    P<0.001
MRI Pathology FFDM FFDMDBT US 
Coefficient of Correlation  0.628** 0.424**  0.586**   0.660** 
Significant Probability P<0.001 P<0.001 P<0.001 P<0.001 
***FFDMDBT: Adjunction of DBT to FFDM 
a. IDC,ILC  (n=136) (Pathological Size; 3-108mm, Average 35.4mm) 
 
FFDM Pathology 
Coefficient of Correlation  0.516* 
Significant Probability 0.017 
 FFDMDBT Pathology FFDM 
Coefficient of Correlation   0.590**   0.932** 
Significant Probability 0.005 P<0.001 
US Pathology FFDM FFDMDBT 
Coefficient of Correlation  0.375   0.587**   0.589** 
Significant Probability 0.094 0.005 0.005 
MRI Pathology FFDM FFDMDBT US 
Coefficient of Correlation  0.688**  0.869**   0.909** 0.542* 
Significant Probability 0.001 P<0.001 P<0.001 0.011 
b. IDC Predominantly DCIS (n=21) (Pathological Size; 14-104mm, Average 46.9mm) 
 
FFDM Pathology 
Coefficient of Correlation  0.454** 
Significant Probability 0.004 
FFDMDBT Pathology FFDM 
Coefficient of Correlation  0.589**  0.883** 
Significant Probability P<0.001 P<0.001 
US Pathology FFDM FFDMDBT 
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Significant Probability 0.431 0.217 0.094 
MRI Pathology FFDM FFDMDBT US 
Coefficient of Correlation  0.558**  0.535**  0.699** 0.266 
Significant Probability P<0.001 P<0.001 P<0.001 0.101 
* Coefficient of correlation is significant at a 5% standard 
** Coefficient of correlation is significant at a 1% standard 
c. DCIS (n=39) (Pathological Size; 4-100m, Average 32.6mm) 
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a. Coefficients of Correlation regarding IDC and ILC 
 
b. Coefficients of Correlation regarding IDC pred DCIS 
 




c. Coefficients of Correlation regarding DCIS 
Fig. 2. Scatter diagrams of coefficients of correlation among pathological sizes and 
diagnostic sizes. 
4. Usefulness of adjunction of Digital Breast Tomosynthesis (DBT) to Full-
Field Digital Mammography (FFDM) in evaluation of pathological response 
after Neoadjuvant Chemotherapy (NAC) for breast cancer  
Purpose 
Neoadjuvant chemotherapy (NAC) is performed to reduce tumor size prior to surgery in 
women with breast cancer. The imaging methods that have been used until now to assess 
tumor response to neoadjuvant chemotherapy have serious limitations; for example, 
mammography alone cannot identify mass lesions in very dense breasts or distinguish viable 
residual lesions from the surrounding fibrous reaction after NAC [8]-[10]. Digital breast 
tomosynthesis has been only recently applied clinically and the diagnostic advantages in 
comparison to mammography have been reported on, including the fact that the slice images 
can be evaluated because tomosynthesis decreases the overlap in breast tissue [1]-[6]. In this 
study, we assessed the radiological findings and capability of DBT in adjunction to FFDM to 
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Fig. 2. Scatter diagrams of coefficients of correlation among pathological sizes and 
diagnostic sizes. 
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images were taken for diagnosis from December, 2009 to October, 2011. Pathological 
diagnosis was confirmed by Core Needle Biopsy (CNB) and the pathological subtypes were 
Invasive Ductal Carcinoma (n=20), Invasive Lobular Carcinoma (n=3), Invasive 
Micropapillary Carcinoma (n=2), and Mucinous Carcinoma (n=1).The clinical stages of the 
patients before NAC were II or III. All patients underwent surgery based on their response 
to NAC and residual tumor size estimated by diagnostic imaging was compared with the 
residual tumor size determined by surgical pathology. The diagnostic procedures were 
performed within one month prior to surgery. MMG and US were performed on each of the 
patients before and after NAC. Contrast-enhanced MRI was performed on 15 patients, and 
contrast-enhanced CT was performed on 10 patients both before NAC and after NAC. 
Adjunction of DBT to FFDM was performed before and after NAC in 10 out of 25 cases. In 
15 out of 25 cases, adjunction of DBT to FFDM was performed only after NAC. Whole-breast 
US was performed with an 8 MHz wide-band high-resolution transducer (aplioTM XV, 
Toshiba Medical Systems, Japan). Transverse and longitudinal scans were acquired. Breast 
MRI was performed with a 3-Tesla system (Magnetom Trio, Siemens, Germany).Patients 
were studied in the prone position with a dedicated breast surface coil. The entire breast 
was imaged once before and four times after intravenous injection of 0.1mmol of Gd-
DTPA/Kg of body weight (Magnevist; Schering, Germany). The post-processing procedures 
included digital image subtraction, Maximum Intensity Projection (MIP) and Multiplanar 
Reconstruction (MPR) by slices of 3mm thickness. Breast CT was performed with multi-
detector raw CT (MDCT) (Aquilion64, Toshiba Medical Systems, Japan). The images were 
acquired before injection an iodine contrast medium, and 60 seconds after, and 3 minutes 
after injection of the total amount of 100ml, at the rate of 3ml/second (Iopamidol 300, Bayer 
AG, Germany). The images were reconstructed as slices of 2mm thickness and evaluated. 
With regard to DBT and FFDM, clinical image data were acquired by an a-Se FFDM system 
with a spatial resolution of 85μm (MAMMOMAT Inspiration, Siemens, Germany).Two-view 
DBT was performed with the same compression angle and compression pressure as the 
FFDM. With one-view DBT, the radiation dose was 1.5 times compared to one-view FFDM. 
The radiation dose with ACR 156 was 1.2mGy with FFDM. FFDM and reconstructed 1mm 
slice images from DBT were reviewed at a dedicated workstation. Two radiologists and four 
breast surgeons evaluated the findings of each diagnostic modality before surgery. The 
clinical response to chemotherapy was classified into the following categories, based on the 
“response evaluation criteria in solid tumors” (RECIST), using the measurements obtained 
with the different imaging methods: 1) Responders: a: Complete Response (CR): no clinical 
evidence of residual tumor or b: Partial Response,  (PR), reduction in size of the tumor by 
more than 30%; 2) Non-Responders : a: Stable disease (SD): reduction in size of the tumor by 
less than 30% or b: Progressive disease (PD): increase in size of tumor or presence of new 
lesions. Pathological response to chemotherapy was classified into four categories: Grade 0 
(No Response), Grade 1(Slight Response), Grade 2 (Fair Response), and Grade 3 (Complete 
Response) [11]. 
Results 
Pathological responses of the lesions to NAC were Grade 0 (n=1), Grade 1 or Grade 2 (n=21), 
and Grade 3 (n=4).MMG findings of pathological Grade 3 were microcalcifications only 
(n=1), scar only (n=1), and microcalcifications with reduced mass lesion (n=2). Two out of 
four (50.0%) lesions demonstrated CR, and two out of four lesions demonstrated PR (50.0%). 
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Regarding the Grades 1-2 cases, lesions were diagnosed as reduced mass with or without 
microcalcifications (n=19) demonstrated  PR (19/21, 90.5%) and 2 lesions diagnosed as only 
distortion or scar demonstrated CR (2/21, 9.5%). Regarding the Grade 0 case, the lesion 
detected as an enlarged mass (n=1) was diagnosed as PD (1/1, 100.0%). Adjunction of DBT 
findings of pathological Grade 3 were microcalcifications only (n=1), Scar only (n=1), and 
microcalcifications with scar without any density (n=2) that suggest CR (Fig.1). Regarding 
pathological Grades 1-2, the lesions were detected as reduced masses with or without 
microcalcifications (n=20) that suggested 20 cases were PR (20/21, 95.2%), and 1 case of only 
distortion or scar (n=1) that suggested CR (1/21, 4.8%). Regarding the Grade 0 case, the 
lesion was detected as an enlarged mass (n=1) that suggested PD (1/1, 100.0%). US findings 
of pathological Grade 3 (n=4) were diagnosed as CR (n=2, 50.0%), SD (n=1, 25.0%) and PR 
(n=1, 25.0%). US findings of pathological Grades 1-2 (n=21) were diagnosed as PR (n=17, 
81.0%), SD (n=3, 14.3%) and CR (n=1, 4.8%). In the case of US findings of pathological Grade 
0 (n=1), the lesion was diagnosed as PD (n=1, 100.0%). MRI (n=15) findings of pathological 
Grade 3 (3 lesions) were diagnosed as CR (n=2, 66.7%) and PR (n=1, 33.3%). MRI (n=15) 
findings of pathological Grades 1-2 (11 lesions) were diagnosed as PR (n=10, 90.5%) and CR 
(n=1, 9.5%). In the case of MRI findings of Grade 0(n=1), the lesion was diagnosed as PD 
(n=1, 100.0%). CT (10 cases with 11 lesions) findings of pathological Grade 3 (n=1) were 
diagnosed as CR (n=1, 100.0%). CT findings of pathological Grades 1-2 (n=10) were 
diagnosed as PR (n=10, 100.0%). MMG only resulted in two under-diagnosed lesions (2/26, 
7.7%) and two over-diagnosed lesions (2/26, 7.7%).US resulted in one under-diagnosed 
lesion (1/26, 3.8%) and five over-diagnosed lesions (5/26, 19.2%). MRI resulted in one 
under-diagnosed lesion (1/15, 6.7%) and one over-diagnosed lesion (1/15, 6.7%) (Table1).  
Discussion 
Accurate evaluation of tumor response to NAC is necessary for optimization of preoperative 
planning. MRI and CT have recently developed the potential to assist the other traditional 
imaging methods in the evaluation of response to NAC [12]-[20]. By mammography, it is 
difficult to identify a mass lesion in dense breasts or to distinguish a viable lesion from a 
fibrous reaction owing to NAC. Using US only can result in over-diagnosis of 
chemotherapy-induced fibrosis, because in the case of a hypo-echoic lesion, it is difficult to 
differentiate between a fibrotic change induced by neoplastic change and a reduction in the 
tumor by NAC. In addition, it is difficult to measure by hand-held probe the overview of a 
large mass lesion or multi-centric lesions, such as locally advanced tumors that could be 
treated by NAC (Fig.1). On the other hand, adjunction of DBT to FFDM has potential 
diagnostic advantages. In accordance with our study, compared to FFDM only, adjunction 
of DBT to FFDM can evaluate the inside of and the outline of the lesion. Compared to US, 
adjunction of DBT to FFDM can evaluate the overview of the lesion objectively. Accurate 
evaluation of tumor response to the pharmacological treatment is fundamental for optimal 
surgical planning. CE-MRI and CE-CT have recently developed the potential to assist the 
other traditional imaging methods in the evaluation of response to chemotherapy. These are 
able to discriminate between neoplastic and fibrotic tissue, based on the rate of contrast 
media enhancement [12]-[17]. In addition, the higher sensitivity of MRI can detect non-
invasive lesions as enhanced lesions that can be over-diagnosed as residual invasive 
components (Fig.2). According to our study, compared to CE-CT or CE-MRI, with 
adjunction of DBT to FFDM, it is possible to correlate the macroscopic evaluation with the 
pathological diagnosis without utilizing a contrast medium. The combination of adjunction 
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of DBT to FFDM with other diagnostic modalities will contribute to improved diagnostic 
accuracy with regard to NAC response to locally advanced breast cancer. 
Conclusion 
The adjunction of DBT to FFDM combined with other diagnostic modalities will contribute 
to more accurate assessment of pathological response to NAC. 
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f. US: Post NAC 
  
g. CE-CT: Pre NAC 
  
h. CE-CT: Post NAC 
FFDM (Fig.1a-b) showed reduced masses after NAC (white arrow). 
DBT (Fig.1c-d) showed reduced masses with scar with partial density inside of the corresponding lesion 
after NAC (white arrow). 
US (Fig.1e-f) showed reduced hypo-echoic masses as suspicious residual lesions after NAC (white arrow).  
The images of CE-CT (Fig.1g-h) showed reduced small enhanced nodules as suspicious residual lesions 
after NAC (white arrow).  
Fig. 3. Pathological Grade 1 Case. 
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  a. FFDM: Pre NAC    b. FFDM: Post NAC        c. DBT: Pre NAC            d. DBT: Post NAC 
  
e. US: Pre NAC      f. US: Post NAC 
   
g. MRI: Pre NAC                                             h. MRI: Post NAC 
FFDM (Fig.2a-b) demonstrated a reduced mass with microcalcifications after NAC (white arrow). 
DBT (Fig.2c-d) demonstrated microcalcifications with scar without core density inside of the 
corresponding lesion after NAC (white arrow).  
US (Fig.2e-f) demonstrated a reduced hypo-echoic mass as a suspicious residual lesion after NAC 
(white arrow).  
The coronal image of CE-MRI (Fig.2g-h) demonstrated small enhanced nodules as a suspicious residual 
lesion after NAC (white arrow). Pathological diagnosis demonstrated residual DCIS corresponding to 
the enhanced lesions by CE-MRI. 
Fig. 4. Pathological Grade 3 Case. 
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Pathological Response  MMG  US (n=26)     
Grade 0 (n=1)  *PD: n=1(100.0%)  PD: n=1(100.0%)   
Grades 1-2 (n=21) PR: n=19(90.5%), CR: 
n=2(9.5%) 
PR: n=17(81.0%), SD: n=3(14.3%), CR: n=1(4.8%) 
Grade3 (n=4) CR: n=2(50.0%), PR: 
n=2(50.0%) 
CR: n=2(50.0%), PR: n=1(25.0%), SD: n=1(25.0%) 
Pathological Response CT (n=11) 
Grades 1-2 (n=10)  PR: n=10 (100.0%) 
Grade 3 (n=1)  CR: n=1 (100.0%)         
Pathological Response  MRI (n=15) 
Grade 0 (n=1)  PD: n=1(100.0%)                             
Grades 1-2 (n=11)   PR: n=10(90.9%), CR: n=1(9.1%)                                    
Grade 3 (n=3)   CR: n=2(66.7%), PR: n=1(33.3%)   
* The clinical response to chemotherapy was classified in accordance with RECIST. 
Table 6. Comparison of NAC Response by Diagnostic Evaluation and Pathological 
Evaluation. 
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1. Introduction 
Fat necrosis is a benign inflammatory process that arises from damage to breast adipose 
tissue. Knowledge about the pathophysiology of fat necrosis is fundamental to enable the 
correct diagnosis of this entity whose appearance on different imaging modalities ranges 
from typically benign findings to findings normally associated with malignant lesions.  
In this chapter, we aim to provide a detailed description of the mechanisms involved in the 
development of fat necrosis as well as of the findings at mammography, sonography, 
magnetic resonance imaging, and other modalities. We also include a diagnostic algorithm 
that can be useful in the management of patients in whom fat necrosis is suspected.  
2. Etiology 
Breast fat necrosis is a benign inflammatory process. Although it is often considered 
idiopathic, breast fat necrosis is usually caused by trauma, and many idiopathic cases are 
probably due to microtrauma. Trauma leading to breast fat necrosis can result from 
accidents or clinical treatment. Among accidental agents, injury from safety belts in traffic 
accidents is common. Iatrogenic agents include  breast surgery (including incisional biopsy; 
lumpectomy; breast reduction; breast augmentation by implants or injection of silicone, 
paraffin, or other exogenous substances; and flap breast construction techniques like TRAM, 
DIEP, etc. ) and, less frequently, percutaneous procedures (including core biopsy, vacuum-
assisted core biopsy, or fine-needle aspiration cytology), radiotherapy, and chemical 
irritation caused by anticoagulants or rupture of cysts or ductal ectasia. Some systemic 
diseases like panniculitis (Weber-Christian syndrome) have a pathogenesis and imaging 
manifestations similar to those of fat necrosis. 
3. Clinical findings 
Breast fat necrosis is often a clinically silent process. It most commonly debuts as a palpable 
mass, which may be accompanied by ecchymosis and erythema, or less frequently by skin 
thickening or retraction. 
As Lee and Adair stated in the first report of breast fat necrosis (Lee&Adair, 1920), these 
clinical manifestations are so similar to those of breast cancer that we are obliged to use all 
the available means to differentiate between these two entities. Conventional imaging 
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techniques like mammography or sonography can help in this differentiation, but they can 
also lead to confusion due to myriad appearances of fat necrosis on these modalities.  
To better understand the wide spectrum of possible manifestations (ranging from perfectly 
differentiated benign findings to findings characteristic of malignant lesions), it is essential 
to know the pathogenesis of breast fat necrosis.   
4. Pathophysiology 
Fat necrosis occurs more often in breasts predominantly composed of adipose tissue; 
likewise, in breasts in which adipose tissue does not predominate, fat necrosis tends to occur 
close to the skin, where adipose tissue is most abundant.  
In breast trauma, damage occurs mainly to adipocytes and to the microvascularization, 
which is abundant in adipose tissue.  
Vascular damage results in an immediate inflammatory reaction consisting of arteriolar 
contraction to check bleeding. This contraction leads to increased arteriolar and capillary 
pressure, which cause transudation of fluid to the interstitial space and increased pressure 
in the venules, which in turn increases the permeability of the venous walls, thus resulting 
in the loss of proteins and consequently of fluid. All these factors that contribute to the 
increase in the amount of fluid in the interstitial space lead to the edema that is 
characteristic of the hyperacute inflammatory phase.  
On the other hand, the release of cytoplasmic triglycerides into the interstitial space after 
adipocyte rupture also leads to a series of chemical and inflammatory reactions. 
Shortly afterward, the damaged vessels release fibrinogen into the interstitial space, where 
the enzyme thrombin will convert it to active fibrin. Fibrin, which is elastic and insoluble, 
combines with the platelets to form a mesh to control bleeding. Furthermore, the “free” fat 
from the adipocytes will be encompassed by a sort of defense conglomerate, granulation 
tissue, which is mainly composed of macrophages, leukocytes (mainly neutrophils), fibrin, 
fibroblasts, and angioblasts. This fat-containing granulation tissue is called an oil cyst. 
With time, the oil cyst can either calcify or it can be reabsorbed and replaced with connective 
tissue. It is important to understand each of these processes. 
The fatty acids that make up the triglycerides can react with the calcium ions in the 
interstitial space to form calcium stearate, which will accumulate around the granulation 
tissue, resulting in a sphere of varying size contained within a shell of calcium, referred to as 
a calcified oil cyst. 
On the other hand, the nonencapsulated fatty acids or even the granulation tissue itself can 
be attacked by the immune system and reabsorbed, leaving a fibrous scar that can also 
calcify with time. 
These are the stages that can take place after trauma to breast adipose tissue. Although these 
stages tend to occur in the same order, the duration of each phase can differ widely, even 
within the same area of adipose tissue, so that different phenomena can be present at the 





The wide variability of phenomena associated with fat necrosis and the wide time window 
in which they can appear can make the diagnosis challenging. For this reason, one of the 
main aims of this chapter is to provide the tools to ensure an accurate imaging diagnosis. It 
is essential to obtain a thorough clinical history including possible trauma or surgery.  
5. Imaging&pathological findings 
5.1 Mammographic findings 
5.1.1 Edema  
In many cases, edema does not manifest on the mammogram. When it does, the findings are 
very subtle, usually consisting of focal skin thickening, which may or may not be associated 
with an increase in the density of subcutaneous fat and trabecular thickening (1). These 
findings have low specificity, being similar to those of mastitis (although the clinical 
presentation tends to be different). In inflammatory carcinoma, these same findings tend to 
be more evident and to involve the entire breast.   
 
 
    
 
Fig. 1. Increased density and trabeculation of subcutaneous fat associated with slight skin 
retraction (arrow). 
5.1.2 Granulation tissue 
The density of granulation tissue is indistinguishable from fibroglandular breast tissue from 
a mass or from an asymmetry (2). However, granulation tissue is easy to recognize if other 
findings of fat necrosis are present. 
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Fig. 2. Nodular image not present on previous mammograms (arrow), with a slightly lower 
density than the fibroglandular tissue in the same area, corresponding to a focus of fat 
necrosis.  
5.1.3 Oil cyst 
Oil cysts are easy to recognize. They are round or oval, with well-defined margins that may 
be partially or completely calcified or not at all, and their fatty content makes them 
radiolucent (3). The calcifications tend to be smooth and curvilinear and distributed from 
the periphery to the center (like an eggshell), although they may also adopt a more irregular 
shape (4). Oil cysts have been classified in function of their size as liponecrosis microcystica 
calcificans (< 3 mm in diameter) and liponecrosis macrocystica calcificans (> 3 mm in diameter) 
(Lanyi, 1986). 
 
Fig. 3. Well-defined oil cysts: 1. Without calcified walls; 2. With partially calcified walls; 3. 






Fig. 4. Irregular oil cysts: 1. After breast reduction surgery; 2. After transverse rectus 
abdominus myocutaneous (TRAM) flap oncoplastic surgery. 
If the salts have not precipitated completely in the peripheral granulation tissue they may 
remain “floating” on the cyst’s fatty fluid, causing a level (5).  
 
Fig. 5. Oil cyst with precipitated calcium salts (arrow) that separate from the oil in the 
mediolateral oblique projection to form a level (1. craniocaudal projection; 2. oblique 
mediolateral projection). 
These findings are sometimes difficult to differentiate from a galactocele or from a bleeding 
oil cyst, although neither of these results are a reason for suspicion.  
In some cases, the immune system can react when the cyst is still radiolucent due to its fatty 
content, and the walls of the cyst can thicken and adopt an irregular or ill-defined shape, 
simulating a malignant lesion (6). 
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Fig. 6. Oil cyst (1). One year later, the patient had a reaction to a foreign body that simulated 
a malignant lesion (2). Core biopsy: fat necrosis. The disappearance of the lesion during 
follow-up (3) confirmed that this was a benign process. 
Again, the clinical context and associated mammographic findings are important in 
distinguishing complicated oil cysts from other, less innocuous entities.  
5.1.4 Fibrous scar 
The fibrous scar that replaces the oil cyst can take on different shapes, and accordingly the 
mammographic findings can vary, ranging from asymmetry to an ill-defined or well-
defined mass. These are the findings that make it most difficult to differentiate fat necrosis 
from a malignant mass, especially when the retraction of the scar tissue gives the mass a 
spiculated or irregular shape. When the scar also calcifies, the findings are completely 
different from those of a calcified oil cyst; the numerous amorphous and even pleomorphic 
calcifications that often occur with the scar (7) make histological study and the differential 
diagnosis with a neoplasm process essential.  
 
Fig. 7. Parenchymal distortion together with pleomorphic calcifications adjacent to the 





5.1.5 Summary of the most common findings over time  
 
Fig. 8. Phases of fat necrosis: 1. Normal mammogram, with no history of trauma. 2. 
Retroareolar trauma in the left breast. Oil cyst and increased density around the cyst, 
together with calcifications, compatible with granulation tissue. 3. The oil cyst and 
granulation tissue are progressive replaced with coarse calcifications. 4. The calcifications 
replace the granulation tissue completely. 
5.1.6 Other classic (and not so classic) examples 
Mammograms in women with seat belt injuries of the breast show typical fat necrosis 
findings in a bandlike distribution corresponding to the path of the safety belt (DiPiro et al, 
1995). 
 
Fig. 9. Mammogram obtained a few months after a traffic accident shows calcifications 
compatible with fat necrosis; the calcifications are distributed throughout the anatomic 
region that comes in contact with the safety belt.  
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Fig. 10. Oil cysts in different phases. In this case, the lesions resulted from the injection of 
autologous  fat for reconstructive-esthetic purposes (lipofilling). 
5.2 Histologic findings. 
Although fine-needle aspiration cytology can be sensitive and specific for the diagnosis of 
fat necrosis, core biopsy or vacuum-assisted biopsy are even more sensitive and specific. 
Nevertheless, in some cases diagnostic uncertainty may persist, requiring excisional surgical 
biopsy. 
The histologic findings vary in function of the phase of the process of fat necrosis. 
Hemorrhagic changes in the adipocytes will give rise to a cavity filled with necrotized fat. 
The walls of this cavity will consist of a mesh of histiocytes, inflammatory cells, and giant 
multinucleated cells; with time, collagen-secreting fibroblasts responsible for scar formation 
will be progressively added. The calcifications mentioned in previous sections may also be 
identified.  
5.3 Sonographic findings 
5.3.1 Edema  
Skin thickening (easily appreciable by comparison with the contralateral breast) and 
increased echogenicity of adipose tissue are characteristic of, although not specific to, fat 
necrosis (11). Other processes, most of them benign (e.g., lipomas) can cause the same 
findings. The clinical history is key. Malignant processes that can present as hyperechogenic 
areas must also be taken into account. Linda et al. found 0.4% of hyperechogenic lesions in a 







Fig. 11. 1. Normal breast adipose tissue. 2. Findings after trauma to the same breast: skin 
thickening (double-headed arrow), minimal free fluid (thick arrow), and increased 
echogenicity of the subcutaneous fat (thin arrow). 
Sonoelastographic techniques can also be useful for evaluating the hardening of 
subcutaneous adipose tissue that occurs in these cases (12). 
 
Fig. 12. Shear-wave quantitative sonoelastography. Variability in the maximum, mean, and 
minimum elasticity of the subcutaneous fat  between two ROIs in the same area (continuous 
line: edematous fat; broken line: normal fat).  
5.3.2 Granulation tissue 
The only way to differentiate granulation tissue on sonography is by taking the absence of 
echogenicity of the oil cyst as a reference. The degree of calcification of the margins of these 
cystic cavities reflects their phase of development.  
Color Doppler can also be useful for demonstrating the increased vascularization in the 
periphery of the cyst that occurs with the formation of the granulation tissue (13). 
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Fig. 13. Increased color Doppler signal reflects the increase in vascularization after trauma. 
5.3.3 Oil cyst 
Oil cysts are round or oval anechoic lesions with smooth, well-defined, generally hyperechoic 
margins. Therefore, they are very easy to recognize and practically impossible to differentiate 
from simple cysts, except for the adjacent structures (generally, areas of echogenic adipose 
tissue) or if we decide to puncture and drain them, thus obtaining an oily fluid.  
Nevertheless, calcium stearate is often seen floating in oil cysts and accumulating in the 
base, forming a level that moves with patient’s movement, simulating a galactocele. 
Depending on the degree of calcification of the wall, we can identify a single or double 
echogenic ring as well as a posterior acoustic shadow which, if considerable, can cause an 
artifact that hinders the visualization of the cyst (14). 
 
Fig. 14. Oil cysts with different degrees of calcification, In case 4, the posterior acoustic 





5.3.4 Fibrous scar 
As mentioned above, sonography can be very useful in the diagnosis during the initial 
phases of fat necrosis. However, in more advanced phases, the scars adopt the form of 
spiculated or irregular-shaped masses that can make it difficult to differentiate fat necrosis 
from malignant disease (15). 
 
Fig. 15. A slightly heterogeneous mass with irregular margins. Core biopsy: fat necrosis. 
Nevertheless, sonography is very useful for guiding interventional procedures that may be 
necessary when suspicious findings are present. 
The role of color Doppler in these cases is uncertain, because like the formation of 
granulation tissue, which can persist for at least two years, some low grade tumors with a 
significant desmoplastic reaction can have scant vascularization.  
Sonoelastography is also not useful for differentiating between a fibrous scar and a 
malignant lesion, because both are very stiff (16). 
 
Fig. 16. A hypoechoic mass with an echogenic halo and irregular margins that has high 
stiffness on sonoelastography (score 5 in Ueno’s classification) and is thus suggestive of 
malignancy. Core biopsy: fat necrosis.  
 




Fig. 13. Increased color Doppler signal reflects the increase in vascularization after trauma. 
5.3.3 Oil cyst 
Oil cysts are round or oval anechoic lesions with smooth, well-defined, generally hyperechoic 
margins. Therefore, they are very easy to recognize and practically impossible to differentiate 
from simple cysts, except for the adjacent structures (generally, areas of echogenic adipose 
tissue) or if we decide to puncture and drain them, thus obtaining an oily fluid.  
Nevertheless, calcium stearate is often seen floating in oil cysts and accumulating in the 
base, forming a level that moves with patient’s movement, simulating a galactocele. 
Depending on the degree of calcification of the wall, we can identify a single or double 
echogenic ring as well as a posterior acoustic shadow which, if considerable, can cause an 
artifact that hinders the visualization of the cyst (14). 
 
Fig. 14. Oil cysts with different degrees of calcification, In case 4, the posterior acoustic 





5.3.4 Fibrous scar 
As mentioned above, sonography can be very useful in the diagnosis during the initial 
phases of fat necrosis. However, in more advanced phases, the scars adopt the form of 
spiculated or irregular-shaped masses that can make it difficult to differentiate fat necrosis 
from malignant disease (15). 
 
Fig. 15. A slightly heterogeneous mass with irregular margins. Core biopsy: fat necrosis. 
Nevertheless, sonography is very useful for guiding interventional procedures that may be 
necessary when suspicious findings are present. 
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Fig. 16. A hypoechoic mass with an echogenic halo and irregular margins that has high 
stiffness on sonoelastography (score 5 in Ueno’s classification) and is thus suggestive of 
malignancy. Core biopsy: fat necrosis.  
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5.4 MRI findings 
5.4.1 Edema  
Edema is hyperintense on T2-weighted sequences and hypointense on T1-weighted 









Fig. 17. Postsurgical changes in a breast treated for carcinoma. Some areas are hyperintense 
in T2-weighted sequences (1) and hypointense on T1-weighted sequences (2), corresponding 
to edema (fluid signal).   
5.4.2 Granulation tissue 
Granulation tissue is the main cause of contrast agent uptake in fat necrosis. Owing to the 
peripheral distribution of the granulation tissue around the oil cyst, ring enhancement, also 
characteristic of malignant lesions, is common. However, the nearly unequivocal MRI 
findings for oil cysts (see below) mean that the benign nature of this ring enhancement is 
rarely in doubt.  
In some cases, however, the arrangement of the granulation tissue is less well defined, so it 
is important to consider the signal intensity in T1-weighted sequences. The presence of fat, 
which is typically hyperintense in T1-weighted sequences, together with the patient’s 
clinical history, can help to rule out a neoplasm and diagnose fat necrosis (18). (Ganau et al., 









Fig. 18. Right breast three years after surgery for infiltrating ductal carcinoma. MRI shows 
an irregular mass with hyperintense foci in T1-weighted sequences (1) that are slightly 
hypointense in T2-weighted sequences (2); the mass has irregular peripheral enhancement 
after intravenous contrast administration (3). In this clinical context, it is imperative to rule 
out relapse of the tumor. Vacuum-assisted biopsy: fat necrosis. 
5.4.3 Oil cyst 
Oil cysts are shown as rounded or oval masses with well-defined margins; they are 
hyperintense in T1-weighted sequences and can be either hypo- or hyper-intense on T2-
weighted sequences. Depending on whether granulation tissue surrounds the cyst, the 
typical ring enhancement may or may not be observed. Depending on the degree of 
calcification of the cyst, a signal void may be present in T1-weighted sequences.  
The contents of oil cysts never enhance (19). 
 
Fig. 19. Typical findings for an oil cyst: A nodular cystic lesion with well-defined margins; it 
is hyperintense on T1-weighted images (1), slightly hypointense on T2-weighted images (2), 
and does not enhance (3).  
5.4.4 Fibrous scar 
MRI is essential for imaging fibrous scars. The greater the fibrotic content of the scar, the less 
likely the scar can take up contrast material. However, the persistence of granulation tissue 
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can cause enhancement of the scar. Hyperintense foci may also be seen within the scar in T1-
weighterd sequences due to the persistence of fat (20). 
 
Fig. 20. A woman with a personal history of infiltrating ductal carcinoma of the left breast 
treated with surgery and radiotherapy. One and a half years later, hyperintense areas are 
seen adjacent to the surgical scar on T1-weighted images (1), with peripheral enhancement 
(2) (arrows). It is essential to rule out relapse. Vacuum-assisted biopsy: Fat necrosis. 
The negative predictive value of screening with MRI approaches 100% in patients with a 
history of surgery for breast cancer. In these cases, it is important to evaluate the 
morphokinetic behavior of the contrast agent in scars. The absence of enhancement suggests 
the absence of malignancy. Nevertheless, uptake in the area of the scar requires relapse to be 
ruled out.   
Echo-planar MRI techniques can be useful in these cases. Thus, for example, high apparent 
diffusion coefficients in diffusion-weighted sequences of these cicatricial lesions suggest the 
absence of tumor recurrence. On the other hand, on MR spectroscopy, choline peaks in a 
fibrous scar suggest tumor recurrence.  
If any uncertainty persists about whether a lesion represents fat necrosis or a malignant 
process, histologic study is necessary. 
In summary, fat necrosis is complex from both the clinical and diagnostic points of view. On 
the one hand, it can be extremely easy to diagnose in patients with a clear history of trauma 
and characteristic clinical and imaging findings.  On the other hand, it can be very difficult 
to diagnose in patients with or without a known history of trauma in whom the imaging 
findings are identical to those of malignant breast disease.  
For this reason, with the aim of preventing underdiagnosis (considering a malignant process 
to be an episode of fat necrosis) and avoiding unnecessary diagnostic procedures 
(considering an episode of fat necrosis to be a malignant process), we present a algorithm 
for the management of these patients that takes into account three fundamental factors: the 
clinical presentation, the personal risk of breast cancer, and the findings on different 













FN No  FN
Follow-up
(MMG + MRI in 1 year) CB/VAB
FN 
(clinicoradiological concordance) 
No  FN 
(clinicoradiological discordance)
Follow-up
(MMG + US in 1 year) CB/VAB
 
 
CB = core biopsy; FN = fat necrosis; MMG = mammography; MRI = magnetic resonance imaging; US = 
ultrasound; VAB = vacuum-assisted biopsy. 
Table 1. Diagnostic algorithm for the management of patients with suspected fat necrosis. 
6. Conclusions 
Knowledge about the pathogenesis of fat necrosis is fundamental for recognizing the many 
different findings that can be seen on different imaging modalities. A multimodal approach, 
assessing the findings in the context of the patient’s risk profile, can improve the accuracy of 
the diagnosis of fat necrosis. 
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1. Introduction 
Secretory carcinoma of the breast is a rare variant (the frequency is below 0.15 %) of breast 
tumor1, 2. It was first described by McDivitt and Stewart in 1966, as a juvenile breast 
carcinoma as it was thought to occur only in childhood3. Subsequently, in 1970 Norris et al.2 
and in 1980 Tavassoli et al.4 advocated “secretory carcinoma” based on histopathological 
feature. It is now well known to occur in all age groups. As review of available literature, 
about 100 cases of secretory carcinoma of the breast has been reported at histopathology5. 
However, its gene expression profiling and the imaging appearances of this carcinoma are 
not well described. We report the gene expression profiling and the imaging characteristics 
of the secretory carcinoma of the breast. 
2. Case report 
The patient had no palpable mass or nipple discharge or axillary lymph node swelling but 
she was pointed out abnormality in her left breast for the screening of mammography and 
ultrasonography. She visited our hospital for further examination and medical treatment. 
Mammography showed multiple iso-density masses with unclear and partly spiculated 
margin on the mid portion of left Mediolateral-oblique view and inner portion of left 
Cranio-caudal view (Figure1A, 1B). Ultrasonography revealed multiple nodular hypo-
echoic masses measured 67 × 14 mm with high Depth/Width ratio, which suggested a 
malignant nature (Figure 2). Then HR-MRI on a 1.5-T system using a surface breast coil was 
performed. Diffusion weighted HR-MR image showed multiple mass-like high signal 
intensities. Contrast enhanced T1 weighted HR-MR image of early phase showed segmental 
distribution of multiple nodular mass-like enhancements measured by 60 × 40 mm (Figure 
3A, 3B). Thus malignancy was suspected. Non-contrast enhanced T1 weighted image of HR-
MRI revealed multiple dot-like high signal intensities in the mass (Figure 3C). Therefore this 
tumor was thought to contain rich protein or hemorrhage. Fat-saturated T2 weighted image 
of HR-MRI revealed nodular high signal intensities in the mass (Figure 3D). 
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           A                 B 
Fig. 1. A. MLO view of mammography, B: CC view of mammography; Multiple iso-density 
masses with unclear and partly spiculated margin are seen on the mid portion of left MLO 
view (A) and inner portion of left CCview (B). 
 
Fig. 2. Ultrasonography of the left breast; Multiple nodular hypo-echoic masses with high 
Depth/Width ratio are seen and which suggested a malignant nature. 
 








Fig. 3A. Diffusion weighted image of HR-MRI; Multiple mass-like high signal intensities are 






Fig. 3B. Contrast enhanced T1 weighted image on early phase of HR-MRI; Segmental 
distribution of multiple nodular mass-like enhancements are seen in the left breast. These 
mass-like enhancements might reflect the nodular growth of the secretory carcinoma. 
 




           A                 B 
Fig. 1. A. MLO view of mammography, B: CC view of mammography; Multiple iso-density 
masses with unclear and partly spiculated margin are seen on the mid portion of left MLO 
view (A) and inner portion of left CCview (B). 
 
Fig. 2. Ultrasonography of the left breast; Multiple nodular hypo-echoic masses with high 
Depth/Width ratio are seen and which suggested a malignant nature. 
 








Fig. 3A. Diffusion weighted image of HR-MRI; Multiple mass-like high signal intensities are 






Fig. 3B. Contrast enhanced T1 weighted image on early phase of HR-MRI; Segmental 
distribution of multiple nodular mass-like enhancements are seen in the left breast. These 
mass-like enhancements might reflect the nodular growth of the secretory carcinoma. 
 




Fig. 3C. Non-contrast enhanced T1 weighted image of HR-MRI; Multiple dot-like high 
signal intensities are seen on the mass (arrows). These high signal intensities might reflect 
the secretory material of the secretory carcinoma. 
 
Fig. 3D. Fat-saturated T2 weighted image of HR-MRI; Multiple nodular high signal 
intensities are seen on the mass (arrows). These high signal intensities might reflect the 
secretory material of the secretory carcinoma. 
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Cytology showed typical aggregated forms of tumor cells like bunches of grapes and the 
cytologic smears revealed grapelike clusters of mucous globular structures (MGSs) and 
speculated as a secretory carcinoma (Figure 4). Then left mastectomy was performed as a 
curative operation. Grossly, the tumor measured 6.8 × 4.5 × 2.0 cm and was gray-whitish 
circumscribed multiple nodular firm mass. And the tumor size was concordant with HR-MR 
imaging findings. The resected specimen of histopathological feature was microcystic or 
glandular architecture and composed of cells that produce abundant intracellular and 
extracellular secretory material, and immunohistochemically the tumor was positive for 
periodic acid-Schiff (PAS) as well as S-100 protein. The tumor consisted cells of pale-to-clear 
or eosinophilic cytoplasm, and small, round, low-grade nuclei with inconspicuous nucleoli. 
The tumor cells showed nodular growth and invasion of the adipose tissue was seen part of 
the tumor. Hence that was diagnosed a secretory carcinoma (Figure 5A, 5B, 5C, 5D). 
Secretory carcinoma is associated with a genetic ETV-6-NTRK3 gene fusion leading to a 
chimeric protein tyrosinase kinase expression, however it was not experimented in the 
present case. 
ER, PgR, and HER2 were all negative and triple negative cancer is suggested in our case. 
Immunohistochemically, the tumor cells are CK5/6, CK8/18, EGFR, vimentin, and c-kit all 
positive and our case of secretory carcinoma was considered to have the spectrum of basal-
like type in gene expression profiling. 
 
Fig. 4. Cytology of the secretory carcinoma (Papanicolaou stain, ×400); Aggregated forms of 
tumor cells like “bunches of grapes” are seen. 
 




Fig. 3C. Non-contrast enhanced T1 weighted image of HR-MRI; Multiple dot-like high 
signal intensities are seen on the mass (arrows). These high signal intensities might reflect 
the secretory material of the secretory carcinoma. 
 
Fig. 3D. Fat-saturated T2 weighted image of HR-MRI; Multiple nodular high signal 
intensities are seen on the mass (arrows). These high signal intensities might reflect the 
secretory material of the secretory carcinoma. 
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            C            D 
Fig. 5. A: Histology of the secretory carcinoma (Haematoxylin and Eosin stain, ×2); Low 
magnification view of the secretory carcinoma. The secretory carcinoma of the nodular 
growth is seen. B: Histology of the secretory carcinoma (Periodic acid-Schiff stain, ×200); 
Higher magnification view of the secretory carcinoma. The secretory material of the 
secretory carcinoma is positive for Periodic acid-Schiff stain. C, D: Histology of the secretory 
carcinoma (Figure 5C; Haematoxylin and Eosin stain ×100, Figure 5D; Haematoxylin and 
Eosin stain, ×400); Higher and high magnification view of the secretory carcinoma. The 
carcinoma cells arranged microcystic or glandular architecture and abundant intracellular 
and extracellular secretory material is seen. 
3. Discussion 
Secretory carcinoma of the breast is a rare but histopathologically distinct variant of invasive 
ductal carcinoma that thought to be indolent growth pattern and a more favorable prognosis 
than that of typical ductal carcinoma6. The frequency is thought to be below 0.15 % of all 
breast tumors1, 2. In our hospital, the frequency was 0.05 %. 
By using DNA microarray techniques, it has been shown that breast cancers can be classified 
into biologically distinct groups based on their gene expression profiles. These groups 
comprise luminal A (ER positive and HER2 negative), luminal B (ER and HER2 positive), 
ERBB2 (ER negative and HER2 positive), and triple negative (ER and HER2 negative) 
subtypes7. Our case was ER, PgR and HER2 negative, hence the triple negative cancer is 
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suggested. The triple negative cancer is a heterogeneous group and is further categorized 
into the basal-like and the normal breast subtypes, which are positive and negative, 
respectively, for myoepithelial/basal markers such as basal CKs. The consensus criteria for 
the basal-like subtype which has been reported is as follows. Nielsen et al. suggested four 
representative surrogate markers for the basal-like subtype: ER, HER2, EGFR, and CK5/68. 
Other additional criteria used for the basal-like subtype comprise (1) ER negativity and 
HER2 negativity, and vimentin, EGFR, CK8/18, and/or CK5/6 positivity, and (2) triple 
negativity, and CK5/6 and/or EGFR positivity7. Other markers that have been included in 
the myoepithelial/basal biomarkers are laminin9, 10, c-kit11, p6312, nestin13, osteonectin14, 
caveolin 115. In the present case, the tumor cells were CK5/6, CK8/18, EGFR, vimentin, and 
c-kit all positive and our case of secretory carcinoma was considered to have the spectrum of 
basal-like type in gene expression profiling. Lae et al reported that secretory carcinomas in 
woman were ER negative, PgR negative and HER2 negative, so called triple negative16. The 
tumors were also reactive for S100 and E-cadherin and focally for CK8/18 and CK5/616. Our 
case was compatible with the report of Lae et al.. Secretory carcinoma has been reported as 
low-grade carcinoma, however our case suggests that not always a secretory carcinoma is 
low-grade carcinoma. Triple negative cancer is considered to be a clinicopathological entity 
with aggressive behaviors and poor prognosis. Our case suggests that the secretory 
carcinoma of the breast should need careful therapeutic follow up. 
Here we will discuss about the imaging features of the secretory carcinoma. Mammography 
of a secretory carcinoma usually reveals a discrete tumor with smooth or irregular borders17. 
Also, our case of mammography showed multiple iso-density masses with unclear and 
partly spiculated margin and this finding was not specific for the entity of a secretory 
carcinoma. On ultrasonography, secretory carcinoma of the breast is frequently shown as a 
small benign-looking nodule or group of nodules with low clinical stage18. And secretory 
carcinoma of ultrasonographic appearance is a solid, well-circumscribed mass and is not 
specific for this entity and mimics benign entities such as fibroadenoma, as well as other 
well-differentiated breast carcinomas19. Ultrasonography of the present case revealed 
multiple nodular hypo-echoic masses measured 67 × 14 mm with high Depth/Width ratio, 
which suggested a malignant nature, however was not specific for a secretory carcinoma. It 
is not well known that the HR-MR imaging feature of secretory carcinoma of the breast. 
However, in our case, dot-like high signal intensities within the mass were observed on T1 
and high signal intensities on T2 weighted images on HR-MRI and additionally nodular 
multiple mass-like early enhancements were seen on contrast enhanced HR-MR imaging. 
Therefore this tumor was thought to contain rich protein or hemorrhage. The rich protein 
lesions reveal high signal intensity not only T1 weighted image but also T2 weighted image 
on HR-MR imaging by the concentration of protein20, 21, 22. Dot-like high signal intensities on 
T1 weighted image and nodular high signal intensities on fat-saturated T2 weighted image 
of HR-MRI might correspond to the groups of intracellular and extracellular secretory milk-
like material of the secretory carcinoma (Figure 3C, 3D, 5C, 5D). And mass-like early 
enhancements on contrast enhanced T1 weighted HR-MR image might correspond to the 
nodular growth of the secretory carcinoma (Figure 3B, 5A). Moreover, these findings of dot-
like high signal intensities on T1 weighted image with the distribution of scattered within 
the mass and high signal intensities on T2 weighted image of HR-MRI besides mass-like 
early enhancement on contrast enhanced T1 weighted HR-MR images are thought to be one 
of the imaging features of secretory carcinoma of the breast. Differential diagnoses of the 
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Fig. 5. A: Histology of the secretory carcinoma (Haematoxylin and Eosin stain, ×2); Low 
magnification view of the secretory carcinoma. The secretory carcinoma of the nodular 
growth is seen. B: Histology of the secretory carcinoma (Periodic acid-Schiff stain, ×200); 
Higher magnification view of the secretory carcinoma. The secretory material of the 
secretory carcinoma is positive for Periodic acid-Schiff stain. C, D: Histology of the secretory 
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secretory carcinoma on imaging characteristics including HR-MRI might theoretically be 
mucinous carcinoma of pure and mixed forms, sarcomas (angiosarcoma, myxofibrosarcoma 
and so on ), and matrix-producing carcinoma as concerning about mucinous or rich protein 
lesion, and invasive ductal carcinoma with hemorrhage and angiosarcoma as concerning 
about hemorrhage on HR-MR images. Mucinous carcinoma of pure and mixed forms might 
typically reveal lobulated shape and very high signal intensity on T2 weighted images, and 
a pattern of gradual enhancement or heterogenous enhancement on dynamic HR-MR 
images23. And the most common appearance of mucinous carcinoma is a hypo-echoic lesion 
with heterogenous internal echo on ultrasonography24. Matrix-producing carcinoma might 
typically reveal hypo- or high-echoic zone in the tumor on ultrasonography and ring-
shaped enhancement on contrast enhanced HR-MRI with high signal intensity in the central 
area of the tumor on T2 weighted imaging25. Angiosarcoma might typically reveal both a 
high- and hypo-echoic lesion without acoustic shadow on ultrasonography26, and HR-MRI 
of angiosarcoma might reveal low intensity tumor on T1 weighted images, markedly high 
intensity on T2 weighted images and prolongation of enhancement on the dynamic study 
and the presence of multiple regions without enhancement in the tumor27. Sarcomas might 
contain mucinous lesion, however the distribution of mucin might not be typically dot-like 
and scattered in the mass on T1 weighted image of HR-MRI. Invasive ductal carcinoma with 
hemorrhage and angiosarcoma might have hemorrhagic lesion and sometimes reveal high 
signal intensity on T1 weighted image of HR-MRI, however their distribution might rarely 
be scattered in the mass on T1 weighted image of HR-MRI.  
In conclusion, these findings of dot-like high signal intensities on T1 weighted image with 
their distribution of scattered within the mass and high signal intensities on T2 weighted 
image of HR-MRI besides mass-like early enhancement on the dynamic HR-MR image are 
thought to be one of the imaging features of secretory carcinoma of the breast. And our 
findings of HR-MR images might be helpful to diagnose the secretory carcinoma of the 
breast on HR-MR imaging. 
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1. Introduction 
Triple negative (TN) breast cancer is defined as cancer with negative expressions of 
hormone receptors and human epidermal growth factor receptor 2 (HER2). This subtype is 
characterized as a cancer with a high malignancy potential and a poor prognosis. Endocrine 
therapy and anti-HER2 therapy are ineffective in the treatment of TN breast cancer as they 
have less specific targets compared with other subtypes of breast cancer. At present, 
chemotherapy is the only option to treat this type of cancer. This subtype is found in 
approximately 15.5% of all breast cancer cases in Japan (Iwase et al., 2010). The percentage of 
other subtypes are as follows; Luminal A (hormone receptors positive and HER2 negative), 
69.0%; Luminal B (hormone receptors positive and HER2 positive), 7.3% and HER2-enriched 
(hormone receptor negative and HER2 positive), 8.2%.  Some reports described a subtype of 
DCIS that correlates to the progression to invasive carcinoma; comedo type DCIS progresses 
to invasive carcinoma, both more often and more rapidly than low-grade DCIS (Pinder SE & 
Ellis IO, 2003; Ketcham AS & Moffat FL, 1990). This may be a reason for the rarity of TN 
DCIS. The incidence of TN DCIS accounts for less than 5% of DCIS. If this is true, early 
detection of this particularly aggressive type of breast cancer is vital. (Moriya et al, 2010) 
There have been reports claiming that TN IDC occurs from ER negative, HER2 positive 
DCIS lesion and loses its HER2 expression when it progresses to an invasive cancer, which 
may indicate a precursor process is at work (Bradley BB et al., 2006; Livasy CA et al., 2007; 
Flora Z et al., 2007). To clarify these hypotheses, comparison between TN IDC and TN DCIS 
is also essential. There are no other reports that we were able to find that focus specifically 
on TN DCIS. We cannot predict the outcome of TN DCIS, if it is not diagnosed and treated, 
because this has not been researched nor documented (Page DL et al., 1995; Page DL et al., 
1982; Betsill WLJ et al., 1978). We reviewed another report on a series of cases in which DCIS 
was not completely excised. The findings from those reports indicate that a more frequent 
and rapid progression from DCIS to invasive cancer is related to the comedo subtype of 
DCIS, which is comparable to low-grade DCIS (Pinder SE & Ellis IO, 2003; Simpson JF, 
2009). We need to investigate the specific features of this subtype, and we need to determine 
the radiological and pathological features of TN breast cancer via retrospective evaluation in 
a large population, in order to make a more precise diagnosis. 
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2. Patients and methods 
TN breast cancer cases were studied by conducting chart reviews between January 2007 and 
January 2011 to assess mammogram (MMG), ultrasound (US), magnetic resonance imaging 
(MRI), methods of detection, and pathology findings. Routine diagnostic breast 
mammography, ultrasound, and MRI were performed before surgeries in our hospital. 
2.1 Mammography 
For each patient, mammograms with mediolateral oblique and craniocaudal view were 
carried out. In all cases, mammograms were retrospectively reviewed by two breast 
radiologists, and classified as focal asymmetric density (FAD), masses, calcifications, or 
architectural distortion, according to the Japanese mammography guidelines (The 
Committee of Mammography Guideline, 2010). Margins of masses were reviewed for being 
circumscribed, microlobulated, indistinct, and speculated. Mammography was performed 
by using Senographe 800T and Senographe DMR units from GE (films, MIN-R EV; screen, 
EV150) till August 2008. In August 2008, digital mammography with the Selenia from 
Hitachi was introduced. 
2.2 Ultrasound 
Each patient underwent whole-breast US which was performed and diagnosed by one of 
two radiologists, specialized in breast imaging. The ultrasound findings were classified as 
masses, low echoic area, distortions, and calcifications. Noted features included shapes 
(oval, lobulated, polygonal, or irregular), patterns of the internal echoes (hypoechoic, 
isoechoic, or hyperechoic), the posterior echoes (accentuating, no change, or attenuating), 
vascularity (avascular, spotty signals, hypovascular, hypervascular) and elasticity scores (1–
5; scores defined as previously reported (Itoh A et al., 2006)).  
For patients, ultrasound was performed by using 10 MHz linear-array transducers (LOGIQ 
7 system, GE) and 12 MHz linear-array transducers (HDI 5000, Philips) until September 
2007, and from October 2007, 12 MHz linear-array transducers (SSA 790A, Toshiba Medical 
Systems) and 14 MHz linear-array transducers (EUB 7500, Hitachi Medical) were used. All 
elasticity images were obtained by using EUB 7500. 
2.3 Magnetic resonance imaging 
The equipment used for MRI was a Signa Excite HD ver. 12 (1.5 Tesla) from GE with 4- or 8-
channel breast coil. The protocol was as follows: fat-suppressed T1WI, sagittal (pre-and 
post-enhancement) fast SPGR: TR/TE 6.5/1.5, FA 15°, FOV 16 cm, matrix 256 9 192, slice 
thickness 2 mm, scan time 2 min 10 s; fat-suppressed T2WI, sagittal FSE: TR/TE; 3,000/85, 
FOV 16 cm, matrix 256 9 224, slice thickness 5 mm, gap 1 mm, scan time 2 min 24 s; and 
delayed axial scan with VIBRANT: TR/TE 6.4/3.0, FOV 34 cm, matrix 350 9 350, slice 
thickness 1.2 mm, ASSET 2.0, scan time 2 min 40 s. 
2.4 Pathological findings 
All resected specimens were diagnosed by whole sectioning. Hematoxilin–eosin staining 
was performed in formalin-fixed, paraffin-embedded material for pathological diagnosis. 
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Immunohistochemistry of estrogen receptor (ER), progesterone receptor (PgR), and HER2 
were evaluated. The assessments of ER and PgR were done using Allred score, and the 
HER2 status was graded as 0, 1+, 2+, and 3+. HER2 score 3+ was defined as positive, and 2+ 
was checked by fluorescence in situ hybridization for its positivity. Five cases were 
eliminated, because the postoperative hormonal status turned out to be positive. In this 
cohort, 61 patients underwent neoadjuvant chemotherapy. 
3. Results 
Our cohort included 2,868 operations performed for primary breast cancer diagnosed in our 
institute between January 2007 and January 2011. Table 1 shows the characteristics of all 
triple-negative cases. Women with triple-negative invasive breast cancer were likely to have 
histologically higher-grade tumors compared to ductal carcinoma in situ. 
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Table 1. Characteristics of TN breast cancer patients (n=121). 
3.1 DCIS 
Our cohort included 657 DCIS patients, who were diagnosed and treated in our institute 
between January 2007 and January 2011. Among all 657 DCIS cases, 20 cases (3.0%) were 
ER-negative, PgR-negative, and HER2-negative. Ages in this group ranged from 40 to 73 
years old, with an average age of 55.8. In 12 cases, patients underwent partial resection, and 
in 8 cases, patients underwent total mastectomy. DCIS was confirmed in all patients by 
whole sectioning of the resected specimens. 
The radiology and pathology findings are shown in Table 2. Mammographic findings of TN 
DCIS were as follows: there were no abnormal findings in six cases, masses were revealed in 
two cases, FAD was detected in three cases, and architectural distortion was noted in five 
cases. However, calcifications, which have been considered as typical radiologcal findings in 
DCIS, were observed in only four cases (20.0%) out of our TN DCIS (Tables 2, 3). US 
findings were as follows: low echoic masses were noted in 7 cases, low echoic areas were 
noted in 14 cases, architectural distortion was noted in four cases. MRI findings revealed 
typical DCIS findings, including 7 masses and 12 non-mass-like enhancements (one patient 
did not undergo MRI). The average lesion size measured 2.9 cm in diameter (with a range of 
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delayed axial scan with VIBRANT: TR/TE 6.4/3.0, FOV 34 cm, matrix 350 9 350, slice 
thickness 1.2 mm, ASSET 2.0, scan time 2 min 40 s. 
2.4 Pathological findings 
All resected specimens were diagnosed by whole sectioning. Hematoxilin–eosin staining 
was performed in formalin-fixed, paraffin-embedded material for pathological diagnosis. 
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typical DCIS findings, including 7 masses and 12 non-mass-like enhancements (one patient 
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0.5–8.5 cm). Fourteen cases were classified as nuclear grade (NG) 1, three cases were 
classified as NG2, and three cases were classified as NG3. Histological findings confirmed 
non-comedo type in 9 cases; mixed types, including some comedo components, were found 
in 8 cases; comedo type in 3 cases. In seven cases, apocrine metaplasia was observed, and in 
seven cases we noted a remarkable sclerosing adenosis in the background breast tissue areas 
of DCIS. 
 
case MMG US MRI NG Type of DCIS 
1 mass low echoic mass Non-mass like, segmental clumped enhancement 1 mixed 
2 distortion low echoic area, distortion 
Non-mass like, ductal 
enhancement 1 non-comedo, SA 
3 distortion low echoic mass Non-mass like, segmental homogenous enhancement 1 non-comedo, SA 




5 no findings low echoic area Mass 1 mixed 
6 no findings low echoic area Non-mass like, segmental homogenous enhancement 3 mixed 
7 mass low echoic mass Not performed 1 comedo 
8 no findings low echoic area Non-mass like, segmental clumped enhancement 2 
mixed, apocrine 
metaplasia 
9 FAD low echoic area, distortion 
Non-mass like, segmental 
clumped enhancement 1 non-comedo, SA 
10 calcifications low echoic area Mass, foci 3 mixed 








13 calcifications low echoic area Non-mass like, segmental heterogenous enhancement 2 mixed 
14 FAD low echoic area Non-mass like, segmental heterogenous enhancement 1 mixed 
15 FAD low echoic mass Mass 2 mixed 




17 calcifications low echoic area Non-mass like, segmental clumped enhancement 3 comedo 
18 calcifications low echoic area Mass 1 comedo 








Table 2. Radiology and pathology findings of TN DCIS cases. 
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Findings Number (%) 
Calcifications 4 (20) 
Mass 2 (10) 
Focal asymmetric density 3 (15) 
Architectural destortion 5 (25) 
No abnormal findings 6 (30) 
Table 3. Mammogram findings of triple negative ductal carcinoma in situ. 
Representative cases are shown in Figs. 1 and 2. In the first case, the MMG revealed an 
architectural distortion in the right breast. Spot view revealed no abnormal calcifications. US 
revealed an irregularly shaped low echoic area with architectural distortion. The MRI 
revealed a non-mass like, segmental heterogenous enhancement. The pathological findings 




    
 
Fig. 1.1. A first representative case of DCIS, mammography of the right breast. 
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Fig. 1.1. A first representative case of DCIS, mammography of the right breast. 
 




Fig. 1.2. A first representative case of DCIS, mammography with spot view. 
 
Fig. 1.3. A first representative case of DCIS, Ultrasound. 
 









Fig. 1.4. A first representative caseof DCIS, MRI.  
In the second case, MMG revealed a focal asymmetric density with architectural distortion 
in the right breast. US revealed an irregularly shaped low echoic mass. The MRI revealed a 
segmental enhancement with an architectural distortion. Pathological diagnosis confirmed 
DCIS with sclerosing adenosis.  
 




Fig. 1.2. A first representative case of DCIS, mammography with spot view. 
 
Fig. 1.3. A first representative case of DCIS, Ultrasound. 
 









Fig. 1.4. A first representative caseof DCIS, MRI.  
In the second case, MMG revealed a focal asymmetric density with architectural distortion 
in the right breast. US revealed an irregularly shaped low echoic mass. The MRI revealed a 
segmental enhancement with an architectural distortion. Pathological diagnosis confirmed 
DCIS with sclerosing adenosis.  
 
















Fig. 2.1. A second representative case of DCIS, mammography of the right breast. 
 





Fig. 2.2. A second representative case of DCIS, Ultrasound; elastography (above) and collar 
Doppler view (below). 
 
















Fig. 2.1. A second representative case of DCIS, mammography of the right breast. 
 





Fig. 2.2. A second representative case of DCIS, Ultrasound; elastography (above) and collar 
Doppler view (below). 
 




Fig. 2.3. A second representative case of DCIS, MRI. 
3.2 IDC 
Table 4 shows the radiological findings of TN invasive cancer in our study. On 
mammography, in almost all patients scattered fibrograndular (44/100, 44%) to 
heterogeneous (46/100, 46%) breast density was noted. Triple-negative breast cancers 
frequently presented with a mass (63/100, 63%) and were less associated with focal 
asymmetric density (13/100, 13%), calcifications (10/100, 10%), and distortion (5/100, 5%). 
Margins of masses were assessed. Masses with microlobulated margins were the most 
frequent (26/63, 41.3%), indistinct margins (19/63, 30.2%) and circumscribed margins 
(12/63, 19.0%) were commonly observed, but spiculated margins were rare (6/63, 9.5%). 
On ultrasound, cancers were less frequently observed as non-mass lesions (7/97, 7.2%), and 
were more likely to present as a mass (90/97, 92.8%); these were lobulated (42/90, 46.7%), 
irregular (17/90, 18.9%), or oval (24/90, 26.7%) in shape, and less likely to show attenuating 
posterior echoes (8/97, 8.2%). Of the 42 cases obtained via elasticity imaging, 35 (83.3%) 
lesions were scored as 4 or 5. 
 






Mammography n=100 Ultrasound n=97  
 Density   Findings  
      Predominant fatty  6       Mass 90 
      Scattered fibrograndular 44       Non-mass like  7 
      Heterogeneously dense 46 Architectural                distortion  0 
      Dense  4       Calcifications  0 
    
 Findings   Shape of mass n=90  
     No abnormal findings 10       Oval 24 
     Focal asymmetric density 13       Lobulated 42 
     Mass 63       Irregular shape 17 
     Calcifications 10       Indistinct  7 
Architectural distortion  5   
   Posterior echoes  
 Border of mass n=63       Accentuating 43 
     Circumscribed 12        No change 46 
     Microlobulated 26       Attenuating  8 
     Indistinct 19   
     Spiculated  6  Vascularity  
        Avascular  7 
        Spotty signals 32 
        Hypovascular 38 
        Hypervascular 14 
    
   Elasticity score n=42 
  1~3  7  
  4, 5 35  
    
 
Table 4. Mammography and ultrasound findings for triple negative breast cancer patients 
Representative cases are shown in Figs. 3 and 4. On the mammogram of the first case, there 
were scattered fibroglandular elements in both breasts. There was a 2.3 cm oval high density 
mass with circumscribed margin in the left breast in the posterior depth of the superior 
region seen on the mediolateral oblique view which likely represents expansively growing 
tumor. On the ultrasound, there was an oval mass with circumscribed margin in the inner 
upper quadrant of the left breast. The tumor size was approximately 2.0 cm, slight spotty 
vasculature was seen at the edge of the tumor, and poor elasticity via elastography 
(elasticity score 4). MRI also showed an oval enhanced mass with circumscribed margin. 
The pathological findings confirmed invasive ductal carcinoma, nuclear grade 3, with fat 
invasion and lymphovascular invasion.  
 




Fig. 2.3. A second representative case of DCIS, MRI. 
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Fig. 3.1. A first representative case of IDC, mammography. 
 
Fig. 3.2. A first representative case of IDC, Ultrasound; B-mode and power Doppler. 
 




Fig. 3.3. A first representative case of IDC, Ultrasound; elastography. 
 
Fig. 3.4. A first representative case of IDC, MRI. 
On the second case, mammogram revealed scattered fibroglandular elements in both 
breasts. There was an oval high density mass with microlobulated margins in the posterior 
depth of the superior region seen on the mediolateral oblique view of the right breast. The 
tumor sizes was 1.8 cm in diameter. On the ultrasound, there was a lobulated mass with 
circumscribed margin in the outer upper quadrant of the right breast. The mass showed 
mosaic pattern vasculature indicating hypervascularity of the tumor, and poor elasticity via 
elastography (elasticity score 4). MRI showed a circumscribed enhanced mass in the upper 
portion of the right breast. Pathological findings revealed invasive ductal cancer, nuclear 
grade 2. 
 




Fig. 3.1. A first representative case of IDC, mammography. 
 
Fig. 3.2. A first representative case of IDC, Ultrasound; B-mode and power Doppler. 
 




Fig. 3.3. A first representative case of IDC, Ultrasound; elastography. 
 
Fig. 3.4. A first representative case of IDC, MRI. 
On the second case, mammogram revealed scattered fibroglandular elements in both 
breasts. There was an oval high density mass with microlobulated margins in the posterior 
depth of the superior region seen on the mediolateral oblique view of the right breast. The 
tumor sizes was 1.8 cm in diameter. On the ultrasound, there was a lobulated mass with 
circumscribed margin in the outer upper quadrant of the right breast. The mass showed 
mosaic pattern vasculature indicating hypervascularity of the tumor, and poor elasticity via 
elastography (elasticity score 4). MRI showed a circumscribed enhanced mass in the upper 
portion of the right breast. Pathological findings revealed invasive ductal cancer, nuclear 
grade 2. 
 




Fig. 4.1. A second representative case of IDC, mammography. 
 
Fig. 4.2. A second representative case of IDC, Ultrasound; B-mode and power Doppler view. 
 




Fig. 4.3. A second representative case of IDC, MRI. 
4. Discussion  
There are a few reports describing mammography and ultrasound findings of triple-
negative breast cancers (Ko ES et al., 2010; Wang Y et al., 2008; Yang WT et al., 2008). In 
those studies, comparisons were made between the mammography and ultrasound 
findings of hormone receptor negative, HER2-negative cancers with hormone receptor 
positive, HER2-negative cancers and hormone receptors negative, HER2-positive cancers. 
The radiological features of TN breast cancers included in our study were similar to the 
features described above. According to the Japanese data, hormone receptor positive 
breast cancer, such as luminal A or B, less likely to be found as a mass with pushing 
border compared to triple negative type cancers (Iwase H et al., 2010). Additionally, a few 
researchers have stated that triple-negative cancer is less frequently associated with 
calcifications, compared to the other subtypes. Collett et al. (Collett K et al., 2005) 
evaluated interval cancers diagnosed in a screening program between 1996 and 2001 and 
found that TN breast cancers were more likely than non-TN breast cancers to present in 
the interval between regular mammograms. The radiological features of TN breast cancer 
would give an answer to this. 
Wang et al. showed that triple–negative cancers are less likely to be associated with 
spiculated margins on mammography than estrogen receptor–negative human epidermal 
growth factor receptor–positive cancers are. In their series of 23 TN breast cancers, 9% were 
mammographically occult and only 23% had associated calcifications. (Wang Y et al., 2008). 
 




Fig. 4.1. A second representative case of IDC, mammography. 
 
Fig. 4.2. A second representative case of IDC, Ultrasound; B-mode and power Doppler view. 
 




Fig. 4.3. A second representative case of IDC, MRI. 
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Dent et al determined that patients with TN breast cancers had a much lower proportion of 
breast cancers first detected by mammography or ultrasound than patients with other breast 
cancers (19.6% versus 36.0%) (Dent R et al., 2007). 
Dogan et al reported that TN breast cancer features include; triple negative cancers were 
mammographically occult in 9% and sonographically occult in 7% of the patients (Dogan BE 
et al, 2010). When they could be visualized, the TN breast cancers had benign or 
indeterminate mammographic and sonographic findings, such as focal asymmetry (21%) 
and circumscribed round or oval masses (15.8%), despite their large size. Only three cases 
(6.8%) were identified as calcifications alone on mammography. Triple negative breast 
cancer is less likely to be detected in the routine screening using mammography alone. In 
contrast, all the cancers were visualized on MRI and showed characteristic findings 
associated with malignancy, as defined by the BI-RADS criteria. The most frequent MRI 
finding was a round or oval contrast-enhanced mass with irregular or spiculated margins 
and rim enhancements, (Schnall MD et al., 2006) and the characteristic shape is a common 
mammographic and ultrasound finding. Jinguji et al., who previously suggested an 
association of poor prognostic factors, such as nodal status, blood vessel invasion, and 
hormone receptor negativity, with rim enhancement on MRI, which are also some of the 
clinicopathological features of TN breast cancer. (Jinguji M et al., 2006) 
Uematsu et al. suggested frequent association of rim enhancements and smooth mass 
margins on their series of TN breast cancers. (Uematsu T et al., 2009) 
There are many reports describing the characteristic findings of MRI, although there are few 
describing those findings of mammogram or ultrasound. 
In our study, we determined the radiological characteristics, which were often observed as a 
mass (65%) on mammography. In the ultrasound findings, we noted that TN breast cancers 
were more likely to be seen as mass lesions (71%), with oval or lobulated shapes, and hypo-
echoic masses. Posterior echoes were less likely to attenuate, and vascularity was identified 
to some extent. From a previous report (Itoh A et al., 2006), the sensitivity, specificity, and 
accuracy of elastography were 83.3, 86.7, and 85.2%, respectively, with a cutoff score of 
between 3 and 4. Among the patients who were able to have elastography, TN breast cancer 
appeared as hard masses, with elasticity scores of 4 or 5. These findings represent TN tumor 
characteristics including high cellularity, less fibrous mass, and an elasticity score as high as 
ordinary invasive ductal carcinoma. 
Our study showed that only 20% (4/20) of TN DCIS were detected because of 
mammographic abnormal calcifications. To gain a better understanding of the character 
of this rare type of DCIS, we retrospectively reviewed the charts and reports of each 
case. 
Ordinarily, DCIS was first described a century ago by Dr. Joseph Bloodgood, but its natural 
history is poorly understood. In a large population-based surveillance, epidemiology, and 
end results series, Ernster et al. (Ernster VL et al., 2000) reported a 10-year mortality risk of 
DCIS of only 1.9%. Therefore, early detection is essential for improving the prognosis of 
breast cancer. The prognosis of TN invasive cancer is considered to be poor. If TN DCIS is a 
precursor of TN invasive carcinoma, detection of TN DCIS is attributed to appropriate 
treatment of the cases that may become TN invasive carcinoma.  
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DCIS was detected because of breast lumps or an abnormal discharge from the nipple. 
Through wider usage of MMG, and the development of radiological detection technologies 
capable of identifying breast abnormalities long before they become palpable, the frequency 
of DCIS detection has increased (Frykberg ER, 1997; Schnitt SJ et al., 1988; Dershaw DD, 
1989; Stomper PC, 1989; Ikeda DM & Anderson I, 1989). Historically, most cases of DCIS 
(72–80%) have been diagnosed by MMG. This is mainly because of abnormal calcifications, 
such as necrotic calcifications representing dead tumor cells or secretory calcifications in 
tumor nests. Only 10–12% of DCIS cases have been discovered because of masses without 
calcifications revealed by MMG. 
Abnormal calcifications are seen in approximately 62% (Ikeda DM & Andersson I, 1989) to 
72% of common DCIS cases (Kopans DB, 1998). The percentage in TN DCIS cases of 
abnormal calcifications is considerably lower than in common DCIS cases. 
In our cohort, the percentage of TN DCIS was only 3.0% of all DCIS. This percentage is 
much less than that of TN cancer rate in IDC cases. 
When we investigated the reason why TN DCIS is so rare, we were able to identify a few 
possibilities. TN DCIS may grow rapidly in a short time span, which makes it difficult to 
detect during its noninvasive term. This is one possibility that TN cancers were reported 
more likely to present in the interval between regular mammograms. TN invasive 
carcinoma is known to have rapid growth characteristics and has a poor prognosis. On the 
basis of pathology and molecular studies, some DCIS represents a precursor to invasive 
breast cancer; however, the proportion of untreated DCIS that will progress to invasive 
breast cancer is uncertain (Bradley BB et al., 2006; Livasy CA, 2007; Flora Z, 2007). Ko et al. 
suggest that triple-negative breast cancer may develope rapidly to an invasive stage with no 
major in situ components or to a precancerous stage; hence, such tumors lack calcifications 
on mammography (Ko ES et al., 2010). Moriya et al. reported the incidence of TN DCIS 
among DCIS as being less than 5% (Moriya T et al., 2010). They also think it is possible that 
TN DCIS transforms to invasive cancer in its early stage, not remaining preinvasive DCIS. 
However, the presence of precursor lesions of TN breast cancer has not been clarified, and 
its origin and development remain to be investigated. 
In our study, we identified a small number of patients (according to their mammograms) 
who were diagnosed as being without any abnormalities. If this were to happen in a normal 
screening process, such patients might slip through undiagnosed. We noted that ultrasound 
did indeed pick up all abnormalities. As a result, we can conclude that ultrasound used in 
combination with mammography is advantageous in detecting TN breast cancer. 
Among DCIS, subtypes of DCIS correlate to the progression to invasive carcinoma; comedo 
type DCIS progresses to invasive carcinoma, both more often and more rapidly than low-
grade DCIS (Pinder SE & Ellis IO, 2003; Ketcham AS & Moffat FL, 1990). From our findings, 
comedo components were frequently seen among lesions, and these comedo components 
are thought to be one reason for the rarity of TN DCIS. These results do not adequately 
explain the rarity of TN DCIS with its growth speed. The expression of ER, PgR, or HER2 is 
different between intraductal and invasive components within a patient in fewer cases, and 
its significance (whether it can be explained by dedifferentiation) has attracted a lot of 
interest recently. TN DCIS is thought to be a complex of several phenotypes. Not all TN 
DCIS cases progress rapidly to invasive cancer. 
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In lesions consistent with noninvasive and invasive components, the expression of HER2 
differs between these two components, positive in the noninvasive part, and negative in the 
invasive part. ER positivity between these two components is almost the same (50–75%), 
however, HER2 positivity in DCIS is much higher than in invasive cancer, 32–55 and 20–
25%, respectively. It is thought that a high proportion of DCIS lesions that progress to 
invasive lesions do lose overexpression of HER2 (Wiechmann L & Kuerer HM, 2008). 
Therefore, when hormone-negative and HER2-positive DCIS progresses to an invasive 
carcinoma, it becomes a TN invasive carcinoma, which might be another reason for the 
rarity of TN DCIS. 
Our findings suggest that TN DCIS cases are less likely to have calcifications in comparison 
with non-TN DCIS. TN DCIS are also detected mainly as masses or asymmetry. US and MRI 
findings of TN DCIS are almost the same as those of DCIS as seen in previous studies. From 
our data, almost all TN DCIS were observed as low echoic masses by US, which leads us to 
believe that US is a more important diagnostic tool than MMG in detecting TN DCIS. By 
using US more frequently, the detection rate of TN DCIS should be elevated. 
5. Conclusion  
We diagnosed TN DCIS in 3.0% of all DCIS cases. There were fewer incidences of 
mammographic abnormal calcifications with TN DCIS than with non-TN DCIS. 
Mammography and ultrasound imaging together revealed that the morphological features 
of TN breast cancer include a lobulated mass, with less attenuating posterior echoes, some 
vascularity, and low elasticity. 
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In this volume, the topics are constructed from a variety of contents: the bases of 
mammography systems, optimization of screening mammography with reference to 
evidence-based research, new technologies of image acquisition and its surrounding 
systems, and case reports with reference to up-to-date multimodality images of breast 
cancer. Mammography has been lagged in the transition to digital imaging systems 
because of the necessity of high resolution for diagnosis. However, in the past ten 
years, technical improvement has resolved the difficulties and boosted new diagnostic 
systems. We hope that the reader will learn the essentials of mammography and will 
be forward-looking for the new technologies. We want to express our sincere gratitude 
and appreciation?to all the co-authors who have contributed their work to this volume.
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